

(19) 日本国特許庁(JP)

(12) 公表特許公報(A)

(11) 特許出願公表番号

特表2005-502315

(P2005-502315A)

(43) 公表日 平成17年1月27日(2005.1.27)

(51) Int. Cl. <sup>7</sup>	F I	テーマコード (参考)
<b>C 1 2 N 15/09</b>	C 1 2 N 15/00 Z N A A	2 G O 4 5
<b>A 6 1 K 39/102</b>	A 6 1 K 39/102	4 B O 2 4
<b>A 6 1 P 31/04</b>	A 6 1 P 31/04	4 B O 6 3
<b>C O 7 K 14/285</b>	A 6 1 P 31/04 1 7 1	4 B O 6 4
<b>C O 7 K 16/12</b>	C O 7 K 14/285	4 B O 6 5
	審査請求 未請求 予備審査請求 有	(全 402 頁) 最終頁に続く

(21) 出願番号	特願2002-574050 (P2002-574050)	(71) 出願人	397006612
(86) (22) 出願日	平成14年1月17日 (2002. 1. 17)		ファルマシア・アンド・アップジョン・カンパニー
(85) 翻訳文提出日	平成15年9月16日 (2003. 9. 16)		PHARMACIA & UPJOHN
(86) 国際出願番号	PCT/US2002/001971		COMPANY
(87) 国際公開番号	W02002/075507		アメリカ合衆国49001 ミシガン州カラ
(87) 国際公開日	平成14年9月26日 (2002. 9. 26)		マズー、ヘンリエッタ・ストリート301
(31) 優先権主張番号	09/809, 665		番
(32) 優先日	平成13年3月15日 (2001. 3. 15)	(74) 代理人	100081422
(33) 優先権主張国	米国 (US)		弁理士 田中 光雄
		(74) 代理人	100106231
			弁理士 矢野 正樹

最終頁に続く

(54) 【発明の名称】 抗菌性ワクチン組成物

## (57) 【要約】

グラム陰性細菌の病原性遺伝子を同定し、それによってこれらの病原性遺伝子およびその産物を標的とする新規な抗菌剤を同定することが可能となる。また、ワクチンに有用な新規なグラム陰性細菌突然変異体を提供する。

## 【特許請求の範囲】

## 【請求項 1】

配列番号：1、3、7、9、21、25、27、29、39、41、51、53、55、57、58、60、68、72、74、76、78、80、82、84、104、108、112、116、118、120、122、124、126、128、および130のいずれか1に記載のヌクレオチド配列またはその種ホモログによって表される遺伝子に突然変異を含み、ここに該突然変異が突然変異遺伝子によってコードされる遺伝子産物の活性の低下を生じるグラム陰性細菌。

## 【請求項 2】

該突然変異が、突然変異遺伝子によってコードされる遺伝子産物の発現の低下を生じる請求項1に記載のグラム陰性細菌。 10

## 【請求項 3】

該突然変異が、突然変異遺伝子によってコードされる不活性遺伝子産物の発現を生じる請求項1記載のグラム陰性細菌。

## 【請求項 4】

該突然変異が該遺伝子の全部または一部分の欠失を生じる請求項1記載のグラム陰性細菌。

## 【請求項 5】

配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172、および174のいずれか1に記載のヌクレオチド配列またはその種ホモログによって表される遺伝子に突然変異を含み、ここに該突然変異が突然変異遺伝子によってコードされる遺伝子産物の活性の低下を生じる弱毒化パストツレラ科細菌。 20

## 【請求項 6】

該突然変異が、突然変異遺伝子によってコードされる遺伝子産物の発現の低下を生じる請求項5記載のパストツレラ科細菌。 30

## 【請求項 7】

該突然変異が、突然変異遺伝子によってコードされる不活性遺伝子産物の発現を生じる請求項5記載のパストツレラ科細菌。

## 【請求項 8】

該突然変異が、該遺伝子の全部または一部分の欠失を生じる請求項5記載のパストツレラ科細菌。

## 【請求項 9】

パストツレラ(マンハイミア)ヘモリティカ(*Pasteurella (Mannheimia) haemolytica*)、パストツレラ・マルトシーダ(*Pasteurella multocida*)、アクチノパチルス・プレウロニューモニエ(*Actinobacillus pleuropneumoniae*)およびヘモフィルス・ソムナス(*Haemophilus somnus*)よりなる群から選択される請求項5記載のパストツレラ科細菌。 40

## 【請求項 10】

該突然変異が、突然変異遺伝子によってコードされる遺伝子産物の発現の低下を生じる請求項9記載のパストツレラ科細菌。

## 【請求項 11】

該突然変異が、突然変異遺伝子によってコードされる不活性遺伝子産物の発現を生じる請求項9記載のパストツレラ科細菌。

## 【請求項 12】

該突然変異が、該遺伝子の全部または一部分の欠失を生じる請求項9記載のパストツレラ科 50

細菌。

【請求項 13】

*P. multocida*細菌である請求項 9 記載の弱毒化パストレラ科細菌。

【請求項 14】

該突然変異が、突然変異遺伝子によってコードされる遺伝子産物の発現の低下を生じる請求項 13 記載のパストレラ科細菌。

【請求項 15】

該突然変異が、突然変異遺伝子によってコードされる不活性遺伝子産物の発現を生じる請求項 13 記載のパストレラ科細菌。

【請求項 16】

該突然変異が、該遺伝子の全部または一部分の欠失を生じる請求項 13 記載のパストレラ科細菌。

【請求項 17】

*A. pleuropneumoniae*細菌である請求項 9 記載の弱毒化パストレラ科細菌。

【請求項 18】

該突然変異が、突然変異遺伝子によってコードされる遺伝子産物の発現の低下を生じる請求項 17 記載のパストレラ科細菌。

【請求項 19】

該突然変異が、突然変異遺伝子によってコードされる不活性遺伝子産物の発現を生じる請求項 17 記載のパストレラ科細菌。

【請求項 20】

該突然変異が、該遺伝子の全部または一部分の欠失を生じる請求項 17 記載のパストレラ科細菌。

【請求項 21】

請求項 1 ないし 20 いずれか 1 項記載の細菌を含む免疫原性組成物。

【請求項 22】

請求項 21 記載の免疫原性組成物および医薬上許容し得る担体を含むワクチン組成物。

【請求項 23】

さらに、アジュバントを含む請求項 22 記載のワクチン組成物。

【請求項 24】

配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172、および174のいずれか1に記載のヌクレオチド配列またはその種ホモログによって表される遺伝子に突然変異を導入する工程を含み、ここに該突然変異が突然変異遺伝子によってコードされる遺伝子産物の活性の低下を生じることを特徴とするグラム陰性細菌突然変異体を作成する方法。

【請求項 25】

配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172、および174のいずれか1に記載のヌクレオチド配列またはその種ホモログによって表される遺伝子に突然変異を導入する工程を含み、ここに該突然変異が突然変異遺伝子によってコードされる遺伝子産物の活性の低下を生じること

10

20

30

40

50

を特徴とする弱毒化パストツレラ科細菌を作成する方法。

【請求項 26】

配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172、および174に記載のヌクレオチド配列よりなる群から選択されるヌクレオチド配列を含む単離および精製されたパストツレラ科細菌のポリヌクレオチド。 10

【請求項 27】

配列番号：1、3、7、9、21、25、27、29、39、41、51、53、55、57、58、60、68、72、74、76、78、80、82、84、104、108、112、116、118、120、122、124、126、128、および130に記載のヌクレオチド配列よりなる群から選択されるヌクレオチド配列を含む単離および精製されたパストツレラ科細菌のポリヌクレオチド。

【請求項 28】

a) 請求項 27 記載のポリヌクレオチド、  
b) (a) のポリヌクレオチドによってコードされるポリペプチドをコードするポリヌクレオチド、および  
c) 中程度のストリンジェンシーの条件下で (a) または (b) のポリヌクレオチドの相補体にハイブリダイズするポリヌクレオチド  
よりなる群から選択されるパストツレラ科細菌の病原性遺伝子の産物またはその種ホモログをコードする単離および精製されたポリヌクレオチド。 20

【請求項 29】

配列番号：2、4、8、10、12、14、16、18、20、22、24、26、30、32、34、38、40、42、52、54、56、59、61、69、71、73、75、77、79、81、83、85、101、103、105、107、109、111、113、115、117、119、121、123、125、127、129、131、133、135、137、139、141、143、145、147、149、151、153、155、157、159、161、165、167、169、171、173、および175に記載のアミノ酸配列を有するポリペプチドよりなる群から選択されるポリペプチドをコードする精製および単離されたパストツレラ科細菌のポリヌクレオチド。 30

【請求項 30】

DNA である請求項 29 記載のポリヌクレオチド。

【請求項 31】

請求項 30 記載の DNA を含むベクター。

【請求項 32】

DNA が発現制御 DNA 配列に制御可能に連結された発現ベクターである請求項 31 記載のベクター。 40

【請求項 33】

宿主細胞におけるコードされたポリペプチドの発現を許容するように請求項 30 記載の DNA で安定に形質転換またはトランスフェクトされた宿主細胞。

【請求項 34】

栄養培地中で請求項 33 記載の宿主細胞を培養し、ついで該宿主細胞または該栄養培地からコードされたポリペプチドを単離することを含む組換えポリペプチドを作製する方法。

【請求項 35】

請求項 34 記載の方法によって作製した精製されたポリペプチド。

【請求項 36】

配列番号：2、4、8、10、12、14、16、18、20、22、24、26、30、32、34、38、40、42、52、54、56、59、61、69、71、73、75、77、79、81、83、85、101、103、105、107、109、111、113、115、117、119、121、123、125、127、129、131、133、135、137、139、141、143、145、147、149、151、153、155、157、159、161、165、167、169、171、173、および175に記載のアミノ酸配列を有するポリペプチドよりなる群から選択されるポリペプチドを含む精製されたポリペプチド。

【請求項37】

請求項36記載のポリペプチドと特異的に反応性である抗体。

10

【請求項38】

モノクローナル抗体である請求項37記載の抗体。

【請求項39】

請求項1、5、9または13記載の細菌の抽出物と請求項38記載のモノクローナル抗体とを接触させ、ついで該モノクローナル抗体の結合の不存在を検出する工程を含む該細菌を同定するための該抗体の使用法。

【請求項40】

配列番号：2、4、8、10、12、14、16、18、20、22、24、26、30、32、34、38、40、42、52、54、56、59、61、69、71、73、75、77、79、81、83、85、101、103、105、107、109、111、113、115、117、119、121、123、125、127、129、131、133、135、137、139、141、143、145、147、149、151、153、155、157、159、161、165、167、169、171、173、および175のいずれか1に記載のアミノ酸配列によって表される遺伝子産物の発現または活性に干渉する能力について潜在的な剤をアッセイし、ついで該遺伝子産物の発現または活性に干渉する剤を同定する工程を含む抗菌剤を同定する方法。

20

【請求項41】

a) 配列番号：2、4、8、10、12、14、16、18、20、22、24、26、30、32、34、38、40、42、52、54、56、59、61、69、71、73、75、77、79、81、83、85、101、103、105、107、109、111、113、115、117、119、121、123、125、127、129、131、133、135、137、139、141、143、145、147、149、151、153、155、157、159、161、165、167、169、171、173、および175に記載の遺伝子産物の発現または活性を測定し；

30

b) (a) の遺伝子産物と試験化合物とを接触させ；

c) 試験化合物の存在下における遺伝子産物の発現または活性を測定し；ついで

d) 試験化合物の不存在下の発現または活性と比較して試験化合物の存在下では遺伝子産物の発現または活性が低下する場合に、試験化合物を抗菌剤として同定する工程を含む抗菌剤を同定する方法。

【発明の詳細な説明】

40

【技術分野】

【0001】

本願は、1999年9月10日に出願された米国仮特許出願番号60/153,453号および1999年4月9日に出願された米国仮特許出願60/128,689号の優先権を主張して2000年4月6日に出願された米国特許出願番号09/545,199号の一部継続出願である。

【0002】

本発明は、一般的に、パストレラ科細菌の病原性に寄与している遺伝子の同定に関し、それによって、ワクチンに有用な新規な弱毒化突然変異株の生成ならびに病原性遺伝子およびその産物を標的とする新しい抗菌剤の同定が可能となる。

【背景技術】

50

## 【0003】

パストレラ科細菌には、広範な種々の動物に感染する幾つかの非常に重要な病原菌が包含される。パストレラ・マルトシーダ (*P. multocida*) に加えて、その科の重要なメンバーには、パストレラ (マンハイミア) ・ヘモリチカ (*Pasteurella (Mannheimia) haemolytica*)、アクチノパチルス・プレウロニューモニア (*Actinobacillus pleuropneumoniae*) およびヘモフィルス・ソムナス (*Haemophilus somnus*) が含まれる。*P. multocida*は、グラム陰性の非運動性の球桿菌であり、それは多くの野生動物および家畜動物の正常細菌叢で見出され、世界中の多数の動物種において疾患を引き起こすことが知られている [M. Kilian, W. Frederickson および E. L. Biberstein (編), *Haemophilus, Pasteurella, and Actinobacillus*. Academic Press, Londonにおける Biberstein, 61-73 (1981)]。感染に続く疾患の発現には、敗血症、気管支肺炎、鼻炎および創傷感染症が含まれる [C. L. Gyles および C. O. Thoen (編), *Pathogenesis of Bacterial Infections in Animals*. Iowa State University Press, Amesにおける Shewen ら, 216-225 (1993) (出典明示して本明細書の一部とみなす) に概説されている]。

10

## 【0004】

*P. multocida*による感染は、一般的には、ストレスの期間の侵入に起因するが、エアロゾルまたは接触曝露による伝播も生じ得、あるいはノミおよびマダニ媒介体によっても生じ得る。家禽においては、*P. multocida*感染症は、急性ないし過急性の敗血症を生じ、特に、混雑する、産卵、換羽、または厳しい気候変動に関連したストレス条件下の国内産七面鳥および野生の水鳥において特に流行する。ウシにおいては、感染につづいて同様の出血性敗血症が発現し、高熱および鬱病を含む症状を発現し、一般的には、続いて短期に死亡する。伝播はエアロゾル接触を最も起るようであるが、感染症は顕著な気候変動の期間にも発生し得る。ウサギにおいては、感染症は、再発性化膿性鼻炎に続いて、一般的には、結膜炎、中耳炎、副鼻腔炎、皮下膿瘍および慢性気管支肺炎を生じる。重篤な感染症においては、急性の線維索性気管支肺炎、敗血症または内毒素血症によってウサギの死亡率が上昇する。疾患状態は通常ストレスの期間に発生する。ブタにおいては、普通の *P. multocida* 疾患状態には、萎縮性鼻炎および細菌性肺炎が含まれる。また、同様の肺炎の症状は、イヌ、ネコ、ヤギおよびヒツジにおいても検出される。*P. multocida*は多くの動物の口腔細菌叢において一般的に検出され、したがって、噛み傷および掻き傷における一般的な汚染菌である。

20

30

## 【0005】

*P. multocida*株は、莢膜血清群および菌体血清型によって通常指定される。5の莢膜血清群 (A、B、D、E および F) および 16の菌体血清型が、特徴的な高温安定性の抗原の発現によって区別されている。大部分の菌株は宿主特異的であって、1または2を超える動物には滅多に感染しない。伝統的な死滅全細胞細菌は通常、血清型特異的な保護しか提供しないので、異なる血清型が存在することは免疫接種に対する問題を示す。しかしながら、1の血清型での自然感染が複数の血清型に対する免疫学的保護に通じ得ること [C. L. Gyles および C. O. Thoen (編), *Pathogenesis of Bacterial Infections in Animals*. Iowa State University Press, Amesにおける Shewen ら, 216-225 (1993)]、交差保護がイン・ビボ (*in vivo*) で増殖させた不活化細菌を用いることによっても刺激し得る [Rimmler ら, *Am J Vet Res.* 42: 2117-2121 (1981)] が実証されている。1の生きている自然発生突然変異 *P. multocida* 株はワクチンとして利用されており、強力な免疫応答を刺激することが示されている [Davis, *Poultry Digest.* 20: 430-434 (1987)、Schlink ら, *Avian Dis.* 31 (1): 13-21 (1987)]。しかしながら、この弱毒化株は、ワクチン受容者がストレスに曝された場合に、病原性状態に戻るまたは死亡を引き起こすことが示されている [Davis, *Poultry Digest.* 20: 430-434 (1987)、Schlink ら, *Avian Dis.* 31 (1): 13-21 (1987)]。

40

## 【0006】

パストレラ科のもう1のメンバーである *A. pleuropneumoniae* は、ブタに対して厳密な宿主特異性を示し、高度に伝染性のブタの胸膜肺炎の原因因子である。感染は、通常、集中

50

的な育種状態で発生し、直接様式の伝播によって起ると考えられる。疾患が致死命的で、その結果、ブタ生産産業において重大な経済的損害に通じる場合もある。A. pleuropneumoniae感染症は、慢性また急性であり得、感染症は線維素性胸膜炎を伴う出血性の壊死性気管支肺炎によって特徴付けられる。現在までのところ、細菌の病原性は、血清型特異的な莢膜多糖、リポ多糖を含めた構造タンパク質、および表面タンパク質、ならびに細胞外細胞溶解性毒素に起因している。これらの病原性因子が精製され、幾つかの例においてはクローニングされているにもかかわらず、A. pleuropneumoniae感染症におけるこれらの病原性因子の正確な役割についてほとんど理解されていない。

#### 【0007】

12の血清型のA. pleuropneumoniaeが莢膜多糖における抗原性の差異および細胞外毒素の産生に基づいて同定されている。血清型1、2、5、7および9はヨーロッパにおいて優勢であるが、血清型1、5および7は、米国におけるA. pleuropneumoniae感染症に最も関連している。溶血素ファミリーのメンバーであり、RTX毒素と呼ばれるA. pleuropneumoniaeの少なくとも3の重要な細胞外毒素が存在する。RTX毒素は、イー・コリ(E. coli)、プロテウス・ブルガリリサ(Proteus vulgaris)およびパストレラ・ヘモリティカ(Pasteurella haemolytica)を含む多くのグラム陰性菌によって産生され、該タンパク質は一般的には構造的および機能的な特徴を共有している。しかしながら、様々な血清型からの毒素は、宿主特異性、標的細胞および生物活性においては異なる。

#### 【0008】

主要なA. pleuropneumoniaeのRTX毒素には、ApxI、ApxIIおよびApxIIIが含まれる。ApxIおよびApxIIは溶血活性を有しているが、ApxIの方がより強力である。ApxIIIは溶血活性を示さないが、肺胞マクロファージおよび好中球に対して細胞毒性である。大部分のA. pleuropneumoniae血清型は、これらの3の毒素のうち2を産生する。例えば、血清型1、5、9および11はApxIおよびApxIIを発現し、血清型2、3、4、6および8はApxIIおよびApxIIIを発現する。しかしながら、血清型10はApxIしか産生せず、血清型7および12はApxIIしか発現しない。ApxIおよびApxIIを共に産生するそれらのA. pleuropneumoniae血清型は、最も病原性の細菌株である。

#### 【0009】

Apx毒素は、ランダムに突然変異した野生型細菌を用いて、げっ歯類モデルおよびブタ感染における病原性因子であることが実証されている[Tasconら, Mol. Microbiol. 14: 207-216 (1994)]。また、他のA. pleuropneumoniae突然変異体も、AopA外膜病原性タンパク質をコードする遺伝子を不活化するために標的化突然変異を用いて生成されている[MulksおよびBuysee, Gene 165: 61-66 (1995)]。

#### 【0010】

新生児、離乳後の、生長しているおよび成体の子ヒツジ、子ウシおよびヤギにおける急性肺炎の重篤な大発生に寄与するパストレラ種であるMannheimia[Pasteurella] haemolytica内では少なくとも11の血清型(1、25-9、12-14および16)が実証されている[Ackermannら, Microbes Infect 2 (9): 1079-88 (2000)]。輸送、ウイルス感染、過密状態、および他のストレスを発生し得る状態は、動物をM. haemolytica感染症に罹りやすくする[Ackermannら, 前掲]。The leukotoxin (Lkt) of M. haemolyticaのロイコトキシン(Lkt)は病原性において重要な役割を果たし、ウシ輸送熱の肺病理の特徴に通じる細胞溶解およびアポトーシスならびにウシ肺炎パストレラ病における肺傷害を引起すると考えられている[Highlanderら, Infect Immun 68 (7): 3916-22 (2000)] as well as lung injury in bovine pneumonic pasteurellosis [Jeyaseelan, et al., Microb Pathog 30 (2): 59-69 (2001)]。Lktは反芻動物の白血球および血小板にのみ細胞溶解を誘導するユニークな特性を有する孔形成外毒素である[Jeyaseelanら, (2001)、前掲]。多くの細胞型の細胞溶解は、アラキドン酸(AA)によって仲介され、ホスホリパーゼによるその生成はG-タンパク質共役型受容体によって調節されている[Jeyaseelanら, (2001)、前掲]。細菌の研究ではM. haemolyticaのLktが全ベータ2インテグリンの共通のサブユニットであるウシCD18に結合することが示されている[Jeyaseelanら, Infect Immun 40

68(1): 72-9 (2000)]. また、L F A - 1 が L k t 受容体であり、L F A - 1 に対する L k t 結合は標的細胞特異的ではなく、ウシ L F A - 1 に対する L k t 結合がカルシウム上昇および細胞溶解と関連し、ウシ L F A - 1 発現が L k t - 1 によって誘導された標的細胞の細胞溶解の程度と関連することも示されている [Jeyaseelanら, *Infect Immun* 68 (1): 72-9 (2000)].

#### 【 0 0 1 1 】

ワクチン組成物を生産する試行において、伝統的な死滅全細菌では血清型特異的な保護しか提供されない [MacInnesおよびSmart、前掲]、しかしながら、強い病原性の血清型を有するものによる自然感染症が複数の血清型に対する強力な保護免疫を刺激し得ることが実証されている [Nielsen, *Nord Vet Med.* 31: 407-13 (1979)、Nielsen, *Nord Vet Med.* 36 :221-234 (1984)、Nielsen, *Can J Vet Res.* 29: 580-582 (1988)、Nielsen, *ACTA Vet Scand.* 15: 80-89 (1994)]。ApxII毒素の不活性形態を産生する1の明確な生存 - 弱毒化ワクチン株がブタにおける交差保護を提供する見込みが示されており [Prideauxら, *Infection & Immunity* 67: 1962-1966 (1999)]、一方、他の不明確な生存 - 弱毒化突然変異体も見込みが示されている [Inzanaら, *Infect Immun.*, 61: 1682-6, (1993)、International Pig Veterinary SocietyにおけるPaltineanuら, 1992, 214、International Pig Veterinary SocietyにおけるUtreraら, 1992, 213]。

10

#### 【 発明の開示 】

#### 【 発明が解決しようとする課題 】

#### 【 0 0 1 2 】

不明確で自然発生突然変異を有する細菌株を含むワクチン処方に関連する問題により、同種および異種のパスツレラ科の血清型に対して保護免疫を安全に刺激するワクチンに使用するための生存弱毒化細菌株の合理的構築について当該技術分野に要望が存在する。さらに、弱毒化細菌株および細菌の病原性に必要である遺伝子を同定する要望がさらに存在し、それによって抗菌剤を同定する方法の開発が促進される。

20

#### 【 課題を解決するための手段 】

#### 【 0 0 1 3 】

一般的には、本発明は弱毒化グラム陰性菌を含むワクチン組成物の生成、ならいびにそれを使用するための材料および方法を提供する。1の態様において、本発明のワクチン組成物は、パスツレラ科細菌における弱毒化種を含み、それは、当該技術分野において知られ、出典明示して本明細書の一部とみなすDewhirstら, *J. Bacteriol.* 174: 2002-2013 (1992) に一部記載されている。該科における種には、限定されるものではないが、*A. actinomycetemcomitans*、*A. capsulatus*、*A. equuli*、*A. lignieresii*、*A. pleuropneumoniae* (*H. pleuropneumoniae*)、*A. seminis*、*A. suis* (*H. suis*)、*A. ureae* (*p. ureae*)、*A. capsulatus*、Bisgaard分類群11、*H. aegyptius*、*H. aphrophilus*、*H. aphrophilus* (*H. parainfluenzae*)、*H. ducreyi*、*H. haemoglobinophilus*、*H. haemolyticus*、*H. influenzae*、*H. paracuniculus*、*H. paragallinarum*、*H. parahaemolyticus*、*H. parainfluenzae*、(*H. paraphrophilus*)、*H. paraphrohaemolyticus*、*H. paraphrophilus*、*H. parasuis*、*H. parasuis* タイプ5、*H. segnis*、*H. somnus*、*Haemophilus* マイナーグループ、*Haemophilus* 分類群C、*P. aerogenes*、*P. anatis*、*P. avium* (*H. avium*)、*P. canis*、*P. dagmatis*、*P. gallinarum*、*P. haemolytica*、*P. trehalosi* (*P. haemolytica* 生物型T)、*P. langaa*、*P. multocida*、*P. pneumotropica*、*P. stomatis*、*P. volantium* (*H. panainflueizae*)、*P. volantium*、*Pasteurella* 種A、*Pasteurella* 種Bおよび*Haemophilus paraphrohaemolyticus*を含む。好ましくは、ワクチン組成物は、弱毒化*Pasteurella haemolytica*、*Actinobacillus pleuropneumoniae*、*Haemophilus somnus*または*Pasteurella multocida*菌を含む。最も好ましい具体例において、本発明のワクチン組成物は、弱毒化*Pasteurella multocida*および*A. plueropneumoniae*菌株を含む。

30

40

#### 【 0 0 1 4 】

本発明の1の態様は、配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、

50



60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170および172のいずれか1によって表わされる遺伝子配列またはその種ホモログ中の機能性突然変異を含むグラム陰性菌を提供し、ここに、該突然変異は、コードされた遺伝子産物（すなわち、遺伝子によってコードされたポリペプチド）の発現および/または生物活性を阻害または廃止し；該機能性突然変異は菌株の病原性の弱毒化を生じる。遺伝子産物の発現および/または生物活性を変調させる（すなわち、増大または低下させる）機能性突然変異には、遺伝子自体の蛋白質コード領域中または、遺伝子発現の制御に寄与もしくは関与する配列中の挿入または欠失が含まれる。欠失突然変異には、特定の遺伝子配列の全部または一部分が欠失したものが含まれる。また、所望により好適なアジュバントおよび/または医薬上許容し得る希釈剤もしくは担体を含んでいてもよい、突然変異し弱毒化されたグラム陰性細菌を含む組成物、好ましくはワクチン組成物も意図する。修飾株をワクチン処方中で有効とするためには、病原菌が重篤な臨床的病徴を発生するのを防ぐのに十分に弱毒化が顕著でなければならぬが、宿主における細菌の制限された複製および増殖を許容するよう十分に顕著でないことが必要である。

10

#### 【0015】

また、本発明は、グラム陰性菌の病原性に必要であるとなる遺伝子産物をコードするポリヌクレオチドも提供する。本発明のポリヌクレオチドには、相補的DNA、相補的もしくはアンチセンスDNAを含むゲノムDNA、および全合成もしくは部分合成DNAのごときDNA；センスおよびアンチセンス鎖を含むRNA；および例えば、Corey, TIBTECH 15:224-229 (1997)に記載のごときペプチド核酸が含まれる。本発明の病原性遺伝子ポリヌクレオチドには、配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172および174に記載のもの、またはその種ホモログ、配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172および174のポリヌクレオチド、またはその種ホモログによってコードされる病原性遺伝子産物をコードするポリヌクレオチド、および中程度ないし高度にストリンジェントな条件下にて、配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172および174に記載されたポリヌクレオチド、またはその種ホモログのいずれか1の非コード鎖（または相補体）にハイブリダイズするポリヌクレオチドが含まれる。したがって、本発明は、配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、

20

30

40

50

60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172および174に記載されたパスツレラ科からの遺伝子配列、ならびに自然発生する(すなわち、種ホモログ)およびその人工的に誘導された変異型を含む他のグラム陰性菌からの関連する遺伝子配列を包含する。また、本発明は、配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、164、166、168、170、172および174に記載されたポリヌクレオチドおよびその種ホモログのいずれか1から推定されるポリペプチドをコードするポリヌクレオチドも包含する。本発明のポリヌクレオチドの配列の知識により、そのポリヌクレオチドの全ての可能な断片の入手が容易となる。したがって、本発明は、本発明のポリヌクレオチドの断片を提供する。

10

## 【0016】

本発明は、本発明のポリヌクレオチドを含む発現構築体をもさらに包含する。また、本発明のポリヌクレオチドで形質変換した、トランスフェクトした、または電気穿孔した宿主細胞も包含する。本発明は、本発明のポリヌクレオチドによってコードされるポリペプチドを生成するための方法を提供し、それは、該ポリヌクレオチドによってコードされる遺伝子産物の発現を許容し、好ましくは促進する条件下にて本発明の宿主細胞を増殖させ、ついで該宿主細胞またはその増殖培地から遺伝子産物を単離する工程を含む。

20

## 【0017】

本発明のポリヌクレオチドの同定により、コード化されたポリペプチドが入手可能となる。本発明のポリペプチドには、同類アミノ酸置換が野生型ポリペプチドに導入されたものを含む、完全長または断片、または切形タンパク質；その変異型；融合またはキメラタンパク質；およびアナログが含まれる。また、本発明のポリペプチドを特異的に認識する抗体も提供し、それにはモノクローナルおよびポリクローナル抗体、単一鎖抗体、キメラ抗体、ヒト化抗体、ヒト抗体および相補性決定領域(CDR)-移植抗体、ならびに本発明のポリペプチドを特異的に認識するCDR配列を含む化合物が含まれる。また、本発明は、本発明の抗体に免疫特異的な抗イディオタイプ抗体も提供する。

30

## 【0018】

本発明のもう1の態様によれば、グラム陰性菌の病原性遺伝子または遺伝子産物の機能を変調する、新規な抗菌剤を同定するための方法を提供する。本発明の方法には、配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172および174のいずれか1に記載されたDNA配列またはその種ホモログによってコード化される病原性遺伝子産物の発現を干渉する能力についての潜在的剤をスクリーニングし、または全体的または部分的に配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135

40

50

、 136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172 および 174 のいずれか 1 に記載された DNA 配列、その種ホモログまたはその相補鎖によってコードされる細菌遺伝子産物の生物機能に干渉する能力につき潜在的剤をスクリーニングし、続いてかかるスクリーニングアッセイにおいてポジティブな結果を供する剤を同定することが含まれる。特に、病原性遺伝子産物の発現に干渉する剤には、病原性遺伝子配列に相補的であるアンチセンスポリヌクレオチドおよびリボザイムが含まれる。本発明は、さらに、オリゴヌクレオチド指令の三重らせん形成の使用を介する本発明の遺伝子産物の転写を変調する方法も包含する。

【0019】

病原性遺伝子産物の機能に干渉する剤には、病原性遺伝子産物の変異型、病原性遺伝子産物の結合パートナーおよびかかる結合パートナーの変異型および（該産物が酵素である場合には）酵素阻害物質を含む。

【0020】

本明細書に記載した方法によって同定された新規な抗菌剤、ならびに細菌の存在を減少させるのに有効な量のかかる新規な抗菌剤の投与を含むグラム陰性菌による感染症に苦しむ対象を治療する方法が提供される。

【0021】

本発明の多数のさらなる態様および利点は、現在準備されたその具体例を記載する以下の発明の詳細な説明を考慮すれば、当業者に明らかとなるであろう。

【0022】

本明細書で用いる「病原性遺伝子」は、機能または産物が宿主動物における細菌感染症の首尾よい確立および/または維持に必要である遺伝子である。したがって、病原性遺伝子および/またはそれによってコードされるタンパク質は、宿主生物における病理に関係するが、増殖には必要ではないかもしれない。

【0023】

本明細書で用いる「シグニチャータグド (signature-tagged) 突然変異 (STM)」は、一般的には、国際公開 WO 96 / 17951 (ここに出典明示して本明細書の一部とみなす) に記載された方法であり、例えば、菌血症のげっ歯類モデルにおける病原性に必要な細菌遺伝子を同定する方法を含む。この方法においては、各々がゲノム中にランダムな突然変異を有する菌株をトランスポゾン組込みを用いて作成し；各挿入突然変異は、突然変異体を互いに区別することを可能とする異なる DNA シグニチャータグ (signature-tag) を運搬する。該タグは、20塩基対の不変の「アーム」によって隣接してはさまれた 40塩基対の可変中央領域を含み、それは、中央部分がポリメラーゼ鎖反応 (PCR) によって共増幅されることを可能とする。タグを付した突然変異株はマイクロタイター皿中で組立て、ついで感染試験のための「接種物プール」を形成するために合する。接種後の適当な時点にて、細菌は動物から単離され、プールして「回収プール」を形成する。回収プール中のタグおよび接種プール中のタグは、別々に増幅し、標識し、ついでそれを用いて、接種源中の突然変異体を示す異なるタグの全てで整列したフィルターを調べる。弱毒化病原性を持つ突然変異株は、感染した動物から回収できないものであり、すなわち、回収プールからのタグで調べた場合にはハイブリダイゼーションシグナルを示さないが、接種プールからのタグで調べた場合にはハイブリダイゼーションシグナルを与えるタグを持つ株である。この方法の変形において、化学ルミネセンスのごとき非放射性的の検出法を用いることができる。

【0024】

シグニチャータグド突然変異は、多数の挿入突然変異株を、病原性の欠失につき単一の動物において同時にスクリーニングすることを可能とする。突然変異体 *P. multocida* 株の 19 のプールのスクリーニングにより、病原性が低下した 60 を超える株を同定し、その多数は、個々の突然変異体についておよそ  $LD_{50}$  のその後の決定によって病原性が弱毒化されることが確認された。*A. pleuropneumoniae* 突然変異体のスクリーニングにより、

10

20

30

40

50

35の異なる遺伝子中に突然変異を有する100を超える株を同定した。これらのうち、22の遺伝子中の突然変異は顕著に弱毒化された*A. pleuropneumoniae*株を生じた。トランスポゾン挿入によって破壊されたオープン・リーディング・フレームのヌクレオチド配列は、両鎖を配列決定し、コードされるアミノ酸配列を推定することによって決定した。ポリヌクレオチドおよびアミノ酸配列の双方の新規性は、DNAおよびタンパク質のデータ・ベース配列と該配列との比較によって決定した。これらの種における病原性遺伝子の知識は、*P. (Mannheimia) haemolytica*中の種ホモログの同定を可能とした。

#### 【0025】

細菌および、より詳細には、*P. multocida*、*A. pleuropneumoniae*および*P. (Mannheimia) haemolytica*病原性遺伝子の同定は、ワクチンに有用である低下した病原性を示す微生物（すなわち、弱毒化株）のために提供された。かかる微生物には、配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172および174のいずれか1によって表わされる遺伝子を不活化する少なくとも1の機能性突然変異を含むPasteurellaceae突然変異体を含む。当業者ならば、「機能性突然変異」が、本発明の遺伝子のタンパク質コード領域、ならびに病原性遺伝子のRNAの転写を調節する調節領域において生じ得ることを認識するであろう。

#### 【0026】

また、当業者ならば、本発明の弱毒化*P. multocida*、*A. pleuropneumoniae*および*P. (Mannheimia) haemolytica*株が1を超える機能性突然変異を有するものを含むことを認識するであろう。1を超える突然変異は付加的または相乗的な程度の弱毒化を生じ得る。設計によって複数の突然変異を調製できるか、または元来単一の突然変異を導入することを意図した欠失事象から偶然に発生し得る。複数の欠失を持つ弱毒化株の例は、*cya*および*crp*の遺伝子が機能的に欠失した*Salmonella typhimurium*株である。この突然変異体*S. typhimurium*株は、生ワクチンとしての見込みを示している。

#### 【0027】

*P. multocida*、*A. pleuropneumoniae*および*P. (Mannheimia) haemolytica*における病原性遺伝子の同定は、他の病原性種における同様の遺伝子に関する情報を提供できる。例えば、*aroA*遺伝子の同定は、*Aeromonas hydrophila*、*Aeromonas salmonicida*、*Salmonella typhimurium*、*Salmonella enteritidis*、*Salmonella dublin*、*Salmonella gallanarum*、*Bordetella pertussis*、*Yersinia enterocolitica*、*Neisseria gonorrhoeae*および*Bacillus anthracis*を含む種々の多数の病原体に保存された遺伝子の同定に導く。これらの種の多くにおいて、*aroA*遺伝子中に突然変異を持つ弱毒化菌株が、ワクチン処方にも有効であることが判明した。*P. multocida*中で同定された病原性遺伝子配列を用いれば、同様または同族の遺伝子を他の生物、特に、*Pasteurella*科ならびに*A. pleuropneumoniae*、*P. (Mannheimia) haemolytica*および*Haemophilus somnus*において同定できる。同様に、*A. pleuropneumoniae*病原性遺伝子の同定は、他の生物中の関連する遺伝子の同定を可能とする。プローブとして*P. multocida*、*A. pleuropneumoniae*および*P. (Mannheimia) haemolytica*遺伝子を用いるサザンハイブリダイゼーションは、他の生物に由来する染色体ライブラリー中のこれらの関連する遺伝子を同定できる。別法として、PCRは、種の境界を超えて遺伝子同定に等しく有効となり得る。また、さらにもう1の別法として、例えば、他の種からの染色体ライブラリーを有する*P. multocida*突然変異体の相補性を用いて、同一または関連する病原活性を有する遺伝子を同定できる。したがって、関連する病原性遺伝子の同定は、なおもう1のワクチン処方として有用となり得る他の生物の弱毒化株の作成に導くことができる。他の種（例えば、*P. (Mannheimia) haemolytica*、*A. pleuropneumoniae*および*H. somnus*）に存在することが実証された*P. multocida*遺伝子の例には、遺伝子*exbB*、*atpG*

、 pnp、 guaBおよび yjpf が含まれる。

【 0 0 2 8 】

S T M を用いて同定された弱毒化 *P. multocida* 株は、病原性遺伝子がオープン・リーディング・フレームまたは調節 D N A 配列のいずれかの中におけるトランスポゾン配列の挿入によって機能性を失った挿入突然変異体である。

これらの挿入突然変異体には、いまだ細菌病原性に必要な遺伝子情報のすべてが含まれており、挿入されたトランスポゾンの欠失によって病原性状態におそらく復帰し得る。したがって、ワクチン処方調製することにおいては、弱毒化株から拾い集めた情報を収集し、幾分か、大部分のまたは全ての病原性遺伝子配列が除去された欠失突然変異株を作成し、それによって細菌が病原性状態に復帰する可能性を排除することが望ましい。

10

【 0 0 2 9 】

S T M を用いて同定した弱毒化挿入突然変異体のワクチン特性は同一遺伝子中に欠失を有する細菌のものと同様または類似していることが予想される。しかしながら、挿入突然変異が隣接する遺伝子配列に対して“極性”効果を発揮する場合があります、その結果、挿入突然変異体が同一の遺伝子配列中に欠失を有する突然変異株とはことなる特徴を有する場合もある。欠失突然変異体は、当該技術分野でよく知られており、かつ日常的に実施されている多くの技術のいずれかを用いて作製し得る。

【 0 0 3 0 】

1 の例において、対選択可能な (counterselectable) マーカーを用いる戦略が使用でき、それは多くの細菌中の遺伝子を欠失するために一般的に利用されている。概説については、例えば、Reyratら、*Infection and Immunity* 66: 4011-4017 (1998) (ここに出典明示して本明細書の一部とみなす) を参照されたい。この技術において、二重の選択戦略がしばしば用いられ、ここでは、目的とする欠失の両側に由来するフランキング D N A 配列を用いて、選択可能および対選択可能なマーカーの両方をコードするプラスミドを構築する。選択可能なマーカーを用いて、適当な場所および様式でプラスミドがゲノムに組み込まれた細菌について選択する。対選択可能なマーカーは、組み込まれたプラスミドを自然に失った非常に低いパーセントの細菌について選択するために用いる。その場合、これらの細菌の画分は、他の外来 D N A が全く存在しない目的の欠失のみを含むであろう。この技術を用いる鍵は、好適な対選択可能なマーカーの入手性である。

20

【 0 0 3 1 】

もう 1 の技術において、D N A の部位特異的組換えに cre-lox 系を用いる。該系は 3 4 塩基対の lox 配列からなり、これは細菌 cre リコンビナーゼ遺伝子によって認識される。lox 部位が適当な向きで D N A 中に存在しない場合には、lox 部位によって挟まれた D N A が cre リコンビナーゼによって切除され 1 の残存する lox 配列のコピー以外の全ての配列の欠失を生じる。標準的な組換え技術を用いると、*P. multocida*、*A. pleuropneumoniae* または *P. (Mannheimi) haemolytica* のゲノム中の目的の標的化遺伝子を欠失し、それと lox 部位によって挟まれた選択可能なマーカー (例えば、カナマイシン耐性をコードする遺伝子) とを入替えることが可能である。( *P. multocida*、*A. pleuropneumoniae* または *P. (Mannheimia) haemolytica* 中で機能するプロモーターの制御下で cre 遺伝子を誘発する自殺プラスミドの電気穿孔による ) cre リコンビナーゼの一時的発現は、lox に挟まれたマーカーの有効な除去を生じるにちがいない。このプロセスは、目的の欠失突然変異および lox 配列の 1 のコピーを含む突然変異体を生じるであろう。選択可能および対選択可能なマーカーの双方をコードし、隣接してはさまれた D N A 配列は、所望の欠失の両側から誘導される。選択可能なマーカーを用いて、該プラスミドが適当な位置および様式でゲノム中に組み込まれた細菌を選択する。対選択可能なマーカーを用いて、統合されたプラスミドを自発的に消失される非常に低いパーセンテージの細菌について選択する。ついで、これらの細菌の画分は、他の外来性 D N A が存在しない所望の欠失だけを含む。この技術の使用のための鍵は、適当な対選択可能なマーカーの有効性である。

30

40

【 0 0 3 2 】

もう 1 の技術において、cre-lox 系を D N A の部位特異的な組換えに用いる。この系は、

50

細菌性cre組換え酵素遺伝子によって認識される34塩基対のlox配列よりなる。該lox部位が、適当な配向でDNA中に存在するならば、lox部位によって隣接してはさまれたDNAは、cre組換え酵素によって切り取られ、その結果、残りの1コピーのlox配列を除き全配列を欠失する。標準的組換え技術を用いて、*P. multocida*または*A. pleuropneumoniae*ゲノム中の注目する標的とされた遺伝子を欠失し、それを該lox部位によって隣接してはさまれた選択可能な標識（例えば、カナマイシン耐性につきコードする遺伝子）と置換することが可能である。cre組換え酵素の（*P. multocida*または*A. pleuropneumoniae*において機能するプロモーターの制御下、cre遺伝子を含む自殺プラスミドの電気穿孔による）一過性発現は、loxが隣接してはさむマーカーの効果的な消失を生じさせるであろう。このプロセスの結果、突然変異体は、所望の欠失突然変異および1コピーのlox配列を含む

10

## 【0033】

もう1のアプローチにおいて、*P. multocida*、*A. pleuropneumoniae*または*P. (Mannheimia) haemolytica*のゲノム中の所望の欠失配列とグリーン蛍光タンパク質（GFP）、 $\beta$ -ガラクトシダーゼまたはルシフェラーゼのごときマーカー遺伝子とを直接的に置換することが可能である。この技術において、所望の欠失を隣接してはさむDNAセグメントをPCRによって調製し、*P. multocida*、*A. pleuropneumoniae*または*P. (Mannheimia) haemolytica*用の自殺（複製しない）ベクターにクローニングする。*P. multocida*、*A. pleuropneumoniae*または*P. (Mannheimia) haemolytica*中で活性なプロモーター、および適当なマーカー遺伝子を含む発現カセットは、フランキング配列の間にクローニングする。該

20

## 【0034】

これらの生物の低下した病原性およびそれらの免疫原性は、対象動物への投与によって確認し得る。本発明の非発病性の微生物については単独で投与できるが、1またはそれを超えるかかる突然変異体微生物は、好適なアジュバントおよび医薬上許容される希釈剤または担体を含むワクチン組成物で好ましくは投与する。担体は本発明の非病原性微生物と適合し得、免疫化する対象に有害でないという意味において「許容される」ものでなければならぬ。典型的には、該担体は、無菌で発熱物質が存在しない水または塩類溶液であろう。免疫化すべき対象は、病原性形態の*P. multocida*、*A. pleuropneumoniae*、*P. (Mannheimia) haemolytica*または他の病原微生物によって引き起こされる疾患から保護する必要がある対象である。

30

## 【0035】

本発明のワクチンがヒト医学および獣医学の分野で有用であり得ることは、認識されるであろう。したがって、免疫化すべき対象には、ヒトまたは他の動物、例えば、ウシ、ヒツジ、ブタ、ウマ、ヤギおよび家禽（例えば、ニワトリ、シチメンチョウ、アヒルおよびガチョウ）を含む農業動物、イヌおよびネコのような愛玩動物；新種の動物および/または動物園動物；ならびにマウス、ラット、ウサギ、モルモットおよびハムスターを含む実験動物が含まれる。

40

## 【0036】

また、本発明は、*P. multocida*、*A. pleuropneumoniae*または*P. (Mannheimia) haemolytica*の病原性に必要なポリペプチドおよび対応するポリヌクレオチドも提供する。本発明には、天然に存在するおよび天然に存在しないポリヌクレオチドおよびそのポリペプチド産物の双方が含まれる。天然に存在する病原性産物には、異なる遺伝子およびポリペプチド種、ならびに*P. multocida*、*A. pleuropneumoniae*または*P. (Mannheimia) haemolytica*株以外の生物において発現される対応する種ホモログが含まれる。天然に存在しない病原性産物には、共有結合修飾を含むアナログおよび病原性産物のごとき天然に存在する産物

50

の変異型が含まれる。好ましい具体例において、本発明は、配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172および174に記載された配列、およびその種ホモログを含む病原性ポリヌクレオチド、ならびに該ポリヌクレオチドによってコードされるアミノ酸配列を有するポリペプチドを提供する。

10

【0037】

本発明は、細菌の病原性遺伝子産物をコードする新規な精製され、単離された*P. multocida*、*A. pleuropneumoniae*および*P. (Mannheimia) haemolytica*のポリヌクレオチド（例えば、DNA配列およびRNA転写物、センス鎖および相補的アンチセンス鎖の双方）を提供する。本発明のDNA配列には、ゲノミックおよびcDNA配列ならびに全体または部分的に化学合成したDNA配列が含まれる。本発明のゲノミックDNAには、本発明のポリペプチドについてのタンパク質コード領域が含まれ、同一種の他の菌株において見出され得る変異型が含まれる。本明細書中で用い、また、当該技術分野において理解されている「合成（された）」とは、酵素的とは反対の純粋に化学的なポリヌクレオチドを製造する方法をいう。したがって、「全（体）」合成したDNA配列は全体的に化学的手段によって作製され、「部分（的）」合成したDNAは、得られたDNAの一部分だけを化学的手段によって作製したものを含む。*P. multocida*病原性遺伝子産物をコードする好ましいDNAは、配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118および120ならびにその種ホモログに記載されている。病原性遺伝子産物をコードする好ましい*A. pleuropneumoniae*のDNA配列は、配列番号：122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163および164ならびにその種ホモログに記載されている。好ましい*P. (Mannheimia) haemolytica*の病原性遺伝子産物は、配列番号：166、168、170、172および174ならびにその種ホモログに記載されている。当業者であれば、本発明の好ましいDNAが、二本鎖分子、例えば配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172および174およびその種ホモログに記載の配列を有する分子を、DNA

20

30

40

50

9、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118および120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172および174に記載されたポリヌクレオチドおよびその種ホモログのいずれか1によってコードされる遺伝子産物をコードするポリヌクレオチドが好ましい。さらに、本発明は、*P. multocida*、*A. pleuropneumoniae*および*P. (Mannheimia) haemolytica*のDNAの種、好ましくは細菌ホモログを含む。

【0038】

本発明によって提供されるポリヌクレオチド配列情報は、サザーンおよび/またはノーザンハイブリダイゼーションおよびポリメラーゼ連鎖反応(PCR)を含むよく知られた技術によって、関連する細菌の病原性分子をコードするポリヌクレオチドの同定および単離を可能とする。関連するポリヌクレオチドの例は、配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172および174に記載されたポリヌクレオチドおよびその種ホモログのいずれか1によってコードされる病原性遺伝子産物に相同的なポリペプチド、ならびに本発明の病原性遺伝子産物の1以上の生物学的および/または物理的特性を共有する構造的に関連するポリペプチドをコードするポリヌクレオチドが含まれる。

【0039】

また、本発明には、中程度ないし高度のストリンジェント条件下で、配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118および120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172および174に記載されたポリヌクレオチドおよびその種ホモログのいずれか1の非コード鎖または相補体にハイブリダイズする細菌の遺伝子産物をコードするDNA配列も包含される。遺伝暗号の縮重を除いてそれらにハイブリダイズする病原性ポリペプチドをコードするDNA配列も本発明によって意図される。例示的な高度のストリンジェンシー条件には、65 ないし75 の0.2×SSC/0.1%SDSを含む緩衝液中の最終洗浄が含まれ、一方、例示的な中程度のストリンジェンシー条件には、35 ないし45 の2×SSC/0.1%SDSを含む緩衝液中の最終洗浄が含まれる。同等のストリンジェンシーの条件を、Ausubelら(編), *Protocols in Molecular Biology*, John Wiley & Sons(1994), 6.0.3ないし6.4.10頁に記載された温度および緩衝液または塩濃度を変化させることによって達成できることは当該技術分野において理解されている。ハイブリダイゼーション条件における修飾は、プローブの長さおよびグアノシン/シトシン(GC)の塩基対合のパーセンテージに基いて経験的に決定でき、または正確に計算できる。ハイブリダイゼーション条件は、Sambrookら(編), *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York(1989), 9.47ないし9.51頁に記載されているごとく算出し得る。

【0040】

また、病原性遺伝子配列を取込むプラスミドおよびウイルスDNAベクターのごとき自律複製性の組換え発現構築体も提供する。また、病原性ポリペプチドをコードするポリヌク

10

20

30

40

50



レオチドが内因性または外因性の発現制御DNA配列および転写ターミネーターに作動可能に連結された発現構築体も提供する。病原性遺伝子は、鋳型として*P. multocida*ゲノムDNAを用いるPCRによってクローン化し得る。発現ベクターに遺伝子を簡単に挿入するために、PCRプライマーは、PCR増幅した遺伝子が開始コドンATGに先行する5'末端に制限酵素部位を有し、かつ終止コドンTAG、TGAまたはTAAの下流の3'末端に制限酵素部位を有するようにPCRプライマーを選択する。望ましい場合には、遺伝子中のコドンを、GrosjeanおよびFiers, *Gene*, 18: 199-209 (1982)、ならびにKonigsbergおよびGodson, *Proc. Natl. Acad. Sci. (USA)*, 80:687-691 (1983)によって記載された*E. coli*コドン優先度に従ってアミノ酸を変化することなく変化させる。*E. coli*中で産生された場合、コドン使用の最適化は、遺伝子産物の発現の増加に導き得る。遺伝子産物が*E. coli*または他の細菌のペリプラズム中または細胞培養基へのいずれかで細胞外に産生される場合には、遺伝子はその開始コドンなくしてクローン化し、シグナル配列の背後で発現ベクターに位置する。

10

#### 【0041】

本発明のもう1の態様によれば、本発明の病原性ポリペプチドを発現できる様式で本発明のポリヌクレオチド配列で安定してまたは一時的に形質変換した、トランスフェクトしたまたは電気穿孔した原核生物および真核細胞を含む宿主細胞を提供する。本発明の発現系には、細菌、酵母、真菌、ウイルス、無脊椎動物および哺乳動物の細胞系が含まれる。本発明の宿主細胞は、病原性遺伝子産物と特異的に免疫反応する抗体を発生させるための価値ある免疫原である。本発明の宿主細胞は、細胞を好適な培養基で増殖させ、目的のポリペプチド産物を細胞からかまたは細胞を増殖させた培養基から、例えば当該技術分野でよく知られており、日常的に実施されている免疫アフィニティー精製または多くの精製技術のうちのいずれかによって単離する。*E. coli*、*P. multocida*、*Bacillus*および*S. aureus*を含む他の細菌、*Pichia pastoris*および*Saccharomyces cerevisiae*を含む酵母、昆虫細胞またはCHO細胞を含む哺乳動物細胞のごときいずれの好適な宿主細胞も、当該技術分野において知られている好適なベクターを利用して、遺伝子産物の発現のために用いることができる。タンパク質は、細菌細胞の細胞周辺腔へ、または細胞培養基への分泌によって細胞内または細胞外のいずれかで直接的に産生されるか、あるいはペプチドまたはポリペプチドに融合し得る。タンパク質の分泌には、シグナルペプチド(プレ配列としても知られている)を必要とし;原核生物および真核生物からの多数のシグナル配列が組換えタンパク質の分泌のために機能することが知られている。タンパク質分泌プロセスの間に、シグナルペプチドはシグナルペプチターゼによって除去されて成熟タンパク質が得られる。

20

30

#### 【0042】

タンパク質精製プロセスを単純化するために、精製タグを遺伝子コード配列の5'または3'末端のいずれかに付加できる。一般的に使用される精製タグには、6のヒスチジン残基のストレッチ(米国特許第5,284,933号および第5,310,663号)、SchmidtおよびSkerra, *Protein Engineering*, 6: 109-122 (1993)によって記載されているストレプトアビジン-親和性タグ、FLAGペプチド[Hoppら, *Biotechnology*, 6: 1205-1210 (1988)]、グルタチオンS-トランスフェラーゼ[SmithおよびJohnson, *Gene*, 67:31-40 (1988)]、およびチオレドキシシン[La Vallieら, *Bio/Technology*, 11: 187-193(1993)]が含まれる。これらのペプチドまたはポリペプチドを取り除くために、タンパク質分解切断認識部位を融合接合部に挿入できる。一般的に使用されるプロテアーゼは、因子Xa、トロンピンおよびエンテロキナーゼである。

40

#### 【0043】

また、本発明は、本発明のポリヌクレオチドによってコードされる精製および単離された*P. multocida*、*A. pleuropneumoniae*および*P. (Mannheimia) haemolytica*病原性ポリペプチドも提供する。配列番号: 1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、

50

106、108、110、112、114、116、118および120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、164、166、168、170、172および174に記載されたポリヌクレオチドならびにその種ホモログのいずれか1によってコードされたアミノ酸配列を含むポリペプチドが現在好ましい。本発明は、a) 配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、164、166、168、170、172および174ならびにその種ホモログのいずれか1に記載されたDNA配列；b) 配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、164、166、168、170、172および174のいずれか1によってコードされた*P. multocida*、*A. pleuropneumoniae*または*P. (Mannheimia) haemolytica*のポリペプチドをコードするDNA分子ならびにその種ホモログ；およびc) 中程度のストリンジェンシー条件下にて、(a)または(b)のDNAにハイブリダイズする病原性遺伝子産物をコードするDNA分子よりなる群から選択されるDNAによってコードされる病原性ポリペプチドを包含する。

10

20

#### 【0044】

本発明は、本発明の好ましいポリペプチドに対して、少なくとも約99%、少なくとも約95%、少なくとも約90%、少なくとも約85%、少なくとも約80%、少なくとも約75%、少なくとも約70%、少なくとも約65%、少なくとも約60%、少なくとも約55%、および少なくとも約50%の同一性および/または相同性を有するポリペプチドも包含する。本発明の好ましいポリペプチドに関するパーセント(%)アミノ酸配列「同一性」とは、病原性遺伝子産物配列と候補配列の両方を並べて、必要ならギャップを導入して、最大パーセント配列同一性を達成した後の病原性遺伝子産物配列中の残基と同一である候補配列中のアミノ酸残基のパーセンテージとして本明細書中では定義し、配列同一性の部分としていずれの保存的置換も考慮していない。本発明の好ましいポリペプチドに関する%配列「相同性」は、候補配列と病原性遺伝子産物の配列の両方を並べて、必要ならギャップを導入して最大%配列同一性を達成した後の病原性遺伝子産物配列中の残基と同一である候補配列中のアミノ酸残基のパーセンテージとして本明細書中では定義し、配列同一性の一部分としていずれの同類置換も考慮しない。同類置換は、表AおよびBに掲載するように定義し得る。

30

#### 【0045】

#### 【表1】

40

表 A  
同類置換 I

側鎖の特徴		アミノ酸
脂肪族	非極性	GAP ILV
	極性-非荷電	CSTM NQ
	極性-荷電	DE KR
芳香族		HFWY
その他		NQDE

10

## 【0046】

本発明のポリペプチドは、天然の細菌細胞起源から単離するかまたは化学合成し得るが、好ましくは本発明の宿主細胞を含む組換え法によって生成する。本発明の病原性遺伝子産物は、完全長ポリペプチド、生物学的に活性なフラグメント、または特異的な生物学的もしくは免疫学的な活性を保持するそれらの変異型とし得る。変異型には病原性ポリペプチドアナログが含まれ、そこにおいては、(1)病原性遺伝子産物に特異的な1またはそれを超える生物学的活性または免疫学的特徴を喪失することなく；あるいは(2)病原性遺伝子産物の特定の生物学的活性の特定の不能性を有しつつ、1またはそれを超える特定の(すなわち、天然にコードされた)アミノ酸が欠失または置換されているか、あるいは1またはそれを超える非特定のアミノ酸が付加されている。意図する欠失変異型には、生物学的活性に必須でないポリペプチドの部分に欠いているフラグメントも含まれ、挿入変異型には野生型ポリペプチドまたはそのフラグメントがもう1のポリペプチドに融合している融合ポリペプチドが含まれる。

20

## 【0047】

変異型病原性ポリペプチドには、本発明のポリペプチドをコードするポリヌクレオチドの改変によって同類置換が導入されているものが含まれる。同類置換は、その関連する物理学的特性に従ってアミノ酸を分類することと当該技術分野では認識されており、(1997年3月13日公開の国際公開W0 97/09433、10頁(9/6/96出願のPCT/GB96/02197)から引用する)表Aに掲載したごとく定義し得る。また、同類アミノ酸は、表Bに掲載したごとくLehninger, [Biochemistry, 第2版; Worth Publishers, Inc.社 NY: NY (1975), pp71-77]で定義されているごとくグループ分けすることもできる。

30

## 【0048】

## 【表2】

表 B  
同類置換 II

側鎖の特徴	アミノ酸
非極性 (疎水性)	
A. 脂肪族:	A L I V P
B. 芳香族:	F W
C. 含硫黄原子:	M
D. 境界:	G
非電荷一極性	
A. ヒドロキシル:	S T Y
B. アミド:	N Q
C. スルフヒドリル:	C
D. 境界:	G
プラスに帯電 (塩基性):	K R H
マイナスに帯電 (酸性):	D E

10

## 【 0 0 4 9 】

本発明の変異型病原性産物には、成熟病原性遺伝子産物、すなわちリーダー配列またはシグナル配列が除去され、さらなるアミノ末端残基を有するものが含まれる。ポジション - 1 にさらなるメチオニン残基を有する病原性遺伝子産物は、ポジション - 2 および - 1 にさらなるメチオニンおよびリシン残基を有する病原性産物と同様に意図される。これらの型の変異型は、細菌細胞型における組換えタンパク質産生に特に有用である。本発明の変異型には、他のタンパク質に由来するアミノ末端配列が導入されている遺伝子産物、ならびに天然発生タンパク質には見出されないアミノ末端配列を含む変異型も含まれる。

20

## 【 0 0 5 0 】

本発明は、特定の発現系の使用から生じるさらなるアミノ酸残基を有する変異型ポリペプチドをも包含する。例えば、グルタチオン - S - トランスフェラーゼ (G S T) との融合タンパク質として目的のポリペプチドを発現する市販のベクターを使用することにより、目的のポリペプチドから G S T 成分を切断した後にポジション - 1 にさらなるグリシン残基を有する目的のポリペプチドが得られる。他のベクター系を用いる発現から生じる変異型も意図される。

30

## 【 0 0 5 1 】

また、本発明によって意図されるのは、抗体 (例えば、本発明のポリペプチドを特異的に認識する C D R 配列を含む複合物を含む、モノクローナルおよびポリクローナル抗体、一本鎖抗体、キメラ抗体、ヒト化、ヒトおよび C D R - グラフト抗体) ならびに病原性遺伝子産物またはそのフラグメントに特異的な他の結合タンパク質である。「~ に特異的な」なる語は、本発明の抗体の可変領域が排他的に病原性ポリペプチドを認識し、かつ、それに結合する (すなわち、ポリペプチドのファミリーに見出される配列の同一性、相同性または類似性にかかわらず、関連する病原性ポリペプチドから単一の病原性ポリペプチドを識別し得る) が、抗体の可変領域の外側の配列、特に分子の定常領域中の配列との相互作用を介して他のタンパク質 (例えば、E L I S A 技術においてはエス・アウレウス (S. aureus) プロテイン A または他の抗体) とも相互作用し得ることを示す。本発明の抗体の結合特異性を測定するスクリーニング・アッセイはよく知られており、当該技術分野で日常的に行われている。かかるアッセイの包括的な議論については、Harlowら (編), *Antibodies A Laboratory Manual*; Cold Spring Harbor Laboratory; Cold Spring Harbor, N Y (1988), 第 6 章を参照されたい。本発明の病原性ポリペプチドのフラグメントを認識し、かつ、それに結合する抗体も意図されるが、但し、当該抗体は、前記に定義したごとく、それからフラグメントが由来する本発明の病原性ポリペプチドに第一にかつ最先に特異

40

50

的である。

【0052】

本発明により提供されるDNAおよびアミノ酸配列情報により、病原性遺伝子およびそれがコードする遺伝子産物の構造および機能の体系的な分析が可能となる。本発明の病原性遺伝子産物をコードするポリヌクレオチドの知見により、本発明の病原性ポリペプチドをコードするポリヌクレオチドを認識し、かつ、それにハイブリダイズするアンチセンス・ポリヌクレオチドも利用可能となる。完全長およびフラグメントのアンチセンス・ポリヌクレオチドが提供される。当業者であれば、本発明のフラグメントのアンチセンス分子に、(i) (他の公知分子をコードするDNAに対する本発明の病原性ポリペプチドをコードするDNAの配列比較によって決定される) 特定のRNAを特異的に認識し、かつ、それにハイブリダイズするもの、ならびに(ii) 病原性タンパク質のファミリーの変異型をコードするRNAを認識し、かつ、それにハイブリダイズするものが含まれることを認識するであろう。タンパク質の病原性ファミリーの他のメンバーをコードするRNAにハイブリダイズするアンチセンス・ポリヌクレオチドは、配列比較を介して同定可能であり、分子のファミリーにつき特徴的または顕著な(signature)配列を同定する。

10

【0053】

さらに、本発明は、リボザイムの使用を介して遺伝子発現をモジュレートする方法も意図する。概説については、GibsonおよびShillitoe, Mol. Biotech. 7: 125-137 (1997)を参照されたい。リボザイム技術を利用して、(i) 標的mRNAへの相補的RNAのハイブリダイゼーション、および(ii) 相補鎖に固有のヌクレアーゼ活性を介するハイブリダイズしたmRNAの切断、を介する配列特異的な方法でmRNAの翻訳を阻害し得る。リボザイムは経験的な方法によって同定し得るが、より好ましくは標的mRNA上のアクセス可能な部位に基づいて特異的に設計する[Bramlageら, Trends in Biotech., 16:434-438 (1998)]。標的細胞へのリボザイムのデリバリーは、当該技術分野でよく知られておりかつ日常的に行われている外因的または内因的のいずれかのデリバリー技術を用いて行い得る。外因的デリバリー法には、標的化リボソームまたは直接局所注射の使用が含まれ得る。内因的な方法には、ウイルスベクターおよび非-ウイルスプラスミドの使用が含まれる。

20

【0054】

リボザイムは、病原性遺伝子産物をコードするポリヌクレオチドにユニークな領域に相補的になるよう設計した場合、病原性遺伝子の発現を特異的にモジュレートし得る。したがって、「特異的にモジュレートする」とは、本発明のリボザイムが単一のポリヌクレオチドのみを認識することを意味することを意図する。同様に、リボザイムは、全てまたは幾つかのファミリーのタンパク質の発現をモジュレートするように設計し得る。この型のリボザイムは、タンパク質のファミリーをコードする全てまたは幾つかのポリヌクレオチド中に保存されたポリヌクレオチド配列を認識するように設計する。

30

【0055】

さらに、本発明は、オリゴヌクレオチド-指向化三重らせん形成の使用を介して本発明の病原性遺伝子の転写をモジュレートする方法を包含する。概説については、Lavrovskyら, Biochem. Mol. Med., 62:11-22 (1997)を参照されたい。三重らせん形成は、ワトソン-クリック・モデルで定義された主溝で二本鎖DNAにハイブリダイズする配列特異的オリゴヌクレオチドを用いて行う。その後、配列特異的オリゴヌクレオチドのハイブリダイゼーションは、例えば転写因子およびポリメラーゼを含むDNA-結合タンパク質の活性をモジュレートし得る。ハイブリダイゼーション用の好ましい標的配列には、病原性遺伝子産物の発現をモジュレートする転写調節領域が含まれる。三重らせん形成することができるオリゴヌクレオチドは、標的DNA配列の部位-特異的共有的改变にも有用である。共有的改变に有用なオリゴヌクレオチドは、Lavrovskyら, [前掲]に記載されているごとき種々のDNA損傷剤にカップリングする。

40

【0056】

*P. multocida*, *A. pleuropneumoniae*および*P. (Mannheimia) haemolytica*の病原性遺伝子

50

の同定は、抗菌剤の同定方法において遺伝子および遺伝子産物を有用としている。かかる方法には、配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172、および174ならびにそれらの種ホモログ（すなわち、配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172、および174のDNA配列によって表される遺伝子）は病原性遺伝子産物をコードし、あるいは配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172、および174のDNA配列が病原性遺伝子産物をコードしている遺伝子に近接しているか、あるいは配列番号：1、3、7、9、11、13、15、17、19、21、23、25、29、31、33、37、39、41、51、53、55、57、58、60、68、70、72、74、76、78、80、82、84、100、102、104、106、108、110、112、114、116、118、および120、122、124、126、128、130、132、134、135、136、138、140、142、144、146、148、150、152、154、156、158、160、162、163、164、166、168、170、172、および174のいずれか1に記載のDNA配列、その種ホモログまたはその相補鎖によって全体または一部分がコードされる細菌遺伝子産物の機能を干渉する能力につき潜在的剤をアッセイし、つづいてかかるアッセイにおいてポジティブである剤を同定することが含まれる。これらのアッセイに有用なポリヌクレオチドおよびポリペプチドには、本明細書中に開示する遺伝子およびコードされるポリペプチドのみならず、野生型の遺伝子およびポリペプチドと実質的に同じ活性を有するその変異型も含まれる。

10

20

30

40

50

**【0057】**

前記した方法によって作製される病原性遺伝子産物は、高処理量アッセイで用いて阻害因子についてスクリーニングする。スクリーニングすべき潜在的剤の起源は、化学化合物ライブラリー、ストレプトマイセテス（Streptomyces）、他の細菌および菌類の醗酵培地、ならびに植物および他の増殖性植物の細胞抽出物である。公知の酵素活性を有するタンパク質については、活性に基づいてアッセイを確立し、多数の潜在的剤を該活性を阻害する能力についてスクリーニングする。他のタンパク質または核酸と相互作用するタンパク質については、結合アッセイを確立して、かかる相互作用を直接測定し、潜在的剤を結合相互作用を阻害する能力についてスクリーニングする。

**【0058】**

当該技術分野で知られている異なるアッセイの使用は、本発明のこの態様に従って意図される。病原性遺伝子産物の機能が公知の遺伝子産物に対する配列類似性によって知られるかまたは予想される場合には、遺伝子産物の機能および/または特性に合わせた酵素的または他のタイプの生物学的および/または生化学的アッセイで潜在的なインヒビターをス

クリーニングし得る。病原性遺伝子産物が他のタンパク質または核酸と相互作用する公知の遺伝子産物に対する配列類似性によって知られるかまたは予想される場合には、相互作用のインヒビターを結合アッセイで直接スクリーニングし得る。本発明は、病原性遺伝子産物によって結合のインヒビターをスクリーニングおよび同定する多数のアッセイを意図する。1の例において、病原性遺伝子産物を固定化し、結合パートナーとの相互作用を推定インヒビター化合物の存在および不存在下で評価する。もう1の例において、病原性遺伝子産物とその結合パートナーとの間の相互作用は、推定インヒビター化合物の存在および不存在下の両方で、溶液アッセイにおいて評価する。両方のアッセイにおいて、インヒビターは病原性遺伝子産物とその結合パートナーとの間の結合を低下させる化合物として同定する。他のアッセイもこれらの例で意図され、ここでは病原性遺伝子産物結合パートナーはタンパク質である。例えば、ジハイブリッドアッセイの変形が意図され、ここではタンパク質/タンパク質相互作用のインヒビターを、1995年8月3日に公開された国際公開番号W0 95/20652号に記載されているごとき形質転換またはトランスフェクトした宿主細胞におけるポジティブ・シグナルの検出によって同定する。

10

**【0059】**

本発明により意図される候補インヒビターには、潜在的なインヒビターのライブラリーから選択される化合物が含まれる。小分子モジュレーターの同定に用いる多数の異なるライブラリーが存在し、これには(1)化学ライブラリー、(2)天然産物ライブラリー、および(3)ランダムなペプチド、オリゴヌクレオチドまたは有機分子からなるコンビナトリアル・ライブラリーが含まれる。化学ライブラリーは、公知の化合物、あるいは天然物のスクリーニングを介して「ヒット(hits)」または「リード」と同定された化合物の構造アナログからなる。天然産物ライブラリーは、(1)土壌、植物または海洋微生物からのプロスの醗酵および抽出、あるいは(2)植物または海洋生物の抽出、によってスクリーニング用の混合物を生成するために用いる微生物、動物、植物または海洋生物の収集である。天然産物ライブラリーには、ポリペプチド、非-リボソームペプチドおよびそれらの変異型(非天然発生)が含まれる。概説については、*Science*, 282:63-68 (1998)を参照されたい。コンビナトリアル・ライブラリーは、混合物として多数のペプチド、オリゴヌクレオチド、または有機化合物よりなる。それは、伝統的な自動化合成法、PCR、クローニングまたは特許合成方法によって調製することが比較的簡単である。特に関心があるのは、ペプチドおよびオリゴヌクレオチドのコンビナトリアル・ライブラリーである。な

お他の関心のあるライブラリーには、ペプチド、タンパク質、ペプチド模倣物、マルチ平行合成収集、組換え、およびポリペプチド・ライブラリーが含まれる。それから創製されたコンビナトリアル化学およびライブラリーの概説については、*Myers, Curr. Opin. Biotechnol.*, 8: 701-707 (1997)を参照されたい。本明細書中に記載する種々のライブラリーの使用を介するモジュレーターの同定により、候補「ヒット」(または「リード」)を改変して活性をモジュレートする「ヒット」の能力を最適化し得る。

20

30

**【0060】**

本発明によって意図されるなお他の候補インヒビターを設計し得、それには可溶性形態の結合パートナー、ならびにキメラタンパク質または融合タンパク質としての結合パートナーが含まれる。本明細書中で用いる結合パートナーは、抗体、抗体フラグメント、ならび

40

**【0061】**

病原性遺伝子産物に対する結合パートナー(すなわち、リガンド)が知られていない場合には、標的タンパク質への試験結合パートナーの直接結合を測定することを介して標的タンパク質の結合パートナーを同定するアッセイ、ならびにイオンスプレー質量分析/HP LC法または他の物理学的方法もしくは分析方法を用いたアフィニティー限外濾過を介して標的タンパク質の結合パートナーを同定するアッセイが含まれる。また、かかる結合相互作用は、両方とも出典明示して本明細書の一部とみなす、*Fields*および*Song, Nature*, 340: 245-246 (1989)、ならびに*Fields*および*Sternglanz, Trends in Genetics*, 10:286-

50

292 (1994)に記載されている酵母ツーハイブリッド系を用いて間接的に評価する。ツーハイブリッド系は、2のタンパク質またはポリペプチド間の相互作用を検出するための遺伝子アッセイである。それを用いて、関心のある公知タンパク質に結合するタンパク質を同定するか、または相互作用に重要なドメインまたは残基を詳細にすることができる。この方法に対する変形が開発されて、DNA-結合タンパク質をコードする遺伝子がクローン化され、タンパク質に結合するペプチドが同定され、薬剤につきスクリーニングされている。ツーハイブリッド系は、レポーター遺伝子の上流活性化配列(UAS)に結合するDNA-結合ドメインのすぐ近接に転写活性ドメインをもってゆく一对の相互作用タンパク質の能力を活用し、一般的に酵母で行う。該アッセイには、(1)第1のタンパク質に融合したDNA-結合ドメイン、および(2)第2のタンパク質に融合した活性ドメイン、をコードするツーハイブリッド遺伝子の構築が必要である。DNA-結合ドメインは第1のハイブリッドタンパク質をレポーター遺伝子のUASに標的化する；しかしながら、大部分のタンパク質は活性化ドメインを欠いているため、このDNA-結合ハイブリッドタンパク質はレポーター遺伝子の転写を活性化することができない。活性化ドメインを含有する第2のハイブリッドタンパク質は、それ自体でレポーター遺伝子の発現を活性化することができない。それはUASに結合しないからである。しかしながら、両方のハイブリッドタンパク質が存在する場合には、第1のタンパク質と第2のタンパク質の非共有的な相互作用が活性化ドメインをUASにつなぎ、レポーター遺伝子の転写を活性化する。病原性遺伝子産物(例えば、第1のタンパク質)がもう1のタンパク質または核酸と相互作用することがすでに知られている場合には、このアッセイを用いて結合相互作用を干渉する剤を検出することができる。異なる試験剤を系に添加しながらレポーター遺伝子の発現をモニターする；インヒビター因子が存在するとレポーター・シグナルの欠失を生じる。

10

20

30

40

50

#### 【0062】

病原性遺伝子産物の機能が知られておらず、かつ、遺伝子産物に結合することが知られているリガンドが存在しない場合には、酵母ツーハイブリッドアッセイを用いて遺伝子産物に結合するタンパク質を同定することもできる。第1のタンパク質(標的タンパク質)に結合するタンパク質を同定するためのアッセイにおいては、各々が異なる第2のタンパク質をコードしている多数のハイブリッド遺伝子をこのアッセイで作製およびスクリーニングする。典型的には、第2のタンパク質は、全cDNAまたはゲノミックDNAが活性化ドメインに連結しているプラスミドのプールによってコードされている。この系は広範な種々のタンパク質に適用可能であり、第2の結合タンパク質の同一性または機能を知ることすら必要でない。該系は非常に感度が高く、他の方法によって明らかにされない相互作用(一時的な相互作用が転写の引き金を引いて、繰返し翻訳することができる安定なmRNAを生成してレポータータンパク質が得られる場合でさえ)を検出することができる。

#### 【0063】

他のアッセイを用いて標的タンパク質に結合する剤を探索し得る。標的タンパク質への試験リガンドの直接結合を同定するための1のかかるスクリーニング法は、出典明示して本明細書の一部とみなす米国特許第5,585,277号に記載されている。この方法は、タンパク質が一般的にホールドおよびアンホールド状態の混合物として存在し、2の状態の間を連続的に交代しているという原理に基づく。試験リガンドがホールド形態の標的タンパク質に結合する場合(すなわち、試験リガンドが標的タンパク質のリガンドである場合には、リガンドによって結合された標的タンパク質分子はそのホールド状態のまま存在する。したがって、ホールド標的タンパク質は、リガンド不存在下よりも、標的タンパク質に結合する試験リガンドの存在下でより多い程度で存在する。標的タンパク質へのリガンドの結合は、標的タンパク質のホールドおよびアンホールド状態の間を識別するいずれの方法によっても判定し得る。このアッセイを行うために、標的タンパク質の機能が知られている必要はない。試験リガンドとしてこの方法によって実質的にいずれの剤も評価し得、限定されるものではないが、金属、ポリペプチド、タンパク質、脂質、多糖、ポリヌクレオチドおよび小有機分子が含まれる。

#### 【0064】



標的タンパク質に対するリガンドを同定するもう1の方法は、出典明示して本明細書の一部とみなす、Wieboldtら, Anal. Chem., 69:1683-1691 (1997)に記載されている。この技術は、標的タンパク質への結合について溶液相中で一時に20 - 30の剤のコンビナトリアル・ライブラリーをスクリーニングする。標的タンパク質に結合する剤は、遠心限外濾過によって他のライブラリー成分から分離する。つづいて、フィルター上に保持された特異的に選択された分子を標的タンパク質から遊離させ、HPLCおよび空気圧アシスト電子スプレー（イオンスプレー）イオン化質量分析によって分析する。この手法は標的タンパク質に対して最高のアフィニティーを有するライブラリー成分を選択し、特に小分子ライブラリーに有用である。

#### 【0065】

初期スクリーニングによって同定されたインヒビター/バインダーは、P. multocida感染症のイン・ビボ (in vivo) マウス・モデルにおける病原性に対するその効果について評価する。菌血症、心内膜炎、敗血性関節炎、柔組織膿瘍または肺炎のモデルを利用し得る。他の動物の使用を含むモデルも本発明によって理解されている。例えば、ウサギを、変化する量の推定インヒビター/バインダー化合物を投与する前後に野生型P. multocida株で攻撃し得る。推定インヒビター/バインダー化合物の代わりに塩類溶液のみを投与した対照動物は、それによって試験動物の悪化を判定し得る基準を提供する。他の動物モデルには、Animal and Plant Health Inspection Service, USDA, 1994年1月1日 編, 第113章, 69-113.70; PancieraおよびCorstvet, Am. J. Vet. Res. 45: 2532-2537; Amesら, Can. J. Comp. Med. 49: 395-400 (1984);ならびにMukkur, Infection and Immunity 18: 583 -585 (1977)に記載されているものが含まれる。細菌の病原性を干渉するインヒビター/バインダーは、感染症の確立を予防し得、あるいは一旦確立した感染症の結果を逆転させ得る。

#### 【0066】

フロイント完全アジュバントおよびフロイント不完全アジュバント、ミコール酸ベースのアジュバント（例えば、トレハロース ジミコレート）、細菌リポ多糖（LPS）、ペプチドグリカン（すなわち、ムレイン、ムコペプチド、またはN - オパカ（N - Opaca）、ムラミルジペプチド [MDP] またはMDPアナログのごとき糖タンパク質）、プロテオグリカン（例えば、クレブシエラ・ニューモニエ（Klebsiella pneumoniae）、連鎖球菌調製物（例えば、OK432）、ピオスチム<sup>T M</sup>（Biostim<sup>TM</sup>）（例えば、01K2）、欧州特許第109 942号、第180 564号および第231 039号の「イスコムス（Iscoms）」、水酸化アルミニウム、サポニン、DEAE - デキストラン、（ミグリオールのごとき）中性油、（落花生油のごとき）植物油、リポソーム、プルロニック<sup>R</sup>（Pluronic<sup>R</sup>）ポリオール、Ribiアジュバント系（例えば、GB - A - 2 189 141号を参照されたい）、またはインターロイキンのごとき油ベースのアジュバントを含む当該技術分野で知られているいずれのアジュバントもワクチン組成物に用い得、特に細胞性免疫を刺激するものを用い得る。アミコラータ（Amycolata）、アクチノマイセテールス（Actinomycetales）目の細菌属の抽出物よりなるもう1のアジュバントは、米国特許第4,877,612号に記載されている。さらに、特許アジュバント混合物が市販されている。用いるアジュバントは、一部分、レシピエント生物に依存するであろう。投与するアジュバントの量は、動物のタイプおよびサイズに依存するであろう。最適投与量は日常的な方法によって容易に決定し得る。

#### 【0067】

ワクチン組成物は、所望により、医薬的なビヒクル、賦形剤または媒体として作用するワクチン - 和合性の医薬上許容し得る（すなわち無菌であって無毒な）液体、半固体または固体の希釈剤を含み得る。当該技術分野で知られているいずれの希釈剤も用い得る。例示的な希釈剤には、限定されるものではないが、モノラウリン酸ポリオキシエチレンソルビタン、ステアリン酸マグネシウム、メチル - およびプロピルヒドロキシベンゾエート、タルク、アルギン酸塩、デンプン、ラクトース、スクロース、デキストロース、ソルビトール、マンニトール、アカシアガム、リン酸カルシウム、鉱油、カカオ脂、およびテオブロマ（theobroma）の油が含まれる。

10

20

30

40

50

## 【0068】

ワクチン組成物はデリバリーに簡便な形態で包装し得る。組成物はカプセル剤、キャプレット剤、サシェ剤、カシェ剤、ゼラチン、紙または他の容器内に入れることができる。レシピエント生物への免疫原性組成物の注入と和合する場合、特に、免疫原性組成物をユニット投与量形でデリバリーする場合、これらのデリバリー形態が好ましい。投与量ユニットは、例えば、錠剤、カプセル剤、坐剤またはカシェ剤に包装し得る。

## 【0069】

ワクチン組成物は、例えば、経口、舌下、鼻腔、肛門、または腔デリバリーによって、静脈内、皮内、筋肉内、乳房内、腹膜内または皮下注射を含む方法いずれかの慣用的な方法によって免疫感作すべき対象に導入し得る。治療は、単一用量または一定期間にわたる複数用量よりなり得る。 10

## 【実施例】

## 【0070】

本発明は、細菌感染症および/またはそれと関連する病徴を予防または軽減するためのワクチン薬剤を製造するための本発明の弱毒細菌株の使用も包含する。本発明は、細菌感染症および/またはそれと関連する病徴を予防または軽減するための医薬を製造するための本発明のインヒビターの使用も提供する。

## 【0071】

本発明を以下の実施例によって説明する。実施例1は*P. multocida*突然変異体の構築を記載する。実施例2は*P. multocida*突然変異体のスクリーニングに関する。実施例3は*P. multocida*突然変異体の病原性を判定する方法を扱う。実施例4は*P. multocida*病原性遺伝子のクローニングを記載する。実施例5は*P. multocida*病原性遺伝子に関連する他の種における遺伝子の同定を扱う。実施例6は*A. pleuropneumoniae*突然変異体の構築を記載する。実施例7は弱毒化*A. pleuropneumoniae*突然変異体のスクリーニングを扱う。実施例8は*A. pleuropneumoniae*病原性遺伝子の同定に関する。実施例9は*A. pleuropneumoniae*の突然変異体および野生型細菌の競合的攻撃を記載する。実施例10は同定した*A. pleuropneumoniae*遺伝子を特徴付ける。実施例11は野生型細菌攻撃に対して保護する*A. pleuropneumoniae*突然変異体の効力を扱う。実施例12は*P. (Mannheimia) haemolytica*における種ホモログ病原性遺伝子の同定を記載する。 20

## 【0072】

実施例1 タグを付加したトランスポゾン*P. multocida*突然変異体のライブラリーの構築  
タグを付加したトランスポゾン突然変異体のライブラリーは、親ベクター pLOF/Km [Herreroら, J. Bacteriol., 172: 6557-67 (1990)]中に構築し、これは*P. multocida*で機能性かつランダムであることが以前に示されている [Leeら, Vet. Microbiol., 50: 143-8(1996)]。プラスミド pLOF/Kmはスーサイド・ベクター pGP704を改変して構築し、それは Tacプロモーター制御下のトランスポザーゼ遺伝子ならびにカナマイシン耐性をコードするミニ-Tn10トランスポザーブル・エレメントを含んでいた。プラスミド pTEF-1は半-ランダム [NK]<sub>3,5</sub> 配列を含む配列タグを受容するように pLOF/Kmを改変することによって以下に記載するごとく構築した。 30

## 【0073】

プラスミド pLOF/Kmをまず改変してマルチプルクローニング領域中のユニーク KpnI制限部位を除去し、ついでミニ-Tn10領域中に新たな KpnI部位を導入した。そのプラスミドを KpnIで消化し、生じた突出末端を製造業者が指示するプロトコールに従ってクレノウ・ポリメラーゼで埋めた。本明細書中に記載する制限消化および連結は、製造業者が指示するプロトコールに従って行った (Gibco BRL, Gaithersburg, MD and Boehringer Mannheim, Indianapolis, IN)。平滑末端生成物は自己連結して、pLOF/Km--KpnIと命名したプラスミドを生成し、これを増幅用のイー・コリ (*E. coli*) DH5 : pir に形質転換した。イー・コリ DH5 : (pir 80dlacZ M15, recA1, endA1, gyrA96, thi-1, hsdR17(r<sub>k</sub><sup>-</sup>, m<sub>k</sub> supE44, relA1, deoR, (lacZYA-argF)U169を、L 40 50

B (Luria-Bertani) 培地中、37 にて増殖させた。プラスミドはQIAGEN Inc. (Santa Clarita, CA) からのQ I A G E N S p i n P r e p s を用いて調製し、ミニ-Tn10トランスポザブル・エレメント内のユニーク部位を切断するS f i Iで消化した。S f i I - K p n I - S f i Iアダプターは、オリゴヌクレオチドT E F 1 (配列番号: 86) およびT E F 3 (配列番号: 87) をアニーリングさせることによって調製し、得られた二本鎖アダプターをS f i I部位に連結させてプラスミドp T E F - 1を作製した。オリゴヌクレオチドT E F 1 およびT E F 3 (ならびに本明細書中に記載する全ての他のオリゴヌクレオチド) は、Genosys Biotechnologies (The Woodlands, TX) によって合成した。

【0074】

10

【化1】

TEF1 5'-AGGCCGGTACCGGCCGCT 配列番号: 86

TEF3 5'-CGGCCGGTACCGGCCTAGG 配列番号: 87

【0075】

p T E F - 1 の K p n I 部位へ挿入するためのユニーク配列タグは以下の通り調製した。250 μMの各d N T P、1.5 mMのM g ( O A c )<sub>2</sub>、テンプレートDNAとしての100ピコモルの各プライマーT E F 1 4 (配列番号: 88) およびT E F 1 5 (配列番号: 89)、1 ngのT E F 2 6 (配列番号: 90) ならびに2.5単位の組換えT t h DNAポリメラーゼX Lを含む条件下で、Gene Amp XL PCRキット (PE Applied Biosystems, Foster City, CA) を用いてPCRを行って二本鎖DNAタグを作製した。

20

【0076】

【化2】

TEF14 5'-CATGGTACCCATTCTAAC 配列番号: 88

TEF15 5'-CTAGGTACCTACAACCTC 配列番号: 89

30

TEF26 配列番号: 90

5'-CTAGGTACCTACAACCTCAAGCTT-[NK]<sub>35</sub>-

AAGCTTGGTTAGAATGGGTACCATG

【0077】

反応条件は、95 にて1分間の初期インキュベーションにつづく、95 にて30秒間、45 にて45秒間、ついで72 にて15秒間の30サイクルにつづく、72 にて2分間の最終インキュベーションを含む。PCR産物をK p n Iで消化し、製造業者の指示するプロトコールに従ってQIAGEN Nucleotide Removal Kit (QIAGEN, Inc., Chatsworth, GA) を用いて精製した。ユニークタグ配列を、標準的な手法を用いて予めK p n Iで消化し、子ウシ腸アルカリホスファターゼ (Boehringer Mannheim) で脱リン酸化した線状p T E F - 1のミニ-Tn10エレメントに連結した。得られたプラスミド・ライブラリーをイー・コリDH5 : p i rに形質転換した。ハイブリダイゼーションおよび検出を以下の通り行いつつ、DIGの使用者案内書 (Boehringer - Mannheim) に従ってコロニープロット分析を行った。

40

【0078】

ハイブリダイゼーションは、Genius Non-Radioactive User's Guide (Boehringer Manne

50

im Biochemicals)、DIG-PCR labeling kit (Boehringer Mannheim Biochemicals)用製品シート、およびCSPD (Boehringer Mannheim Biochemicals)用製品シートに従って本質的に行った。プローブの調製については、Amplitaq PCR緩衝液 (PE Applied Biosystems)、200  $\mu$ MのdNTP、140ピコモルの各プライマーTEF5 (配列番号: 9) およびTEF6 (配列番号: 92)、2mMのMgCl<sub>2</sub>、2.5単位のAmplitaq (PE Applied Biosystems) および1ngのプラスミドDNAを用いて、100  $\mu$ lの一次PCR反応を設定した。

【0079】

【化3】

TEF5 5'-TACCTACAACCTCAAGCT 配列番号: 91

10

TEF6 5'-TACCCATTCTAACCAAGC 配列番号: 92

【0080】

サイクル条件は、95にて2分間の初期インキュベーションにつづく、95にて30秒間、50にて45秒間、72にて15秒間の35サイクルにつづく72にて3分間の最終インキュベーションを含んでいた。増幅産物を2% - 3:1 NuSieve GTG (FMC BioProducts, Rockland, ME, USA): アガロースゲル上の電気泳動を用いて分離し、109bpを切除して精製した。ゲル抽出はQIAGEN Gel Extraction Kit (QIAGEN)を用いて行った。約15ngの一次産物を、DIG PCR Kit、50ピコモルの各プライマーTEF24およびTEF25およびDIG Probe Synthesis Mixと2mMのdNTP保存溶液の1:1混合物を用いる50  $\mu$ lのPCR反応中で標識した。

20

【0081】

【化4】

TEF24 5'-TACCTACAACCTCAAGCTT 配列番号: 93

TEF25 5'-TACCCATTCTAACCAAGCTT 配列番号: 94

30

【0082】

PCR条件は、95にて4分間の初期インキュベーションにつづく、95にて30秒間、50にて45秒間、72にて15秒間の25サイクル、ならびに72にて3分間の最終インキュベーションを含んでいた。標識したPCR産物を90  $\mu$ lの合計反応体積中でHindIIIで消化し、2% - 3:1 NuSieve GTG (FMC BioProducts): アガロースゲルを用いるコンスタント・プライマーアームから精製した。標識した可変タグを含有する領域を切除し、全ゲルスライスを10mlのDIG EasyHyb中、95にて10分間溶解および変性させた。

【0083】

ドットプロットは、Hybond<sup>R</sup> - N<sup>+</sup>膜 (Amersham - Pharmacia Biotech)を用いて調製した。各タグ用の標的DNAは、ほぼ30ngのPCR産物を用いて96ウェルプレート中で調製した。等容量の0.1N NaOHを添加して試料を変性させ、各試料をSchleicher and Schuell (Keene, NH, USA)からのManifold I<sup>TM</sup> Dot-Blot Apparatusを用いて最小限の真空で膜に適用した。各ウェルを150  $\mu$ lの中和溶液(0.5M トリス/3M NaCl、pH 7.5)および150  $\mu$ lの2xSSCで洗浄した。膜をStratalinker (Stratagene, La Jolla, CA, USA)中でUV-架橋し、20mlのDIG EasyHyb Buffer中、42にて1時間プレハイブリダイズさせた。変性したプローブを添加し、ハイブリダイゼーションを42にて一晩行った。膜を0.1% SDSを含有する2xSSCで各洗浄につき5分間2回洗浄

40

50

した。標準Genius Detectionプロトコール (Genius Manual) を用いて進行する前に、2の高ストリンジェンシー洗浄を0.1%のSDSを含有する予め加温した50mlの0.1×SSC緩衝液中、68にて15分間行った。

#### 【0084】

安全性、低コスト、使用し易さ、および危険な材料を減少させるために、非-放射性検出系を用いることが望ましい。以前に記載された同様な手法[Meiら, Mol. Microbiol. 26: 399-407 (1997)]を用いる初期実験においては、ネガティブ対照において許容できないバックグラウンド・レベルのハイブリダイゼーションが得られた。バックグラウンドを低下させるために、タグの長さを30bp増加させて合計70とし、増幅プライマーを長くして可変領域を挟む全ての配列を含め、低濃度のdig-dUTPを用い、配列タグ領域を挟む保存配列をゲル精製によって取り出した。最も重要なことは、PCRを用いて、トランスポゾンそれ自体からのバックグラウンド・ハイブリダイゼーションを検出した後にタグを付加したトランスポゾン含有する全プラスミドよりもむしろ、ドット・プロットにおける標的DNAとして[NK]<sub>35</sub>配列タグを作製した。これらの改変を用いて、バックグラウンドを排除し、化学ルミネセンス/非放射性スクリーニングをより効果的とした。

10

#### 【0085】

PCR生成配列タグとpTEF-1の連結から生じたほぼ400の異なる形質転換体をコロニープロットによってスクリーニングし、さらなる使用のために96の最も強いハイブリダイズ・コロニーをマイクロタイター・プレートに結合させた。二重のタグの可能性は非常に低いが、マスタータグのプレートの半分を他のものに対してプローブして、タグが二重になっていないことを確認した。これらのタグを含有するプラスミドを精製して、イー・コリス17-1: pir(pir, recA, thi, pro, hsd, (r-m+), RP4-2, (Tc::Mu), (Km::Tn7), [TmpR], [SmR])に形質転換し、その形質転換細菌をLB培地中、37にて増殖させた。各96のタグを付加したプラスミドpTEF-1を含有するイー・コリス17-1: pir形質転換体を接合交配に用いて、P. multocidaのトランスポゾン突然変異体を作製した。P. multocida株TF5は、ウシ臨床単離株である、UC6731由来の自然発生ナリジキシン酸耐性突然変異体である。P. multocida株は、プレート上で増殖させる場合には、5%CO<sub>2</sub>下、ブレインハート浸出液(BHI)培地(Difco Laboratories, Detroit, MI, USA)上、37にて増殖させた。交配は各イー・コリス17-1: pir/pTEF1:[NK]<sub>35</sub>クローンおよびTF5株を後期対数増加期まで増殖させることによって設定した。各タグを付加したpTEF-1クローンにつき50μlの培地を200μlのTF5培地と混合し、100mMのIPTGおよび10mMのMgSO<sub>4</sub>を含有するBHIプレート上に予め置いておいた0.22TMフィルターに50μlの各交配混合物をスポットした。5%CO<sub>2</sub>下、37にて一晚インキュベートした後に、各フィルターを3mlのPBSに入れて交配混合物を洗い取り、各25μlをBHIN<sup>50</sup>K<sup>100</sup>プレートに平板した。選択的一晩増殖後に、コロニーを200μlのBHIN<sup>50</sup>K<sup>50</sup>へのトウスピーク移植(toothpick transfer)によってマイクロタイター・プレートに合して、マイクロタイター・プレート中の各ウェルが同じ配列タグを有するトランスポゾン突然変異体を常に含むことを確かめた。一晚増殖後に、50μlの75%グリセリンを各ウェルに添加し、プレートを一80にて凍結保存した。

20

30

40

#### 【0086】

トランスポゾン突然変異体をマイクロタイター・プレートに移すことによって19のプールを合して、そのウェルに対して適当なタグを有するトランスポゾン突然変異体を各ウェルが含んでいたことを確かめた。他言すれば、これらの突然変異体内のトランスポゾンの位置は異なり得るが、各マイクロタイター・プレート中の特定のウェルは同一配列タグを有するトランスポゾン突然変異体を常に含んでいた。

#### 【0087】

実施例2 弱毒化P. multocida突然変異体のげっ歯類スクリーニング

敗血症のげっ歯類モデルを用いて、Pasteurella multocidaのトランスポゾン突然変異体

50

の19のプールをスクリーニングした。プールした*P. multocida*トランスポゾン突然変異体の凍結プレートを-80℃保存から取り出し、各ウェルからの10 $\mu$ lを50 $\mu$ g/mlのナリジキシン酸(Sigma)および50 $\mu$ l/mlのカナマイシン(Sigma)と共に200 $\mu$ lのブレインハート浸出液(DIFCO)(BHI N<sup>50</sup> K<sup>50</sup>)を含有する新たな96ウェル丸底プレート(Corning Costar, Cambridge, MA, USA)に移すことによって二次培養した。プレートを振盪せずに5%CO<sub>2</sub>下、37℃にて一晩インキュベートした。各ウェルからの10 $\mu$ lをウェル当り100 $\mu$ lのBHIを含有する新たな平底96-ウェルプレート(Corning Costar)に移し、ほぼ150rpmで振盪しつつ37℃にてインキュベートすることによって一晩プレートを二次培養した。マイクロタイター・プレートリーダーを用いてOD<sub>540</sub>をモニターした。ほぼ0.2ないし0.25のOD<sub>540</sub>で、各プレートをプールして、マイクロタイター・プレートの各ウェルからの100 $\mu$ lを合することによって「投入プール」を形成した。その培養物をBHI中で適当に希釈してほぼ10<sup>4</sup>、10<sup>5</sup>、10<sup>6</sup>CFU/mlの用量とし、0.2mlの各希釈物を用いて、腹腔内投与によって雌性14-16gのBALB/cマウスに感染させた。感染後2日に、1または2の生存しているマウスを安楽死させて脾臓を採取した。全脾臓を1.0mlの無菌0.9%塩類溶液中でホモジナイズした。10<sup>-2</sup>から10<sup>-5</sup>のホモジネートの希釈物を調製し、BHI N<sup>50</sup> K<sup>50</sup>プレートに平板した。一晩増殖後に、少なくとも20,000コロニーを10mlのBHIプロス中にプールして「回収プール」を形成し、以前に記載されたプロトコール[F. M. Ausubelら(編), Current Protocols in Molecular Biology, vol. 1. John Wiley and Sons, New York, p.2.4.1-2.4.5.(1997)中のWilson]に従って、0.5mlの回収プールを3,500 $\times$ gにて遠心し、そのペレットを用いてゲノミックDNAを調製した。

10

20

30

40

50

#### 【0088】

病原性野生型*P. multocida*を用いた初期実験は、生物を脾臓、肺、腎臓および肝臓から回収し得ることを示し、これは感染の真正な敗血症モデルを示している。「投入」および「回収」の両方のプールについてのドット・プロットを実施例1に記載したのと同様に行い、視覚的検査および半-定量分析の両方によって評価した。ハイブリダイゼーションは、投入および回収プールからの5 $\mu$ gのゲノミックDNAをテンプレートとして用いる以外は、実施例1に記載したのと同様に行った。半-定量分析は、単一クローンにおける顕著な減少が起こったか否かを示している。突然変異体が宿主内で生存することができない場合には、回収シグナルは投入シグナルに比して非常に低く、高い投入/回収比を与えるにちがいない。大部分の突然変異体はイン・ビトロ(in vitro)と同様にイン・ビボ(in vivo)で増殖するであろう。したがって、それらのシグナルの比はほぼ1に等しいにちがいない。回収プールで非常に減少しているとして定量分析によって選抜したクローンを、さらなる実験用に選抜した。疑わしい投入/回収比を有するさらなるクローンは、ドット・プロットから作成したフィルムを視覚的に評価した後にも選抜した。

#### 【0089】

実施例3 *P. multocida*候補突然変異体についての病原性の決定

脾臓細胞から低い回収率を示した各潜在的な突然変異体を原プールプレートから単離し、個別に攻撃試験に用いて、該トランスポゾン突然変異体により生じた弱毒化を確認し、おおざっぱに評価した。in vivoスクリーンからの個々の候補突然変異体をヒツジ血液寒天プレート上、5%CO<sub>2</sub>中、37℃にて一晩増殖させた。各突然変異体のおよそ6のコロニーをBHIプロスに接種し、6時間増殖させた。希釈物を調製し、各々5のマウスに、各々10<sup>2</sup>、10<sup>3</sup>、10<sup>4</sup>および10<sup>5</sup>CFUで上記したごとく感染させた。弱毒化を6日後の死亡率をその野生型と比較することによって決定した。生存しているマウスは保護されていたものと推定され、ついで、当該野生型株のLD<sub>50</sub>のおよそ200倍の濃度の野生型*P. multocida*の用量で攻撃した。ついで、各攻撃した群のマウスについて生存率を決定した。

#### 【0090】

結果は、120の潜在的トランスポゾン突然変異体のうちの62が弱毒化し、野生型株よ

りも少なくとも10倍高い概算LD<sub>50</sub>を有することを示した。該クローンおよびそれらの概算LD<sub>50</sub>値を表1に掲載する。野生型株での対照実験を各セットの攻撃と並行して行ったが、全ての場合において野生型攻撃群の死亡率は100%であった。

【0091】

LD<sub>50</sub>値に加えて、表1にはワクチン化および攻撃実験からのデータも掲載している。簡単には、マウス群(n=5ないし10)は、病原性の野生型株のLD<sub>50</sub>よりもほぼ200倍高い用量で表1に示す個々の*P. multocida*株を腹膜内注射によりワクチン化した。死亡率の数字を算出した後28日間、動物を観察した。

【0092】

【表3】

表1  
*P. multocida* 病原性遺伝子

ヌクレオチド 配列番号:	代表的単離株	可能性のある 遺伝子の機能	ワクチン化 生存数/合計	攻撃 生存数/合計	LD <sub>50</sub>
-	野生型	-	0/10	-	<10
23	PM1B1	<i>guaB</i>	10/10, 10/10, 10/10	9/10, 9/10	4.3 x 10 <sup>6</sup>
11	PM1D1	<i>dsbB</i>	10/10, 5/10	10/10, 5/5	8.4 x 10 <sup>4</sup>
3	PM1B7	<i>atpG</i>	5/5, 10/10	10/10	>3 x 10 <sup>5</sup>
74	PM1BE11	<i>yhcJ</i> (HI0145)	10/10	5/10	>2 x 10 <sup>5</sup>
70	PM1BF6	<i>yabK</i> (HI1020)	3/5, 8/10	9/9	>2 x 10 <sup>5</sup>
19	PM2G8	<i>fhaC</i>	4/5, 9/10	9/9	>4 x 10 <sup>5</sup>
76	PM3C9	<i>yiaO</i> (HI0146)	3/5		>6 x 10 <sup>5</sup>
118	PM3G11	UnkO	4/5, 10/10	10/10	>3 x 10 <sup>5</sup>
31	PM7B4	<i>iroA</i> (UnkB)	0/5		
17	PM4C6	<i>fhaB</i> ( <i>fhaB2</i> )	2/5, 10/10, 9/10	10/10, 9/9	>3 x 10 <sup>6</sup>
9	PM4G10-T9	<i>dnaA</i>	4/5		>5 x 10 <sup>5</sup>
1	PM4D5-T5	<i>atpB</i>	5/5		>4 x 10 <sup>5</sup>
53	PM4D5-T1	UnkC2	5/5		>4 x 10 <sup>5</sup>
15	PM4F2	<i>fhaB</i> ( <i>fhaB1</i> )	3/5, 6/10, 10/10	6/6, 10/10	>3 x 10 <sup>5</sup>
41	PM5F7	<i>mreB</i>	4/5		1 x 10 <sup>3</sup>
7	PM5E2	<i>devB</i>	0/5, 3/10	2/3	ND
68	PM6H5-T1	<i>xylA</i>	5/5		>3 x 10 <sup>5</sup>
78	PM6H8	<i>yigF</i> (HI0719)	5/5, 9/10	9/9	>3 x 10 <sup>5</sup>
108	PM7D12	<i>pnp</i>	5/5, 9/10	9/9	
51	PM8C1R1-T2	UnkC1	5/5		-6 x 10 <sup>5</sup>
37	PM8C1-T3	<i>mgIB</i>	5/5		-6 x 10 <sup>5</sup>
58	PM8C1R1-T6	UnkD1	5/5		-6 x 10 <sup>5</sup>
45	PM10H7	<i>purF</i> (HI1007)	3/5, 8/10, 8/10	8/8, 8/8	>3 x 10 <sup>5</sup>
25	PM10H10-T2	HI1501	5/5		>1 x 10 <sup>4</sup>
72	PM11G8-T2	<i>ygiK</i>	5/5		>2.4 x 10 <sup>3</sup>
21	PM11G8-T4	<i>greA</i>	5/5		>2.4 x 10 <sup>3</sup>
84	PM12H6	<i>yyam</i> (HI0687)	3/5, 0/10		-2.2 x 10 <sup>3</sup>
33	PM15G8-T2	<i>kdtB</i>	5/5		>1.2 x 10 <sup>5</sup>
116	PM15G8-T1	UnkK	5/5		>1.2 x 10 <sup>5</sup>
104	PM16G11-T1	<i>hmbR</i>	3/5		>1.9 x 10 <sup>5</sup>
29	PM16G11-T2	<i>hxC</i>	3/5		>1.9 x 10 <sup>5</sup>
35	PM16H8	<i>lgtC</i>	5/5, 10/10	10/10	>2.4 x 10 <sup>5</sup>
80	PM16H3	<i>yleA</i> (HI0019)	5/5, 10/10		>2.0 x 10 <sup>5</sup>
49	PM17H6-T1	<i>sopE</i>	4/5		-6 x 10 <sup>5</sup>
120	PM17H6	UnkP	4/5		-6 x 10 <sup>5</sup>
5	PM18F5-T8	<i>cap5E</i>	5/5		>2.4 x 10 <sup>5</sup>
82	PM18F5-T10	<i>yoyB</i> (HI0345)	5/5		>2.4 x 10 <sup>5</sup>
13	PM19A1	<i>exbB</i>	5/5, 10/10	10/10	>1.2 x 10 <sup>5</sup>
112	PM19D4	<i>rci</i>	5/5, 8/10	8/8	-1.6 x 10 <sup>5</sup>
39	PM20A12	<i>mioC</i> (HI0669)	3/5, 8/10	8/8	-2 x 10 <sup>4</sup>
60	PM20C2	UnkD2	5/5, 10/10	10/10	>8.2 x 10 <sup>6</sup>

10

20

30

40

50

## 【0093】

実施例4 P. multocida病原性に必要な遺伝子のクローニングおよび同定  
弱毒化していることが確認された各トランスポゾン突然変異体を分析して、破壊されたオープン・リーディング・フレームの同一性をさらに決定した。各突然変異体からのDNAを増幅し、精製し、ついでトランスポゾン内を切断せず、該トランスポゾンとハイブリダイズする4~8kbフラグメントを通常生成することが知られている制限酵素で消化した。該トランスポゾンによりコードされるカナマイシン抵抗性についての選抜を用いて、各トランスポゾン突然変異体につき少なくとも1のフラグメントをクローン化した。

## 【0094】

複数の制限酵素を用いたサザンハイブリダイゼーションを、クローニングに好適なサイズのフラグメントを同定するためのプローブとしてpLOF/Kmからの標識化1.8kb MluIフラグメントを用いて、各弱毒化突然変異体につき行った。各突然変異体からのミニ-Tn10エレメントおよびフランキングDNAを、内部プライマーTEF32およびTEF40、プライマーウォーキング、およびある場合においてはユニバーサルpUC-19プライマーを用いて決定したpUC19および該フランキング配列にクローン化した。

## 【0095】

## 【化5】

TEF-32 GGCAGAGCATTACGCTGAC 配列番号:95

TEF-40 GTACCGGCCAGGCGGCCACGCGTATTC 配列番号:96 20

## 【0096】

配列決定反応は、PE Applied Biosystems (Foster City, CA)からのBigDye™ Dye Terminator Chemistry kitを用いて行い、ABI Prism 377 DNA Sequencer上で行った。推定される中断 (interrupted) オープン・リーディング・フレームの二本鎖配列を各クローンにつき得た。Sequencer3.0ソフトウェア (Genecodes, Corp., Ann Arbor, MI)を用いて、配列データを収集して解析した。GCGプログラム [Devereuxら, 1997. Wisconsin Package Version 9.0, 9.0 ed. Genetics Computer Group, Inc., Madison]を用いて、現在入手可能なデータベースにおいて相同な配列を検索した。

## 【0097】

弱毒化していることが同定されたクローンの37%に、該ミニ-Tn10トランスポザブルエレメントの多重挿入が存在していた。そのフランキング配列を含む各挿入を個別にpGP704中にクローン化し、該野生型株中に交配して、P. multocidaの新たな突然変異体を作成し、その各々は、複数の起源挿入の1のみを運搬していた。個々の突然変異体を個別に再試験して、弱毒化表現型に寄与している挿入を決定した。該破壊された予想オープン・リーディング・フレームのヌクレオチド配列を両方の鎖を配列決定することによって決定し、ついで予想アミノ酸配列を用いて類似配列について現在入手可能なデータベースを検索した。配列は、知られている遺伝子、知られていない遺伝子および以前に配列決定された仮想オープン・リーディング・フレームに適合するか、または以前同定された配列のいずれにも適合しないかのいずれかであった。以前同定された配列にホモロジーを有する遺伝子については、表1に示すごとく、潜在的な機能を割当てた。

## 【0098】

実施例5 他の種における関連遺伝子の同定  
別の実験において、Actinobacillus pleuropneumoniae (APP)を用いてSTMも行った。App株の1は、配列決定した遺伝子 (配列番号:97)中に挿入を含有し、P. multocidaのatpG遺伝子の種ホモログとして同定された。この結果は、以前に知られていなかったP. multocida遺伝子に対するホモログが他の細菌種にも存在することを示し、それを突然変異させてワクチン組成物に使用するための他の細菌種の弱毒化株を生成することもできることを示した。他のP. multocida遺伝子のホモログが他の細菌種に存在するかどうかを決定するために、プローブとしてA. pleuropneumoniaeのatpG遺伝子を用いて 50



他の種からのゲノムDNAに対してサザンハイブリダイゼーションを行った。

【0099】

Actinobacillus pleuropneumoniae、Pasteurella haemolytica (Ph)、P. multocida、およびHaemophilus somnus (Hs)のゲノムDNAをCTAB法を用いて単離し、EcoRIおよびHindIIIで37にて2時間消化した。消化したDNAを、0.7%寒天ゲル上、TAEバッファー中で40Vにて一晩分離した。該ゲルを、順次、0.1M HCl中に30分間、0.5M NaOH / 1.5M NaCl中に15分間を各々2回、ついで2.5M NaCl / 1M Tris、pH 7.5中に2回浸漬した。そのDNAを20x SSCバッファー(3M NaCl / 0.3M クエン酸ナトリウム)を用いて、ニトロセルロース膜(Amersham Hybond N<sup>+</sup>)に一晩転写した。該DNAは、自己架橋設定(120ミリジュール)したUV Stratalinkerを用いて該膜に架橋した。該膜を5x SSC / 1%ブロッキング溶液 / 0.1% ラウロイルサルコシナトリウム / 0.02% SDS中、50にて、ほぼ7時間プレハイブリダイズさせ、ついでPCR生成atgプローブを含有する同溶液中、50にて一晩ハイブリダイズさせた。

【0100】

プローブは、GeneAmp PCRシステム2400において、GeneAmp XLP CRキットのプライマーDEL-1389(配列番号:98)およびTEF-46(配列番号:99)を用いて調製した。テンプレートはゲノムA. pleuropneumoniae DNAを用いた。

【0101】

【化6】

DEL-1389 TCTCCATTCCCTTGCTGCGGCAGGG 配列番号:98

TEF-46 GGAATTACAGCCGGATCCGGG 配列番号:99

【0102】

PCRは、初期加熱工程を94にて5分間、94にて30秒間の変性、50にて30秒間のアニーリング、および72にて3分間の伸長の30サイクル、ついで72にて3分間の最終増幅で行った。増幅産物はアガロースゲル上で分離し、QIAquickゲル精製キット(QIAGEN)を用いて精製し、ついでおよびDIG-High Primerキット(Boehringer Mannheim)を用いて標識した。プロットをハイブリダイゼーション溶液から取り出し、2x SSC中で濯ぎ、同バッファー中で各洗浄につき5分間、2回洗浄した。ついで、該プロットを0.5x SSC中、60にて各々15分間、2回洗浄した。相同なバンドをDIG Nucleic Acid Detection Kit(Boehringer Mannheim)を用いて視覚化した。

【0103】

EcoRI消化DNAを用いて、Pasteurella haemolytica、Haemophilus somnusおよびA. pleuropneumoniaeにおいて単一のバンドを検出した。Pasteurella multocidaからはEcoRI消化DNAを用いて2のバンドを検出した。

【0104】

実施例6 タグを付加したトランスポゾンP. multocida突然変異体のライブラリーの構築 pLof / Kmを用いるトランスポゾン突然変異誘発は、A. pleuropneumoniaeにおいて機能的かつランダムであることが以前に報告されている[Tasconら, J. Bacteriol. 175: 5717-22 (1993)]。A. pleuropneumoniaeのタグを付加したトランスポゾン突然変異体を構築するために、予め選択したタグを付加したプラスミド(pTEF-1:[NK]<sub>35</sub>)を含む96の各E.coli S17-1:pir形質転換体を接合性交配に用いて、A. pleuropneumoniae株AP225、in vivo継代したATCC27088株由来の血清型1の自然発生ナリジキシン酸抵抗性突然変異体を生成した。A. pleuropneumoniae株は、10μg/mlのB-ニコチンアミドアデニン=ジヌクレオチド(V<sup>10</sup>) (Sigma, St. Louis, Missouri)を含有するブレインハート滲出液(BHI) (Difco Laboratories, Detroit,

MI)培地上、37にて増殖させ、プレート上で増殖させる場合は5% CO<sub>2</sub>中で増殖させた。E.coli S17-1: pir (pir, recA, thi, pro, hsdR (r<sub>k</sub><sup>-</sup>, m<sub>k</sub><sup>+</sup>), RP4-2, (Tc<sup>R</sup>:Mu), (Km<sup>R</sup>:Tn7), [Tm p<sup>R</sup>], [Sm<sup>R</sup>])をルリア-ベルターニ(Luria-Bertani; LB)培地中、37にて繁殖させた。必要な場合には、抗生物質を100 μm/mlアンピシリン(Sigma)、50 μm/mlナリジキシン酸(N<sup>50</sup>) (Sigma)、および50 (K<sup>50</sup>)もしくは100 (K<sup>100</sup>) μg/mlのカナマイシン(Sigma)で用いた。

#### 【0105】

交配は、各E.coli S17-1: pir/pTEF1:[NK]<sub>35</sub>クローンおよびAPP225株を後期対数増加期まで増殖させることによって設定した。各タグを付加したpTEF-1クローンにつき50 μlのアリコートの培養液を150 μlのAPP255培養液と混合し、ついで100 μM IPTGおよび10 mM MgSO<sub>4</sub>を含有するBHIV<sup>10</sup>プレート上に予め設置した0.22 μM フィルター上に50 μlの各交配混合物をスポットした。5% CO<sub>2</sub>下、37にて一晩インキュベートした後に、各フィルターの交配混合物を2 mlのPBS中に洗い出し、各々の200 μlをBHIV<sup>10</sup>N<sup>50</sup>K<sup>100</sup>プレートに平板した。選択的に一晩増殖させた後に、200 μl BHIV<sup>10</sup>N<sup>50</sup>K<sup>50</sup>に楊枝で移動させることによってコロニーをマイクロタイタープレートに集めて、マイクロタイタープレートの各ウェルが常に同一の配列タグを有するトランスポゾン突然変異体を含むことを確認した。一晩増殖させた後に、50 μlの75%グリセリンを各ウェルに添加し、プレートを-80にて凍結保存した。

#### 【0106】

APPは、P. multocidaほどの多くの偏重を該ミニ-Tn10エレメントの多重挿入に対して有していないようである。該突然変異体のうちのほぼ3%しか多重挿入を含んでいないことが決定され、それは以前に報告された4%と一致する[Tasconら, J Bacteriol. 175:5717-22 (1993)]。APPにおける問題は、23S RNA領域への挿入を含有する多数の突然変異体(以下で論ずる): 13のユニーク部位への挿入を有する合計28の突然変異体を同定することからなる。これは、23S RNAが優先挿入部位を含有すること、およびAPPの増殖が宿主内で異なる生存を生じるのに十分なこれらの挿入によって影響を受けることを示しているのかも知れない。APP 23S RNAプローブを用いるサザンブロット解析は、H. influenzae中の5[Fleischmannら, Science 269:496-512 (1995)]およびE.coli中の7の完全オペロン[Blattnerら, Science 277:1453-1474 (1997)]と比較して、APPが3のリボソームオペロンしか含有していない可能性があることを示している。この部位の優先性および増殖速度に対するその影響は「飽和突然変異誘発」に対する明らかな障害となり得る。何故ならば、相当数のクローンがこれらrRNAに挿入を含有し、さらなるユニークな弱毒性突然変異体を得るために大量のスクリーニングが必要であろうからである。

#### 【0107】

実施例7 弱毒化A. pleuropneumoniae突然変異体についてのブタ・スクリーニング  
合計ほぼ800の突然変異体を含有するA. pleuropneumoniaeトランスポゾン突然変異体の20のプールを、ブタ気管内感染症モデルを用いてスクリーニングした。各プールを20の別々の動物でスクリーニングした。

#### 【0108】

プールしたA. pleuropneumoniaeトランスポゾン突然変異体の凍結プレートを-80の貯蔵庫から取り出し、各ウェルからの20 μlを180 μlのBHIV<sup>10</sup>N<sup>50</sup>K<sup>50</sup>を含有する新たな96ウェル丸底プレート(Corning Costar, Cambridge, MA, USA)に移すことによって継代培養した。プレートを振盪することなく5% CO<sub>2</sub>中、37にて一晩インキュベートした。ついで、一晩置いたプレートを、各ウェルからの10 μlをウェルあたり100 μlのBHIV<sup>10</sup>を含有する新たな平底96ウェルプレート(Corning Costar)に移すことによって継代培養し、150 rpmにて振盪しつつ、37にてインキュベートした。マイクロタイタープレートリーダーを用いてOD<sub>562</sub>をモニターし

た。約0.2ないし0.25のOD<sub>562</sub>にて、各プレートプールして、該マイクロタイタープレートの各ウェルからの100 $\mu$ lと合することによって、「投入プール(input pool)」を形成した。培養物をBHI中に適当に希釈して、約 $2 \times 10^6$  CFU/mlとした。各希釈プールにつき、4.0 mlを用いて、気管チューブを用いる気管内投与により10~20 kg SPFブタ(Whitshire-Hamroc, Albion, IN)に感染させた。感染後約20時間にて、生存している全動物を麻酔し、肺を取り出した。洗浄を行って該肺に150 mlの殺菌PBSを灌流させることによって生存する細菌を回収し、ついで、それを揉んで流体を分散させた。洗浄流体を回収し、このプロセスを2回繰り返した。洗浄流体を450 $\times$ gにて10分間遠心して、大量のデブリを分離した。ついで、上清を2,800 $\times$ gにて遠心して、該細菌をペレット化した。ペレットを5 ml BHIに再懸濁し、 $10^{-2}$ ないし $10^{-5}$ の範囲の希釈率でBHIV<sup>10</sup>N<sup>50</sup>K<sup>50</sup>プレートに平板した。一晚増殖させた後に、少なくとも100,000のコロニーを10 $\mu$ lのBHIブロス中にプールして、「回収プール」を形成した。各回収プールの0.7 mlを用いて、CTAB法[Wilson, In Ausubelら, (eds.), Current Protocols in Molecular Biology, vol. 1. John Wiley and Sons, New York, p.2.4.1-2.4.5 (1997)]によりゲノムDNAを調製した。通常の動物からの回収率は、肺洗浄物から $10^8$  CFU範囲であった。

10

## 【0109】

先に記載したごとくドットプロットを行い、視覚検査および半定量的分析の両方によって評価した。全てのハイブリダイゼーションおよび検出は記載したごとく行った。簡単には、プローブは、一次PCR増幅につづく目的産物のアガロースゲル精製およびdig-dUTPを取込ませる(incorporating)二次PCR増幅によって調製した。TEF5、TEF6、TEF24、TEF25、TEF48およびTEF62を含むオリゴヌクレオチドは、Genosys Biotechnologies(The Woodlands, TX)により合成した。プライマーTEF69、TEF65およびTEF66もインバースPCRおよび配列決定に用いた。

20

## 【0110】

## 【化7】

TEF69 GACGTTTCCCGTTGAATATGGCTC

配列番号:166

TEF65 GCCGGATCCGGGATCATATGACAAGA

配列番号:167

TEF66 GACAAGATGTGTATCCACCTTAAC

配列番号:168

30

## 【0111】

ついで、標識したPCR産物をHindIIIで消化して、ユニークタグ領域から一定のプライマーアームを分離した。標識した変化し得るタグを含むリュイ基を切り出し、全体のゲルスライス溶解し、DIG EasyHyb中で変性した。ドットプロットを調製し、標準CSPD検出プロトコルを用いて検出した。フィルム露光を視覚評価のために行い、ルミネセントカウント・パー・秒(LCPs)を各ドットプロット試料につき測定した。各突然変異体に対するLCPs投入/LCPs回収比を用いて、弱毒化しているようである突然変異体を決定した。

投入プール中に存在するが、回収プール中では非常に減少しているとして選択したクローンをさらなる研究のために選択した。疑問のある投入/回収比を有するさらなるクローンも、ドットプロットから作成したフィルムを視覚評価した後に選択した。合計110のコロニーを選択した。

40

## 【0112】

実施例8 A. pleuropneumoniae病原性遺伝子の同定

部分的ランキング配列を、インバースPCRおよび直接産物配列決定により該110の突然変異体の各々について決定した。インバースPCRを用いて、上記した直接配列決定用のランキングDNA産物を作製した。配列決定反応は、PE Applied Biosystems(Foster City, CA)からのBigDye<sup>TM</sup> Terminator Chemistryキットを用いて行い、ABI Prism 377 DNA Sequencer上で行った。Sequencher 3.0ソフトウェア(Genecodes, Corp., Ann

50

Arbor, MI) を用いて、配列データをアセンブルして解析した。GCGプログラム [DevereuxおよびHarberli, 1997. Wisconsin Package Version 9.0, 9.0 ed. Genetics Computer Group, Inc., Madison] を用いて、現在入手可能なデータベース中の相同的配列を検索した。

表 2 は、同定した *A. pleuropneumoniae* 遺伝子およびオープン・リーディング・フレームを決定し得る範囲を示す。配列番号は、ヌクレオチド配列および位置する推定されるアミノ酸配列に付される。

【 0 1 1 3 】

【 表 4 】

表 2

*A. pleuropneumoniae* オープンリーディングフレーム

<u>完全オープンリーディングフレーム</u>		<u>開始コドンなしー終止コドン</u>	
atpH	配列番号: 134	dksA	配列番号: 136
aptG	配列番号: 132	dnaK	配列番号: 138
exbB	配列番号: 140	HI0379	配列番号: 144
OmpP5	配列番号: 152		
OmpP5-2	配列番号: 150	<u>開始コドンなしー終止コドンなし</u>	
tig	配列番号: 160	pnp	配列番号: 154
fkpA	配列番号: 142	apvA-or 1	配列番号: 122
hupA	配列番号: 146	apvA-or 2	配列番号: 124
rpmF	配列番号: 158	apvB	配列番号: 126
		apvD	配列番号: 130
<u>開始コドンー終止コドンなし</u>		<u>RNAまたは非コード配列</u>	
lpdA	配列番号: 148	tRNA-leu	配列番号: 162
potD	配列番号: 156	tRNA-glu	配列番号: 163
yaeE	配列番号: 164		
apvC	配列番号: 128		

【 0 1 1 4 】

表 3 (後記、実施例 9) に掲載する推定同一性は、細菌データベースと比較することによって割当てた。110 の突然変異体は 35 群のユニークなトランスポゾン挿入を表した。遺伝子座あたりの異なる突然変異体の個数は変化し、いくつかのコロニーは、常に、同一 ORF の異なる部位内に挿入を含有するクローンに対する ORF 内の単一部位に挿入を含有した。3 の多重挿入が、多重 PCR バンドの産出および多重配列電気泳動図の生成による決定でスクリーンされた該 110 個のコロニー中に検出された。

【 0 1 1 5 】

実施例 9 *A. pleuropneumoniae* 突然変異体と野生型 AP225 との競争攻撃

回収した集団中に存在しないかあるいは非常に減少していた前記に同定した各ユニークな弱毒化突然変異体群からの代表的なクローンを、起源プールプレートから単離し、野生型株 (AP225) との競争攻撃実験に用いて、トランスポゾン突然変異により生じた相対的弱毒化を確認した。突然変異体および野生型株を  $BHVI^{10}$  中で  $0.6 - 0.9$  の  $OD_{590}$  まで増殖させた。ほぼ  $5.0 \times 10^6$  CFU の野生型および突然変異体株を各々 4 ml の BHI に添加した。合計 4 ml の用量を用いて気管チューブを用いた気管内投与により 10 - 20 kg の SPF ブタに感染させた。感染後ほぼ 20 時間に、全生存動物を麻酔し、肺を取り出した。肺洗浄を記載したごとく行った。プレートカウントを  $BHIV^{10} N^{50}$  および  $BHIV^{10} N^{50} K^{100}$  で行って、両方の投入培養物および肺洗浄試料中の突然変異体に対する野生型の相対数を決定した。競争指数 (Competitive Index; CI) は、[突然変異体 CFU / 野生型 CFU] 投入 / [突然変異体 CFU / 野生型 CFU] 回収として算出した。

10

20

30

40

50

## 【0116】

35の潜在的トランスポゾン突然変異体のうちで、22が著しく弱毒化し、0.2未満の競争指数(CI)を有していた。STMスクリーニングの結果に基づくと弱毒化していないようであったトランスポゾン突然変異体を、ポジティブコントロールとして1のプールから選択した。この突然変異体はほぼ0.6のin vivoのCIを有していた。この突然変異体についてin vitro競争も行い、0.8のCIを得た。その後、該突然変異体は、2のフェニルアラニンtRNAの間に挿入を含むことが決定された。

## 【0117】

ユニークな弱毒化単一挿入突然変異体の競争指数を表3に掲載する。atpG、pnp、およびexbB App突然変異体についての競争指数は、該突然変異体が野生型株と有効に競争できず、したがって弱毒化していることを示した。

## 【0118】

## 【表5】

表3  
A. pleuropneumoniae 突然変異体の病原性および提唱機能

突然変異体	類似	推定または既知の機能	C.I.
AP20A6	<i>atpH</i>	ATP合成酵素	.009
AP7F10	<i>atpG</i>	ATP合成酵素	.013
AP17C6	<i>lpdA</i>	ジヒドロリポアミド・デヒドロゲナーゼ	.039
AP11E7	<i>exbB</i>	鉄化合物の輸送	.003,.003,.006
AP3H7	<i>potD</i>	スベルミジン/ブテレシンの輸送	.308
AP8H6	<i>OmpP5</i>	アドヘシン/OmpAホモログ	.184
AP18H8	<i>OmpP5-2</i>	アドヘシン/OmpAホモログ	.552
AP13E9	<i>tig</i>	ペプチジル-プロリル・イソメラーゼ	.050
AP13C2	<i>fkpA</i>	ペプチジル-プロリル・イソメラーゼ	<.001
AP15C11	<i>pnp</i>	ポリヌクレオチド・ホスホリアーゼ	.032
AP18F12	<i>hupA</i>	ヒストン様タンパク質	.001
AP20F8	<i>dkxA</i>	<i>dnaK</i> 突然変異の用量依存性サプレッサー	.075
AP5G4	<i>dnaK</i>	ヒートショックタンパク質-分子シャペロン	.376
AP17C9	<i>tRNA-leu</i>	タンパク質合成	.059
AP5D6	<i>tRNA-glu</i>	タンパク質合成	.055
AP18B2	<i>rpmF</i>	タンパク質合成	.112
AP10E7	<i>yaeA</i>	未知	.001
AP19A5	H10379	未知	.061
AP10C10	<i>apvA</i>	未知	.157
AP18F5	<i>apvB</i>	未知	.103
AP2A6	<i>apvC</i>	未知	.091
AP2C11	<i>apvD</i>	未知	.014

## 【0119】

exbB突然変異体が3の異なる動物内で競争して0.003、0.003および0.006のCIが得られたことから、CIの精度は非常に良好のようであった。大きな動物実験における1の競争に基づき弱毒化を割当てするための競争指数の数の使用を、実施例11に

後記するごとく7の突然変異体を用いたブタ ( n = 8 ) における予備ワクチン接種の結果に基づいてさらに確かめた。

#### 【 0 1 2 0 】

実施例 1 0 弱毒化 *A. pleuropneumoniae* 病原性遺伝子の特徴付け

同定した *A. pleuropneumoniae* 遺伝子は4の広い機能的分類を表す：生合成酵素、細胞内輸送成分、細胞内調節成分および未知物質。

$F_0 F_1 H^+$  - *ATPase* 複合体の  $F_1$  - サブユニットをコードする *atpG* 遺伝子は、*ATP* の産生において、または、*ATP* を加水分解することによるプロトンの輸送において機能し得る。関連する *atpG* 弱毒化突然変異体は、*P. multocida* においても同定された。 $F_1$  サブユニットをコードするもう1の *atp* 遺伝子、すなわち *atpH* も同定された。*atp* 突然変異体の表現型には、非適合性酸 - 感受性表現型 [ Foster, *J Bacteriol.* 173:6896-6902 (1991) ]、*Salmonella typhimurium* [ Garacia del Portillo ら, *Infect Immun.* 61:4489-4492 (1993) ] および *P. multocida* [ 前掲 ] における病原性の喪失、および *Haemophilus influenzae* R d における形質転換頻度と反応能調節遺伝子の誘発との両方における低下 [ Gwinn ら, *J Bacteriol.* 179:7351-20 (1997) ] が含まれる。

10

#### 【 0 1 2 1 】

*LpdA* は、2の酵素複合体：ピルビン酸デヒドロゲナーゼおよび2 - オキソグルタル酸デヒドロゲナーゼのコンポーネントであるジヒドロリポアミド・デヒドロゲナーゼである。病原性に対する関連性は知られていないが、*LpdA* の産生は *Saomonella typhimurium* においてはヒト由来の殺菌性タンパク質にさらされた場合に誘導され、このことは、この誘導が外膜を修復しようとすることに関与している可能性があることを示唆しているかもしれない [ Qi ら, *Mol Microbiol.* 17:523-31 (1993) ]。

20

#### 【 0 1 2 2 】

増殖および生存に必要な欠乏性化合物の輸送は *in vivo* において極めて重要である。*ExbB* は、*TonB* 輸送複合体の一部であり [ Hantke および Zimmerman, *Microbiology Letters.* 49:31-35 (1981) ]、少なくとも2の異なる方法で *TonB* と相互作用する [ Karlsson ら, *Mol Microbiol.* 8:389-96 (1993); Karlsson ら, *Mol Microbiol.* 8:379-88 (1993) ]。鉄を獲得することは病理に必須である。この研究において、*APP* および *P. multocida* の両方において弱毒化 *exbB* 突然変異体を同定した。いくつかの *TonB* 依存性の鉄受容体が他の細菌において同定されている [ Biswas ら, *Mol. Microbiol.* 24:169-179 (1997); Braun, *FEMS Microbiol Rev.* 16:295-307 (1995); Elkins ら, *Infect Immun.* 66:151-160 (1998); Occhino ら, *Mol Microbiol.* 29:1493-507 (1998); Stojiljkovic および Srinivasan, *J Bacteriol.* 179:805-12 1997 ]。 *A. pleuropneumoniae* は2のトランスフェリン結合タンパク質を産生し、それらは鉄の獲得について *ExbB* / *ExbD* / *TonB* 系に依存するようである。*PotD* は、細胞周辺結合タンパク質であって、それはスペルミジン ( ポリアミン ) 輸送に必要である [ Kashiwagi ら, *J Biol Chem.* 268:19358-63 (1993) ]。 *Pasteurellaceae* ファミリーのもう1のメンバーである *Pasteurella haemolytica* は、回復期患者または外膜タンパク質でワクチン化した子ウシにおける主要な免疫原である *potD* ( *Lpp38* ) のホモログを含んでいる [ Pandher および Murphy, *Vet Microbiol.* 51:331-41 (1996) ]。 *P. haemolytica* において、*PotD* は内外膜の両方に関連するようである。以前の研究が *Streptococcus pneumoniae* の *potD* 突然変異体が弱毒化していることを示している [ Polissi ら, *Infect. Immun.* 66:5620-9 (1998) ] にも拘わらず、病原性または保護抗体に対する関係における *PotD* の役割は知られていない。

30

40

#### 【 0 1 2 3 】

アドヘシンシンまたはトキシンのごとき比較的わずかな「典型的病原性因子」しか、*Haemophilus influenzae* の *OMP P5* のホモログを除いて、同定されていない。*H. influenzae* の *OMP P5* は主たる外膜タンパク質であり、それはタンパク質の *OmpA* ポリンファミリーのタンパク質と関係がある [ Munson ら, *M Infect Immun.* 61:4017-20 (1993) ]。非分類 *Haemophilus influenzae* の *OMP P5* は、繊維状構造として発現されるフィンブリンのサブユニットタンパク質をコードすることが示されており [ Sirakova ら, *Infect I*

50

mmun. 62:2002-20 (1994) ]、それは病原性ならびにムチンおよび上皮細胞の両方の結合に寄与している [ MiyamotoおよびBakaletz, Microb Pathog. 21:343-56 (1996); Reddyら, Infect Immun, 64:1477-9 (1996); Sirakovaら, Infect Immun. 62:2002-20 (1994) ]。極めて重要な発見は、OMP P5ホモログをコードするようである2の異なるORFが同定されたことである。これは、Haemophilus ducreyi由来の2の非常に類似するタンパク質、MOMPおよびOmpA2の場合も同様である。両方ともフィンプリエの産生に機能的に関与しているのか、および、2のかかるORFの存在が重複するまたは相補的な機能を有する分岐複製を表すのかを決定することが残っている。興味深いことに、該2のOMP P5突然変異体は全く異なるCI値を有するようであり、1のみのコピーについての必須性または機能性の差異を示している。OMP P5は長期の感染の間に分子的な変化を受けていることが示されている [ Duimら, Infect Immun. 65:1351-1356 (1997) ] が、これは点突然変異を受けている単一の遺伝子に限定されているようであり、多重遺伝子の分別発現 (differential expression) に起因する「タイプ・スイッチング」よりもアミノ酸変化を生じる。

10

#### 【0124】

タンパク質折畳み酵素は、細胞周辺および細胞外タンパク質を効果的に折畳むための重要な補助物であり、2の遺伝子が同定され、それらの産物はペプチジル - プロリルイソメラーゼ活性を有する：fkpAおよびtig (トリガー因子)。FkpAはFK506 - 結合タンパク質ファミリーのメンバーである細胞周辺タンパク質である [ HorneおよびYoung, Arch Microbiol. 163:357-65 (1995); Missiakasら, Mol Microbiol. 21:871-84 (1996) ]。FkpAは、Salmonella typhimurium [ Horneら, Infect Immun. 65:806-10 (1997) ] およびLegionella pneumophilaホモログ、mip [ Englebergら, Infect Immun. 57:1263-1270 (1989) ] の細胞内生存に寄与することが示されており、病原性およびマクロファージの感染に寄与している [ Cianciottoら, J. Infect. Dis. 162:121-6 (1990); Cianciottoら, Infect Immun. 57:1255-1262 (1989) ]。Tig、すなわちトリガー因子 [ CrookeおよびWickner, Proc. Natl. Acad. Sci. USA. 84:5261-20 (1987); GuthrieおよびWickner, J Bacteriol 172:5555-62 (1990); Hesterkampおよび Bukau., FEBS Lett. 389:32-4 (1996) に概説されている ] は典型的なFKBP領域を含有するペプチジルプロリルイソメラーゼであるが [ CallebautおよびMornon, FEBS Lett. 374:211-215 (1995) ]、FK506によって影響されない [ Stollerら, EMBO J. 14:4939-48 (1995) ]。Tigは、リボソームおよび発生期ポリペプチド鎖に関連することが示されている [ Hesterkampら, Proc Natl. Acad Sci USA 93:4437-41 (1996); Stollerら, EMBO J. 14:4939-48 (1995) ]。可能性のある役割には、E.coli中の細胞分裂 [ Guthrie, およびWickner, J Bacteriol. 172:5555-62 (1990) ]、Streptococcus pyogenesシステインプロテイナーゼの分泌および活性化における役割 [ Lyonら, EMBO J. 1:6263-75 (1998) ]、およびBacillus subtilis中の飢餓条件下での生存 [ Gotheら, Biochemistry 37:13392-9 (1998) ] への知られていない影響を含む。

20

30

#### 【0125】

細菌の病理は、宿主内の広く様々な環境条件下で生存するために、多くのメカニズムを用いて、遺伝子発現を配位的に調節する。mRNA安定性における差異は、原核生物中の遺伝子発現を調整し得る [ BelascoおよびHiggins, Gene, 72:15-23 (1988) ]。例えば、rnr (vacB) がShigella flexneri中のプラスミド運搬毒性遺伝子の発現に要求され [ Tobeら, J Bacteriol. 174:6359-67 (1992) ]、RnaseRリボヌクレアーゼをコード化する [ Chengら, J. Biol. Chem. 273:14077-14080 (1998) ]。PNPはmRNAの分解に関わるポリヌクレオチドホスホリラーゼである。致死のpnp / rnr突然変異はなく、機能のありそうな重複を示唆する。したがって、rnrおよびpnpの両方が毒性遺伝子発現に関わる可能性がある。P.mulcosidaのpnp突然変異体は、マウス敗血症モデルにおいて無毒である (実施例2)。他のpnp関連表現型はBacillus subtilisにおける反応能欠乏および低温感受性を含む [ WangおよびBechhofer, J Bacteriol. 178:2357-82 (1996) ]。

40

50

## 【 0 1 2 6 】

H u p A は細菌性ヒストン様タンパク質であり、それはH u p Bと組み合わさって、E. coli中にH Uタンパク質を構築する。報告は、h u p Aおよびh u p Bは、いかなる観察可能な表現型をも示さないことを示しているが [Huismanら, J Bacteriol. 171:3704-12 (1989); Wadaら, J Mol. Biol. 204:581-91 (1988)]。h u p A - h u p B二重突然変異体は、低温感受性でありヒートショックに感受性であって、部位特異的D N A組換えの多くの形態においてブロックされることが示されている [Wadaら, J Mol. Biol. 204:581-91 (1988); Wadaら, Gene. 76:345-52 (1989)]。一つの限定的データは、以前、h u p Aは毒性に直接関わることを示した [Turnerら, Infect Immun. 66:2099-106 (1998)]。h u p A弱毒化のメカニズムが知られないまま残っている。

10

## 【 0 1 2 7 】

D n a Kは、よく知られ、高度に保存されたヒートショックタンパク質であり、様々なストレスの多い環境変化に対する調節的反応に関わる ([LindquistおよびCraig, Annu Rev Genet. 22:631-77 (1988)]に論評されている)。D n a Kは、マクロファージに食された後に著しく誘発されたストレスタンパク質であり [Yamamotoら, Microbiol Immunol. 38:295-300 (1994)]、Brucella suis d n a K突然変異体は、ヒトマクロファージ様細胞内で繁殖はできなかった [Kohlerら, Mol Microbiol. 20:701-12 (1996)]。対症的に、もう一つの細胞内病気素因、Listeria monocytogenesは食作用後d n a Kの誘発を示さなかった [Hanawaraら, Infect Immun. 63:4595-9 (1995)]。Vibrio choleraのdnaK突然変異体はT o x Rの産生およびin vitroでその調節された毒性因子に影響したが、同様の結果は、in vivo成長細胞からは得られなかった [Chakarabartiら, Infect Immun. 67:1025-1033 (1999)]。A. pleuropneumonia d n a K突然変異体のC Iはほとんどの病因性減弱した突然変異体より高かったが、依然として、陽性対象株のおよそ半分であった。

20

## 【 0 1 2 8 】

D k s Aは、E. coliのd n a K突然変異体におけるフィラメンタス (filamentous) および温度感受性成長の用量依存性サプレッサーである [KangおよびCraig, J Bacteriol. 172:205-64 (1990)]。現在、D k s Aについて明らかな分子機能はないが、該遺伝子はニワトリおよび孵化したばかりのヒヨコにおけるSalmonella typhimuriumの毒性に重要であることが確認された [Turnerら, Infect Immun. 66:2099-106 (1998)]。その研究において、該D k s A突然変異体はグルコースまたはヒスチジンと一緒にではよく成長しなかったが、単に炭素源としてグルタミンまたはグルタミン酸エステルと一緒にだとよく成長したことが記されている。この観察は、該d k s A突然変異体は、グルタミン酸エステルの生合成において、幾分、力が減じられることを示すのであろう [Turnerら, Infect Immun. 66:2099-106 (1998)]。

30

## 【 0 1 2 9 】

3つの遺伝子がタンパク質合成において役割を有することが確認された：t R N A - l e u、t R N A - g l u、およびr p m F。タンパク質合成を除いて、t R N Aは、ペプチドグリカン合成 [Stewartら, Nature 230:36-38 (1971)]、ポルフィリン環合成 [Jahnら, Trends Biochem Sci. 17:215-8 (1992)]、分解のためのタンパク質の標的 [Tobiasら, Science 254:1374-7 (1991)]、タンパク質への翻訳後アミノ酸付加 [LeibowitzおよびS offer, B.B.R.C. 36:47-53 (1969)]、および細菌 - 真核細胞相互作用 [Grayら, J Bacteriol. 174:1086-98 (1992); Hromokyjら, Mol Microbiol. 6:2113-24 (1992)]においても、広汎な機能的な役割を有する。より詳しくは、t R N A - l e uは、転写減衰 [Carterら, Proc. Natl. Acad. Sci. USA 83:8127-8131 (1986)]、Pseudomonas syringaeによる病変形成 [RichおよびWillis, J Bacteriol. 179:2247-58 (1997)]およびウロパソゲンE. coliの毒性 [Dorbrindtら, FEMS Microbiol Lett. 162:135-141 (1998); Ritterら, Mol Microbiol. 17:109-21 (1995)]に関連する。本発明者らが同定したt R N AがA. pleuropneumoniaeにおけるt R N A - l e uのマイナー種を代表するかどうかは分らない。それにもかかわらず、t R N A - l e uは広汎な機能のいずれか1を有する可能性がある。R p m Fはリボ染色体タンパク質であり、その遺伝子もE. coli中の脂肪酸生合成酵素を

40

50



含有するオペロンの部分である。f a b 遺伝子および r p m F の同一のクラスター形成が Haemophilus influenzae においても発生するが [Fleischmannら, Science 269:496-512 (1995)]、これは A. pleuropneumoniae において事実であるかどうかを示すためのさらなる研究が必要である。該 f a b 遺伝子の発現は、必ずしも、r p m F n o 上流を開始する転写物に依存するとは限らない。それは、r p m F 中に同定された第2のプロモータが存在しているからである [ZhangおよびCronan, Jr., J Bacteriol. 180:3295-303 (1998)]。

## 【0130】

病因性減弱した突然変異体の最終クラスは、未知の機能を持つ遺伝子、すなわち、以前に同定されていない遺伝子内の突然変異を含む。y a e A および H I 0 3 7 9 のホモログは、それぞれ、Escherichia coli [Blattnerら, Science 277:1453-1474 (1997)] および Haemophilus influenzae [Fleischmannら, Science 269:496-512 (1995)] において、以前同定された。残る未知物は Actinobacillus pleuropneumoniae virulence 遺伝子 (a p v) と名付けられている。a p v C 遺伝子は、H I 0 8 9 3 に著しい類似性を示すが、脂肪酸反応調節 B m 3 R 1 に類似する転写レプレッサーとしての H I 0 8 3 9 の提案された類似性 [Palmer, J Biol Chem. 273:18109-16 (1998)] は疑わしい。a p v D 遺伝子も E. coli 由来の未知の機能を持つ推定膜タンパク質 (b 0 8 7 8) に最も類似している [Blattnerら, Science 277:1453-1474 (1997)]。2つの他の未知物、a p v A および a p v B は公開データベースには明らかに適合するものもなかった。

## 【0131】

実施例 1 1 A. pleuropneumoniae 突然変異体の安全性および効能 9つの群 (n = 8) の S P F ブタ (4 ~ 5 週齢、3 ~ 10 kg) を用いて、生きた弱毒化したワクチン株として 7つの A. pleuropneumoniae の安全性および効能を決定した。7つの群は、1日目に  $10^{1.0}$  C F U の各突然変異体で鼻腔内感染させた。1つの群は、1日目および15日目に市販のワクチン Pleuromune (Bayer) でワクチン化し、1つのナイーブ群 (naive group) はワクチン化しなかった。29日目に、全群は、ブタあたり  $1 \sim 5 \times 10^5$  C F U の野生型 A P P 2 2 5 で、鼻腔内免疫性テストした。この研究の42日目に、全ての生存している動物を麻酔し、剖検した。結果を表4に示す。

## 【0132】

## 【表6】

表4

*A. pleuropneumoniae* 突然変異体の効力

鼻腔内攻撃後の%死亡率

ワクチン	ワクチン化	攻撃
プレウロミュン (Pleuromune)	0	37.5
exbB	0	0
tig	12.5	0
fkpA	12.5	0
HI0385	50.0	0
pnp	0	0
yaeE	0	0
atpG	0	0
なし	N/A	50.0

## 【0133】

該 *exbB*、*atpG*、*pnp*、および *yaeA* 突然変異体は、 $10^{10}$  CFU の用量を鼻腔内投与したときに死亡を引き起こさなかった。該 *fkpA* および *tig* 突然変異体群は、各々 1 匹の死亡があり、該 HI 0379 群（最高 2000 年 4 月 6 日、試験した 7 の突然変異体の CI は実施例 9 に示す）は 4 匹の死亡があった。このモデルに用いた野生型 LD 50 は、通常、 $1 \times 10^7$  CFU であり、これらの突然変異体の各々は少なくとも 100 倍弱毒化され、CI と弱毒化との間にもっともな相関性があることを示している。

## 【0134】

実施例 12 *P. (Mannheimia) haemolytica* 種ホモログの同定

*P. multocida* および *A. pleuropneumoniae* において同定した病原性遺伝子に基づいて、*P. (Mannheimia) haemolytica* における関連する遺伝子、すなわち種ホモログを同定する試みを行った。示したように *P. (Mannheimia) haemolytica* 遺伝子を増幅するために以下の縮重プライマーを用いて PCR を行った。Sigma-Genosys (The Woodlands, TX) によって合成されたプライマー配列は標準的な一次略号を含み、ここで B は (C、G または T) のいずれかを示し、D は (G、A または T) のいずれかを示し、H は (A、C または T) のいずれかを示し、K は (G または T) のいずれかを示し、M は (A または C) のいずれかを示し、N は (A、G、C または T) のいずれかを示し、R は (A または G) のいずれかを示し、S は (G または C) のいずれかを示し、V は (G、A または C) のいずれかを示し、W は (A または T) のいずれかを示し、および Y は (C または T) のいずれかを示す。

## 【0135】

## 【化 8】

<i>atpG</i>	TEF146	ATG GCN GGN GCN AAR GAR AT	配列番号: 176
	TEF148	GCN GCY TTC ATN GCN ACC AT	配列番号: 177
<i>guaB</i>	TEF240	GGN TTY ATY CAY AAA AAY ATG	配列番号: 178
	TEF243	TCT TTN GTR ATN GTN ACA TCR TG	配列番号: 179
<i>pnp</i>	TEF141	GCS GGY AAA CCR CGT TGG GAT TGG	配列番号: 180
	TEF142	CRC CTA ARA TRT CTG AAA GCA CCA C	配列番号: 181
<i>purF</i>	TEF244	ATG TGY GGN ATY GTN GGN AT	配列番号: 182
	TEF247	CAT ATC AAT ACC ATA CAC ATT	配列番号: 183
<i>yjgF</i>	TEF162	GGN CCN TAY GTN CAR G	配列番号: 184
	TEF163	NGC NAC YTC NAC RCA	配列番号: 185

## 【0136】

最初の変性 PCR 産物を増幅するために、 $3.3 \times$  XL バッファー II (PE Applied Biosystems)、 $200 \mu\text{M}$  の dNTP、 $25$  ピコモルの各適当なプライマー、 $0.8 \text{ mM}$  の  $\text{MgCl}_2$ 、 $0.5 \text{ U}$  の *rTth* DNA ポリメラーゼ、XL (PE Applied Biosystems) およびほぼ  $1 \mu\text{g}$  の TFI DNA を用いて  $50 \mu\text{l}$  反応を設定した。

## 【0137】

サイクル条件は  $94^\circ\text{C}$  にて  $1.5$  分間につづいて； $94^\circ\text{C}$  にて  $15$  秒間、 $40-60^\circ\text{C}$  にて  $60$  秒間、 $72^\circ\text{C}$  にて  $1.5$  分間を  $35$  サイクル；および  $72^\circ\text{C}$  にて  $4$  分間を最終ホールとした。各 PCR 産物を QIAGEN Gel Extraction Kit (QIAGEN, Valencia CA) を用いたアガロースゲルからバンド精製した。

## 【0138】

配列決定反応は、PE Applied Biosystems (Foster City, CA) からの BigDye<sup>TM</sup> Dye Terminator Chemistry kit を用いて行い、ABI Prism 377 DNA Sequencer 上で行った。各クローンについてのオープンリーディングフレーム (ORF) 用の二本鎖配列を得た。Sequench

10

20

30

40

50

er 3.0ソフトウェア (Genecodes, Corp., Ann Arbor, MI)を用いて配列データをアSEMBルし、解析した。GCGプログラムを用い、現在利用可能なデータベース中でホモログ配列を検索することによってORFの同一性を確認した。

【0139】

Vectorette Kit (Genosys Biotechnologies, The Woodlands, TX)を用いて、各遺伝子のさらなるランキング配列を得た。Vectoretteライブラリーを製造業者の指示するプロトコールに従って調製した。Perkin Elmer Applied Biosystems GeneAmp XL PCR Kitコンポーネントを用いて、以下の反応条件を用いてVectorette PCR産物を作製した。50  $\mu$ lの反応は、3.3  $\times$  XLバッファーII (PE Applied Biosystems)、200  $\mu$ MのdNTP、25 pmolの各々の適当なプライマー (以下に示す)、0.8 mMのMgCl<sub>2</sub>、0.5 UのrTth DNAポリメラーゼ、XL (PE Applied Biosystems)および1  $\mu$ lの適当なvectoretteライブラリーを用いて設定した。サイクル条件は、94 にて1.5分間；につづく94 にて20秒間、60 にて45秒間、72 にて4分間の35サイクル；および72 にて7分間の最終保持であった。各ライブラリーの第2のプライマーは製造業者のvectoretteプライマーとした。

10

【0140】

【表7】

表 5

遺伝子	Vectoretteライブラリ	プライマー
atpG	BglII, HindIII	TEF217 GAAGCCGCCATACGCTCTTGGG 配列番号: 186
	Clal	TEF218 GTTGCTTCCTTTGCCTGCACTGG 配列番号: 187
guaB	EcoRI	TEF265 GGCTCAGAAACAATACCACITTC A 配列番号: 188
	HindIII, TaqI	TEF268 GCACCAAAGCAGAATTTGTCC 配列番号: 189
pnp	Clal, HincII	TEF219 GGTGATGATGTCGATGATAGTCCC 配列番号: 190
	TaqI,	TEF220 GCGTATTAGCCGTGATGCCAACC 配列番号: 191
	BamHI	TEF286 GACCACTTAGGCGATATGGACTT 配列番号: 192
purF	TaqI	TEF271 ACCATCATAAATCGCCTGATTC 配列番号: 193
		TEF292 ACCTGCGGCATCTTGTCCCTC 配列番号: 194
	HincII	TEF274 ACGGGTTTATTTTGCCTCTG 配列番号: 195
yjgF	Clal	TEF221 CGCCGGTTTCAGGATTCACGGG 配列番号: 196
	EcoRV	TEF281 CTGAACAACGTGAAAGCCAT 配列番号: 197

10

20

30

40

## 【0141】

VectorettePCR産物を前記したごとくバンド精製し、配列決定した。atpG、guaB、pnp、purFおよびyjgF遺伝子のポリヌクレオチドを各々配列番号: 166、168、170、172および174に記載する。これらの遺伝子によってコードされるポリペプチドを各々配列番号: 167、169、171、173および175に記載する。

## 【0142】

上記の例示的实施例に記載された本発明の数多くの修飾および変形が当業者にとって生じるものと予測される。したがって、添付した特許請求の範囲に表されるごとき単にそのような限定を本発明におくべきである。

## 【国際公開パンフレット】

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number  
**WO 02/075507 A2**

- (51) International Patent Classification: **G06F 1/00**
- (21) International Application Number: PCT/US02/01971
- (22) International Filing Date: 17 January 2002 (17.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/809,665 15 March 2001 (15.03.2001) US
- (71) Applicant (for all designated States except US): **PHARMACIA & UPJOHN COMPANY** [US/US]; 301 Henrietta Street, Kalamazoo, MI 49007 (US).
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): **LOWERY, David, E.** [US/US]; 1207 Woodland Drive, Portage, MI 49024 (US); **FULLER, Troy, E.** [US/US]; 111 Dreamfield Drive, Battle Creek, MI 49014 (US); **KENNEDY, Michael, J.** [US/US]; 2364 Quincy Avenue, Portage, MI 49024 (US).
- (74) Agent: **WILLIAMS, Joseph, A., Jr.**; Marshall, Gerstein & Borun, 6300 Sears Tower, 253 South Wacker Drive, Chicago, IL 60606 (US).
- (81) Designated States (national): AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, HE, IT, LU, MC, NL, PT, SI, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/075507 A2

(54) Title: ANTI-BACTERIAL VACCINE COMPOSITIONS

(57) Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.

## ANTI-BACTERIAL VACCINE COMPOSITIONS

This application is a continuation-in-part of U.S. Patent Application Serial No: 09/545,199, filed April 6, 2000, which claims benefit of U.S. Provisional Patent Application Serial Nos. 60/153,453, filed September 10, 1999 and 60/128,689, filed April 9, 1999.

### FIELD OF THE INVENTION

The present invention relates generally to the identification of genes responsible for virulence of *Pasteurellaceae* bacteria, thereby allowing for production of novel attenuated mutant strains useful in vaccines and identification of new anti-bacterial agents that target the virulence genes and their products.

### BACKGROUND OF THE INVENTION

The family *Pasteurellaceae* encompasses several significant pathogens that infect a wide variety of animals. In addition to *P. multocida*, prominent members of the family include *Pasteurella (Mannheimia) haemolytica*, *Actinobacillus pleuropneumoniae* and *Haemophilus somnus*. *P. multocida* is a gram-negative, nonmotile coccobacillus which is found in the normal flora of many wild and domestic animals and is known to cause disease in numerous animal species worldwide [Biberstein, In M. Kilian, W. Frederickson, and E. L. Biberstein (ed.), *Haemophilus, Pasteurella, and Actinobacillus*. Academic Press, London, p. 61-73 (1981)]. The disease manifestations following infection include septicemias, bronchopneumonias, rhinitis, and wound infections [Reviewed in Shewen, *et al.*, In C. L. Gyles and C. O. Thoen (ed.), *Pathogenesis of Bacterial Infections in Animals*. Iowa State University Press, Ames, p. 216-225 (1993), incorporated herein by reference].

Infection by *P. multocida* generally results from invasion during periods of stress, but transmission may also occur by aerosol or contact exposure, or via flea and tick vectors. In fowl, *P. multocida* infection gives rise to acute to peracute septicemia, particularly prevalent in domestic turkeys and wild waterfowl under stress conditions associated with overcrowding, laying, molting, or severe

WO 02/075507

PCT/US02/01971

climatic change. In cattle, a similar hemorrhagic septicemia follows infection and manifests conditions including high fever and depression, generally followed by quick death. Transmission is most likely through aerosol contact, but infection can also arise during periods of significant climatic change. In rabbits, infection gives rise to  
5 recurring purulent rhinitis, generally followed by conjunctivitis, otitis media, sinusitis, subcutaneous abscesses, and chronic bronchopneumonia. In severe infections, rabbit mortality arises from acute fibrinous bronchopneumonia, septicemia, or endotoxemia. Disease states normally arise during periods of stress. In pigs, common *P. multocida* disease states include atrophic rhinitis and bacterial pneumonia. Similar pneumonia  
10 conditions are also detected in dogs, cats, goats, and sheep. *P. multocida* is commonly detected in oral flora of many animals and is therefore a common contaminant in bite and scratch wounds.

*P. multocida* strains are normally designated by capsular serogroup and somatic serotype. Five capsular serogroups (A, B, D, E, and F) and 16 somatic  
15 serotypes are distinguished by expression of characteristic heat-stable antigens. Most strains are host specific and rarely infect more than one or two animals. The existence of different serotypes presents a problem for vaccination because traditional killed whole cell bacteria normally provide only serotype-specific protection. However, it has been demonstrated that natural infection with one serotype can lead to  
20 immunological protection against multiple serotypes [Shewen, *et al.*, *In C. L. Gyles and C. O. Thoen (Ed.), Pathogenesis of Bacterial Infections in Animals*, Iowa State University Press, Ames, p. 216-225 (1993)] and cross protection can also be stimulated by using inactivated bacteria grown *in vivo* [Rimler, *et al.*, *Am J Vet Res.* 42:2117-2121 (1981)]. One live spontaneous mutant *P. multocida* strain has been  
25 utilized as a vaccine and has been shown to stimulate a strong immune response [Davis, *Poultry Digest.* 20:430-434 (1987), Schlink, *et al.*, *Avian Dis.* 31(1):13-21 (1987)]. This attenuated strain, however, has been shown to revert to a virulent state or cause mortality if the vaccine recipient is stressed [Davis, *Poultry Digest.* 20:430-434 (1987), Schlink, *et al.*, *Avian Dis.* 31(1):13-21 (1987)].

WO 02/075507

PCT/US02/01971

Another member of the *Pasteurella* family, *A. pleuropneumoniae* exhibits strict host specificity for swine and is the causative agent of highly contagious porcine pleuropneumonia. Infection normally arises in intensive breeding conditions, and is believed to occur by a direct mode of transmission. The disease is often fatal and, as a result, leads to severe economic loss in the swine producing industry. *A. pleuropneumoniae* infection may be chronic or acute, and infection is characterized by a hemorrhagic, necrotic bronchopneumonia with accompanying fibrinous pleuritis. To date, bacterial virulence has been attributed to structural proteins, including serotype-specific capsular polysaccharides, lipopolysaccharides, and surface proteins, as well as extracellular cytolytic toxins. Despite purification and, in some instances cloning, of these virulence factors, the exact role of these virulence factors in *A. pleuropneumoniae* infection is poorly understood.

Twelve serotypes of *A. pleuropneumoniae* have been identified based on antigenic differences in capsular polysaccharides and production of extracellular toxins. Serotypes 1, 5, and 7 are most relevant to *A. pleuropneumoniae* infection in the United States, while serotypes 1, 2, 5, 7, and 9 are predominant in Europe. There are at least three significant extracellular toxins of *A. pleuropneumoniae* that are members of the haemolysin family and are referred to as RTX toxins. RTX toxins are produced by many Gram negative bacteria, including *E. coli*, *Proteus vulgaris*, and *Pasteurella haemolytica*, and the proteins generally share structural and functional characteristics. Toxins from the various serotypes differ, however, in host specificity, target cells, and biological activities.

The major *A. pleuropneumoniae* RTX toxins include ApxI, ApxII, and ApxIII. ApxI and ApxII have haemolytic activity, with ApxI being more potent. ApxIII shows no haemolytic activity, but is cytotoxic for alveolar macrophages and neutrophils. Most *A. pleuropneumoniae* serotypes produce two of these three toxins. For example, serotypes 1, 5, 9, and 11 express ApxI and ApxII, and serotypes 2, 3, 4, 6, and 8 express ApxII and ApxIII. Serotype 10, however, produces only ApxI, and serotypes 7 and 12 express only ApxII. Those *A. pleuropneumoniae* serotypes that produce both ApxI and ApxII are the most virulent strains of the bacteria.



WO 02/075507

PCT/US02/01971

The Apx toxins were demonstrated to be virulence factors in murine models and swine infection using randomly mutated wild type bacteria [Tascon, *et al.*, *Mol. Microbiol.* 14:207-216 (1994)]. Other *A. pleuropneumoniae* mutants have also been generated with targeted mutagenesis to inactivate the gene encoding the AopA outer membrane virulence protein [Mulks and Buysee, *Gene* 163:61-66 (1995)].

At least eleven serotypes (1, 2, 5-9, 12-14 and 16) have been demonstrated within *Mannheimia* [*Pasteurella*] *haemolytica* [Angen, *et al.*, *Vet Microbiol* 65(4):283-90 (1999)], a *Pasteurellaceae* species which is responsible for serious outbreaks of acute pneumonia in neonatal, weaned, growing and adult lambs, calves, and goats [Ackermann, *et al.*, *Microbes Infect* 2(9):1079-88 (2000)]. Transportation, viral infections, overcrowding, and other stressful conditions predispose animals to *M. haemolytica* infection [Ackermann, *et al.*, *supra.*] The leukotoxin (Lkt) of *M. haemolytica* is believed to play a significant role in pathogenesis, causing cell lysis and apoptosis that lead to the lung pathology characteristic of bovine shipping fever [Highlander, *et al.*, *Infect Immun* 68(7):3916-22 (2000)] as well as lung injury in bovine pneumonic pasteurellosis [Jeyaseelan, *et al.*, *Microb Pathog* 30(2):59-69 (2001)]. Lkt is a pore-forming exotoxin that has the unique property of inducing cytolysis only in ruminant leukocytes and platelets [Jeyaseelan, *et al.*, (2001), *supra.*]. Cytolysis of many cell types is mediated by arachidonic acid (AA) and its generation by phospholipases is regulated by G-protein-coupled receptors [Jeyaseelan, *et al.*, (2001) *supra.*] Recent studies indicate that *M. haemolytica* Lkt binds to bovine CD18, the common subunit of all beta2 integrins [Jeyaseelan, *et al.*, *Infect Immun* 68(1):72-9 (2000)]. It has also been shown that LFA-1 is a Lkt receptor, Lkt binding to LFA-1 is not target cell specific, Lkt binding to bovine LFA-1 correlates with calcium elevation and cytolysis, and bovine LFA-1 expression correlates with the magnitude of Lkt-induced target cell cytolysis [Jeyaseelan, *et al.*, *Infect Immun* 68(1):72-9 (2000)].

In attempts to produce vaccine compositions, traditional killed whole cell bacteria have provided only serotype-specific protection [MacInnes and Smart, *supra.*], however, it has been demonstrated that natural infection with a highly virulent

WO 02/075507

PCT/US02/01971

serotype can stimulate strong protective immunity against multiple serotypes [Nielsen, *Nord Vet Med.* 31:407-13 (1979), Nielsen, *Nord Vet Med.* 36:221-234 (1984), Nielsen, *Can J Vet Res.* 29:580-582 (1988), Nielsen, *ACTA Vet Scand.* 15:80-89 (1994)]. One defined live-attenuated vaccine strain producing an inactive form of the ApxII toxin has shown promise for cross protection in swine [Prideaux, *et al.*, *Infection & Immunity* 67:1962-1966 (1999)], while other undefined live-attenuated mutants have also shown promise [Inzana, *et al.*, *Infect Immun.* 61:1682-6, (1993), Paltineanu, *et al.*, *In International Pig Veterinary Society*, 1992, p. 214, Utrera, *et al.*, *In International Pig Veterinary Society*, 1992, p. 213].

Because of the problems associated with vaccine formulations comprising bacterial strains with undefined, spontaneous mutations, there exists a need in the art for rational construction of live attenuated bacterial strains for use in vaccines that will safely stimulate protective immunity against homologous and heterologous *Pasteurellaceae* serotypes. There further exists a need to identify attenuated bacterial strains and genes required for bacterial virulence, thereby facilitating development of methods to identify anti-bacterial agents.

#### SUMMARY OF THE INVENTION

In general, the present invention provides materials and methods for production and use of vaccine compositions comprising attenuated gram negative bacteria. In one aspect, vaccine compositions of the invention comprise attenuated species in the *Pasteurellaceae* family of bacteria, which is known in the art and described, in part, in Dewhirst, *et al.*, *J. Bacteriol.* 174:2002-2013 (1992), incorporated herein by reference in its entirety. Species in the family include, but are not limited to, *A. actinomycetemcomitans*, *A. capsulatus*, *A. equuli*, *A. lignieresii*, *A. pleuropneumoniae* (*H. pleuropneumoniae*), *A. seminis*, *A. suis* (*H. suis*), *A. ureae* (*p. ureae*), *A. capsulatus*, Bisgaard taxon 11, *H. aegyptius*, *H. aphrophilus*, *H. aphrophilus* (*H. parainfluenzae*), *H. ducreyi*, *H. haemoglobinophilus*, *H. haemolyticus*, *H. influenzae*, *H. paracuniculus*, *H. paragallinarum*, *H. parahaemolyticus*, *H. parainfluenzae*, (*H. paraphrophilus*), *H.*

WO 02/075507

PCT/US02/01971

*paraphrohaemolyticus*, *H. paraphrophilus*, *H. parasuis*, *H. parasuis* type S, *H. segnis*, *H. somnus*, *Haemophilus* minor group, *Haemophilus* taxon C, *P. aerogenes*, *P. anatis*, *P. avium* (*H. avium*), *P. canis*, *P. dagmatis*, *P. gallinarum*, *P. (Mannheimia) haemolytica*, *P. trehalosi* (*P. haemolytica* biotype T), *P. langaa*, *P. multocida*, *P. pneumotropica*, *P. stomatis*, *P. volantium* (*H. parainfluenzae*), *P. volantium*, *Pasteurella* species A, *Pasteurella* species B, and *Haemophilus paraphrohaemolyticus*. Preferably, vaccine compositions comprise attenuated *Pasteurella (Mannheimia) haemolytica*, *Actinobacillus pleuropneumoniae*, *Haemophilus somnus*, or *Pasteurella multocida* bacteria. In a most preferred embodiment, vaccine compositions of the invention comprise attenuated *Pasteurella multocida* and *A. pleuropneumoniae* bacterial strains.

One aspect of the invention provides gram negative bacterial organisms containing a functional mutation in a gene sequence represented by any one of SEQ ID NOS: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174, or species homologs thereof, wherein the mutation inhibits or abolishes expression and/or biological activity of an encoded gene product (*i.e.*, the polypeptide encoded by a gene); said functional mutation resulting in attenuated virulence of the bacterial strain. Functional mutations that modulate (*i.e.*, increase or decrease) expression and/or biological activity of a gene product include insertions or deletions in the protein coding region of the gene itself or in sequences responsible for, or involved in, control of gene expression. Deletion mutants include those wherein all or part of a specific gene sequence is deleted. Also contemplated are compositions, and preferably vaccine compositions, comprising mutated and attenuated gram negative bacterial organisms, optionally comprising a suitable adjuvant and/or a pharmaceutically acceptable diluent or carrier. In order for a modified strain to be effective in a vaccine formulation, the attenuation must be significant enough to

WO 02/075507

PCT/US02/01971

prevent the pathogen from evoking severe clinical symptoms, but also insignificant enough to allow limited replication and growth of the bacteria in the host.

The invention also provides polynucleotides encoding gene products that are required for virulence in gram negative bacteria. Polynucleotides of the invention include DNA, such as complementary DNA, genomic DNA including complementary or anti-sense DNA, and wholly or partially synthesized DNA; RNA, including sense and antisense strands; and peptide nucleic acids as described, for example in Corey, *TIBTECH 15:224-229* (1997). Virulence gene polynucleotides of the invention include those set forth in SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174, or species homologs thereof, polynucleotides encoding a virulence gene product encoded by a polynucleotide of SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174, or a species homolog thereof, and polynucleotide that hybridize, under moderately to highly stringent conditions, to the noncoding strand (or complement) of any one of the polynucleotides set out in SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174, or species homologs thereof. The invention therefore comprehends gene sequences from *Pasteurellaceae* set out in SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174, as well as related gene sequences from other

WO 02/075507

PCT/US02/01971

gram negative bacterial organisms, including naturally occurring (*i.e.*, species homologs) and artificially induced variants thereof. The invention also comprehends polynucleotides which encode polypeptides deduced from any one of the polynucleotides set out in SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 164, 166, 168, 170, 172, and 174, and species homologs thereof. Knowledge of the sequence of a polynucleotide of the invention makes readily available every possible fragment of that polynucleotide. The invention therefore provides fragments of a polynucleotide of the invention.

The invention further embraces expression constructs comprising polynucleotides of the invention. Host cells transformed, transfected or electroporated with a polynucleotide of the invention are also contemplated. The invention provides methods to produce a polypeptide encoded by a polynucleotide of the invention comprising the steps of growing a host cell of the invention under conditions that permit, and preferably promote, expression of a gene product encoded by the polynucleotide, and isolating the gene product from the host cell or the medium of its growth.

Identification of polynucleotides of the invention makes available the encoded polypeptides. Polypeptides of the invention include full length and fragment, or truncated, proteins; variants thereof; fusion, or chimeric proteins; and analogs, including those wherein conservative amino acid substitutions have been introduced into wild-type polypeptides. Antibodies that specifically recognize polypeptides of the invention are also provided, and include monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, humanized antibodies, human antibodies, and complementary determining region (CDR)-grafted antibodies, as well as compounds that include CDR sequences which specifically recognize a polypeptide of the invention. The invention also provides anti-idiotypic antibodies immunospecific for antibodies of the invention.

WO 02/075507

PCT/US02/01971

According to another aspect of the invention, methods are provided for identifying novel anti-bacterial agents that modulate the function of gram negative bacteria virulence genes or gene products. Methods of the invention include screening potential agents for the ability to interfere with expression of virulence gene products encoded by the DNA sequences set forth in any one of SEQ ID NOS: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174, or species homologs thereof, or screening potential agents for the ability to interfere with biological function of a bacterial gene product encoded in whole or in part by a DNA sequence set forth in any one of SEQ ID NOS: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174, species homologs thereof, or the complementary strand thereof, followed by identifying agents that provide positive results in such screening assays. In particular, agents that interfere with the expression of virulence gene products include anti-sense polynucleotides and ribozymes that are complementary to the virulence gene sequences. The invention further embraces methods to modulate transcription of gene products of the invention through use of oligonucleotide-directed triplet helix formation.

Agents that interfere with the function of virulence gene products include variants of virulence gene products, binding partners of the virulence gene products and variants of such binding partners, and enzyme inhibitors (where the product is an enzyme).

Novel anti-bacterial agents identified by the methods described herein are provided, as well as methods for treating a subject suffering from infection with gram negative bacteria involving administration of such novel anti-bacterial agents in an amount effective to reduce bacterial presence.

WO 02/075507

PCT/US02/01971

Numerous additional aspects and advantages of the invention will become apparent to those skilled in the art upon consideration of the following detailed description of the invention which describes presently prepared embodiments thereof.

5

#### DETAILED DESCRIPTION OF THE INVENTION

"Virulence genes," as used herein, are genes whose function or products are required for successful establishment and/or maintenance of bacterial infection in a host animal. Thus, virulence genes and/or the proteins encoded thereby are involved in pathogenesis in the host organism, but may not be necessary for growth.

"Signature-tagged mutagenesis (STM)," as used herein, is a method generally described in International Patent Publication No. WO 96/17951, incorporated herein by reference, and includes, for example, a method for identifying bacterial genes required for virulence in a murine model of bacteremia. In this method, bacterial strains that each have a random mutation in the genome are produced using transposon integration; each insertional mutation carries a different DNA signature tag which allows mutants to be differentiated from each other. The tags comprise 40 bp variable central regions flanked by invariant "arms" of 20 bp which allow the central portions to be co-amplified by polymerase chain reaction (PCR). Tagged mutant strains are assembled in microtiter dishes, then combined to form the "inoculum pool" for infection studies. At an appropriate time after inoculation, bacteria are isolated from the animal and pooled to form the "recovered pool." The tags in the recovered pool and the tags in the inoculum pool are separately amplified, labeled, and then used to probe filters arrayed with all of the different tags representing the mutants in the inoculum. Mutant strains with attenuated virulence are those which cannot be recovered from the infected animal, *i.e.*, strains with tags that give hybridization signals when probed with tags from the inoculum pool but not when probed with tags from the recovered pool. In a variation of this method, non-radioactive detection methods such as chemiluminescence can be used

30

WO 02/075507

PCT/US02/01971

Signature-tagged mutagenesis allows a large number of insertional mutant strains to be screened simultaneously in a single animal for loss of virulence. Screening nineteen pools of mutant *P. multocida* strains resulted in the identification of more than 60 strains with reduced virulence, many of which were confirmed to be attenuated in virulence by subsequent determination of an approximate LD<sub>50</sub> for the individual mutants. Screening of *A. pleuropneumoniae* mutants resulted in identification of more than 100 strains having mutations in 35 different genes. Of these, mutations in 22 genes results in significantly attenuated *A. pleuropneumoniae* strains. The nucleotide sequence of the open reading frame disrupted by the transposon insertion was determined by sequencing both strands and an encoded amino acid sequence was deduced. Novelty of both the polynucleotide and amino acid sequences was determined by comparison of the sequences with DNA and protein database sequences. Knowledge of the virulence genes in these species permitted identification of species homologs in *P. (Mannheimia) haemolytica*.

The identification of bacterial, and more particularly *P. multocida*, *A. pleuropneumoniae* and *P. (Mannheimia) haemolytica* virulence genes provides for microorganisms exhibiting reduced virulence (*i.e.*, attenuated strains), which are useful in vaccines. Such microorganisms include *Pasteurellaceae* mutants containing at least one functional mutation inactivating a gene represented by any one of SEQ ID NOS: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174. The worker of ordinary skill in the art will realize that a "functional mutation" may occur in protein coding regions of a gene of the invention, as well as in regulatory regions that modulate transcription of the virulence gene RNA.

The worker of ordinary skill will also appreciate that attenuated *P. multocida*, *A. pleuropneumoniae* and *P. (Mannheimia) haemolytica* strains of the invention include those bearing more than one functional mutation. More than one mutation may result in additive or synergistic degrees of attenuation. Multiple



mutations can be prepared by design or may fortuitously arise from a deletion event originally intended to introduce a single mutation. An example of an attenuated strain with multiple deletions is a *Salmonella typhimurium* strain wherein the *cya* and *crp* genes are functionally deleted. This mutant *S. typhimurium* strain has shown promise as a live vaccine.

5 Identification of virulence genes in *P. multocida*, *A. pleuropneumoniae* and *P. (Mannheimia) haemolytica* can provide information regarding similar genes in other pathogenic species. As an example, identification of the *aroA* gene led to identification of conserved genes in a diverse number of pathogens, including  
10 *Aeromonas hydrophila*, *Aeromonas salmonicida*, *Salmonella typhimurium*, *Salmonella enteritidis*, *Salmonella dublin*, *Salmonella gallinarum*, *Bordetella pertussis*, *Yersinia enterocolitica*, *Neisseria gonorrhoeae*, and *Bacillus anthracis*. In many of these species, attenuated bacterial strains bearing mutations in the *aroA* gene have proven to be effective in vaccine formulations. Using the virulence genes sequences identified in *P. multocida*, similar or homologous genes can be identified in other  
15 organisms, particularly within the *Pasteurella* family, as well as *A. pleuropneumoniae*, *P. (Mannheimia) haemolytica*, and *Haemophilus somnus*. Likewise, identification of *A. pleuropneumoniae* virulence genes can permit identification of related genes in other organisms. Southern hybridization using the *P. multocida*, *A. pleuropneumoniae* and *P. (Mannheimia) haemolytica* genes as probes  
20 can identify these related genes in chromosomal libraries derived from other organisms. Alternatively, PCR can be equally effective in gene identification across species boundaries. As still another alternative, complementation of, for example, a *P. multocida* mutant with a chromosomal library from other species can also be used  
25 to identify genes having the same or related virulence activity. Identification of related virulence genes can therefore lead to production of an attenuated strain of the other organism which can be useful as still another vaccine formulation. Examples of *P. multocida* genes that have been demonstrated to exist in other species (e.g. *P. (Mannheimia) haemolytica*, *A. pleuropneumoniae* and *H. somnus*) include genes *exxB*,  
30 *atpG*, *pnp*, *guaB* and *yjgF*.

WO 02/075507

PCT/US02/01971

Attenuated *P. multocida* strains identified using STM are insertional mutants wherein a virulence gene has been rendered non-functional through insertion of transposon sequences in either the open reading frame or regulatory DNA sequences. These insertional mutants still contain all of the genetic information  
5 required for bacterial virulence and can possibly revert to a pathogenic state by deletion of the inserted transposon. Therefore, in preparing a vaccine formulation, it is desirable to take the information gleaned from the attenuated strain and create a deletion mutant strain wherein some, most, or all of the virulence gene sequence is removed, thereby precluding the possibility that the bacteria will revert to a virulent  
10 state.

The vaccine properties of an attenuated insertional mutant identified using STM are expected to be the same or similar to those of a bacteria bearing a deletion in the same gene. However, it is possible that an insertion mutation may exert "polar" effects on adjoining gene sequences, and as a result, the insertion mutant  
15 may possess characteristic distinct from a mutant strain with a deletion in the same gene sequence. Deletion mutants can be constructed using any of a number of techniques well known and routinely practiced in the art.

In one example, a strategy using counterselectable markers can be employed which has commonly been utilized to delete genes in many bacteria. For a  
20 review, see, for example, Reyrat, *et al.*, *Infection and Immunity* 66:4011-4017 (1998), incorporated herein by reference. In this technique, a double selection strategy is often employed wherein a plasmid is constructed encoding both a selectable and counterselectable marker, with flanking DNA sequences derived from both sides of the desired deletion. The selectable marker is used to select for bacteria in which the  
25 plasmid has integrated into the genome in the appropriate location and manner. The counterselectable marker is used to select for the very small percentage of bacteria that have spontaneously eliminated the integrated plasmid. A fraction of these bacteria will then contain only the desired deletion with no other foreign DNA present. The key to the use of this technique is the availability of a suitable  
30 counterselectable marker.

WO 02/075507

PCT/US02/01971

In another technique, the *cre-lox* system is used for site specific recombination of DNA. The system consists of 34 base pair *lox* sequences that are recognized by the bacterial *cre* recombinase gene. If the *lox* sites are present in the DNA in an appropriate orientation, DNA flanked by the *lox* sites will be excised by the *cre* recombinase, resulting in the deletion of all sequences except for one remaining copy of the *lox* sequence. Using standard recombination techniques, it is possible to delete the targeted gene of interest in the *P. multocida*, *A.*

*pleuropneumoniae* or *P. (Mannheimia) haemolytica* genome and to replace it with a selectable marker (e.g., a gene coding for kanamycin resistance) that is flanked by the *lox* sites. Transient expression (by electroporation of a suicide plasmid containing the *cre* gene under control of a promoter that functions in *P. multocida*, *A.*

*pleuropneumoniae*, or *P. (Mannheimia) haemolytica*) of the *cre* recombinase should result in efficient elimination of the *lox* flanked marker. This process would result in a mutant containing the desired deletion mutation and one copy of the *lox* sequences.

In another approach, it is possible to directly replace a desired deleted sequence in the *P. multocida*, *A. pleuropneumoniae* or *P. (Mannheimia) haemolytica* genome with a marker gene, such as green fluorescent protein (GFP),  $\beta$ -galactosidase, or luciferase. In this technique, DNA segments flanking a desired deletion are prepared by PCR and cloned into a suicide (non-replicating) vector for *P. multocida*, *A. pleuropneumoniae*, or *P. (Mannheimia) haemolytica*. An expression cassette, containing a promoter active in *P. multocida*, *A. pleuropneumoniae*, or *P.*

*(Mannheimia) haemolytica* and the appropriate marker gene, is cloned between the flanking sequences. The plasmid is introduced into wild-type *P. multocida*, *A. pleuropneumoniae* or *P. (Mannheimia) haemolytica*. Bacteria that incorporate and express the marker gene (probably at a very low frequency) are isolated and examined for the appropriate recombination event (i.e., replacement of the wild type gene with the marker gene).

The reduced virulence of these organisms and their immunogenicity may be confirmed by administration to a subject animal. While it is possible for an avirulent microorganism of the invention to be administered alone, one or more of

WO 02/075507

PCT/US02/01971

such mutant microorganisms are preferably administered in a vaccine composition containing suitable adjuvant(s) and pharmaceutically acceptable diluent(s) or carrier(s). The carrier(s) must be "acceptable" in the sense of being compatible with the avirulent microorganism of the invention and not deleterious to the subject to be immunized. Typically, the carriers will be water or saline which will be sterile and pyrogen free. The subject to be immunized is a subject needing protection from a disease caused by a virulent form of *P. multocida*, *A. pleuropneumoniae*, *P. (Mannheimia) haemolytica* or other pathogenic microorganisms.

It will be appreciated that the vaccine of the invention may be useful in the fields of human medicine and veterinary medicine. Thus, the subject to be immunized may be a human or other animal, for example, farm animals including cows, sheep, pigs, horses, goats and poultry (e.g., chickens, turkeys, ducks and geese) companion animals such as dogs and cats; exotic and/or zoo animals; and laboratory animals including mice, rats, rabbits, guinea pigs, and hamsters.

The invention also provides polypeptides and corresponding polynucleotides required for *P. multocida*, *A. pleuropneumoniae* or *P. (Mannheimia) haemolytica* virulence. The invention includes both naturally occurring and non-naturally occurring polynucleotides and polypeptide products thereof. Naturally occurring virulence products include distinct gene and polypeptide species as well as corresponding species homologs expressed in organisms other than *P. multocida*, *A. pleuropneumoniae*, or *P. (Mannheimia) haemolytica* strains. Non-naturally occurring virulence products include variants of the naturally occurring products such as analogs and virulence products which include covalent modifications. In a preferred embodiment, the invention provides virulence polynucleotides comprising the sequences set forth in SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174 and species homologs thereof, and polypeptides having amino acids sequences encoded by the polynucleotides.

WO 02/075507

PCT/US02/01971

The present invention provides novel purified and isolated *P. multocida*, *A. pleuropneumoniae* and *P. (Mannheimia) haemolytica* polynucleotides (e.g., DNA sequences and RNA transcripts, both sense and complementary antisense strands) encoding the bacterial virulence gene products. DNA sequences of the invention include genomic and cDNA sequences as well as wholly or partially chemically synthesized DNA sequences. Genomic DNA of the invention comprises the protein coding region for a polypeptide of the invention and includes variants that may be found in other bacterial strains of the same species. "Synthesized," as used herein and is understood in the art, refers to purely chemical, as opposed to enzymatic, methods for producing polynucleotides. "Wholly" synthesized DNA sequences are therefore produced entirely by chemical means, and "partially" synthesized DNAs embrace those wherein only portions of the resulting DNA were produced by chemical means. Preferred DNA sequences encoding *P. multocida* virulence gene products are set out in SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, and 120, and species homologs thereof. Preferred *A. pleuropneumoniae* DNA sequences encoding virulence gene products are set out in SEQ ID NOs: 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, and 164, and species homologs thereof. Preferred *P. (Mannheimia) haemolytica* virulence gene products are set out in SEQ ID NOs: 166, 168, 170, 172 and 174, and species homologs thereof. The worker of skill in the art will readily appreciate that the preferred DNA of the invention comprises a double stranded molecule, for example, molecules having the sequences set forth in SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174 and species homologs thereof, along with the complementary molecule (the "non-coding strand" or "complement") having a sequence deducible from the sequence of SEQ ID NO: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53,

WO 02/075507

PCT/US02/01971

55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174, according to Watson-Crick base pairing rules for DNA. Also preferred are

5 polynucleotides encoding the gene products encoded by any one of the polynucleotides set out in SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166,

10 168, 170, 172, and 174 and species homologs thereof. The invention further embraces species, preferably bacterial, homologs of the *P. multocida*, *A. pleuropneumoniae* and *P. (Mannheimia) haemolytica* DNA.

The polynucleotide sequence information provided by the invention makes possible the identification and isolation of polynucleotides encoding related bacterial virulence molecules by well known techniques including Southern and/or Northern hybridization, and polymerase chain reaction (PCR). Examples of related polynucleotides include polynucleotides encoding polypeptides homologous to a virulence gene product encoded by any one of the polynucleotides set out in SEQ ID

15 NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174, and species homologs thereof, and structurally related polypeptides sharing one or more biological and/or physical properties of a virulence gene product of the invention.

25 The invention also embraces DNA sequences encoding bacterial gene products which hybridize under moderately to highly stringent conditions to the non-coding strand, or complement, of any one of the polynucleotides set out in SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116,

30 118, and 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146,

WO 02/075507

PCT/US02/01971

148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172 and 174, and species homologs thereof. DNA sequences encoding virulence polypeptides which would hybridize thereto but for the degeneracy of the genetic code are contemplated by the invention. Exemplary high stringency conditions include a final wash in buffer  
5 comprising 0.2X SSC/0.1% SDS, at 65°C to 75°C, while exemplary moderate stringency conditions include a final wash in buffer comprising 2X SSC/0.1% SDS, at 35°C to 45°C. It is understood in the art that conditions of equivalent stringency can be achieved through variation of temperature and buffer, or salt concentration as described in Ausubel, *et al.* (Eds.), Protocols in Molecular Biology, John Wiley &  
10 Sons (1994), pp. 6.0.3 to 6.4.10. Modifications in hybridization conditions can be empirically determined or precisely calculated based on the length and the percentage of guanine/cytosine (GC) base pairing of the probe. The hybridization conditions can be calculated as described in Sambrook, *et al.*, (Eds.), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New  
15 York (1989), pp. 9.47 to 9.51.

Autonomously replicating recombinant expression constructions such as plasmid and viral DNA vectors incorporating virulence gene sequences are also provided. Expression constructs wherein virulence polypeptide-encoding polynucleotides are operatively linked to an endogenous or exogenous expression  
20 control DNA sequence and a transcription terminator are also provided. The virulence genes may be cloned by PCR, using *P. multocida* genomic DNA as the template. For ease of inserting the gene into expression vectors, PCR primers are chosen so that the PCR-amplified gene has a restriction enzyme site at the 5' end preceding the initiation codon ATG, and a restriction enzyme site at the 3' end after  
25 the termination codon TAG, TGA or TAA. If desirable, the codons in the gene are changed, without changing the amino acids, according to *E. coli* codon preference described by Grosjean and Fiers, *Gene*, 18:199-209 (1982), and Konigsberg and Godson, *Proc. Natl. Acad. Sci. (USA)*, 80:687-691 (1983). Optimization of codon usage may lead to an increase in the expression of the gene product when produced in  
30 *E. coli*. If the gene product is to be produced extracellularly, either in the periplasm of

WO 02/075507

PCT/US02/01971

*E. coli* or other bacteria, or into the cell culture medium, the gene is cloned without its initiation codon and placed into an expression vector behind a signal sequence.

According to another aspect of the invention, host cells are provided, including procaryotic and eukaryotic cells, either stably or transiently transformed, transfected, or electroporated with polynucleotide sequences of the invention in a manner which permits expression of virulence polypeptides of the invention.

Expression systems of the invention include bacterial, yeast, fungal, viral, invertebrate, and mammalian cells systems. Host cells of the invention are a valuable source of immunogen for development of antibodies specifically immunoreactive with the virulence gene product. Host cells of the invention are conspicuously useful in methods for large scale production of virulence polypeptides wherein the cells are grown in a suitable culture medium and the desired polypeptide products are isolated from the cells or from the medium in which the cells are grown by, for example, immunoaffinity purification or any of the multitude of purification techniques well known and routinely practiced in the art. Any suitable host cell may be used for expression of the gene product, such as *E. coli*, other bacteria, including *P. multocida*, *Bacillus* and *S. aureus*, yeast, including *Pichia pastoris* and *Saccharomyces cerevisiae*, insect cells, or mammalian cells, including CHO cells, utilizing suitable vectors known in the art. Proteins may be produced directly or fused to a peptide or polypeptide, and either intracellularly or extracellularly by secretion into the periplasmic space of a bacterial cell or into the cell culture medium. Secretion of a protein requires a signal peptide (also known as pre-sequence); a number of signal sequences from prokaryotes and eukaryotes are known to function for the secretion of recombinant proteins. During the protein secretion process, the signal peptide is removed by signal peptidase to yield the mature protein.

To simplify the protein purification process, a purification tag may be added either at the 5' or 3' end of the gene coding sequence. Commonly used purification tags include a stretch of six histidine residues (U.S. Patent Nos. 5,284,933 and 5,310,663), a streptavidin-affinity tag described by Schmidt and Skerra, *Protein Engineering*, 6:109-122 (1993), a FLAG peptide [Hopp *et al.*, *Biotechnology*, 6:1205-



WO 02/075507

PCT/US02/01971

1210 (1988)], glutathione S-transferase [Smith and Johnson, *Gene*, 67:31-40 (1988)], and thioredoxin [LaVallie *et al.*, *Bio/Technology*, 11:187-193 (1993)]. To remove these peptide or polypeptides, a proteolytic cleavage recognition site may be inserted at the fusion junction. Commonly used proteases are factor Xa, thrombin, and enterokinase.

5 The invention also provides purified and isolated *P. multocida*, *A. pleuropneumoniae* and *P. (Mannheimia) haemolytica* virulence polypeptides encoded by a polynucleotide of the invention. Presently preferred are polypeptides comprising the amino acid sequences encoded by any one of the polynucleotides set out in SEQ ID NOs : 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 164, 166, 168, 170, 172 and 174, and species homologs thereof. The invention embraces virulence polypeptides encoded by a DNA selected from the group consisting of : a) the DNA sequence set out in any one of SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 164, 166, 168, 170, 172, and 174 and species homologs thereof; b) DNA molecules encoding *P. multocida*, *A. pleuropneumoniae* or *P. (Mannheimia) haemolytica*. polypeptides encoded by any one of SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 164, 166, 168, 170, 172, and 174, and species homologs thereof; and c) a DNA molecule, encoding a virulence gene product, that hybridizes under moderately stringent conditions to the DNA of (a) or (b).

20 The invention also embraces polypeptides that have at least about 99%, at least about 95%, at least about 90%, at least about 85%, at least about 80%, at least about 75%, at least about 70%, at least about 65%, at least about 60%, at least

WO 02/075507

PCT/US02/01971

about 55%, and at least about 50% identity and/or homology to the preferred polypeptides of the invention. Percent amino acid sequence "identity" with respect to the preferred polypeptides of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in the virulence gene product sequence after aligning both sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Percent sequence "homology" with respect to the preferred polypeptides of the invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical with the residues in one of the virulence polypeptide sequences after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and also considering any conservative substitutions as part of the sequence identity. Conservative substitutions can be defined as set out in Tables A and B.

15

**Table A**  
**Conservative Substitutions I**

<u>SIDE CHAIN CHARACTERISTIC</u>	<u>AMINO ACID</u>	
Aliphatic	Non-polar	G A P I L V
	Polar - uncharged	C S T M N Q
	Polar - charged	D E K R
	Aromatic	H F W Y
Other	N Q D E	

20

25

30

Polypeptides of the invention may be isolated from natural bacterial cell sources or may be chemically synthesized, but are preferably produced by recombinant procedures involving host cells of the invention. Virulence gene products of the invention may be full length polypeptides, biologically active fragments, or variants thereof which retain specific biological or immunological activity. Variants may comprise virulence polypeptide analogs wherein one or more

WO 02/075507

PCT/US02/01971

of the specified (*i.e.*, naturally encoded) amino acids is deleted or replaced or wherein one or more non-specified amino acids are added: (1) without loss of one or more of the biological activities or immunological characteristics specific for the virulence gene product; or (2) with specific disablement of a particular biological activity of the virulence gene product. Deletion variants contemplated also include fragments lacking portions of the polypeptide not essential for biological activity, and insertion variants include fusion polypeptides in which the wild-type polypeptide or fragment thereof have been fused to another polypeptide.

Variant virulence polypeptides include those wherein conservative substitutions have been introduced by modification of polynucleotides encoding polypeptides of the invention. Conservative substitutions are recognized in the art to classify amino acids according to their related physical properties and can be defined as set out in Table A (from WO 97/09433, page 10, published March 13, 1997 (PCT/GB96/02197, filed 9/6/96). Alternatively, conservative amino acids can be grouped as defined in Lehninger, [Biochemistry, Second Edition; Worth Publishers, Inc. NY:NY (1975), pp.71-77] as set out in Table B.

**Table B**  
**Conservative Substitutions II**

	<b>SIDE CHAIN CHARACTERISTIC</b>	<b>AMINO ACID</b>
	Non-polar (hydrophobic)	
25	A. Aliphatic:	A L I V P
	B. Aromatic:	F W
	C. Sulfur-containing:	M
	D. Borderline:	G
	Uncharged-polar	
30	A. Hydroxyl:	S T Y
	B. Amides:	N Q
	C. Sulfhydryl:	C
	D. Borderline:	G
	Positively Charged (Basic):	K R H
35	Negatively Charged (Acidic):	D E

WO 02/075507

PCT/US02/01971

Variant virulence products of the invention include mature virulence gene products, *i.e.*, wherein leader or signal sequences are removed, having additional amino terminal residues. Virulence gene products having an additional methionine residue at position -1 are contemplated, as are virulence products having additional methionine and lysine residues at positions -2 and -1. Variants of these types are particularly useful for recombinant protein production in bacterial cell types. Variants of the invention also include gene products wherein amino terminal sequences derived from other proteins have been introduced, as well as variants comprising amino terminal sequences that are not found in naturally occurring proteins.

10 The invention also embraces variant polypeptides having additional amino acid residues which result from use of specific expression systems. For example, use of commercially available vectors that express a desired polypeptide as a fusion protein with glutathione-S-transferase (GST) provide the desired polypeptide having an additional glycine residue at position -1 following cleavage of the GST component from the desired polypeptide. Variants which result from expression using other vector systems are also contemplated.

Also comprehended by the present invention are antibodies (*e.g.*, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, humanized, human, and CDR-grafted antibodies, including compounds which include CDR sequences which specifically recognize a polypeptide of the invention) and other binding proteins specific for virulence gene products or fragments thereof. The term "specific for" indicates that the variable regions of the antibodies of the invention recognize and bind a virulence polypeptide exclusively (*i.e.*, are able to distinguish a single virulence polypeptides from related virulence polypeptides despite sequence identity, homology, or similarity found in the family of polypeptides), but may also interact with other proteins (for example, *S. aureus* protein A or other antibodies in ELISA techniques) through interactions with sequences outside the variable region of the antibodies, and in particular, in the constant region of the molecule. Screening assays to determine binding specificity of an antibody of the invention are well known and routinely practiced in the art. For a comprehensive discussion of such assays, see

WO 02/075507

PCT/US02/01971

Harlow *et al.* (Eds), *Antibodies A Laboratory Manual*; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988), Chapter 6. Antibodies that recognize and bind fragments of the virulence polypeptides of the invention are also contemplated, provided that the antibodies are first and foremost specific for, as  
5 defined above, a virulence polypeptide of the invention from which the fragment was derived.

The DNA and amino acid sequence information provided by the present invention also makes possible the systematic analysis of the structure and function of the virulence genes and their encoded gene products. Knowledge of a  
10 polynucleotide encoding a virulence gene product of the invention also makes available anti-sense polynucleotides which recognize and hybridize to polynucleotides encoding a virulence polypeptide of the invention. Full length and fragment anti-sense polynucleotides are provided. The worker of ordinary skill will appreciate that fragment anti-sense molecules of the invention include (i) those which  
15 specifically recognize and hybridize to a specific RNA (as determined by sequence comparison of DNA encoding a virulence polypeptide of the invention to DNA encoding other known molecules) as well as (ii) those which recognize and hybridize to RNA encoding variants of the family of virulence proteins. Antisense polynucleotides that hybridize to RNA encoding other members of the virulence  
20 family of proteins are also identifiable through sequence comparison to identify characteristic, or signature, sequences for the family of molecules.

The invention further contemplates methods to modulate gene expression through use of ribozymes. For a review, see Gibson and Shillito, *Mol. Biotech.* 7:125-137 (1997). Ribozyme technology can be utilized to inhibit translation  
25 of mRNA in a sequence specific manner through (i) the hybridization of a complementary RNA to a target mRNA and (ii) cleavage of the hybridized mRNA through nuclease activity inherent to the complementary strand. Ribozymes can be identified by empirical methods but more preferably are specifically designed based on accessible sites on the target mRNA [Bramlage, *et al.*, *Trends in Biotech* 16:434-  
30 438 (1998)]. Delivery of ribozymes to target cells can be accomplished using either

WO 02/075507

PCT/US02/01971

exogenous or endogenous delivery techniques well known and routinely practiced in the art. Exogenous delivery methods can include use of targeting liposomes or direct local injection. Endogenous methods include use of viral vectors and non-viral plasmids.

5 Ribozymes can specifically modulate expression of virulence genes when designed to be complementary to regions unique to a polynucleotide encoding a virulence gene product. "Specifically modulate" therefore is intended to mean that ribozymes of the invention recognizes only a single polynucleotide. Similarly, ribozymes can be designed to modulate expression of all or some of a family of  
10 proteins. Ribozymes of this type are designed to recognize polynucleotide sequences conserved in all or some of the polynucleotides which encode the family of proteins.

The invention further embraces methods to modulate transcription of a virulence gene of the invention through use of oligonucleotide-directed triplet helix formation. For a review, see Lavrovsky, *et al.*, *Biochem. Mol. Med.* 62:11-22 (1997).  
15 Triplet helix formation is accomplished using sequence specific oligonucleotides which hybridize to double stranded DNA in the major groove as defined in the Watson-Crick model. Hybridization of a sequence specific oligonucleotide can thereafter modulate activity of DNA-binding proteins, including, for example, transcription factors and polymerases. Preferred target sequences for hybridization  
20 include transcriptional regulatory regions that modulate virulence gene product expression. Oligonucleotides which are capable of triplet helix formation are also useful for site-specific covalent modification of target DNA sequences. Oligonucleotides useful for covalent modification are coupled to various DNA damaging agents as described in Lavrovsky, *et al.* [*supra*].

25 The identification of *P. multocida*, *A. pleuropneumoniae* and *P. (Mannheimia) haemolytica* virulence genes renders the genes and gene products useful in methods for identifying anti-bacterial agents. Such methods include assaying potential agents for the ability to interfere with expression of virulence gene products represented by the DNA sequences set forth in any one of SEQ ID NOS: 1,  
30 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68,

WO 02/075507

PCT/US02/01971

70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174 and species homologs thereof (*i.e.*, the genes represented by DNA sequences of SEQ ID NOS: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174 encode the virulence gene product, or the DNA sequences of SEQ ID NOS: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174 are adjacent the gene encoding the virulence gene product, or are involved in regulation of expression of the virulence gene product), or assaying potential agents for the ability to interfere with the function of a bacterial gene product encoded in whole or in part by a DNA sequence set forth in any one of SEQ ID NOS: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174, species homologs thereof, or the complementary strand thereof, followed by identifying agents that are positive in such assays. Polynucleotides and polypeptides useful in these assays include not only the genes and encoded polypeptides as disclosed herein, but also variants thereof that have substantially the same activity as the wild-type genes and polypeptides.

The virulence gene products produced by the methods described above are used in high throughput assays to screen for inhibitory agents. The sources for potential agents to be screened are chemical compound libraries, fermentation media of *Streptomyces*, other bacteria and fungi, and cell extracts of plants and other vegetations. For proteins with known enzymatic activity, assays are established based

WO 02/075507

PCT/US02/01971

on the activity, and a large number of potential agents are screened for ability to inhibit the activity. For proteins that interact with another protein or nucleic acid, binding assays are established to measure such interaction directly, and the potential agents are screened for ability to inhibit the binding interaction.

5           The use of different assays known in the art is contemplated according to this aspect of the invention. When the function of the virulence gene product is known or predicted by sequence similarity to a known gene product, potential inhibitors can be screened in enzymatic or other types of biological and/or biochemical assays keyed to the function and/or properties of the gene product. When  
10 the virulence gene product is known or predicted by sequence similarity to a known gene product to interact with another protein or nucleic acid, inhibitors of the interaction can be screened directly in binding assays. The invention contemplates a multitude of assays to screen and identify inhibitors of binding by the virulence gene product. In one example, the virulence gene product is immobilized and interaction  
15 with a binding partner is assessed in the presence and absence of a putative inhibitor compound. In another example, interaction between the virulence gene product and its binding partner is assessed in a solution assay, both in the presence and absence of a putative inhibitor compound. In both assays, an inhibitor is identified as a compound that decreases binding between the virulence gene product and its binding  
20 partner. Other assays are also contemplated in those instances wherein the virulence gene product binding partner is a protein. For example, variations of the di-hybrid assay are contemplated wherein an inhibitor of protein/protein interactions is identified by detection of a positive signal in a transformed or transfected host cell as described in PCT publication number WO 95/20652, published August 3, 1995.

25           Candidate inhibitors contemplated by the invention include compounds selected from libraries of potential inhibitors. There are a number of different libraries used for the identification of small molecule modulators, including: (1) chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules. Chemical  
30 libraries consist of structural analogs of known compounds or compounds that are



WO 02/075507

PCT/US02/01971

identified as "hits" or "leads" via natural product screening. Natural product libraries are collections of microorganisms, animals, plants, or marine organisms which are used to create mixtures for screening by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of plants or marine organisms. Natural product libraries include polyketides, non-ribosomal peptides, and variants (non-naturally occurring) thereof. For a review, see *Science* 282:63-68 (1998). Combinatorial libraries are composed of large numbers of peptides, oligonucleotides, or organic compounds as a mixture. They are relatively easy to prepare by traditional automated synthesis methods, PCR, cloning, or proprietary synthetic methods. Of particular interest are peptide and oligonucleotide combinatorial libraries. Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created therefrom, see Myers, *Curr. Opin. Biotechnol.* 8:701-707 (1997). Identification of modulators through use of the various libraries described herein permits modification of the candidate "hit" (or "lead") to optimize the capacity of the "hit" to modulate activity.

Still other candidate inhibitors contemplated by the invention can be designed and include soluble forms of binding partners, as well as binding partners as chimeric, or fusion, proteins. Binding partners as used herein broadly encompasses antibodies, antibody fragments, and modified compounds comprising antibody domains that are immunospecific for the expression product of the identified virulence gene.

Other assays may be used when a binding partner (*i.e.*, ligand) for the virulence gene product is not known, including assays that identify binding partners of the target protein through measuring direct binding of test binding partner to the target protein, and assays that identify binding partners of target proteins through affinity ultrafiltration with ion spray mass spectroscopy/HPLC methods or other physical and analytical methods. Alternatively, such binding interactions are evaluated indirectly using the yeast two-hybrid system described in Fields and Song, *Nature*, 340:245-246 (1989), and Fields and Stemglanz, *Trends in Genetics*, 10:286-292 (1994), both of

WO 02/075507

PCT/US02/01971

which are incorporated herein by reference. The two-hybrid system is a genetic assay for detecting interactions between two proteins or polypeptides. It can be used to identify proteins that bind to a known protein of interest, or to delineate domains or residues critical for an interaction. Variations on this methodology have been developed to clone genes that encode DNA-binding proteins, to identify peptides that bind to a protein, and to screen for drugs. The two-hybrid system exploits the ability of a pair of interacting proteins to bring a transcription activation domain into close proximity with a DNA-binding domain that binds to an upstream activation sequence (UAS) of a reporter gene, and is generally performed in yeast. The assay requires the construction of two hybrid genes encoding (1) a DNA-binding domain that is fused to a first protein and (2) an activation domain fused to a second protein. The DNA-binding domain targets the first hybrid protein to the UAS of the reporter gene; however, because most proteins lack an activation domain, this DNA-binding hybrid protein does not activate transcription of the reporter gene. The second hybrid protein, which contains the activation domain, cannot by itself activate expression of the reporter gene because it does not bind the UAS. However, when both hybrid proteins are present, the noncovalent interaction of the first and second proteins tethers the activation domain to the UAS, activating transcription of the reporter gene. When the virulence gene product (the first protein, for example) is already known to interact with another protein or nucleic acid, this assay can be used to detect agents that interfere with the binding interaction. Expression of the reporter gene is monitored as different test agents are added to the system; the presence of an inhibitory agent results in lack of a reporter signal.

When the function of the virulence gene product is unknown and no ligands are known to bind the gene product, the yeast two-hybrid assay can also be used to identify proteins that bind to the gene product. In an assay to identify proteins that bind to the first protein (the target protein), a large number of hybrid genes each encoding different second proteins are produced and screened in the assay. Typically, the second protein is encoded by a pool of plasmids in which total cDNA or genomic DNA is ligated to the activation domain. This system is applicable to a wide variety

WO 02/075507

PCT/US02/01971

of proteins, and it is not even necessary to know the identity or function of the second binding protein. The system is highly sensitive and can detect interactions not revealed by other methods; even transient interactions may trigger transcription to produce a stable mRNA that can be repeatedly translated to yield the reporter protein.

5 Other assays may be used to search for agents that bind to the target protein. One such screening method to identify direct binding of test ligands to a target protein is described in U.S. Patent No. 5,585,277, incorporated herein by reference. This method relies on the principle that proteins generally exist as a mixture of folded and unfolded states, and continually alternate between the two  
10 states. When a test ligand binds to the folded form of a target protein (i.e., when the test ligand is a ligand of the target protein), the target protein molecule bound by the ligand remains in its folded state. Thus, the folded target protein is present to a greater extent in the presence of a test ligand which binds the target protein, than in the absence of a ligand. Binding of the ligand to the target protein can be determined  
15 by any method which distinguishes between the folded and unfolded states of the target protein. The function of the target protein need not be known in order for this assay to be performed. Virtually any agent can be assessed by this method as a test ligand, including, but not limited to, metals, polypeptides, proteins, lipids, polysaccharides, polynucleotides and small organic molecules.

20 Another method for identifying ligands for a target protein is described in Wieboldt *et al.*, *Anal. Chem.*, 69:1683-1691 (1997), incorporated herein by reference. This technique screens combinatorial libraries of 20-30 agents at a time in solution phase for binding to the target protein. Agents that bind to the target protein are separated from other library components by centrifugal ultrafiltration. The  
25 specifically selected molecules that are retained on the filter are subsequently liberated from the target protein and analyzed by HPLC and pneumatically assisted electrospray (ion spray) ionization mass spectroscopy. This procedure selects library components with the greatest affinity for the target protein, and is particularly useful for small molecule libraries.

WO 02/075507

PCT/US02/01971

The inhibitors/binders identified by the initial screens are evaluated for their effect on virulence in *in vivo* mouse models of *P. multocida* infections. Models of bacteremia, endocarditis, septic arthritis, soft tissue abscess, or pneumonia may be utilized. Models involving use of other animals are also comprehended by the invention. For example, rabbits can be challenged with a wild type *P. multocida* strain before or after administration of varying amounts of a putative inhibitor/binder compound. Control animals, administered only saline instead of putative inhibitor/binder compound provide a standard by which deterioration of the test animal can be determined. Other animal models include those described in the Animal and Plant Health Inspection Service, USDA, January 1, 1994 Edition, §§113.69-113.70; Panciera and Corstvet, *Am. J. Vet. Res.* 45:2532-2537; Ames, *et al.*, *Can. J. Comp. Med.* 49:395-400 (1984); and Mukkur, *Infection and Immunity* 18:583-585 (1977). Inhibitors/binders that interfere with bacterial virulence are can prevent the establishment of an infection or reverse the outcome of an infection once it is established.

Any adjuvant known in the art may be used in the vaccine composition, including oil-based adjuvants such as Freund's Complete Adjuvant and Freund's Incomplete Adjuvant, mycolate-based adjuvants (*e.g.*, trehalose dimycolate), bacterial lipopolysaccharide (LPS), peptidoglycans (*i.e.*, mureins, mucopeptides, or glycoproteins such as N-Opaca, muramyl dipeptide [MDP], or MDP analogs), proteoglycans (*e.g.*, extracted from *Klebsiella pneumoniae*), streptococcal preparations (*e.g.*, OK432), Biostim™ (*e.g.*, 01K2), the "Iscoms" of EP 109 942, EP 180 564 and EP 231 039, aluminum hydroxide, saponin, DEAE-dextran, neutral oils (such as miglyol), vegetable oils (such as arachis oil), liposomes, Phuronic® polyols, the Ribi adjuvant system (see, for example GB-A-2 189 141), or interleukins, particularly those that stimulate cell mediated immunity. An alternative adjuvant consisting of extracts of *Amycolata*, a bacterial genus in the order Actinomycetales, has been described in U.S. Patent No. 4,877,612. Additionally, proprietary adjuvant mixtures are commercially available. The adjuvant used will depend, in part, on the

recipient organism. The amount of adjuvant to administer will depend on the type and size of animal. Optimal dosages may be readily determined by routine methods.

The vaccine compositions optionally may include vaccine-compatible pharmaceutically acceptable (*i.e.*, sterile and non-toxic) liquid, semisolid, or solid diluents that serve as pharmaceutical vehicles, excipients, or media. Any diluent known in the art may be used. Exemplary diluents include, but are not limited to, polyoxyethylene sorbitan monolaurate, magnesium stearate, methyl- and propylhydroxybenzoate, talc, alginates, starches, lactose, sucrose, dextrose, sorbitol, mannitol, gum acacia, calcium phosphate, mineral oil, cocoa butter, and oil of theobroma.

The vaccine compositions can be packaged in forms convenient for delivery. The compositions can be enclosed within a capsule, caplet, sachet, cachet, gelatin, paper, or other container. These delivery forms are preferred when compatible with entry of the immunogenic composition into the recipient organism and, particularly, when the immunogenic composition is being delivered in unit dose form. The dosage units can be packaged, *e.g.*, in tablets, capsules, suppositories or cachets.

The vaccine compositions may be introduced into the subject to be immunized by any conventional method including, *e.g.*, by intravenous, intradermal, intramuscular, intramammary, intraperitoneal, or subcutaneous injection; by oral, sublingual, nasal, anal, or vaginal, delivery. The treatment may consist of a single dose or a plurality of doses over a period of time.

The invention also comprehends use of an attenuated bacterial strain of the invention for manufacture of a vaccine medicament to prevent or alleviate bacterial infection and/or symptoms associated therewith. The invention also provides use of inhibitors of the invention for manufacture of a medicament to prevent or alleviate bacterial infection and/or symptoms associated therewith.

The present invention is illustrated by the following examples. Example 1 describes constructions of *P. multocida* mutants. Example 2 relates to screening for *P. multocida* mutants. Example 3 addresses methods to determine



WO 02/075507

PCT/US02/01971

produce a plasmid designated pLOF/Km--*KpnI* which was transformed into *E. coli* DH5 $\alpha$ : $\lambda$ pir for amplification. *E. coli* DH5 $\alpha$ : ( $\lambda$ pir  $\phi$ 80dlacZ $\Delta$ M15, recA1, endA1, gyrA96, thi-1, hsdR17(r<sub>k</sub>, m<sub>s</sub>, supE44, relA1, deoR,  $\Delta$ (lacZYA-argF)U169, was propagated at 37°C in Luria-Bertani (LB) medium. Plasmids were prepared using

5 QIAGEN SpinPreps from QIAGEN Inc. (Santa Clarita, CA) and digested with *SfiI* which cuts at a unique site within the mini-Tn10 transposable element. A *SfiI-KpnI-SfiI* adaptor was prepared by annealing oligonucleotides TEF1 (SEQ ID NO: 86) and TEF3 (SEQ ID NO: 87) and the resulting double-stranded adaptor was ligated into the *SfiI* site to create plasmid pTEF-1. Oligonucleotides TEF1 and TEF3 (as well as all

10 other oligonucleotides described herein) were synthesized by Genosys Biotechnologies (The Woodlands, TX).

TEF1 5'-AGGCCGGTACCGCCGCCT SEQ ID NO: 86

15 TEF3 5'-CGGCCGGTACCGCCTAGG SEQ ID NO: 87

Unique sequence tags for insertion into the *KpnI* site of pTEF-1 were prepared as follows. PCR was carried out to generate double stranded DNA tags using a GeneAmp XL PCR Kit (PE Applied Biosystems, Foster City, CA) under

20 conditions including 250  $\mu$ M each dNTP, 1.5 mM Mg(OAc)<sub>2</sub>, 100 pmol each primer TEF14 (SEQ ID NO: 88) and TEF15 (SEQ ID NO: 89), 1 ng TEF26 (SEQ ID NO: 90) as template DNA and 2.5 units recombinant *Tth* DNA Polymerase XL.

25 TEF14 5'-CATGGTACCCATTCTAAC SEQ ID NO: 88

TEF15 5'-CTAGGTACCTACAACCTC SEQ ID NO: 89

TEF26 SEQ ID NO: 90

30 5'-CTAGGTACCTACAACCTCAAGCTT-[NK]<sub>35</sub>-  
AAGCTTGGTTAGAATGGGTACCATG

WO 02/075507

PCT/US02/01971

Reaction conditions included an initial incubation at 95°C for one minute, followed by thirty cycles of 30 seconds at 95°C, 45 seconds at 45°C, and 15 seconds at 72°C, followed by a final incubation at 72°C for two minutes. The PCR products were digested with *KpnI* and purified using a QIAGEN Nucleotide Removal Kit (QIAGEN, Inc., Chatsworth, GA) according to the manufacturer's suggested protocol. The unique tag sequences were ligated into the mini-Tn10 element of linearized pTEF-1, previously digested with *KpnI* and dephosphorylated with calf intestinal alkaline phosphatase (Boehringer Mannheim) using standard procedures. The resulting plasmid library was transformed into *E.coli* DH5 $\alpha$ : $\lambda$ pir. Colony blot analysis was performed according to the DIG User's Guide (Boehringer-Mannheim) with hybridization and detection performed as follows.

Hybridizations were essentially performed according to the Genius Non-Radioactive User's Guide (Boehringer Mannheim Biochemicals), the product sheet for the DIG-PCR labeling kit (Boehringer Mannheim Biochemicals), and the product sheet for CSPD (Boehringer Mannheim Biochemicals). For preparation of probes, a 100  $\mu$ l primary PCR reaction was set up using Amplitaq PCR buffer (PE Applied Biosystems), 200  $\mu$ M dNTPs, 140 pmol each of primers TEF5 (SEQ ID NO: 91) and TEF6 (SEQ ID NO: 92), 2 mM MgCl<sub>2</sub>, 2.5 units Amplitaq (PE Applied Biosystems) and 1 ng of plasmid DNA.

TEF5 5'-TACCTACAACCTCAAGCT SEQ ID NO: 91

TEF6 5'-TACCCATTCTAACCAAGC SEQ ID NO: 92

Cycle conditions included an initial incubation at 95°C for two minutes, followed by 35 cycles of 95°C for 30 seconds, 50°C for 45 seconds, 72°C for 15 seconds and a final incubation at 72°C for three minutes. The amplification products were separated using electrophoresis on a 2% - 3:1 NuSieve GTG (FMC BioProducts, Rockland, ME, USA):Agarose gel and the 109 bp product was excised and purified. Gel extractions were carried out using a QIAGEN Gel Extraction kit (QIAGEN).



WO 02/075507

PCT/US02/01971

Approximately 15 ng of the primary product was labeled in a 50  $\mu$ l PCR reaction using the DIG PCR Kit, 50 pmol each of primers TEF24 and TEF25, and a 1:1 mix of DIG Probe Synthesis Mix with 2 mM dNTP stock solution.

5                    TEF24     5'-TACCTACAACCTCAAGCTT     SEQ ID NO: 93

                  TEF25     5'-TACCCATTCTAACCAAGCTT     SEQ ID NO: 94

10                    PCR conditions included an initial incubation at 95°C for four minutes, followed by 25 cycles of 95°C for 30 seconds, 50°C for 45 seconds, 72°C for 15 seconds and a final incubation at 72°C for three minutes. The labeled PCR product was digested with *Hind*III in a total reaction volume of 90  $\mu$ l and purified from the constant primer arms using a 2% - 3:1 NuSieve GTG (FMC BioProducts):Agarose gel. The region containing the labeled variable tag was excised and the entire gel slice was dissolved and denatured in 10 ml of DIG EasyHyb at 95°C for ten minutes.

15                    Dot blots were prepared using a Hybond<sup>®</sup>-N<sup>+</sup> membrane (Amersham-Pharmacia Biotech). Target DNA for each tag was prepared in 96 well plates using approximately 30 ng of PCR product. An equal volume of 0.1 N NaOH was added to denature the sample and each sample was applied to the membrane with minimal vacuum using a Minifold P<sup>™</sup> Dot-Blot Apparatus from Schleicher and Schuell (Keene, NH, USA). Each well was washed with 150  $\mu$ l of Neutralization Solution (0.5 M Tris /3 M NaCl, pH 7.5) and 150  $\mu$ l of 2X SSC. Membranes were UV-crosslinked in a Stratelinker (Stratagene, La Jolla, CA, USA) and prehybridized for one hour in 20 mls DIG EasyHyb Buffer at 42°C. The denatured probe was added and hybridization carried out overnight at 42°C. The membrane was washed two times in 25                    2X SSC containing 0.1% SDS for five minutes each wash. Two high stringency washes were performed in 50 ml of pre-warmed 0.1X SSC buffer containing 0.1% SDS at 68°C for 15 minutes before proceeding with standard Genius Detection protocols (Genius Manual).

WO 02/075507

PCT/US02/01971

It is desirable to use a non-radioactive detection system for safety, lower cost, ease of use, and reduction of hazardous materials. In initial experiments using similar procedures previously described [Mei, *et al.*, *Mol Microbiol.* 26:399-407 (1997)], unacceptable background levels of hybridization were obtained in  
5 negative controls. In order to decrease background, tag length was increased by 30 bp to a total of 70, amplification primers were lengthened to include all sequence flanking the variable region, a lower concentration of dig-dUTP was used, and the conserved sequences flanking the sequence tag region were removed by gel  
10 purification. Most significantly, PCR was used to generate [NK]<sub>3</sub> sequence tags as the target DNA in dot blots rather than the entire plasmids containing the tagged transposons after detecting background hybridization from the transposon itself. Using these modifications background was eliminated making chemiluminescent/non-radioactive screening more effective.

Approximately four hundred different transformants resulting from the  
15 ligation of pTEF-1 with the PCR generated sequence tags were screened by colony blot and the 96 strongest hybridizing colonies were assembled into microtiter plates for further use. Even though the likelihood of duplicated tags was very low, half of the plate of master tags was probed against the other to confirm that no tags were duplicated. The plasmids containing these tags were purified and transformed into  
20 *E.coli* S17-1:λpir (pir, *recA*, *thi*, *pro*, *hsd*, (r-m<sup>+</sup>), RP4-2, (Tc::Mu), (Km::Tn7), [TnpR], [SmR]), and the transformed bacteria propagated at 37°C in Luria-Bertani (LB) medium. Each of the 96 *E.coli* S17-1:λpir transformants containing the tagged plasmid pTEF-1 was used in conjugative matings to generate transposon mutants of *P. multocida*. *P. multocida* strain TF5 is a spontaneous nalidixic acid resistant mutant  
25 derived from UC6731, a bovine clinical isolate. *P. multocida* strains were grown on brain heart infusion (BHI) media (Difco Laboratories, Detroit, MI, USA) at 37°C and in 5% CO<sub>2</sub> when grown on plates. Matings were set up by growing each *E.coli* S17-1:λpir /pTEF1:[NK]<sub>3</sub> clone and the TF5 strain to late log phase. Fifty μl of culture for each tagged-pTEF-1 clone was mixed with 200 μl of the TF5 culture and 50 μl of  
30 each mating mixture was spotted onto 0.22 TM filters previously placed on BHI plates

WO 02/075507

PCT/US02/01971

containing 100 mM IPTG and 10 mM MgSO<sub>4</sub>. Following overnight incubation at 37°C with 5% CO<sub>2</sub>, mating mixtures were washed off of each filter into 3 ml of PBS and 25 µl of each was plated onto BHIN<sup>50</sup>K<sup>100</sup> plates. Following selective overnight growth, colonies were assembled into microtiter plates by toothpick transfer into 200  
5 µl BHIN<sup>50</sup>K<sup>50</sup> making sure that each well in a microtiter plate always contained a transposon mutant with the same sequence tag. Following overnight growth, 50 µl of 75% glycerol was added to each well and plates were stored frozen at -80°C.

Nineteen pools were assembled by transferring the transposon mutants to microtiter plates making sure that each well contained a transposon mutant with  
10 appropriate tag for that well. In other words, a specific well in each microtiter plate always contained a transposon mutant with the same sequence tag even though the location of the transposon within those mutants may be different.

15 **Example 2**  
**Murine Screening for Attenuated *P. multocida* Mutants**

Nineteen pools of *Pasteurella multocida* transposon mutants were screened using a murine model of septicemia. Frozen plates of pooled *P. multocida* transposon mutants were removed from -80°C storage and subcultured by transferring  
20 10 µl from each well to a new 96 well round bottom plate (Corning Costar, Cambridge, MA, USA) containing 200 µl of brain heart infusion (DIFCO) with 50 µg/ml nalidixic acid (Sigma) and 50 µg/ml kanamycin (Sigma) (BHIN<sup>50</sup>K<sup>50</sup>). Plates were incubated without shaking overnight at 37°C in 5% CO<sub>2</sub>. Overnight plates were subcultured by transferring 10 µl from each well to a new flat bottomed 96-well plate (Corning Costar) containing 100 µl of BHI per well and incubating at 37°C with  
25 shaking at approximately 150 rpm. The OD<sub>540</sub> was monitored using a micro-titer plate reader. At an OD<sub>540</sub> of approximately 0.2 to 0.25, each plate was pooled to form the "input pool" by combining 100 µl from each of the wells of the micro-titer plate. The culture was diluted appropriately in BHI to doses of approximately 10<sup>4</sup>, 10<sup>5</sup>, 10<sup>6</sup> CFU/ml and 0.2 ml of each dilution was used to infect female 14-16 g BALB/c mice  
30 by intraperitoneal administration. At two days post-infection, one or two surviving mice were euthanized and the spleens harvested. The entire spleen was homogenized

WO 02/075507

PCT/US02/01971

in 1.0 ml sterile 0.9 % saline. Dilutions of the homogenate from  $10^2$  to  $10^3$  were prepared and plated onto BHI<sup>90K30</sup> plates. Following overnight growth, at least 20,000 colonies were pooled in 10 mls BHI broth to form the "recovered pool" and 0.5 ml of the recovered pool was centrifuged at 3,500 X g and the pellet used to  
5 prepare genomic DNA according to a previously described protocol [Wilson, *In F. M. Ausubel, et al.,(ed.), Current Protocols in Molecular Biology*, vol. 1. John Wiley and Sons, New York, p. 2.4.1-2.4.5. (1997)].

Initial experiments with virulent wild-type *P. multocida* indicated that organisms could be recovered from the spleen, lungs, kidneys, and liver indicating a truly septicemic model of infection. Dot blots for both the "input" and "recovered" pools were performed as described in Example 1 and evaluated both by visual  
10 inspection and by semi-quantitative analysis. Hybridization was carried out as described in Example 1 except that 5  $\mu$ g of genomic DNA from input and recovered pools was used as template. Semi-quantitative analysis indicates whether a significant  
15 reduction in a single clone has occurred. If a mutant is unable to survive within the host, then the recovered signal should be very low compared to the input signal yielding a high input/recovered ratio. Most mutants will grow as well *in vivo* as *in vitro* and therefore a ratio of their signals should be approximately equal to 1. Clones selected by quantitative analysis as being highly reduced in the recovered pool were  
20 selected for further study. Additional clones with questionable input/recovered ratios were also selected after visually evaluating films made from the dot blots.

**Example 3**  
**Determination of Virulence for *P. multocida* Candidate Mutants**

Each potential mutant which exhibited reduced recovery from splenic tissue was isolated from the original pool plate and used individually in a challenge  
25 experiment to verify and roughly estimate the attenuation caused by the transposon mutation. Individual candidate mutants from *in vivo* screens were grown on Sheep Blood Agar plates overnight in 5% CO<sub>2</sub> at 37°C. Approximately six colonies of each  
30 mutant were inoculated into BHI broth and allowed to grow for six hours. Dilutions were prepared and five mice each were infected as described above with  $10^2$ ,  $10^3$ ,  $10^4$

WO 02/075507

PCT/US02/01971

and  $10^5$  CFU each. Attenuation was determined by comparing mortality after six days relative to the wild type. Surviving mice were presumed to be protected and then challenged with a dose of wild type *P. multocida* at a concentration approximately 200-fold greater than the LD<sub>50</sub> for the wild type strain. Survival rate was then determined for each challenged group of mice.

Results indicated that 62 of 120 potential transposon mutants were attenuated, having an approximate LD<sub>50</sub> of at least 10 fold higher than the wild type strain. The clones and their approximate LD<sub>50</sub> values are listed in Table 1. A control experiment with the wild type strain was run in parallel with each set of challenges and in all cases mortality in wild type-challenged groups was 100%.

In addition to LD<sub>50</sub> values, Table 1 also provides data from vaccination and challenge experiments. Briefly, groups of mice (n = 5 to 10) were vaccinated by intraperitoneal injection with the individual *P. multocida* strains shown in Table 1 at a dose that was approximately 200 times greater than the LD<sub>50</sub> of the virulent, wild type strain. Animals were observed for 28 days after which mortality figures were calculated.

Table 1  
*P. multocida* Virulence Genes

Nucleotide SEQ ID NO:	Representative Isolate	Possible Gene Function	Vaccination # survivors/total	Challenge # survivors/total	LD <sub>50</sub>
—	wild type	—	0/10	—	<10
23	PM1B1	gusB	10/10, 10/10, 10/10	9/10, 9/10	4.3 x 10 <sup>6</sup>
11	PM1D1	dsxB	10/10, 5/10	10/10, 5/5	8.4 x 10 <sup>4</sup>
3	PM1BD7	atpG	5/5, 10/10	10/10	>3 x 10 <sup>5</sup>
74	PM1BE11	yhcJ (HI0145)	10/10	5/10	>2 x 10 <sup>5</sup>
70	PM1BF6	yabK (HI1020)	3/5, 9/10	9/9	>2 x 10 <sup>5</sup>
19	PM2G8	rhaC	4/5, 9/10	9/9	>4 x 10 <sup>5</sup>
76	PM3C9	yraO (HI0146)	3/5	—	>6 x 10 <sup>5</sup>
118	PM3G11	UnkO	4/5, 10/10	10/10	>3 x 10 <sup>5</sup>
31	PM7B4	rnaA (UnkB)	0/5	—	—
17	PM4C6	rhaB (RaB2)	2/5, 10/10, 9/10	10/10, 9/9	>3 x 10 <sup>6</sup>
9	PM4G10-T9	dnaA	4/5	—	>5 x 10 <sup>5</sup>
1	PM4D5-T5	atpB	5/5	—	>4 x 10 <sup>5</sup>
53	PM4D5-T1	UnkC2	5/5	—	>4 x 10 <sup>5</sup>
15	PM4F2	rhaB (RaB1)	3/5, 6/10, 10/10	6/6, 10/10	>3 x 10 <sup>5</sup>
41	PM5F7	rreB	4/5	—	1 x 10 <sup>3</sup>
7	PM5E2	devB	0/5, 3/10	2/3	ND
68	PM6H5-T1	yjIA	5/5	—	>3 x 10 <sup>5</sup>
78	PM6H8	yjgF (HI0719)	5/5, 9/10	9/9	>3 x 10 <sup>5</sup>
106	PM7D12	pnp	5/5, 9/10	9/9	—
31	PM8C1R1-T2	UnkC1	5/5	—	>6 x 10 <sup>5</sup>

WO 02/075507

PCT/US02/01971

Nucleotide SEQ ID NO:	Representative Isolate	PossibleGene Function	Vaccination # survivors/total	Challenge # survivors/total	LD <sub>50</sub>
37	PM8C1-T3	mgjB	5/5		-8 x 10 <sup>5</sup>
58	PM8C1R1-T6	UnkD1	5/5		-6 x 10 <sup>5</sup>
45	PM10H7	purF (H11707)	3/5, 8/10, 8/10	8/8, 8/8	>3 x 10 <sup>5</sup>
25	PM10H10-T2	Hll501	5/5		>1 x 10 <sup>4</sup>
72	PM11G8-T2	ygjK	5/5		>2.4 x 10 <sup>3</sup>
21	PM11G8-T4	greA	5/5		>2.4 x 10 <sup>3</sup>
84	PM12H6	yyam (H10687)	3/5, 0/10		-2.2 x 10 <sup>3</sup>
33	PM15Q8-T2	kubB	5/5		>1.2 x 10 <sup>5</sup>
116	PM15Q8-T1	UnkK	5/5		>1.2 x 10 <sup>5</sup>
104	PM16G11-T1	hmbR	3/5		>1.9 x 10 <sup>5</sup>
29	PM16G11-T2	hxcC	3/5		>1.9 x 10 <sup>5</sup>
35	PM16H8	IgtC	5/5, 10/10	10/10	>2.4 x 10 <sup>5</sup>
80	PM16H1	yleA (H10019)	5/5, 10/10		>2.0 x 10 <sup>5</sup>
49	PM17H6-T1	stopE	4/5		-8 x 10 <sup>5</sup>
120	PM17H6	UnkP	4/5		-8 x 10 <sup>5</sup>
5	PM18F5-T8	cap5E	5/5		>2.4 x 10 <sup>5</sup>
82	PM18F5-T10	yopB (H10345)	5/5		>2.4 x 10 <sup>5</sup>
13	PM19A1	exbB	5/5, 10/10	10/10	>1.2 x 10 <sup>5</sup>
112	PM19D4	rci	5/5, 8/10	8/8	-1.6 x 10 <sup>5</sup>
39	PM20A12	mioC (H10669)	3/5, 8/10	8/8	-2 x 10 <sup>4</sup>
60	PM20C2	UnkD2	5/5, 10/10	10/10	>8.2 x 10 <sup>6</sup>

**Example 4**  
**Cloning and Identification of Genes Required for *P. multocida* Virulence**

Each transposon mutant which was verified to be attenuated was analyzed further to determine the identity of the disrupted open reading frame. DNA from each mutant was amplified, purified, and digested with restriction enzymes that were known not to cut within the transposon and generally produced 4-8 kb fragments that hybridized with the transposon. Using selection for kanamycin resistance encoded by the transposon, at least one fragment for each transposon mutant was cloned.

Southern hybridization with multiple restriction enzymes was performed for each attenuated mutant using a labeled 1.8 kb *Mlu*I fragment from pLOF/Km as a probe to identify a suitably sized fragment for cloning. The mini-Tn10 element and flanking DNA from each mutant was cloned into pUC19 and the flanking sequence determined using internal primers TEF32 and TEF40, primer walking and in some cases universal pUC-19 primers.

WO 02/075507

PCT/US02/01971

TEF-32 GGCAGAGCATTACGCTGAC SEQ ID NO: 95  
TEF-40 GTACCGGCCAGGCGGCCACGCGTATTC SEQ ID NO:96

Sequencing reactions were performed using the BigDye™ Dye Terminator Chemistry  
5 kit from PE Applied Biosystems (Foster City, CA) and run on an ABI Prism 377  
DNA Sequencer. Double stranded sequence for putative interrupted open reading  
frames was obtained for each clone. Sequencer 3.0 software (Genecodes, Corp., Ann  
Arbor, MI) was used to assemble and analyze sequence data. GCG programs  
[Devereux, *et al.*, 1997. Wisconsin Package Version 9.0, 9.0 ed. Genetics Computer  
10 Group, Inc., Madison] were used to search for homologous sequences in currently  
available databases.

In 37% of the clones that were identified as being attenuated, there  
were multiple insertions of the mini-Tn10 transposable element. Each insertion  
including its flanking sequence was cloned individually into pGP704 and mated into  
15 the wild-type strain to produce new mutants of *P. multocida*, each carrying only one  
of the multiple original insertions. Individual mutants were retested individually to  
determine the insertion responsible for the attenuated phenotype. The nucleotide  
sequence of the disrupted, predicted open reading frame was determined by  
sequencing both strands, and the predicted amino acid sequence was used to search  
20 currently available databases for similar sequences. Sequences either matched known  
genes, unknown genes, and hypothetical open reading frames previously sequenced or  
did not match any previously identified sequence. For those genes having homology  
to previously identified sequences, potential functions were assigned as set out in  
Table 1.

25

#### Example 5 Identification of Related Genes in Other Species

In separate experiments, STM was also performed using *Actinobacillus*  
*pleuropneumoniae* (App). One of the App strains contained an insertion in a gene that  
30 was sequenced (SEQ ID NO: 97) and identified as a species homolog of the *P.*  
*multocida* atpG gene. This result suggested the presence in other bacterial species of

WO 02/075507

PCT/US02/01971

homologs to previously unknown *P. multocida* genes that can also be mutated to produce attenuated strains of the other bacterial species for use in vaccine compositions. In order to determine if homologs of other *P. multocida* genes exists in other bacterial species, Southern hybridization was performed on genomic DNA from other species using the *A. pleuropneumoniae atpG* gene as a probe.

5  
10  
15  
20  
*Actinobacillus pleuropneumoniae*, *Pasteurella haemolytica* (Ph), *P. multocida*, and *Haemophilus somnus* (Hs) genomic DNA was isolated using the CTAB method and digested with *EcoRI* and *HindIII* for two hours at 37°C. Digested DNA was separated on a 0.7% agarose gel at 40V in TAE buffer overnight. The gel was immersed sequentially in 0.1 M HCL for 30 minutes, twice in 0.5 M NaOH/1.5 M NaCl for 15 minutes each, and twice in 2.5 M NaCl/1 M Tris, pH 7.5. The DNA was transferred to nitrocellulose membranes (Amersham Hybond N<sup>+</sup>) overnight using 20X SSC buffer (3 M NaCl/0.3 M sodium citrate). The DNA was crosslinked to the membrane using a UV Stratalinker on autocrosslink setting (120 millijoules). The membrane was prehybridized in 5X SSC/1% blocking solution/0.1% sodium lauroyl sarcosine/0.02% SDS at 50°C for approximately seven hours and hybridized overnight at 50°C in the same solution containing a PCR generated atpG probe.

The probe was prepared using primers DEL-1389 (SEQ ID NO: 98) and TEF-46 (SEQ ID NO: 99) in a GeneAmp XL PCR kit in a GeneAmp PCR System 2400. Template was genomic *A. pleuropneumoniae* DNA.

DEL-1389 TCTCCATTCCCTTGCTGCGGCAGGG SEQ ID NO: 98  
TEF-46 GGAATTACAGCCGGATCCGGG SEQ ID NO: 99

25  
30  
The PCR was performed with an initial heating step at 94°C for five minutes, 30 cycles of denaturation at 94°C for 30 sec, annealing at 50°C for 30 sec, and elongation at 72°C for three minutes, and a final extension step at 72°C for five minutes. The amplification products were separated on an agarose gel, purified using a QIAquick gel purification kit (QIAGEN), and labeled using a DIG-High Primer kit (Boehringer Mannheim). The blot was removed from the hybridization solution and rinsed in 2X



WO 02/075507

PCT/US02/01971

SSC and washed two times for five minutes each wash in the same buffer. The blot was then washed two times for 15 minutes each in 0.5X SSC at 60°C. Homologous bands were visualized using a DIG Nucleic Acid Detection Kit (Boehringer Mannheim).

5 Single bands were detected in *Pasteurella haemolytica*, *Haemophilus somnus* and *A. pleuropneumoniae* using *EcoRI* digested DNA. Two bands were detected using *EcoRI* digested DNA from *Pasteurella multocida*.

#### Example 6

##### 10 Construction of a Library of Tagged-Transposon *P. multocida* Mutants

Transposon mutagenesis using pLOF/Km has previously been reported to be functional and random in *A. pleuropneumoniae* [Tascon, et al., *J Bacteriol.* 175:5717-22 (1993)]. To construct tagged transposon mutants of *A. pleuropneumoniae*, each of 96 *E. coli* S17-1:λpir transformants containing pre-selected tagged plasmids (pTEF-1:[NK]<sub>35</sub>) was used in conjugative matings to generate transposon mutants of *A. pleuropneumoniae* strain AP225, a serotype 1 spontaneous nalidixic acid resistant mutant derived from an in vivo passaged ATCC 27088 strain. *A. pleuropneumoniae* strains were grown on Brain Heart Infusion (BHI) (Difco Laboratories, Detroit, MI) media with 10 µg/ml B-nicotinamide adenine dinucleotide (V<sup>10</sup>), (Sigma, St. Louis, Missouri) at 37°C and in 5% CO<sub>2</sub> when grown on plates. *E. coli* S17-1:λpir (λpir, *recA*, *thi*, *pro*, *hsdR*(r<sub>k</sub><sup>-</sup>,m<sub>k</sub><sup>+</sup>), RP4-2, (Tc<sup>R</sup>::Mu), (Km<sup>R</sup>::Tn7), [Tnp<sup>R</sup>], [Sm<sup>R</sup>]) was propagated at 37°C in Luria-Bertani (LB) medium. Antibiotics when necessary were used at 100 µg/ml ampicillin (Sigma), 50 µg/ml nalidixic acid (N<sup>50</sup>)(Sigma), and 50 (K<sup>50</sup>) or 100 (K<sup>100</sup>) µg/ml of kanamycin (Sigma).

25 Matings were set up by growing each *E. coli* S17-1:λpir/pTEF1:[NK]<sub>35</sub> clone and the AP225 strain to late log phase. A 50 µl aliquot of culture for each tagged-pTEF-1 clone was mixed with 150 µl of the APP225 culture, and then 50 µl of each mating mixture was spotted onto 0.22 µM filters previously placed onto BHIV<sup>10</sup> plates containing 100 µM IPTG and 10 mM MgSO<sub>4</sub>. Following overnight incubation at 37°C with 5% CO<sub>2</sub>, mating mixtures were washed off of each filter into 2 ml of PBS and 200 µl of each was plated onto BHIV<sup>10</sup>N<sup>50</sup>K<sup>100</sup> plates. After selective

WO 02/075507

PCT/US02/01971

overnight growth, colonies were assembled into microtiter plates by toothpick transfer into 200  $\mu$ l BHIV<sup>10</sup>N<sup>30</sup>K<sup>50</sup> making sure that each well in a microtiter plate always contained a transposon mutant with the same sequence tag. Following overnight growth, 50  $\mu$ l of 75% glycerol was added to each well and plates were stored frozen at  
5 -80°C.

APP does not appear to have as much bias towards multiple insertions of the mini-Tn10 element as did *P. multocida*. Only approximately 3% of the mutants were determined to contain multiple insertions, which is in agreement with the 4% previously reported [Tascon, *et al.*, *J Bacteriol.* 175:5717-22 (1993)]. A problem in  
10 APP consisted of identifying numerous mutants (discussed below) containing insertions into 23S RNA regions: 28 total mutants with insertions into 13 unique sites. This may indicate that 23S RNA contains preferential insertion sites and that the growth of APP is affected by these insertions enough to result in differential survival within the host. Southern blot analysis using an APP 23S RNA probe suggests that  
15 APP may contain only three ribosomal operons as compared to five in *H. influenzae* [Fleischmann, *et al.*, *Science* 269:496-512 (1995)] and seven complete operons in *E. coli* [Blattner, *et al.*, *Science* 277:1453-1474 (1997)]. This site preference and its effect on growth rate may be a significant barrier to "saturation mutagenesis" since a significant number of clones will contain insertions into these rRNAs and large  
20 volume screening will be necessary to obtain additional unique attenuating mutations.

#### Example 7

##### Porcine Screening for Attenuated *A. pleuropneumoniae* Mutants

Twenty pools of *A. pleuropneumoniae* transposon mutants, containing  
25 a total of approximately 800 mutants, were screened using a porcine intratracheal infection model. Each pool was screened in two separate animals.

Frozen plates of pooled *A. pleuropneumoniae* transposon mutants were removed from -80°C storage and subcultured by transferring 20  $\mu$ l from each well to a new 96 well round bottom plate (Corning Costar, Cambridge, MA, USA) containing  
30 180  $\mu$ l of BHIV<sup>10</sup>N<sup>30</sup>K<sup>50</sup>. Plates were incubated without shaking overnight at 37°C in

WO 02/075507

PCT/US02/01971

5% CO<sub>2</sub>. Overnight plates were then subcultured by transferring 10 µl from each well to a new flat bottomed 96 well plate (Corning Costar) containing 100 µl of BHIV<sup>10</sup> per well and incubating at 37°C with shaking at 150 rpm. The OD<sub>562</sub> was monitored using a microtiter plate reader. At an OD<sub>562</sub> of approximately 0.2 to 0.25, each plate was pooled to form the "input pool" by combining 100 µl from each of the wells of the microtiter plate. The culture was diluted appropriately in BHI to approximately 2 X 10<sup>6</sup> CFU/ml. For each diluted pool, 4.0 ml was used to infect 10-20 kg SPF pigs (Whiteshire-Hamroc, Albion, IN) by intratracheal administration using a tracheal tube. At approximately 20 hours post-infection, all surviving animals were euthanized and the lungs removed. Lavage was performed to recover surviving bacteria by infusing 150 mls of sterile PBS into the lungs, which were then massaged to distribute the fluid. The lavage fluid was recovered, and the process was repeated a second time. The lavage fluid was centrifuged at 450 x g for 10 minutes to separate out large debris. Supernatants were then centrifuged at 2,800 x g to pellet the bacteria. Pellets were resuspended in 5 mls BHI and plated in dilutions ranging from 10<sup>-2</sup> to 10<sup>-3</sup> onto BHIV<sup>10</sup>N<sup>50</sup>K<sup>50</sup> plates. Following overnight growth, at least 100,000 colonies were pooled in 10 mls BHI broth to form the "recovered pools". A 0.7 ml portion of each recovered pool was used to prepare genomic DNA by the CTAB method [Wilson, *In Ausubel, et al., (eds.), Current Protocols in Molecular Biology, vol. 1. John Wiley and Sons, New York, p. 2.4.1-2.4.5 (1997)*].

Recovery from the animals routinely was in the 10<sup>8</sup> CFU range from lung lavage.

Dot blots were performed and evaluated both by visual inspection and by semi-quantitative analysis as described previously. All hybridizations and detections were performed as described. Briefly, probes were prepared by a primary PCR amplification, followed by agarose gel purification of the desired product and secondary PCR amplification incorporating dig-dUTP. Oligonucleotides including TEF5, TEF6, TEF24, TEF25, TEF48 and TEF62, were synthesized by Genosys Biotechnologies (The Woodlands, TX). Primers TEF69, TEF65, and TEF66 were also used for inverse PCR reactions and sequencing.

WO 02/075507

PCT/US02/01971

TEF69	GACGTTCCCGTTGAATATGGCTC	SEQ ID NO: 166
TEF65	GCCGGATCCGGGATCATATGACAAGA	SEQ ID NO: 167
TEF66	GACAAGATGTGTATCCACCTTAAC	SEQ ID NO: 168

5

The labeled PCR product was then digested with *Hind*III to separate the constant primer arms from the unique tag region. The region containing the labeled variable tag was excised and the entire gel slice was then dissolved and denatured in DIG EasyHyb. Dot blots were prepared and detected using the standard

10

CSPD detection protocol. Film exposures were made for visual evaluation, and luminescent counts per second (LCPS) were determined for each dot blot sample. The  $LCPS_{input} / LCPS_{recovered}$  ratio for each mutant was used to determine mutants likely to be attenuated.

15

Clones selected as being present in the input pool but highly reduced in the recovered pool were selected for further study. Additional clones with questionable input/recovered ratios were also selected after visually evaluating films made from the dot blots. A total of 110 clones were selected.

20

#### **Example 8** **Identification of *A. pleuropneumoniae* Virulence Genes**

A partial flanking sequence was determined for each of the 110 mutants by inverse PCR and direct product sequencing. Inverse PCR was used to generate flanking DNA products for direct sequencing as described above. Sequencing reactions were performed using the BigDye™ Dye Terminator Chemistry kit from PE Applied Biosystems (Foster City, CA) and run on an ABI Prism 377 DNA Sequencer. Sequencher 3.0 software (Genecodes, Corp., Ann Arbor, MI) was used to assemble and analyze sequence data. GCG programs [Devereux and Haeberli, Wisconsin Package Version 9.0, 9.0 ed. Genetics Computer Group, Inc., Madison (1997)] were used to search for homologous sequences in currently available

25

30

databases.

WO 02/075507

PCT/US02/01971

Table 2 shows the *A. pleuropneumoniae* genes identified and extent to which open reading frames were determinable. Sequence identification numbers are provided for nucleotide sequences as well as deduced amino acid sequences where located.

5

**Table 2**  
***A. pleuropneumoniae* Open Reading Frames**

	<u>Complete Open Reading Frame</u>		<u>NO Start Codon - Stop Codon</u>
10	atpH	SEQ ID NO: 134	dksA
	aptG	SEQ ID NO: 132	dnaK
	exbB	SEQ ID NO: 140	HI0379
	OmpP5	SEQ ID NO: 152	
	OmpP5-2	SEQ ID NO: 150	
	tig	SEQ ID NO: 160	<u>NO Start Codon - NO Stop Codon</u>
15	fkpA	SEQ ID NO: 142	pnp
	hupA	SEQ ID NO: 146	apvA-or 1
	rpmF	SEQ ID NO: 158	apvA-or 2
			apvB
			apvD
20			
	<u>Start Codon - NO Stop Codon</u>		<u>RNA or Noncoding Sequences</u>
	lpdA	SEQ ID NO: 148	tRNA-leu
	potD	SEQ ID NO: 156	tRNA-glu
	yaeE	SEQ ID NO: 164	
	apvC	SEQ ID NO: 128	

25

The putative identities listed in Table 3 (below, Example 9) were assigned by comparison with bacterial databases. The 110 mutants represented 35 groups of unique transposon insertions. The number of different mutations per loci varied, with some clones always containing an insertion at a single site within an ORF to clones containing insertions within different sites of the same ORF. Three multiple insertions were detected in the 110 mutants screened as determined by production of multiple PCR bands and generation of multiple sequence electropherograms.

30

**Example 9**  
**Competition Challenge of *A. pleuropneumoniae***  
**Mutants with Wild Type APP225**

A representative clone from each of the unique attenuated mutant groups identified above that was absent or highly reduced in the recovered population was isolated from the original pool plate and used in a competition challenge experiment with the wild type strain (AP225) to verify the relative attenuation caused by the transposon mutation. Mutant and wild type strains were grown in BHIV<sup>10</sup> to an OD<sub>590</sub> of 0.6 - 0.9. Approximately 5.0 x 10<sup>8</sup> CFU each of the wild type and mutant strains were added to 4 ml BHL. The total 4 ml dose was used to infect a 10-20 kg SPF pig by intratracheal administration with a tracheal tube. At approximately 20 hours post-infection, all surviving animals were euthanized and the lungs removed. Lung lavages were performed as described above. Plate counts were carried out on BHIV<sup>10</sup>N<sup>50</sup> and BHIV<sup>10</sup>N<sup>100</sup>K<sup>100</sup> to determine the relative numbers of wild type to mutant in both the input cultures and in the lung lavage samples. A Competitive Index (CI) was calculated as the [mutant CFU / wild type CFU]<sub>input</sub> / [mutant CFU / wild type CFU]<sub>recovered</sub>.

Of the 35 potential transposon mutants, 22 were significantly attenuated, having a competitive index (CI) of less than 0.2. A transposon mutant that did not seem to be attenuated based on the STM screening results was chosen from one of the pools as a positive control. This mutant had a CI in vivo of approximately 0.6. An in vitro competition was also done for this mutant resulting in a CI of 0.8. The mutant was subsequently determined to contain an insertion between 2 phenylalanine tRNA's.

Competitive indices for unique attenuated single-insertion mutants are listed in Table 3. Competitive indices for *atpG*, *pnp*, and *exbB* App mutants indicated that the mutants were unable to compete effectively with the wild type strains and were therefore attenuated.

WO 02/075507

PCT/US02/01971

**Table 3**  
**Virulence and Proposed Function of *A. pleuropneumoniae* Mutants**

Mutant	Similarity	Putative or Known Functions	C.I.
5 AP20A6	<i>atpH</i>	ATP synthase	.009
AP7F10	<i>atpG</i>	ATP synthase	.013
AP17C6	<i>tpdA</i>	dihydroliipoamide dehydrogenase	.039
AP11E7	<i>exbB</i>	transport of iron compounds	.003,.003,.006
10 AP3H7	<i>potD</i>	Spermidine/putrescine transport	.308
AP8H6	<i>OmpP5</i>	Adhesin / OmpA homolog	.184
AP18H8	<i>OmpP5-2</i>	Adhesin / OmpA homolog	.552
AP13E9	<i>tig</i>	Peptidyl-prolyl isomerase	.050
15 AP13C2	<i>fbpA</i>	Peptidyl-prolyl isomerase	<.001
AP15C11	<i>pnp</i>	Polynucleotide phosphorylase	.032
AP18F12	<i>hupA</i>	Histone - like protein	.001
AP20F8	<i>dksA</i>	Dosage dependent suppressor of <i>dnaK</i> mutations	.075
20 AP5G4	<i>dnaK</i>	Heat shock protein - molecular chaperone	.376
AP17C9	<i>tRNA-leu</i>	Protein Synthesis	.059
AP5D6	<i>tRNA-glu</i>	Protein Synthesis	.055
AP18B2	<i>rpmF</i>	Protein Synthesis	.112
25 AP10E7	<i>yaeA</i>	Unknown	.001
AP19A5	HI0379	Unknown	.061
AP10C10	<i>apvA</i>	Unknown	.157
AP18F5	<i>apvB</i>	Unknown	.103
AP2A6	<i>apvC</i>	Unknown	.091
30 AP2C11	<i>apvD</i>	Unknown	.014

Accuracy of the CI appeared to be very good as the *exbB* mutant was competed within three different animals yielding CIs of 0.003, 0.003 and 0.006. The use of a Competitive Index number to assign attenuation based upon one competition in a large animal study was further confirmed based on preliminary vaccination results in pigs with 7 mutants (n=8) described below in Example 11.

**Example 10**  
**Characterization of Attenuated *A. pleuropneumoniae* Virulence Genes**

The *A. pleuropneumoniae* genes identified represent four broad functional classes: biosynthetic enzymes, cellular transport components, cellular regulation components and unknowns.

The *atpG* gene, encoding the F1- $\gamma$  subunit of the F<sub>0</sub>F<sub>1</sub> H<sup>+</sup>-ATPase complex, can function in production of ATP or in the transport of protons by hydrolyzing ATP. A related *atpG* attenuated mutant was also identified in *P. multocida*. Another *atp* gene, *atpH*, that encodes the F<sub>1</sub>  $\delta$  subunit was also identified. Phenotypes of *atp* mutants include non-adaptable acid-sensitivity phenotype [Foster, *J Bacteriol.* 173:6896-6902 (1991)], loss of virulence in *Salmonella typhimurium* [Garcia del Portillo, *et al.*, *Infect Immun.* 61:4489-4492 (1993)] and *P. multocida* (above) and a reduction in both transformation frequencies and induction of competence regulatory genes in *Haemophilus influenzae* Rd [Gwinn, *et al.*, *J Bacteriol.* 179:7315-20 (1997)].

LpdA is a dihydrolipoamide dehydrogenase that is a component of two enzymatic complexes: pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase. While the relationship to virulence is unknown, production of LpdA is induced in *Salmonella typhimurium* when exposed to a bactericidal protein from human which may suggest that this induction may be involved in attempts to repair the outer membrane [Qi, *et al.*, *Mol Microbiol.* 17:523-31 (1995)].

Transport of scarce compounds necessary for growth and survival are critical in vivo. ExbB is a part of the TonB transport complex [Hantke, and Zimmerman, *Microbiology Letters.* 49:31-35 (1981)], interacting with TonB in at least two distinct ways [Karlsson, *et al.*, *Mol Microbiol.* 8:389-96 (1993), Karlsson, *et al.*, *Mol Microbiol.* 8:379-88 (1993)]. Iron acquisition is essential for pathogens. In this work, attenuated *exbB* mutants in both APP and *P. multocida* have been identified. Several TonB-dependent iron receptors have been identified in other bacteria [Biswas, *et al.*, *Mol. Microbiol.* 24:169-179 (1997), Braun, *FEMS Microbiol Rev.* 16:295-307 (1995), Elkins, *et al.*, *Infect Immun.* 66:151-160 (1998), Occhino, *et*



al., *Mol Microbiol.* 29:1493-507 (1998), Stojiljkovic and Srinivasan, *J Bacteriol.* 179:805-12 (1997)]. *A. pleuropneumoniae* produces 2 transferrin-binding proteins, which likely depend on the ExbB/ExbD/TonB system, for acquisition of iron. PotD is a periplasmic binding protein that is required for spermidine (a polyamine) transport [Kashiwagi, et al., *J Biol Chem.* 268:19358-63 (1993)]. Another member of the *Pasteurellaceae* family, *Pasteurella haemolytica*, contains a homologue of *potD* (Lpp38) that is a major immunogen in convalescent or outer membrane protein vaccinated calves [Pandher and Murphy, *Vet Microbiol.* 51:331-41 (1996)]. In *P. haemolytica*, PotD appeared to be associated with both the inner and outer membranes. The role of PotD in virulence or in relationship to protective antibodies is unknown although previous work has shown *potD* mutants of *Streptococcus pneumoniae* to be attenuated [Polissi, et al., *Infect. Immun.* 66:5620-9 (1998)].

Relatively few "classical virulence factors," such as adhesins or toxins with the exception of homologues to OMP P5 of *Haemophilus influenzae*, were identified. *H. influenzae* OMP P5 is a major outer membrane protein that is related to the OmpA porin family of proteins [Munson, et al., *M Infect Immun.* 61:4017-20 (1993)]. OMP P5 in nontypeable *Haemophilus influenzae* has been shown to encode a fimbrial subunit protein expressed as a filamentous structure [Sirakova, et al., *Infect Immun.* 62:2002-20 (1994)] that contributes to virulence and binding of both mucin and epithelial cells [Miyamoto and Bakaletz, *Microb Pathog.* 21:343-56 (1996), Reddy, et al., *Infect Immun.* 64:1477-9 (1996), Sirakova, et al., *Infect Immun.* 62:2002-20 (1994)]. A significant finding was identification of two distinct ORFs that appear to encode OMP P5 homologues. This is also the case with two very similar proteins, MOMP and OmpA2 from *Haemophilus ducreyi*. It remains to be determined whether both are functionally involved in the production of fimbriae and whether the presence of two such ORFs represents a divergent duplication with redundant or complementing functions. Interestingly, the two OMP P5 mutants seem to have disparate CI values, suggesting a difference in essentiality or functionality for only one copy. OMP P5 has been shown to undergo molecular variation during chronic infections [Duum, et al., *Infect Immun.* 65:1351-1356 (1997)], however, this

WO 02/075507

PCT/US02/01971

appears to be restricted to a single gene undergoing point mutations resulting in amino acid changes rather than "type switching" due to differential expression of multiple genes.

Protein folding enzymes are important accessories for the efficient  
5 folding of periplasmic and extracellular proteins, and two genes were identified whose products have peptidyl-prolyl isomerase activity: *fkpA* and *tig* (trigger factor). FkpA is a periplasmic protein that is a member of the FK506-binding protein family [Horne and Young, *Arch Microbiol.* 163:357-65 (1995); Missiakas, *et al.*, *Mol Microbiol.* 21:871-84 (1996)]. FkpA has been shown to contribute to intracellular survival of  
10 *Salmonella typhimurium* [Horne, *et al.*, *Infect Immun.* 65:806-10 (1997)] and a *Legionella pneumophila* homolog, *mip* [Engleberg, *et al.*, *Infect Immun.* 57:1263-1270 (1989)], is responsible for virulence and infection of macrophages [Cianciotto, *et al.*, *J. Infect. Dis.* 162:121-6 (1990); Cianciotto, *et al.*, *Infect. Immun.* 57:1255-1262 (1989)]. *Tig*, or trigger factor [Crooke and Wickner, *Proc. Natl. Acad. Sci. USA.* 84:5216-20 (1987), Guthrie, and Wickner, *J. Bacteriol.* 172:5555-62 (1990), reviewed in Hesterkamp, and Bukau., *FEBS Lett.* 389:32-4 (1996)], is a peptidyl prolyl  
15 isomerase containing a typical FKBP region [Callebaut and Mornon, *FEBS Lett.* 374:211-215 (1995)], but is unaffected by FK506 [Stoller, *et al.*, *EMBO J.* 14:4939-48 (1995)]. *Tig* has been shown to associate with the ribosomes and nascent polypeptide chains [Hesterkamp, *et al.*, *Proc Natl Acad Sci USA* 93:4437-41 (1996), Stoller, *et al.*, *EMBO J.* 14:4939-48 (1995)]. Possible roles include an unknown influence on cell  
20 division [Guthrie, and Wickner, *J. Bacteriol.* 172:5555-62 (1990)] in *E. coli*, a role in the secretion and activation of the *Streptococcus pyogenes* cysteine proteinase [Lyon, *et al.*, *EMBO J.* 17:6263-75 (1998)] and survival under starvation conditions in  
25 *Bacillus subtilis* [Gothel, *et al.*, *Biochemistry* 37:13392-9 (1998)].

Bacterial pathogens employ many mechanisms to coordinately regulate gene expression in order to survive a wide variety of environmental conditions within the host. Differences in mRNA stability can modulate gene expression in prokaryotes [Belasco and Higgins, *Gene* 72:15-23 (1988)]. For example, *rnr* (*vacB*) is required  
30 for expression of plasmid borne virulence genes in *Shigella flexneri* [Tobe, *et al.*, *J*

WO 02/075507

PCT/US02/01971

*Bacteriol.* 174:6359-67 (1992)] and encodes the RnaseR ribonuclease [Cheng, *et al.*, *J. Biol. Chem.* 273:14077-14080 (1998)]. PNP is a polynucleotide phosphorylase that is involved in the degradation of mRNA. Null *pnp / rnr* mutants are lethal, suggesting a probable overlap of function. It therefore is possible that both *rnr* and *pnp* are involved in the regulation of virulence gene expression. A *pnp* mutant of *P. multocida* is avirulent in a mouse septicemic model (Example 2). Other *pnp*-associated phenotypes include competence deficiency and cold sensitivity in *Bacillus subtilis* [Wang and Bechhofer, *J Bacteriol.* 178:2375-82 (1996)].

HupA is a bacterial histone-like protein, which in combination with HupB constitute the HU protein in *E. coli*. Reports have suggested that *hupA* and *hupB* single mutants do not demonstrate any observable phenotype [Huisman, *et al.*, *J Bacteriol.* 171:3704-12 (1989), Wada, *et al.*, *J Mol Biol.* 204:581-91 (1988)], however, *hupA-hupB* double mutants have been shown to be cold sensitive, sensitive to heat shock and blocked in many forms of site-specific DNA recombination [Wada, *et al.*, *J Mol Biol.* 204:581-91 (1988), Wada, *et al.*, *Gene.* 76:345-52 (1989)]. One limited data previously indicated that *hupA* is directly involved in virulence [Turner, *et al.*, *Infect Immun.* 66:2099-106 (1998)]. The mechanism of *hupA* attenuation remains unknown.

DnaK is a well known and highly conserved heat shock protein involved in regulatory responses to various stressful environmental changes [reviewed in Lindquist and Craig, *Annu Rev Genet.* 22:631-77 (1988)]. DnaK is also one of the most significantly induced stress proteins in *Yersinia enterocolitica* after being phagocytosed by macrophages [Yamamoto, *et al.*, *Microbiol Immunol.* 38:295-300 (1994)] and a *Brucella suis dnaK* mutant failed to multiply within human macrophage-like cells [Kohler, *et al.*, *Mol Microbiol.* 20:701-12 (1996)]. In contrast, another intracellular pathogen, *Listeria monocytogenes*, did not show induction of *dnaK* after phagocytosis [Hanawa, *et al.*, *Infect Immun.* 63:4595-9 (1995)]. A *dnaK* mutant of *Vibrio cholera* affected the production of ToxR and its regulated virulence factors in vitro but similar results were not obtained from in vivo grown cells [Chakrabarti, *et al.*, *Infect Immun.* 67:1025-1033 (1999)]. The CI of *A.*

*pleuropneumonia dnaK* mutant was higher than most of the attenuated mutants although still approximately half of the positive control strain.

DksA is a dosage dependent suppressor of filamentous and temperature-sensitive growth in a *dnaK* mutant of *E. coli* [Kang and Craig, *J Bacteriol.* 172:2055-64 (1990)]. There is currently no defined molecular function for DksA, but the gene has been identified as being critical for the virulence of *Salmonella typhimurium* in chickens and newly hatched chicks [Turner, *et al., Infect Immun.* 66:2099-106 (1998)]. In that work, it was noted that the *dksA* mutant did not grow well with glucose or histidine but did grow well with glutamine or glutamate as the sole carbon source. This observation may indicate that the *dksA* mutant is somehow impaired in the biosynthesis of glutamate [Turner, *et al., Infect Immun.* 66:2099-106 (1998)].

Three genes were identified that have roles in protein synthesis: tRNA-leu, tRNA-glu and *rpmF*. Excluding protein synthesis, tRNA's also have a wide variety of functional roles in peptidoglycan synthesis [Stewart, *et al., Nature* 230:36-38 (1971)], porphyrin ring synthesis [Jahn, *et al., Trends Biochem Sci.* 17:215-8 (1992)], targeting of proteins for degradation [Tobias, *et al., Science* 254:1374-7 (1991)], post-translational addition of amino acids to proteins [Leibowitz and Soffer, *B.B.R.C.* 36:47-53 (1969)] and mediation of bacterial-eukaryotic interactions [Gray, *et al., J Bacteriol.* 174:1086-98 (1992), Hromockyj, *et al., Mol Microbiol.* 6:2113-24 (1992)]. More specifically, tRNA-leu is implicated in transcription attenuation [Carter, *et al., Proc. Natl. Acad. Sci. USA* 83:8127-8131 (1986)], lesion formation by *Pseudomonas syringae* [Rich and Willis, *J Bacteriol.* 179:2247-58 (1997)] and virulence of uropathogenic *E. coli* [Dobrindt, *et al., FEMS Microbiol Lett.* 162:135-141 (1998), Ritter, *et al., Mol Microbiol.* 17:109-21 (1995)]. It is unknown whether the tRNA that we have identified represents a minor species of tRNA-leu in *A. pleuropneumoniae*. Regardless, it is possible that tRNA-leu may have any one of a wide range of functions. RpmF is a ribosomal protein whose gene is also part of an operon containing fatty acid biosynthesis enzymes in *E. coli*. Further work will be required to indicate if this is the case in *A. pleuropneumoniae*, although the same

WO 02/075507

PCT/US02/01971

clustering of *fab* genes and *rpmF* occurs in *Haemophilus influenzae* [Fleischmann, *et al.*, *Science* 269:496-512 (1995)]. The expression of the *fab* genes is not necessarily dependent on transcripts originating upstream of *rpmF* as there has been a secondary promoter identified within *rpmF* [Zhang and Cronan, Jr., *J Bacteriol.* 180:3295-303 (1998)].

The final class of attenuated mutants includes mutations within genes of unknown function or genes that have not been previously identified. Homologs of *yaeA* and HI0379 have previously been identified in *Escherichia coli* [Blattner, *et al.*, *Science* 277:1453-1474 (1997)] and *Haemophilus influenzae* [Fleischmann, *et al.*, *Science* 269:496-512 (1995)], respectively. The remaining unknowns have been designated *Actinobacillus pleuropneumoniae* virulence genes (*apv*). The *apvC* gene shows significant similarity to HI0893, however, the proposed similarity of HI0893 as a transcriptional repressor similar to the fatty acid response regulator Bm3R1 [Palmer, *J Biol Chem.* 273:18109-16 (1998)] is doubtful. The *apvD* gene is also most similar to a putative membrane protein (b0878) with unknown function from *E. coli* [Blattner, *et al.*, *Science* 277:1453-1474 (1997)]. Two other unknowns, *apvA* and *apvB* had no significant matches in the public databases.

#### Example 11

##### Safety and Efficacy of *A. pleuropneumoniae* Mutants

Nine groups (n=8) of SPF pigs (4-5 weeks old, 3-10 kg) were used to determine the safety and efficacy of seven *A. pleuropneumoniae* mutants as live attenuated vaccine strains. Seven groups were infected intranasally with  $10^{10}$  CFU of each mutant on day 1. One group was vaccinated on days 1 and 15 with the commercially available vaccine Pleuromune (Bayer), and one naive group was not vaccinated. On day 29, all groups were challenged intranasally with  $1.5 \times 10^5$  CFU per pig of wild type APP225. All surviving animals were euthanized and necropsied on day 42 of the study. Results are shown in Table 4.

WO 02/075507

PCT/US02/01971

**Table 4**  
**Efficacy of *A. pleuropneumoniae* Mutants**

	Vaccine	% Mortality following intranasal challenge	
		Vaccination	Challenge
5	Pleuromune	0	37.5
	exbB	0	0
	tig	12.5	0
	fkpA	12.5	0
	HI0385	50.0	0
10	pnp	0	0
	yaeE	0	0
	atpG	0	0
	None	N/A	50.0

15 The *exbB*, *atpG*, *pnp*, and *yaeA* mutants caused no mortality when administered at a dosage of  $10^{10}$  CFU intranasally. The *fkpA* and *tig* mutant groups had one death each and the HI0379 group (highest CI of the 7 mutants tested shown in Example 9) had four deaths. Wildtype  $LD_{50}$  using this model was generally  $1 \times 10^7$  CFU, indicating that each of these mutants is at least 100 fold attenuated and that

20 there is a reasonable correlation between CI and attenuation.

**Example 12**  
**Identification of *P. (Mannheimia) haemolytica* Species Homologs**

25 Based on the sequences of virulence genes identified in *P. multocida* and *A. pleuropneumoniae*, attempt were made to identify related genes, *i.e.*, species homologs, in *P. (Mannheimia) haemolytica*. PCR was utilized with the degenerate primers shown below to attempt amplification of the *P. (Mannheimia) haemolytica* genes as indicated. Primer sequences, synthesized by Sigma-Genosys (The Woodlands, TX), include standard single letter designations, wherein B indicates

WO 02/075507

PCT/US02/01971

either (C,G or T), D indicates either (G,A or T), H indicates either (A,C or T), K indicates either (G or T), M indicates either (A or C), N indicates either (A,G,C or T), R indicates either (A or G), S indicates either (G or C), V indicates either (G, A, or C), W indicates either (A or T), and Y indicates either (C or T).

5

atpG TEF146 ATG GCN GGN GCN AAR GAR AT SEQ ID NO: 176  
TEF148 GCN GCY TTC ATN GCN ACC AT SEQ ID NO: 177

10

guaB TEF240 GGN TTY ATY CAY AAA AAY ATG SEQ ID NO: 178  
TEF243 TCT TTN GTR ATN GTN ACA TCR TG SEQ ID NO: 179

pnp TEF141 GCS GGY AAA CCR CGT TGG GAT TGG SEQ ID NO: 180  
TEF142 CRC CTA ARA TRT CTG AAA GCA CCA C SEQ ID NO: 181

15

purF TEF244 ATG TGY GGN ATY GTN GGN AT SEQ ID NO: 182  
TEF247 CAT ATC AAT ACC ATA CAC ATT SEQ ID NO: 183

20

yjgF TEF162 GGN CCN TAY GTN CAR G SEQ ID NO: 184  
TEF163 NGC NAC YTC NAC RCA SEQ ID NO: 185

For amplification of initial degenerate PCR products, a 50  $\mu$ l reaction was set up using 3.3X XL buffer II (PE Applied Biosystems), 200  $\mu$ M dNTPs, 25 pmol each of the appropriate primers, 0.8 mM MgCl<sub>2</sub>, 0.5 U *rTth* DNA polymerase, XL (PE Applied Biosystems) and approximately 1  $\mu$ g of TF1 DNA.

25

Cycle conditions were 94°C for 1.5 min; followed by 35 cycles of 94°C for 15 s, 40-60°C for 60 s, 72°C for 1.5 min; and a final hold at 72°C for 5 min. Each PCR product was band purified from an agarose gel using the QIAGEN Gel Extraction Kit (QIAGEN, Valencia CA).

30

Sequencing reactions were performed using the BigDye™ Dye Terminator Chemistry kit from PE Applied Biosystems (Foster City, CA) and run on an ABI Prism 377 DNA Sequencer. Double stranded sequence for the open reading frame (ORF) for each clone was obtained. Sequencher 3.0 software (Genecodes, Corp., Ann Arbor, MI) was used to assemble and analyze sequence data. GCG programs were used to confirm the identity of the ORF by searching for homologous sequences in currently available databases.

35

WO 02/075507

PCT/US02/01971

The Vectorette Kit (Genosys Biotechnologies, The Woodlands, TX) was used to obtain additional flanking sequence for each of the genes. Vectorette libraries were prepared according to the manufacturer's suggested protocol. Perkin Elmer Applied Biosystems GeneAmp XL PCR Kit components were used to create the

5 Vectorette PCR products with the following reaction conditions. A 50  $\mu$ l reaction was set up using 3.3X XL buffer II (PE Applied Biosystems), 200  $\mu$ M dNTPs, 25 pmol each of the appropriate primers (shown below), 0.8 mM MgCl<sub>2</sub>, 0.5 U *r7h* DNA polymerase, XL (PE Applied Biosystems) and 1  $\mu$ l of the appropriate vectorette library. Cycle

10 conditions were 94°C for 1.5 min; followed by 35 cycles of 94°C for 20 s, 60°C for 45s, 72°C for 4 min; and a final hold of 72°C for 7 min. The second primer for each library was the manufacturer's vectorette primer.



WO 02/075507

PCT/US02/01971

Table 5

Gene	Vectorette library	Primer(s)
atpG	BglII, HindIII	TEF217 GAAGCCGCCATACGCTCTTGGG SEQ ID NO: 186
	Clal	TEF218 GTTGCTTCCTTGCCTGCACTGG SEQ ID NO: 187
guaB	EcoRI	TEF265 GGCTCAGAAACAATACCACTTCA SEQ ID NO: 188
	HindIII, TaqI	TEF268 GCACCAAAGCAGAATTGTCC SEQ ID NO: 189
pnp	Clal, HincII	TEF219 GGTGATGATGTCGATGATAGTCCC SEQ ID NO: 190
	TaqI	TEF220 GCGGTATTAGCCGTGATGCCAACC SEQ ID NO: 191
	BamHI	TEF286 GACCACTTAGGCGATATGGACTT SEQ ID NO: 192
purF	TaqI	TEF271 ACCATCATAAATCGCCTGATTC SEQ ID NO: 193
		TEF292 ACCTGGCGCATCTTGTCTC SEQ ID NO: 194
	HincII	TEF274 ACGGGTTATTTGCCTCTG SEQ ID NO: 195
yjfF	Clal	TEF221 CGCCGGTTTCAGGATTCACGGG SEQ ID NO: 196
	EcoRV	TEF281 CTGAACAACGTGAAAGCCAT SEQ ID NO: 197

Vectorette PCR products were band purified and sequenced as described above.

Polynucleotide sequences for the atpG, guaB, pnp, purF, and yjfF genes are set out in SEQ ID NOs: 166, 168, 170, 172 and 174, respectively. Polypeptides encoded by these genes are set out in SEQ ID NOs: 167, 169, 171, 173, and 175, respectively.

WO 02/075507

PCT/US02/01971

;

Numerous modifications and variations in the invention as set forth in the above illustrative examples are expected to occur to those skilled in the art. Consequently only such limitations as appear in the appended claims should be placed on the invention.

WO 02/075507

PCT/US02/01971

## WHAT IS CLAIMED IS:

1. A gram-negative bacteria comprising a mutation in a gene represented by a nucleotide sequence set forth in any one of SEQ ID NOs: 1, 3, 7, 9, 21, 25, 27, 29, 39, 41, 51, 53, 55, 57, 58, 60, 68, 72, 74, 76, 78, 80, 82, 84, 104, 108, 112, 116, 118, 120, 122, 124, 126, 128, and 130, or species homologs thereof, said mutation resulting in decreased activity of a gene product encoded by the mutated gene.
2. The gram-negative bacteria of claim 1 wherein said mutation results in decreased expression of a gene product encoded by the mutated gene.
3. The gram-negative bacteria of claim 1 wherein said mutation results in expression of an inactive gene product encoded by the mutated gene.
4. The gram-negative bacteria of claim 1 wherein said mutation results in deletion of all or part of said gene.
5. An attenuated *Pasteurellaceae* bacteria comprising a mutation in a gene represented by a nucleotide sequence set forth in any one of SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172 and 174 or a species homolog thereof, said mutation resulting in decreased activity of a gene product encoded by the mutated gene.
6. The *Pasteurellaceae* bacteria of claim 5 wherein said mutation results in decreased expression of a gene product encoded by the mutated gene.
7. The *Pasteurellaceae* bacteria of claim 5 wherein said mutation results in expression of an inactive gene product encoded by the mutated gene.

8. The *Pasteurellaceae* bacteria of claim 5 wherein said mutation results in deletion of all or part of said gene.

9. The *Pasteurellaceae* bacteria of claim 5 selected from the group consisting of *Pasteurella (Mannheimia) haemolytica*, *Pasteurella multocida*, *Actinobacillus pleuropneumoniae* and *Haemophilus sommus*.

10. The *Pasteurellaceae* bacteria of claim 9 wherein said mutation results in decreased expression of a gene product encoded by the mutated gene.

11. The *Pasteurellaceae* bacteria of claim 9 wherein said mutation results in expression of an inactive gene product encoded by the mutated gene.

12. The *Pasteurellaceae* bacteria of claim 9 wherein said mutation results in deletion of all or part of said gene.

13. The attenuated *Pasteurellaceae* bacteria of claim 9 that is a *P. multocida* bacteria.

14. The *Pasteurellaceae* bacteria of claim 13 wherein said mutation results in decreased expression of a gene product encoded by the mutated gene.

15. The *Pasteurellaceae* bacteria of claim 13 wherein said mutation results in expression of an inactive gene product encoded by the mutated gene.

16. The *Pasteurellaceae* bacteria of claim 13 wherein said mutation results in deletion of all or part of said gene.

17. The attenuated *Pasteurellaceae* bacteria of claim 9 that is a *A. pleuropneumoniae* bacteria.

WO 02/075507

PCT/US02/01971

18. The *Pasteurellaceae* bacteria of claim 17 wherein said mutation results in decreased expression of a gene product encoded by the mutated gene.

19. The *Pasteurellaceae* bacteria of claim 17 wherein said mutation results in expression of an inactive gene product encoded by the mutated gene.

20. The *Pasteurellaceae* bacteria of claim 17 wherein said mutation results in deletion of all or part of said gene.

21. An immunogenic composition comprising the bacteria according to any one of claims 1 through 20.

22. A vaccine composition comprising the immunogenic composition according to claim 21 and a pharmaceutically acceptable carrier.

23. The vaccine composition according to claim 22 further comprising an adjuvant.

24. A method for producing a gram-negative bacteria mutant comprising the step of introducing a mutation in a gene represented by a nucleotide sequence set forth in any one of SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174 or a species homolog thereof, said mutation resulting in decreased activity of a gene product encoded by the mutated gene.

25. A method for producing an attenuated *Pasteurellaceae* bacteria comprising the step of introducing a mutation in a gene represented by a nucleotide sequence set forth in any one of SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29,

WO 02/075507

PCT/US02/01971

31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172, and 174 or a species homolog thereof, said mutation resulting in decreased activity of a gene product encoded by the mutated gene.

26. A purified and isolated *Pasteurellaceae* polynucleotide comprising a nucleotide sequence selected from the group consisting of nucleotide sequences set forth in SEQ ID NOs: 1, 3, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 29, 31, 33, 37, 39, 41, 51, 53, 55, 57, 58, 60, 68, 70, 72, 74, 76, 78, 80, 82, 84, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 135, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 163, 164, 166, 168, 170, 172 and 174.

27. A purified and isolated *Pasteurellaceae* polynucleotide comprising a nucleotide sequence selected from the group consisting of nucleotide sequences set forth in SEQ ID NOs: 1, 3, 7, 9, 21, 25, 27, 29, 39, 41, 51, 53, 55, 57, 58, 60, 68, 72, 74, 76, 78, 80, 82, 84, 104, 108, 112, 116, 118, 120, 122, 124, 126, 128, and 130.

28. A purified and isolated polynucleotide encoding a *Pasteurellaceae* virulence gene product, or species homolog thereof, selected from the group consisting of:

- a) the polynucleotide according to claim 27,
- b) polynucleotides encoding a polypeptide encoded by the polynucleotide of (a), and
- c) polynucleotides that hybridize to the complement of the polynucleotides of (a) or (b) under moderate stringency conditions.

29. A purified and isolated *Pasteurellaceae* polynucleotide encoding a polypeptide selected from the group consisting of polypeptides having amino acid sequences set forth in SEQ ID NOs: 2, 4, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 30, 32, 34, 38, 40, 42, 52, 54, 56, 59, 61, 69, 71, 73, 75, 77, 79, 81, 83, 85, 101, 103, 105, 107, 109,

WO 02/075507

PCT/US02/01971

111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 165, 167, 169, 171, 173, and 175.

30. The polynucleotide of claim 29 which is a DNA.

31. A vector comprising the DNA of claim 30.

32. The vector of claim 31 that is an expression vector, wherein the DNA is operatively linked to an expression control DNA sequence.

33. A host cell stably transformed or transfected with the DNA of claim 30 in a manner allowing the expression of the encoded polypeptide in said host cell.

34. A method for producing a recombinant polypeptide comprising culturing the host cell of claim 33 in a nutrient medium and isolating the encoded polypeptide from said host cell or said nutrient medium.

35. A purified polypeptide produced by the method of claim 34.

36. A purified polypeptide comprising a polypeptide selected from the group consisting of polypeptides having amino acid sequences set forth in SEQ ID NOs: 2, 4, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 30, 32, 34, 38, 40, 42, 52, 54, 56, 59, 61, 69, 71, 73, 75, 77, 79, 81, 83, 85, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 165, 167, 169, 171, 173, and 175.

37. An antibody that is specifically reactive with the polypeptide of claim 36.

38. The antibody of claim 37 that is a monoclonal antibody.

39. A method of using the monoclonal antibody of claim 39 for identifying a bacteria of claim 1, 5, 9, or 13 comprising the step of contacting an extract of bacteria with said monoclonal antibody and detecting the absence of binding of said monoclonal antibody.

40. A method of identifying an anti-bacterial agent comprising the steps of assaying potential agents for the ability to interfere with expression or activity of gene products represented by the amino acid sequences set forth in any one of SEQ ID NOS: 2, 4, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 30, 32, 34, 38, 40, 42, 52, 54, 56, 59, 61, 69, 71, 73, 75, 77, 79, 81, 83, 85, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 165, 167, 169, 171, 173, and 175 and identifying an agent that interferes with expression or activity of said gene products.

41. A method of identifying an anti-bacterial agent comprising the steps of:

a) measuring expression or activity of a gene product as set out in SEQ ID NOS: 2, 4, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 30, 32, 34, 38, 40, 42, 52, 54, 56, 59, 61, 69, 71, 73, 75, 77, 79, 81, 83, 85, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 165, 167, 169, 171, 173, and 175;

b) contacting the gene product in (a) with a test compound

c) measuring expression or activity of the gene product in the presence of the test compound; and

d) identifying the test compound as an antibacterial agent when expression or activity of the gene product is decreased in the presence of the test compound as compared to expression or activity in the presence of the test compound.



WO 02/075507

PCT/US02/01971

## SEQUENCE LISTING

```

<110> Lowery E., David, et al.
<120> Anti-Bacterial Vaccine Compositions
<130> 28341/00435
<140> 09/809,665
<141> 2001-03-15
<150> 60/153,453
<151> 1999-09-10
<150> 60/128,689
<151> 1999-04-09
<150> 09/545,199
<151> 2000-04-06
<160> 197
<170> PatentIn Ver. 2.0
<210> 1
<211> 1112
<212> DNA
<213> Pasteurella multocida
<220>
<221> CDS
<222> (210)..(1001)
<220>
<223> atpB
<220>
<221> misc_feature
<222> 1099
<223> n = A or T or G or C
<220>
<221> misc_feature
<222> 1104
<223> n = A or T or G or C

<400> 1
gtcaacaaca ttttatggtg gagaggccgt taaatttata tccacaattt ttttgattgt 60
acttgccttt aaactgttca attcaatgca ttttattgca ttttttgttg gatattttat 120
aacaatagtt ttaacaata ttcttccatt ttttataagt aagtacttaa atataagca 180
ttttcataaa tatcaataaa ggattagtt atg gca gca gag ctt aca aca gcg 233
Met Ala Ala Glu Leu Thr Thr Ala
1 5
gga tat att ggg cac cat tta gca ttc ttg aaa aca ggg gat tct ttc 281
Gly Tyr Ile Gly His His Leu Ala Phe Leu Lys Thr Gly Asp Ser Phe
10 15 20

```

WO 02/075507

PCT/US02/01971

```

tgg cat gtt cat tta gat acc ctt cta ttt tca att att tca ggt gca 329
Trp His Val His Leu Asp Thr Leu Leu Phe Ser Ile Ile Ser Gly Ala
25 30 35 40
att ttt ctt ttt gtt ttt tca aaa gtt gca aaa aaa gca acg ccg ggt 377
Ile Phe Leu Phe Val Phe Ser Lys Val Ala Lys Lys Ala Thr Pro Gly
45 50 55
gtg cct agc aag atg caa tgt ttt gtt gag ata atg gtt gat tgg att 425
Val Pro Ser Lys Met Gln Cys Phe Val Glu Ile Met Val Asp Trp Ile
60 65 70
gat ggg atc gta aaa gaa aat ttc cat ggt cct cgt cat gct gtt gga 473
Asp Gly Ile Val Lys Glu Asn Phe His Gly Pro Arg His Ala Val Gly
75 80 85
cca tta gca tta act att ttc tgc tgg gta ttc att atg aat gct atc 521
Pro Leu Ala Leu Thr Ile Phe Cys Trp Val Phe Ile Met Asn Ala Ile
90 95 100
gat ttg atc cca gta gat ttc cta cct caa tta gcc cat tta ttt ggt 569
Asp Leu Ile Pro Val Asp Phe Leu Pro Gln Leu Ala His Leu Phe Gly
105 110 115 120
att gaa tac tta aga gct gtt cca aca gca gat atc agt gga aca tta 617
Ile Glu Tyr Leu Arg Ala Val Pro Thr Ala Asp Ile Ser Gly Thr Leu
125 130 135
ggc tta tca att ggt gtc ttc ttc tta att att ttc tat aca atc aaa 665
Gly Leu Ser Ile Gly Val Phe Phe Leu Ile Ile Phe Tyr Thr Ile Lys
140 145 150
tca aaa ggt atg agt ggc ttt gtt aaa gaa tat acg ctt cat cct ttt 713
Ser Lys Gly Met Ser Gly Phe Val Lys Glu Tyr Thr Leu His Pro Phe
155 160 165
aat cat cct ttg tta att ccg gtt aac tta gcg ctt gaa tca gtc aca 761
Asn His Pro Leu Leu Ile Pro Val Asn Leu Ala Leu Glu Ser Val Thr
170 175 180
tta tta gca aaa cct gtt tct ttg gcg ttc cgt ctt ttc ggg aat atg 809
Leu Leu Ala Lys Pro Val Ser Leu Ala Phe Arg Leu Phe Gly Asn Met
185 190 195 200
tat gca ggt gaa ctt atc ttt att ctt att gca gtg atg tac atg gca 857
Tyr Ala Gly Glu Leu Ile Phe Ile Leu Ile Ala Val Met Tyr Met Ala
205 210 215
aat aat ttt gca ctt aat tca atg ggt att ttc atg cat ttg gct tgg 905
Asn Asn Phe Ala Leu Asn Ser Met Gly Ile Phe Met His Leu Ala Trp
220 225 230
gct att ttc cat att ctt gtg att acc tta caa gca ttt att ttt atg 953
Ala Ile Phe His Ile Leu Val Ile Thr Leu Gln Ala Phe Ile Phe Met
235 240 245
atg ctt aca gtg gtt tat ttg agt atg ggt tat aac aaa gca gaa cac 1001
Met Leu Thr Val Val Tyr Leu Ser Met Gly Tyr Asn Lys Ala Glu His
250 255 260
taatttttta taaacaaaac cagacctgg gtctaaattt caatcttatg gagaacatta 1061
tggaacactg taattactac aacaatcacc gcactcgnaa ttntctttgc t 1112

```

WO 02/075507

PCT/US02/01971

<210> 2  
 <211> 264  
 <212> PRT  
 <213> Pasteurella multocida  
  
 <400> 2  
 Met Ala Ala Glu Leu Thr Thr Ala Gly Tyr Ile Gly His His Leu Ala  
 1 5 10 15  
 Phe Leu Lys Thr Gly Asp Ser Phe Trp His Val His Leu Asp Thr Leu  
 20 25 30  
 Leu Phe Ser Ile Ile Ser Gly Ala Ile Phe Leu Phe Val Phe Ser Lys  
 35 40 45  
 Val Ala Lys Lys Ala Thr Pro Gly Val Pro Ser Lys Met Gln Cys Phe  
 50 55 60  
 Val Glu Ile Met Val Asp Trp Ile Asp Gly Ile Val Lys Glu Asn Phe  
 65 70 75 80  
 His Gly Pro Arg His Ala Val Gly Pro Leu Ala Leu Thr Ile Phe Cys  
 85 90 95  
 Trp Val Phe Ile Met Asn Ala Ile Asp Leu Ile Pro Val Asp Phe Leu  
 100 105 110  
 Pro Gln Leu Ala His Leu Phe Gly Ile Glu Tyr Leu Arg Ala Val Pro  
 115 120 125  
 Thr Ala Asp Ile Ser Gly Thr Leu Gly Leu Ser Ile Gly Val Phe Phe  
 130 135 140  
 Leu Ile Ile Phe Tyr Thr Ile Lys Ser Lys Gly Met Ser Gly Phe Val  
 145 150 155 160  
 Lys Glu Tyr Thr Leu His Pro Phe Asn His Pro Leu Leu Ile Pro Val  
 165 170 175  
 Asn Leu Ala Leu Glu Ser Val Thr Leu Leu Ala Lys Pro Val Ser Leu  
 180 185 190  
 Ala Phe Arg Leu Phe Gly Asn Met Tyr Ala Gly Glu Leu Ile Phe Ile  
 195 200 205  
 Leu Ile Ala Val Met Tyr Met Ala Asn Asn Phe Ala Leu Asn Ser Met  
 210 215 220  
 Gly Ile Phe Met His Leu Ala Trp Ala Ile Phe His Ile Leu Val Ile  
 225 230 235 240  
 Thr Leu Gln Ala Phe Ile Phe Met Met Leu Thr Val Val Tyr Leu Ser  
 245 250 255  
 Met Gly Tyr Asn Lys Ala Glu His  
 260

<210> 3  
 <211> 1972  
 <212> DNA  
 <213> Pasteurella multocida

WO 02/075507

PCT/US02/01971

```

<220>
<221> CDS
<222> (364)...(1230)

<220>
<223> atpG

<400> 3
agcgggccat ttggctcagt tgggcttcgg attottatga tgcacacgta agcaattatc 60
acatggctaa aaagtaactg aattattgaa acaaaaccaa tactctccgt tatctgtagc 120
acaacaagca ttagtggtat ttgcaqtaga gtttggttac ttagaagaag tggacttaga 180
tcgtattggt tcatttgaat cagcactttt agagtatgct aaccataact atgctgattt 240
tatgctgtgag ttaacccaat ctggcaatta caatgatgaa attaaagagt cattaaaagg 300
cattttggat agcttcaag caaacagtgc gtgtaagtt aacactttaa atggagagac 360
aaa atg gca ggt gct aaa gag ata aga acc aaa atc gcg agt gta aaa 408
Met Ala Gly Ala Lys Glu Ile Arg Thr Lys Ile Ala Ser Val Lys
1 5 10 15

agt aca caa aaa att act aaa gcg atg gaa atg gtt gct gcc tcg aaa 456
Ser Thr Gln Lys Ile Thr Lys Ala Met Glu Met Val Ala Ala Ser Lys
20 25 30

atg cgt aaa acg caa gaa cgc atg tct tct tca cgc cct tat tca gaa 504
Met Arg Lys Thr Gln Glu Arg Met Ser Ser Arg Pro Tyr Ser Glu
35 40 45

aca ata cgt aac gtg att agc cac gtt tcc aaa gca acg att ggt tac 552
Thr Ile Arg Asn Val Ile Ser His Val Ser Lys Ala Thr Ile Gly Tyr
50 55 60

aag cat cca ttt tta gtg gat cgc gaa gta aaa aaa gtg ggc atg att 600
Lys His Pro Phe Leu Val Asp Arg Glu Val Lys Lys Val Gly Met Ile
65 70 75

gtt gtg tcc aca gat cgt ggt ctt tgt ggt ggc tta aac gtg aac ttg 648
Val Val Ser Thr Asp Arg Gly Leu Cys Gly Gly Leu Asn Val Asn Leu
80 85 90

ttt aaa act gta tta aat gaa atg aaa gaa tgg aaa gaa aaa gat gtt 656
Phe Lys Thr Val Leu Asn Glu Met Lys Glu Trp Lys Glu Lys Asp Val
100 105 110

tcc gtt caa ttg agt tta atc ggt tct aaa tct atc aac ttt ttc caa 744
Ser Val Gln Leu Ser Leu Ile Gly Ser Lys Ser Ile Asn Phe Phe Gln
115 120 125

tct ttg gga att aaa att tta acc caa gat tca ggt att ggt gat act 792
Ser Leu Gly Ile Lys Ile Leu Thr Gln Asp Ser Gly Ile Gly Asp Thr
130 135 140

ccc tct gtt gag cag tta att ggt tca gtc aat tct atg att gat gct 840
Pro Ser Val Glu Gln Leu Ile Gly Ser Val Asn Ser Met Ile Asp Ala
145 150 155

tat aaa aaa ggg gaa gta gat gtt gtg tat tta gtt tat aac aaa ttt 888
Tyr Lys Lys Gly Glu Val Asp Val Val Tyr Leu Val Tyr Asn Lys Phe
160 165 170 175

```

WO 02/075507

PCT/US02/01971

```

att aac acg atg tcg caa aag cca gta ttg gaa aaa tta att cca tta 936
Ile Asn Thr Met Ser Gln Lys Pro Val Leu Glu Lys Leu Ile Pro Leu
180 185 190

cca gaa tta gat aat gat gaa tta ggc gaa aga aaa caa gtt tgg gat 984
Pro Glu Leu Asp Asn Asp Glu Leu Gly Glu Arg Lys Gln Val Trp Asp
195 200 205

tat att tac gaa cct gat gcg aaa gta tta tta gat aat tta ttg gtt 1032
Tyr Ile Tyr Glu Pro Asp Ala Lys Val Leu Leu Asp Asn Leu Leu Val
210 215 220

cgt tat tta gaa tct cag gtt tat caa gca gca gtt gaa aac ctt gct 1080
Arg Tyr Leu Glu Ser Gln Val Tyr Gln Ala Ala Val Glu Asn Leu Ala
225 230 235

tct gag caa gcc gct cga atg gtc gcc atg aaa gca gca aca gat aac 1128
Ser Glu Gln Ala Ala Arg Met Val Ala Met Lys Ala Ala Thr Asp Asn
240 245 250 255

gca ggt aac tta att aat gag tta cag tta gtc tat aac aaa gct cgt 1176
Ala Gly Asn Leu Ile Asn Glu Leu Gln Leu Val Tyr Asn Lys Ala Arg
260 265 270

caa gca agt att aca aat gaa tta aat gaa att gtt gcc ggt gca gca 1224
Gln Ala Ser Ile Thr Asn Glu Leu Asn Glu Ile Val Ala Gly Ala Ala
275 280 285

gca att taacaaatag aggatcggta atggcaactg gaaaaattgt acaaatcacc 1280
Ala Ile

ggcgcggtta ttgacgttga attcccacaa gatgcagtac caaaagtata tgatgcctta 1340

aatgttgaaa caggtttagt acttgaagtt caacaacaat taggtggtgg tgtagtctgc 1400

tgtatcgcaa tgggatcacc tgatggatta aaacgcggtt taagcgtaac aaatacgaat 1460

aaaccaatct ctgtccagc gggaaacgaaa acattgggtc gtatcatgaa cgtattgggt 1520

gaaccaatcg atgagcaagg tgaatcggc gcagaagaga attggtctat tcaccgtgcg 1580

ccaccaagtt atgaagaaca atctaacagt actgaacttt tagaaaaggg aattaaagtt 1640

atcgacttag ttgtccggt tgcgaaaggg ggtaaagtag gtttattcgg tggcgcggtt 1700

gtcggtaaaa cgtcaatat gatggaatta atccgtaaca tcgcaattga gcaactcagg 1760

tactctgtct ttgcgggggt aggtgagcgt acgcgtgaag gtaacgactt ctatcatgag 1820

atgaaagact ctaacgtatt agataaagtg tctcttgttt atggtcaaat gaacgagcca 1880

ccaggtaacc gtttacgtgt ggcattaaca ggcttaacta tggcggaaaa attccctgat 1940

gaaggtcgtg atgtcttatt ctctcgtgat aa 1972

<210> 4
<211> 289
<212> PRT
<213> Pasteurella multocida

<400> 4
Met Ala Gly Ala Lys Glu Ile Arg Thr Lys Ile Ala Ser Val Lys Ser

```

WO 02/075507

PCT/US02/01971

```

1           5           10           15
Thr Gln Lys Ile Thr Lys Ala Met Glu Met Val Ala Ala Ser Lys Met
20           25           30
Arg Lys Thr Gln Glu Arg Met Ser Ser Ser Arg Pro Tyr Ser Glu Thr
35           40           45
Ile Arg Asn Val Ile Ser His Val Ser Lys Ala Thr Ile Gly Tyr Lys
50           55           60
His Pro Phe Leu Val Asp Arg Glu Val Lys Lys Val Gly Met Ile Val
65           70           75
Val Ser Thr Asp Arg Gly Leu Cys Gly Gly Leu Asn Val Asn Leu Phe
85           90           95
Lys Thr Val Leu Asn Glu Met Lys Glu Trp Lys Glu Lys Asp Val Ser
100          105          110
Val Gln Leu Ser Leu Ile Gly Ser Lys Ser Ile Asn Phe Phe Gln Ser
115          120          125
Leu Gly Ile Lys Ile Leu Thr Gln Asp Ser Gly Ile Gly Asp Thr Pro
130          135          140
Ser Val Glu Gln Leu Ile Gly Ser Val Asn Ser Met Ile Asp Ala Tyr
145          150          155
Lys Lys Gly Glu Val Asp Val Val Tyr Leu Val Tyr Asn Lys Phe Ile
165          170          175
Asn Thr Met Ser Gln Lys Pro Val Leu Glu Lys Leu Ile Pro Leu Pro
180          185          190
Glu Leu Asp Asn Asp Glu Leu Gly Glu Arg Lys Gln Val Trp Asp Tyr
195          200          205
Ile Tyr Glu Pro Asp Ala Lys Val Leu Leu Asp Asn Leu Leu Val Arg
210          215          220
Tyr Leu Glu Ser Gln Val Tyr Gln Ala Ala Val Glu Asn Leu Ala Ser
225          230          235
Glu Gln Ala Ala Arg Met Val Ala Met Lys Ala Ala Thr Asp Asn Ala
245          250          255
Gly Asn Leu Ile Asn Glu Leu Gln Leu Val Tyr Asn Lys Ala Arg Gln
260          265          270
Ala Ser Ile Thr Asn Glu Leu Asn Glu Ile Val Ala Gly Ala Ala Ala
275          280          285
Ile

```

```

<210> 5
<211> 1357
<212> DNA
<213> Pasteurella multocida
<220>

```

WO 02/075507

PCT/US02/01971

```

<221> CDS
<222> (1)..(813)
<220>
<223> cap5E
<400> 5
gtc gac tat att tat cat gct gcc gca tta aag caa gtg cct tca tgc 48
Val Asp Tyr Ile Tyr His Ala Ala Ala Leu Lys Gln Val Pro Ser Cys
1 5 10 15
gag ttt tat ccg tta gag gca gtg aaa acc aat att tta ggt acg gca 96
Glu Phe Tyr Pro Leu Glu Ala Val Lys Thr Asn Ile Leu Gly Thr Ala
20 25 30
aat gtc tta gaa gcc gcc atc caa aac cag ata aaa cgc gtc gtc tgt 144
Asn Val Leu Glu Ala Ala Ile Gln Asn Gln Ile Lys Arg Val Val Cys
35 40 45
ctt agc aca gat aaa gcg gtg tac cca att aat gcg atg ggc att tct 192
Leu Ser Thr Asp Lys Ala Val Tyr Pro Ile Asn Ala Met Gly Ile Ser
50 55 60
aaa gca atg atg gaa aaa gtc atc atc gca aaa tcg cgt aac cta gaa 240
Lys Ala Met Met Glu Lys Val Ile Ile Ala Lys Ser Arg Asn Leu Glu
65 70 75 80
ggc aca cca acg aca atc tgt tgt act cgc tat ggc aat gtc atg gca 288
Gly Thr Pro Thr Thr Ile Cys Cys Thr Arg Tyr Gly Asn Val Met Ala
85 90 95
tcg cgt ggt tcg gtt atc cca tta ttt gtc gat caa ata cgt caa ggc 336
Ser Arg Gly Ser Val Ile Pro Leu Phe Val Asp Gln Ile Arg Gln Gly
100 105 110
aag cct ttt act att act gat cct gag atg aca cgc ttt atg atg aca 384
Lys Pro Phe Thr Ile Thr Asp Pro Glu Met Thr Arg Phe Met Met Thr
115 120 125
ttg gaa gat gct gtg gat tta gtc cta tat gca ttt aaa aat ggt caa 432
Leu Glu Asp Ala Val Asp Leu Val Leu Tyr Ala Phe Lys Asn Gly Gln
130 135 140
aat ggt gat gtt ttr gta caa aaa gcc ccc gca gca acc att ggt acc 480
Asn Gly Asp Val Phe Val Gln Lys Ala Pro Ala Ala Thr Ile Gly Thr
145 150 155 160
ctt gcc aaa gca att acc gaa tta tta tct gtc cca aat cac cct att 528
Leu Ala Lys Ala Ile Thr Glu Leu Leu Ser Val Pro Asn His Pro Ile
165 170 175
tcc att ata ggt acg cgt cat gga gag aaa gca ttc gaa gct tta tta 576
Ser Ile Ile Gly Thr Arg His Gly Glu Lys Ala Phe Glu Ala Leu Leu
180 185 190
agc cgt gaa gaa atg gtt cat gca att aat gaa ggt aat tat tat cgc 624
Ser Arg Glu Glu Met Val His Ala Ile Asn Glu Gly Asn Tyr Tyr Arg
195 200 205
atc cca gcc gat caa cgc agt tta aat tac agt aaa tat gtc gaa aaa 672
Ile Pro Ala Asp Gln Arg Ser Leu Asn Tyr Ser Lys Tyr Val Glu Lys
210 215 220

```

WO 02/075507

PCT/US02/01971

```

ggg gaa cca aaa att acc gaa gtc acc gac tac aac tca cat aat act 720
Gly Glu Pro Lys Ile Thr Glu Val Thr Asp Tyr Asn Ser His Asn Thr
225                230                235                240

gag cgt ttg act gtc aag gaa atg aag cag tta ctg ctt aaa ctt gaa 768
Glu Arg Leu Thr Val Lys Glu Met Lys Gln Leu Leu Leu Lys Leu Glu
245                250                255

ttc ata cag aaa atg att gag ggt gaa tac atc tca ccg gag gta 813
Phe Ile Gln Lys Met Ile Glu Gly Glu Tyr Ile Ser Pro Glu Val
260                265                270

taaaaatgaa agtcttagta actggttcaa atggttttat tgcgaaaaat ctgattcagt 873
ctttatctga ggaacaagat attgagattt tatgttatca ccgtcaatcc tctgagaaaa 933
cgcttatcca tcattgtatt agtctgtgatt ggattatcca tcttgccgggt gcgaaatcgtc 993
caectgaaga acaagaattt atgacatcaa atacacaatt gacgaaaaaa atttgccgta 1053
ttttacagcg tcactcagaaa aaaacgcctt tgttatattc ctctagcatt caagtagaaa 1113
gtcccaaat aagtacttat tcgcaaacca aattagaag tgaatatcat gttcatcaat 1173
tacataaaga aaatggtaat ccgatttata tctgccgttt agctaagtcc tttggcaaat 1233
ggtcacgacc tcactataac tcggtagtcg ccacattttg ccataactta attcatgatt 1293
taccatcaga aattcatgat catactgcag aaataaggct catttatatt gatgatgctg 1353
ttga                1357

```

```

<210> 6
<211> 271
<212> PRT
<213> Pasteurella multocida

```

```

<400> 6
Val Asp Tyr Ile Tyr His Ala Ala Ala Leu Lys Gln Val Pro Ser Cys
1          5          10          15
Glu Phe Tyr Pro Leu Glu Ala Val Lys Thr Asn Ile Leu Gly Thr Ala
20          25          30
Asn Val Leu Glu Ala Ala Ile Gln Asn Gln Ile Lys Arg Val Val Cys
35          40          45
Leu Ser Thr Asp Lys Ala Val Tyr Pro Ile Asn Ala Met Gly Ile Ser
50          55          60
Lys Ala Met Met Glu Lys Val Ile Ile Ala Lys Ser Arg Asn Leu Glu
65          70          75          80
Gly Thr Pro Thr Thr Ile Cys Cys Thr Arg Tyr Gly Asn Val Met Ala
85          90          95
Ser Arg Gly Ser Val Ile Pro Leu Phe Val Asp Gln Ile Arg Gln Gly
100         105         110
Lys Pro Phe Thr Ile Thr Asp Pro Glu Met Thr Arg Phe Met Met Thr
115         120         125

```



WO 02/075507

PCT/US02/01971

```

Leu Glu Asp Ala Val Asp Leu Val Leu Tyr Ala Phe Lys Asn Gly Gln
 130          135          140
Asn Gly Asp Val Phe Val Gln Lys Ala Pro Ala Ala Thr Ile Gly Thr
 145          150          155
Leu Ala Lys Ala Ile Thr Glu Leu Leu Ser Val Pro Asn His Pro Ile
 165          170          175
Ser Ile Ile Gly Thr Arg His Gly Glu Lys Ala Phe Glu Ala Leu Leu
 180          185          190
Ser Arg Glu Glu Met Val His Ala Ile Asn Glu Gly Asn Tyr Tyr Arg
 195          200          205
Ile Pro Ala Asp Gln Arg Ser Leu Asn Tyr Ser Lys Tyr Val Glu Lys
 210          215          220
Gly Glu Pro Lys Ile Thr Glu Val Thr Asp Tyr Asn Ser His Asn Thr
 225          230          235
Glu Arg Leu Thr Val Lys Glu Met Lys Gln Leu Leu Lys Leu Glu
 245          250          255
Phe Ile Gln Lys Met Ile Glu Gly Glu Tyr Ile Ser Pro Glu Val
 260          265          270

```

```

<210> 7
<211> 6132
<212> DNA
<213> Pasteurella multocida

```

```

<220>
<221> CDS
<222> (4032)..(4727)

```

```

<220>
<223> devB

```

```

<400> 7
gtcaacaatt accgcacttt agtggagtaa ataacaatgg cgaaaaagaa taacgggcat 60
gaaaaagagg atgatgttcg cctagataaa tggctttggg ctgcccgttt ttataaaaca 120
cgtactttag caaaagacat gattgatggc ggtaaagtgc attataatgg gcagcgcacg 180
aaacccaata aaacggttga aattggtggt gtgatcaaac ttcgtcaagg taatgacgaa 240
aaagaagtgg aagtgccttc gctttctacg caacgtcgtg gggcgccaga agcacaattg 300
ttgatcaag aaacagaaaa aagccttgaa caacgtcgtg aaatggcgat tgcacgtaag 360
attaatgcat taacgatgcc gcatcctgat cgtcgccgca ataaaaaga gcggcgtgat 420
ttattgaaat ttaaacatca agatagcttt tcactctgat gatgtgattt acctactttt 480
cttattaaag aaaggaatat ggggaagctg tgtgcttgcc cttaacctga ataaaggctt 540
tttatgacag acaacacaga caatgacaaa ctgtatcgtt accttttcca agatcgcgcy 600
gtcgcgcytg aatgggtacg gttaaaccaa acgtttactg atacgttaaa tacacatcaa 660

```

WO 02/075507

PCT/US02/01971

tatccgaaag tcatccaaaa cttgctcggg gaaatgatgg tggcgaccag tttattgacg 720  
 gcgacgttaa aatttgaagg ggatattact gttcaagtac aaggtgatgg accattaaaa 780  
 ttagcattag ttaattggcaa tcatcagcag caaatttcgcg cattagcgcg tttaacaagcg 840  
 gatgtcagtg atgatatgag tttgagcga ttagtcggga aaggggtatt agtgattaccg 900  
 attgcaccga cagaagcgca gcgttaccaa ggcgtgattg cgttagataa gccaccatt 960  
 actgcctgtc ttgaagatta ttttgtcgtc tcagaacaat tgcaaaccca gcttattatt 1020  
 cgtgctggcg aatttgaagg acaacctgtg gcagccggta tgttgttaca aattatgccc 1080  
 gacggttcag gttctccaga ggattttgaa cacttagcaa cattggcagc gacggtgaaa 1140  
 gaggaagaac tatttggttt aacagcagaa gaattattgt accgtttata tcatgaagag 1200  
 cgtgttgaaa ttttcccttc acagccgac tcatttttct gtggctgctc acaagaacgt 1260  
 tctggtcccg catttggttt gattttctgat gaagaattgg atgaagtctt ggcagagcat 1320  
 aacggtacca ttgatatgca gtgtgaatgt tgtgggacgc attatttctt caataaagca 1380  
 gcgattatgc aattgaaagt agaaaaataa gtcttggtat tatggatttt gttgcaggct 1440  
 atcaagata ttgatagcct gtttttctt tgcagcaaac gattttatga gaaaaacgcc 1500  
 gttcttctca acagtagttt aggtattgca tagcatgaag cgggaaacta tgtttggcgc 1560  
 ttgtctgttt aaaaaggtta tctatgttag cacttccacc atcattactt gaaaaaacac 1620  
 ttgaaatcgc ggatcaagca ggagattttt laacgcgatt ttataccgac tcagggcaaa 1680  
 atgcgttagc aattcaaac aaacaagata acagccagc gactgcgctg gatttatttt 1740  
 ttagtcaatt ttaattgaa aaattgaccg cactgacacc tgaggtcccg attctttccg 1800  
 aagagagttg taaatcccc ttacaagatc gtgcacattg ggcagaatat tggttaattg 1860  
 acccactcga tggaaaccaa caatttatta atcgcaaccg tcaattttcc attttgatta 1920  
 cacttgcca acacaatcaa cccgtcttaa gcattacca tgcccctatt ttacaaacga 1980  
 cclattatgc tatgcagggc tttggtgctt acagaaggca gggcaatcaa caagaaaagc 2040  
 taaacaacca agcgcgacct gagcagcga aaatcaaat tgcgtgggga gt.cggggcgc 2100  
 ttgaacggaa aatcagccc ttgttaaatc cagcttatca atatgaattt ttggtttatg 2160  
 gttcaagtgg cttaaaaggc ggcttagtgg cagatggcac ttgtgatgc tatattcgag 2220  
 taggaaaaac gggatgaatg gatacggggg cggctgaaat cctcttacgt gaaatgggag 2280  
 gtgctgtgtt tgactttgct tttcaaccgc ttagctataa tcagagagaa agttttatta 2340  
 atccaattt tgtgatgga gcgaatacag aatttgattg gcagaaaatt tttcaatttc 2400  
 attcgcacta ggcattatit attataagat gcgatatctt atgacctcta ttttaacaa 2460  
 acggatttca ggaaaaaaat gaaaattgaa gcagacaaca attgtattgt aatttttggg 2520  
 gcacacgggt atttaactta tcgtaattg attcctgcac tgtataactt atataaaac 2580

WO 02/075507

PCT/US02/01971

```

ggctcgttga cfcgacatt ctcctgtta ggtgtggcaa gaacggaatt aagtgatgag 2640
ggttccctg aaaaaatg ccaagcgttg atcaaaagtg aaaaagcgaa tggcgaaca 2700
ctcgatcaat ttgttagcca cctttattat caggcattaa atacocgga tgcctccgat 2760
tatggcaagt taattcctcg tcttgatgac ttacatgata aatatcaaac ttgtggtaac 2820
acactttact atttatctac gcgcgcaagc ctttatggcg tgattccaga atgccttgcg 2880
gcacatgggt taaactgta agagtttggc tggagcgggt taattgtgga aaaaccggtt 2940
ggttatgata tacgcacggc aaaagaactc gatattcaaa ttcacocgtt ctttgatgaa 3000
caccaaattt atcgtattga ccactatcct ggtaagaaa cggttcaaaa tctgcttgtg 3060
ttcgttttt ctaatggatg gttgaacca ctctggaacc gtaatttcac tgattatatt 3120
gaaatcacgg gcgcagaatc tctcgggtga gaagagcgtg gtggttatta cgatgatctt 3180
ggcgcaatgc gtgatatggt ccaaaaacct ttgttgcaag tgttagccat ggttgcgatg 3240
gagccaccag caattattaa tgcgactca atgcgtgatg aagtggcaaa agtcttgat 3300
tgtttacatc cattaagtga ggatgactta gaaaatcatt tagtcttagg gcaatatacg 3360
gcaggcacag ttgaaggtga agcggttaag gctacttac aggaaaaagg tgcgccgca 3420
gagtctaata cggaaactta catggcatta cgttgtgaaa ttgacaactg gcgttggcg 3480
ggtgtgccat tttatgtgcg tactgggaaa cggttacca gtcgagtgac cgaattgtg 3540
attcatttca aaaccacacc acatccggtt tttagccaaa aagcaccaga aaacaaatta 3600
attatccgta ttcaaccgga tgaagcgatt tcgatcgtt ttggtttgaa aaaaccggga 3660
gcaggttttg aagcaaaaga agtgcgatg gattccggtt atgcgatct tgccaccaca 3720
agcttactga ccgcttatga gcgcttatta ttggattcta tgaagcgca tgccactctg 3780
tttgcgcgta ctgatcgggt acatgcctgt tggcagtttg tggagccgat tttacaatat 3840
aaagcacaac atggcgctgt ttatgagtat gaagccggtt cttggggacc gacagaagcc 3900
gacaaactga tcgcgaaaac ggtcgtgtgt tggcgtaaac caagtggatt aatgaaaaag 3960
aaagtgtaat gtcgcctctt ttctgaagaa atgcgagggg ctaatgtgag cagattgagt 4020
aaggaaagat c atg aat aca atc att ttt gac agt gca cag cat gcc gta 4070
Met Asn Thr Ile Ile Phe Asp Ser Ala Gln His Ala Val
1 5 10
gag aaa att gca caa gaa ttg tta gcg tat agc tta gaa ggt cgc cct 4118
Glu lys Ile Ala Gln Glu Leu Leu Ala Tyr Ser Leu Glu Gly Arg Pro
15 20 25
gtg cat att tcc tta tcc gga ggc tca acg ccg aaa ttg tta ttt aaa 4166
Val His Ile Ser Leu Ser Gly Gly Ser Thr Pro Lys Leu Leu Phe Lys
30 35 40 45
act tta gct caa gca ccg tat aac acc gag att caa tgg aaa aat ttg 4214
Thr Leu Ala Gln Ala Pro Tyr Asn Thr Glu Ile Gln Trp Lys Asn Leu
50 55 60

```

WO 02/075507

PCT/US02/01971

```

cat ttt tgg tgg ggc gat gat cgt atg gtg cca cca acc gat cca gaa 4262
His Phe Trp Trp Gly Asp Asp Arg Met Val Pro Pro Thr Asp Pro Glu
65 70 75

agt aat tac ggc gag gtg caa aaa ttg tta ttc gat cat att cag atc 4310
Ser Asn Tyr Gly Glu Val Gln Lys Leu Leu Phe Asp His Ile Gln Ile
80 85 90

cct gca gaa aat att cac cgc att cgt ggt gaa gcc ccc gtt gag agt 4358
Pro Ala Glu Asn Ile His Arg Ile Arg Gly Glu Ala Pro Val Glu Ser
95 100 105

gaa ctt cac cgt ttt gaa caa cgc cta agt gcg gtc att cct ggg caa 4406
Glu Leu His Arg Phe Glu Gln Ala Leu Ser Ala Val Ile Pro Gly Gln
110 115 120

gtt ttt gat tgg att att ttg ggc atg gga acg gac ggg cac acg gcc 4454
Val Phe Asp Trp Ile Ile Leu Gly Met Gly Thr Asp Gly His Thr Ala
130 135 140

tca tta ttc ccg cat caa acc gat ttt gac gat cct cat ttc gcc gtg 4502
Ser Leu Phe Pro His Gln Thr Asp Phe Asp Pro His Phe Ala Val
145 150 155

atc gcg aaa cac cct gaa aca ggg caa att cgt att tca aaa aca cgc 4550
Ile Ala Lys His Pro Glu Thr Gly Gln Ile Arg Ile Ser Lys Thr Ala
160 165 170

aaa ttg att gaa caa gca aag cgg gtg acc tat ttg gtg aca ggt agc 4598
Lys Leu Ile Glu Gln Ala Lys Arg Val Thr Tyr Leu Val Thr Gly Ser
175 180 185

agt aaa gcc gag atc tta aaa gaa att caa act act ccg gca gaa caa 4646
Ser Lys Ala Glu Ile Leu Lys Glu Ile Gln Thr Thr Pro Ala Glu Gln
190 195 200 205

ctg cct tat cct gct gcg aaa atc aaa gcg aag cat ggg gtg acg gaa 4694
Leu Pro Tyr Pro Ala Ala Lys Ile Lys Ala Lys His Gly Val Thr Glu
210 215 220

tgg tat ttg gat aag gat gcg gca aaa tta ctg taatgcgtcg tgagatTTTT 4747
Trp Tyr Leu Asp Lys Asp Ala Ala Lys Leu Leu
225 230

caacattttt gcaaaagagac ttgaaacaaa atagaccata gcgttcgttt tcaacgagtg 4807

ctgaaaaatga aggcctctcgt tgaaaatggc gccatttagt gggtaagctt aaggttcgct 4867

cagacagcgc tatcaaaaagg gtaaaagaat gtatcaactc tattttaatc caccaaaatc 4927

ttcatggtea ttacgcggtt ggggtgttatt gaaagaactg gcaattcctt ttgagcctaa 4987

aattgtacgt tatttggatg atttaagtga acaacgccaa caatttaagg cgttttcgcc 5047

gacttcaaaa atcccagtat tgcctgctga tgggtttgtc atttgggaca gtttagcgat 5107

tatcgagttt ttggcagaaa gttatccgca cgtgtggcgc caagataagg cgacaagagc 5167

gtggtcacgt tctgcttctg ctgaaatgca ctctgctt gaaaatttgc gtgaaatggt 5227

tgatttcgcc cctttagctc gcaaacctgt acaagaatg cccgctgtgt taagccaaga 5287

gctaacaagg cttaatcaat tattagaaga agggttaaca aatcacactg ggcgatttaa 5347

```

WO 02/075507

PCT/US02/01971

tgcaaacctc cagtgctttt ggctcagtac aatcctcgtt gtcttttttc cgtaattcct 5407  
 atgatgactt tgccgcttat cgtgcggtgt taaatcgttt aactggcttt catagcgcga 5467  
 ttaaagcggc taatgccca agcaaatag tgctcacaga aagtcgtcat gatattggtt 5527  
 ttcatgatct caactagag accccgcaag gaaaaacctt aattgacaag ctcaacctac 5587  
 aatttcctct cgtacatgg ttattaattc aaggacattc tgggttaggg aaaacaacct 5647  
 tgtaagaac cattgcggga ctatggcctt atgctagtgg gacaattcaa cgtccacaac 5707  
 aagatactct gttctttct caaaaacctt attgccaca aggtcgctta cttgatgccc 5767  
 tattttatcc tgaactggcg cctgaagacg tgaatgagca acaagttata gacatactcg 5827  
 cgaagtagta actcgggcat ttaagcgata aactagaaca agaaaatgat tggacacggg 5887  
 tactctcttt aggtgaacaa caacgtctgt cgtttgctcg cattttattg cataaaccta 5947  
 ctggtgtttt cttagatgaa gccactgccca gcatggatga aggactggaa gatgcgatgt 6007  
 accgcttact gaaagatgaa ctgcctcaga ttactgtgat cagtggtgga caccgttcca 6067  
 cgttaattcc gcaccattca cagcaattac acattcaata acaagacagg gcgtgtgtga 6127  
 gtcga 6132

<210> 8  
 <211> 232  
 <212> PRT  
 <213> Pasteurella multocida

<400> 8  
 Met Asn Thr Ile Ile Phe Asp Ser Ala Gln His Ala Val Glu Lys Ile  
 1 5 10 15  
 Ala Gln Glu Leu Leu Ala Tyr Ser Leu Glu Gly Arg Pro Val His Ile  
 20 25 30  
 Ser Leu Ser Gly Gly Ser Thr Pro Lys Leu Leu Phe Lys Thr Leu Ala  
 35 40 45  
 Gln Ala Pro Tyr Asn Thr Glu Ile Gln Trp Lys Asn Leu His Phe Trp  
 50 55 60  
 Trp Gly Asp Asp Arg Met Val Pro Pro Thr Asp Pro Glu Ser Asn Tyr  
 65 70 75 80  
 Gly Glu Val Gln Lys Leu Leu Phe Asp His Ile Gln Ile Pro Ala Glu  
 85 90 95  
 Asn Ile His Arg Ile Arg Gly Glu Ala Pro Val Glu Ser Glu Leu His  
 100 105 110  
 Arg Phe Glu Gln Ala Leu Ser Ala Val Ile Pro Gly Gln Val Phe Asp  
 115 120 125  
 Trp Ile Ile Leu Gly Met Gly Thr Asp Gly His Thr Ala Ser Leu Phe  
 130 135 140  
 Pro His Gln Thr Asp Phe Asp Asp Pro His Phe Ala Val Ile Ala Lys

WO 02/075507

PCT/US02/01971

145                    150                    155                    160  
 His Pro Glu Thr Gly Gln Ile Arg Ile Ser Lys Thr Ala Lys Leu Ile  
    165                    170                    175  
 Glu Gln Ala Lys Arg Val Thr Tyr Leu Val Thr Gly Ser Ser Lys Ala  
    180                    185                    190  
 Glu Ile Leu Lys Glu Ile Gln Thr Thr Pro Ala Glu Gln Leu Pro Tyr  
    195                    200                    205  
 Pro Ala Ala Lys Ile Lys Ala Lys His Gly Val Thr Glu Trp Tyr Leu  
    210                    215                    220  
 Asp Lys Asp Ala Ala Lys Leu Leu  
    225                    230

<210> 9  
 <211> 2438  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (1635)..(2396)

<220>  
 <221> dnaA

<400> 9  
 gaccaaatgc ttgccaccgg cggctctatg attgccgaca tcgatcttct aaaagcgaaa 60  
 ggtgttaaac acattaaagt gctcgtgtta gtccgcgcgc ctgaagccat taaagcatta 120  
 gaagctgccc accctgatat cgaattatat accgcacag ttgatagtca cttaaatgaa 180  
 caaggctata ttattccagg tcttggtgat gccgggata aaatttttgg cactaaataa 240  
 tcccacaca agcggcatct tatgccgctt ttttcggttc aatttatagc gttacaate 300  
 ttaacagctt gaacctata aaatgaaaag ttaattcaga cagagagttg aaacttaaca 360  
 tgacaaatca aaatcccct gtctctctag aacaaaatca cgcacaaaca gccctcgttg 420  
 ggetacaaat gctttttgtt gccctcggtg ctttagtctt tgttcccctg attacgggtt 480  
 taaatgccaa tactgcctta ttgaccgcag ggattgggac accttatttc caactttgta 540  
 ctggacgcca agtcccaatt ttotttagcct ctctctttgc ttttattgca ccaattcaat 600  
 atggcgtggc aacatggggc attgctacta ctatgggggg gctgggtgtt actggactgg 660  
 tttattttgc cctcagtagc ttagtcaaaa ttaaagggtc tgggtgctta caaaaagctc 720  
 ttccgccagt agttgttggc cccgttatta tcatcctcgg tatgggactt gccctgtttg 780  
 ccgtggacat ggcattaggt aaaaacagca cttatcaata taacgatgcc gtattcgttt 840  
 cgatggcaac attattgaca acgttaggtg ttgcggtgtt tgctaaaggc atgatgaaat 900  
 taattcctat catgtttggc attgcgtcgc gctatctct ctgcttattc ttaggcttaa 960

WO 02/075507

PCT/US02/01971

```

ttaatttcca acctgtcatt gatgcacctt ggttttagtgt gccagaaatt actacccttg 1020
aatttaaatt agaagctatt ctttatttat taccgattgc tatcgcccca gcagttgagc 1080
atgtcggtagg gatcatggca atcagttcgg tgacagggaa agacttccta caaaaaccag 1140
gattacatcg cactttatta ggggatggta ttgcaacgag tgcgcctca tcttaggag 1200
gaccacctaa tacaacttat gctgaagtca ctgggtcgtg catgcttacg cgcaacttta 1260
accctaaat catgacatgg gcagccggtt gggcaattgc gatttccttc tgtggtaaag 1320
tcggggcttt cctctctacc attcctaacta ttgcatggg tggcattatg atgttagtgt 1380
ttggctctat cgcctagtc ggtatgagta cactgatccg tggtaaatg gatgtaacg 1440
aagcgcgtaa tctgtgtatt atttccgttg tgatgacgtt tggcatcggg ggtatgttg 1500
tgaactttgg agaagtctcc ttaaaagga ttagtttatg cgcctgttc gcgattttac 1560
tcaacttaat cttaccctaaa gccaaaaaca cccaataga agaaaatcga taagagaaa 1620
ttaagggta agtc ttg ctt aac cct tca ttt ttc gtt tat cct tat tct 1670
      Leu Leu Asn Pro Ser Phe Phe Val Tyr Pro Tyr Ser
      1           5           10

oct ttt ttc gat ttt gta ggt tgc ttt ttg tta gaa aat ttc caa tta 1718
Pro Phe Phe Asp Phe Val Gly Cys Phe Leu Leu Glu Asn Phe Gln Leu
      15           20           25

cct ttg cct att cat caa ctc gat gat gaa acg ctg gat aat ttc tat 1766
Pro Leu Pro Ile His Gln Leu Asp Asp Glu Thr Leu Asp Asn Phe Tyr
      30           35           40

ccc gac aat aat tta ttg ttg ctc aat tgc cta cgc aaa aat ttt act 1814
Pro Asp Asn Asn Leu Leu Leu Leu Asn Ser Leu Arg Lys Asn Phe Thr
      45           50           55           60

tgt cta aca caa caa ttt ttt tat att tgg ggc gag caa agc agt ggt 1862
Cys Leu Thr Gln Gln Phe Phe Tyr Ile Trp Gly Glu Gln Ser Ser Gly
      65           70           75

aaa agt cac ctc tta aaa ggc att act cat cat ttt ttc ctt tta cag 1910
Lys Ser His Leu Leu Lys Gly Ile Thr His His Phe Phe Leu Leu Gln
      80           85           90

cgc ccc gct atc tat gtg ccc tta gaa aaa tcc caa tat ttc tca ccg 1958
Arg Pro Ala Ile Tyr Val Pro Leu Glu Lys Ser Gln Tyr Phe Ser Pro
      95           100           105

gcg gta ctc gaa aac tta gaa caa caa caa ttg gtt tgt tta gat aat 2006
Ala Val Leu Glu Asn Leu Glu Gln Gln Leu Val Cys Leu Asp Asn
      110           115           120

tta cag gca att ata ggc aat act gaa tgg gaa tta gcg att ttt gat 2054
Leu Gln Ala Ile Ile Gly Asn Thr Glu Trp Glu Leu Ala Ile Phe Asp
      125           130           135           140

tta ttt aat cgc ata aaa tct gtt gaa aat aca ctg ctt gtg atc agt 2102
Leu Phe Asn Arg Ile Lys Ser Val Glu Asn Thr Leu Leu Val Ile Ser
      145           150           155

gca aat caa tcc cca act gca tta cct gta agt tta cct gac tta gct 2150

```

WO 02/075507

PCT/US02/01971

Ala Asn Gln Ser Pro Thr Ala Leu Pro Val Ser Leu Pro Asp Leu Ala  
 160 165 170

tca cgt tta cgc tgg gga gaa agc tat cag ctg gtc ccc tta aat gat 2198  
 Ser Arg Leu Arg Trp Gly Glu Ser Tyr Gln Leu Val Pro Leu Asn Asp  
 175 180 185

caa caa aaa atc cat gta ttg caa aaa aat gca cat caa cgt ggt atc 2246  
 Gln Gln Lys Ile His Val Leu Gln Lys Asn Ala His Gln Arg Gly Ile  
 190 195 200

gaa ctc ccc gat gaa gta gct aat ttt ctt ttg aaa cgc tta gag cgc 2294  
 Glu Leu Pro Asp Glu Val Ala Asn Phe Leu Leu Lys Arg Leu Glu Arg  
 205 210 215 220

gat atg aaa acg tta ttt gaa gca cta agt aaa tta gat aaa gca tca 2342  
 Asp Met Lys Thr Leu Phe Glu Ala Leu Ser Lys Leu Asp Lys Ala Ser  
 225 230 235

tta caa gcc caa cgt aaa tta scg att ccc ttt gta aaa gaa att tta 2390  
 Leu Gln Ala Gln Arg Lys Leu Thr ile Pro Phe Val Lys Glu Ile Leu  
 240 245 250

aag cta taaaaaaaaa ccaacctttt atcaggtgat ctttcttgtc ga 2438  
 Lys Leu

<210> 10  
 <211> 254  
 <212> PRT  
 <213> Pasteurella multocida

<400> 10  
 Leu Leu Asn Pro Ser Phe Phe Val Tyr Pro Tyr Ser Pro Phe Phe Asp  
 1 5 10 15

Phe Val Gly Cys Phe Leu Leu Glu Asn Phe Gln Leu Pro Leu Pro Ile  
 20 25 30

His Gln Leu Asp Asp Glu Thr Leu Asp Asn Phe Tyr Pro Asp Asn Asn  
 35 40 45

Leu Leu Leu Leu Asn Ser Leu Arg Lys Asn Phe Thr Cys Leu Thr Gln  
 50 55 60

Gln Phe Phe Tyr Ile Trp Gly Glu Gln Ser Ser Gly Lys Ser His Leu  
 65 70 75 80

Leu Lys Gly Ile Thr His His Phe Phe Leu Leu Gln Arg Pro Ala Ile  
 85 90 95

Tyr Val Pro Leu Glu Lys Ser Gln Tyr Phe Ser Pro Ala Val Leu Glu  
 100 105 110

Asn Leu Glu Gln Gln Leu Val Cys Leu Asp Asn Leu Gln Ala Ile  
 115 120 125

Ile Gly Asn Thr Glu Trp Glu Leu Ala Ile Phe Asp Leu Phe Asn Arg  
 130 135 140

Ile Lys Ser Val Glu Asn Thr Leu Leu Val Ile Ser Ala Asn Gln Ser  
 145 150 155 160



WO 02/075507

PCT/US02/01971

Pro Thr Ala Leu Pro Val Ser Leu Pro Asp Leu Ala Ser Arg Leu Arg  
165 170 175  
Trp Gly Glu Ser Tyr Gln Leu Val Pro Leu Asn Asp Gln Gln Lys Ile  
180 185 190  
His Val Leu Gln Lys Asn Ala His Gln Arg Gly Ile Glu Leu Pro Asp  
195 200 205  
Glu Val Ala Asn Phe Leu Leu Lys Arg Leu Glu Arg Asp Met Lys Thr  
210 215 220  
Leu Phe Glu Ala Leu Ser Lys Leu Asp Lys Ala Ser Leu Gln Ala Gln  
225 230 235 240  
Arg Lys Leu Thr Ile Pro Phe Val Lys Glu Ile Leu Lys Leu  
245 250

<210> 11  
<211> 2060  
<212> DNA  
<213> Pasteurella multocida

<220>  
<221> CDS  
<222> (856)..(1389)

<220>  
<223> dsbB

<400> 11  
gaattcttct tacgtatgct cccagtcacg ttgccagttc tcattttggtg tttagtgacc 60  
tgcttcttag tggaaaaatt tgggtgtatt ggctatggcg ccaaattgcc acgtaaagt 120  
tggggcatct tggcaaaagt tgatcgcaat aatcaacaaa aaatgtcacg acaagatcgt 180  
ttgaaaacttt ttgtgcaagc ttttaattggt atttggttgg ttggtggact cgcattccat 240  
ctgcgcgcg tgggtatcat tggtttaacg gtgattatct tggetaettc atttttggt 300  
gtcaccagcg agcatgctat tggtaaaagcc ttccaggaat ccttacocct cacagcattg 360  
ttagtgggtg tcttctcggg tgttgccgct atcattgacc aacatctgtt tgcgcaatt 420  
attcagttg tgcgggctgc cagtgaacat actcagcttg ctcttttcta tatttttaac 480  
ggtttggttat cgcaccattc agataatgtg ttgtggcca cagtttatat caatgaaacc 540  
aaagcggcat tagaggctgg cttaattgct caaccacaat atgaattact ggcagtagca 600  
atfaataccg gtaccaatct tccttctggt gcaaccccaa atggtcaagc cgcatttcta 660  
ttttattga cctcatcact ggcaccatta atcgtcttt cttatggtag aatggtttat 720  
atggcattgc cttataccat cgtattatcc tgtattgggt tattgactgt ggaatatatt 780  
ttgcttggcg caaccaatgt gctcattcaa atgggttat taaaaccaat gtaatgacaa 840  
gtaaaaggag gaaac atg cta agc ttt ttt aag aca ctc tca aca aaa cga 891  
Met Leu Ser Phe Lys Thr Leu Ser Thr Lys Arg  
1 5 10

WO 02/075507

PCT/US02/01971

```

agc gca tgg ttt cta ttg ttt agc tca gct tta cta tta gag gct atc 939
Ser Ala Trp Phe Leu Leu Phe Ser Ser Ala Leu Leu Leu Glu Ala Ile
15 20 25

gct ctt tat ttt caa cat ggc atg ggg ctc gcc cct tgt gtc atg tgt 987
Ala Leu Tyr Phe Gln His Gly Met Gly Leu Ala Pro Cys Val Met Cys
30 35 40

att tac gag agg gta gct att ctt ggc att gct ttc tcc ggt tta ttg 1035
Ile Tyr Glu Arg Val Ala Ile Leu Gly Ile Ala Phe Ser Gly Leu Leu
45 50 55 60

ggg tta ctc tac ccg agt tgg atg ctt ttg cgc ctt gtg geg tta tta 1083
Gly Leu Leu Tyr Pro Ser Ser Met Leu Leu Arg Leu Val Ala Leu Leu
65 70 75

att ggt tta agc agt gca atc aaa ggc tta atg att agc atc acc cat 1131
Ile Gly Leu Ser Ser Ala Ile Lys Gly Leu Met Ile Ser Ile Thr His
80 85 90

tta gat cta caa ctt tac cct gca cct tgg aaa caa tgt tca geg gtg 1179
Leu Asp Leu Gln Leu Tyr Pro Ala Pro Trp Lys Gln Cys Ser Ala Val
95 100 105

gca gaa ttt ccc gag act tta ccc tta gat cag tgg ttt cct gca ctc 1227
Ala Glu Phe Pro Glu Thr Leu Pro Leu Asp Gln Trp Phe Pro Ala Leu
110 115 120

ttc ctc cct tca ggc tca tgc agt gaa gta aca tgg caa ttt ctc ggc 1275
Phe Leu Pro Ser Gly Ser Cys Ser Glu Val Thr Trp Gln Phe Leu Gly
125 130 135

ttt tct atg gtg caa tgg atc gtc gtc att ttt gca ctc tat acc tta 1323
Phe Ser Met Val Gln Trp Ile Val Val Ile Phe Ala Leu Tyr Thr Leu
145 150 155

tta ctt gct ctc att ttc atc agc caa gtc aaa cgt cta aaa ccc aag 1371
Leu Leu Ala Leu Ile Phe Ile Ser Gln Val Lys Arg Leu Lys Pro Lys
160 165 170

cag cgc aga ctc ttt cat taagtcataa aaaatggtgc gataaagcac 1419
Gln Arg Arg Leu Phe His
175

catttttcat ttctcgttcg gtatagatta aalltcttgc acgacaaact gcagggaaatg 1479

tcttgctaata aatcttgctt taogctgctt taagcgtttt aaacgtaatg cgcgtccttg 1539

tgataaacga tataaatttt ttgtggctt caaaaagctt ttacgtctcg ccatactctt 1599

cctcttatgt tgcgttaag gttgctgcta acgtatcctt ttctttcttg atttcgttga 1659

tgttttctat ttccggcggt tgggtatcta atgtttcttc aatttggtct tgcgtaccc 1719

gataataatg cacaaatgctg ttcatataac gacggatatt ttccacatag tgatagctt 1779

catagcctcg cgcatacccg tattttaacc cegtgttaata gcgtttttct gctaatagtg 1839

gcaaattctt ctccacatct aaccaattat cgggatcacc acctaggctc ttggttaaac 1899

ggcgcgcac taacaaatgc cctaatacca tattatagc cgttaaggca aaccaaatac 1959

gctcatcttc ttaaatcgtg tcaggcattt gcgtaataag ccaatgtaaa tattctgaac 2019

```

WO 02/075507

PCT/US02/01971

eggctttaat accttggttcc ggatccggttc tgccttgaat t 2060  
  
 <210> 12  
 <211> 178  
 <212> PRT  
 <213> Pasteurella multocida  
  
 <400> 12  
 Met Leu Ser Phe Phe Lys Thr Leu Ser Thr Lys Arg Ser Ala Trp Phe  
 1 5 10 15  
 Leu Leu Phe Ser Ser Ala Leu Leu Leu Glu Ala Ile Ala Leu Tyr Phe  
 20 25 30  
 Gln His Gly Met Gly Leu Ala Pro Cys Val Met Cys Ile Tyr Glu Arg  
 35 40 45  
 Val Ala Ile Leu Gly Ile Ala Phe Ser Gly Leu Leu Gly Leu Leu Tyr  
 50 55 60  
 Pro Ser Ser Met Leu Leu Arg Leu Val Ala Leu Leu Ile Gly Leu Ser  
 65 70 75 80  
 Ser Ala Ile Lys Gly Leu Met Ile Ser Ile Thr His Leu Asp Leu Gln  
 85 90 95  
 Leu Tyr Pro Ala Pro Trp Lys Gln Cys Ser Ala Val Ala Glu Phe Pro  
 100 105  
 Glu Thr Leu Pro Leu Asp Gln Trp Phe Pro Ala Leu Phe Leu Pro Ser  
 115 120 125  
 Gly Ser Cys Ser Glu Val Thr Trp Gln Phe Leu Gly Phe Ser Met Val  
 130 135 140  
 Gln Trp Ile Val Val Ile Phe Ala Leu Tyr Thr Leu Leu Leu Ala Leu  
 145 150 155  
 Ile Phe Ile Ser Gln Val Lys Arg Leu Lys Pro Lys Gln Arg Arg Leu  
 165 170 175  
  
 Phe His  
  
 <210> 13  
 <211> 4426  
 <212> DNA  
 <213> Pasteurella multocida  
  
 <220>  
 <221> CDS  
 <222> (2756)..(3211)  
  
 <220>  
 <223> exbB  
  
 <400> 13  
 gaattcttga cctgggtgta ggcttttatt gacttccacc ccaattgcgc gttctttcac 60  
 ttatataata aagtcacgta ccacttgtaa cgccacatcc gcttctaata atgcatcgcg 120

WO 02/075507

PCT/US02/01971

gacttcacgt agcgtttcct taalatgtc atcagttaaa cgtccacgtc cactaatgtt 180  
 acgtagcgtt ttgacaagc gatccgacaa attctcaaac atgcaatctt cctatttaat 240  
 ctgaaaaaaa ttgccctaatt tatactgaaa tcccatagat ttctactctt tghtaataat 300  
 ttatagcgtt ttcacagtga gaaagttaga atggacggag aacaaaagtg agggaaattc 360  
 aatgtgctt tcaattttt ccgtgtttt ttatctattg agtgtcttac tcattacccc 420  
 tatgttgta aaaattcaag cgggcgaacc cgcactcgtt cccaatagga tgcctttttt 480  
 aacggcagca ttaactcgca ttctctgca ctttatcaat cttattcttc tttttaccga 540  
 ttaaccagc ggtcaaaatt tctcggttat cgaatcagt tccttaatca gtgttatgac 600  
 agcaacgac gccacattag cgtttttatt tcgcatacac actttatggt ttttattacc 660  
 gattatttat tctttcgca tcattaatct ggtcctcagt accttaatgc cggcgcattt 720  
 ttatatcat cttaatcaag atatgggctt atttattcat gtaggcttat cactgttgac 780  
 ttatcggctc tgttcgattg tccggttata tccattcag ttagtttga tcgategcgc 840  
 cttaaaaat aaaaaactgc cttttcacc aatgattcca ccgttaatga ccgtagagcg 900  
 ccattttttt cgtttaatgc tgataggtag aatattactc acgattgtcc tcatttcagg 960  
 gagctacctt ttatcgaaaa cctttgcccc acaagacatc cagaaagctg tttttctttt 1020  
 ctggcttg atagtcttg ggaagtcaact ggttggtcat tggaaagctc attggcgtgg 1080  
 aaaaaaagtg gtgtattatg cgtttttagg tatcattctc ctgactatcg cctattttgg 1140  
 tagtctgta atgcttgaaa tataaacaag atttatttat gctacgccat agtaaaagtg 1200  
 cggttcaaaa aacgaaaaaa tgaccgcaact ttctgatttt tgattaactc gaaaagagat 1260  
 gcattttgga cagtattccc cttagtacc cttttattac actcaatc tttattgatca 1320  
 tctctgcta tttttcaggc tctgaaaccg gttttgtgtc tgccaatcgt tctcgactac 1380  
 gccatttagc cgaaaaaggg catagagggt cgaaaaaagc ggaaaaatta ctgaaaaaaa 1440  
 cagatgtttt gcttagcctg attttaattt gtaataactt agtcaatatt actgcttctg 1500  
 ccattaccac gattatcggc atgcgtttat atggcgatgc gggagtcgcc attgcaactg 1560  
 gggcaatac ctttctgatg cttatttttg ccgaaatttt gccgaaaact atcgccgcc 1620  
 gttatcaga aaaagtggca ttcacgtcca gtcatttgtt gtccgttttt ctgagacttt 1680  
 ttaccgccgt ggtctattta atgaatttaa ttattcaggg gattttggca ctattacgct 1740  
 taaaaataga taataaatca acctcattaa gccagagga attacgttcc atcgtaaatg 1800  
 aatcaggtaa atttattcct tccgccacc aagaaatgct gttatctatt ttggatttag 1860  
 aaggggtcac cgtagatgac attatggtgc cactaatga cattgggggt attgatattg 1920  
 acgatgattg gaaagccatt atgcgtcaac ttaaccatgc agcgcacggg cgtgtgtac 1980  
 tgtataaagg aatatggat gaaaatattt tggggatgct acgtgtacgt gaagcctatc 2040

WO 02/075507

PCT/US02/01971

```

gcttaatgct cgataaaaat gaatttaaca aagaacttt aatccgtgcc gccgatgaag 2100
tgtattttat tctgaaggt acgccactga atagccaatt attaaatttc cgcaacaata 2160
aagaaaggat tggtttagtt gtgatgaat atggtgatat taaagctta gtcaccttag 2220
aagatatctt agaagagatt gtcggtgaat ttaccacttc aacagcccca tcaattaacy 2280
atgaagttat cccacaatca gacggttcgc ttatcattga gggatccgcc aatttacgtg 2340
atttgaataa attatttgac tggaaactcg ataccgaaga tgcacgtacc ttcaacggct 2400
taattttaga gcatttagaa gaaattccag aagaaggaac ggtatgtgaa attaatgggc 2460
tacaatcac gattctagaa gtgaatgaca acatgattaa acaagccaaa gtcattaaac 2520
tttaattcaa catctggcta agcgaatgca tcaagacatc gctttttat tccgtacatg 2580
aatgtttgat ccaacacaac atttattcaa cattggataa ataactatcc taaatcgcac 2640
gaatttctta tttaccocgt ttttgcttt tgotagaatc ttgcaattga aattaattct 2700
caataccgta taatgttcaa cattattttg cgatacaaat taaaggatta ttaa atg 2758
Met
1

cca caa tta ttc caa ttc tta caa caa tat att gat tac att cta 2806
Pro Gln Leu Phe Gln Phe Leu Gln Gln Tyr Ile Asp Tyr Ile Ile Leu
5 10 15

ggc tta ctt gcc ttc atg agc ttt att atg gtt tgg ctt gtg att gaa 2854
Gly Leu Leu Ala Phe Met Ser Phe Ile Met Val Trp Leu Val Ile Glu
20 25 30

cgc ttt ctt ttc tta agt cgc gtc aac gtg gca tct tat gaa agc ata 2902
Arg Phe Leu Phe Leu Ser Arg Val Asn Val Ala Ser Tyr Glu Ser Ile
35 40 45

cat gaa tta gac att gac tta caa cgc cac ctg aca gct atc tct aca 2950
His Glu Leu Asp Ile Asp Leu Gln Arg His Leu Thr Ala Ile Ser Thr
50 55 60 65

atc ggt tct aat gca cct tat gta ggt ttg ctt ggt acc gtc att ggt 2998
Ile Gly Ser Asn Ala Pro Tyr Val Gly Leu Leu Gly Thr Val Ile Gly
70 75 80

att ctg tta act ttc tat gaa tta ggt cac tcc ggt ggc gat att gat 3046
Ile Leu Leu Thr Phe Tyr Glu Leu Gly His Ser Gly Gly Asp Ile Asp
85 90 95

gcy gcg gcc att atg gtg cac tta tca tta gcc tta asa gcc aca gca 3094
Ala Ala Ala Ile Met Val His Leu Ser Leu Ala Leu Lys Ala Thr Ala
100 105 110

gta ggt att tta gtc gcc att cct gca atg gtg tgt tac aac ggt tta 3142
Val Gly Ile Leu Val Ala Ile Pro Ala Met Val Cys Tyr Asn Gly Leu
115 120 125

gga cgt asa gtc gaa gtt aat cgt ttg aaa tgg ttt gcc tta aat gag 3190
Gly Arg Lys Val Glu Val Asn Arg Leu Lys Trp Phe Ala Leu Asn Glu
130 135 140 145

aaa aaa gcc aaa caa caa gca tagggagcgy tcatgaaaaa gtttgatgaa 3241

```

WO 02/075507

PCT/US02/01971

Lys Lys Ala Lys Gln Gln Ala  
150

atcaacatta tcccttttat tgacatcatg ttggtactat tggctatcgt tctgattaca 3301  
 gcctctttta ttccacaagg taaatccaa gtgaatgtac caaaagcaag ttcaacagtt 3361  
 gcgtttcgtt cagatgattt agccaaattg ctgactatta cggaaaagcgg tgaattttt 3421  
 taccacgata aaccgattac gatagaggc. ttggaacaag aaatcagtaa ttgggaaaaa 3481  
 gatcaaaaag tacccttgaa ggtagatgca aaatccagtt tccaagattt cgtttctatc 3541  
 actgatatta tggctaaaaa tgaattaaa aatgtcgcta tcgtgacggt taaagaaaag 3601  
 gcatctcaat gatagataaa agtcgttctt gcatcgggtt tgcatttca ttgcttttc 3661  
 acgcaagttt tgcctcttcc ctgtattgga ttgtacaaaa agacgatgac agcgcgaaag 3721  
 gatttgcctc cgatctcatc tcaactcata ttccatgga aatgctggcg gctaccggtt 3781  
 tagaagaacc agagccggaa ccagagccgg cgcctccggt agtagaacct gaactgcaa 3841  
 aagaagtagt cgcagatccg acggtaaaac ctgagccacc aaaagaacc gaaaaacca 3901  
 aagagcctga aaagccaaaa gagaaccga aagaaaaacc aaagaaaaag ccgaaaaaac 3961  
 cgaagaaga acaactgat ttaccaaagt cagatcgcca aattgattct aattcatcga 4021  
 tcaatcaaca agcaccaca acaggcaaca tcacaacca taatccgat ctggtcgta 4081  
 aagytaatag cacagatgaa gtcaatgctt atcgtcggc ttacgcaga gaaattgaaa 4141  
 aacataaacg ctatccaaac cgtgcacgca tgatgcgcaa acaaggtgtg gtaacaatca 4201  
 cgttccatct taataatgcc ggcgtaatta gtaatgcgcg aatcagcaaa tcttccggct 4261  
 cagaagaatt agataacgct gcaactgtag ctgtcaataa tgcccgtcca attggtccac 4321  
 tgcctgttg tatccaaat gaagtgcgcg ttcctgtcag ttccagaatc acaattaaa 4381  
 aaagtgcggt aaaatttacc gcactttttt ctctctatta gaatt 4426

&lt;210&gt; 14

&lt;211&gt; 152

&lt;212&gt; PRT

&lt;213&gt; Pasteurella multocida

&lt;400&gt; 14

Met Pro Gln Leu Phe Gln Phe Leu Gln Gln Tyr Ile Asp Tyr Ile Ile  
1 5 10 15Leu Gly Leu Leu Ala Phe Met Ser Phe Ile Met Val Trp Leu Val Ile  
20 25 30Glu Arg Phe Leu Phe Leu Ser Arg Val Asn Val Ala Ser Tyr Glu Ser  
35 40 45Ile His Glu Leu Asp Ile Asp Leu Gln Arg His Leu Thr Ala Ile Ser  
50 55 60

Thr Ile Gly Ser Asn Ala Pro Tyr Val Gly Leu Leu Gly Thr Val Ile

WO 02/075507

PCT/US02/01971

```

65              70              75              80
Gly Ile Leu Leu Thr Phe Tyr Glu Leu Gly His Ser Gly Gly Asp Ile
      85              90
Asp Ala Ala Ala Ile Met Val His Leu Ser Leu Ala Leu Lys Ala Thr
      100             105             110
Ala Val Gly Ile Leu Val Ala Ile Pro Ala Met Val Cys Tyr Asn Gly
      115             120             125
Leu Gly Arg Lys Val Glu Val Asn Arg Leu Lys Trp Phe Ala Leu Asn
      130             135             140
Glu Lys Lys Ala Lys Gln Gln Ala
      145             150

<210> 15
<211> 6876
<212> DNA
<213> Pasteurella multocida

<220>
<221> CDS
<222> (534)...(6863)

<220>
<223> fhaB1

<400> 15
agatgcgtga tctgatcctt caactcagca aaagttcgat ttattcaaca aagccgcgct 60
cccgtaagt cagcgtaatg tctgccagtg ttacaccaat taaccaatc tgattagaaa 120
aactcaatga gcaatcaaatg aaactgcaat ttattcatat caggattatc aataccatat 180
ttttgaaaaa gccgtttctg taatgaagga gaaaactcac cgaggcagtt ccataggatg 240
gcaagatcct ggtatcggtc tgcgattcgg actcgtccaa catcaataca acctattaat 300
ttcccctcgt caaaaaataag gttatcaagt gagaatcac catgagtgac gactgaatcc 360
ggtgagaatg gcaaaagctt atgcatttct ttcoagactt gttcaacagg coagccatta 420
cgctcgtcat caaaatcact cgcatacacc aaaccgttat tcattcgtga ttgcccctga 480
gcgagacgaa atacgcgata gctgttaaaa ggacaattac aaacaggaat cga atg 536
                                     Met
                                     1
caa ccg gcg cag gaa cac tgc cag cgc atc aac aat att gtt aac caa 584
Gln Pro Ala Gln Glu His Cys Gln Arg Ile Asn Asn Ile Val Asn Gln
      5              10              15
gaa aac ggt tta ttc cat aca ctc ggt aat atg atg tta gaa gca gag 632
Glu Asn Gly Leu Phe His Thr Leu Gly Asn Met Met Leu Glu Ala Glu
      20              25              30
cgt tct gtt tat aat att ggc gat att tat gcg agt aaa aaa tta aca 680
Arg Ser Val Tyr Asn Ile Gly Asp Ile Tyr Ala Ser Lys Lys Leu Thr
      35              40              45

```

WO 02/075507

PCT/US02/01971

```

ggt cat act cat aat ttg att aat gat gtg cgt tta tct ggc aat gtg 728
Val His Thr His Asn Leu Ile Asn Asp Val Arg Leu Ser Gly Asn Val
50 55 60 65
agt tat aag cct atc ggt tca agt cgt gat tat gat atc agt cgt gtt 776
Ser Tyr Lys Pro Ile Gly Ser Ser Arg Asp Tyr Asp Ile Ser Arg Val
70 75 80
gcg gta cat ggt tgg cac aat aat gtt tat aag ctc aac tta aat ctg 824
Ala Val His Gly Trp His Asn Asn Val Tyr Lys Leu Asn Leu Asn Leu
85 90 95
caa gaa caa gat aaa acc gat att aaa gtt gtg aaa atg ggg gct atc 872
Gln Glu Gln Asp Lys Thr Asp Ile Lys Val Val Lys Met Gly Ala Ile
100 105 110
cgt tct gat ggt gat ttt gac ttt aag gga ata aag gcg aca tca tca 920
Arg Ser Asp Gly Asp Phe Asp Phe Lys Gly Ile Lys Ala Thr Ser Ser
115 120 125
gaa tca aaa ccg cag tta att aat cat gga tta att aat gtc aaa gga 968
Glu Ser Lys Pro Gln Leu Ile Asn His Gly Leu Ile Asn Val Lys Gly
130 135 140 145
aca ttt aat gcg gaa gct gat caa gtg gtg aac caa atg aaa gcg ttt 1016
Thr Phe Asn Ala Glu Ala Asp Gln Val Val Asn Gln Met Lys Ala Phe
150 155 160
aac caa aat gca tta gca agc gtg ttt aag aat cca gcg aaa atc acg 1064
Asn Gln Asn Ala Leu Ala Ser Val Phe Lys Asn Pro Ala Lys Ile Thr
165 170 175
atg tac tat caa cca ctt act cgt tat att tgg aca cca tta tcg ggt 1112
Met Tyr Tyr Gln Pro Leu Thr Arg Tyr Ile Trp Thr Pro Leu Ser Gly
180 185 190
aat gca tcg cgt gaa ttt aac aat tta gag tct ttc ctc gat gcc ttg 1160
Asn Ala Ser Arg Glu Phe Asn Asn Leu Glu Ser Phe Leu Asp Ala Leu
195 200 205
ttt ggc tca aca aca atc tta aaa tca agt ttc tat agt acg gaa aat 1208
Phe Gly Ser Thr Thr Ile Leu Lys Ser Ser Phe Tyr Ser Thr Glu Asn
210 215 220 225
ttt agt gct tat cag ctt cta tct cat att cag cat tca cca atg tac 1256
Phe Ser Ala Tyr Gln Leu Leu Ser His Ile Gln His Ser Pro Met Tyr
230 235 240
caa aaa gcg atg gca caa gtg ttt ggt gca gag tgg cat agt aaa tcc 1304
Gln Lys Ala Met Ala Gln Val Phe Gly Ala Glu Trp His Ser Lys Ser
245 250 255
tat gat gag atg cga aac aaa tgg aaa agc ttt aaa gaa aat cca aca 1352
Tyr Asp Glu Met Arg Asn Lys Trp Lys Ser Phe Lys Glu Asn Pro Thr
260 265 270
gat ttc att tat tac cca tca gaa aaa gca aaa atc cta gcg gga aaa 1400
Asp Phe Ile Tyr Tyr Pro Ser Glu Lys Ala Lys Ile Leu Ala Gly Lys
275 280 285
cta gaa ggt aag ctt aca acg cta caa aat ggt gaa tat gcc gaa cgt 1448
Leu Glu Gly Lys Leu Thr Thr Leu Gln Asn Gly Glu Tyr Ala Glu Arg
290 295 300 305

```



WO 02/075507

PCT/US02/01971

ggt aag ttt gat gag agt atc caa att ggt aaa cac caa tta tcg cta 1496  
 Gly Lys Phe Asp Glu Ser Ile Gln Ile Gly Lys His Gln Leu Ser Leu  
 310 315 320

cca tca gta gag ctt aaa gcg gag ttt agt gat aaa gaa cgt ttg gaa 1544  
 Pro Ser Val Glu Leu Lys Ala Glu Phe Ser Asp Lys Glu Arg Leu Glu  
 325 330 335

gag gac ggg gta gat tta tcc tcg atc gcc gaa ctc tta gaa atg cca 1592  
 Pro Asp Gly Val Asp Leu Ser Ser Ile Ala Glu Leu Leu Glu Met Pro  
 340 345 350

aac tta ttt att gat aat agt atc caa tta gaa aag aaa aag ttg tct 1640  
 Asn Leu Phe Ile Asp Asn Ser Ile Gln Leu Glu Lys Lys Leu Ser  
 355 360 365

cct att gag gat cta gat gaa gaa cca cgt aaa aat ctg gat ata gaa 1688  
 Pro Ile Glu Asp Leu Asp Glu Glu Pro Arg Lys Asn Leu Asp Ile Glu  
 370 375 380 385

gaa agc cat tct aat tca tcg gat gac gtg ctt agc atg aat gat gat 1736  
 Glu Ser His Ser Asn Ser Ser Asp Asp Val Leu Ser Met Asn Asp Asp  
 390 395 400

gag tct gat aca gac gat agc aag tgg agt atg ggc aat gat gag aaa 1784  
 Glu Ser Asp Thr Asp Asp Ser Lys Trp Ser Met Gly Asn Asp Glu Lys  
 405 410 415

gag atg ccc gat gat aag ctg ggt ata agt cgt gat gat cgt gga aat 1832  
 Glu Met Pro Asp Asp Lys Leu Gly Ile Ser Arg Asp Arg Gly Asn  
 420 425 430

aaa cca cct cgt act gat cct aca gtt gat tat ctt aac cct gat gaa 1880  
 Lys Pro Pro Arg Thr Asp Pro Thr Val Asp Tyr Leu Asn Pro Asp Glu  
 435 440 445

ttc ttt gaa aat ggt tat ctc ttg aat gag cta cta cag gag ctt gga 1928  
 Phe Phe Glu Asn Gly Tyr Leu Leu Asn Glu Leu Leu Gln Glu Leu Gly  
 450 455 460 465

gaa gag ccg tta cta aaa gaa ggg gaa gat cat ttt aaa cgt tct acc 1976  
 Glu Glu Pro Leu Leu Lys Glu Gly Glu Asp His Phe Lys Arg Ser Thr  
 470 475 480

aat cta gtc cgt cta ggc gag aga gat agg caa aat aga gaa aag aga 2024  
 Asn Leu Val Arg Leu Gly Glu Arg Asp Arg Gln Asn Arg Glu Lys Arg  
 485 490 495

gaa aaa gag ggg tat ttt gat ctg cct ggt aca tta gat atg aaa ctg 2072  
 Glu Lys Glu Gly Tyr Phe Asp Leu Pro Gly Thr Leu Asp Met Lys Leu  
 500 505 510

cag gag tta ttc gaa aaa aga aaa caa aaa cac gaa gca gaa cag aaa 2120  
 Gln Glu Leu Phe Glu Lys Arg Lys Gln Lys His Glu Ala Glu Gln Lys  
 515 520 525

gca aga ata gaa aaa gca ctt cta caa aaa tca gaa caa caa gaa aaa 2168  
 Ala Arg Ile Glu Lys Ala Leu Leu Gln Lys Ser Glu Gln Gln Glu Lys  
 530 535 540 545

cgt gtt gaa gaa cgt aag caa gag gaa aaa cgt caa gcg caa gat aaa 2216  
 Arg Val Glu Glu Arg Lys Gln Glu Glu Lys Arg Gln Ala Gln Asp Lys  
 550 555 560

WO 02/075507

PCT/US02/01971

att gct aag caa gta gaa att gca aaa gaa atg caa cgg gta gaa gaa 2264  
 Ile Ala Lys Gln Val Glu Ile Ala Lys Glu Met Gln Arg Val Glu Glu  
 565 570 575

att cgc cag aga gaa aaa caa ctt gcg atc caa ctg caa gaa gaa gag 2312  
 Ile Arg Gln Arg Glu Lys Gln Leu Ala Ile Gln Leu Gln Glu Glu  
 580 585 590

aag aaa caa caa gaa gaa aaa cat tta tcc gag gag aaa aaa caa gct 2360  
 Lys Lys Gln Gln Glu Glu Lys His Leu Ser Glu Glu Lys Lys Gln Ala  
 595 600 605

gaa cag aaa caa aaa gct gag gag aaa gtt gca caa gaa aga tta gac 2408  
 Glu Gln Lys Gln Lys Ala Glu Glu Lys Val Ala Gln Glu Arg Leu Asp  
 610 615 620 625

att gaa caa cag aaa cgc tat gaa gaa atg cgc aag cga gag gca gag 2456  
 Ile Glu Gln Gln Lys Ala Tyr Glu Glu Met Ala Lys Arg Glu Ala Glu  
 630 635 640

gca tca aaa aat gtt tta ttg aaa cgc att gat gaa gaa cgt cca aaa 2504  
 Ala Ser Lys Asn Val Leu Leu Lys Ala Ile Asp Glu Glu Arg Pro Lys  
 645 650 655

gtg gaa act gat cca ctt ttc cgt aca aaa ttg aaa tat atc aat caa 2552  
 Val Glu Thr Asp Pro Leu Phe Arg Thr Lys Leu Lys Tyr Ile Asn Gln  
 660 665 670

gat gac tat gct ggt gca aat tat ttc ttc aat aaa gtt ggt tta aat 2600  
 Asp Asp Tyr Ala Gly Ala Asn Tyr Phe Phe Asn Lys Val Gly Leu Asn  
 675 680 685

aca aaa ggt cat caa aaa gta aat gtg tta ggg gat aac tat ttt gat 2648  
 Thr Lys Gly His Gln Lys Val Asn Val Leu Gly Asp Asn Tyr Phe Asp  
 690 695 700 705

cat caa gtg att act cgc tcg att gag aaa aaa gta gat aac cac ctt 2696  
 His Gln Val Ile Thr Arg Ser Ile Glu Lys Lys Val Asp Asn His Leu  
 710 715 720

aac caa aaa tac aat ctc agc gat gtg gaa tta gtt aaa cag ctg atg 2744  
 Asn Gln Lys Tyr Asn Leu Ser Asp Val Glu Leu Val Lys Gln Leu Met  
 725 730 735

gac aat tcc aca aca caa cgc cag gag ttg gat ttg aaa cta ggt cgc 2792  
 Asp Asn Ser Thr Thr Gln Ala Gln Glu Leu Asp Leu Lys Leu Gly Ala  
 740 745 750

gca tta act aaa gaa caa caa gct aac ttg acc caa gat atc gtt tgg 2840  
 Ala Leu Thr Lys Glu Gln Gln Ala Asn Leu Thr Gln Asp Ile Val Trp  
 755 760 765

tat gtc aaa acg aag gta aag ggc aaa gat gtg ttt gtt cca aag gtt 2888  
 Tyr Val Lys Thr Lys Val Lys Gly Lys Asp Val Phe Val Pro Lys Val  
 770 775 780 785

tat ttc gct tct gaa acg ctc gta gaa gcc caa aaa tta caa ggt tta 2936  
 Tyr Phe Ala Ser Glu Thr Leu Val Glu Ala Gln Lys Leu Gln Gly Leu  
 790 795 800

ggc act ggg act atc aga gtt ggt gaa gct aag att aaa gcc aaa gat 2984  
 Gly Thr Gly Thr Ile Arg Val Gly Glu Ala Lys Ile Lys Ala Lys Asp  
 805 810 815

WO 02/075507

PCT/US02/01971

gtg gtg aat acc ggg aca tta gct ggg aga aaa ctc aat gtt gaa gcg 3032  
 Val Val Asn Thr Gly Thr Leu Ala Gly Arg Lys Leu Asn Val Glu Ala  
 820 825 830  
 agt aat aaa atc aaa aat caa ggg agt atc tta agt act caa gaa aca 3080  
 Ser Asn Lys Ile Lys Asn Gln Gly Ser Ile Leu Ser Thr Gln Glu Thr  
 835 840 845  
 cgt tta gtc ggg cgt aaa ggt att gaa aac gta tct cgt tca ttt gca 3128  
 Arg Leu Val Gly Arg Lys Gly Ile Glu Asn Val Ser Arg Ser Phe Ala  
 850 855 860 865  
 aat gat gaa tta gga gtc act gca caa cgc tca gaa atc aaa acg gaa 3176  
 Asn Asp Glu Leu Gly Val Thr Ala Gln Arg Ser Glu Ile Lys Thr Glu  
 870 875 880  
 ggt cat tta cat ctt gaa aca gat aag gat tca act att gat gta caa 3224  
 Gly His Leu His Leu Glu Thr Asp Lys Asp Ser Thr Ile Asp Val Gln  
 885 890 895  
 gca tcg gat att aaa gca aaa aca agc ttt gtg aag act ggt gat gtg 3272  
 Ala Ser Asp Ile Lys Ala Lys Thr Ser Phe Val Lys Thr Gly Asp Val  
 900 905 910  
 aat ctc aaa aat aca tac aat act aaa cat gcc tac cgt gag aaa ttc 3320  
 Asn Leu Lys Asn Thr Tyr Asn Thr Lys His Ala Tyr Arg Glu Lys Phe  
 915 920 925  
 tcg ccg agt gca cta caa gtt gca gaa ctt gat gtg gca ggg ctt aaa 3368  
 Ser Pro Ser Ala Leu Gln Val Ala Glu Leu Asp Val Ala Gly Leu Lys  
 930 935 940 945  
 gtc cca ctt tta ggc gtg tcg tct cca tcc agt tat tca gag cat act 3416  
 Val Pro Leu Leu Gly Val Ser Ser Pro Ser Ser Tyr Ser Glu His Thr  
 950 955 960  
 agt gag gca act tca gag gga tca atc ttc gaa gta ggg cac tta cat 3464  
 Ser Glu Ala Thr Ser Glu Gly Ser Ile Phe Glu Val Gly His Leu His  
 965 970 975  
 ctt gcg gta gac aga gat gtg aac caa gcg ggg agt aaa att aag gct 3512  
 Leu Ala Val Asp Arg Asp Val Asn Gln Ala Gly Ser Lys Ile Lys Ala  
 980 985 990  
 aag tat acc act ggt gtt gtg aaa ggg aac ttt aat act gaa gcg ggc 3560  
 Lys Tyr Thr Thr Gly Val Val Lys Gly Asn Phe Asn Thr Glu Ala Gly  
 995 1000 1005  
 aag aat att aaa cat gtc gaa aaa gaa gaa tat agt tca cag cta ttt 3608  
 Lys Asn Ile Lys His Val Glu Lys Glu Glu Tyr Ser Ser Gln Leu Phe  
 1010 1015 1020 1025  
 gct tca gca cac gcg agt ggt ggt gcc acc tca gtt cgt tat gac tat 3656  
 Ala Ser Ala His Ala Ser Gly Gly Gly Thr Ser Val Arg Tyr Asp Tyr  
 1030 1035 1040  
 aac agc caa gat ggt ggc aat gcc tct gtt ggt gtt ccg aca aac cat 3704  
 Asn Ser Gln Asp Gly Gly Asn Ala Ser Val Gly Val Pro Thr Asn His  
 1045 1050 1055  
 act gga gtt ggg gca gag gca gga atg tca ttc acc cat acc aaa gac 3752  
 Thr Gly Val Gly Ala Glu Ala Gly Met Ser Phe Thr His Thr Lys Asp  
 1060 1065 1070

WO 02/075507

PCT/US02/01971

aaa gaa aca ctg ctc act cac acc aat agt gaa tta caa gtc aaa cat 3800  
 Lys Glu Thr Leu Leu Thr His Thr Asn Ser Glu Leu Gln Val Lys His  
 1075 1080 1085

ggg aaa tta cat gtg ctt ggt tat gcc gat att ggt gga gta gat att 3848  
 Gly Lys Leu His Val Leu Gly Tyr Ala Asp Ile Gly Gly Val Asp Ile  
 1090 1095 1100 1105

aat act aaa cta cca gaa gat gca caa agc aaa gca cag aaa gag ata 3896  
 Asn Thr Lys Leu Pro Glu Asp Ala Gln Ser Lys Ala Gln Lys Glu Ile  
 1110 1115 1120

gcg gct agc aag cca gag aag acc gag caa tct gca cag gat gtg gct 3944  
 Ala Ala Ser Lys Pro Glu Lys Thr Glu Gln Ser Ala Gln Asp Val Ala  
 1125 1130 1135

caa gct caa tca aat gcc aat aag gat aag gaa aat aaa gcc cca gaa 3992  
 Gln Ala Gln Ser Asn Ala Asn Lys Asp Lys Glu Asn Lys Ala Pro Glu  
 1140 1145 1150

ata aaa gaa tta tca gag gct gaa atc gcg gat ctc atg tca gaa aaa 4040  
 Ile Lys Glu Leu Ser Glu Ala Glu Ile Ala Asp Leu Met Ser Glu Lys  
 1155 1160 1165

tca aaa gcg tat ttt gat gat ttt gca gag caa gcg aaa aaa gca cct 4088  
 Ser Lys Ala Tyr Phe Asp Asp Phe Ala Glu Gln Ala Lys Lys Ala Pro  
 1170 1175 1180 1185

gaa aac aat cga ttt gaa ttg tct gcg aaa gaa att aag tcg agc aaa 4136  
 Glu Asn Asn Arg Phe Glu Leu Ser Ala Lys Glu Ile Lys Ser Ser Lys  
 1190 1195 1200

caa aaa gac caa tat gat cat gag tct gaa cgg acg act ttt aaa gtt 4184  
 Gln Lys Asp Gln Tyr Asp His Glu Ser Glu Arg Thr Thr Phe Lys Val  
 1205 1210 1215

gga cct gaa gcg gag gct cat tct gcg gtt gcc gat atg gtg agc cat 4232  
 Gly Pro Glu Ala Glu Ala His Ser Ala Val Ala Asp Met Val Ser His  
 1220 1225 1230

tta gtg aaa gaa tat aga gat gca caa aat ggg act aaa caa gac ggt 4280  
 Leu Val Lys Glu Tyr Arg Asp Ala Gln Asn Gly Thr Lys Gln Asp Gly  
 1235 1240 1245

aca gta gca tta caa cat gct agt gat gtc tta aat att gtg acg ggg 4328  
 Thr Val Ala Leu Gln His Ala Ser Asp Val Leu Asn Ile Val Thr Gly  
 1250 1255 1260 1265

gat tta gcg ggg agt tca gct aaa ttg tct gtt gaa aga aca cat gag 4376  
 Asp Leu Ala Gly Ser Ser Ala Lys Leu Ser Val Glu Arg Thr His Glu  
 1270 1275 1280

aca aaa cga acg aca gaa acg ggg gat att gtt act aag att ggt ggc 4424  
 Thr Lys Arg Thr Thr Glu Thr Gly Asp Ile Val Thr Lys Ile Gly Gly  
 1285 1290 1295

aat gtc aca ctg tca gca cgc agt ggt agt gtg aac ctt aaa aat gta 4472  
 Asn Val Thr Leu Ser Ala Arg Ser Gly Ser Val Asn Leu Lys Asn Val  
 1300 1305 1310

caa agt gat gaa caa gct aat ttg acc tta aga gca aaa gaa gat gtg 4520  
 Gln Ser Asp Glu Gln Ala Asn Leu Thr Leu Arg Ala Lys Glu Asp Val  
 1315 1320 1325

WO 02/075507

PCT/US02/01971

aat gtg ctg tct ggt gaa aaa aca cga gaa acc aca gaa aca gta tca 4568  
Asn Val Leu Ser Gly Glu Lys Thr Arg Glu Thr Thr Glu Thr Val Ser  
1330 1335 1340 1345  
aga cag aaa ctt tct cat ggt gtg aac gca ggt tgc agt atg atg agt 4616  
Arg Gln Lys Leu Ser His Gly Val Asn Ala Gly Cys Ser Met Met Ser  
1350 1355 1360  
ggc gcc tgt act gcc ggt gtt agc aca tca ctt gaa gga aat gaa agc 4664  
Gly Ala Cys Thr Ala Gly Val Ser Thr Ser Leu Glu Gly Asn Glu Ser  
1365 1370 1375  
tat acg tca gaa cgt gaa acg gct caa aat aac agt ttc tta aaa gca 4712  
Tyr Thr Ser Glu Arg Glu Thr Ala Gln Asn Asn Ser Phe Leu Lys Ala  
1380 1385 1390  
cgc aac atg aaa gtt gaa gca ggt cgc gat ttt aat gtt gtc agt tcg 4760  
Arg Asn Met Lys Val Glu Ala Gly Arg Asp Phe Asn Val Val Ser Ser  
1395 1400 1405  
aat att gat gca gat aag ctc gat ctc cac gtt aaa gga aaa acg aat 4808  
Asn Ile Asp Ala Asp Lys Leu Asp Leu His Val Lys Gly Lys Thr Asn  
1410 1415 1420 1425  
gtg gta tcc aaa caa gat acg tta caa aaa gtg acg cat gga gtt gac 4856  
Val Val Ser Lys Gln Asp Thr Leu Gln Lys Val Thr His Gly Val Asp  
1430 1435 1440  
tat aat ctt tcc gct ggc gtt gca ctt tct agt gca aca att gct acc 4904  
Tyr Asn Leu Ser Ala Gly Val Ala Leu Ser Ser Ala Thr Ile Ala Thr  
1445 1450 1455  
cca acc ggt aat gtt ggt ttc ggt tat acc aat gag acc gaa agc aag 4952  
Pro Thr Gly Asn Val Gly Phe Gly Tyr Thr Asn Glu Thr Glu Ser Lys  
1460 1465 1470  
cgg acg gtt aat caa caa gca ggg att aaa gcg aat aaa att aca ggg 5000  
Arg Thr Val Asn Gln Gln Ala Gly Ile Lys Ala Asn Lys Ile Thr Gly  
1475 1480 1485  
caa acg cat gac tta aat ctt gag ggg gga tat ctt gtc agc aac gat 5048  
Gln Thr His Asp Leu Asn Leu Glu Gly Gly Tyr Leu Val Ser Asn Asp  
1490 1495 1500 1505  
aag gat aat cag ctg aaa gtt acc ggc gat gtc aca act aaa gcc ctt 5096  
Lys Asp Asn Gln Leu Lys Val Thr Gly Asp Val Thr Thr Lys Ala Leu  
1510 1515 1520  
cac gat caa cat gat aaa gat ggt gga aca ttt ggt tta tct gtg ggt 5144  
His Asp Gln His Asp Lys Asp Gly Gly Thr Phe Gly Leu Ser Val Gly  
1525 1530 1535  
atc agt gaa cgt ggt act acc gcc ttt aat gta cga ggt ggg cga gct 5192  
Ile Ser Glu Arg Gly Thr Thr Ala Phe Asn Val Arg Gly Gly Arg Ala  
1540 1545 1550  
gaa cag aaa cac tat aat gca acg cag aaa tcc act ctt tct ggc gtg 5240  
Glu Gln Lys His Tyr Asn Ala Thr Gln Lys Ser Thr Leu Ser Gly Val  
1555 1560 1565  
gat acc tct caa gcg aat gta tca ggt caa gtg aat aca gat tta acc 5288  
Asp Thr Ser Gln Ala Asn Val Ser Gly Gln Val Asn Thr Asp Leu Thr  
1570 1575 1580 1585

WO 02/075507

PCT/US02/01971

aag gca aaa gct gtc aca cgt gat gat act tac gca agt acg caa ttt 5336  
Lys Ala Lys Ala Val Thr Arg Asp Asp Thr Tyr Ala Ser Thr Gln Phe  
1590 1595 1600  
agt ttt gaa gtg gca gat att gtg gaa tta gga cag aga gcg aaa aac 5384  
Ser Phe Glu Val Ala Asp Ile Val Glu Leu Gly Gln Arg Ala Lys Asn  
1605 1610 1615  
aag ctg tca gca cca aac aat gac acc gat atg gcg tca ggc tcc aca 5432  
Lys Leu Ser Ala Pro Asn Asn Asp Thr Asp Met Ala Ser Gly Ser Thr  
1620 1625 1630  
tta cgc tcg cgt tct act aca gaa gaa gca gat gta cca aca aca aga 5480  
Leu Arg Ser Arg Ser Thr Thr Glu Glu Ala Asp Val Pro Thr Thr Arg  
1635 1640 1645  
tcg cgt gta acg gat gag gcg gat tct gta tcc gtg aaa aat ccg att 5528  
Ser Arg Val Thr Asp Glu Ala Asp Ser Val Ser Val Lys Asn Pro Ile  
1650 1655 1660 1665  
tat gaa agt gca gat gct gtt gta cca aca cca cgt agt aga aat gtg 5576  
Tyr Glu Ser Ala Asp Ala Val Val Pro Thr Pro Arg Ser Arg Asn Val  
1670 1675 1680  
gac agt acc gat ctt gtg gac aat cca ctg tat gct agt gcc act aca 5624  
Asp Ser Thr Asp Leu Val Asp Asn Pro Leu Tyr Ala Ser Ala Thr Thr  
1685 1690 1695  
aaa gca aac atc cat gat tat gaa gaa att cca gcc gtt tat agc aaa 5672  
Lys Ala Asn Ile His Asp Tyr Glu Glu Ile Pro Ala Val Tyr Ser Lys  
1700 1705 1710  
gtc ggt gat aac aat gct gat ctt gtt cgt cat aaa acg gca act agt 5720  
Val Gly Asp Asn Asn Ala Asp Leu Val Arg His Lys Thr Ala Thr Ser  
1715 1720 1725  
gat gag cat ctt tat gca gag att aat gaa cca aca tat agc cgt gtt 5768  
Asp Glu His Leu Tyr Ala Glu Ile Asn Glu Pro Thr Tyr Ser Arg Val  
1730 1735 1740 1745  
ggt gat aaa aat gca gat atg aga cgt cat aac gcg gca ggt aca aca 5816  
Gly Asp Lys Asn Ala Asp Met Arg Arg His Asn Ala Ala Gly Thr Thr  
1750 1755 1760  
gac tat gcc gat gtc gtg caa gca cat aca aga aag gca gat gat cca 5864  
Asp Tyr Ala Asp Val Val Gln Ala His Thr Arg Lys Ala Asp Asp Pro  
1765 1770 1775  
cta cca gca tta ccg aat cag ggt aaa gca aga acg gta aac gac ggt 5912  
Leu Pro Ala Leu Pro Asn Gln Gly Lys Ala Arg Thr Val Asn Asp Gly  
1780 1785 1790  
tca gag cat att tat act gat att agc gac gtg ggc act caa act aaa 5960  
Ser Glu His Ile Tyr Thr Asp Ile Ser Asp Val Gly Thr Gln Thr Lys  
1795 1800 1805  
gct att gat agt act tat gca aca gta ggc atg ccg aaa gcg aat gcc 6008  
Ala Ile Asp Ser Thr Tyr Ala Thr Val Gly Met Pro Lys Ala Asn Ala  
1810 1815 1820 1825  
glt aac ttg ata ggg caa aat ggc tta ggc agc att tat cac agc cca 6056  
Val Asn Leu Ile Gly Gln Asn Gly Leu Gly Ser Ile Tyr His Ser Pro  
1830 1835 1840

WO 02/075507

PCT/US02/01971

gac agt gct tat aaa aca tgg caa ttg ctt gat caa ttt gcc aac aaa 6104  
 Asp Ser Ala Tyr Lys Thr Trp Gln Leu Leu Asp Gln Phe Ala Asn Lys  
 1845 1850 1855

ggc gga gat gcg gtc ttc tta cgc cct gca aca gaa atg aaa tgt gca 6152  
 Gly Gly Asp Ala Val Phe Leu Arg Pro Ala Thr Glu Met Lys Cys Ala  
 1860 1865 1870

ggt gca cct tta aaa tat acc ttt atc gtg cgt gat tat ttg ctc aga 6200  
 Gly Ala Pro Leu Lys Tyr Thr Phe Ile Val Arg Asp Tyr Leu Leu Arg  
 1875 1880 1885

cgc cat acc tta gat aaa tca aga tta ttt tat aac gca cat aat aaa 6248  
 Arg His Thr Leu Asp Lys Ser Arg Leu Phe Tyr Asn Ala His Asn Lys  
 1890 1895 1900

acc tta ttt agc gtg cct atc gtt gat gca aaa gtc aaa atg ctg ttt 6296  
 Thr Leu Phe Ser Val Pro Ile Val Asp Ala Lys Val Lys Met Leu Phe  
 1910 1915 1920

gct gaa aaa aat atc caa gtc aat tac gat cgt agc ctt aca gcc att 6344  
 Ala Glu Lys Asn Ile Gln Val Asn Tyr Asp Arg Ser Leu Thr Ala Ile  
 1925 1930 1935

gat ctg agt aaa cgt att gcg acc ttt aat agc cca gaa gga gtt gta 6392  
 Asp Leu Ser Lys Arg Ile Ala Thr Phe Asn Ser Pro Glu Gly Val Val  
 1940 1945 1950

gaa gtc cct tat gat ttt att aat gtg gta cct cca atg cga gca cct 6440  
 Glu Val Pro Tyr Asp Phe Ile Asn Val Val Pro Pro Met Arg Ala Pro  
 1955 1960 1965

gat gcc gtt cgt caa tca gca ctc gcg tgg caa gaa gga aaa tgg gct 6488  
 Asp Ala Val Arg Gln Ser Ala Leu Ala Trp Gln Glu Gly Lys Trp Ala  
 1970 1975 1980 1985

aac gat ggt tgg gtt gaa gta gaa aaa cat acc ttg cgt cac cgt cgt 6536  
 Asn Asp Gly Trp Val Glu Val Glu Lys His Thr Leu Arg His Arg Arg  
 1990 1995 2000

tat gcc aat gtg ttt gct gtg ggt gat gat gca ggg gtc cca aaa ggc 6584  
 Tyr Ala Asn Val Phe Ala Val Gly Asp Val Ala Gly Val Pro Lys Gly  
 2005 2010 2015

aaa acg gct gcc agt gtc aaa tgg caa gtt cct gtt gca gtg gca cat 6632  
 Lys Thr Ala Ala Ser Val Lys Trp Gln Val Pro Val Ala Val Ala His  
 2020 2025 2030

tta ctc gca gaa tta gag ggc aaa cct tgt gat gaa att tac aac ggt 6680  
 Leu Leu Ala Glu Leu Glu Gly Lys Pro Cys Asp Glu Ile Tyr Asn Gly  
 2035 2040 2045

tat aca tct tgt cca tta att act caa tta gga aag ggg atg cta gta 6728  
 Tyr Thr Ser Cys Pro Leu Ile Thr Gln Leu Gly Lys Gly Met Leu Val  
 2050 2055 2060 2065

gaa ttt gat tat aac aac cac tta aca cct tct ttc ccc ggt gta ata 6776  
 Glu Phe Asp Tyr Asn Asn His Leu Thr Pro Ser Phe Pro Gly Val Ile  
 2070 2075 2080

gcg cca tta gaa gaa ctg tgg gca aca tgg gca att aaa aca tta ggt 6824  
 Ala Pro Leu Glu Glu Leu Trp Ala Thr Trp Ala Ile Lys Thr Leu Gly  
 2085 2090 2095

WO 02/075507

PCT/US02/01971

```

tta aaa ccc act tat tta ggt atg tta cgt gga tta gct taaggagcgt 6873
Leu Lys Pro Thr Tyr Leu Gly Met Leu Arg Gly Leu Ala
2100 2105 2110

tga 6876

<210> 16
<211> 2110
<212> PRT
<213> Pasteurella multocida

<400> 16
Met Gln Pro Ala Gln Glu His Cys Gln Arg Ile Asn Asn Ile Val Asn
1 5 10 15
Gln Glu Asn Gly Leu Phe His Thr Leu Gly Asn Met Met Leu Glu Ala
20 25 30
Glu Arg Ser Val Tyr Asn Ile Gly Asp Ile Tyr Ala Ser Lys Lys Leu
35 40 45
Thr Val His Thr His Asn Leu Ile Asn Asp Val Arg Leu Ser Gly Asn
50 55 60
Val Ser Tyr Lys Pro Ile Gly Ser Ser Arg Asp Tyr Asp Ile Ser Arg
65 70 75 80
Val Ala Val His Gly Trp His Asn Asn Val Tyr Lys Leu Asn Leu Asn
85 90 95
Leu Gln Glu Gln Asp Lys Thr Asp Ile Lys Val Val Lys Met Gly Ala
100 105 110
Ile Arg Ser Asp Gly Asp Phe Asp Phe Lys Gly Ile Lys Ala Thr Ser
115 120 125
Ser Glu Ser Lys Pro Gln Leu Ile Asn His Gly Leu Ile Asn Val Lys
130 135 140
Gly Thr Phe Asn Ala Glu Ala Asp Gln Val Val Asn Gln Met Lys Ala
145 150 155 160
Phe Asn Gln Asn Ala Leu Ala Ser Val Phe Lys Asn Pro Ala Lys Ile
165 170 175
Thr Met Tyr Tyr Gln Pro Leu Thr Arg Tyr Ile Trp Thr Pro Leu Ser
180 185 190
Gly Asn Ala Ser Arg Glu Phe Asn Asn Leu Glu Ser Phe Leu Asp Ala
195 200 205
Leu Phe Gly Ser Thr Thr Ile Leu Lys Ser Ser Phe Tyr Ser Thr Glu
210 215 220
Asn Phe Ser Ala Tyr Gln Leu Leu Ser His Ile Gln His Ser Pro Met
225 230 235 240
Tyr Gln Lys Ala Met Ala Gln Val Phe Gly Ala Glu Trp His Ser Lys
245 250 255
Ser Tyr Asp Glu Met Arg Asn Lys Trp Lys Ser Phe Lys Glu Asn Pro
260 265 270

```



WO 02/075507

PCT/US02/01971

Thr Asp Phe Ile Tyr Tyr Pro Ser Glu Lys Ala Lys Ile Leu Ala Gly  
 275 280 285  
 Lys Leu Glu Gly Lys Leu Thr Thr Leu Gln Asn Gly Glu Tyr Ala Glu  
 290 295 300  
 Arg Gly Lys Phe Asp Glu Ser Ile Gln Ile Gly Lys His Gln Leu Ser  
 305 310 315 320  
 Leu Pro Ser Val Glu Leu Lys Ala Glu Phe Ser Asp Lys Glu Arg Leu  
 325 330 335  
 Glu Glu Asp Gly Val Asp Leu Ser Ser Ile Ala Glu Leu Leu Glu Met  
 340 345 350  
 Pro Asn Leu Phe Ile Asp Asn Ser Ile Gln Leu Glu Lys Lys Lys Leu  
 355 360 365  
 Ser Pro Ile Glu Asp Leu Asp Glu Glu Pro Arg Lys Asn Leu Asp Ile  
 370 375 380  
 Glu Glu Ser His Ser Asn Ser Ser Asp Asp Val Leu Ser Met Asn Asp  
 385 390 395 400  
 Asp Glu Ser Asp Thr Asp Asp Ser Lys Trp Ser Met Gly Asn Asp Glu  
 405 410 415  
 Lys Glu Met Pro Asp Asp Lys Leu Gly Ile Ser Arg Asp Asp Arg Gly  
 420 425 430  
 Asn Lys Pro Pro Arg Thr Asp Pro Thr Val Asp Tyr Leu Asn Pro Asp  
 435 440 445  
 Glu Phe Phe Glu Asn Gly Tyr Leu Leu Asn Glu Leu Leu Gln Glu Leu  
 450 455 460  
 Gly Glu Glu Pro Leu Leu Lys Glu Gly Glu Asp His Phe Lys Arg Ser  
 465 470 475 480  
 Thr Asn Leu Val Arg Leu Gly Glu Arg Asp Arg Gln Asn Arg Glu Lys  
 485 490 495  
 Arg Glu Lys Glu Gly Tyr Phe Asp Leu Pro Gly Thr Leu Asp Met Lys  
 500 505 510  
 Leu Gln Glu Leu Phe Glu Lys Arg Lys Gln Lys His Glu Ala Glu Gln  
 515 520 525  
 Lys Ala Arg Ile Glu Lys Ala Leu Leu Gln Lys Ser Glu Gln Gln Glu  
 530 535 540  
 Lys Arg Val Glu Glu Arg Lys Gln Glu Glu Lys Arg Gln Ala Gln Asp  
 545 550 555 560  
 Lys Ile Ala Lys Gln Val Glu Ile Ala Lys Glu Met Gln Arg Val Glu  
 565 570 575  
 Glu Ile Arg Gln Arg Glu Lys Gln Leu Ala Ile Gln Leu Gln Glu Glu  
 580 585 590  
 Glu Lys Lys Gln Gln Glu Glu Lys His Leu Ser Glu Glu Lys Lys Gln  
 595 600 605

WO 02/075507

PCT/US02/01971

Ala Glu Gln Lys Gln Lys Ala Glu Glu Lys Val Ala Gln Glu Arg Leu  
 610 615 620  
 Asp Ile Glu Gln Gln Lys Ala Tyr Glu Glu Met Ala Lys Arg Glu Ala  
 625 630 635 640  
 Glu Ala Ser Lys Asn Val Leu Leu Lys Ala Ile Asp Glu Glu Arg Pro  
 645 650 655  
 Lys Val Glu Thr Asp Pro Leu Phe Arg Thr Lys Leu Lys Tyr Ile Asn  
 660 665 670  
 Gln Asp Asp Tyr Ala Gly Ala Asn Tyr Phe Phe Asn Lys Val Gly Leu  
 675 680 685  
 Asn Thr Lys Gly His Gln Lys Val Asn Val Leu Gly Asp Asn Tyr Phe  
 690 695 700  
 Asp His Gln Val Ile Thr Arg Ser Ile Glu Lys Lys Val Asp Asn His  
 705 710 715 720  
 Leu Asn Gln Lys Tyr Asn Leu Ser Asp Val Glu Leu Val Lys Gln Leu  
 725 730 735  
 Met Asp Asn Ser Thr Thr Gln Ala Gln Glu Leu Asp Leu Lys Leu Gly  
 740 745 750  
 Ala Ala Leu Thr Lys Glu Gln Gln Ala Asn Leu Thr Gln Asp Ile Val  
 755 760 765  
 Trp Tyr Val Lys Thr Lys Val Lys Gly Lys Asp Val Phe Val Pro Lys  
 770 775 780  
 Val Tyr Phe Ala Ser Glu Thr Leu Val Glu Ala Gln Lys Leu Gln Gly  
 785 790 795 800  
 Leu Gly Thr Gly Thr Ile Arg Val Gly Glu Ala Lys Ile Lys Ala Lys  
 805 810 815  
 Asp Val Val Asn Thr Gly Thr Leu Ala Gly Arg Lys Leu Asn Val Glu  
 820 825 830  
 Ala Ser Asn Lys Ile Lys Asn Gln Gly Ser Ile Leu Ser Thr Gln Glu  
 835 840 845  
 Thr Arg Leu Val Gly Arg Lys Gly Ile Glu Asn Val Ser Arg Ser Phe  
 850 855 860  
 Ala Asn Asp Glu Leu Gly Val Thr Ala Gln Arg Ser Glu Ile Lys Thr  
 865 870 875 880  
 Glu Gly His Leu His Leu Glu Thr Asp Lys Asp Ser Thr Ile Asp Val  
 885 890 895  
 Gln Ala Ser Asp Ile Lys Ala Lys Thr Ser Phe Val Lys Thr Gly Asp  
 900 905 910  
 Val Asn Leu Lys Asn Thr Tyr Asn Thr Lys His Ala Tyr Arg Glu Lys  
 915 920 925  
 Phe Ser Pro Ser Ala Leu Gln Val Ala Glu Leu Asp Val Ala Gly Leu  
 930 935 940

WO 02/075507

PCT/US02/01971

Lys Val Pro Leu Leu Gly Val Ser Ser Pro Ser Ser Tyr Ser Glu His  
 945 950 955 960  
 Thr Ser Glu Ala Thr Ser Glu Gly Ser Ile Phe Glu Val Gly His Leu  
 965 970 975  
 His Leu Ala Val Asp Arg Asp Val Asn Gln Ala Gly Ser Lys Ile Lys  
 980 985 990  
 Ala Lys Tyr Thr Thr Gly Val Val Lys Gly Asn Phe Asn Thr Glu Ala  
 995 1000 1005  
 Gly Lys Asn Ile Lys His Val Glu Lys Glu Glu Tyr Ser Ser Gln Leu  
 1010 1015 1020  
 Phe Ala Ser Ala His Ala Ser Gly Gly Gly Thr Ser Val Arg Tyr Asp  
 1025 1030 1035 1040  
 Tyr Asn Ser Gln Asp Gly Gly Asn Ala Ser Val Gly Val Pro Thr Asn  
 1045 1050 1055  
 His Thr Gly Val Gly Ala Glu Ala Gly Met Ser Phe Thr His Thr Lys  
 1060 1065 1070  
 Asp Lys Glu Thr Leu Leu Thr His Thr Asn Ser Glu Leu Gln Val Lys  
 1075 1080 1085  
 His Gly Lys Leu His Val Leu Gly Tyr Ala Asp Ile Gly Gly Val Asp  
 1090 1095 1100  
 Ile Asn Thr Lys Leu Pro Glu Asp Ala Gln Ser Lys Ala Gln Lys Glu  
 1105 1110 1115 1120  
 Ile Ala Ala Ser Lys Pro Glu Lys Thr Glu Gln Ser Ala Gln Asp Val  
 1125 1130 1135  
 Ala Gln Ala Gln Ser Asn Ala Asn Lys Asp Lys Glu Asn Lys Ala Pro  
 1140 1145 1150  
 Glu Ile Lys Glu Leu Ser Glu Ala Glu Ile Ala Asp Leu Met Ser Glu  
 1155 1160 1165  
 Lys Ser Lys Ala Tyr Phe Asp Asp Phe Ala Glu Gln Ala Lys Lys Ala  
 1170 1175 1180  
 Pro Glu Asn Asn Arg Phe Glu Leu Ser Ala Lys Glu Ile Lys Ser Ser  
 1185 1190 1195 1200  
 Lys Gln Lys Asp Gln Tyr Asp His Glu Ser Glu Arg Thr Thr Phe Lys  
 1205 1210 1215  
 Val Gly Pro Glu Ala Glu Ala His Ser Ala Val Ala Asp Met Val Ser  
 1220 1225 1230  
 His Leu Val Lys Glu Tyr Arg Asp Ala Gln Asn Gly Thr Lys Gln Asp  
 1235 1240 1245  
 Gly Thr Val Ala Leu Gln His Ala Ser Asp Val Leu Asn Ile Val Thr  
 1250 1255 1260  
 Gly Asp Leu Ala Gly Ser Ser Ala Lys Leu Ser Val Glu Arg Thr His  
 1265 1270 1275 1280

WO 02/075507

PCT/US02/01971

Glu Thr Lys Arg Thr Thr Glu Thr Gly Asp Ile Val Thr Lys Ile Gly  
 1285 1290 1295  
 Gly Asn Val Thr Leu Ser Ala Arg Ser Gly Ser Val Asn Leu Lys Asn  
 1300 1305 1310  
 Val Gln Ser Asp Glu Gln Ala Asn Leu Thr Leu Arg Ala Lys Glu Asp  
 1315 1320 1325  
 Val Asn Val Leu Ser Gly Glu Lys Thr Arg Glu Thr Thr Glu Thr Val  
 1330 1335 1340  
 Ser Arg Gln Lys Leu Ser His Gly Val Asn Ala Gly Cys Ser Met Met  
 1345 1350 1355 1360  
 Ser Gly Ala Cys Thr Ala Gly Val Ser Thr Ser Leu Glu Gly Asn Glu  
 1365 1370 1375  
 Ser Tyr Thr Ser Glu Arg Glu Thr Ala Gln Asn Asn Ser Phe Leu Lys  
 1380 1385 1390  
 Ala Arg Asn Met Lys Val Glu Ala Gly Arg Asp Phe Asn Val Val Ser  
 1395 1400 1405  
 Ser Asn Ile Asp Ala Asp Lys Leu Asp Leu His Val Lys Gly Lys Thr  
 1410 1415 1420  
 Asn Val Val Ser Lys Gln Asp Thr Leu Gln Lys Val Thr His Gly Val  
 1425 1430 1435 1440  
 Asp Tyr Asn Leu Ser Ala Gly Val Ala Leu Ser Ser Ala Thr Ile Ala  
 1445 1450 1455  
 Thr Pro Thr Gly Asn Val Gly Phe Gly Tyr Thr Asn Glu Thr Glu Ser  
 1460 1465 1470  
 Lys Arg Thr Val Asn Gln Gln Ala Gly Ile Lys Ala Asn Lys Ile Thr  
 1475 1480 1485  
 Gly Gln Thr His Asp Leu Asn Leu Glu Gly Gly Tyr Leu Val Ser Asn  
 1490 1495 1500  
 Asp Lys Asp Asn Gln Leu Lys Val Thr Gly Asp Val Thr Thr Lys Ala  
 1505 1510 1515 1520  
 Leu His Asp Gln His Asp Lys Asp Gly Gly Thr Phe Gly Leu Ser Val  
 1525 1530 1535  
 Gly Ile Ser Glu Arg Gly Thr Thr Ala Phe Asn Val Arg Gly Gly Arg  
 1540 1545 1550  
 Ala Glu Gln Lys His Tyr Asn Ala Thr Gln Lys Ser Thr Leu Ser Gly  
 1555 1560 1565  
 Val Asp Thr Ser Gln Ala Asn Val Ser Gly Gln Val Asn Thr Asp Leu  
 1570 1575 1580  
 Thr Lys Ala Lys Ala Val Thr Arg Asp Asp Thr Tyr Ala Ser Thr Gln  
 1585 1590 1595 1600  
 Phe Ser Phe Glu Val Ala Asp Ile Val Glu Leu Gly Gln Arg Ala Lys  
 1605 1610 1615

WO 02/075507

PCT/US02/01971

Asn Lys Leu Ser Ala Pro Asn Asn Asp Thr Asp Met Ala Ser Gly Ser  
 1620 1625 1630  
 Thr Leu Arg Ser Arg Ser Thr Thr Glu Glu Ala Asp Val Pro Thr Thr  
 1635 1640 1645  
 Arg Ser Arg Val Thr Asp Glu Ala Asp Ser Val Ser Val Lys Asn Pro  
 1650 1655 1660  
 Ile Tyr Glu Ser Ala Asp Ala Val Val Pro Thr Pro Arg Ser Arg Asn  
 1665 1670 1675 1680  
 Val Asp Ser Thr Asp Leu Val Asp Asn Pro Leu Tyr Ala Ser Ala Thr  
 1685 1690 1695  
 Thr Lys Ala Asn Ile His Asp Tyr Glu Glu Ile Pro Ala Val Tyr Ser  
 1700 1705 1710  
 Lys Val Gly Asp Asn Asn Ala Asp Leu Val Arg His Lys Thr Ala Thr  
 1715 1720 1725  
 Ser Asp Glu His Leu Tyr Ala Glu Ile Asn Glu Pro Thr Tyr Ser Arg  
 1730 1735 1740  
 Val Gly Asp Lys Asn Ala Asp Met Arg Arg His Asn Ala Ala Gly Thr  
 1745 1750 1755 1760  
 Thr Asp Tyr Ala Asp Val Val Gln Ala His Thr Arg Lys Ala Asp Asp  
 1765 1770 1775  
 Pro Leu Pro Ala Leu Pro Asn Gln Gly Lys Ala Arg Thr Val Asn Asp  
 1780 1785 1790  
 Gly Ser Glu His Ile Tyr Thr Asp Ile Ser Asp Val Gly Thr Gln Thr  
 1795 1800 1805  
 Lys Ala Ile Asp Ser Thr Tyr Ala Thr Val Gly Met Pro Lys Ala Asn  
 1810 1815 1820  
 Ala Val Asn Leu Ile Gly Gln Asn Gly Leu Gly Ser Ile Tyr His Ser  
 1825 1830 1835 1840  
 Pro Asp Ser Ala Tyr Lys Thr Trp Gln Leu Leu Asp Gln Phe Ala Asn  
 1845 1850 1855  
 Lys Gly Gly Asp Ala Val Phe Leu Arg Pro Ala Thr Glu Met Lys Cys  
 1860 1865 1870  
 Ala Gly Ala Pro Leu Lys Tyr Thr Phe Ile Val Arg Asp Tyr Leu Leu  
 1875 1880 1885  
 Arg Arg His Thr Leu Asp Lys Ser Arg Leu Phe Tyr Asn Ala His Asn  
 1890 1895 1900  
 Lys Thr Leu Phe Ser Val Pro Ile Val Asp Ala Lys Val Lys Met Leu  
 1905 1910 1915 1920  
 Phe Ala Glu Lys Asn Ile Gln Val Asn Tyr Asp Arg Ser Leu Thr Ala  
 1925 1930 1935  
 Ile Asp Leu Ser Lys Arg Ile Ala Thr Phe Asn Ser Pro Glu Gly Val  
 1940 1945 1950

WO 02/075507

PCT/US02/01971

Val Glu Val Pro Tyr Asp Phe Ile Asn Val Val Pro Pro Met Arg Ala  
 1955 1960 1965  
 Pro Asp Ala Val Arg Gln Ser Ala Leu Ala Trp Gln Glu Gly Lys Trp  
 1970 1975 1980  
 Ala Asn Asp Gly Trp Val Glu Val Glu Lys His Thr Leu Arg His Arg  
 1985 1990 1995 2000  
 Arg Tyr Ala Asn Val Phe Ala Val Gly Asp Val Ala Gly Val Pro Lys  
 2005 2010 2015  
 Gly Lys Thr Ala Ala Ser Val Lys Trp Gln Val Pro Val Ala Val Ala  
 2020 2025 2030  
 His Leu Leu Ala Glu Leu Glu Gly Lys Pro Cys Asp Glu Ile Tyr Asn  
 2035 2040 2045  
 Gly Tyr Thr Ser Cys Pro Leu Ile Thr Gln Leu Gly Lys Gly Met Leu  
 2050 2055 2060  
 Val Glu Phe Asp Tyr Asn Asn His Leu Thr Pro Ser Phe Pro Gly Val  
 2065 2070 2075 2080  
 Ile Ala Pro Leu Glu Glu Leu Trp Ala Thr Trp Ala Ile Lys Thr Leu  
 2085 2090 2095  
 Gly Leu Lys Pro Thr Tyr Leu Gly Met Leu Arg Gly Leu Ala  
 2100 2105 2110

<210> 17  
 <211> 3247  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (1479)..(3245)

<220>  
 <223> fhaB2

<400> 17  
 gtgacottg cgggtgaaaa ggtatctcta aattttggcg atatcattca tgcttaccaa 60  
 aaccagcccc tatcaacaaa agttgttttt caattagtga aagatttgac ggaagtttta 120  
 taccgttctg gctacgtgac aagtgcaatt ggtttaaaaa attcaaaaat cagcaatggc 180  
 gatottgaat ttattgtact gtggggaaga actcgcgato tgtttgtgaa tggggagaaa 240  
 ccaaccogtt ttagagataa aacaatgta tcagtcctac ccaatttaat cggaaatcgc 300  
 ttaagtattc acgacattga ccagttgatc gaaattctaa atactacgaa taaaaaagcc 360  
 acagtgaatg tggttgcaag tgaagaaaaa ggcagctcaa atctaaatat tgaagacaaa 420  
 tatgatgttt ttccgcaagt gagtgcgga ttcaataatt caggtgctgg caataatgcc 480  
 aatgggcgta atcaagctac attgaatatt gcttggagtg atctattagg cacgaatgat 540  
 cgttggagtt tctcgagtag ttaccgttta tataaaaatc atcctgctaa ccagcaacgc 600

WO 02/075507

PCT/US02/01971

```

aattatactt tgtcttacag tcagccctata ggcttttcta cagtagaaat taaagcatcg 660
gaatctacgt atgaaaaaga acttcgcggt ataatactc attctctca tgggaaaacc 720
caagcttag ctgtcaagct gatgcatgtg ttattgcgta ataaggagag tattttatct 780
acataaccg agttcaggtt taaaaaacgg attagtattt ttctgatat tttgattggg 840
aaatatacaca ataataaagt gagcgtaggg ttatcttaca tgactaattt tgcttacggg 900
aagctttaca gcgacattgc ttacgcgaat gggttgagat ggtttggggc gaattattca 960
gcataatgat caaatcgtga aaaaacctta aaattattgt caggaagtat taattggcag 1020
cgtccaatat cctctgttga acgtgcgatg aattatcaat tacgtattgg tgcccaatat 1080
ggttttgata gtttgatttc tgaaaatcaa ttttcaattg gtgatgaata tacagtaaga 1140
ggatttaaag gtggtcggtt ttctggtgat agtgggtcgt attatcaca aacctgacg 1200
gtctcttttt atccacaaaa agcataltta tctcaggtat ccccttttat tggatttgat 1260
atgggtaaag tacatattaa atcaaacgat aaaaacaacca ctttagtcgg ttttgccta 1320
ggcttgaaaa cgcaataaaa gttattttca ttatcattaa cctatgcaca accaatgat 1380
gggtgagtg gtgttacgca acatcgtcaa aaaccgattt attatttctc aggatcactt 1440
ctctttaat ctctttaag ttaaggatt aacttaat atg aac aaa aat cgt tac 1496
Met Asn Lys Asn Arg Tyr
1 5

aaa ctc att ttt agt caa gtc aaa ggt tgt ctc gtt cct gtg gca gaa 1544
Lys Leu Ile Phe Ser Gln Val Lys Gly Cys Leu Val Pro Val Ala Glu
10 15 20

tgt att aac tca gct att agc aat ggt tca tct gat tca aca tcc aca 1592
Cys Ile Asn Ser Ala Ile Ser Asn Gly Ser Ser Asp Ser Thr Ser Thr
25 30 35

tca gaa caa gtt gaa gag gaa cct ttc ctt cta gaa caa tat tca ctt 1640
Ser Glu Gln Val Glu Glu Glu Pro Phe Leu Leu Glu Gln Tyr Ser Leu
40 45 50

tcc tcc gtg tct tta tta gta aaa agc acg ttc aat cct gtt tcg tat 1688
Ser Ser Val Ser Leu Leu Val Lys Ser Thr Phe Asn Pro Val Ser Tyr
55 60 65 70

gca atg caa ttg act tgg aaa cag ctt tct att tta ttt tta act gtg 1736
Ala Met Gln Leu Thr Trp Lys Gln Leu Ser Ile Leu Phe Leu Thr Val
75 80 85

att tct gtt cct gtt ttg gct gag gga aaa ggg gat gaa aga aat caa 1784
Ile Ser Val Pro Val Leu Ala Glu Gly Lys Gly Asp Glu Arg Asn Gln
90 95 100

tta aca gtg att gat aat agc gat cat att aaa tta gat gca tct aat 1832
Leu Thr Val Ile Asp Asn Ser Asp His Ile Lys Leu Asp Ala Ser Asn
105 110 115

ctt gct ggt aat gat aaa aca aaa atc tat caa gca gaa aat aaa gtt 1880
Leu Ala Gly Asn Asp Lys Thr Lys Ile Tyr Gln Ala Glu Asn Lys Val
120 125 130

```

WO 02/075507

PCT/US02/01971

ctg gtt att gat att gct aaa cca aat ggg aaa ggg att tca gat aac 1928  
 Leu Val Ile Asp Ile Ala Lys Pro Asn Gly Lys Gly Ile Ser Asp Asn  
 135 140 145 150  
 cgt ttt gaa aaa ttt aat att cca aat agc gcg gtg ttt aat aat aat 1976  
 Arg Phe Glu Lys Phe Asn Ile Pro Asn Ser Ala Val Phe Asn Asn Asn  
 155 160 165  
 ggg act gaa gcg cag gca aga tca aca tta att ggt tac att ccg caa 2024  
 Gly Thr Glu Ala Gln Ala Arg Ser Thr Leu Ile Gly Tyr Ile Pro Gln  
 170 175 180  
 aat caa aat tta agg gga ggg aaa gaa gct gat gtt ata tta aat caa 2072  
 Asn Gln Asn Leu Arg Gly Gly Lys Glu Ala Asp Val Ile Leu Asn Gln  
 185 190 195  
 gtg aca ggt cct caa gaa agt aaa att gtt ggc gcg ctt gaa gta tta 2120  
 Val Thr Gly Pro Gln Glu Ser Lys Ile Val Gly Ala Leu Glu Val Leu  
 200 205 210  
 ggt aaa aaa gct gat atc gtc att gca aac caa aat ggt att acc tta 2168  
 Gly Lys Lys Ala Asp Ile Val Ile Ala Asn Gln Asn Gly Ile Thr Leu  
 215 220 225 230  
 aat ggt gta aga aca ata aat tca gat cgt ttt gtt gcc act acg agt 2216  
 Asn Gly Val Arg Thr Ile Asn Ser Asp Arg Phe Val Ala Thr Thr Ser  
 235 240 245  
 gag ctt ata gat ccg aat cag atg atg tta aag gtt aca aaa gga aat 2264  
 Glu Leu Ile Asp Pro Asn Gln Met Met Leu Lys Val Thr Lys Gly Asn  
 250 255 260  
 gtg atc att gat att gat ggt ttt tcg aca gat gga tta aag tat tta 2312  
 Val Ile Ile Asp Ile Asp Gly Phe Ser Thr Asp Gly Leu Lys Tyr Leu  
 265 270 275  
 gat att att gct aaa aaa att gaa caa aag caa tca att aca tca ggg 2360  
 Asp Ile Ile Ala Lys Lys Ile Glu Gln Lys Gln Ser Ile Thr Ser Gly  
 280 285 290  
 gat aat tca gaa gca aaa aca gat gtc act ctt att gcg ggt tcc agt 2408  
 Asp Asn Ser Glu Ala Lys Thr Asp Val Thr Leu Ile Ala Gly Ser Ser  
 295 300 305 310  
 gaa tat gat tta agc aaa cat gag ctg aaa aaa acg agc ggt gaa aat 2456  
 Glu Tyr Asp Leu Ser Lys His Glu Leu Lys Lys Thr Ser Gly Glu Asn  
 315 320 325  
 gta tct aat gat gtt att gct atc acg gga tct agt aca ggc gca atg 2504  
 Val Ser Asn Asp Val Ile Ala Ile Thr Gly Ser Ser Thr Gly Ala Met  
 330 335 340  
 cat ggt aaa aat att aag ttg att gtg aca gat aaa ggt gca ggc gta 2552  
 His Gly Lys Asn Ile Lys Leu Ile Val Thr Asp Lys Gly Ala Gly Val  
 345 350 355  
 aaa cat gat gga att att ttg tct gaa aat gat att cag att gaa atg 2600  
 Lys His Asp Gly Ile Ile Leu Ser Glu Asn Asp Ile Gln Ile Glu Met  
 360 365 370  
 aat gaa ggt gac tta gaa ctt ggc aat acg att cag caa aca gtg gta 2648  
 Asn Glu Gly Asp Leu Glu Leu Gly Asn Thr Ile Gln Gln Thr Val Val  
 375 380 385 390



WO 02/075507

PCT/US02/01971

```

aaa aaa gac cga aat att cga gcc aag aaa aaa att gaa gtg aaa aac 2696
Lys Lys Asp Arg Asn Ile Arg Ala Lys Lys Lys Ile Glu Val Lys Asn
395 400 405

gct aat cgt gtt ttt gtt ggt agt caa acg aaa tca gat gaa att tcg 2744
Ala Asn Arg Val Phe Val Gly Ser Gln Thr Lys Ser Asp Glu Ile Ser
410 415 420

tta gag gcg aaa caa gtt aaa atc aga aaa aac gca gag att agg agt 2792
Leu Glu Ala Lys Lys Val Lys Ile Arg Lys Asn Ala Glu Ile Arg Ser
425 430 435

acg aca caa gcc aaa atc gta gca aag ggt gcc ctg tct att gag caa 2840
Thr Thr Gln Ala Lys Ile Val Ala Lys Gly Ala Leu Ser Ile Glu Gln
440 445 450

aat gcg aag ctc gtc gct aaa aag ata gat gtg gca aca gaa act cta 2888
Asn Ala Lys Leu Val Ala Lys Lys Ile Asp Val Ala Thr Glu Thr Leu
455 460 465

act aat gct ggg cgt att tat ggt cga gag gtt aag ctt gac act aat 2936
Thr Asn Ala Gly Arg Ile Tyr Gly Arg Glu Val Lys Leu Asp Thr Asn
475 480 485

aat ttg att aat gat aaa gaa att tat gct gaa cgg aaa ttg agt att 2984
Asn Leu Ile Asn Asp Lys Glu Ile Tyr Ala Glu Arg Lys Leu Ser Ile
490 495 500

ttg acg aaa gga aaa gat ctt gaa att att caa gat aga tat ttg tct 3032
Leu Thr Lys Gly Lys Asp Leu Glu Ile Ile Gln Asp Arg Tyr Leu Ser
505 510 515

cca ctg atg cgc gta aaa agt agt gtc cgc ttt tta ggc tct ccg ttt 3080
Pro Leu Met Arg Val Lys Ser Ser Val Arg Phe Leu Gly Ser Pro Phe
520 525 530

ttc tca ata tct ccg tcg atg ctc gca agc ctt agt gca cag ttt aag 3128
Phe Ser Ile Ser Pro Ser Met Leu Ala Ser Leu Ser Ala Gln Phe Lys
535 540 545

cct ggt ttt gtg aat aag gga ctc att gaa agt ccg ggg agt gca gaa 3176
Pro Gly Phe Val Asn Lys Gly Leu Ile Glu Ser Ala Gly Ser Ala Glu
555 560 565

tta act ttt aaa gaa aaa acc agt ttt tta aca gag ggc aat aat ttt 3224
Leu Thr Phe Lys Glu Lys Thr Ser Phe Leu Thr Glu Gly Asn Asn Phe
570 575 580

att aga gct aaa gat gcg tta ac 3247
Ile Arg Ala Lys Asp Ala Leu
585

```

<210> 18  
 <211> 589  
 <212> PRT  
 <213> Pasteurella multocida

<400> 18  
 Met Asn Lys Asn Arg Tyr Lys Leu Ile Phe Ser Gln Val Lys Gly Cys  
 1 5 10 15

WO 02/075507

PCT/US02/01971

Leu Val Pro Val Ala Glu Cys Ile Asn Ser Ala Ile Ser Asn Gly Ser  
                   20                  25                  30  
 Ser Asp Ser Thr Ser Thr Ser Glu Gln Val Glu Glu Pro Phe Leu  
                   35                  40                  45  
 Leu Glu Gln Tyr Ser Leu Ser Ser Val Ser Leu Leu Val Lys Ser Thr  
                   50                  55                  60  
 Phe Asn Pro Val Ser Tyr Ala Met Gln Leu Thr Trp Lys Gln Leu Ser  
                   65                  70                  75                  80  
 Ile Leu Phe Leu Thr Val Ile Ser Val Pro Val Leu Ala Glu Gly Lys  
                   85                  90                  95  
 Gly Asp Glu Arg Asn Gln Leu Thr Val Ile Asp Asn Ser Asp His Ile  
                   100                  105                  110  
 Lys Leu Asp Ala Ser Asn Leu Ala Gly Asn Asp Lys Thr Lys Ile Tyr  
                   115                  120                  125  
 Gln Ala Glu Asn Lys Val Leu Val Ile Asp Ile Ala Lys Pro Asn Gly  
                   130                  135                  140  
 Lys Gly Ile Ser Asp Asn Arg Phe Glu Lys Phe Asn Ile Pro Asn Ser  
                   145                  150                  155                  160  
 Ala Val Phe Asn Asn Asn Gly Thr Glu Ala Gln Ala Arg Ser Thr Leu  
                   165                  170                  175  
 Ile Gly Tyr Ile Pro Gln Asn Gln Asn Leu Arg Gly Gly Lys Glu Ala  
                   180                  185                  190  
 Asp Val Ile Leu Asn Gln Val Thr Gly Pro Gln Glu Ser Lys Ile Val  
                   195                  200                  205  
 Gly Ala Leu Glu Val Leu Gly Lys Lys Ala Asp Ile Val Ile Ala Asn  
                   210                  215                  220  
 Gln Asn Gly Ile Thr Leu Asn Gly Val Arg Thr Ile Asn Ser Asp Arg  
                   225                  230                  235                  240  
 Phe Val Ala Thr Thr Ser Glu Leu Ile Asp Pro Asn Gln Met Met Leu  
                   245                  250                  255  
 Lys Val Thr Lys Gly Asn Val Ile Ile Asp Ile Asp Gly Phe Ser Thr  
                   260                  265                  270  
 Asp Gly Leu Lys Tyr Leu Asp Ile Ile Ala Lys Lys Ile Glu Gln Lys  
                   275                  280                  285  
 Gln Ser Ile Thr Ser Gly Asp Asn Ser Glu Ala Lys Thr Asp Val Thr  
                   290                  295                  300  
 Leu Ile Ala Gly Ser Ser Glu Tyr Asp Leu Ser Lys His Glu Leu Lys  
                   305                  310                  315                  320  
 Lys Thr Ser Gly Glu Asn Val Ser Asn Asp Val Ile Ala Ile Thr Gly  
                   325                  330                  335  
 Ser Ser Thr Gly Ala Met His Gly Lys Asn Ile Lys Leu Ile Val Thr  
                   340                  345                  350

WO 02/075507

PCT/US02/01971

```

Asp Lys Gly Ala Gly Val Lys His Asp Gly Ile Ile Leu Ser Glu Asn
 355                360                365
Asp Ile Gln Ile Glu Met Asn Glu Gly Asp Leu Glu Leu Gly Asn Thr
 370                375                380
Ile Gln Gln Thr Val Val Lys Lys Asp Arg Asn Ile Arg Ala Lys Lys
 385                390                395
Lys Ile Glu Val Lys Asn Ala Asn Arg Val Phe Val Gly Ser Gln Thr
 405                410                415
Lys Ser Asp Glu Ile Ser Leu Glu Ala Lys Gln Val Lys Ile Arg Lys
 420                425                430
Asn Ala Glu Ile Arg Ser Thr Thr Gln Ala Lys Ile Val Ala Lys Gly
 435                440                445
Ala Leu Ser Ile Glu Gln Asn Ala Lys Leu Val Ala Lys Lys Ile Asp
 450                455                460
Val Ala Thr Glu Thr Leu Thr Asn Ala Gly Arg Ile Tyr Gly Arg Glu
 465                470                475
Val Lys Leu Asp Thr Asn Asn Leu Ile Asn Asp Lys Glu Ile Tyr Ala
 485                490                495
Glu Arg Lys Leu Ser Ile Leu Thr Lys Gly Lys Asp Leu Glu Ile Ile
 500                505                510
Gln Asp Arg Tyr Leu Ser Pro Leu Met Arg Val Lys Ser Ser Val Arg
 515                520                525
Phe Leu Gly Ser Pro Phe Phe Ser Ile Ser Pro Ser Met Leu Ala Ser
 530                535                540
Leu Ser Ala Gln Phe Lys Pro Gly Phe Val Asn Lys Gly Leu Ile Glu
 545                550                555
Ser Ala Gly Ser Ala Glu Leu Thr Phe Lys Glu Lys Thr Ser Phe Leu
 565                570                575
Thr Glu Gly Asn Asn Phe Ile Arg Ala Lys Asp Ala Leu
 580                585

<210> 19
<211> 3247
<212> DNA
<213> Pasteurella multocida

<220>
<221> CDS
<222> (1)..(1446)

<220>
<223> fhaC

<400> 19
gtc gac ctt gcg ggt gaa aag gta tct cta aat ttt ggc gat atc att 48
Val Asp Leu Ala Gly Glu Lys Val Ser Leu Asn Phe Gly Asp Ile Ile
 1                5                10                15

```

WO 02/075507

PCT/US02/01971

```

cat gct tac caa aac cag ccc cta tca aca aaa gtt gtt ttt caa tta 96
His Ala Tyr Gln Asn Gln Pro Leu Ser Thr Lys Val Val Phe Gln Leu
      20                25                30
gtg aaa gat ttg acg gaa gtt tta tac cgt tct ggc tac gtg aca agt 144
Val Lys Asp Leu Thr Glu Val Leu Tyr Arg Ser Gly Tyr Val Thr Ser
      35                40                45
gca att ggt tta aaa aat tca aaa atc agc aat ggc gat ctt gaa ttt 192
Ala Ile Gly Leu Lys Asn Ser Lys Ile Ser Asn Gly Asp Leu Glu Phe
      50                55                60
att gta ctg tgg gga aga act cgc gat ctg ttt gtg aat ggg gag aaa 240
Ile Val Leu Trp Gly Arg Thr Arg Asp Leu Phe Val Asn Gly Glu Lys
      65                70                75                80
cca acc cgt ttt aga gat aaa aca atg tta tca gtc cta ccc aat tta 288
Pro Thr Arg Phe Arg Asp Lys Thr Met Leu Ser Val Leu Pro Asn Leu
      85                90                95
atc gga aat cgc tta agt att cac gac att gac cag ttg atc gaa atc 336
Ile Gly Asn Arg Leu Ser Ile His Asp Ile Asp Gln Leu Ile Glu Ile
      100               105               110
tta aat act acg aat aaa aaa gcc aca gtg aat gtg gtt gca agt gaa 384
Leu Asn Thr Thr Asn Lys Lys Ala Thr Val Asn Val Val Ala Ser Glu
      115               120               125
gaa aaa ggc agc tca aat cta aat att gaa aga caa tat gat gtt ttt 432
Glu Lys Gly Ser Ser Asn Leu Asn Ile Glu Arg Gln Tyr Asp Val Phe
      130               135               140
ccg caa gtg agt gtc gga ttc aat aat tca ggt gct ggc aat aat gcc 480
Pro Gln Val Ser Val Gly Phe Asn Asn Ser Gly Ala Gly Asn Asn Ala
      145               150               155               160
aat ggg cgt aat caa gct aca ttg aat att gct tgg agt gat cta tta 528
Asn Gly Arg Asn Gln Ala Thr Leu Asn Ile Ala Trp Ser Asp Leu Leu
      165               170               175
ggc acg aat gat cgt tgg agt ttc tcg agt agt tac cgt tta tat aaa 576
Gly Thr Asn Asp Arg Trp Ser Phe Ser Ser Ser Tyr Arg Leu Tyr Lys
      180               185               190
aat cat cat gct aac cag caa cgc aat tat act ttg tct tac agt cag 624
Asn His His Ala Asn Gln Gln Arg Asn Tyr Thr Leu Ser Tyr Ser Gln
      195               200               205
cct ata ggc ttt tct aca gta gaa att aaa gca tcg gaa tct acg tat 672
Pro Ile Gly Phe Ser Thr Val Glu Ile Lys Ala Ser Glu Ser Thr Tyr
      210               215               220
gaa aaa gaa ctt cgc ggt ata aat act cat tct tct cat ggg aaa acc 720
Glu Lys Glu Leu Arg Gly Ile Asn Thr His Ser Ser His Gly Lys Thr
      225               230               235               240
caa agc tta gct gtc aag ctg atg cat gtg tta ttg cgt aat aag gag 768
Gln Ser Leu Ala Val Lys Leu Met His Val Leu Leu Arg Asn Lys Glu
      245               250               255
agt att tta tct aca tat acc gag ttc gag ttt aaa aaa cgg att agt 816
Ser Ile Leu Ser Thr Tyr Thr Glu Phe Glu Phe Lys Lys Arg Ile Ser
      260               265               270

```

WO 02/075507

PCT/US02/01971

tat ttt tct gat att ttg att ggg aaa tat cac aat aat aaa gtg agc 864  
 Tyr Phe Ser Asp Ile Leu Ile Gly Lys Tyr His Asn Asn Lys Val Ser  
 275 280 285

gta ggg tta tct tac atg act aat ttt gct tac ggg aag ctt tac agc 912  
 Val Gly Leu Ser Tyr Met Thr Asn Phe Ala Tyr Gly Lys Leu Tyr Ser  
 290 295 300

gac att gct tac gcg aat ggg ttg aga tgg ttt ggg gcg aat tat tca 960  
 Asp Ile Ala Tyr Ala Asn Gly Leu Arg Trp Phe Gly Ala Asn Tyr Ser  
 305 310 315 320

gca tat gat gca aat cgt gaa aaa acc tta aaa tta ttg tca gga agt 1008  
 Ala Tyr Asp Ala Asn Arg Glu Lys Thr Leu Lys Leu Leu Ser Gly Ser  
 325 330 335

att aat tgg cag cgt cca ata tcc ctg ttt gaa cgt gcg atg aat tat 1056  
 Ile Asn Trp Gln Arg Pro Ile Ser Leu Phe Glu Arg Ala Met Asn Tyr  
 340 345 350

caa tta cgt att ggt gcc caa tat ggt ttt gat agt ttg tat tct gaa 1104  
 Gln Leu Arg Ile Gly Ala Gln Tyr Gly Phe Asp Ser Leu Tyr Ser Glu  
 355 360 365

aat caa ttt tca att ggt gat gaa tat aca gta aga gga ttt aaa ggt 1152  
 Asn Gln Phe Ser Ile Gly Asp Glu Tyr Thr Val Arg Gly Phe Lys Gly  
 370 375 380

ggt gcg gtt tct ggt gat agt ggt gcg tat tta tca caa aca ctg acg 1200  
 Gly Ala Val Ser Gly Asp Ser Gly Ala Tyr Leu Ser Gln Thr Leu Thr  
 385 390 395 400

gtt cct ttt tat cca caa aaa gca tat tta tct cag gta tcc cct ttt 1248  
 Val Pro Phe Tyr Pro Gln Lys Ala Tyr Leu Ser Gln Val Ser Pro Phe  
 405 410 415

att gga ttt gat atg ggt aaa gta cat att aaa tca aag cat aaa aca 1296  
 Ile Gly Phe Asp Met Gly Lys Val His Ile Lys Ser Lys His Lys Thr  
 420 425 430

acc act tta gtc ggt ttt gcc cta gcc ttg aaa acg caa ata aag tta 1344  
 Thr Thr Leu Val Gly Phe Ala Leu Gly Leu Lys Thr Gln Ile Lys Leu  
 435 440 445

ttt tca tta tca tta acc tat gca caa cca atg aat ggt gtg agt ggt 1392  
 Phe Ser Leu Ser Leu Thr Tyr Ala Gln Pro Met Asn Gly Val Ser Gly  
 450 455 460

gtt acg caa cat cgt caa aaa cgg att tat tat ttc tca gga tca ctt 1440  
 Val Thr Gln His Arg Gln Lys Pro Ile Tyr Tyr Phe Ser Gly Ser Leu  
 465 470 475 480

tct ttt taactcttt taagtttaag gattaactta atatgaacaa aaatcgttac 1496  
 Ser Phe

aaactcattt ttagtcaagt caaaggttgt ctgcttctg tggcagaatg tattaactca 1556

gctattagca atggttcacg tgattcaaca tccacatcag aacaagttga agaggaacct 1616

ttcctctbag aacaatatcc actttctctc gtgtctttat tagtaaaaag cacttcaat 1676

cctgcttctg atgcaatgca attgacttgg aaacagcttt ctattttatt ttttaactgtg 1736

WO 02/075507

PCT/US02/01971

```

atctctgttc ctgttttggc tgagggaaaa ggggatgaaa gaaatcaatt aacagtgatt 1796
gataatagcg atcatattaa attagatgca tctaattctg ctggtaatga taaaacaaaa 1856
atctatcaag cagaaaaataa agttctggtt attgatattg ctaaaccaaa tgggaaaggg 1916
atctcagata accgtrttga aaaatttaat attccaaata gcgcgggtgt taataataat 1976
gggactgaag cgcaggcaag atcaacatta attggttaca ttccgcaaaa tcaaaattha 2036
aggggagggg aagaagctga tgttatatta aatcaagtga caggtcctca agaaagtaaa 2096
attgttggcg cgcttgaagt attaggtaaa aaagctgata tcgtcattgc aaaccaaat 2156
ggttattacct taaatgggtt aagaacaata aattcagatc gttttgttgc cactacgagt 2216
gagcttag atccgaatca gatgatgta aaggttaca aaggaatgt gatcattgat 2276
attgatggtt ttccgacaga tggattaag tatttagata ttattgctaa aaaaatgaa 2336
caaaagcaat caattacatc aggggataat tcagaagcaa aaacagatgt cactcttatt 2396
gcgggttcca gtgaatatga ttttaagcaaa catgagctga aaaaaacgag cggtgaaaaa 2456
gtatcfaatg atgttattgc tatcacggga tctagtacag gcgcaatgca tggtaaaaa 2516
attaagtga tctgacaga taaagtgca ggcgtaaaac atgatggaat tattttgtct 2576
gaaaatgata ttcagattga aatgaatgaa ggtgacttag aacttggcaa tacgattcag 2636
caaacagtg cgtgaaatga cgcgaatatt cgagccaaga aaaaaattga agtgaaaaac 2696
gctaactcgt tttttgtg tagtcaaacg aaatcagatg aaatttcgtt agaggcgaaa 2756
caagttaaaa tcagaaaaaa cgcagagatt aggagtacga cacaaacca aatcgtagca 2816
aaggggtccc tctctattga gcaaaatgcg aagctcgtcg ctaaaaagat agatgtggca 2876
acagaaactc taactaatgc tggcgtatt tatggtcag aggttaagct tgacactaat 2936
aatttgatta atgataaaga aatttatgct gaacggaaat tgagtatttt gacgaaagga 2996
aaagatcttg aaattattca agatagatat ttgtctccac tgatgcgcgt aaaaagttagt 3056
gtccgctttt taggctctcc gttttctca atatctcctg cgatgctcgc aagccttagt 3116
gcacagttta agcctgggtt tgtgaataag ggaactcattg aaagtgcggg gagtgcagaa 3176
ttaacttta aagaaaaaac cagttttta acagagggca ataattttat tagagctaaa 3236
gatgcgttaa c 3247

```

```

<210> 20
<211> 482
<212> PRT
<213> Pasteurella multocida

```

```

<400> 20
Val Asp Leu Ala Gly Glu Lys Val Ser Leu Asn Phe Gly Asp Ile Ile
1 5 10 15

```

WO 02/075507

PCT/US02/01971

His Ala Tyr Gln Asn Gln Pro Leu Ser Thr Lys Val Val Phe Gln Leu  
 20 25 30  
 Val Lys Asp Leu Thr Glu Val Leu Tyr Arg Ser Gly Tyr Val Thr Ser  
 35 40 45  
 Ala Ile Gly Leu Lys Asn Ser Lys Ile Ser Asn Gly Asp Leu Glu Phe  
 50 55 60  
 Ile Val Leu Trp Gly Arg Thr Arg Asp Leu Phe Val Asn Gly Glu Lys  
 65 70 75 80  
 Pro Thr Arg Phe Arg Asp Lys Thr Met Leu Ser Val Leu Pro Asn Leu  
 85 90 95  
 Ile Gly Asn Arg Leu Ser Ile His Asp Ile Asp Gln Leu Ile Glu Ile  
 100 105 110  
 Leu Asn Thr Thr Asn Lys Lys Ala Thr Val Asn Val Val Ala Ser Glu  
 115 120 125  
 Glu Lys Gly Ser Ser Asn Leu Asn Ile Glu Arg Gln Tyr Asp Val Phe  
 130 135 140  
 Pro Gln Val Ser Val Gly Phe Asn Asn Ser Gly Ala Gly Asn Asn Ala  
 145 150 155 160  
 Asn Gly Arg Asn Gln Ala Thr Leu Asn Ile Ala Trp Ser Asp Leu Leu  
 165 170 175  
 Gly Thr Asn Asp Arg Trp Ser Phe Ser Ser Ser Tyr Arg Leu Tyr Lys  
 180 185 190  
 Asn His His Ala Asn Gln Gln Arg Asn Tyr Thr Leu Ser Tyr Ser Gln  
 195 200 205  
 Pro Ile Gly Phe Ser Thr Val Glu Ile Lys Ala Ser Glu Ser Thr Tyr  
 210 215 220  
 Glu Lys Glu Leu Arg Gly Ile Asn Thr His Ser Ser His Gly Lys Thr  
 225 230 235 240  
 Gln Ser Leu Ala Val Lys Leu Met His Val Leu Leu Arg Asn Lys Glu  
 245 250 255  
 Ser Ile Leu Ser Thr Tyr Thr Glu Phe Glu Phe Lys Lys Arg Ile Ser  
 260 265 270  
 Tyr Phe Ser Asp Ile Leu Ile Gly Lys Tyr His Asn Asn Lys Val Ser  
 275 280 285  
 Val Gly Leu Ser Tyr Met Thr Asn Phe Ala Tyr Gly Lys Leu Tyr Ser  
 290 295 300  
 Asp Ile Ala Tyr Ala Asn Gly Leu Arg Trp Phe Gly Ala Asn Tyr Ser  
 305 310 315 320  
 Ala Tyr Asp Ala Asn Arg Glu Lys Thr Leu Lys Leu Leu Ser Gly Ser  
 325 330 335  
 Ile Asn Trp Gln Arg Pro Ile Ser Leu Phe Glu Arg Ala Met Asn Tyr  
 340 345 350

WO 02/075507

PCT/US02/01971

Gln Leu Arg Ile Gly Ala Gln Tyr Gly Phe Asp Ser Leu Tyr Ser Glu  
 355 360 365  
 Asn Gln Phe Ser Ile Gly Asp Glu Tyr Thr Val Arg Gly Phe Lys Gly  
 370 375 380  
 Gly Ala Val Ser Gly Asp Ser Gly Ala Tyr Leu Ser Gln Thr Leu Thr  
 385 390 395 400  
 Val Pro Phe Tyr Pro Gln Lys Ala Tyr Leu Ser Gln Val Ser Pro Phe  
 405 410 415  
 Ile Gly Phe Asp Met Gly Lys Val His Ile Lys Ser Lys His Lys Thr  
 420 425 430  
 Thr Thr Leu Val Gly Phe Ala Leu Gly Leu Lys Thr Gln Ile Lys Leu  
 435 440 445  
 Phe Ser Leu Ser Leu Thr Tyr Ala Gln Pro Met Asn Gly Val Ser Gly  
 450 455 460  
 Val Thr Gln His Arg Gln Lys Pro Ile Tyr Tyr Phe Ser Gly Ser Leu  
 465 470 475 480  
 Ser Phe

<210> 21  
 <211> 1170  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (639)...(1022)

<220>  
 <223> greA

<400> 21  
 gtcaacaaac ggcaaccact tggcaaaaa gogattgogc ttgtgtctcg ctctaagctc 60  
 aagcgttggg atcgcgcgaa ttgcgltgac cactggtgag atcggggtea cctgtaaaac 120  
 gtacgataag atcgcgatgc atttcattgt tttttatttt tccattgggtt aatagaactgg 180  
 ttcaaatgg aaattgggta cttagtacga gtttggcggg taaggcggg agcaacttttt 240  
 gtgtactggc gggtaacata aagggtactgg cttgggtgogc tacaattttt tcattacgat 300  
 ttaagttttt agccacaaaa cctaggctgg tcccttcggg taaatgagcg ttgatttcag 360  
 caagatcaat ctcagcataa ctgaaatgac tgacgagtaa actacatata agtatcgttc 420  
 gtttgaaaag gcytaaaagc gtggcagtaa aaaaagaaga tattttatata ataattggct 480  
 cgagcagttg ctattttttt attgtcgaac aataatagta ttgaaacct cgagagtaaa 540  
 tccctttctc gttaaacct tattttttta ttaactacy gcattgtttt tacaatgctg 600



WO 02/075507

PCT/US02/01971

```

rggttttggtt tttatctaaa aaggaagaaa aaacgatt atg aaa cag att cca atg 656
Met Lys Gln Ile Pro Met
1 5

act ata cgt ggt gcg gaa caa tta aga caa gaa ctc gat ttt ttg aaa 704
Thr Ile Arg Gly Ala Glu Gln Leu Arg Gln Glu Leu Asp Phe Leu Lys
10 15 20

aac act cgt cgc cca gaa att att aat gct atc gca gaa gct cgt gaa 752
Asn Thr Arg Arg Pro Glu Ile Ile Asn Ala Ile Ala Glu Ala Arg Glu
25 30 35

cat ggc gat cta aaa gaa aat gca gaa tac cat gct gcg cgt gaa cag 800
His Gly Asp Leu Lys Glu Asn Ala Glu Tyr His Ala Ala Arg Glu Gln
40 45 50

caa gga ttt tgt gaa gga cga atc caa gaa att gaa ggg aaa tta gcg 848
Gln Gly Phe Cys Glu Gly Arg Ile Gln Glu Ile Glu Gly Lys Leu Ala
55 60 65 70

aat agt caa att att gat gtc aca aag atc cca aat aat ggc aaa gtg 896
Asn Ser Gln Ile Ile Asp Val Thr Lys Ile Pro Asn Asn Gly Lys Val
75 80 85

att ttt ggt gcc aca att ttg tta ctg aat att gac acg gaa gaa gaa 944
Ile Phe Gly Ala Thr Ile Leu Leu Asn Ile Asp Thr Glu Glu Glu
90 95 100

gtc tcg tac caa att gta ggc gat gat gaa gcc aat att aaa gca ggg 992
Val Ser Tyr Gln Ile Val Gly Asp Asp Glu Ala Asn Ile Lys Ala Gly
105 110 115

cta att tca gtt aac gcc acg cga ttg aat tagagaaagc taaatggatt 1042
Leu Ile Ser Val Asn Ala Thr Arg Leu Asn
120 125

gcccaagatc ttggcgtcaa acaaacgtta attgacactt ccgtcattaa agcgattacg 1102
caaaatgcct taatggacga acaggcaaga attgagcaac atggcagtac accgaatact 1162
ttcgttga 1170

```

<210> 22  
<211> 128  
<212> PRT  
<213> Pasteurella multocida

```

<400> 22
Met Lys Gln Ile Pro Met Thr Ile Arg Gly Ala Glu Gln Leu Arg Gln
1 5 10 15
Glu Leu Asp Phe Leu Lys Asn Thr Arg Arg Pro Glu Ile Ile Asn Ala
20 25 30
Ile Ala Glu Ala Arg Glu His Gly Asp Leu Lys Glu Asn Ala Glu Tyr
35 40 45
His Ala Ala Arg Glu Gln Gln Gly Phe Cys Glu Gly Arg Ile Gln Glu
50 55 60
Ile Glu Gly Lys Leu Ala Asn Ser Gln Ile Ile Asp Val Thr Lys Ile
65 70 75 80

```

WO 02/075507

PCT/US02/01971

Pro Asn Asn Gly Lys Val Ile Phe Gly Ala Thr Ile Leu Leu Leu Asn  
85 90 95

Ile Asp Thr Glu Glu Val Ser Tyr Gln Ile Val Gly Asp Asp Glu  
100 105 110

Ala Asn Ile Lys Ala Gly Leu Ile Ser Val Asn Ala Thr Arg Leu Asn  
115 120 125

<210> 23  
<211> 4666  
<212> DNA  
<213> Pasteurella multocida

<220>  
<221> CDS  
<222> (980)..(2440)

<220>  
<223> guaB

<400> 23  
aacacatgaa cctcttcccc aaaatacgca tccatatctc gccaatcttg gcgaaatgct 60  
tcatcaaltc ctgcttgctc aaaatgttgt aaacgtgcaa tcaacttttt acctaatctc 120  
gcgatcaatt tattccgac aatcgttgtt aatactcaa tcagctctgc ccaaggttga 180  
tcaatttgct gtgtttgttt tgggaaagac aaattaatgc caaagccaat cagcagatta 240  
tgttgattat tctgacgatt ggcgatttcg accaaaatcc ctgctaattt gcgcccattg 300  
aatagcaaat catttggcca ttttaatacca atgttcaaac caactgcttg ctttagcgtt 360  
tctgogattg coatacccaac tactaaactc aagccttcta aattgacctt ttggtcacat 420  
gcccaataca aactcataat cacttgcca gcaaaaggag aaagccattg acgaccacgt 480  
cgtccacgtc cgcagtttg atattctgct aagcaaatag cgcttttttc caaatgtgca 540  
atattgtcaa gcaagaattg attggtcgag ttaataatcg gcttaataata aagtgggtaa 600  
gggtgtaacg cttgctgcaa ataagattca ttaagcgcac ttaattgagg tatgagacga 660  
aaatgttggc cttgctgttc tatttgtatc cctgttgtt tcaatttttc gatattggtg 720  
aagatatcct gttctgaata acctaaaagt gcagtcgaat ctgctaagaa aagtgttga 780  
tagctaagca gtaatgcaag tacgttttgc ataaaaatcc ttatttatat aaccaagag 840  
aggcaactta ttatagacaa tgattttctc gaaaatcgat aaaaaaatcc attttcaaac 900  
agcaacgaaa tctgtataat ggcaccgcaa tattttttac ccttttattt tccatatcaa 960  
cctaagagag aatattgca atg tta cga gta ata aaa gaa gca tta acc ttc 1012  
Met Leu Arg Val Ile Lys Glu Ala Leu Thr Phe  
1 5 10  
gat gat gtt ttg ctt gtc cca gca cat tct act gtg ctc cca aat acc 1060  
Asp Asp Val Leu Leu Val Pro Ala His Ser Thr Val Leu Pro Asn Thr  
15 20 25

WO 02/075507

PCT/US02/01971

gca gac ctt tcc act caa ctc acc aaa act atc cgc ctc aat atc cca 1108  
Ala Asp Leu Ser Thr Gln Leu Thr Lys Thr Ile Arg Leu Asn Ile Pro  
30 35 40  
atg tta tcc gcc gcc atg gat acc gtg aca gaa act aaa ctg gca atc 1156  
Met Leu Ser Ala Ala Met Asp Thr Val Thr Glu Thr Lys Leu Ala Ile  
45 50 55  
tct ctt gca caa gaa ggt ggc atc ggg ttt att cat aaa aat atg tct 1204  
Ser Leu Ala Gln Glu Gly Gly Ile Gly Phe Ile His Lys Asn Met Ser  
60 65 70 75  
att gag cgt caa gcg gaa cgt gtc cgc aaa gtg aaa aaa ttt gag agc 1252  
Ile Glu Arg Gln Ala Glu Arg Val Arg Lys Val Lys Lys Phe Glu Ser  
80 85 90  
ggg att gta tcc gat cct gtc acc gtt tca cca acc tta tct tta gca 1300  
Gly Ile Val Ser Asp Pro Val Thr Val Ser Pro Thr Leu Ser Leu Ala  
95 100 105  
gaa tta agt gaa tta gtg aag aaa aat ggt ttt gcg agt ttc cct gtt 1348  
Glu Leu Ser Glu Leu Val Lys Lys Asn Gly Phe Ala Ser Phe Pro Val  
110 115 120  
ggt gat gat gaa aaa aat ctt gtc ggt atc att act ggt cgt gat aca 1396  
Val Asp Asp Glu Lys Asn Leu Val Gly Ile Ile Thr Gly Arg Asp Thr  
125 130 135  
cgc ttt gtc acg gat tta aat aaa aca gtg gcg gac ttt atg acc cct 1444  
Arg Phe Val Thr Asp Leu Asn Lys Thr Val Ala Asp Phe Met Thr Pro  
140 145 150 155  
aaa gct cgt ctt gtc acg gtg aaa cgc aat gca agt cgc gat gaa att 1492  
Lys Ala Arg Leu Val Thr Val Lys Arg Asn Ala Ser Arg Asp Glu Ile  
160 165 170  
ttt ggt cta atg cat aca cac cgt gta gaa aaa gtc ctt gtt gtc agc 1540  
Phe Gly Leu Met His Thr His Arg Val Glu Lys Val Leu Val Val Ser  
175 180 185  
gac gat ttc aaa tta aaa ggc atg atc acc tta aaa gac tac caa aaa 1588  
Asp Asp Phe Lys Leu Lys Gly Met Ile Thr Leu Lys Asp Tyr Gln Lys  
190 195 200  
tcc gag caa aaa cca caa gcc tgt aaa gat gaa ttt ggt cgt tta cgt 1636  
Ser Glu Gln Lys Pro Gln Ala Cys Lys Asp Glu Phe Gly Arg Leu Arg  
205 210 215  
gtc ggt gct gca gta gga gca gga cct ggt aat gaa gaa cgt att gat 1684  
Val Gly Ala Ala Val Gly Ala Gly Pro Gly Asn Glu Glu Arg Ile Asp  
220 225 230 235  
gca tta gtg aaa gca ggg gtc gat gtg tta ttg att gac tca tca cac 1732  
Ala Leu Val Lys Ala Gly Val Asp Val Leu Leu Ile Asp Ser Ser His  
240 245 250  
ggg cat tca gaa ggt gtg tta caa cgt gtg cgt gaa act cgt gcg aaa 1780  
Gly His Ser Glu Gly Val Leu Gln Arg Val Arg Glu Thr Arg Ala Lys  
255 260 265  
tac cca gat ttg cca att gtt gca ggt aat gtg gca acc gct gaa ggc 1828  
Tyr Pro Asp Leu Pro Ile Val Ala Gly Asn Val Ala Thr Ala Glu Gly  
270 275 280

WO 02/075507

PCT/US02/01971

gca att gcg ttg gct gat gca ggg gca agt gca gtg aaa gtg ggg att 1876  
 Ala Ile Ala Leu Ala Asp Ala Gly Ala Ser Ala Val Lys Val Gly Ile  
 285 290 295  
 ggt cct ggt tca att tgt aca aca cgt att gtc aca ggc gtg ggc gtt 1924  
 Gly Pro Gly Ser Ile Cys Thr Thr Arg Ile Val Thr Gly Val Gly Val  
 300 305 310 315  
 cca caa att aca gcg att gcc gat gcg gca gaa gca cta aaa gat cgg 1972  
 Pro Gln Ile Thr Ala Ile Ala Asp Ala Ala Glu Ala Leu Lys Asp Arg  
 320 325 330  
 ggt att cct gtg att gca gat ggc ggt atc cgt ttc tct ggt gat att 2020  
 Gly Ile Pro Val Ile Ala Asp Gly Gly Ile Arg Phe Ser Gly Asp Ile  
 335 340 345  
 tcg aaa gcc att gcg gcg ggc gcc tct tgt gtt atg gtg ggt tcc atg 2068  
 Ser Lys Ala Ile Ala Ala Gly Ala Ser Cys Val Met Val Gly Ser Met  
 350 355 360  
 ttt gca ggt aca gaa gaa gca cca ggt gaa atc gaa ctt tat caa ggt 2116  
 Phe Ala Gly Thr Glu Glu Ala Pro Gly Glu Ile Glu Leu Tyr Gln Gly  
 365 370 375  
 cgt gcc ttt aaa tct tat cga ggt atg gga tcg tta ggt gcg atg agc 2164  
 Arg Ala Phe Lys Ser Tyr Arg Gly Met Gly Ser Leu Gly Ala Met Ser  
 380 385 390 395  
 aaa ggc tca agc gac cgc tat ttc cag tcc gat aat gca gct gac aaa 2212  
 Lys Gly Ser Ser Asp Arg Tyr Phe Gln Ser Asp Asn Ala Ala Asp Lys  
 400 405 410  
 tta gta cca gaa ggt att gaa gga cgt att cca tat aaa gga ttc tta 2260  
 Leu Val Pro Glu Gly Ile Glu Gly Arg Ile Pro Tyr Lys Gly Phe Leu  
 415 420 425  
 aaa gaa att atc cat caa caa atg ggt gga ttg cgt tct tgt atg ggc 2308  
 Lys Glu Ile Ile His Gln Gln Met Gly Gly Leu Arg Ser Cys Met Gly  
 430 435 440  
 tta acg ggt tgt gca acc att gat gaa ctc cgt acc aaa gcg cag ttt 2356  
 Leu Thr Gly Cys Ala Thr Ile Asp Glu Leu Arg Thr Lys Ala Gln Phe  
 445 450 455  
 gtg cgc att agt ggt gca ggg atc caa gaa agc cat gtg cat gat gtg 2404  
 Val Arg Ile Ser Gly Ala Gly Ile Gln Glu Ser His Val His Asp Val  
 460 465 470 475  
 act atc aca aaa gaa gcc cct aat tat cgt atg ggt taaacattgc 2450  
 Thr Ile Thr Lys Glu Ala Pro Asn Tyr Arg Met Gly  
 480 485  
 ttagggtggg attatcccca cctaagtta ttttaataa caacgttaat agagaagctt 2510  
 attttatgt atggcattaa aattaaaaat gttattaaac tttttctatt aaagttttta 2570  
 agaataaat atcgatataa aatcaatatt caacatcatc tcattagtat tgaaggaaaa 2630  
 tgcggtgagt ttgatttaag ccagctaaac tatgtttatt tgggtgaaaga tcctgagata 2690  
 agaataatc gactgacct gtaactgaat gatttttca aaattgggtt aaattatcat 2750  
 ggatttactc aaatgtatca gacactatca tccaagtatg gttttgatga cgcaacgttt 2810

WO 02/075507

PCT/US02/01971

```

tttgaatc tttgtaagaa agggccttt tctattcaaa ttggcgtaa aaaacaaact 2870
caaaattatg tgattcttga tgaagcctat actgactata cacaaagttt tgaattcaa 2930
ctcctgaaa aaatatttat tcttggggg actacttatg aagcctatt tcagcagaca 2990
caatttaag aaaaggaat ctctatgac tttatctcc ctattcgat agggcgтта 3050
ttactcaagg atgtgtggat cacaccaagt gtccgaaaag atgtaccgat tttagcgtta 3110
tacctgagt gctatcatga atccgcgaca gaaaaagtt atcaggaatt aacgcgcga 3170
ttacgtgaga accaacagtt aatcagatca tgtgttgaag aacgagccga tccgaaatta 3230
tataagtctg ttttacgct taacgcgaca gaatttgaat tgcgttatta tcgacatata 3290
cgagacgatt ttgatagggg atacactaaa ttcagcatta gagatacgac agactattta 3350
gattatgtga tcaacgagcc ttatgaaaa caattagtga taacggatta tttagtatt 3410
gagggcgaaa atttaataaa aatgattat accgataatt ccattattaa acgcgcacca 3470
craaaataa aagaaaagt tctgtatgca caaagcctga ttgggacaga tgatctcaat 3530
cataaaatcg gttttaccag tgatgaccgc gctatcgtct ttgataaagc ggaattgaa 3590
tctttactc tggcaaatat agagacaacc cgaagacata atcgcagttc actcagcacc 3650
tgttttggg aaaaaataa ggaagccatc actgtatttc tagctgaaca tcattttctg 3710
ataccctatg tggataaaat aaaaacactg acacaaaaag aggtgttgtt tcttgaagaa 3770
tatatagagg atgttataaa aaccgataac atcttgatgt catcgcaaat tcaaacctct 3830
tttacacaat atatttaaac ttttaaccga ttttaattt acgtaaaaac aactaagaga 3890
acttaaatga acaacattca caaccataaa attttaatt tggactcgg ttcacaatat 3950
accagttga ttgcccgcg tgtaogtga attgccgtgt actgcgaact ttggcattgg 4010
gatgatccg aagccgatat tctgtgattt aatccaactg ggattattct ttctgggtgt 4070
cctgaaagta ccaactgaaga aaacagccca cgagctccc aatacgtatt caacgccggt 4130
gtaccgctat tagggatctg ttatgggatg caaacatgg cgatgcaact aggtggttta 4190
actgaaactt ctactcaccg agaatttggg tatgcatcag tgaatctaaa agccgcggac 4250
gcttatttg ctcaattaaa tgatgatgto gcaagttcac agcccaaat agacgtttgg 4310
atgagccatg cggataaagt gacgcgtttg ccagatcatt tccaagtcac cgcaatgacc 4370
tcaacctgto caatcgagc tatgtcggat gaacgtcgtc gtttttatgg tgtccaattc 4430
caccagaaag tgactcatac aaaaagcggg cttgaattat taacgaattt tgtggtgaag 4490
atctgtggtt gtgaacgtaa ctggacacca gaaaatatca ttgaagatgc cgttgctcgt 4550
cttaaaagc aagtgggcga tgatgaagt attttaggct tatctgggtg cgttaactgc 4610
cgtatagcca gcttagaaaa agtgtccgcg ctcaegttaa tcccctgaag cgttga 4666

```

WO 02/075507

PCT/US02/01971

```

<210> 24
<211> 487
<212> PFT
<213> Pasteurella multocida

<400> 24
Met Leu Arg Val Ile Lys Glu Ala Leu Thr Phe Asp Asp Val Leu Leu
 1           5           10           15
Val Pro Ala His Ser Thr Val Leu Pro Asn Thr Ala Asp Leu Ser Thr
 20           25           30
Gln Leu Thr Lys Thr Ile Arg Leu Asn Ile Pro Met Leu Ser Ala Ala
 35           40           45
Met Asp Thr Val Thr Glu Thr Lys Leu Ala Ile Ser Leu Ala Gln Glu
 50           55           60
Gly Gly Ile Gly Phe Ile His Lys Asn Met Ser Ile Glu Arg Gln Ala
 65           70           75
Glu Arg Val Arg Lys Val Lys Lys Phe Glu Ser Gly Ile Val Ser Asp
 85           90           95
Pro Val Thr Val Ser Pro Thr Leu Ser Leu Ala Glu Leu Ser Glu Leu
100           105           110
Val Lys Lys Asn Gly Phe Ala Ser Phe Pro Val Val Asp Asp Glu Lys
115           120           125
Asn Leu Val Gly Ile Ile Thr Gly Arg Asp Thr Arg Phe Val Thr Asp
130           135           140
Leu Asn Lys Thr Val Ala Asp Phe Met Thr Pro Lys Ala Arg Leu Val
145           150           155
Thr Val Lys Arg Asn Ala Ser Arg Asp Glu Ile Phe Gly Leu Met His
165           170           175
Thr His Arg Val Glu Lys Val Leu Val Val Ser Asp Asp Phe Lys Leu
180           185           190
Lys Gly Met Ile Thr Leu Lys Asp Tyr Gln Lys Ser Glu Gln Lys Pro
195           200           205
Gln Ala Cys Lys Asp Glu Phe Gly Arg Leu Arg Val Gly Ala Ala Val
210           215           220
Gly Ala Gly Pro Gly Asn Glu Glu Arg Ile Asp Ala Leu Val Lys Ala
225           230           235           240
Gly Val Asp Val Leu Leu Ile Asp Ser Ser His Gly His Ser Glu Gly
245           250           255
Val Leu Gln Arg Val Arg Glu Thr Arg Ala Lys Tyr Pro Asp Leu Pro
260           265           270
Ile Val Ala Gly Asn Val Ala Thr Ala Glu Gly Ala Ile Ala Leu Ala
275           280           285
Asp Ala Gly Ala Ser Ala Val Lys Val Gly Ile Gly Pro Gly Ser Ile
290           295           300

```

WO 02/075507

PCT/US02/01971

Cys Thr Thr Arg Ile Val Thr Gly Val Gly Val Pro Gln Ile Thr Ala  
 305 310 315 320  
 Ile Ala Asp Ala Ala Glu Ala Leu Lys Asp Arg Gly Ile Pro Val Ile  
 325 330 335  
 Ala Asp Gly Gly Ile Arg Phe Ser Gly Asp Ile Ser Lys Ala Ile Ala  
 340 345 350  
 Ala Gly Ala Ser Cys Val Met Val Gly Ser Met Phe Ala Gly Thr Glu  
 355 360 365  
 Glu Ala Pro Gly Glu Ile Glu Leu Tyr Gln Gly Arg Ala Phe Lys Ser  
 370 375 380  
 Tyr Arg Gly Met Gly Ser Leu Gly Ala Met Ser Lys Gly Ser Ser Asp  
 385 390 395 400  
 Arg Tyr Phe Gln Ser Asp Asn Ala Ala Asp Lys Leu Val Pro Glu Gly  
 405 410 415  
 Ile Glu Gly Arg Ile Pro Tyr Lys Gly Phe Leu Lys Glu Ile Ile His  
 420 425 430  
 Gln Gln Met Gly Gly Leu Arg Ser Cys Met Gly Leu Thr Gly Cys Ala  
 435 440 445  
 Thr Ile Asp Glu Leu Arg Thr Lys Ala Gln Phe Val Arg Ile Ser Gly  
 450 455 460  
 Ala Gly Ile Gln Glu Ser His Val His Asp Val Thr Ile Thr Lys Glu  
 465 470 475 480  
 Ala Pro Asn Tyr Arg Met Gly  
 485

<210> 25  
 <211> 2364  
 <212> DNA  
 <213> Pasteurella multocida  
 <220>  
 <221> CDS  
 <222> (191)..(1828)  
 <220>  
 <223> Hi1501

<400> 25  
 gtcaaacactc atcgcacagc tgaggcattt cccgaaagct gatcatgatg atggacctga 50  
 tgcgctagag atgctgtgga aaaatgcggt aagcagctct gccccgattg agttcatgac 120  
 aattgacggc gatttagggc gtgatgaatt tgatgacggc gattataca gtattggcg 180  
 gagataaaaa atg gcg aag aaa aag aaa aaa tta caa caa gcg aaa aaa 229  
 Met Ala Lys Lys Lys Lys Lys Leu Gln Gln Ala Lys Lys  
 1 5 10  
 gta caa gtt ggc tta gat aca caa aca aat gag gcg cgt gtc acg gag 277  
 Val Gln Val Gly Leu Asp Thr Gln Thr Asn Glu Ala Arg Val Thr Glu  
 15 20 25

WO 02/075507

PCT/US02/01971

```

aca gga aga att att tct gat cac cca agc aat aaa att acc ccc gca 325
Thr Gly Arg Ile Ile Ser Asp His Pro Ser Asn Lys Ile Thr Pro Ala
30 35 40 45
aag tta aaa ggg att tta gaa gat gct gaa ggt ggt gat att acc gcg 373
Lys Leu Lys Gly Ile Leu Glu Asp Ala Glu Gly Gly Asp Ile Thr Ala
50 55 60
caa cat gag ctt ttc atg gat att gaa gaa cgc gac agr tgc atc ggg 421
Gln His Glu Leu Phe Met Asp Ile Glu Glu Arg Asp Ser Cys Ile Gly
65 70 75
gca aat att caa acc cgt aag cgt gcg att tta acc ctt gac tgg cgc 469
Ala Asn Ile Gln Thr Arg Lys Arg Ala Ile Leu Thr Leu Asp Trp Arg
80 85 90
att gca gag cca cgt aat gcc aca ccg caa gaa gaa aaa ctg caa gtc 517
Ile Ala Glu Pro Arg Asn Ala Thr Pro Gln Glu Glu Lys Leu Gln Val
95 100 105
gaa att gac gag ctt ttc tat caa ttc cca atg cta gaa gat tta atg 565
Glu Ile Asp Glu Leu Phe Tyr Gln Phe Pro Met Leu Glu Asp Leu Met
110 115 120 125
gtg gat atg atg gat gcg gta gga cat ggt ttt tcg gcg tta gaa att 613
Val Asp Met Met Asp Ala Val Gly His Gly Phe Ser Ala Leu Glu Ile
130 135 140
gaa tgg aag caa gct gaa agt aaa tgg att cca gtt aat ttt atc gca 661
Glu Trp Lys Gln Ala Glu Ser Lys Trp Ile Pro Val Asn Phe Ile Ala
145 150 155
cgt ccg cag tcg tgg ttt aaa cta gac aag gat gat aat tta ctg ctt 709
Arg Pro Gln Ser Trp Phe Lys Leu Asp Lys Asp Asp Asn Leu Leu Leu
160 165 170
aaa acg cca gat aat caa gac ggt gag ccg ttg aga caa tat gcc tgg 757
Lys Thr Pro Asp Asn Gln Asp Gly Glu Pro Leu Arg Gln Tyr Gly Trp
175 180 185
gta gtg cat acc cac aaa tca aga aca gta cag ctt gct cgt atg ggt 805
Val Val His Thr His Lys Ser Arg Thr Val Gln Leu Ala Arg Met Gly
190 195 200 205
tta ttt aga acg ctc gca tgg ctt tat atg ttt aaa cac tac tcg gtg 853
Leu Phe Arg Thr Leu Ala Trp Leu Tyr Met Phe Lys His Tyr Ser Val
210 215 220
cat gat ttt gcc gaa ttt cta gag ctt tat ggt atg ccg att cgt att 901
His Asp Phe Ala Glu Phe Leu Glu Leu Tyr Gly Met Pro Ile Arg Ile
225 230 235
ggt aaa tac cca ttt ggg gca acg aat gac gaa aag cgc aca tta ttg 949
Gly Lys Tyr Pro Phe Gly Ala Thr Asn Asp Glu Lys Arg Thr Leu Leu
240 245 250
cgt gca ctt gct caa atc gga cat aac gca gca ggg att atg cca gaa 997
Arg Ala Leu Ala Gln Ile Gly His Asn Ala Ala Gly Ile Met Pro Glu
255 260 265
gga atg aat gtt gag ttg cat aat gtg aca aac act act ggc tcg gct 1045
Gly Met Asn Val Glu Leu His Asn Val Thr Asn Thr Thr Gly Ser Ala
270 275 280 285

```



WO 02/075507

PCT/US02/01971

gga agc aac ccg ttt ttg caa atg gtg gac tgg tgt gaa aag tcc gcc 1093  
 Gly Ser Asn Pro Phe Leu Gln Met Val Asp Trp Cys Glu Lys Ser Ala  
 290 295 300

gca cgt ttg att cta ggg caa aca tta aca agc ggt gca gat ggt aaa 1141  
 Ala Arg Leu Ile Leu Gly Gln Thr Leu Thr Ser Gly Ala Asp Gly Lys  
 305 310 315

act tca act aat gcc ctt gga caa gtg cat aat gaa gtc aga cgt gac 1189  
 Thr Ser Thr Asn Ala Leu Gly Gln Val His Asn Glu Val Arg Arg Asp  
 320 325 330

ttg ctt gtg tct gat gct aaa cag att gca caa act att aca caa cag 1237  
 Leu Leu Val Ser Asp Ala Lys Gln Ile Ala Gln Thr Ile Thr Gln Gln  
 335 340 345

att att ctg cca tat ctt caa att aac att gat ccg aat att ttg cct 1285  
 Ile Ile Leu Pro Tyr Leu Gln Ile Asn Ile Asp Pro Asn Ile Leu Pro  
 350 355 360

tct cgt gtg ccg tat ttc gag ttt gac acg aaa gaa tat gct gat tta 1333  
 Ser Arg Val Pro Tyr Phe Glu Phe Asp Thr Lys Glu Tyr Ala Asp Leu  
 370 375 380

agt gtc cta gcg gat gct att cct aag ctt gtg agc gta gga gtg cgc 1381  
 Ser Val Leu Ala Asp Ala Ile Pro Lys Leu Val Ser Val Gly Val Arg  
 385 390 395

att cct gaa aat tgg gtg cgt gat aaa gcg gcc att cca gaa ccg cag 1429  
 Ile Pro Glu Asn Trp Val Arg Asp Lys Ala Gly Ile Pro Glu Pro Gln  
 400 405 410

gaa aat gaa acg att tta agt gcg gtt caa cat gat ttt aaa aca gat 1477  
 Glu Asn Glu Thr Ile Leu Ser Ala Val Gln His Asp Phe Lys Thr Asp  
 415 420 425

tta aac gat gtt gaa aat ccg aaa aaa cag acc gca ctt tct gta caa 1525  
 Leu Asn Asp Val Glu Asn Pro Lys Lys Gln Thr Ala Leu Ser Val Gln  
 430 435 440 445

aat cac gtg aca ggt tgt cag tgt gat gcc tgt cgt ggt gtt gca tta 1573  
 Asn His Val Thr Gly Cys Gln Cys Asp Gly Cys Arg Gly Val Ala Leu  
 450 455 460

tct gcg aat aat aac agt tct act gcg cag gcc gtg cta gat ggt gga 1621  
 Ser Ala Asn Asn Asn Ser Ser Thr Ala Gln Gly Val Leu Asp Gly Gly  
 465 470 475

ctt gcg caa gca ttt aat gag cct gat ttt aat aaa caa tta aat cca 1669  
 Leu Ala Gln Ala Phe Asn Glu Pro Asp Phe Asn Lys Gln Leu Asn Pro  
 480 485 490

atg gta aag aaa gct gtt gcg gta ctc atg gca tgt gac tct tac gat 1717  
 Met Val Lys Lys Ala Val Ala Val Leu Met Ala Cys Asp Ser Tyr Asp  
 495 500 505

gag gcg gca gaa aaa ctc gct gaa gca tac cca gaa att tca agt cac 1765  
 Glu Ala Ala Glu Lys Leu Ala Glu Ala Tyr Pro Glu Ile Ser Ser His  
 510 515 520 525

gaa cac gaa cag tat ctc tca aat gcg ctg ttt tta gct gat tta ctt 1813  
 Glu His Glu Gln Tyr Leu Ser Asn Ala Leu Phe Leu Ala Asp Leu Leu  
 530 535 540

WO 02/075507

PCT/US02/01971

gga gga act aat gtc taaaccgctt agttttctat toggacttga accaacgcaa 1868  
 Gly Gly Thr Asn Val  
 545

gccatgagct ttttacataa taaaaaatta cttgcaacga aagtggttaa aaaatcaactg 1928

catgatagtg ccatcgcaag agctacaaca atcgcgagat tatctagtct tgagatgacg 1988

aatgatattt ataatcaat ggaagttgcc aaaaaagagg gtaagagctt tacacaatgg 2048

aaaaagact tgtaagtga gtttgagaaa aaaggctggg tattcgggca tgataaatct 2108

atcagtcgcg gtatcgacgg aaaactgttg gctgatccga aaacagcgca atattttgg 2168

acaccgctc ggctgaatac aatttatcgt acaaacgtgc aagccgcata ttctgcgcg 2228

cgctatcagc gcatgatgga taatattgat catcgcccct attggcaata ttcgctgtc 2288

agcgatgagc gtacacgacc ctctcatctt gcactaaacg gtcgaattta tcgctatgat 2348

gacccgtttt ggtcga 2364

<210> 26  
 <211> 546  
 <212> PRT  
 <213> Pasteurella multocida

<400> 26  
 Met Ala Lys Lys Lys Lys Lys Leu Gln Ala Lys Lys Val Gln Val  
 1 5 10 15

Gly Leu Asp Thr Gln Thr Asn Glu Ala Arg Val Thr Glu Thr Gly Arg  
 20 25 30

Ile Ile Ser Asp His Pro Ser Asn Lys Ile Thr Pro Ala Lys Leu Lys  
 35 40 45

Gly Ile Leu Glu Asp Ala Glu Gly Gly Asp Ile Thr Ala Gln His Glu  
 50 55 60

Leu Phe Met Asp Ile Glu Glu Arg Asp Ser Cys Ile Gly Ala Asn Ile  
 65 70 75 80

Gln Thr Arg Lys Arg Ala Ile Leu Thr Leu Asp Trp Arg Ile Ala Glu  
 85 90 95

Pro Arg Asn Ala Thr Pro Gln Glu Glu Lys Leu Gln Val Glu Ile Asp  
 100 105 110

Glu Leu Phe Tyr Gln Phe Pro Met Leu Glu Asp Leu Met Val Asp Met  
 115 120 125

Met Asp Ala Val Gly His Gly Phe Ser Ala Leu Glu Ile Glu Trp Lys  
 130 135 140

Gln Ala Glu Ser Lys Trp Ile Pro Val Asn Phe Ile Ala Arg Pro Gln  
 145 150 155 160

Ser Trp Phe Lys Leu Asp Lys Asp Asp Asn Leu Leu Leu Lys Thr Pro  
 165 170 175

WO 02/075507

PCT/US02/01971

Asp Asn Gln Asp Gly Glu Pro Leu Arg Gln Tyr Gly Trp Val Val His  
 180 185 190  
 Thr His Lys Ser Arg Thr Val Gln Leu Ala Arg Met Gly Leu Phe Arg  
 195 200 205  
 Thr Leu Ala Trp Leu Tyr Met Phe Lys His Tyr Ser Val His Asp Phe  
 210 215 220  
 Ala Glu Phe Leu Glu Leu Tyr Gly Met Pro Ile Arg Ile Gly Lys Tyr  
 225 230 235 240  
 Pro Phe Gly Ala Thr Asn Asp Glu Lys Arg Thr Leu Leu Arg Ala Leu  
 245 250 255  
 Ala Gln Ile Gly His Asn Ala Ala Gly Ile Met Pro Glu Gly Met Asn  
 260 265 270  
 Val Glu Leu His Asn Val Thr Asn Thr Thr Gly Ser Ala Gly Ser Asn  
 275 280 285  
 Pro Phe Leu Gln Met Val Asp Trp Cys Glu Lys Ser Ala Ala Arg Leu  
 290 295 300  
 Ile Leu Gly Gln Thr Leu Thr Ser Gly Ala Asp Gly Lys Thr Ser Thr  
 305 310 315 320  
 Asn Ala Leu Gly Gln Val His Asn Glu Val Arg Arg Asp Leu Leu Val  
 325 330 335  
 Ser Asp Ala Lys Gln Ile Ala Gln Thr Ile Thr Gln Gln Ile Ile Leu  
 340 345 350  
 Pro Tyr Leu Gln Ile Asn Ile Asp Pro Asn Ile Leu Pro Ser Arg Val  
 355 360 365  
 Pro Tyr Phe Glu Phe Asp Thr Lys Glu Tyr Ala Asp Leu Ser Val Leu  
 370 375 380  
 Ala Asp Ala Ile Pro Lys Leu Val Ser Val Gly Val Arg Ile Pro Glu  
 385 390 395 400  
 Asn Trp Val Arg Asp Lys Ala Gly Ile Pro Glu Pro Gln Glu Asn Glu  
 405 410 415  
 Thr Ile Leu Ser Ala Val Gln His Asp Phe Lys Thr Asp Leu Asn Asp  
 420 425 430  
 Val Glu Asn Pro Lys Lys Gln Thr Ala Leu Ser Val Gln Asn His Val  
 435 440 445  
 Thr Gly Cys Gln Cys Asp Gly Cys Arg Gly Val Ala Leu Ser Ala Asn  
 450 455 460  
 Asn Asn Ser Ser Thr Ala Gln Gly Val Leu Asp Gly Gly Leu Ala Gln  
 465 470 475 480  
 Ala Phe Asn Glu Pro Asp Phe Asn Lys Gln Leu Asn Pro Met Val Lys  
 485 490 495  
 Lys Ala Val Ala Val Leu Met Ala Cys Asp Ser Tyr Asp Glu Ala Ala  
 500 505 510

WO 02/075507

PCT/US02/01971

Glu Lys Leu Ala Glu Ala Tyr Pro Glu Ile Ser Ser His Glu His Glu  
 515 520 525

Gln Tyr Leu Ser Asn Ala Leu Phe Leu Ala Asp Leu Leu Gly Gly Thr  
 530 535 540

Asn Val  
 545

<210> 27  
 <211> 1353  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <223> hmbR

<220>  
 <221> CDS  
 <222> (2)..(1351)

<220>  
 <221> misc\_feature  
 <222> 125  
 <223> Xaa = any or unknown amino acid

<220>  
 <221> misc\_feature  
 <222> 133  
 <223> Xaa = any or unknown amino acid

<220>  
 <221> misc\_feature  
 <222> 141  
 <223> Xaa = any or unknown amino acid

<220>  
 <221> misc\_feature  
 <222> 151  
 <223> Xaa = any or unknown amino acid

<400> 27  
 g tca acg aaa gtc ggt tac gat att aat aac act cat cgt ttt aca ctg 49  
 Ser Thr Lys Val Gly Tyr Asp Ile Asn Asn Thr His Arg Phe Thr Leu  
 1 5 10 15  
 ttt tta gaa gat cgc cgt gaa aag aag ctt acc gaa gaa aaa aca tta 97  
 Phe Leu Glu Asp Arg Arg Glu Lys Lys Leu Thr Glu Glu Lys Thr Leu  
 20 25 30  
 ggg ctt agt gat gca gtg cgt ttt gct aat gat caa acc cct tat ctc 145  
 Gly Leu Ser Asp Ala Val Arg Phe Ala Asn Asp Gln Thr Pro Tyr Leu  
 35 40 45  
 cgt tat ggt att gaa tat cga tat aac ggc ttg tct tgg ttg gaa acg 193  
 Arg Tyr Gly Ile Glu Tyr Arg Tyr Asn Gly Leu Ser Trp Leu Glu Thr  
 50 55 60  
 gta aag ctt ttt ttg gca aag cag aaa atc gaa caa cgt tct gct ctc 241  
 Val Lys Leu Phe Leu Ala Lys Gln Lys Ile Glu Gln Arg Ser Ala Leu  
 65 70 75 80

WO 02/075507

PCT/US02/01971

caa gag ttt gat att aat aat agg aat aaa ttg gat tgg act atg tgg 289  
 Gln Glu Phe Asp Ile Asn Asn Arg Asn Lys Leu Asp Ser Thr Met Ser  
                   85                  90                  95

ttt gta tat tta caa aga cag aat ata gct cgg gga gaa ttt tca acg 337  
 Phe Val Tyr Leu Gln Arg Gln Asn Ile Ala Arg Gly Glu Phe Ser Thr  
                   100                  105                  110

agt cct tta tat tgg ggg cgg ggt cgc cat cgt tta tnt gcg aaa ttc 385  
 Ser Pro Leu Tyr Trp Gly Pro Ser Arg His Arg Leu Xaa Ala Lys Phe  
                   115                  120                  125

gaa ttt cgt gat ang ttt tta gaa aat atg aat aag cnt ttt acg ttt 433  
 Glu Phe Arg Asp Xaa Phe Leu Glu Asn Met Asn Lys Xaa Phe Thr Phe  
                   130                  135                  140

cgg ccg tgg caa atc aat ana ttc aga caa caa ggt cga aat aac tat 481  
 Arg Pro Trp Gln Ile Asn Xaa Phe Arg Gln Gln Gly Arg Asn Asn Tyr  
                   145                  150                  155                  160

aca gaa gtg ttt ccc gtt aaa tcc cga gag ttt tct ttt tct ctt atg 529  
 Thr Glu Val Phe Pro Val Lys Ser Arg Glu Phe Ser Phe Ser Leu Met  
                   165                  170                  175

gac gac att aag att ggc gaa ttg cta cat ctc gga ttg ggc ggt cgg 577  
 Asp Asp Ile Lys Ile Gly Glu Leu Leu His Leu Gly Leu Gly Gly Arg  
                   180                  185                  190

tgg gat cac tat aac tat aag cca tta tta aat tct cag cat aat atc 625  
 Trp Asp His Tyr Asn Tyr Lys Pro Leu Leu Asn Ser Gln His Asn Ile  
                   195                  200                  205

aac agg aca cag aga tta cct tat cca aaa aca tca tcc aaa ttt tgg 673  
 Asn Arg Thr Gln Arg Leu Pro Tyr Pro Lys Thr Ser Ser Lys Phe Ser  
                   210                  215                  220

tat caa ttg agt tta gag tat caa tta cat cca tca cat caa att gca 721  
 Tyr Gln Leu Ser Leu Glu Tyr Gln Leu His Pro Ser His Gln Ile Ala  
                   225                  230                  235                  240

tac cgt tta agt acc ggt ttt agg gtt ccc cgt gtt gaa gat ctt tat 769  
 Tyr Arg Leu Ser Thr Gly Phe Arg Val Pro Arg Val Glu Asp Leu Tyr  
                   245                  250                  255

ttt gaa gac cga gga aaa agt tct tca caa ttt ctt cct aac ccc gat 817  
 Phe Glu Asp Arg Gly Lys Ser Ser Ser Gln Phe Leu Pro Asn Pro Asp  
                   260                  265                  270

cta caa cgg gaa act gca ctg aat cat gaa ata agt tac cgt ttc caa 865  
 Leu Gln Pro Glu Thr Ala Leu Asn His Glu Ile Ser Tyr Arg Phe Gln  
                   275                  280                  285

aat caa tat gcc cat ttc agc gtc ggg ctt ttc cgt aca cgt tat cat 913  
 Asn Gln Tyr Ala His Phe Ser Val Gly Leu Phe Arg Thr Arg Tyr His  
                   290                  295                  300

aac ttt att caa gaa cgt gag atg acc tgt gat aaa att cca tat gag 961  
 Asn Phe Ile Gln Glu Arg Glu Met Thr Cys Asp Lys Ile Pro Tyr Glu  
                   305                  310                  315                  320

tat aat agg act tat gga tat tgc acg cat aat act tat gta atg ttt 1009  
 Tyr Asn Arg Thr Tyr Gly Tyr Cys Thr His Asn Thr Tyr Val Met Phe  
                   325                  330                  335

WO 02/075507

PCT/US02/01971

```

gtt aat gaa cct gaa gcc gtg att aaa ggg gtt gaa gta agc ggt gct 1057
Val Asn Glu Pro Glu Ala Val Ile Lys Gly Val Glu Val Ser Gly Ala
      340                345                350
tta aat ggg tcg gca ttc gga ctt tcc gac ggt tta act ttc cgt ctc 1105
Leu Asn Gly Ser Ala Phe Gly Leu Ser Asp Gly Leu Thr Phe Arg Leu
      355                360                365
aaa ggg agc tac agc aaa ggt caa aat cat gac ggc gat ccg tta aaa 1153
Lys Gly Ser Tyr Ser Lys Gly Gln Asn His Asp Gly Asp Pro Leu Lys
      370                375                380
tct att caa cca tgg aca gtg gta acc ggt att gat tac gaa act gaa 1201
Ser Ile Gln Pro Trp Thr Val Val Thr Gly Ile Asp Tyr Glu Thr Glu
      385                390                395
ggg tgg agc gtg agt ttg agc ggg cgt tat agt gcg gct aaa aaa gcc 1249
Gly Trp Ser Val Ser Leu Ser Gly Arg Tyr Ser Ala Ala Lys Lys Ala
      405                410                415
aaa gat gcg ata gaa acg gaa tac aca cat gat aaa aag gtt gtc aaa 1297
Lys Asp Ala Ile Glu Thr Glu Tyr Thr His Asp Lys Lys Val Val Lys
      420                425                430
caa tgg ccg cat tta agt cca tcc tac ttt gtt gtt gat ttt acg ggg 1345
Gln Trp Pro His Leu Ser Pro Ser Tyr Phe Val Val Asp Phe Thr Gly
      435                440                445

caa gtt ga 1353
Gln Val
      450

```

```

<210> 28
<211> 450
<212> PRT
<213> Pasteurella multocida

```

```

<220>
<221> misc_feature
<222> 125
<223> Xaa = any or unknown amino acid

```

```

<220>
<221> misc_feature
<222> 133
<223> Xaa = any or unknown amino acid

```

```

<220>
<221> misc_feature
<222> 141
<223> Xaa = any or unknown amino acid

```

```

<220>
<221> misc_feature
<222> 151
<223> Xaa = any or unknown amino acid

```

```

<400> 28
Ser Thr Lys Val Gly Tyr Asp Ile Asn Asn Thr His Arg Phe Thr Leu
      1           5           10           15

```

WO 02/075507

PCT/US02/01971

Phe Leu Glu Asp Arg Arg Glu Lys Lys Leu Thr Glu Glu Lys Thr Leu  
                   20                  25                  30  
 Gly Leu Ser Asp Ala Val Arg Phe Ala Asn Asp Gln Thr Pro Tyr Leu  
                   35                  40                  45  
 Arg Tyr Gly Ile Glu Tyr Arg Tyr Asn Gly Leu Ser Trp Leu Glu Thr  
                   50                  55                  60  
 Val Lys Leu Phe Leu Ala Lys Gln Lys Ile Glu Gln Arg Ser Ala Leu  
                   65                  70                  75                  80  
 Gln Glu Phe Asp Ile Asn Asn Arg Asn Lys Leu Asp Ser Thr Met Ser  
                   85                  90                  95  
 Phe Val Tyr Leu Gln Arg Gln Asn Ile Ala Arg Gly Glu Phe Ser Thr  
                   100                  105                  110  
 Ser Pro Leu Tyr Trp Gly Pro Ser Arg His Arg Leu Xaa Ala Lys Phe  
                   115                  120                  125  
 Glu Phe Arg Asp Xaa Phe Leu Glu Asn Met Asn Lys Xaa Phe Thr Phe  
                   130                  135                  140  
 Arg Pro Trp Gln Ile Asn Xaa Phe Arg Gln Gln Gly Arg Asn Asn Tyr  
                   145                  150                  155                  160  
 Thr Glu Val Phe Pro Val Lys Ser Arg Glu Phe Ser Phe Ser Leu Met  
                   165                  170  
 Asp Asp Ile Lys Ile Gly Glu Leu Leu His Leu Gly Leu Gly Gly Arg  
                   180                  185                  190  
 Trp Asp His Tyr Asn Tyr Lys Pro Leu Leu Asn Ser Gln His Asn Ile  
                   195                  200                  205  
 Asn Arg Thr Gln Arg Leu Pro Tyr Pro Lys Thr Ser Ser Lys Phe Ser  
                   210                  215                  220  
 Tyr Gln Leu Ser Leu Glu Tyr Gln Leu His Pro Ser His Gln Ile Ala  
                   225                  230                  235                  240  
 Tyr Arg Leu Ser Thr Gly Phe Arg Val Pro Arg Val Glu Asp Leu Tyr  
                   245                  250                  255  
 Phe Glu Asp Arg Gly Lys Ser Ser Ser Gln Phe Leu Pro Asn Pro Asp  
                   260                  265                  270  
 Leu Gln Pro Glu Thr Ala Leu Asn His Glu Ile Ser Tyr Arg Phe Gln  
                   275                  280                  285  
 Asn Gln Tyr Ala His Phe Ser Val Gly Leu Phe Arg Thr Arg Tyr His  
                   290                  295                  300  
 Asn Phe Ile Gln Glu Arg Glu Met Thr Cys Asp Lys Ile Pro Tyr Glu  
                   305                  310                  315                  320  
 Tyr Asn Arg Thr Tyr Gly Tyr Cys Thr His Asn Thr Tyr Val Met Phe  
                   325                  330                  335  
 Val Asn Glu Pro Glu Ala Val Ile Lys Gly Val Glu Val Ser Gly Ala  
                   340                  345                  350

WO 02/075507

PCT/US02/01971

Leu Asn Gly Ser Ala Phe Gly Leu Ser Asp Gly Leu Thr Phe Arg Leu  
 355 360 365  
 Lys Gly Ser Tyr Ser Lys Gly Gln Asn His Asp Gly Asp Pro Leu Lys  
 370 375 380  
 Ser Ile Gln Pro Trp Thr Val Val Thr Gly Ile Asp Tyr Glu Thr Glu  
 385 390 395 400  
 Gly Trp Ser Val Ser Leu Ser Gly Arg Tyr Ser Ala Ala Lys Lys Ala  
 405 410 415  
 Lys Asp Ala Ile Glu Thr Glu Tyr Thr His Asp Lys Lys Val Val Lys  
 420 425 430  
 Gln Trp Pro His Leu Ser Pro Ser Tyr Phe Val Val Asp Phe Thr Gly  
 435 440 445  
 Gln Val  
 450

<210> 29  
 <211> 4936  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (1078)..(2769)

<220>  
 <223> hxuC

<400> 29  
 gtcacaaca aagcgcacag gcattacttc atgcacaaca catcatcacg aaagtacgta 60  
 ccgatttaac gcaaattaat gcgcacaaca ttcattcttt cctatcataa agcgtttcat 120  
 catggctagc attctagcaa aaattagttg aggaaaatag cggctctggt ttgcttaaaa 180  
 aacaacccac ccgtaagggc acggctgttt ctttttgaga aattacgctt cttcatcttg 240  
 atcttttttc aagatctcat cttcattgag ttttaaaga cgggcaatcg cattgcggtta 300  
 ggagatttca agcctttctc gactagtagc aatgacacct tgatcgatta agaaacgctc 360  
 attgacatca taaacccaac catgtaatga gagtttttcc coatttttcc acgcggattt 420  
 aatgattgac gagcgacctt agttataaac ttgctctgcg acgttaattt tcgtagcat 480  
 atcagccggt ttttcaggcg gtaaattgcc aagtaaatga ctatgcttat accaaatato 540  
 gcgtaagtgg agtaaccagt tattaattaa acctaaatct tgatccgcca ttgcggcttt 600  
 aattccacca cagtttgat gtccacaat aataatgtgt tcaatattta agacctcaac 660  
 ggcatattgc acaacagata aacagtttaa atcgggtgta atgacttgat ttgcaacatt 720  
 acgatgcaca aacagctcac ccggtcctaa atttgttaat tttctgcag gaacacggct 780  
 atccgagcaa ccaatccaaa gatagctcgg ggtttgatga tcagccaatt ctttaaagta 840



WO 02/075507

PCT/US02/01971

```

agaggagttt tccctttca tccgtaacgc ccagctataa ttattggcaa aaagttgttc 900
aatttttttc attagagtga ttcctatacc gcaaaaataa gggggctagt atagcttaga 960
aatagacagt gggtaaagaa aggcataaaa ttgtatagga taacttgttt tttattgcca 1020
tttatttaga attagaatct ttaataataa aaataattat cattaagggtt aatagtt 1077
atg gat aaa aat tta atg aag gga tgt gta ttc tta tca ata gtc ggt 1125
Met Asp Lys Asn Leu Met Lys Gly Cys Val Phe Leu Ser Ile Val Gly
1 5 10 15
tgc ggt atc caa ata ggg cta gca tca aat cca aat cct cca gat gtg 1173
Cys Gly Ile Gln Ile Gly Leu Ala Ser Asn Pro Asn Pro Pro Asp Val
20 25 30
gat gag tta tta cct att att gtg aat gct gat gaa gat aat aaa tta 1221
Asp Glu Leu Leu Pro Ile Ile Val Asn Ala Asp Glu Asp Asn Lys Leu
35 40 45
cca ggt cgt tct gta tta aaa cag aaa aat atc gat caa caa caa gca 1269
Pro Gly Arg Ser Val Leu Lys Gln Lys Asn Ile Asp Gln Gln Gln Ala
50 55 60
gat aat gcc gct gac tta ata aat att tta cct ggg gta aat atg gcg 1317
Asp Asn Ala Ala Asp Leu Ile Asn Ile Leu Pro Gly Val Asn Met Ala
65 70 75 80
gga gga ttt cgc cct ggt ggt caa aca tta aat att aat gga atg ggt 1365
Gly Gly Phe Arg Pro Gly Gly Gln Thr Leu Asn Ile Asn Gly Met Gly
85 90 95
gat gct gaa gat gtt aga gtt caa cta gac gcc gca aca aaa agt ttc 1413
Asp Ala Glu Asp Val Arg Val Gln Leu Asp Gly Ala Thr Lys Ser Phe
100 105 110
gaa aaa tat caa caa gcc tct att ttt att gaa cct gag tta tta aga 1461
Glu Lys Tyr Gln Gln Gly Ser Ile Phe Ile Glu Pro Glu Leu Leu Arg
115 120 125
aag gtg aca gta gac aaa gga aat tat tct cct caa tat gcc aat ggt 1509
Lys Val Thr Val Asp Lys Gly Asn Tyr Ser Pro Gln Tyr Gly Asn Gly
130 135 140
ggc ttt gct ggt act gta aaa ttt gaa aca aaa gat gca act gat ttt 1557
Gly Phe Ala Gly Thr Val Lys Phe Glu Thr Lys Asp Ala Thr Asp Phe
145 150 155 160
ttg aaa gaa aat cag aaa ata ggt gga tta ttt aaa tat gga aat aat 1605
Leu Lys Glu Asn Gln Lys Ile Gly Gly Leu Phe Lys Tyr Gly Asn Asn
165 170 175
agc aat aat aac caa aaa act tat agt aca gcc cta gtt tta cag aat 1653
Ser Asn Asn Asn Gln Lys Thr Tyr Ser Thr Ala Leu Val Leu Gln Asn
180 185 190
gaa caa aaa aat att gat ttg tta tta ttt ggt tct gta aga aat gca 1701
Glu Gln Lys Asn Ile Asp Leu Leu Leu Phe Gly Ser Val Arg Asn Ala
195 200 205
agc aat tat aca aga cct gat aaa agt aaa att ctt ttt tca aaa aac 1749
Ser Asn Tyr Thr Arg Pro Asp Lys Ser Lys Ile Leu Phe Ser Lys Asn
210 215 220

```

WO 02/075507

PCT/US02/01971

aat caa aaa agt gga tta ata aaa gta aat tgg caa att act cct gaa 1797  
 Asn Gln Lys Ser Gly Leu Ile Lys Val Asn Trp Gln Ile Thr Pro Glu  
 225 230 235 240  
 cat tta tta act tta tcc agr gtt tat ggc att cat aaa ggg tgg gaa 1845  
 His Leu Leu Thr Leu Ser Ser Val Tyr Gly Ile His Lys Gly Trp Glu  
 245 250 255  
 cct tgg gca gca aaa aga gat gtg atg tgc aga cca aca gaa aca gaa 1893  
 Pro Trp Ala Ala Lys Arg Asp Val Met Ser Arg Pro Thr Glu Thr Glu  
 260 265 270  
 ata aaa cac tat ggg att gat gtt gcg tgg aaa cgt aaa ctt gtt tat 1941  
 Ile Lys His Tyr Gly Ile Asp Val Ala Trp Lys Arg Lys Leu Val Tyr  
 275 280 285  
 cga gat caa aaa gat gaa agt tat tca ttg aaa tat cgc tat tta cct 1989  
 Arg Asp Gln Lys Asp Glu Ser Tyr Ser Leu Lys Tyr Arg Tyr Leu Pro  
 290 295 300  
 gaa aat aat aag tgg att aat ttg tct gtt cag ctg agt tat agt aaa 2037  
 Glu Asn Asn Lys Trp Ile Asn Leu Ser Val Gln Leu Ser Tyr Ser Lys  
 305 310 315 320  
 aca gag cag aat gat act cgc cat gag aaa gtc act tct tca ttc cta 2085  
 Thr Glu Gln Asn Asp Thr Arg His Glu Lys Val Thr Ser Ser Phe Leu  
 325 330 335  
 ggt aca tta gga aat aaa agt tgg ata act tat tca gat ctt act ttt 2133  
 Gly Thr Leu Gly Asn Lys Ser Trp Ile Thr Tyr Ser Asp Leu Thr Phe  
 340 345 350  
 gat ata agt aac aca agt act cta aat att ggg cgt gct gag cat gaa 2181  
 Asp Ile Ser Asn Thr Ser Thr Leu Asn Ile Gly Arg Ala Glu His Glu  
 355 360 365  
 cta cta ttt ggt tta cag tgg tta aaa aat aaa aga aat acc ctt atg 2229  
 Leu Leu Phe Gly Leu Gln Trp Leu Lys Asn Lys Arg Asn Thr Leu Met  
 370 375 380  
 tat cat aaa ggg gga gtc aag aag gca gac tat aat tat ggc tat ttt 2277  
 Tyr His Lys Gly Gly Val Lys Lys Ala Asp Tyr Asn Tyr Gly Tyr Phe  
 385 390 395 400  
 cag cct tat tat atg cct tct gga cgc cag tat aca caa gca ttt tat 2325  
 Gln Pro Tyr Tyr Met Pro Ser Gly Arg Gln Tyr Thr Gln Ala Phe Tyr  
 405 410 415  
 tta caa gat caa ata aaa tgg cag aat ttc ctc ttt aca gga ggg ata 2373  
 Leu Gln Asp Gln Ile Lys Trp Gln Asn Phe Leu Phe Thr Gly Gly Ile  
 420 425 430  
 aga tat gac cat atc aat aat ata ggg cag aaa aat tta gcg cca cga 2421  
 Arg Tyr Asp His Ile Asn Asn Ile Gly Gln Lys Asn Leu Ala Pro Arg  
 435 440 445  
 tat aat gat atc tct gca gga cat gat tat agc cag aaa aat tat aat 2469  
 Tyr Asn Asp Ile Ser Ala Gly His Asp Tyr Ser Gln Lys Asn Tyr Asn  
 450 455 460  
 ggt tgg tct tat tat tta ggc ctt aag tat gat gta aat cat tat tta 2517  
 Gly Trp Ser Tyr Tyr Leu Gly Leu Lys Tyr Asp Val Asn His Tyr Leu  
 465 470 475 480

WO 02/075507

PCT/US02/01971

```

agt tta ttt acg aat ttt agt aaa act tgg cga gcc cct gtt att gat 2565
Ser Leu Phe Thr Asn Phe Ser Lys Thr Trp Arg Ala Pro Val Ile Asp
          485          490          495
gaa cag tat gag aca caa tat agt caa gct tct gta tct gcg act tct 2613
Glu Gln Tyr Glu Thr Gln Tyr Ser Gln Ala Ser Val Ser Ala Thr Ser
          500          505          510
tta aat tta gaa aaa gaa atg att aat caa acc aga gtg ggt gga att 2661
Leu Asn Leu Glu Lys Glu Met Ile Asn Gln Thr Arg Val Gly Gly Ile
          515          520          525
att act ctc aat cat cta ttt cag gaa aat gat gct ttt caa ttt aga 2709
Ile Thr Leu Asn His Leu Phe Gln Glu Asn Asp Ala Phe Gln Phe Arg
          530          535          540
act act tat ttt tac aat cgc gcc aag aat gaa atc ttc aaa acg aga 2757
Thr Thr Tyr Phe Tyr Asn Arg Gly Lys Asn Glu Ile Phe Lys Thr Arg
          545          550          555          560
ggg gtt aac cgt tagagttggt tgaatgact gaaaattag acctatacgt 2809
Gly Val Asn Arg
tactgttaaa ggtggcggta tttctggtca agcgggtgca atccgctcagc gtatcactcg 2869
tgcattaatc gaatatgatg agagtttacg ctctgtatta cgcgcagctg gttctgttac 2929
tcgcgatgca cgtcaagttg aacgtaaaaa agtgggttta cgcaaagcgc gtcgtcgtcc 2989
acaattctca aaacgttaat tttcttttta cgttttatat tcagattgca agcccaaaag 3049
gcttgcaatt tttttatctc aataaaaattt acgataatct ttggaaatca gtggcgatt 3109
tgtggtagaa taaacgcecca ttttttatat aaaatcatgc cagaatcagg caaagttaa 3169
taaattttaa ttcatttttag agctgtcggg ggaatagatg acaagcgcg caaataaacg 3229
ttcaataatg acactttttt cagataaaac agatatttat tgcaccaag taaggattgt 3289
ttggctgaaa aagggtgttg cttatgaaac ggaagttgta gatcctcaag tcgtatcaga 3349
agatttaatg gaattaaatc cgtatggcac gttgccgaca ttagttagtc gtgatttagt 3409
gttatttaat tcacgtatta ttatggaata tcttgatgag cgtttccctc atocaccttt 3469
gatgcctggt tatccagtg cactgggaa aagccgttta ttaatgttac gtattgagca 3529
agattggtac ccagtattag caaaagctga aaaaggcacg gacgcagaac gtgctgtcgc 3589
attaaaacaa ttaagagaag agatttttagc gattgcccct attttcaegc agatgcctta 3649
ttttatgagc gaagagttta gtttagtaga ttgttatatc gccccattat tatggcgtat 3709
gcaagaactg ggtgtggatt tcagtggggc gggtagcaaa gcaattaag cttacatggc 3769
acgtgttttt gaacgcgatt catttatgca atctttaggc gtgtcggctc cgaaaaactt 3829
aatggatgag aaataatcag tatgctacat aaatcatcac caaagcgtcc ttacttgta 3889
agagcgtatt atgattgggt agtggataat gatttcacc cttatttagt ggtggacgcg 3949
acttatgttg gctgaaaagt cctctggaaa tatgtcaaag atgggcaaat tgcctcaat 4009

```

WO 02/075507

PCT/US02/01971

ttatctgcga atcgacagc taactcggta ctaagcaatg aaagtattca gtttagcgcg 4069  
 cgttttcgtg gtatttcaca agatattttt attcctatgg gggctgcgct agccatttat 4129  
 gctcgtgaaa atggtgatgg tgaactgattt gaacctgaag cgatttatga tgagctcgca 4189  
 acacaaaata ttggtattga gcagccactg agctttgttg aggctgtcga taaaccaaaa 4249  
 accagtgaga atactcaaaa aagcacaaac aaagcaaaa cgacggaaaa aaaagcgact 4309  
 tctcatttaa gaattattaa ataaaagagg ttttctttct tcataaaaa acacgctttt 4369  
 acgcgtgttt ttttgttgcg gacagtttat tgtgccattt tttttgcggc ttttaagaag 4429  
 ccttgcgcac tcgtgtagat gtaactttta ttctgtgccg ctaaaatcat atccgacatt 4489  
 tcacgaaagg ccccttgtcc accttccagg cttagtacgt gatcagcgtg cattttgata 4549  
 taagcggcgc atcttgtact gcaaaaggcaa caccacagcg gcaaaagcag gcagatcaac 4609  
 gctgtcatca ccaatataag ccttttcttg cgcacagaca ttggcttgtt gbatcaattc 4669  
 aagacagcgc ctttcttttt ccaatttgcc gaggaaaaag tgttggatgc ctagatctgc 4729  
 aatacgtttg cgtagaatcg gggaaatcgc ccccgagagt acccgactt gaatgccaga 4789  
 ttccattaac attctgatcc ccaagccatc acgaacatga aaggttttga aagcttcacc 4849  
 atgggcacgc taatgcaaag agccgtcggc cagtacaccg tcgatattcg taatcacaaa 4909  
 ttttaatttt ttgagttttt cegtga 4936

<210> 30  
 <211> 564  
 <212> PRT  
 <213> Pasteurella multocida

<400> 30  
 Met Asp Lys Asn Leu Met Lys Gly Cys Val Phe Leu Ser Ile Val Gly  
 1 5 10 15  
 Cys Gly Ile Gln Ile Gly Leu Ala Ser Asn Pro Asn Pro Pro Asp Val  
 20 25 30  
 Asp Glu Leu Leu Pro Ile Ile Val Asn Ala Asp Glu Asp Asn Lys Leu  
 35 40 45  
 Pro Gly Arg Ser Val Leu Lys Gln Lys Asn Ile Asp Gln Gln Gln Ala  
 50 55 60  
 Asp Asn Ala Ala Asp Leu Ile Asn Ile Leu Pro Gly Val Asn Met Ala  
 65 70 75 80  
 Gly Gly Phe Arg Pro Gly Gly Gln Thr Leu Asn Ile Asn Gly Met Gly  
 85 90 95  
 Asp Ala Glu Asp Val Arg Val Gln Leu Asp Gly Ala Thr Lys Ser Phe  
 100 105 110  
 Glu Lys Tyr Gln Gln Gly Ser Ile Phe Ile Glu Pro Glu Leu Leu Arg  
 115 120 125

WO 02/075507

PCT/US02/01971

Lys Val Thr Val Asp Lys Gly Asn Tyr Ser Pro Gln Tyr Gly Asn Gly  
130 135 140

Gly Phe Ala Gly Thr Val Lys Phe Glu Thr Lys Asp Ala Thr Asp Phe  
145 150 155 160

Leu Lys Glu Asn Gln Lys Ile Gly Gly Leu Phe Lys Tyr Gly Asn Asn  
165 170 175

Ser Asn Asn Asn Gln Lys Thr Tyr Ser Thr Ala Leu Val Leu Gln Asn  
180 185 190

Glu Gln Lys Asn Ile Asp Leu Leu Leu Phe Gly Ser Val Arg Asn Ala  
195 200 205

Ser Asn Tyr Thr Arg Pro Asp Lys Ser Lys Ile Leu Phe Ser Lys Asn  
210 215 220

Asn Gln Lys Ser Gly Leu Ile Lys Val Asn Trp Gln Ile Thr Pro Glu  
225 230 235

His Leu Leu Thr Leu Ser Ser Val Tyr Gly Ile His Lys Gly Trp Glu  
245 250 255

Pro Trp Ala Ala Lys Arg Asp Val Met Ser Arg Pro Thr Glu Thr Glu  
260 265 270

Ile Lys His Tyr Gly Ile Asp Val Ala Trp Lys Arg Lys Leu Val Tyr  
275 280 285

Arg Asp Gln Lys Asp Glu Ser Tyr Ser Leu Lys Tyr Arg Tyr Leu Pro  
290 295 300

Glu Asn Asn Lys Trp Ile Asn Leu Ser Val Gln Leu Ser Tyr Ser Lys  
305 310 315 320

Thr Glu Gln Asn Asp Thr Arg His Glu Lys Val Thr Ser Ser Phe Leu  
325 330 335

Gly Thr Leu Gly Asn Lys Ser Trp Ile Thr Tyr Ser Asp Leu Thr Phe  
340 345 350

Asp Ile Ser Asn Thr Ser Thr Leu Asn Ile Gly Arg Ala Glu His Glu  
355 360 365

Leu Leu Phe Gly Leu Gln Trp Leu Lys Asn Lys Arg Asn Thr Leu Met  
370 375 380

Tyr His Lys Gly Gly Val Lys Lys Ala Asp Tyr Asn Tyr Gly Tyr Phe  
385 390 395 400

Gln Pro Tyr Tyr Met Pro Ser Gly Arg Gln Tyr Thr Gln Ala Phe Tyr  
405 410 415

Leu Gln Asp Gln Ile Lys Trp Gln Asn Phe Leu Phe Thr Gly Gly Ile  
420 425 430

Arg Tyr Asp His Ile Asn Asn Ile Gly Gln Lys Asn Leu Ala Pro Arg  
435 440 445

Tyr Asn Asp Ile Ser Ala Gly His Asp Tyr Ser Gln Lys Asn Tyr Asn  
450 455 460

WO 02/075507

PCT/US02/01971

Gly Trp Ser Tyr Tyr Leu Gly Leu Lys Tyr Asp Val Asn His Tyr Leu  
465 470 475 480  
Ser Leu Phe Thr Asn Phe Ser Lys Thr Trp Arg Ala Pro Val Ile Asp  
485 490 495  
Glu Gln Tyr Glu Thr Gln Tyr Ser Gln Ala Ser Val Ser Ala Thr Ser  
500 505 510  
Leu Asn Leu Glu Lys Glu Met Ile Asn Gln Thr Arg Val Gly Gly Ile  
515 520 525  
Ile Thr Leu Asn His Leu Phe Gln Glu Asn Asp Ala Phe Gln Phe Arg  
530 535 540  
Thr Thr Tyr Phe Tyr Asn Arg Gly Lys Asn Glu Ile Phe Lys Thr Arg  
545 550 555 560  
Gly Val Asn Arg

<210> 31  
<211> 9814  
<212> DNA  
<213> Pasteurella multocida  
<220>  
<221> CDS  
<222> (4762)..(7662)  
<223> iroA

<400> 31  
gtcgacctgc agcagacaat gtccactgtg taatagtcca acgactgtta taaaaatctt 60  
cogctgcttt ttctaagtgt tgtacacggg gttttcaaa ttcttcctaaa ttcttggttg 120  
gttggactaa aagttgttca gccgccgctt taaaattggc gacaaaatcc gattggttga 180  
ttaaaccata ggattttgct tggatttgtg cgcggctgctc ttcacccaat ttatcgaaaa 240  
atcaggcgt ataagtcacg tttgggatcg taggcgcgat gatctgatta acaccagcct 300  
gttqtaatgc tcccattgct tgtgccatcg tttgtgcoat ggttttaata ctggctaaca 360  
cgtaggcttg tttctcttca ggtgttgtct tctgtactgc tgttgtaaat actgtcgcca 420  
aatcattacc acctgcccac agaatatgta aagcttcttt tttgactggc gcatgtaaat 480  
actcgttgat ctgcttttct agtgctaaat gaggttggct tgcgtttcta gtattatgtg 540  
caccaacaat caccaccgcg ctgtacgcgt agttcaaac accctgtgta gaaggtatta 600  
atTTTTtccc aaatgcttga gctaaatatt catcataaag gtgatgatag ttccatcag 660  
cctttaaata agaggcttct ttattccaac ctgtttgccc catatcactt aaactatcac 720  
caaacacgac aacatcttgt gccagagcag ccgaacttag tgaacaaaaaat aatgcgaatg 780  
aaagtgtatt aattttcaca ataatgcctt tcaattatc atcgtcagtc aaaaatttgc 840

WO 02/075507

PCT/US02/01971

gtcatcatic gttgattata ggaagatacc tagccagacc actactggta tgaacagaag 900  
tcaatgttta atcacataaa aaagcctctg tgctttcaca cagaggcttt tatgtccatt 960  
cacctaactca aattacatcg cttagtaaaa ggtacgogta atcacgtctt gttgttgctc 1020  
tttggttaac gagttaaagc gtaactgcata acccgaaaca cgaatggta atgtgggata 1080  
ttttccgga tttccattg catctaaca catttcacgg ttcattgact tcacgtttaa 1140  
gtgtgtccg cttcaatcg ttgcttcag gtggaagtaa cgtccatta gacctgcaag 1200  
gttacgtttt tggcttctg aatctttacc taaggcattt ggtacgattg agaaggata 1260  
agaaatacca tctttcgcac aagcaaatgg caatttcgca acagaagta acgatgctac 1320  
tgcacctttt tggtcacgac cgtgcattgg gttcgcacc ggcccaatg gtgcaccaga 1380  
acgacgacca tctggggtgt taccgtttt cttaccataa accacgttag atgtaatagt 1440  
aagtacagat tgggtcggg togcattacg ataagtacc aatttttggg tttttctcat 1500  
aaagcgttca actaaatcac aagcatttc atcaacacgg ttatcgttgt taccgaattg 1560  
tggatattcg cttcaattt caaagtcgat tgccacatct tttgcaatc caaccacttc 1620  
accgccttta tttttgatt cgatatacc acgaactggt ttcactttcg catatttaat 1680  
ggcagataaa gagtccgctg cgcacagaag ccctgcgata ccacaagcca tagtcggaa 1740  
taccatcaga tcatgaagtg ccattagtgc ggttcatac gcgtatttat cgtgataaaa 1800  
gtgaatgatg ttaaatgacg taacatattg tttcgtaac caatccataa agctgtctaa 1860  
gctgctcatg acatcatcat aatctaagta ttcgctggta atggatcgg ttttcggctc 1920  
tacttggtca cctgatttct catccacacc gccattgatt gcgtataaca aggttttcgc 1980  
taagttggca cgtgcaccga agaattgcat cattttacc acgatcattg gcgatacaca 2040  
gcattgcaatc gcattgcat cgttttggaa gtcaggacgc attaatgcat cgttttcata 2100  
ctgaacagaa gacgtatcga tagacacttt tgcgcataa cgtttgaaac cttctggtaa 2160  
tttttcagac caaagaatcg ttaagtttg ctctggtgac ggtccatcg tataaaggg 2220  
gtgtaagata cggaaagctgt ttttggttac taaagtacga ccacttaagc ccataccgc 2280  
taaggttcc gttcccaca ttgggtgccc cgaataat tgatcgtact ctggggtacg 2340  
taagaacgc accatcgtta atttcatgac taagtgtca attaatctt gtgcttcttg 2400  
ttctgtaatt ttgctgctt ttaaatcacg ctcaataaa atatctaaga aagtcgatac 2460  
acgaccaaat gacatggcag caccgttttg tgatttcaact gcagcggtac gactttgcac 2520  
agttatcggg agataattga aatcataacc agcaacaaat gtcagccgtt ctattttctc 2580  
tgaagaatat cggcatttgc gttctggcgg aatggctggt tttttcacat tcttgagatg 2640  
attttcttcc aagtatttcc attctgctg tgcctgctga ataatgtgcg aaagagtatt 2700  
ccattcteta agcaacactg ccgcactaac ttgtgaaagt cgttcacac gccactgcac 2760

WO 02/075507

PCT/US02/01971

aaagtgatgt tcttgtaaat cgattaatct caggttagaa atcggcatat ttagcaagcg 2820  
aagtaaacgc aacttttcag cagcatagcc ctttttattt atgctcactt ctttgatata 2880  
ttatcgaca agttgtgcaa aagtgatgct gggaatatca gtgaatacac cgtttatgat 2940  
ttttgttct atgtctaacg cccacgcttg cgcacagct ttagtccgaa atggtgctga 3000  
tttatagaca ccttttttgc gaatttgaa cgcacaacct gatttttgtt tgttaaaagt 3060  
cgccacgctt aactaccatt aattttgac aattcgtgtt gcaattttgt gcaattttat 3120  
ttcttaaatg atgttttagc gatcataaat gaagaaaaaa cagaagtaaa acactatata 3180  
aaaaaacagt atattttttg ttgaagtgct taatgtagtt tgaacttat tgatttttaa 3240  
atattaaaga taaagaaaaa gccgacaaaa gtcggcttct tttttttatg ctgtttatca 3300  
atggtgccta gggccggact cgaaccggca caccgaagg cggttgattt tgaatcaact 3360  
gctctacca attcggccac ccaggctaatt atgataaag agcatcaat taggtctgta 3420  
ttatacctt tcattgatag gttacaagca aaaaatgatt ttagatattc aattgcttt 3480  
atttcatca gtgtggctgt tctctctac tttattcagg tgcagtgaag taaccttata 3540  
aaaaaaagg tttttgtt aaatttttaa taactttttt gtaaaaagat cgcagtttct 3600  
ttgaaaaa agaccgatta caaatataat taaaaactat tatcaatatt gataataatg 3660  
ggattttaac catgacattt ataaggataa agtcaagatg atgctaaaaa cacaaaatgc 3720  
agattatatt acacaaaatc cactggcaat tactttggat atggcttcgc actttggcaa 3780  
acctgaaggt gaaattttat gtgctttacc tgatgagttt gttcagatgt ttctcgcgga 3840  
acgtgocggg gaagtgttg ctgagatcag tagttggggg attttcacga ccattattga 3900  
aaaagaagga tcgatttttg aaattaaaga ccgttttccg accgggatgg ttggcgctgg 3960  
ttattataat ttgaatatga aagatgaaga aggcacgctt catggtcacc ttaaattaga 4020  
taacatcagc aaaattgcct ttgtgagttt accgtttcgc ggtaaagaaa gttataacat 4080  
cgcatttatt gcgaataatg ggcaactat ttttaaagt tttttgggc gcgatgctga 4140  
gcgtraatta ttccagaac aagtcaaaa atttaaagca ttattttaga aggttaaaaa 4200  
agtaatgaca acaaatcgtc aagaagtatt acaaaatcgt ttaggtccag aaattcaaga 4260  
gtlaaaggca caatgtaaaa cagtcactgt cgtactgtc ggtgaagatg gtaatcccaa 4320  
tgtgagttat gcgccatttg caattaataa tggggaatac caagtcttta tttctactat 4380  
tgcacgtcat gcacgtaac tacaagaagt accaaaagtt tcttlaatgt tgatcgaaga 4440  
tgaagttaa agtcgcaga tttttgctc tcgtcgttta tctttgatg cggttgocg 4500  
tgtgtcgag agagaaagt aagaatggca ttctggtgtt gaggcactca aagcaagaca 4560  
tgggtcatta atggatgaat tctctcggat gaaagattt catttgitta gtttaagcc 4620  
ctcaaaagg ttattttaa aaggttttg tcaagcttct caagtgaata atgatgattt 4680



WO 02/075507

PCT/US02/01971

```

agtgagcttt gttcacttgg ttgaaggaca ccaagaataa attttgcac ctttttaggg 4740
tatttacttg aggttaggaa a atg cgt aca aca aca ata aaa ttt tct gca 4791
Met Arg Thr Thr Thr Ile Lys Phe Ser Ala
1 5 10
att aca ttg gca tta ttg agt tat tgt ggg acc att ttg gcg gat agt 4839
Ile Thr Leu Ala Leu Leu Ser Tyr Cys Gly Thr Ile Leu Ala Asp Ser
15 20 25
cat caa gag gcg act gaa ctt gat acg att acc gtt tct tct caa caa 4887
His Gln Glu Ala Thr Glu Leu Asp Thr Ile Thr Val Ser Ser Gln Gln
30 35 40
gat gag atg aat att aaa gag aaa aaa atc ggt gaa act gtg aaa acg 4935
Asp Glu Met Asn Ile Lys Lys Lys Lys Ile Gly Glu Thr Val Lys Thr
45 50 55
gcg agt caa ttg aaa cgc cag caa gta cag gat agt cgt gat ctt gtg 4983
Ala Ser Gln Leu Lys Arg Gln Gln Val Gln Asp Ser Arg Asp Leu Val
60 65 70
cgc tat gaa acc ggt gtg act gtg gta gaa gct gga cgt ttt ggt tcg 5031
Arg Tyr Glu Thr Gly Val Thr Val Val Glu Ala Gly Arg Phe Gly Ser
75 80 85 90
agc ggt tat gcc att cgt ggt gtg gat gag aac cga gta gca att aca 5079
Ser Gly Tyr Ala Ile Arg Gly Val Asp Glu Asn Arg Val Ala Ile Thr
95 100 105
gta gat ggc tta cat caa gca gaa acc ctt tct tct caa ggc ttt aaa 5127
Val Asp Gly Leu His Gln Ala Glu Thr Leu Ser Ser Gln Gly Phe Lys
110 115 120
gaa tta ttc gaa ggt tac ggc aat ttt aac aat acc cga aat agt gtg 5175
Glu Leu Phe Glu Gly Tyr Gly Asn Phe Asn Asn Thr Arg Asn Ser Val
125 130 135
gaa att gag acg ttg aaa gtc gct aaa atc gcg aaa ggt gct gat tct 5223
Glu Ile Glu Thr Leu Lys Val Ala Lys Ile Ala Lys Gly Ala Asp Ser
140 145 150
gta aaa gtg ggt agt ggt tct ttg gga ggc gct gta ctt ttt gaa aca 5271
Val Lys Val Gly Ser Gly Ser Leu Gly Gly Ala Val Leu Phe Glu Thr
155 160 165 170
aaa gat gcc aga gat ttc ctg act gaa aaa gat tgg cat atc ggc tat 5319
Lys Asp Ala Arg Asp Phe Leu Thr Glu Lys Asp Trp His Ile Gly Tyr
175 180 185
aaa gcg ggc tac tca acg gca gat aat cag gga tta aat gca gtg act 5367
Lys Ala Gly Tyr Ser Thr Ala Asp Asn Gln Gly Leu Asn Ala Val Thr
190 195 200
ctt gca ggt cgc tat caa atg ttt gat gca ttg att atg cat tct aag 5415
Leu Ala Gly Arg Tyr Gln Met Phe Asp Ala Leu Ile Met His Ser Lys
205 210 215
cga cat gga cat gaa tta gaa aat tat gac tat aaa aat ggc aga gat 5463
Arg His Gly His Glu Leu Glu Asn Tyr Asp Tyr Lys Asn Gly Arg Asp
220 225 230

```

WO 02/075507

PCT/US02/01971

att caa ggg aaa gaa aga gag aaa gcg gat cct tat acg att acg aaa 5511  
 Ile Gln Gly Lys Glu Arg Glu Lys Ala Asp Pro Tyr Thr Ile Thr Lys  
 235 240 245 250

gaa agt aca tta gfg aaa ttc tct ttt tgg cca aca gaa aat cat cgt 5559  
 Glu Ser Thr Leu Val Lys Phe Ser Phe Ser Pro Thr Glu Asn His Arg  
 255 260

ttt aca gtc gct tct gat act tat ctt cag cat tcc cgc gga cat gat 5607  
 Phe Thr Val Ala Ser Asp Thr Tyr Leu Gln His Ser Arg Gly His Asp  
 270 275 280

ctt tca tat aat ctt gtt gca aca aca cat att cag tta gat gag aaa 5655  
 Leu Ser Tyr Asn Leu Val Ala Thr Thr His Ile Gln Leu Asp Glu Lys  
 285 290 295

gaa tct cgt cat gca aat gat ttg aca aaa cgt aaa aat gtt tcc ttt 5703  
 Glu Ser Arg His Ala Asn Asp Leu Thr Lys Arg Lys Asn Val Ser Phe  
 300 305 310

act tat gaa aat tat act gtt acg cca ttt tgg gat acg ctc aag tta 5751  
 Thr Tyr Glu Asn Tyr Thr Val Thr Pro Phe Trp Asp Thr Leu Lys Leu  
 315 320 325 330

agc tat tca caa caa aga att aca aca aga gca aga aca gaa gat tat 5799  
 Ser Tyr Ser Gln Gln Arg Ile Thr Thr Arg Ala Arg Thr Glu Asp Tyr  
 335 340 345

tgt gat gga aat gag tta tgt gat tct tat aaa aat cca tta ggt ctc 5847  
 Cys Asp Gly Asn Glu Leu Cys Asp Ser Tyr Lys Asn Pro Leu Gly Leu  
 350 355 360

caa ttt aaa gat ggt cag att ctt gat cct gca ggg aat aaa att aaa 5895  
 Gln Phe Lys Asp Gly Gln Ile Leu Asp Pro Ala Gly Asn Lys Ile Lys  
 365 370 375

cta cag ggg tct gga ttg agc act cag att gta gat gaa aat gga aaa 5943  
 Leu Gln Gly Ser Gly Leu Ser Thr Gln Ile Val Asp Glu Asn Gly Lys  
 380 385 390

cca ttt cct aca aca aca ggt act aat aat gct gct ttt agt aat aat 5991  
 Pro Phe Pro Thr Thr Thr Gly Thr Asn Asn Ala Ala Phe Ser Asn Asn  
 395 400 405 410

tta cga ctc agg cct aca ggt ttt tgg tta gat tgc tgc gtt ttt gac 6039  
 Leu Arg Leu Arg Pro Thr Gly Phe Trp Leu Asp Cys Ser Val Phe Asp  
 415 420 425

tgt aat aaa cca ttc act gtt tat aat att agt aat gga aca tat caa 6087  
 Cys Asn Lys Pro Phe Thr Val Tyr Asn Ile Ser Asn Gly Thr Tyr Gln  
 430 435 440

gca aga gag gtt cta ctg tct gaa gag ata act gtg gat ggt aaa tta 6135  
 Ala Arg Glu Val Leu Leu Ser Glu Glu Ile Thr Val Asp Gly Lys Leu  
 445 450 455

tac aaa aca gct aag gaa gaa gga ggg ctt cca aat tat ttg att tta 6183  
 Tyr Lys Thr Ala Lys Glu Glu Gly Gly Leu Pro Asn Tyr Leu Ile Leu  
 460 465 470

cct aat tct aaa ggt tat ctt cct tat gat tat aaa gaa agg gat ctt 6231  
 Pro Asn Ser Lys Gly Tyr Leu Pro Tyr Asp Tyr Lys Glu Arg Asp Leu  
 475 480 485 490

WO 02/075507

PCT/US02/01971

aat acg aat aca aaa caa att aat tta gat tta act aaa aca ttt tta 6279  
 Asn Thr Asn Thr Lys Gln Ile Asn Leu Asp Leu Thr Lys Thr Phe Leu  
 495 500 505

act ttc aac atc gaa aat aat ctg tca tat ggt gga gtt tat tct cgg 6327  
 Thr Phe Asn Ile Glu Asn Asn Leu Ser Tyr Gly Gly Val Tyr Ser Arg  
 510 515 520

ata gag aaa gaa atg att aat aaa gct ggt tat gag ggg aga aat cct 6375  
 Ile Glu Lys Glu Met Ile Asn Lys Ala Gly Tyr Glu Gly Arg Asn Pro  
 525 530 535

act tgg tgg gct gat aga att tta ggg caa agt agt tac tgt ggt tat 6423  
 Thr Trp Trp Ala Asp Arg Ile Leu Gly Gln Ser Ser Tyr Cys Gly Tyr  
 540 545

aat gca ttg aag tgt ccg aaa cat gag cca tta acg tca ttt tta att 6471  
 Asn Ala Leu Lys Cys Pro Lys His Glu Pro Leu Thr Ser Phe Leu Ile  
 555 560 565

cca gtt gaa gca acg aca cag tca tta tat ttt gca aat att ctt aag 6519  
 Pro Val Glu Ala Thr Thr Gln Ser Leu Tyr Phe Ala Asn Ile Leu Lys  
 575 580 585

gta cat aat atg att agc ata gat tta gga tat cgt tat gat cat att 6567  
 Val His Asn Met Ile Ser Ile Asp Leu Gly Tyr Arg Tyr Asp His Ile  
 590 595 600

aaa tat aac cct gaa tac act cca gga gta act cca aaa att cca gat 6615  
 Lys Tyr Asn Pro Glu Tyr Thr Pro Gly Val Thr Pro Lys Ile Pro Asp  
 605 610 615

gat atg gta aaa ggt ttg ttt att cct atg cca aaa gag cca cag cta 6663  
 Asp Met Val Lys Gly Leu Phe Ile Pro Met Pro Lys Glu Pro Gln Leu  
 620 625 630

aag gat ttt gat tat aac tat gct aaa ttt ggt gag gcc tat aaa aaa 6711  
 Lys Asp Phe Asp Tyr Asn Tyr Ala Lys Phe Gly Glu Ala Tyr Lys Lys  
 635 640 645 650

tgg aaa gaa tat ctg cca aaa aat gcg gaa gaa aat att gct tac att 6759  
 Trp Lys Glu Tyr Leu Pro Lys Asn Ala Glu Glu Asn Ile Ala Tyr Ile  
 655 660 665

gct caa gat aag aca ttt aaa aaa cat tct tat tct ctt ggt gca act 6807  
 Ala Gln Asp Lys Thr Phe Lys Lys His Ser Tyr Ser Leu Gly Ala Thr  
 670 675 680

ttc gat cct ctg aat ttt tta cga gta caa gta aaa tat tca aaa ggg 6855  
 Phe Asp Pro Leu Asn Phe Leu Arg Val Gln Val Lys Tyr Ser Lys Gly  
 685 690 695

ttt aga gcc ceg act teg gat gaa ctt tat ttt acc ttt aag cat cca 6903  
 Phe Arg Ala Pro Thr Ser Asp Glu Leu Tyr Phe Thr Phe Lys His Pro  
 700 705 710

gat ttt acg att tta ccg aac ccc gtg ttg aaa cca gag gaa gca aaa 6951  
 Asp Phe Thr Ile Leu Pro Asn Pro Val Leu Lys Pro Glu Glu Ala Lys  
 715 720 725 730

aat caa gag att gca tta aca gtc cac gat aat tgg gga ttt gtt agc 6999  
 Asn Gln Glu Ile Ala Leu Thr Val His Asp Asn Trp Gly Phe Val Ser  
 735 740 745

WO 02/075507

PCT/US02/01971

aca agt gtt ttc caa aca aag tat cgt cat ttt att gat tta gcg tat 7047  
 Thr Ser Val Phe Gln Thr Lys Tyr Arg His Phe Ile Asp Leu Ala Tyr  
 750 755 760  
 tta ggt tca aga aat tta tcy aat tcc gtg gga ggg cag gca caa gca 7095  
 Leu Gly Ser Arg Asn Leu Ser Asn Ser Val Gly Gly Gln Ala Gln Ala  
 765 770 775  
 aga gat ttc caa gtt tat caa aat gtc aat gtc gat aat gcc aaa gtt 7143  
 Arg Asp Phe Gln Val Tyr Gln Asn Val Asn-Val Asp Asn Ala Lys Val  
 780 785 790  
 aaa gga ctt gaa att aat gca cgt ttg aat ttg gga tat ttt tgg cat 7191  
 Lys Gly Leu Glu Ile Asn Ala Arg Leu Asn Leu Gly Tyr Phe Trp His  
 795 800 805  
 gtg ttg gat gga ttt aat acg agc tat aaa ttc act tac caa cgt ggt 7239  
 Val Leu Asp Gly Phe Asn Thr Ser Tyr Lys Phe Thr Tyr Gln Arg Gly  
 815 820 825  
 cgt ttg gat gcc gat cgt cca atg aat gcg att cag cct aaa gct tct 7287  
 Arg Leu Asp Gly Asp Arg Pro Met Asn Ala Ile Gln Pro Lys Ala Ser  
 830 835 840  
 gtt ttt ggt ttg gcc tac gat cat aaa gaa aat aaa ttt gcc gct gat 7335  
 Val Phe Gly Leu Gly Tyr Asp His Lys Glu Asn Lys Phe Gly Ala Asp  
 845 850 855  
 tta tat att aca cgt gtg agt gag aaa aaa gcg aaa gac act tat aat 7383  
 Leu Tyr Ile Thr Arg Val Ser Glu Lys Lys Ala Lys Asp Thr Tyr Asn  
 860 865 870  
 atg ttc tat aaa gaa cag gga tat aaa gat agt gct gtt cgt tgg aga 7431  
 Met Phe Tyr Lys Glu Gln Gly Tyr Lys Asp Ser Ala Val Arg Trp Arg  
 875 880 885 890  
 agt gat gac tat acg cta gtt gat gcg gtt ggt tat att aaa ccg att 7479  
 Ser Asp Asp Tyr Thr Leu Val Asp Ala Val Gly Tyr Ile Lys Pro Ile  
 895 900 905  
 aag aat tta acg tta cag ttt gcc gtt tat aat ttg aca gac cgt aaa 7527  
 Lys Asn Leu Thr Leu Gln Phe Gly Val Tyr Asn Leu Thr Asp Arg Lys  
 910 915 920  
 tac ttg aca tgg gaa tct gct cgt tcy att aaa cca ttt ggt aca agt 7575  
 Tyr Leu Thr Trp Glu Ser Ala Arg Ser Ile Lys Pro Phe Gly Thr Ser  
 925 930 935  
 aat tta att aat caa aaa aca gcc gca gga att aat cgt ttt tac tca 7623  
 Asn Leu Ile Asn Gln Lys Thr Gly Ala Gly Ile Asn Arg Phe Tyr Ser  
 940 945 950  
 cca ggt cgt aac ttt aaa ctc agt gcc gaa atc acc ttc taatcctaag 7672  
 Pro Gly Arg Asn Phe Lys Leu Ser Ala Glu Ile Thr Phe  
 955 960 965  
 cctgcgtatg caggetttct ttttagggaa agtgcggtgg atttgacaaa gattttattgc 7732  
 ttttctgtaa atcaatgcta aaattcacac tcctttgtcg tagctggatt agagatcggc 7792  
 tagcgatgta tttttaactt aacttttagg agttatcaaa tgcctcctaag tacagaaaaa 7852  
 aaagcagcaa ttgttgctga atttggctgt gatgcaaaag ataccggttc ttcagaagtg 7912

WO 02/075507

PCT/US02/01971

caaatcgcat tattaactgc acaaatcaac cacttacaat ctcactttgc aacgcacaaa 7972  
 aaagaccacc acggtcgtcg tggtttattg cgtatggttt ctcgtcgtcg taaactttta 8032  
 gattacttaa aacgtactaa tcttgagctt tacacttcaa ctatcgtcg tttaggttta 8092  
 cgtcgtcaat ttgtattagg atttattcca aacaaaaaac ccttgataat tttatcaagg 8152  
 gttttctttt ttctgcatac taggcatggt taaattatcg caaacacac cgcacatttc 8212  
 gtgaaaaagt cgggtcattt ttttaattta ctttactctt ttaaacatga tctcacttgg 8272  
 gattactgaa ccttgcaggt aaagtcaggt agcagctttt tcagctaatt gcataaacga 8332  
 ttgggcaatg tcgctttcag gtgogggcag aacggttggg atacctttgt ctaaatcttc 8392  
 acgtaagcga atatgtaatg cctgttgtcc taaaactttg acattatatt tttgtgcaat 8452  
 gcgctcagca ccgctgttcc cgaaaatcgt ttcttgatga ccacaattgc tacaaatag 8512  
 catcagcata ttttcgataa tgcctaaaac gggtaacagaa acacgctcaa acatcgccac 8572  
 accttaatc gcacccagta aagcaatata ttgtgtgtgt gtcaccacga cgcctccctg 8632  
 cactggaatt tgttgagaaa gggtcagctg gatccccct gtaccgggtg gcataatcaat 8692  
 gactaaataa tctaaatcag gccataaggt ttcttgcaaa agctgactta aggcactgct 8752  
 tgcctattga ccgcgccaaa tctgagcatt gtcctgttcc attaagaac caatggaatt 8812  
 ggcaaaaata tgatgtgctt gaattggggt aatgtgctgg ttactctggc aagttgggag 8872  
 ttgatcagca acccctaaca tgtgtggaat agatggacca taaatctgg catctaaaat 8932  
 tccaacacga gcaccttgc tttgtaagc aagagcaaga tggacggaaa tagtagattt 8992  
 tcttacacca cctttaccg atgtcacggc aataatattt tttaccctt ttaccgctgg 9052  
 gtgctatta gcgctttta atgtcgcgat ttgataattt aattgccatt tgatgtcttt 9112  
 geattctgct aatgtgagaa gttctgtgga gagagcctc ttgagttgtt cgaatgcagt 9172  
 attccaagca aacggcatgc tgatttcaat acgtaacgtc tcaccgctt tttcaatttt 9232  
 ttgatagca tttaggctga cgagatcttt ttgtaagcta ggatgttga attgtgaaa 9292  
 tgtgttttg atagcttctt tttgactgtc cgttaaacgt tcagaaaaata aaattccat 9352  
 tgattttatc ccgttatatt tgggtgctaa ttaaagccct agttaatcac tcaactatat 9412  
 ttaaccacga agctgtagaa ctgtaagca gaaatgtgga aaagcgggt taaagtagaa 9472  
 aaaatactgc gaataaggta acataagcgc caattttttg atgaaaaata ggaatgataa 9532  
 catggcaaat tcggcacgag atatttttgg cacttgcgcc ttaccttatg caaatggtgc 9592  
 aattcattta gggcatttat tagaacatat tcaagcagat atttgggtgc gttccaactg 9652  
 atcgtgggc ataaagtgca ttttatttgt gcagatgat cccatggcac accaatcatg 9712  
 ttaaatgca taaattaggt attacaccaa agcattaatt gctcctcgaa agcagaacat 9772  
 gtggcggatt tgaaggctta atattageta tgataatata at 9814

WO 02/075507

PCT/US02/01971

<210> 32  
 <211> 967  
 <212> PRT  
 <213> *Pasteurella multocida*  
 <400> 32  
 Met Arg Thr Thr Thr Ile Lys Phe Ser Ala Ile Thr Leu Ala Leu Leu  
 1 5 10 15  
 Ser Tyr Cys Gly Thr Thr Ile Leu Ala Asp Ser His Gln Glu Ala Thr Glu  
 20 25 30  
 Leu Asp Thr Ile Thr Val Ser Ser Gln Gln Asp Glu Met Asn Ile Lys  
 35 40 45  
 Glu Lys Lys Ile Gly Glu Thr Val Lys Thr Ala Ser Gln Leu Lys Arg  
 50 55 60  
 Gln Gln Val Gln Asp Ser Arg Asp Leu Val Arg Tyr Glu Thr Gly Val  
 65 70 75 80  
 Thr Val Val Glu Ala Gly Arg Phe Gly Ser Ser Gly Tyr Ala Ile Arg  
 85 90 95  
 Gly Val Asp Glu Asn Arg Val Ala Ile Thr Val Asp Gly Leu His Gln  
 100 105 110  
 Ala Glu Thr Leu Ser Ser Gln Gly Phe Lys Glu Leu Phe Glu Gly Tyr  
 115 120 125  
 Gly Asn Phe Asn Asn Thr Arg Asn Ser Val Glu Ile Glu Thr Leu Lys  
 130 135 140  
 Val Ala Lys Ile Ala Lys Gly Ala Asp Ser Val Lys Val Gly Ser Gly  
 145 150 155 160  
 Ser Leu Gly Gly Ala Val Leu Phe Glu Thr Lys Asp Ala Arg Asp Phe  
 165 170 175  
 Leu Thr Glu Lys Asp Trp His Ile Gly Tyr Lys Ala Gly Tyr Ser Thr  
 180 185 190  
 Ala Asp Asn Gln Gly Leu Asn Ala Val Thr Leu Ala Gly Arg Tyr Gln  
 195 200 205  
 Met Phe Asp Ala Leu Ile Met His Ser Lys Arg His Gly His Glu Leu  
 210 215 220  
 Glu Asn Tyr Asp Tyr Lys Asn Gly Arg Asp Ile Gln Gly Lys Glu Arg  
 225 230 235 240  
 Glu Lys Ala Asp Pro Tyr Thr Ile Thr Lys Glu Ser Thr Leu Val Lys  
 245 250 255  
 Phe Ser Phe Ser Pro Thr Glu Asn His Arg Phe Thr Val Ala Ser Asp  
 260 265 270  
 Thr Tyr Leu Gln His Ser Arg Gly His Asp Leu Ser Tyr Asn Leu Val  
 275 280 285  
 Ala Thr Thr His Ile Gln Leu Asp Glu Lys Glu Ser Arg His Ala Asn  
 290 295 300

WO 02/075507

PCT/US02/01971

Asp Leu Thr Lys Arg Lys Asn Val Ser Phe Thr Tyr Glu Asn Tyr Thr  
 305 310 315 320  
 Val Thr Pro Phe Trp Asp Thr Leu Lys Leu Ser Tyr Ser Gln Gln Arg  
 325 330 335  
 Ile Thr Thr Arg Ala Arg Thr Glu Asp Tyr Cys Asp Gly Asn Glu Leu  
 340 345 350  
 Cys Asp Ser Tyr Lys Asn Pro Leu Gly Leu Gln Phe Lys Asp Gly Gln  
 355 360 365  
 Ile Leu Asp Pro Ala Gly Asn Lys Ile Lys Leu Gln Gly Ser Gly Leu  
 370 375 380  
 Ser Thr Gln Ile Val Asp Glu Asn Gly Lys Pro Phe Pro Thr Thr Thr  
 385 390 395 400  
 Gly Thr Asn Asn Ala Ala Phe Ser Asn Asn Leu Arg Leu Arg Pro Thr  
 405 410 415  
 Gly Phe Trp Leu Asp Cys Ser Val Phe Asp Cys Asn Lys Pro Phe Thr  
 420 425 430  
 Val Tyr Asn Ile Ser Asn Gly Thr Tyr Gln Ala Arg Glu Val Leu Leu  
 435 440 445  
 Ser Glu Glu Ile Thr Val Asp Gly Lys Leu Tyr Lys Thr Ala Lys Glu  
 450 455 460  
 Glu Gly Gly Leu Pro Asn Tyr Leu Ile Leu Pro Asn Ser Lys Gly Tyr  
 465 470 475 480  
 Leu Pro Tyr Asp Tyr Lys Glu Arg Asp Leu Asn Thr Asn Thr Lys Gln  
 485 490 495  
 Ile Asn Leu Asp Leu Thr Lys Thr Phe Leu Thr Phe Asn Ile Glu Asn  
 500 505 510  
 Asn Leu Ser Tyr Gly Gly Val Tyr Ser Arg Ile Glu Lys Glu Met Ile  
 515 520 525  
 Asn Lys Ala Gly Tyr Glu Gly Arg Asn Pro Thr Trp Trp Ala Asp Arg  
 530 535 540  
 Ile Leu Gly Gln Ser Ser Tyr Cys Gly Tyr Asn Ala Leu Lys Cys Pro  
 545 550 555 560  
 Lys His Glu Pro Leu Thr Ser Phe Leu Ile Pro Val Glu Ala Thr Thr  
 565 570 575  
 Gln Ser Leu Tyr Phe Ala Asn Ile Leu Lys Val His Asn Met Ile Ser  
 580 585 590  
 Ile Asp Leu Gly Tyr Arg Tyr Asp His Ile Lys Tyr Asn Pro Glu Tyr  
 595 600 605  
 Thr Pro Gly Val Thr Pro Lys Ile Pro Asp Asp Met Val Lys Gly Leu  
 610 615 620  
 Phe Ile Pro Met Pro Lys Glu Pro Gln Leu Lys Asp Phe Asp Tyr Asn  
 625 630 635 640

WO 02/075507

PCT/US02/01971

Tyr Ala Lys Phe Gly Glu Ala Tyr Lys Lys Trp Lys Glu Tyr Leu Pro  
 645 650 655  
 Lys Asn Ala Glu Glu Asn Ile Ala Tyr Ile Ala Gln Asp Lys Thr Phe  
 660 665 670  
 Lys Lys His Ser Tyr Ser Leu Gly Ala Thr Phe Asp Pro Leu Asn Phe  
 675 680  
 Leu Arg Val Gln Val Lys Tyr Ser Lys Gly Phe Arg Ala Pro Thr Ser  
 690 695 700  
 Asp Glu Leu Tyr Phe Thr Phe Lys His Pro Asp Phe Thr Ile Leu Pro  
 705 710 715 720  
 Asn Pro Val Leu Lys Pro Glu Glu Ala Lys Asn Gln Glu Ile Ala Leu  
 725 730 735  
 Thr Val His Asp Asn Trp Gly Phe Val Ser Thr Ser Val Phe Gln Thr  
 740 745 750  
 Lys Tyr Arg His Phe Ile Asp Leu Ala Tyr Leu Gly Ser Arg Asn Leu  
 755 760 765  
 Ser Asn Ser Val Gly Gly Gln Ala Gln Ala Arg Asp Phe Gln Val Tyr  
 770 775 780  
 Gln Asn Val Asn Val Asp Asn Ala Lys Val Lys Gly Leu Glu Ile Asn  
 785 790 795 800  
 Ala Arg Leu Asn Leu Gly Tyr Phe Trp His Val Leu Asp Gly Phe Asn  
 805 810 815  
 Thr Ser Tyr Lys Phe Thr Tyr Gln Arg Gly Arg Leu Asp Gly Asp Arg  
 820 825 830  
 Pro Met Asn Ala Ile Gln Pro Lys Ala Ser Val Phe Gly Leu Gly Tyr  
 835 840 845  
 Asp His Lys Glu Asn Lys Phe Gly Ala Asp Leu Tyr Ile Thr Arg Val  
 850 855 860  
 Ser Glu Lys Lys Ala Lys Asp Thr Tyr Asn Met Phe Tyr Lys Glu Gln  
 865 870 875 880  
 Gly Tyr Lys Asp Ser Ala Val Arg Trp Arg Ser Asp Asp Tyr Thr Leu  
 885 890 895  
 Val Asp Ala Val Gly Tyr Ile Lys Pro Ile Lys Asn Leu Thr Leu Gln  
 900 905 910  
 Phe Gly Val Tyr Asn Leu Thr Asp Arg Lys Tyr Leu Thr Trp Glu Ser  
 915 920 925  
 Ala Arg Ser Ile Lys Pro Phe Gly Thr Ser Asn Leu Ile Asn Gln Lys  
 930 935 940  
 Thr Gly Ala Gly Ile Asn Arg Phe Tyr Ser Pro Gly Arg Asn Phe Lys  
 945 950 955 960  
 Leu Ser Ala Glu Ile Thr Phe  
 965



WO 02/075507

PCT/US02/01971

```

<210> 33
<211> 2990
<212> DNA
<213> Pasteurella multocida

<220>
<221> CDS
<222> (1106)..(1564)

<220>
<223> kdtB

<400> 33
gtcaaccctt ttggctttga gttgtgctaa taaagcatcg tcaaaatgca agccggcagt 60
tgggtgccga accgcgccag ggaactttgtt ataaacggtt tgataacggt ctttatccgc 120
ttcttcgtca gggcgatcaa tataaggggg caatggcata tgccaattt gctgtaacac 180
gtctaaaagt gcggtctggt ttgcgcgat ttctaattca aataaggat catggcgcgc 240
aacatgac atttgacac catgatgttc acctactta tcttcgccta accacagttc 300
tgccctctc ttccgtgctt ttgagggagc cacatggcct aaaaagcgtg tctcggataa 360
aatccgctcg accaacactt ccaccttacc gccactggct ttacgtccaa acatccttgc 420
aggaatcacg cgcgtgttat taaaaattaa taagtcgctt tcatgaatt gatcaaggat 480
atcagcaaaa gtgcggtggg taatctcacc atttcgcgc ttaagttgta ataagcagct 540
agcgggtcga tccggttttg ggtaacgagc aatcagctca tccggtaaat caaataaaaa 600
gtcagaaaac cgcataaata gggttataaa aagttatcta aaaaatcgtg ggcgtaagtc 660
tagtgtgaat tccgctcttg cacaaagaaa aatccagatt ttgtgttga gtatcgaatt 720
gagatgatt tggacaaaa aaaagccctt tcaagaaga cgaaggcgcg aaaatatatt 780
tggagtcata ctttttaggg tatgtgtcgg attatacaca caaaaataac aaatgcaaca 840
ttttttaac aatcatatgt aagcgtattg tgtgagaacg agcgtaaaaa tgaacgcatt 900
ctaaaggatg atttatttag cctattaaaa aaacacatga gatgagagt tgcgagagcg 960
gtaataaaag tgcggtgggt tttagaaaag ttttgaatag gatcacaat taacaagaat 1020
ttgtgaaata ccaagtagta gtttttaagt atatgatgan tcatatgcta aagtttaaac 1080
ccgttaaata accaagaggt ggaag atg aca gaa gaa aat aaa gga aag aga 1132
Met Thr Glu Glu Asn Lys Gly Lys Arg
1 5

tat ttt tta tgg ttc ata ttg ttt atc ctt tca atc tat tta ttt att 1180
Tyr Phe Leu Trp Phe Ile Leu Phe Ile Leu Ser Ile Tyr Leu Phe Ile
10 15 20 25

acc ata caa gaa aga cga ggt tat tgt ttt gac aaa cgt gca tat att 1228
Thr Ile Gln Glu Arg Arg Gly Tyr Cys Phe Asp Lys Arg Ala Tyr Ile
30 35 40

```

WO 02/075507

PCT/US02/01971

```

cat gag ctt tat act gag caa gag tta att gat cgg ggg att gaa tat 1276
His Glu Leu Tyr Thr Glu Gln Glu Leu Ile Asp Arg Gly Ile Glu Tyr
      45
      50
      55
gtg gta tcc acc atg ccg tca ggt gtt att aaa cca gat ggc aca ata 1324
Val Val Ser Thr Met Pro Ser Gly Val Ile Lys Pro Asp Gly Thr Ile
      60
      65
      70
aaa gaa gta aag cgt tac acg agt gtc gag gag ttt aaa cag atg aac 1372
Lys Glu Val Lys Arg Tyr Thr Ser Val Glu Glu Phe Lys Gln Met Asn
      75
      80
      85
cca gct tgt tgt aca tta acc acc ttt att gat gaa gga ggc gat ggc 1420
Pro Ala Cys Cys Thr Leu Thr Thr Phe Ile Asp Glu Gly Gly Asp Gly
      90
      95
      100
      105
tat cca gat gat gat gga tat ggt tat gtc aga att gaa tat tta aga 1468
Tyr Pro Asp Asp Asp Gly Tyr Gly Tyr Val Arg Ile Glu Tyr Leu Arg
      110
      115
      120
cat tat gtt gag aat cta aaa cct tat cat aga gtg att tat ctt gaa 1516
His Tyr Val Glu Asn Leu Lys Pro Tyr His Arg Val Ile Tyr Leu Glu
      125
      130
      135
tat acg ccc tgt gga gag tta agg gaa gag gcg gct ttt tca aaa aat 1564
Tyr Thr Pro Cys Gly Glu Leu Arg Glu Glu Ala Ala Phe Ser Lys Asn
      140
      145
      150
taagagtgag gtgaagaat ggcattacca acagcaacaa taatgaggaa tttatcttta 1624
tctaaaaatc aattcactct gaaaggatg gaatgcgat attccctatt tcaagcatgc 1684
agtaatatgg atcatgggta ctgaggtgga agatggcaga agaaaataaa ggaagagat 1744
atTTTTatg gttcatattg tttatccttt caatctattt atttattacc atacaagaaa 1804
gacgaggtta ttgttttgac aaatgggaat atatccataa cctttatacc gagcaagagt 1864
tgatcgatag aggggttgaa tatgtggtat ccaccatgcc gtcaggtgtt ttgaaaccag 1924
atggcacaaac aaccgaaata aaacgttatg ctagtgttga ggagtttaaa cagatgaacc 1984
ctgattgttg taaattaaca agatttatta atgaaggaat agatggcraa ccagatgatg 2044
atggataggg ttatataaga attgaatatt taagacatta tgttgggaat tttaaacctg 2104
atcatagagt gctttatctc gaataacgc cttgtggaga attaaggaa gaggtttctt 2164
tttaaaaaat aaataatagt gaggtgaaga aatggcatta ccaacagcaa cagaaatcac 2224
aaatgcatat ttatataaaa ataaattaac tctaaagcg gaggaagag tagattcaat 2284
acaaattctt gaaaaaggag atgaacattt cgaagtaaat tttattgat caaagtactc 2344
tattgattga aggaaaaaca gtggaattaa tggcaggtat ggcagtttct gggaaatta 2404
aaacaggtaa acgcaagtga ttgattact tatttagccc attaaaaacc acaaaataat 2464
attaaggaga ataatatgtc gtataataaa tatactgttg ctttgattac gttctcaaca 2524
gggatctgta ttccggcaat atgctacgct ctaaattcgc tgggatacag atcctgtttg 2584
agactatgta gaaaagacta aactttgtgt ggttaactgg gcttcggtaa aattctggaa 2644

```

WO 02/075507

PCT/US02/01971

acaaatgggc ttaaccgagc tgaattatc cgtgagctt tcgcttgatg aaattgccga 2704  
 aattcgtcag caagtgccag aaatggaat tgaagtgttc gtgcatgggg cattatgcat 2764  
 ggcgtattct ggacgttgtt tattatcagg ctatattaat aaacgtgac caaatcaagg 2824  
 cacctgtacc aatgcgtgcc gttgggaata cagtgtacc gaagccaaag aagatgagat 2884  
 cggcaacatt gtgaatgtgg gtgaagaat tccagtgaat aatgtagcac cgacaattgg 2944  
 cgaaggcgac accaccagta aagratTTTT attagcagaa agtcga 2990

<210> 34  
 <211> 153  
 <212> PRT  
 <213> Pasteurella multocida

<400> 34  
 Met Thr Glu Glu Asn Lys Gly Lys Arg Tyr Phe Leu Trp Phe Ile Leu  
 1 5 10 15  
 Phe Ile Leu Ser Ile Tyr Leu Phe Ile Thr Ile Gln Glu Arg Gly  
 20 25 30  
 Tyr Cys Phe Asp Lys Arg Ala Tyr Ile His Glu Leu Tyr Thr Glu Gln  
 35 40 45  
 Glu Leu Ile Asp Arg Gly Ile Glu Tyr Val Val Ser Thr Met Pro Ser  
 50 55 60  
 Gly Val Ile Lys Pro Asp Gly Thr Ile Lys Glu Val Lys Arg Tyr Thr  
 65 70 75 80  
 Ser Val Glu Glu Phe Lys Gln Met Asn Pro Ala Cys Cys Thr Leu Thr  
 85 90 95  
 Thr Phe Ile Asp Glu Gly Gly Asp Gly Tyr Pro Asp Asp Asp Gly Tyr  
 100 105 110  
 Gly Tyr Val Arg Ile Glu Tyr Leu Arg His Tyr Val Glu Asn Leu Lys  
 115 120 125  
 Pro Tyr His Arg Val Ile Tyr Leu Glu Tyr Thr Pro Cys Gly Glu Leu  
 130 135 140  
 Arg Glu Glu Ala Ala Phe Ser Lys Asn  
 145 150

<210> 35  
 <211> 1683  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (325)..(1230)

<220>  
 <223> lgtC

WO 02/075507

PCT/US02/01971

```

<220>
<221> misc_feature
<222> 219
<223> Xaa = any or unknown amino acid

<220>
<221> misc_feature
<222> 226
<223> Xaa = any or unknown amino acid

<220>
<221> misc_feature
<222> 269
<223> Xaa = any or unknown amino acid

<220>
<221> misc_feature
<222> 270
<223> Xaa = any or unknown amino acid

<220>
<221> misc_feature
<222> 274
<223> Xaa = any or unknown amino acid

<400> 35
atatcaaaagt ctcatggcaa gaaaattaga aaagagcgat caattattat ttgcaagatt 60
tgggtattat tcatagagcta ggtgaaagat atatttttcc atgatattaa aacgattcag 120
gcagaactgg cttagcttacc acttttagat aattgtatta ttaaagaag ctgtatgatt 180
gttattctat cattagtggg taataaatat tctttatttt ttgagagata aaaacaattc 240
atatttcaat agaaaacaga aaataaagat tatcaaaaga attatccgtc cttataaata 300
tgagtcctgta ttgtgagatg atat atg aat att tta ttt gtt tct gat gat 351
Met Asn Ile Leu Phe Val Ser Asp Asp
1 5

ggt tat gct aaa cat ctg gtg gtt gcg att aaa agc att ata aat cat 399
Val Tyr Ala Lys His Leu Val Val Ala Ile Lys Ser Ile Ile Asn His
10 15 20 25

aat gaa aaa ggt att tca ttt tat att ttt gat ttg ggt ata aag gat 447
Asn Glu Lys Gly Ile Ser Phe Tyr Ile Phe Asp Leu Gly Ile Lys Asp
30 35 40

gaa aat aag aga aat att aat gat att gtt tct tct tat gga agt gaa 495
Glu Asn Lys Arg Asn Ile Asn Asp Ile Val Ser Ser Tyr Gly Ser Glu
45 50 55

gtc aac ttt att gct gtg aat gag aaa gaa ttt gag agt ttt cct gtt 543
Val Asn Phe Ile Ala Val Asn Glu Lys Glu Phe Glu Ser Phe Pro Val
60 65 70

caa att agt tat att tct tta gca aca tat gca agg cta aaa gcg gca 591
Gln Ile Ser Tyr Ile Ser Leu Ala Thr Tyr Ala Arg Leu Lys Ala Ala
75 80 85

gag tat ttg ccg gat aat tta aat aaa att att tat tta gat gtt gat 639
Glu Tyr Leu Pro Asp Asn Leu Asn Lys Ile Ile Tyr Leu Asp Val Asp
90 95 100 105

```

WO 02/075507

PCT/US02/01971

gtt ttg gtt ttt aac tca tta gaa atg tta tgg aat gtt gat gtt aat 687  
 Val Leu Val Phe Asn Ser Leu Glu Met Leu Trp Asn Val Asp Val Asn  
 110 115 120  
 aat ttt ctt acc gca gcc tgt tat gat tct ttc atc gaa aat gaa aag 735  
 Asn Phe Leu Thr Ala Ala Cys Tyr Asp Ser Phe Ile Glu Asn Glu Lys  
 125 130 135  
 tct gag cat aaa aaa tgg att tca atg tca gat aag gaa tat tat ttt 783  
 Ser Glu His Lys Lys Ser Ile Ser Met Ser Asp Lys Glu Tyr Tyr Phe  
 140 145 150  
 aat gca gga gta atg cta ttt aat tta gat gaa tgg cgg aag atg gat 831  
 Asn Ala Gly Val Met Leu Phe Asn Leu Asp Glu Trp Arg Lys Met Asp  
 155 160 165  
 gta ttc tca aga gct tta gac ctg tta gct atg tat cct aat caa atg 879  
 Val Phe Ser Arg Ala Leu Asp Leu Leu Ala Met Tyr Pro Asn Gln Met  
 170 175 180 185  
 att tat cag gat caa gat ata ttg aat atc ctt ttt agg aat aaa gtc 927  
 Ile Tyr Gln Asp Gln Asp Ile Leu Asn Ile Leu Phe Arg Asn Lys Val  
 190 195 200  
 tgt tat tta gat tgc aga ttt aat ttc atg cca aat caa ctt gaa aga 975  
 Cys Tyr Leu Asp Cys Arg Phe Asn Phe Met Pro Asn Gln Leu Glu Arg  
 205 210 215  
 ata aan caa tac cat aaa gga aaa ntg agc aac tta cat tct tta gaa 1023  
 Ile Xaa Gln Tyr His Lys Gly Lys Xaa Ser Asn Leu His Ser Leu Glu  
 220 225 230  
 aaa aca acg atg cct gtc gtt att tca cat tat tgt ggt cca gaa aaa 1071  
 Lys Thr Thr Met Pro Val Val Ile Ser His Tyr Cys Gly Pro Glu Lys  
 235 240 245  
 gcg tgg cat gcg gat tgt aaa cat ttt aat gta tat ttc tat cag aaa 1119  
 Ala Trp His Ala Asp Cys Lys His Phe Asn Val Tyr Phe Tyr Gln Lys  
 250 255 260 265  
 ata tta gca naa atn tgc aga gcc ncg gat aaa gaa cgc gta tta tct 1167  
 Ile Leu Ala Xaa Xaa Ser Arg Gly Xaa Asp Lys Glu Arg Val Leu Ser  
 270 275 280  
 ata aaa act tat ctc aag gcc ttg att aga agg att aga tat aaa ttc 1215  
 Ile Lys Thr Tyr Leu Lys Ala Leu Ile Arg Arg Ile Arg Tyr Lys Phe  
 285 290 295  
 aaa tat caa gtc tat taactattga atttttgcaa atgagataag agtatagtgc 1270  
 Lys Tyr Gln Val Tyr  
 300  
 tgatttcttc aaagcgaaaa ggaggaaata gcttgttcta atttattaca ataatggttg 1330  
 tattcatcct gattttgaag gaaagagagt gttttttgta taaaagcatt ttctcacct 1390  
 aaatttacta atctccaaa ttctctctct cgnagaattt ctttcggacc ggtagggcag 1450  
 tccatggata ttacaggtgt accgcaagcc atgctttcta ggataactgt cggtaacccc 1510  
 tctttcaag aggtgtgtaa aaatagctta gcatttttta ttaatggata cggattatct 1570  
 ttatttccta aaagaaaaca atcttcttgc agattgagtg atctctattg tttctctaat 1630

WO 02/075507

PCT/US02/01971

ttttctcgac actcaccatc ccaacaata tatanenttt ctggatacc tcc 1683

<210> 36  
 <211> 302  
 <212> PRT  
 <213> Pasteurella multocida  
 <220>  
 <221> misc\_feature  
 <222> 219  
 <223> Xaa = any or unknown amino acid  
 <220>  
 <221> misc\_feature  
 <222> 226  
 <223> Xaa = any or unknown amino acid  
 <220>  
 <221> misc\_feature  
 <222> 259  
 <223> Xaa = any or unknown amino acid  
 <220>  
 <221> misc\_feature  
 <222> 270  
 <223> Xaa = any or unknown amino acid  
 <220>  
 <221> misc\_feature  
 <222> 274  
 <223> Xaa = any or unknown amino acid

<400> 36  
 Met Asn Ile Leu Phe Val Ser Asp Asp Val Tyr Ala Lys His Leu Val  
 1 5 10 15  
 Val Ala Ile Lys Ser Ile Ile Asn His Asn Glu Lys Gly Ile Ser Phe  
 20 25 30  
 Tyr Ile Phe Asp Leu Gly Ile Lys Asp Glu Asn Lys Arg Asn Ile Asn  
 35 40 45  
 Asp Ile Val Ser Ser Tyr Gly Ser Glu Val Asn Phe Ile Ala Val Asn  
 50 55 60  
 Glu Lys Glu Phe Glu Ser Phe Pro Val Gln Ile Ser Tyr Ile Ser Leu  
 65 70 75 80  
 Ala Thr Tyr Ala Arg Leu Lys Ala Ala Glu Tyr Leu Pro Asp Asn Leu  
 85 90 95  
 Asn Lys Ile Ile Tyr Leu Asp Val Asp Val Leu Val Phe Asn Ser Leu  
 100 105 110  
 Glu Met Leu Trp Asn Val Asp Val Asn Asn Phe Leu Thr Ala Ala Cys  
 115 120 125  
 Tyr Asp Ser Phe Ile Glu Asn Glu Lys Ser Glu His Lys Lys Ser Ile  
 130 135 140

WO 02/075507

PCT/US02/01971

Ser Met Ser Asp Lys Glu Tyr Tyr Phe Asn Ala Gly Val Met Leu Phe  
 145 150 155 160  
 Asn Leu Asp Glu Trp Arg Lys Met Asp Val Phe Ser Arg Ala Leu Asp  
 165 170 175  
 Leu Leu Ala Met Tyr Pro Asn Gln Met Ile Tyr Gln Asp Gln Asp Ile  
 180 185 190  
 Leu Asn Ile Leu Phe Arg Asn Lys Val Cys Tyr Leu Asp Cys Arg Phe  
 195 200 205  
 Asn Phe Met Pro Asn Gln Leu Glu Arg Ile Xaa Gln Tyr His Lys Gly  
 210 215 220  
 Lys Xaa Ser Asn Leu His Ser Leu Glu Lys Thr Thr Met Pro Val Val  
 225 230 235  
 Ile Ser His Tyr Cys Gly Pro Glu Lys Ala Trp His Ala Asp Cys Lys  
 245 250 255  
 His Phe Asn Val Tyr Phe Tyr Gln Lys Ile Leu Ala Xaa Xaa Ser Arg  
 260 265 270  
 Gly Xaa Asp Lys Glu Arg Val Leu Ser Ile Lys Thr Tyr Leu Lys Ala  
 275 280 285  
 Leu Ile Arg Arg Ile Arg Tyr Lys Phe Lys Tyr Gln Val Tyr  
 290 295 300

<210> 37  
 <211> 2029  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (2)..(499)

<220>  
 <223> mglB

<220>  
 <221> misc\_feature  
 <222> 33  
 <223> Xaa = any or unknown amino acid

<220>  
 <221> misc\_feature  
 <222> 99  
 <223> Xaa = any or unknown amino acid

<220>  
 <221> misc\_feature  
 <222> 101  
 <223> Xaa = any or unknown amino acid

<220>  
 <221> misc\_feature  
 <222> 928  
 <223> n = A or T or G or C

WO 02/075507

PCT/US02/01971

```

<220>
<221> misc_feature
<222> 1007
<223> n = A or T or G or C

<220>
<221> misc_feature
<222> 1740
<223> n = A or T or G or C

<220>
<221> misc_feature
<222> 1808
<223> n = A or T or G or C

<220>
<221> misc_feature
<222> 1816
<223> n = A or T or G or C

<220>
<221> misc_feature
<222> 1820
<223> n = A or T or G or C

<400> 37
c tta aat aaa gcc ggt aaa att caa tac gtt tta tta aaa ggt aac caa 49
  Leu Asn Lys Ala Gly Lys Ile Gln Tyr Val Leu Leu Lys Gly Asn Gln
   1           5           10           15

gga cac cca gat gca gaa gct cgt aca aaa ttc gtc att aaa gaa tta 97
  Gly His Pro Asp Ala Glu Ala Arg Thr Lys Phe Val Ile Lys Glu Leu
   20           25           30

nat aat aaa ggc att caa gat gag caa tta ttc atc gac acg ggg atg 145
  Xaa Asn Lys Gly Ile Gln Asp Glu Gln Leu Phe Ile Asp Thr Gly Met
   35           40           45

tgg gat gcc gct tta gcg aaa gat aaa atg gat gca tgg tta tct agc 193
  Trp Asp Ala Ala Leu Ala Lys Asp Lys Met Asp Ala Trp Leu Ser Ser
   50           55           60

tct aaa gca aat caa att gaa gtg atc atc gct aac aac gat ggt atg 241
  Ser Lys Ala Asn Gln Ile Glu Val Ile Ile Ala Asn Asn Asp Gly Met
   65           70           75           80

gcg atg ggg gca ttg gaa gcc acg aaa gca cat ggt aaa aaa tta cca 289
  Ala Met Gly Ala Leu Glu Ala Thr Lys Ala His Gly Lys Lys Leu Pro
   85           90           95

atc ttc ngt gta nat gcg tta cca gaa gtc ctc caa tta atc aaa aaa 337
  Ile Phe Xaa Val Xaa Ala Leu Pro Glu Val Leu Gln Leu Ile Lys Lys
  100           105           110

ggt gaa att gca ggt acg gtg tta aat gac ggt gtg aac caa ggt aaa 385
  Gly Glu Ile Ala Gly Thr Val Leu Asn Asp Gly Val Asn Gln Gly Lys
  115           120           125

gcc gtt gtt caa tta agt aat aat ctt gca aaa gga aaa cct gcc act 433
  Ala Val Val Gln Leu Ser Asn Asn Leu Ala Lys Gly Lys Pro Ala Thr
  130           135           140

```



WO 02/075507

PCT/US02/01971

```

gaa ggc aca aaa tgg cag tta aaa cga tgg tgt cct acg tat ccc tta 481
Glu Gly Thr Lys Trp Gln Leu Lys Arg Ser Cys Pro Thr Tyr Pro Leu
145 150 155 160
tgt tgg tgt gga tgc gga taacttaaac gagttcctaa aataataaac 529
Cys Trp Cys Gly Cys Gly
165
tatacaaaa caagamtgtg taattctcgg ggaggtatac cctccccctt tttatgtgag 589
gttggatag acaactcaaa ttccaatca agacagttaa atactgctca caatgaccaa 649
cgtctgtaaa tcctttcccg gtgttaaac gttagacaat gcaaacctaa ctgtcgcctc 709
gcattctgtc catgccttaa tgggcgaaaa tggggcgggc aaatcgacct tattaaaatg 769
cttatttggg atttacagta aagatgaagg tgacatcctt ttcttaggca agccagtcaa 829
ctttaaacyc tcgaaagaag ccttagagaa cgggattttc atggtgcacc aagaacttaa 889
cttgggtaaa caatgtactg taatggataa tcctttggnt aggcagttat ccattaaaag 949
caggctttgt cgatcacggc aaaaatgatc gtgataccaa agcagatttt tgaagaanta 1009
gatatcgata tcgatccaaa agaaaaatg gccaaaattg cagtgtcaca aatgcaaatg 1069
atcgagatcg caaagccctt ttcatacaat gccaaaatcg taatcatgga cgaaccgact 1129
tcctcgtctt cagaaaaaaga agttgaacac ctatttaaaa ttatcgcgaa gctaaaaaaa 1189
cgtggctgtg gcattattta tatttcgcac aaaaatggac aaatcttcaa aatttgtgac 1249
gaaattacga ttttacgca tggtaaatgg atcaatacgg tcgctgttaa aggcaccaca 1309
atggatcaga ttgtatccat gatggttggg cgtgaactca cgcacacgtt cccacccaaa 1369
accaatccc caaaagaaac catcttaacg gtggaaaatc tgaccgcaat taatcagcca 1429
tcatttcaag atgttagttt tgaattacgc aaaggcgaag tgcctggcat tgcgggactg 1489
gttggggcaa aacggtaccg atattgtgga aacgatcttc ggggtgcgtg aacgtaaatc 1549
tgggtgtgatt aaactacacg ataaggaat gaaaaaccgg aatgcgttcg aagccattaa 1609
caatggtttt gccttggta cggaaagaacg tcgctctaca gggatttatg cgaatctcag 1669
tattgagttt aactcattaa tttctaact gaagaaatcc tatatcagca agtttaggttt 1729
attgagtaac ncaaaaatga aaagcgacac gcaatggggt cattgatcc atgaatgtga 1789
aaacgcccac acaaaaaccna tattgntca ntatctgggg tggtaacca caaaaagtgg 1849
tcatttggctg ttggttatta acccaccctg aaatcttgat gttagacyaa ccaaacctg 1909
gtatcgacat tggtcgaaa tatgaaatt atcagctgat tatggagttt gccaaaaaag 1969
ataaaggtat catcatgatt tcatctaaa gccagagttt ttaggggtac tgaccgaatt 2029

```

```

<210> 38
<211> 166
<212> PRT
<213> Pasteurella multocida

```

WO 02/075507

PCT/US02/01971

```

<220>
<221> misc_feature
<222> 33
<223> Xaa = any or unknown amino acid

<220>
<221> misc_feature
<222> 99
<223> Xaa = any or unknown amino acid

<220>
<221> misc_feature
<222> 101
<223> Xaa = any or unknown amino acid

<400> 38
Leu Asn Lys Ala Gly Lys Ile Gln Tyr Val Leu Leu Lys Gly Asn Gln
 1           5           10           15
Gly His Pro Asp Ala Glu Ala Arg Thr Lys Phe Val Ile Lys Glu Leu
 20           25           30
Xaa Asn Lys Gly Ile Gln Asp Glu Gln Leu Phe Ile Asp Thr Gly Met
 35           40           45
Trp Asp Ala Ala Leu Ala Lys Asp Lys Met Asp Ala Trp Leu Ser Ser
 50           55           60
Ser Lys Ala Asn Gln Ile Glu Val Ile Ile Ala Asn Asn Asp Gly Met
 65           70           75           80
Ala Met Gly Ala Leu Glu Ala Thr Lys Ala His Gly Lys Lys Leu Pro
 85           90           95
Ile Phe Xaa Val Xaa Ala Leu Pro Glu Val Leu Gln Leu Ile Lys Lys
100          105          110
Gly Glu Ile Ala Gly Thr Val Leu Asn Asp Gly Val Asn Gln Gly Lys
115          120          125
Ala Val Val Gln Leu Ser Asn Asn Leu Ala Lys Gly Lys Pro Ala Thr
130          135          140
Glu Gly Thr Lys Trp Gln Leu Lys Arg Ser Cys Pro Thr Tyr Pro Leu
145          150          155          160
Cys Trp Cys Gly Cys Gly
165

<210> 39
<211> 2628
<212> DNA
<213> Pasteurella multocida

<220>
<221> CDS
<222> (326)..(766)

<220>
<223> micC

<400> 39

```

WO 02/075507

PCT/US02/01971

```

gtcaactaga graaaataga cacactraat tacattgtag aggaatcctt ttatgtcttt 60
agaaatttta gatcagttag aagaaaaaat taacaagcgg gttgaaacta tccaattact 120
tcaattggaa attgatgaat taaaagaaaa aaataaccaa tctcaacaag caaatgacgc 180
attacgcagt gaaaaatgaac aactaaagag tgagcaccaa aactggcaag aacgtttacg 240
ctcattatta ggcaaaattg ataactata attcacttct tattaaggct tagttttct 300
aagccttatt ttttaggaga aatta atg aaa aca aaa att tgt att atc act 352
Met Lys Thr Lys Ile Cys Ile Ile Thr
1 5
ggc agt acg ctt ggt ggt gca gaa tat gtt gca gaa cat att gct gaa 400
Gly Ser Thr Leu Gly Gly Ala Glu Tyr Val Ala Glu His Ile Ala Glu
10 15 20 25
ata tta gaa caa caa gat tat cct gta cgt tta gaa cat gga cca aat 448
Ile Leu Glu Gln Gln Asp Tyr Pro Val Arg Leu Glu His Gly Pro Asn
30 35 40
ttt gaa gaa gtg atc gat gaa aaa tgt tgg ctt gtt gtc acc tct acc 496
Phe Glu Glu Val Ile Asp Glu Lys Cys Trp Leu Val Val Thr Ser Thr
45 50 55
cat ggt gca ggt gaa tta ccg gat aat att aaa cct ctg ttt gaa aaa 544
His Gly Ala Gly Glu Leu Pro Asp Asn Ile Lys Pro Leu Phe Glu Lys
60 65 70
tta gca ttt cac cca aaa cag tta gct gac tta cgc ttt gcg gtg atc 592
Leu Ala Phe His Pro Lys Gln Leu Ala Asp Leu Arg Phe Ala Val Ile
75 80 85
ggg tta ggt aat tcg gat tat gat acc ttc tgt cac gca gtg gat cat 640
Gly Leu Gly Asn Ser Asp Tyr Asp Thr Phe Cys His Ala Val Asp His
90 95 100 105
gtg gaa caa tta ctg cta agc aaa gat gct tta caa ctg tgt gaa tcg 688
Val Glu Gln Leu Leu Leu Ser Lys Asp Ala Leu Gln Leu Cys Glu Ser
110 115 120
cta aga atg gat atg cta acc att act gat cct gaa cac acg gcc gaa 736
Leu Arg Met Asp Met Leu Thr Ile Thr Asp Pro Glu His Thr Ala Glu
125 130 135
caa tgg ctg cca caa ttt ctg agt caa tta taatattat tccctataca 786
Gln Trp Leu Pro Gln Phe Leu Ser Gln Leu
140 145
atgcatatg taaatcaaat atgccatttt tcatctcgat caagcataat atttaacca 846
tcaaatcaat attttctctg tggataacta agatcaaac tgtataaag ctgtttttat 906
tccctgaata agattgaatg ttttttattc tgtggataac taaagaagtt attcacagt 966
ttttctggg ccaaatggag atcttaacaa cttaaaaaat gatctaagtt attcattaa 1026
aaaaagaaaa ggatcttaat cacagcacta taggatccta ataatacaaa taataagatc 1086
tctttatata aaaagatcct atctttatta actcaagatc tttttcacga tcatcgata 1146
gcttgatca aaaatgttc tttcaaggat ccataaattt cagtagaata gccaccagc 1206

```

WO 02/075507

PCT/US02/01971

```

aaaaaggatc aaaagatcca taaaatccga gataaattaa caaggttact atgttttata 1266
ctgaaaatta tgatgttatt gtgatcgggtg gtggacacgc aggtactgaa gctgcacttg 1326
caccggcacg catgggactc aagaccctat tattaaccca taatgttgat acactagggc 1386
aatgtcttg taatcctcgg attggtggga ttggtaaagg ccatttagtc cgagaaattg 1446
atgcgatggg cggtttaatg gcaactcctg cggaccaacg aggaatccaa tttcgtacct 1506
taaacagcag caaaggaccg gcggtacgtg ctacacgtgc gcaagctgac cgcgttttat 1566
atcccaacgc agtacgtatt gcattagaaa atcaagaaaa tttagatatt tttcaacaag 1626
aagtgaccga tattatttta gatcaggatc gtgtctcggg tgttgttact aaaatgggtt 1686
taaaatttca cgcaaaagca gtgatittaa cagccggtag tttcctttct ggtaagatcc 1746
acattgggtt agaaaattat acaggtggac gcgcgggtga tctctgttca gtgatgttag 1806
ccgatcgttt aagagaactg aatttactgt tanatcgttt aaaaacgggt acaccgcccc 1866
gtattgatgc acgtactatt gatttctcaa tactggctaa acaacatggc gatgaaaaat 1926
tacctgtctt ttccttcacg ggatcgttg atcaacaccc acgtcaaat ccatgtttta 1986
ttaccacatc aaatgaacaa acgcataag tgatccgtaa taactacat cgcagcccaa 2046
tgtatcctgg gatcattgaa gggatcggtc cacgttattg cccttctatt gaagataaag 2106
taatgcgttt tctgagcgt aattctcacc aaatctacct tgaacctgaa gggttgaca 2166
acaaaacaaa gaaattgctg atttacaana acaagtcaaa gcactgcaag cagatttaag 2226
cyaatggca aagaaaaacc gcaatcaagc gttgattgca ggtggtattg gcggtggcat 2286
tgttcagtc ggtattgagc tcattcctt gcaatttggg ggctaactga tggcatttga 2346
tgaaaaaca cgtgcctcgg ttcctcgtca ctatgtattt gagttttat cgttgagca 2406
atcagcaagt aaagctaaag tctcatttaa caccgcgca cgtggaaga aagaggcggc 2466
aagcaagggc gatgactggg ataaagtgcg tgatgtacaa gtaatggcgg gcaatgagct 2526
gactgatgc acaaaaggat tggatcggg ctttattatt caatatcggc caacctgga 2586
tgagattcaa aactcggatt taaaagcaca agataaagtc ga 2628

```

```

<210> 40
<211> 147
<212> PRT
<213> Pasteurella multocida

```

```

<400> 40
Met Lys Thr Lys Ile Cys Ile Ile Thr Gly Ser Thr Leu Gly Gly Ala
 1          5          10          15
Glu Tyr Val Ala Glu His Ile Ala Glu Ile Leu Glu Gln Gln Asp Tyr
 20          25          30
Pro Val Arg Leu Glu His Gly Pro Asn Phe Glu Glu Val Ile Asp Glu
 35          40          45

```

WO 02/075507

PCT/US02/01971

Lys Cys Trp Leu Val Val Thr Ser Thr His Gly Ala Gly Glu Leu Pro  
50 55 60

Asp Asn Ile Lys Pro Leu Phe Glu Lys Leu Ala Phe His Pro Lys Gln  
65 70 75 80

Leu Ala Asp Leu Arg Phe Ala Val Ile Gly Leu Gly Asn Ser Asp Tyr  
85 90 95

Asp Thr Phe Cys His Ala Val Asp His Val Glu Gln Leu Leu Leu Ser  
100 105 110

Lys Asp Ala Leu Gln Leu Cys Glu Ser Leu Arg Met Asp Met Leu Thr  
115 120 125

Ile Thr Asp Pro Glu His Thr Ala Glu Gln Trp Leu Pro Gln Phe Leu  
130 135 140

Ser Gln Leu  
145

<210> 41  
<211> 5191  
<212> DNA  
<213> Pasteurella multocida

<220>  
<221> CDS  
<222> (3203)..(4255)

<220>  
<223> mreB

<400> 41  
ctgcagtacc aaccacccaa atgttggtct tctgctgtaa ttcacgcaa gtgcgcgca 60  
ggttggttac acggattaat ggcacgactt cagcggcacc acaagctact ttacgtcgca 120  
tagcggttaa ttggcagat ttatcttttg gtactatcac agcacacag ccgctgcat 180  
cgcagtagc caaacaagca cctaagttat gtggatcagt cacaccatct aacaetaata 240  
gcaacggatt ggactgattt tgtaaaagcg tatcraaatc tgcttcatto aattctttcg 300  
ctggctaac acgtgccatg atgccttggg taacttcgcc ctctgctttt ttatcaaggg 360  
tttggcgatt aacaaattgg atagtaatac ccaaccgatg aagttcattg agcaaagggt 420  
gtaaacgttt atcgtcgcgc cctttgagtg cataaacttc aattaacgc tctggcgcgt 480  
tgtttaaaaa ggcacttact gcatgaatgc cataaatatt ttcactcadc tactttctct 540  
ttttagctga tttcttactg gctttttctg tggttgttga tggtttaaca acgcttgttt 600  
tcttaaccgc acttttactg gtgcttgggt taegtattat gegtgtttt tcgagacttt 660  
cagcgtagcg tgcatttttc ttgagcttgt ctttggctgt tttgccttct cgtaatgggt 720  
tacgctcact cgacactaaa gaaaaatcca cttggcgttg ttcaaggcta actgcttcca 780  
cacggatttt taccttatcg ccaatgcggt agateatacc actattttca ccgattaaac 840

WO 02/075507

PCT/US02/01971

gttgtcagc gagatcaaat tggtagtagt cgttatctaa ggtagaatg tggactaagc 900  
 catcaataaa gaggtcatct aagcggacaa ataagccaaa acctgtcaca gatgaaatca 960  
 cacctgtaaa ttcttcgcct acatgatctt gcataatctt gcattttagc cagtctgcaa 1020  
 catcacgagt ggcacatcag gcccgtcggt ctgtcatgga gcagtggteg cctaatacat 1080  
 ccatgtcatc aagtgtatag tgataccctc ccgtatcagt ggtctccgt ttcgagcctt 1140  
 ttagtttggc taacaagtat ttaatccac gatgcaaat caaatcagga taacggcgaa 1200  
 ttggcgaagt aaaatgcgca tattcttcca gtgcaagccc aaagtgcaca atattgtcag 1260  
 gatgataaac ggcctgactt aacgaacgta atacatggtt tgcaataact catgatctgg 1320  
 acgttcgcga atttgtcca ataatttagc gtagtctcgc gtaactgggt tactgccacc 1380  
 ttcaaggctt aaaccacatt cactgaggaa ttggcgaag cccgtcactt tttcttcgct 1440  
 tggaccgca tgaatacga aaagggctgg ctcttgatgt tttccataa agtttgccgc 1500  
 cgaatattg ccgaggatca tacattcttc aatgatttta tgcgatcat tacgaataac 1560  
 aggtcaatc cgttcgattc gccccatttc attaaacaca aacttacttt caatggtttc 1620  
 aaagtcaat gcgccacggt gatgacgggc ttccactaag gcttggtaca ttacatggag 1680  
 ttcttttaa tgggaacca gtgcttgata acgagtaca agttcttcat cgtctcttaa 1740  
 aatacagaca actttggtat aggttaagcg agcatgagag ttcatgaccg ctccataaaa 1800  
 ttcatagect gtgattttac cltttgctga aacattoagc tcacagacca tacataagcg 1860  
 atcgactgt gggtttaatg aacaaagtcc attggagagg atttccgcta gcataggaac 1920  
 aacgcgatt gggaaatata ccgagtttc ccgcgatgt gcttcgglat caagggcagt 1980  
 acgtaaacga acatagtagc tgacatcggc aatggcaacc cacagtttc aaccgcctcc 2040  
 acgttttttc tggcaaaaaa ccgcatcgtc aaaatcgcga gcactctcac catcaatggt 2100  
 gactaacga agatggcgta aatcaatag tcttgatttg gcttcttcgc gtactcttc 2160  
 actcagttta gaaacttgtt tgaggaccgc gcttggaaaa acatggggaa tatcatgatt 2220  
 aoggatagca atttccacct ccattccctt tgccatattt tcaccgagaa tttcgctaat 2280  
 cattccaaca ggttggctaa atgttgcggt acgtggtttt aattcaacta caaccacttg 2340  
 tccatacga gcgccttggc ggtgttcatt cggaaataaa atgtcggcat taattcgact 2400  
 atcgtcaggt actacataac caataccatc ttctaagaaa aaacgacca caatctgttt 2460  
 tttacgctgt tgttaagacg ggaacatccg cacttttgg ccaccacgac ggtcaaaacc 2520  
 gctaggttgg ccgaggacat agtccaccgt cattactcgc tgcatttggc tgttgggtat 2580  
 aaaccaatcg ctgtctttac ctctgacttg taaaaacca taaccatcac gatgacctaa 2640  
 tacggctcct ttaataaat ccagttttc cggtaaacg tagcgtttac gtttagtgaa 2700  
 aaccaattgt ccgtcatttt ccatcgtctc taagcagcg cgcattggctt cttgtgttc 2760

WO 02/075507

PCT/US02/01971

```

ttcatttga atagcaaatg tggtcagtaa ttcttcttt gagataggtg cattatgttg 2820
acgaattgta tcaagaataa attcgcgact tgggatcggg ttctcatatt ttgcgagttc 2880
ttcttgatag tttggatctt gcaaatgagg attgtttttg atttttgcca taatgactcc 2940
ctttgagaat ggaataacgc attcgtttaa tgacctcaag ttgacaactc tgatttgttg 3000
aaagcaagta aaaaacctgt tcgtgactga aacaatctgt actcgcggga tttgtcgtgc 3060
atgaaagcgt aaagacaaag caaatttcga caatttacag aaaattctct gttataaagg 3120
tacatttttt gatacattta gcacaatttt tcaatactca aatcagagtg tccattattt 3180
aatttagttc agcggaaatc tt atg tta ttt aaa aaa att cga ggc tta ttt 3232
Met Leu Phe Lys Lys Ile Arg Gly Leu Phe
1 5 10
tca aat gat ctg tcc atc gat ctt ggc aca gcg aat acc tta att tat 3280
Ser Asn Asp Leu Ser Ile Asp Leu Gly Thr Ala Asn Thr Leu Ile Tyr
15 20 25
gtc aaa gga caa ggg att gtt tta gat gaa cct tct gtt gtg gcg att 3328
Val Lys Gly Gln Gly Ile Val Leu Asp Glu Pro Ser Val Val Ala Ile
30 35 40
cgc caa gaa cgt tca ggt gca tta aaa agc att gct gcg gtt ggt cgt 3376
Arg Gln Glu Arg Ser Gly Ala Leu Lys Ser Ile Ala Ala Val Gly Arg
45 50 55
gat gcc aaa tta atg tta ggc cgt aca cgc aaa agc att gca gcg att 3424
Asp Ala Lys Leu Met Leu Gly Arg Thr Pro Lys Ser Ile Ala Ala Ile
60 65 70
cgt cct atg aaa gat ggg gtg atc gca gat ttc ttt gtg aca gaa aaa 3472
Arg Pro Met Lys Asp Gly Val Ile Ala Asp Phe Phe Val Thr Glu Lys
75 80 85 90
atg ttg caa tat ttt att aaa caa gtg cac agc agc aat ttt atg cgt 3520
Met Leu Gln Tyr Phe Ile Lys Gln Val His Ser Ser Asn Phe Met Arg
95 100 105
cca agt cca cgt gtc tta gtt tgt gta cct gcg gga gct acg caa gtc 3568
Pro Ser Pro Arg Val Leu Val Cys Val Pro Ala Gly Ala Thr Gln Val
110 115 120
gaa cga cgt gca atc aaa gaa tct gcc att ggt gct ggg gca cgc gag 3616
Glu Arg Arg Ala Ile Lys Glu Ser Ala Ile Gly Ala Gly Ala Arg Glu
125 130 135
gtg tac ttg att gag gaa ccg atg gcg gca gcg att ggt gct aaa tta 3664
Val Tyr Leu Ile Glu Glu Pro Met Ala Ala Ala Ile Gly Ala Lys Leu
140 145 150
cct gtt tcg act gcc aca ggt tcg atg gtg atc gat atc ggt ggt ggt 3712
Pro Val Ser Thr Ala Thr Gly Ser Met Val Ile Asp Ile Gly Gly Gly
155 160 165 170
acg acg gaa gtt gcg gtg att tct tta aat gcc att gtg tat tcc tct 3760
Thr Thr Glu Val Ala Val Ile Ser Leu Asn Gly Ile Val Tyr Ser Ser
175 180 185
tca gtc cgc att ggt ggt gat cgt ttt gat gag gcg att att tct tat 3808

```

WO 02/075507

PCT/US02/01971

```

Ser Val Arg Ile Gly Gly Asp Arg Phe Asp Glu Ala Ile Ile Ser Tyr
      190                195                200
gta cgc aag acg ttc ggt tca att att ggg gaa ccg aca gca gag cgt 3856
Val Arg Lys Thr Phe Gly Ser Ile Ile Gly Glu Pro Thr Ala Glu Arg
      205                210                215
atc aaa caa gag att ggt agt gcg ttt att caa gaa ggc gat gaa gtc 3904
Ile Lys Gln Glu Ile Gly Ser Ala Phe Ile Gln Glu Gly Asp Glu Val
      220                225                230
cgt gaa att gaa gtg cat ggt cat aac tta gca gaa ggt gcg ccg cgt 3952
Arg Glu Ile Glu Val His Gly His Asn Leu Ala Glu Gly Ala Pro Arg
      235                240                245
tct ttc aaa ctc acc tca cgt gat gtg tta gaa gct att caa gcc ccg 4000
Ser Phe Lys Leu Thr Ser Arg Asp Val Leu Glu Ala Ile Gln Ala Pro
      255                260                265
tta aat ggc att gtt gcg gca gtg cgc acg gcc ttg gaa gag tgt caa 4048
Leu Asn Gly Ile Val Ala Ala Val Arg Thr Ala Leu Glu Glu Cys Gln
      270                275                280
cca gaa cat gct gcg gat att ttt gaa cgt ggc atg gtc tta act ggt 4096
Pro Glu His Ala Ala Asp Ile Phe Glu Arg Gly Met Val Leu Thr Gly
      285                290                295
ggc ggt gcc ctt att cgt aat att gat gtt tta ctg tca aaa gaa acc 4144
Gly Gly Ala Leu Ile Arg Asn Ile Asp Val Leu Leu Ser Lys Glu Thr
      300                305                310
ggg gtg ccg gtt atc atc gcc gat gat cct tta acc tgt gtt gcc cgt 4192
Gly Val Pro Val Ile Ile Ala Asp Asp Pro Leu Thr Cys Val Ala Arg
      315                320                325
ggg ggt ggc gag gca tta gag atg atc gat atg cac ggt ggt gat att 4240
Gly Gly Gly Glu Ala Leu Met Ile Asp Met His Gly Gly Asp Ile
      335                340                345
ttt agt gac gat atc taatatgatt taaaagtgcg gtgatattag accgcacttt 4295
Phe Ser Asp Asp Ile
      350
tacttctctt ttattgctga caaggctagc ctaattcgtat tatgaaacct atttttgaa 4355
aagcacctcc tttaggtctt cgcttaattc tggcgatttc agcatccatt gcattgattg 4415
ttcggacggt tcaatccaat gcgatgatta aagcacgcag tattatggaa accgcagtag 4475
gcgggctgta ttatcttgcc aatacaccga gaacggtatt ggatgggggt tcagataatt 4535
tgggtgatac caataaattg caaattgaaa accgagtttt gcgtgatcaa ctgcgtgaaa 4595
aaaatgcaga ttattgttg tttagatcaac tcaaaagtag aaatcaacgc ctgcgcttat 4655
tgcttaattc cccctacgt acagatgagt ataaaaaaaa tgctgaagtt ttaacggcag 4715
aaactgatgt gtatcgtaa caagtcgtga ttaaccaagg acaacgtgac ggtgcttatg 4775
tcgggcagcc gattattgat gaaaaggta ttgttggca acttatctcc gttggtgaaa 4835
atcagctcg cgctcttcta ttgacagatg tgaetcatc tattccagta caagtactac 4895

```



WO 02/075507

PCT/US02/01971

gtaatgatgt ccgtttgatt gctagtggaa caggacggaa tgatgaactg agtttagatc 4955  
 atgtgccgcy ttcggtcgat attgtcaaaag gggatttatt agtcacttct ggattaggtg 5015  
 ggcgcttttt agaaggttat ccgttgcca ttgtggaatc cgtatcacgt gatgggcaaa 5075  
 attattttgc tactgtaaca gcaaagccat tagcttcgat tgaacgttta cgctatgttt 5135  
 tgcttttatg gccgaagaat gaagagatgc gcaaagtcca gtctatttca cctgca 5191

<210> 42  
 <211> 351  
 <212> PRT  
 <213> Pasteurella multocida

<400> 42  
 Met Leu Phe Lys Lys Ile Arg Gly Leu Phe Ser Asn Asp Leu Ser Ile  
 1 5 10 15  
 Asp Leu Gly Thr Ala Asn Thr Leu Ile Tyr Val Lys Gly Gln Gly Ile  
 20 25 30  
 Val Leu Asp Glu Pro Ser Val Val Ala Ile Arg Gln Glu Arg Ser Gly  
 35 40 45  
 Ala Leu Lys Ser Ile Ala Ala Val Gly Arg Asp Ala Lys Leu Met Leu  
 50 55  
 Gly Arg Thr Pro Lys Ser Ile Ala Ala Ile Arg Pro Met Lys Asp Gly  
 65 70 75 80  
 Val Ile Ala Asp Phe Phe Val Thr Glu Lys Met Leu Gln Tyr Phe Ile  
 85 90 95  
 Lys Gln Val His Ser Ser Asn Phe Met Arg Pro Ser Pro Arg Val Leu  
 100 105 110  
 Val Cys Val Pro Ala Gly Ala Thr Gln Val Glu Arg Arg Ala Ile Lys  
 115 120 125  
 Glu Ser Ala Ile Gly Ala Gly Ala Arg Glu Val Tyr Leu Ile Glu Glu  
 130 135 140  
 Pro Met Ala Ala Ala Ile Gly Ala Lys Leu Pro Val Ser Thr Ala Thr  
 145 150 155 160  
 Gly Ser Met Val Ile Asp Ile Gly Gly Gly Thr Thr Glu Val Ala Val  
 165 170 175  
 Ile Ser Leu Asn Gly Ile Val Tyr Ser Ser Ser Val Arg Ile Gly Gly  
 180 185 190  
 Asp Arg Phe Asp Glu Ala Ile Ile Ser Tyr Val Arg Lys Thr Phe Gly  
 195 200 205  
 Ser Ile Ile Gly Glu Pro Thr Ala Glu Arg Ile Lys Gln Glu Ile Gly  
 210 215 220  
 Ser Ala Phe Ile Gln Glu Gly Asp Glu Val Arg Glu Ile Glu Val His  
 225 230 235 240  
 Gly His Asn Leu Ala Glu Gly Ala Pro Arg Ser Phe Lys Leu Thr Ser

WO 02/075507

PCT/US02/01971

```

                245                250                255
Arg Asp Val Leu Glu Ala Ile Gln Ala Pro Leu Asn Gly Ile Val Ala
 260                265                270
Ala Val Arg Thr Ala Leu Glu Glu Cys Gln Pro Glu His Ala Ala Asp
 275                280                285
Ile Phe Glu Arg Gly Met Val Leu Thr Gly Gly Ala Leu Ile Arg
 290                295                300
Asn Ile Asp Val Leu Leu Ser Lys Glu Thr Gly Val Pro Val Ile Ile
 305                310                315
Ala Asp Asp Pro Leu Thr Cys Val Ala Arg Gly Gly Glu Ala Leu
 325                330                335
Glu Met Ile Asp Met His Gly Gly Asp Ile Phe Ser Asp Asp Ile
 340                345                350

<210> 43
<211> 2172
<212> DNA
<213> Pasteurella multocida

<220>
<221> CDS
<222> (1)..(1464)

<220>
<223> pnp

<400> 43
acc cgc gtt ggg att ggg tgg cac ctg aac cca aat acc gcg tta att 48
Thr Arg Val Gly Ile Gly Trp His Leu Asn Pro Asn Thr Ala Leu Ile
 1                5                10                15

gaa aaa gtg aaa gcg att gca gaa gcg cgt tta ggc gaa gca tac cgt 96
Glu Lys Val Lys Ala Ile Ala Glu Ala Arg Leu Gly Glu Ala Tyr Arg
 20                25                30

atc act gaa aac aag cac gtt atg aac aaa att gat gcg att aaa gct 144
Ile Thr Glu Asn Lys His Val Met Asn Lys Ile Asp Ala Ile Lys Ala
 35                40                45

gat gtg att gca caa atc aca gct gaa gta gca gaa ggc gaa gac atc 192
Asp Val Ile Ala Gln Ile Thr Ala Glu Val Ala Glu Gly Glu Asp Ile
 50                55                60

agt gaa ggg aaa att gtc gat att ttc acc gca ctt gaa agc caa atc 240
Ser Glu Gly Lys Ile Val Asp Ile Phe Thr Ala Leu Glu Ser Gln Ile
 65                70                75                80

gta cgt agc cgt atc att gct ggt gaa cca cgt att gat ggt cgt aca 288
Val Arg Ser Arg Ile Ile Ala Gly Glu Pro Arg Ile Asp Gly Arg Thr
 85                90                95

gtg gat act gtt cgt gca tta gat att tgt act ggt gtt tta cca cgt 336
Val Asp Thr Val Arg Ala Leu Asp Ile Cys Thr Gly Val Leu Pro Arg
 100                105                110

aca cac ggt tct gcg att ttc acc cgt ggt gaa aca cag gcg tta gct 384

```

WO 02/075507

PCT/US02/01971

```

Thr His Gly Ser Ala Ile Phe Thr Arg Gly Glu Thr Gln Ala Leu Ala
115                               120                               125
gtc gcg aca tta ggt aca gaa cgt gat gca caa att att gat gaa tta 432
Val Ala Thr Leu Gly Thr Glu Arg Asp Ala Gln Ile Ile Asp Glu Leu
130                               135                               140
aca ggt gag cgt tca gat cac ttc tta ttc cac tac aac ttc ccg cca 480
Thr Gly Glu Arg Ser Asp His Phe Leu Phe His Tyr Asn Phe Pro Pro
145                               150                               155                               160
tat tct gtc ggt gaa acc ggt atg att ggt tca cca aaa cgt cgt gaa 528
Tyr Ser Val Gly Glu Thr Gly Met Ile Gly Ser Pro Lys Arg Arg Glu
165                               170                               175
att ggt cat ggt cgt tta gcg aaa cgc ggt gta gct gca gtg atg cca 576
Ile Gly His Gly Arg Leu Ala Lys Arg Gly Val Ala Ala Val Met Pro
180                               185                               190
aca ctt gcc gag ttc ccg tat gtg gta cgt gtt gtc tct gaa atc aca 624
Thr Leu Ala Glu Phe Pro Tyr Val Val Arg Val Val Ser Glu Ile Thr
195                               200                               205
gaa tca aat ggt tct tct tct atg gca tcg gtt tgt ggt gcg tct tta 672
Glu Ser Asn Gly Ser Ser Ser Met Ala Ser Val Cys Gly Ala Ser Leu
210                               215                               220
gca tta atg gat gcg ggt gta cca att aaa gcg gcg gtt gca ggt att 720
Ala Leu Met Asp Ala Gly Val Pro Ile Lys Ala Ala Val Ala Gly Ile
225                               230                               235                               240
gca atg gcc tta gtc aaa gaa gac gaa aaa ttt gtg gtg ctt tca gac 768
Ala Met Gly Leu Val Lys Glu Asp Glu Lys Phe Val Val Leu Ser Asp
245                               250                               255
atc tta ggt gat gaa gat cac tta ggt gac atg gac ttc aaa gtc gcg 816
Ile Leu Gly Asp Glu Asp His Leu Gly Asp Met Asp Phe Lys Val Ala
260                               265                               270
ggg aca cgt acg ggt gtg acg gca tta caa atg gat atc aaa atc gaa 864
Gly Thr Arg Thr Gly Val Thr Ala Leu Gln Met Asp Ile Lys Ile Glu
275                               280                               285
ggg atc aca gca gaa atc atg caa att gcg tta aac caa gcg aaa agc 912
Gly Ile Thr Ala Glu Ile Met Gln Ile Ala Leu Asn Gln Ala Lys Ser
290                               295                               300
gca cgt tta cac att tta ggt gtg atg gag caa gcg atc cca gcg cca 960
Ala Arg Leu His Ile Leu Gly Val Met Glu Gln Ala Ile Pro Ala Pro
305                               310                               315                               320
cgt gcg gat att tct gat ttt gca ccg cgt att tac act atg aaa att 1008
Arg Ala Asp Ile Ser Asp Phe Ala Pro Arg Ile Tyr Thr Met Lys Ile
325                               330                               335
gat ccg aag aaa atc aaa gat gtg atc ggt aaa ggt ggt gca acc att 1056
Asp Pro Lys Lys Ile Lys Asp Val Ile Gly Lys Gly Gly Ala Thr Ile
340                               345                               350
cgt gcc tta aca gaa gaa aca ggt acc tca att gat atc gat gat gat 1104
Arg Ala Leu Thr Glu Glu Thr Gly Thr Ser Ile Asp Ile Asp Asp Asp
355                               360                               365

```

WO 02/075507

PCT/US02/01971

```

ggg acg gta aag att gct gcg gtt gat ggc aat tca gca aaa gag gtg 1152
Gly Thr Val Lys Ile Ala Ala Val Asp Gly Asn Ser Ala Lys Glu Val
370 375 380
atg gcg cgt att gaa gat att act gca gaa gtt gaa gcg ggt gca gtg 1200
Met Ala Arg Ile Glu Asp Ile Thr Ala Glu Val Glu Ala Gly Ala Val
385 390 395 400
tat aaa ggt aaa gtt act cgt tta gct gat ttt ggt gcc ttc gtt tct 1248
Tyr Lys Gly Lys Val Thr Arg Leu Ala Asp Phe Gly Ala Phe Val Ser
405 410 415
atc gta ggt aac aaa gaa ggc tta gtg cat att tct caa atc gcg gaa 1296
Ile Val Gly Asn Lys Glu Gly Leu Val His Ile Ser Gln Ile Ala Glu
420 425 430
gag cgt gtt gag aaa gtg agt gat tat ctt gca gtg ggg caa gaa gtg 1344
Glu Arg Val Glu Lys Val Ser Asp Tyr Leu Ala Val Gly Gln Glu Val
435 440 445
act gtt aaa gtg gtt gag att gat cgt caa ggt cgt att cgt tta acc 1392
Thr Val Lys Val Val Glu Ile Asp Arg Gln Gly Arg Ile Arg Leu Thr
450 455 460
atg aaa gaa gtt gca cca aag caa gaa cac gtt gat tct gtt gtc gca 1440
Met Lys Glu Val Ala Pro Lys Gln Glu His Val Asp Ser Val Val Ala
465 470 475 480
gac gtt gcc gca gaa aac gca taagcaataa acaccaacgc ccttgatgat 1494
Asp Val Ala Ala Glu Glu Asn Ala
485
aaagggcgtt ggtgtgatg ttgataagta caatttggc ttaagggcga agcgaaatga 1554
agcaatttca tccgtgggta aagtgcctgc taattttccc attttgggta tgttgtttaa 1614
cagcttgtgt taatcatgaa caagtttttc ttccaaaaga gaaattaatg ttagcagagc 1674
aacatccgaa tgatcatctt gagcatgagg tgatggttgc gcaaattagc gaattgttac 1734
ttgttaaagg gttaaaaaaa gaagaacgtg cgattttaca ttttgagcga ggcgtgctgt 1794
acgatagctt aggattgtgg gcattggcgc gttatgattt tgaccaaaaca ttagcgttgt 1854
atccaaagtt ggcagcagcg ttaattatt taggtttata tttattgtta gaggaagatt 1914
acagcgatc tctagatata ttaaatgtgt ttttgaact tgatcctcaa tatgagtatg 1974
cattcctaaa tagagggcta aatttttatt acgtcgagc ttatgaatta gctcagcggg 2034
attttttca attttatcaa gccgataaat cagatccata ccgcacttta tggctttatt 2094
taaatgaatt aaagcataat cctcaggatg cttctaaaaa tcttgctcaa cgagcaatgg 2154
ggctttctga tgaatatt 2172

<210> 44
<211> 488
<212> PRT
<213> Pasteurella multocida
<400> 44

```

WO 02/075507

PCT/US02/01971

Thr Arg Val Gly Ile Gly Trp His Leu Asn Pro Asn Thr Ala Leu Ile  
 1 5 10 15  
 Glu Lys Val Lys Ala Ile Ala Glu Ala Arg Leu Gly Glu Ala Tyr Arg  
 20 25 30  
 Ile Thr Glu Asn Lys His Val Met Asn Lys Ile Asp Ala Ile Lys Ala  
 35 40 45  
 Asp Val Ile Ala Gln Ile Thr Ala Glu Val Ala Glu Gly Glu Asp Ile  
 50 55 60  
 Ser Glu Gly Lys Ile Val Asp Ile Phe Thr Ala Leu Glu Ser Gln Ile  
 65 70 75 80  
 Val Arg Ser Arg Ile Ile Ala Gly Glu Pro Arg Ile Asp Gly Arg Thr  
 85 90 95  
 Val Asp Thr Val Arg Ala Leu Asp Ile Cys Thr Gly Val Leu Pro Arg  
 100 105 110  
 Thr His Gly Ser Ala Ile Phe Thr Arg Gly Glu Thr Gln Ala Leu Ala  
 115 120 125  
 Val Ala Thr Leu Gly Thr Glu Arg Asp Ala Gln Ile Ile Asp Glu Leu  
 130 135 140  
 Thr Gly Glu Arg Ser Asp His Phe Leu Phe His Tyr Asn Phe Pro Pro  
 145 150 155 160  
 Tyr Ser Val Gly Glu Thr Gly Met Ile Gly Ser Pro Lys Arg Arg Glu  
 165 170 175  
 Ile Gly His Gly Arg Leu Ala Lys Arg Gly Val Ala Ala Val Met Pro  
 180 185 190  
 Thr Leu Ala Glu Phe Pro Tyr Val Val Arg Val Val Ser Glu Ile Thr  
 195 200 205  
 Glu Ser Asn Gly Ser Ser Ser Met Ala Ser Val Cys Gly Ala Ser Leu  
 210 215 220  
 Ala Leu Met Asp Ala Gly Val Pro Ile Lys Ala Ala Val Ala Gly Ile  
 225 230 235 240  
 Ala Met Gly Leu Val Lys Glu Asp Glu Lys Phe Val Val Leu Ser Asp  
 245 250 255  
 Ile Leu Gly Asp Glu Asp His Leu Gly Asp Met Asp Phe Lys Val Ala  
 260 265 270  
 Gly Thr Arg Thr Gly Val Thr Ala Leu Gln Met Asp Ile Lys Ile Glu  
 275 280 285  
 Gly Ile Thr Ala Glu Ile Met Gln Ile Ala Leu Asn Gln Ala Lys Ser  
 290 295 300  
 Ala Arg Leu His Ile Leu Gly Val Met Glu Gln Ala Ile Pro Ala Pro  
 305 310 315 320  
 Arg Ala Asp Ile Ser Asp Phe Ala Pro Arg Ile Tyr Thr Met Lys Ile  
 325 330 335

WO 02/075507

PCT/US02/01971

Asp Pro Lys Lys Ile Lys Asp Val Ile Gly Lys Gly Gly Ala Thr Ile  
 340 345 350  
 Arg Ala Leu Thr Glu Glu Thr Gly Thr Ser Ile Asp Ile Asp Asp Asp  
 355 360 365  
 Gly Thr Val Lys Ile Ala Ala Val Asp Gly Asn Ser Ala Lys Glu Val  
 370 375 380  
 Met Ala Arg Ile Glu Asp Ile Thr Ala Glu Val Glu Ala Gly Ala Val  
 385 390 395 400  
 Tyr Lys Gly Lys Val Thr Arg Leu Ala Asp Phe Gly Ala Phe Val Ser  
 405 410 415  
 Ile Val Gly Asn Lys Glu Gly Leu Val His Ile Ser Gln Ile Ala Glu  
 420 425 430  
 Glu Arg Val Glu Lys Val Ser Asp Tyr Leu Ala Val Gly Gln Glu Val  
 435 440 445  
 Thr Val Lys Val Val Glu Ile Asp Arg Gln Gly Arg Ile Arg Leu Thr  
 450 455 460  
 Met Lys Glu Val Ala Pro Lys Gln Glu His Val Asp Ser Val Val Ala  
 465 470 475 480  
 Asp Val Ala Ala Glu Glu Asn Ala  
 485

<210> 45  
 <211> 633  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (2)...(631)

<220>  
 <223> purF

<400> 45  
 c gat ggg gtt tct gtt tat gct gcc cgt gtt cat atg gga caa cgt tta 49  
 Asp Gly Val Ser Val Tyr Ala Ala Arg Val His Met Gly Gln Arg Leu  
 1 5 10 15  
 ggt gaa aaa att gca cgg gaa tgg gcg gat gtg gat gat att gat gtg 97  
 Gly Glu Lys Ile Ala Arg Glu Trp Ala Asp Val Asp Asp Ile Asp Val  
 20 25 30  
 gtc att cct gtg cct gaa acc tct aac gat att gct tta cgt att gcg 145  
 Val Ile Pro Val Pro Glu Thr Ser Asn Asp Ile Ala Leu Arg Ile Ala  
 35 40 45  
 cgc gtg tta aat aaa ccg tat cgt caa ggt ttt gtg aaa aat cgc tat 193  
 Arg Val Leu Asn Lys Pro Tyr Arg Gln Gly Phe Val Lys Asn Arg Tyr  
 50 55 60  
 gta gga cgt acg ttt att atg cgg ggg cag gca ttg cga gtc agt tct 241  
 Val Gly Arg Thr Phe Ile Met Pro Gly Gln Ala Leu Arg Val Ser Ser  
 65 70 75 80

WO 02/075507

PCT/US02/01971

```

ggt aga cgt aaa ctc aat acc att gct tca gaa ttt aaa gat aag aat 289
Val Arg Arg Lys Leu Asn Thr Ile Ala Ser Glu Phe Lys Asp Lys Asn
85 90 95
gtg tta tta gtt gac gac tcg att gta cgt ggt acc acg tct gaa caa 337
Val Leu Leu Val Asp Asp Ser Ile Val Arg Gly Thr Thr Ser Glu Gln
100 105 110
att gtc gaa atg gcg aga gcg gca ggt gcg aag aaa att tat ttt gcc 385
Ile Val Glu Met Ala Arg Ala Ala Gly Ala Lvs Lys Ile Tyr Phe Ala
115 120 125
tct gct gca cca gaa att cgt tat cca aat gtg tat ggt att gat atg 433
Ser Ala Ala Pro Glu Ile Arg Tyr Pro Asn Val Tyr Gly Ile Asp Met
130 135 140
cca acc aaa aat gaa ttg atc gct tat ggt cgt gat gta gat gaa att 481
Pro Thr Lys Asn Glu Leu Ile Ala Tyr Gly Arg Asp Val Asp Glu Ile
145 150 155
gct aac tta att ggt gtg gat aaa ttg att ttc caa gat ttg gat gcg 529
Ala Asn Leu Ile Gly Val Asp Lys Leu Ile Phe Gln Asp Leu Asp Ala
165 170 175
tta act ggt tct gtg caa caa gaa aat cca agt att caa gac ttt gat 577
Leu Thr Gly Ser Val Gln Gln Glu Asn Pro Ser Ile Gln Asp Phe Asp
180 185 190
tgt tcg gtg ttt aca ggg gtt tat gtg acg gcc gat att aca cct gaa 625
Cys Ser Val Phe Thr Gly Val Tyr Val Thr Gly Asp Ile Thr Pro Glu
195 200 205
tat ctg ga 633
Tyr Leu
210

<210> 46
<211> 210
<212> PRT
<213> Pasteurella multocida

<400> 46
Asp Gly Val Ser Val Tyr Ala Ala Arg Val His Met Gly Gln Arg Leu
1 5 10 15
Gly Glu Lys Ile Ala Arg Glu Trp Ala Asp Val Asp Asp Ile Asp Val
20 25 30
Val Ile Pro Val Pro Glu Thr Ser Asn Asp Ile Ala Leu Arg Ile Ala
35 40 45
Arg Val Leu Asn Lys Pro Tyr Arg Gln Gly Phe Val Lys Asn Arg Tyr
50 55 60
Val Gly Arg Thr Phe Ile Met Pro Gly Gln Ala Leu Arg Val Ser Ser
65 70 75 80
Val Arg Arg Lys Leu Asn Thr Ile Ala Ser Glu Phe Lys Asp Lys Asn
85 90 95
Val Leu Leu Val Asp Asp Ser Ile Val Arg Gly Thr Thr Ser Glu Gln
100 105 110

```

103

WO 02/075507

PCT/US02/01971

```

Ile Val Glu Met Ala Arg Ala Ala Gly Ala Lys Lys Ile Tyr Phe Ala
   115                               120                               125
Ser Ala Ala Pro Glu Ile Arg Tyr Pro Asn Val Tyr Gly Ile Asp Met
   130                               135                               140
Pro Thr Lys Asn Glu Leu Ile Ala Tyr Gly Arg Asp Val Asp Glu Ile
   145                               150                               155
Ala Asn Leu Ile Gly Val Asp Lys Leu Ile Phe Gln Asp Leu Asp Ala
   165                               170                               175
Leu Thr Gly Ser Val Gln Gln Glu Asn Pro Ser Ile Gln Asp Phe Asp
   180                               185                               190
Cys Ser Val Phe Thr Gly Val Tyr Val Thr Gly Asp Ile Thr Pro Glu
   195                               200                               205
Tyr Leu
   210

<210> 47
<211> 4788
<212> DNA
<213> Pasteurella multocida

<220>
<221> CDS
<222> (1)..(876)

<220>
<223> rci

<220>
<223> Nucleotide at position 3084 is A, T, G, or C.

<400> 47
gac gag gag aga aaa tta gct gat ttg gca aaa ggt atc gct cca gat 48
Asp Glu Glu Arg Lys Leu Ala Asp Leu Ala Lys Gly Ile Ala Pro Asp
   1                               5                               10                               15
att att ttt aga gat gta ata gaa cgc tat caa aat gaa gtg tct ata 96
Ile Ile Phe Arg Asp Val Ile Glu Arg Tyr Gln Asn Glu Val Ser Ile
   20                               25                               30
act aaa aaa ggc gcg cga aat gaa att ata aga tta aac cgc ttt tta 144
Thr Lys Lys Gly Ala Arg Asn Glu Ile Ile Arg Leu Asn Arg Phe Leu
   35                               40                               45
aga tat gat att tct aat ctg tat att cgt gat tta aga aaa gaa gat 192
Arg Tyr Asp Ile Ser Asn Leu Tyr Ile Arg Asp Leu Arg Lys Glu Asp
   50                               55                               60
ttt gag gag tgg atc aga att cgc cta acc gaa gta tgg gat gct agc 240
Phe Glu Glu Trp Ile Arg Ile Arg Leu Thr Glu Val Ser Asp Ala Ser
   65                               70                               75
gtt aga cgt gag ctt gtt act ata tgc tca gtg ctg aca aca gca ata 288
Val Arg Arg Glu Leu Val Thr Ile Ser Ser Val Leu Thr Thr Ala Ile
   85                               90                               95
aat aag tgg gga tat att tca agg cat cca atg act ggt att gaa aaa 336

```



WO 02/075507

PCT/US02/01971

Asn	Lys	Trp	Gly	Tyr	Ile	Ser	Arg	His	Pro	Met	Thr	Gly	Ile	Glu	Lys							
			100					105					110									
cca	aaa	aac	tcg	gca	gaa	aga	aaa	gaa	cga	tat	tca	gaa	cag	gac	att	384						
Pro	Lys	Asn	Ser	Ala	Glu	Arg	Lys	Glu	Arg	Tyr	Ser	Glu	Gln	Asp	Ile							
			115				120					125										
aaa	aca	ata	tta	gaa	aca	gct	aga	tat	tgt	gaa	gat	aaa	cta	ccc	ata	432						
Lys	Thr	Ile	Leu	Glu	Thr	Ala	Arg	Tyr	Cys	Glu	Asp	Lys	Leu	Pro	Ile							
			130			135					140											
aca	ctc	aaa	caa	aga	gta	gca	att	gca	atg	tta	ttt	gct	att	gaa	acc	480						
Thr	Leu	Lys	Gln	Arg	Val	Ala	Ile	Ala	Met	Leu	Phe	Ala	Ile	Glu	Thr							
					150					155				160								
gct	atg	cgt	gct	ggt	gag	att	gct	agt	ata	aaa	tgg	gat	aat	ggt	ttt	528						
Ala	Met	Arg	Ala	Gly	Glu	Ile	Ala	Ser	Ile	Lys	Trp	Asp	Asn	Val	Phe							
				165				170						175								
ctt	gaa	aag	aga	ata	gta	cat	tta	ccg	aca	act	aaa	aac	ggg	cac	tct	576						
Leu	Glu	Lys	Arg	Ile	Val	His	Leu	Pro	Thr	Thr	Lys	Asn	Gly	His	Ser							
							180		185				190									
aga	gat	gtg	ccg	ctt	tcg	caa	aga	gct	gtt	gcg	cta	att	tta	aaa	atg	624						
Arg	Asp	Val	Pro	Leu	Ser	Gln	Arg	Ala	Val	Ala	Leu	Ile	Leu	Lys	Met							
			195				200				205											
aaa	gag	gta	gaa	aat	gga	gat	ctt	gtg	ttt	cag	acc	acg	cct	gaa	tca	672						
Lys	Glu	Val	Glu	Asn	Gly	Asp	Leu	Val	Phe	Gln	Thr	Thr	Pro	Glu	Ser							
			210		215					220												
tta	agc	acc	acg	ttt	aga	gtg	tta	aag	aaa	gag	tgt	gga	ctt	gaa	cat	720						
Leu	Ser	Thr	Thr	Phe	Arg	Val	Leu	Lys	Lys	Glu	Cys	Gly	Leu	Glu	His							
				225	230				235					240								
ctc	cat	ttt	cat	gat	acg	aga	agg	gaa	gcg	ttg	acg	aga	tta	tct	aag	768						
Leu	His	Phe	His	Asp	Thr	Arg	Arg	Glu	Ala	Leu	Thr	Arg	Leu	Ser	Lys							
				245			250						255									
aaa	gta	gat	gta	atg	act	cta	gcc	aaa	att	agc	gga	cat	aga	gat	tta	816						
Lys	Val	Asp	Val	Met	Thr	Leu	Ala	Lys	Ile	Ser	Gly	His	Arg	Asp	Leu							
				260			265						270									
aga	att	tta	caa	aac	aca	tat	tac	gca	ccg	aat	atg	agt	gaa	gtg	gca	864						
Arg	Ile	Leu	Gln	Asn	Thr	Tyr	Tyr	Ala	Pro	Asn	Met	Ser	Glu	Val	Ala							
			275				280					285										
aac	ttg	ttg	gat	taattcactc	ttcttaata	cgcttttgc	cacttgatta									916						
Asn	Leu	Leu	Asp																			
			290																			
cat	gcc	cag	ctt	at	tctt	ttcat	tacttcttt	ttctaata	gaa	actgggga	g					976						
gaa	agt	cttg	gcg	gta	ata	atg	gcg	gat	gtg	taatt	gta	aga	acg	ta	aat	cat	g	1036				
tag	aa	atg	tc	ca	acta	aga	ga	actg	gact	atctt	ttta	agt	tga	gcta	agg	ctc		1096				
caa	ac	ctc	ac	ag	ag	ctag	ac	tt	ca	ctt	gtt	gtt	ctt	tg	ta	ga	ga	aa	1156			
ttt	tt	ac	ctc	act	ta	aa	taa	aaa	ag	ccg	tc	at	gg	ac	gg	ct	ta	aa	ag	ca	1216	
cag	tt	ctt	ctt	g	agg	gt	acc	ca	at	at	cg	aa	ctt	ga	ll	tg	g	aa	tt	g	1276	

WO 02/075507

PCT/US02/01971

cagtgcttct tttcgatcaa caaatcttec gaagttgga ataacacct gtttcttacc 1336  
 aattagcggg tattgtgtac cgttctcaat agatttaatt tggttacgca taaacatgct 1396  
 atagtgtctc gcgccaagtca ctaaatgaag ttcttttggc gtgtaattct caagctcgca 1456  
 cgcagcgcag acgattaatt ctggaacgac tcccattttc ctatctccga gcatttttca 1516  
 tagcctcaaa ccaagottgt gcgtctcctt cactgtaaaa taatgaaccg cttttctagca 1576  
 tttttctgtg cttatctota ttagcatcaa aatagaatct aataattgtt gagttacctc 1636  
 ttttaaagac ctcttgattg tgggtgtgctg ttttgattgg agcgggcaaa gtaagcgta 1696  
 ctgttggcgg tggttcttcc cacattccga ctatatcaaa tggattttct aaatgggat 1756  
 atttgtatg tcaaaaaaa gaagatccat caatctcca agaattttct tcaaatgtg 1816  
 tcttgcctct gccaatgtg aatacaccct gatataagaa agtgttgaac ggaagaact 1876  
 ttgaataac agcagttaca taccctttac tccattttct aagcacaact gctcaccgg 1936  
 ttaatgcttt ttctaagtca aatgcttca ttttttact tccagcttgc tcatcaataa 1996  
 gctcatcaat ccattctcga atttcagatt ggaattttct taacgaatta ttttcaataa 2056  
 aataatctgc tctttttaa ttaactaccg ctgttttact aaagcattta taaaaagac 2116  
 gcttttctc aacaaatca tcttttgaga ttgagcatac ttttctacg cctctatac 2176  
 ttttgcctg aataaaacta taaaaagaa cctctcttct ctgcttgttt tctaactaaa 2236  
 tagaaatgt atattttttt ggatattcca tttttaatcc tttcttttag ataacaaaa 2296  
 accgcatctc tgcggttatt ctgtgtattt atttaaaaa ttaactatag tttcagcctc 2356  
 ttctaagtgt aatttagaat agcttgaggt ctttttctct ttaacggcaa tctcaattc 2416  
 ttccagcttt aagctataca agtagctttt ttlatcttta taaatcagac cgtacaccat 2476  
 tccggataat ttacccttct catacccat agataaattg atctttctat ctgacccgct 2536  
 cactotaatt gttaaatatt tcttccaat ttttaagact tcagcctcat gttcaatgtt 2596  
 tgagcgcag agtgtttcta aaaaatatac ggtatcgcca actttaagat ttttaatcca 2656  
 atctttatc ataaatccc ttatacttcc ggtggcagtg gaagtgttg ccaatgatt 2716  
 actgaagata gatgtaagt acgaagagac ataaagaaaa catcatctcg ccacgcgatt 2776  
 tttatttccc ctctatctgt ataaatcaga atactctctc tctcactggg caatctatct 2836  
 tttacactaa tccagccate atcttgcgaa aattccaaa tttctgctt ttaagcacc 2896  
 aatcagagc cgtaatcttc ttttctctct tctctcaact gcttttctct gcagtcagcc 2956  
 ttgccaagga cgacaccgta cccggcataa ggtaaatcat tcaacgcaaa atctctatga 3016  
 tcacacatat catctgcgaa ctcatgagct tctactgcac catctaaaca actttgctta 3076  
 gcttgatnta atgtttctgt taagttaacg atatgtatgt cattagatac atctactgag 3136  
 aaaaattttt tttctgttcc taccatagtt aaattcotta ttttttatt aatggcgag 3196

WO 02/075507

PCT/US02/01971

```

gaatcggttg ccagtgtgta acgttaatag ctgatcata aattggacca ttctgattta 3256
tagctaccca aaaatattca ccatacagcaa ttctcttga tgcaattgcg taatgctegc 3316
catattcacc ttcacaaaaa gcaatgactg gtgtttcaac ttctggtaac ttgtcatcaa 3376
caactaacca gtgtctatat tcccaatgaa aattaagctt ctcatagcca ttgatgactt 3436
gatctaagcg aggtcttaat tgggtttctc caacaataat atgtgttgtt atcttaatct 3496
ctgggattcc atctattact tcacaccagt ttttttcaat aaagtccaat ctttttttat 3556
ctgtaaaaag actttcatat tctgcttttg tgattgttac tgtttctgtc atagttaaat 3616
tcctcatgat aaattccatg tttatttacc tttttctggy cacaaaaaaa cacgctattg 3676
cgtgctgtct tgattgatat aatcaattaa tctaagccca atccatttca taactggaac 3736
agccatactg ttccaattg ctttgtatcg tggagaatca gggcattcat ctattgattt 3796
gttgcgatat gggattttag tgtaatctgc tggaaatccc tgtaatcttt cacactcagc 3856
cggcgttagt ttttaacaa ctgattctac tgataaagca acgcaaggaa cattattacc 3916
accagttccc atcttgcctt tlaaggttgg tgaatatca tctgtaatac gacaagcttc 3976
ttaccctta acctcaataa gaatatttcc caatcctcca tttcttccaa tgcaatgcgc 4036
tgtattttta gaaatgattg gatcttctga acctggaaca acaaaagttt cactaccgcc 4096
agcaagaact ccaccgcttg ctcttaatgt tcccgcaaca tccgatttgc gatattgagc 4156
aaagcttctc tcaataaagg cggcaatate ttttgcctgc gttccgctct gtccaatatt 4216
ccctgcacg cttttggaact caatgagtat ttgtgcaaca ctctgcttcc tagcacttgc 4276
cacaagaaac actcttttac gacgttgggc aactcgaag tattgagcat cgagaactcg 4336
ccagcagatt gttcggattg aatgcacata accagcgttc gtccatcttc tcccgtgtg 4396
ctgcaatggc tcaactctt gaaccagtc agccagaagg tgtccgaatg cgttgtccga 4456
ggtggatagc acaccggaa cgttttccca cagagaatg cacggtggtt tgttgtcatt 4516
gaactaaca tagtcgatcg ctctaaaat ttttaataaa actaacgtga gatttctctg 4576
ctcatcgtct aaactttgac gattgccagc aactgaaaaa gattgacaag gattaccacc 4636
aactaaaacg tctggtgccg gaatttccag atctaataat ttctgttcca atcagtcac 4696
atcaccaaga ttgggaacgt taggtaatg gtaagctaat actgcgcttg ggaattgctc 4756
aatttcagaa aaccagagtg gctctgcgaa tt 4788

```

<210> 48  
<211> 292  
<212> PRT  
<213> Pasteurella multocida

<400> 48  
Asp Glu Glu Arg Lys Leu Ala Asp Leu Ala Lys Gly Ile Ala Pro Asp  
1 5 10 15

WO 02/075507

PCT/US02/01971

Ile Ile Phe Arg Asp Val Ile Glu Arg Tyr Gln Asn Glu Val Ser Ile  
 20 25 30  
 Thr Lys Lys Gly Ala Arg Asn Glu Ile Ile Arg Leu Asn Arg Phe Leu  
 35 40 45  
 Arg Tyr Asp Ile Ser Asn Leu Tyr Ile Arg Asp Leu Arg Lys Glu Asp  
 50 55 60  
 Phe Glu Glu Trp Ile Arg Ile Arg Leu Thr Glu Val Ser Asp Ala Ser  
 65 70 75 80  
 Val Arg Arg Glu Leu Val Thr Ile Ser Ser Val Leu Thr Thr Ala Ile  
 85 90 95  
 Asn Lys Trp Gly Tyr Ile Ser Arg His Pro Met Thr Gly Ile Glu Lys  
 100 105 110  
 Pro Lys Asn Ser Ala Glu Arg Lys Glu Arg Tyr Ser Glu Gln Asp Ile  
 115 120 125  
 Lys Thr Ile Leu Glu Thr Ala Arg Tyr Cys Glu Asp Lys Leu Pro Ile  
 130 135 140  
 Thr Leu Lys Gln Arg Val Ala Ile Ala Met Leu Phe Ala Ile Glu Thr  
 145 150 155 160  
 Ala Met Arg Ala Gly Glu Ile Ala Ser Ile Lys Trp Asp Asn Val Phe  
 165 170 175  
 Leu Glu Lys Arg Ile Val His Leu Pro Thr Thr Lys Asn Gly His Ser  
 180 185 190  
 Arg Asp Val Pro Leu Ser Gln Arg Ala Val Ala Leu Ile Leu Lys Met  
 195 200 205  
 Lys Glu Val Glu Asn Gly Asp Leu Val Phe Gln Thr Thr Pro Glu Ser  
 210 215 220  
 Leu Ser Thr Thr Phe Arg Val Leu Lys Lys Glu Cys Gly Leu Glu His  
 225 230 235 240  
 Leu His Phe His Asp Thr Arg Arg Glu Ala Leu Thr Arg Leu Ser Lys  
 245 250 255  
 Lys Val Asp Val Met Thr Leu Ala Lys Ile Ser Gly His Arg Asp Leu  
 260 265 270  
 Arg Ile Leu Gln Asn Thr Tyr Tyr Ala Pro Asn Met Ser Glu Val Ala  
 275 280 285  
 Asn Leu Leu Asp  
 290

<210> 49  
 <211> 1618  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (2)...(1195)

WO 02/075507

PCT/US02/01971

```

<220>
<223> sopE
<400> 49
g ggc gat cta tgt ctg aaa ata tct aca tgg tgt caa agt cac aga atc 49
Gly Asp Leu Cys Leu Lys Ile Ser Thr Trp Cys Gln Ser His Arg Ile
1 5 10 15
aat caa gca att cgc aca att caa agt cta tca acc gca gtc atc ggt 97
Asn Gln Ala Ile Arg Thr Ile Gln Ser Leu Ser Thr Ala Val Ile Gly
20 25 30
att gtc tgt act gca aat gac gca gac aat gaa aca ttc cca ctg aat 145
Ile Val Cys Thr Ala Asn Asp Ala Asp Asn Glu Thr Phe Pro Leu Asn
35 40 45
gaa ccc gtt ctg atc aca aac gtg gca gcg gca att ggc aag gct gga 193
Glu Pro Val Leu Ile Thr Asn Val Ala Ala Ala Ile Gly Lys Ala Gly
50 55 60
aaa caa ggc acg ctt tca cgt gcg ctt gac ggg att tct gat gta gtc 241
Lys Gln Gly Thr Leu Ser Arg Ala Leu Asp Gly Ile Ser Asp Val Val
65 70 75 80
aat tgc aaa gtg att gtt gtg cga gtg caa gaa agt gcg caa gaa gac 289
Asn Cys Lys Val Ile Val Val Arg Val Gln Glu Ser Ala Gln Glu Asp
85 90 95
gaa gaa aca aaa gca agt gaa atg aac acg gca att att ggc aca atc 337
Glu Glu Thr Lys Ala Ser Glu Met Asn Thr Ala Ile Ile Gly Thr Ile
100 105 110
aca gaa gaa ggg cag tac aca ggc ttg aag gcg tta ttg att gcg aaa 385
Thr Glu Glu Gly Gln Tyr Thr Gly Leu Lys Ala Leu Leu Ile Ala Lys
115 120 125
aac aaa ttc ggt atc aaa cca cgt att tta tgt gtg cca aaa ttc gac 433
Asn Lys Phe Gly Ile Lys Pro Arg Ile Leu Cys Val Pro Lys Phe Asp
130 135 140
aca aaa gaa gtc gcc aca gag ctt gca agt atc gcc gcc aaa ctg aac 481
Thr Lys Glu Val Ala Thr Glu Leu Ala Ser Ile Ala Ala Lys Leu Asn
145 150 155 160
gca ttt gct tac att tca tgt caa ggg tgt aaa acg aaa gaa caa gcg 529
Ala Phe Ala Tyr Ile Ser Cys Gln Gly Cys Lys Thr Lys Glu Gln Ala
165 170 175
gtg caa tat aaa cgc aac ttc tca caa cgt gaa gtc atg ctg atc atg 577
Val Gln Tyr Lys Arg Asn Phe Ser Gln Arg Glu Val Met Leu Ile Met
180 185 190
ggc gat ttt ctg tca ttt aat gtc aac aca tca aaa gtt gag att gac 625
Gly Asp Phe Leu Ser Phe Asn Val Asn Thr Ser Lys Val Glu Ile Asp
195 200 205
tat gcc gtc act cgt gcg gcg gca atg cgt gca tat ctt gat aaa gaa 673
Tyr Ala Val Thr Arg Ala Ala Ala Met Arg Ala Tyr Leu Asp Lys Glu
210 215 220
cag gcc tgg cat acg tct att tca aat aaa ggc att aat ggc gtg acg 721
Gln Gly Trp His Thr Ser Ile Ser Asn Lys Gly Ile Asn Gly Val Ser
225 230 235 240

```

WO 02/075507

PCT/US02/01971

```

ggg gtc aca caa cca ctc tat ttt gac att aac gac agc tcg act gat 769
Gly Val Thr Gln Pro Leu Tyr Phe Asp Ile Asn Asp Ser Ser Thr Asp
245 250 255

gtg aac tat ctc aat gaa caa ggc atc acg tgt tgc gtg aat cat aat 817
Val Asn Tyr Leu Asn Glu Gln Gly Ile Thr Cys Cys Val Asn His Asn
260 265 270

ggc ttt cgt ttt tgg ggc tta cgc acg act gca gaa gat cca tta ttc 865
Gly Phe Arg Phe Trp Gly Leu Arg Thr Thr Ala Glu Asp Pro Leu Phe
275 280 285

aag ttt gaa gtg tac acc cgc act gca caa atc tta aaa gat acg att 913
Lys Phe Glu Val Tyr Thr Arg Thr Ala Gln Ile Leu Lys Asp Thr Ile
290 295 300

gca ggg gcg ttt gat tgg gca gtg gat aaa gat att tct gtc acg cta 961
Ala Gly Ala Phe Asp Trp Ala Val Asp Lys Asp Ile Ser Val Thr Leu
305 310 315

gtg aaa gat att att gaa gca atc aat gcg aag tgg cgt gat tac acc 1009
Val Lys Asp Ile Ile Glu Ala Ile Asn Ala Lys Trp Arg Asp Tyr Thr
325 330 335

aca aaa ggc tac tta att ggc ggt aaa gcg tgg ctt aat aaa gag ctt 1057
Thr Lys Gly Tyr Leu Ile Gly Gly Lys Ala Trp Leu Asn Lys Glu Leu
340 345 350

aac agt gca acg aat tta aaa gat gcg aag ttg ttg atc tct tat gat 1105
Asn Ser Ala Thr Asn Leu Lys Asp Ala Lys Leu Leu Ile Ser Tyr Asp
355 360 365

tat cac cca gta cca ccg ctc gaa cag cta ggc ttt aat cag tac att 1153
Tyr His Pro Val Pro Pro Leu Glu Gln Leu Gly Phe Asn Gln Tyr Ile
370 375 380

tct gat gaa tac ctt gtt gat ttt tca aat cgt tta gca tcg 1195
Ser Asp Glu Tyr Leu Val Asp Phe Ser Asn Arg Leu Ala Ser
385 390 395

taaggggtag aaaatggcctt taccacgcaa acctaaattg atgaatttaa tcatcgacgg 1255
taacaaatat ctggcggaag tcacggaagt gactcaacca aaattagcaa tgaaaaatcga 1315
agaatttcgc gcggcggtta tgattgggtc ggtggatgac aatctcgggc ttgaaaaagct 1375
cgaagcggaa tttaaagccg gtggctacat ggtcgaatta attaaaaaat tcggcgggtc 1435
aatcaacggc attccattgc gttttcttgg ctcatatcag cgtgatgaca cagaagaagt 1495
cacatctggt gagcttgta tgcaaggtcg atttactgaa attgacagcg gaaacagcaa 1555
agtggcgat gacactgaac aaacattcaa agtgccttta acgtattaca aaatcattgt 1615
tga 1618

<210> 50
<211> 398
<212> PRT
<213> Pasteurella multocida
<400> 50

```

WO 02/075507

PCT/US02/01971

Gly Asp Leu Cys Leu Lys Ile Ser Thr Trp Cys Gln Ser His Arg Ile  
 1 5 10 15  
 Asn Gln Ala Ile Arg Thr Ile Gln Ser Leu Ser Thr Ala Val Ile Gly  
 20 25 30  
 Ile Val Cys Thr Ala Asn Asp Ala Asp Asn Glu Thr Phe Pro Leu Asn  
 35 40 45  
 Glu Pro Val Leu Ile Thr Asn Val Ala Ala Ala Ile Gly Lys Ala Gly  
 50 55 60  
 Lys Gln Gly Thr Leu Ser Arg Ala Leu Asp Gly Ile Ser Asp Val Val  
 65 70 75 80  
 Asn Cys Lys Val Ile Val Val Arg Val Gln Glu Ser Ala Gln Glu Asp  
 85 90 95  
 Glu Glu Thr Lys Ala Ser Glu Met Asn Thr Ala Ile Ile Gly Thr Ile  
 100 105 110  
 Thr Glu Glu Gly Gln Tyr Thr Gly Leu Lys Ala Leu Leu Ile Ala Lys  
 115 120 125  
 Asn Lys Phe Gly Ile Lys Pro Arg Ile Leu Cys Val Pro Lys Phe Asp  
 130 135 140  
 Thr Lys Glu Val Ala Thr Glu Leu Ala Ser Ile Ala Ala Lys Leu Asn  
 145 150 155 160  
 Ala Phe Ala Tyr Ile Ser Cys Gln Gly Cys Lys Thr Lys Glu Gln Ala  
 165 170 175  
 Val Gln Tyr Lys Arg Asn Phe Ser Gln Arg Glu Val Met Leu Ile Met  
 180 185 190  
 Gly Asp Phe Leu Ser Phe Asn Val Asn Thr Ser Lys Val Glu Ile Asp  
 195 200 205  
 Tyr Ala Val Thr Arg Ala Ala Ala Met Arg Ala Tyr Leu Asp Lys Glu  
 210 215 220  
 Gln Gly Trp His Thr Ser Ile Ser Asn Lys Gly Ile Asn Gly Val Ser  
 225 230 235 240  
 Gly Val Thr Gln Pro Leu Tyr Phe Asp Ile Asn Asp Ser Ser Thr Asp  
 245 250 255  
 Val Asn Tyr Leu Asn Glu Gln Gly Ile Thr Cys Cys Val Asn His Asn  
 260 265 270  
 Gly Phe Arg Phe Trp Gly Leu Arg Thr Thr Ala Glu Asp Pro Leu Phe  
 275 280 285  
 Lys Phe Glu Val Tyr Thr Arg Thr Ala Gln Ile Leu Lys Asp Thr Ile  
 290 295 300  
 Ala Gly Ala Phe Asp Trp Ala Val Asp Lys Asp Ile Ser Val Thr Leu  
 305 310 315 320  
 Val Lys Asp Ile Ile Glu Ala Ile Asn Ala Lys Trp Arg Asp Tyr Thr  
 325 330 335

WO 02/075507

PCT/US02/01971

Thr Lys Gly Tyr Leu Ile Gly Gly Lys Ala Trp Leu Asn Lys Glu Leu  
 340 345 350  
 Asn Ser Ala Thr Asn Leu Lys Asp Ala Lys Leu Leu Ile Ser Tyr Asp  
 355 360 365  
 Tyr His Pro Val Pro Pro Leu Glu Gln Leu Gly Phe Asn Gln Tyr Ile  
 370 375 380  
 Ser Asp Glu Tyr Leu Val Asp Phe Ser Asn Arg Leu Ala Ser  
 385 390 395

<210> 51  
 <211> 353  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (1)..(351)

<220>  
 <223> unknown C1

<400> 51  
 atg aca tta ttt gat gaa tgt aaa tta gct ctt aga gac gat ttt aat 48  
 Met Thr Leu Phe Asp Glu Cys Lys Leu Ala Leu Arg Asp Asp Phe Asn  
 1 5 10 15  
 cta att tgt gat gaa gag aag gat tgt gta atg gat aag ttt tat ttc 96  
 Leu Ile Cys Asp Glu Glu Lys Asp Cys Val Met Asp Lys Phe Tyr Phe  
 20 25 30  
 tat ttc ttg gaa aag aaa gag gaa ttt aat ttt caa gat tat tca ttt 144  
 Tyr Phe Leu Glu Lys Lys Glu Glu Phe Asn Phe Gln Asp Tyr Ser Phe  
 35 40 45  
 gaa gaa atg tat ata ttt tca aaa atg gaa cct gfg tat gtt tta tgt 192  
 Glu Glu Met Tyr Ile Phe Ser Lys Met Glu Pro Val Tyr Val Leu Cys  
 50 55 60  
 gat agc tct aat ata cct ttg ttt agg agt aat tgg gaa ttg att atc 240  
 Asp Ser Ser Asn Ile Pro Leu Phe Arg Ser Asn Trp Glu Leu Ile Ile  
 65 70 75 80  
 aat aat ata tat gat gtt gtc tgt tta tct aca aaa gta ttt ttt cta 288  
 Asn Asn Ile Tyr Asp Val Val Cys Leu Ser Thr Lys Val Phe Phe Leu  
 85 90 95  
 gat gat gaa aag tta atg atg gaa tta ttt cct gaa gat aaa gta aga 336  
 Asp Asp Glu Lys Leu Met Met Glu Leu Phe Pro Glu Asp Lys Val Arg  
 100 105 110  
 gtc atc tat aaa aga ta 353  
 Val Ile Tyr Lys Arg  
 115

<210> 52  
 <211> 117  
 <212> PRT  
 <213> Pasteurella multocida



WO 02/075507

PCT/US02/01971

<400> 52  
 Met Thr Leu Phe Asp Glu Cys Lys Leu Ala Leu Arg Asp Asp Phe Asn  
 1 5 10 15  
 Leu Ile Cys Asp Glu Glu Lys Asp Cys Val Met Asp Lys Phe Tyr Phe  
 20 25 30  
 Tyr Phe Leu Glu Lys Lys Glu Glu Phe Asn Phe Gln Asp Tyr Ser Phe  
 35 40 45  
 Glu Glu Met Tyr Ile Phe Ser Lys Met Glu Pro Val Tyr Val Leu Cys  
 50 55  
 Asp Ser Ser Asn Ile Pro Leu Phe Arg Ser Asn Trp Glu Leu Ile Ile  
 65 70 75 80  
 Asn Asn Ile Tyr Asp Val Val Cys Leu Ser Thr Lys Val Phe Phe Leu  
 85 90 95  
 Asp Asp Glu Lys Leu Met Met Glu Leu Phe Pro Glu Asp Lys Val Arg  
 100 105 110  
 Val Ile Tyr Lys Arg  
 115

<210> 53  
 <211> 509  
 <212> DNA  
 <213> *Pasteurella multocida*

<220>  
 <221> CDS  
 <222> (1)..(507)

<220>  
 <223> unknown C2

<400> 53  
 atg aaa aat ttt agg aat ata aat att tat agt gat tat gga aag gtt 48  
 Met Lys Asn Phe Arg Asn Ile Asn Ile Tyr Ser Asp Tyr Gly Lys Val  
 1 5 10 15  
 gat aag gaa att ata tta gaa ttc gaa aat gaa ttt aat ata aag ctt 96  
 Asp Lys Glu Ile Ile Leu Glu Phe Glu Asn Glu Phe Asn Ile Lys Leu  
 20 25 30  
 cct tct tta tac ata gat tta att acg gcg cat aat gct ccg aag agt 144  
 Pro Ser Leu Tyr Ile Asp Leu Ile Thr Ala His Asn Ala Pro Lys Ser  
 35 40 45  
 gaa gag aat tgc ttt gaa tat tac aat gag cgt aat gag ccc acg ttt 192  
 Glu Glu Asn Cys Phe Glu Tyr Tyr Asn Glu Arg Asn Glu Pro Thr Phe  
 50 55 60  
 tct tcc ttt gga ttt gaa ggg ttt gag aca gag cgg tct agc gcc tct 240  
 Ser Ser Phe Gly Phe Glu Gly Phe Glu Thr Glu Arg Ser Ser Ala Ser  
 65 70 75 80  
 ctt gaa aat ata tat gct cag tat att tat gat gat cca atc tat ggt 288  
 Leu Glu Asn Ile Tyr Ala Gln Tyr Ile Tyr Asp Asp Pro Ile Tyr Gly  
 85 90 95

WO 02/075507

PCT/US02/01971

tat gaa cat gat ggt tat tct ttt ggt agt act ggc gag gga cat ttt atc 336  
 Tyr Glu His Val Tyr Ser Phe Gly Ser Thr Gly Glu Gly His Phe Ile  
                   100                  105                  110

tgt ttt gat tat cgt gat gat cca aaa ggt gat gaa ccc aaa atc tgt 384  
 Cys Phe Asp Tyr Arg Asp Asp Pro Lys Gly Asp Glu Pro Lys Ile Cys  
                   115                  120                  125

atc gtg att cac gat gaa tat gat gaa aaa aca ggg aaa atg cga ctg 432  
 Ile Val Ile His Asp Glu Tyr Asp Glu Lys Thr Gly Lys Met Arg Leu  
                   130                  135                  140

ttt cct ata gca gag aat ttt gaa gcg ttt tta gat agt ttg aaa tca 480  
 Phe Pro Ile Ala Glu Asn Phe Glu Ala Phe Leu Asp Ser Leu Lys Ser  
 145                  150                  155

ttt gat gaa atg ata gag aag tat tcg ta 509  
 Phe Asp Glu Met Ile Glu Lys Tyr Ser  
                   165

<210> 54  
 <211> 169  
 <212> PRT  
 <213> Pasteurella multocida

<400> 54  
 Met Lys Asn Phe Arg Asn Ile Asn Ile Tyr Ser Asp Tyr Gly Lys Val  
 1                  5                  10                  15

Asp Lys Glu Ile Ile Leu Glu Phe Glu Asn Glu Phe Asn Ile Lys Leu  
                   20                  25                  30

Pro Ser Leu Tyr Ile Asp Leu Ile Thr Ala His Asn Ala Pro Lys Ser  
                   35                  40                  45

Glu Glu Asn Cys Phe Glu Tyr Tyr Asn Glu Arg Asn Glu Pro Thr Phe  
                   50                  55                  60

Ser Ser Phe Gly Phe Glu Gly Phe Glu Thr Glu Arg Ser Ser Ala Ser  
                   65                  70                  75                  80

Leu Glu Asn Ile Tyr Ala Gln Tyr Ile Tyr Asp Asp Pro Ile Tyr Gly  
                   85                  90                  95

Tyr Glu His Val Tyr Ser Phe Gly Ser Thr Gly Glu Gly His Phe Ile  
                   100                  105                  110

Cys Phe Asp Tyr Arg Asp Asp Pro Lys Gly Asp Glu Pro Lys Ile Cys  
                   115                  120                  125

Ile Val Ile His Asp Glu Tyr Asp Glu Lys Thr Gly Lys Met Arg Leu  
                   130                  135                  140

Phe Pro Ile Ala Glu Asn Phe Glu Ala Phe Leu Asp Ser Leu Lys Ser  
 145                  150                  155

Phe Asp Glu Met Ile Glu Lys Tyr Ser  
                   165

<210> 55  
 <211> 443

WO 02/075507

PCT/US02/01971

```

<212> DNA
<213> Pasteurella multocida

<220>
<221> CDS
<222> (1)..(441)
<220>
<223> unknown C3

<400> 55
atg ata aaa tat tta gag gga aat att aac tgg ttt ata tgg gca tta 48
Met Ile Lys Tyr Leu Glu Gly Asn Ile Asn Ser Phe Ile Ser Ala Leu
1 5 10 15
ggt aaa aac gaa agt aat aaa gat att tta aaa tta gta gaa ata gtt 96
Gly Lys Asn Glu Ser Asn Lys Asp Ile Leu Lys Leu Val Glu Ile Val
20 25 30
tct tca gat ttt gaa tgg gat gaa cta agt cat aaa gat gaa cac gag 144
Ser Ser Asp Phe Glu Val Asp Glu Leu Ser His Lys Asp Glu His Glu
35 40 45
ata tat tat tgg ttt tat aag agg ggt gtt gaa ttt tgt ttt aaa aga 192
Ile Tyr Tyr Leu Phe Tyr Lys Arg Gly Val Glu Phe Cys Phe Lys Arg
50 55 60
ata gat gaa gag tat gtc tta tat tgg gtt ttc ttt ttc tgg gta gag 240
Ile Asp Glu Glu Tyr Val Leu Tyr Ser Val Phe Phe Phe Leu Val Glu
65 70 75 80
ggt gat aat tat ttt tca tgc cca ttt att cat gaa tta ata tgt gat 288
Val Asp Asn Tyr Phe Ser Cys Pro Phe Ile His Glu Leu Ile Cys Asp
85 90 95
ctt aaa cac gga ttc tca ata gag gat att ata agg ttt tta ggg gag 336
Leu Lys His Gly Phe Ser Ile Glu Asp Ile Ile Arg Phe Leu Gly Glu
100 105 110
cca aat ttt aaa ggt agt ggc tgg gta aga tat tct tat aat gga aga 384
Pro Asn Phe Lys Gly Ser Gly Trp Val Arg Tyr Ser Tyr Asn Gly Arg
115 120 125
aat att cat ttc gaa ttt aat gaa tct aat gaa tta tcc cag att agc 432
Asn Ile His Phe Glu Phe Asn Glu Ser Asn Glu Leu Ser Gln Ile Ser
130 135 140
att ttt att ta 443
Ile Phe Ile
145

<210> 56
<211> 147
<212> PRT
<213> Pasteurella multocida

<400> 56
Met Ile Lys Tyr Leu Glu Gly Asn Ile Asn Ser Phe Ile Ser Ala Leu
1 5 10 15
Gly Lys Asn Glu Ser Asn Lys Asp Ile Leu Lys Leu Val Glu Ile Val
20 25 30

```

WO 02/075507

PCT/US02/01971

Ser Ser Asp Phe Glu Val Asp Glu Leu Ser His Lys Asp Glu His Glu  
35 40 45  
Ile Tyr Tyr Leu Phe Tyr Lys Arg Gly Val Glu Phe Cys Phe Lys Arg  
50 55 60  
Ile Asp Glu Glu Tyr Val Leu Tyr Ser Val Phe Phe Leu Val Glu  
65 70 75 80  
Val Asp Asn Tyr Phe Ser Cys Pro Phe Ile His Glu Leu Ile Cys Asp  
85 90 95  
Leu Lys His Gly Phe Ser Ile Glu Asp Ile Ile Arg Phe Leu Gly Glu  
100 105 110  
Pro Asn Phe Lys Gly Ser Gly Trp Val Arg Tyr Ser Tyr Asn Gly Arg  
115 120 125  
Asn Ile His Phe Glu Phe Asn Glu Ser Asn Glu Leu Ser Gln Ile Ser  
130 135 140  
Ile Phe Ile  
145

<210> 57  
<211> 8498  
<212> DNA  
<213> Pasteurella multocida  
<220>  
<223> unknown C

<400> 57  
gaattcgaat taagcgagaa aattgctgaa acactagaac aaagtcaatt aaatattagt 60  
caattatcaa ttgttgaat ttatcctttc aatgaagaac aagggatacg ttttcataat 120  
aaaagtgtgg tacaacttaa accagaagag gtggaatggt catcaatcca ttatcctttc 180  
tttctgtggc atattcagca agtcgctcat ctccggaag ccgcagaaat gggttgcgtg 240  
gtgattgata tgaagggat ttgtgccagc ttgcaagac tcctgtggt gatacggga 300  
gtaaatcagg aaaaattggt agatttacgt cagcgtaata ttgtgctctt agccgatcca 360  
caagtgcac aacttgcat agtcacgccc tcgttgatgt caaatcacga aatcaagac 420  
attgccgtaa cctcgttatt acctgcatct tatactaacg gagaacggt aggtaaatta 480  
gcgggacaaa cagcgcgatt gttaaatggc attccacttg atgaaggcga acaacgttta 540  
gcttttgatg ttttcctac gcttgcacg catttaata tgcaaatcca caagatcttt 600  
ccacaattag ataatgtcgt atttcattct atccaagtgc ctgttttcta cgggatgggg 660  
caaatgggta gcgtattatc ggattatgca ttagatcctc aatcttgctt agcgagctgg 720  
actgacaatc cgttgatgac ttatcatgca gaaaaatatt gcacccacgt gacgaatggc 780  
gaacaggaaa tggcagaaga gcaagcagca aaattacata taagtgggtt aagtgcgggtg 840  
gaaaatggtc tacaattttg gtcggttgca gatgaacagc gcttitaatct tgcctttattg 900

WO 02/075507

PCT/US02/01971

agtgltacgc ttgcagagtt aatttactcg caagggttatt aatttaaatg tgtttttgca 960  
cgatattttt atcttgaact ttgagagcgc actcgttttt gacgagtgcg tttttgtaa 1020  
aacattcgtt tgaagacag tgaatgaata gccggattat tgataagaat caattatac 1080  
aaaagcaact gaatgttatt aatcgaggca ataaacctat tgatagtttt agttggcgcc 1140  
ataatacata aactgtactt aataatatgc aatcaatacc tagaataatt catgacgtaa 1200  
tccaacatat cggggagggg attttaagtg atggtagaaa aaacatttag aaatctaaaa 1260  
atatatgatg attatggttc tgcctctcag gaaattttt ttaattttga aaaagagttt 1320  
gatataaaac tccctttatc ctatatctca cttgtgaaaa agtataatgg cgtttggttt 1380  
aaggaaagtg attttgaata tttatctcaa aatgggaaaa gaataataag ctcatgtagt 1440  
tttgatagtt ttgagacaaa agataatgc gaaccaatga ataataatatt aagacaatat 1500  
atttatgatg atgaattta tggatataag aatgtttatt cctttgggta cactggaat 1560  
ggtagactttg tctgttttga ttatcgtgat gacccaaaag gtgatgagcc caaaatctgt 1620  
atcgtgatcc atgatgaata tgatgaaaaa acaggcaagc gtttgttatt gcctgtggca 1680  
gaaaaatttg aggcattttt agatagctt tacgattttg atgaacgcta tccgaatggt 1740  
tatgaatagg tatttgttta aataatgtgt tgtattttt aagcattatt tacaactaac 1800  
attttaagtg cgggtcaattt tgaaaaagtt ttggccttg agaattgggc gcattttttt 1860  
tgaatatctc ttcaatgatg agcactaatt atggattaga taatgggaat tatcgagata 1920  
tggatggtaa taaaggatgg aggctagatt ttgatcctga gaaagtgtt catgtaata 1980  
tttttgactt tactaaaggt aaaggactag gtaaagcagt taaaaagtca ttcttttga 2040  
tagtactgaa caagagtttg aaaaatttta aagcaattaa ataaggaaga taaatgaca 2100  
ttatttgatg aatgtaaatt agctcttaga gacgatttta atctaatttg tgatgaagag 2160  
aaggattgtg taatggataa gttttattc tatttcttgg aaaagaaaga ggaatttaat 2220  
tttcaagatt attcatttga agaaatgtat atattttcaa aaatggaacc tgtgtatgtt 2280  
ttatgtgata gctctaatat acctttgttt aggagtaatt ggganttgat tatcaataat 2340  
atatatgatg ttgtctgttt atctacaaaa gtatttttct tagatgatga aaagttaatg 2400  
atggaattat ttcttgaaga taaagtaaga gtcactata aaagataatt accccttgat 2460  
cgcctcgtg tcagcacgag ttcgcttca ttaaagctct cgttaaagac tagcactagc 2520  
agtgagggtg atcgtaatca atttactgaa gaacagttaa ttaaaattaa taagaggctt 2580  
gataaaaatg agggatttac atggcatcat aactcacaaa gtatgccca aaatagttag 2640  
ttaataccta caccaattca taaggctggt cagcatatag gtgaaggcgc tttaaagtga 2700  
ggaaagtgat aaaaatgaaa attttaggaa tataaatatt tatagtgatt atggaaaggt 2760  
tgataaggaa attatattag aattcgaaaa tgaatttaat ataaagcttc cttctttata 2820

WO 02/075507

PCT/US02/01971

catagattta attacggcgc ataatgctcc gaagagtga gagaaattgct ttgaatatta 2880  
caatgagcgt aatgagccca cgttttcttc ctttggattt gaagggtttg agacagagcg 2940  
gtctagcgcc tctcttgaaa atatatatgc tcagtatatt tatgatgac caatctatgg 3000  
ttatgaacat gtgtattott ttggtagtac tggcgagggg cattttatct gttttgatta 3060  
tcgtgatgat ccaaaaagtg atgaacccaa aatctgtatc gtgattcacg atgaatatga 3120  
tgaaaaaca gggaaaatgc gactgtttcc tatagcagag aattttgaag cgtttttaga 3180  
tagtttgaaa tcatttgatg aaatgataga gaagtattcg taatgtctcc gtctcatctc 3240  
catagcagtg ctctctcccc tgattttatg gaaattttgt ttaaattagg agggcactaa 3300  
aatgaaaaaa ttttatttaa tttttttatt attcctaagt ggatgttttt atcatgatgg 3360  
atgtatctat actcctcaga tggtaaatg ttttggatg aaaggagata tatttccatc 3420  
aatatctcgg tatcaaaagc ctatagtct aggaaaaacc aattcagaac agcgttgga 3480  
ggatgttatg ttttggag gtaaatatgg tgattataaa ttagagaata taaaacagc 3540  
ggaacaatcg gataaattac atcattgtat gacccaaaaa gggtatatcc atttaactcc 3600  
cgcagaatgt ggataccaaa atcctaaatg ggataaagc gtttgaatt tataagtgt 3660  
ttggatttta ctttacgaat tttttttgaa aaaagtacc gcaggtatgt ttttaacaa 3720  
agcccaggcg gcgctgttg gatgtgttat tcgcatagta gttattatgc ggaagtgcta 3780  
aatgaattca ttattaaaaa tggaaataaa gacgtaatt agcaccgttt gcggtgagtg 3840  
atttaatttc tctgatgtt atggaaatat tatttaagtt aggaggtgat taggatgaaa 3900  
aagtgttat tgttcagttt attattactt ttaaattgat gcctatattc ttttgaagag 3960  
gagtgtttta gaccgttaat tcaggtggg tcactctgct gtcataagaa taaaggagat 4020  
atatttccat caatagcacg tttccaaaaa gttagagaaca tcgaaaaac tgatgccaag 4080  
caactgtgga aagatcggtg tgattgtgga agtaagtatg gcgatgaaga tttatata 4140  
ataaatgata ataattata tagcattttt cactcctgta tggtaaaaa aggatataaa 4200  
aagtttcatc ccgcagaatg tggataccaa aatcctaaat gggataaggg tatttgtaat 4260  
ttataagtg tttgaatttt actttacaaa ctttttttga aaaaattac cgcgtgagtg 4320  
tctgtttta gggataaaga ttcgttcatt ttctttaat ttaggacgg tataaagag 4380  
cttgattatc aaataataat atcgtgttcg tgtccacacg agtagggttt gattaagta 4440  
ctcctcaaaa gcgagtgcta gctgtgggtt aaacggtggg aaagaaagta aagagtatat 4500  
aaaccaattg accgcataac gtgcggtcaa tttctaagat ttatgagttc cagaaaaata 4560  
gaccgaaaag tgcggtaaag gggtaacgaa acacaaaaaa taaaaatag acagcaagct 4620  
gtgtcattaa accccagaaa aaaactgac cgattgttgc actgctgaaa atggcaaaaa 4680  
gtaagccgat ttcataaggt agcattgcaa taaaccagat taatccactt ggatgatcac 4740

WO 02/075507

PCT/US02/01971

ttttcattac ggactcetta tttatggctg ataacttaac acttgattg aaaattaaag 4800  
cagatttaa caatgcgttg agcgattta aagcgctaa aacggaatg caacgcgag 4860  
gctggagtc tctcagtaag taactcgcca gtttttgcaa tcatttatca tattcaciaa 4920  
gctgtaatgc atattggaga aggttaagtg taagtgaagg aagataaaat gaaatttaga 4980  
cattttggca tttattatga ttatggcgta gtttcccaag agattatatt agattttgag 5040  
gaaacgtttg gtattaaatt accaaaattg tatattgagt tgatcaciaa acataattcc 5100  
ccaagattga atagagatca tttcaattat tatgatttct ctacgagtga ggaagaagga 5160  
acggaattta tattcaaaag atttgaaca gaaagtaata ggcacgccc gccagaaaat 5220  
atttatgac aatattctta tgatgatgaa atatatggtt atgaacatgt gtattctttt 5280  
ggcagtagc ctagtgtgta ctttgtctgt tttgattacc gagataatc gaaaggcagt 5340  
gaactaaaa tttgtcttgt gattcatgat gaatatgat aagaacagg caagcattta 5400  
ttgttctctg tggcagaaaa ttttgaggta tttttagata tgctttacga ttttgatgaa 5460  
cgtatccga atggttatga ataggtatatt aaataatgta ttgtattttt taagcgttat 5520  
ttaataactg ttttaagtgc gtaaatcca aaaaagtatt gctttgagga attgacctt 5580  
ttgtatctg gatatgatg tgagcaattg atactctgt tgtgttaact ggcacgtggt 5640  
aaagcattcg tcaagacga gctctagtgg tgagggaact atcatgaatg aactattgga 5700  
ctttataga aatataactt ttttgaaga atagatgaa aactcattca taggaagatg 5760  
gcttgattac tcggaatgga atgataaaga atattgaaa ttgagaagag atttactgaa 5820  
aatgtctcaa atgtatagaa ctactaatga agttttcca gatattttaa taggggttat 5880  
gctatcatt gaattattaa tgatacctaa ctggaatagt tttataat ctactcaga 5940  
aagtgtgat atttatgata gatatgaacg atttaaat ataatcca tacttttcaa 6000  
taataaagat gttagactag atgcttttc atatacagaa aagaatgat atgtattta 6060  
taataaagat aaaaattaaa agtaagctaa ttttagaaa taataaagt ctgcttcta 6120  
tttttcttt gagatcgtgc ttgagtcac acgagtgcta gctgtaggca gagtgcttg 6180  
gtattataa aaagttaagg atagtattgt tgatagaaa gaaaagacta aatattcaat 6240  
ggggaatcaa agtgataaaa aataaatttt atattcttg gttaggattt tcaatcat 6300  
tatatgttt gctttatgt agagattgt tttattctt ttatatgatt tttattatga 6360  
tgtattgtc ttaaaatttt cttttaagga ggcgtttttt actatctta tttttattgt 6420  
gctatgttc attattcatt attcattatt cattattcat tattcattat tcattatttt 6480  
atataaat atggtaaaag gctcgaatgc ccaaaaaaga aaccatttag tgaataatgta 6540  
acatacaata aaaggtatga ggaataata aaatattagg aataacagaa tgataaata 6600  
tttagagga aatattaact cgtttatct ggcattaggt aaaaacgaaa gtaataaaga 6660

WO 02/075507

PCT/US02/01971

tattttaaaa ttagtagaaa tagtttcttc agattttgaa gtggatgaac taagtcataa 6720  
agatgaacac gagatatatt atttgtttta taagaggggt gttgaatttt gttttaaaaa 6780  
aatagatgaa gagtatgtct tatattcggg tttctttttc ttggtagagg ttgataatta 6840  
tttttcacgc ccatttattc atgaattaat atgtgatctt aaacacggat tctcaataga 6900  
ggatattata aggttttttag gggagccaaa ttttaaaagt agtggctggg taagatattc 6960  
ttataatgga agaaatattc atttcgaatt taatgaatct aatgaattat cccagattag 7020  
catttttatt taataattta ggattgggaa cgcctctcgtg ttcacacaag tgcggtttga 7080  
ttaaagcact tgtcaaagc gagatccagc tgtgggagat ttgatagaga aatggctctc 7140  
aggattgacg ttagtagagg gagcataaat caagaaaaaa catttaaat aggaacatta 7200  
ggtggtagt aatggaatc actcgtttta aaatcctact tattgccttg attatattag 7260  
gtaatgggta tgtgtttctt ggtggaccag ctaaaaaaca attcgtata gaagcagaaa 7320  
caagcgggat ttatcgtact ttaacgaaag aaattatttt tatgaatgga gaatataaac 7380  
aattggagg gcgagtatt caaggatta ctttagtcat tctttttct cattcaagta 7440  
cagaaaaccg cattaagatt ttagaaaaa ttaaagagat gggatttgat tcaaaaaata 7500  
aaacatcaaa accgagctct catctttttt gtcaaggaga aatgggtttt ttgatcgcag 7560  
aaaaacctga atttagaata gattatgaga aaaagatgac ttattgttg gagtagcaaa 7620  
ggaaggcaat gataaagtga ttttctaac agatttaatt taagtattaa agtgcggtca 7680  
attttgaaaa cgttttactt tgaaaaaatg accgtttttt tacatgagag agtgaagta 7740  
caccacctta gccaatgtg ttgtggataa ggtgattaag gaatacccaa atgggggtta 7800  
tgaagcagg gtgctgatcc ctaaccgaa agcgaanaacc gatcctgatg cgcgaaatt 7860  
tttgagaaa ägggaaatg aaggtgtat cacaatgttt ccaagaacat ggacagagg 7920  
taggtgaaa gtgagtag agcatgcgtt taataataga gtaccaatgg aaaagtttga 7980  
aaataaatgg gaaggtataa caaaatcagg cgtgaaagta gaatgggttc tggatagaaa 8040  
tggtaaatg ttgactctat tttgttaatt ttctgtct ttttgtaaaa aataagtgt 8100  
tgaataaca tttttctcta taatcaaat ttaatgataa ttaatatcat taataagaa 8160  
tggatactta gatgaggatt atatgaaaga tttatcaaaa atgacctgcc ttgaagaact 8220  
acgccgtgtt gcgcaacgta aagtgcctaaa aatgttttat gactatgtag tttcaggatc 8280  
ttggagcga agcacattgc atgccaaccg taatgatatt caagcaatta agctacgtcg 8340  
acctgtggcg attttgccca tttctgact cagctctgca attcgtcgt tgtcctgttc 8400  
tgttgcgcgc gcaagctctc ttgtgactt gccllttcta attggccttg ttgctcccaa 8460  
taacgtgagg tgcacacac cactttacgt agtgttga 8498



WO 02/075507

PCT/US02/01971

<210> 58  
 <211> 5798  
 <212> DNA  
 <213> *Pasteurella multocida*

<220>  
 <221> CDS  
 <222> (2686)..(4446)

<220>  
 <223> unknown D1

<400> 58  
 gtcgacaaga ataaaacgaa acagcaata gaattagaat tactacttat taacaataat 60  
 ccttttttaa agattctagc tgtttttagat aaaaatatac gbtggaagct tttggtcaca 120  
 ttattattat caggcctata ttatttatat gcagtaaaaa acgattcaaa tttgtcaca 180  
 ggtttatcta ttattttagt ttttattatt gtcattccag ggattttgac aaatgctatt 240  
 ttgaaagcta aggtgaaaa aatcatgta gattaccag gttttatga cttagtgtca 300  
 gtaaatgttc aaacagggat tagtattgat gcggctttaa aacaagtgcc aatcgatttt 360  
 aagaaacctt atccagatct tacttatgtg atgtaagga ttattagaaa atctgaactt 420  
 acgggattat cacaagcgtt acaggatctt tegatctcat tgccaacaac agaataaga 480  
 atgttttga ctgttttaca acagagtta aattttggtt ctccaatta ttctcacta 540  
 attcagttgt ctgcagatat caggagata caattattaa tcattgagga aaagttaggt 600  
 acattatcag ctaaaatgag tatcccattg atttgttta ttatgtccc aataatcatt 660  
 ttaattctag caccaggtat aatgagggta ttccaaatg ttttttaaat ttaccaaga 720  
 aatcgttttt gttagttag ctttatctgt cgttggttgt tctaccatt ctcaagaag 780  
 catgacacag aaaagtatgt catctgaaac aataacggca aaagagactt tatatgaaag 840  
 tacgcaaaat tattcggcac tcatttcaact gtatcggat gtgttgaag ccaagaaga 900  
 tccttcaata cgtataaat tagcgaagac atactatcag cgaggtgaca gcaaatcttc 960  
 ttactttat ttaacgcat tactgatga taatacgaag cttgctacac aagcgaatat 1020  
 attacagata aaaaatctaa ttcaattaaa taatttcaa gaagcaattt ctgtcgcaaa 1080  
 tgaactctta ttaaatcac ctaatgaagg agaagtatat aatttaagag gtatcgctta 1140  
 tgcgcaaaat gggattttgg tgaatgcccg aaatgatatc aataaagcaa gagagtcttt 1200  
 tattaatgat aatgttgcta ttaataattt agccatgcta aatattatta atggcgattt 1260  
 taataatgct gtttctttac tgttgccaca atatttaaa ggcgttaaga attctcgatt 1320  
 gattcataat cttgtttttg ctttagttaa aaatggtgat cttgattatg caaaagatat 1380  
 cattgttaaa gagcgtttaa atacttcacc agatgattta attaatgcat tgaaaaaac 1440  
 tacacatgta tcaaaagggt taactcggta acactaagga tttgatatga aaaagtcttc 1500

WO 02/075507

PCT/US02/01971

```

atcaaata aaaggaacct cgtcaattga atttgctttg acgatagcgt tctatttatt 1560
tgttgtgat tttatttttg aattttgtcg attagcgggt ggcacagcgt attgggattt 1620
agctataacg gaaagtgtca gaattgcgaa gaatgaacaa gcaatttctg gaaattatga 1680
agaagcattt aggaaagctc ttacaaagca aaaaaaattc catgatgaat cgacaattgg 1740
atatttggcg ttgtagaag ataataaatt tgatgtaaaa gtccaatag tggaattgta 1800
taaagaaacg gaatgtatta aaaaattctt gcttaataaa ttctgccaac cacaaaaaaa 1860
tcataaagga gagttaatct ctctacggg gagtcgcgcg actttagcac aatattcttt 1920
aacctataaa tataagtta ttggtcgggt agtatttatt cctgagcctt ggtotcaagt 1980
agtgctgaac cgtgaatttg ttggtgtaca ggaatttgag cgttctcaat ttaigttagg 2040
agcaaaacca agttctcttg ggaacgaatc atagaaaatt tactcattat ttcgagctat 2100
atatgaaaga gtcaggttta gttaaattca agcatttttg gaaaaataaa aaggcgccag 2160
tgacgataga gttccttttt atgtcaatgt ttctgattgt gctattttgca tttctcttcg 2220
atttagaat gttacgtttc acattaggca agttagataa gcctcctaat acattagtta 2280
gtattctcgg tgaacgtaca cagttgtacg atagagttgc acaaattaat attgatgac 2340
ataagcaatt tgaagagctt gctaagaaac tgatttatgt tgatcagaat agtaataaaa 2400
ggatcgatgt tgttttagaa tattggggcac aagacggttc tggacggagg attccaaata 2460
tcattggcga ttgtacgctt tacaaaaaac tttctgattt atcctattta tctctcgcgt 2520
cagaactcaa taatgaaaga aaaataccgc tttatcaaat tactctttgt gttgaaactc 2580
agggcttgtt tgaacaata ttactggata agtctgagcg ttcaacgggg ctgattagat 2640
catcgtcaat gtcagatca cgataaata tcgtaggga acttt atg aaa aaa ctt 2697
Met Lys Lys Leu
1
tat tta att cgt tct tgc tat gat tca gtc aga aaa ttt tat gag aat 2745
Tyr Leu Ile Arg Ser Cys Tyr Asp Ser Val Arg Lys Phe Tyr Glu Asn
5 10 15 20
gag cta ggt gtt tat aca gta atg act gca tta cta gca ttt cca tta 2793
Glu Leu Gly Val Tyr Thr Val Met Thr Ala Leu Leu Ala Phe Pro Leu
25 30 35
tta gtt ttg att gga ttt acg gtt gat gga act ggg gtt gtg ctt gat 2841
Leu Val Leu Ile Gly Phe Thr Val Asp Gly Thr Gly Val Val Leu Asp
40 45 50
aaa gca cgt tta gct caa gga atg gat caa gct gct tta gct ttg gtt 2889
Lys Ala Arg Leu Ala Gln Gly Met Asp Gln Ala Ala Leu Ala Leu Val
55 60 65
gct gaa aac aat gac tac cga gaa aat aaa aaa cat ggt gat gtt aat 2937
Ala Glu Asn Asn Asp Tyr Arg Glu Asn Lys Lys His Gly Asp Val Asn
70 75 80
cgg caa gta gta tcg cct caa gac aaa gca aaa ttt ggt ggt aat gaa 2985

```

WO 02/075507

PCT/US02/01971

Arg	Gln	Val	Val	Ser	Pro	Gln	Asp	Lys	Ala	Lys	Phe	Gly	Gly	Asn	Glu		
85					90					95					100		
ttt atg gcg aaa caa gaa aag cgt aat caa gag ctt atc cag ggt att	3033																
Phe Met Ala Lys Gln Glu Lys Arg Asn Gln Glu Leu Ile Gln Gly Ile					105				110					115			
gcc aaa ctt tat tta cgt tca gaa aat gcg aat gct tca tct gat gca	3081																
Ala Lys Leu Tyr Leu Arg Ser Glu Asn Ala Asn Ala Ser Ser Asp Ala					120				125					130			
cca atc act att gat aaa cct ttt cat tat tca tgt gag gag tta gat	3129																
Pro Ile Thr Ile Asp Lys Pro Phe His Tyr Ser Cys Glu Glu Leu Asp					135				140					145			
tta cct aca gct aat gag tat gca cgt cgt aaa cct att gtt tgt gaa	3177																
Leu Pro Thr Ala Asn Glu Tyr Ala Arg Arg Lys Pro Ile Val Cys Glu					150				155					160			
gtg caa ggt ggc gtc aat cgt aaa ttt tgg ctt cct gtc agt gaa tcg	3225																
Val Gln Gly Gly Val Asn Arg Lys Phe Trp Leu Pro Val Ser Glu Ser					165				170					175			180
tta gtt agt gaa gat aaa ctg aaa aaa gat cga gtt aga ctg gaa tcc	3273																
Leu Val Ser Glu Asp Lys Leu Lys Lys Asp Arg Val Arg Leu Glu Ser					185				190					195			
gat acc agt tat gcg att aaa gaa aaa ggc atc gtg att cct gtg gag	3321																
Asp Thr Ser Tyr Ala Ile Lys Glu Lys Gly Ile Val Ile Pro Val Glu					200				205					210			
cta atg ctt gtt tcg gat tat tct ggt tcg atg aat agt cat tta cag	3369																
Leu Met Leu Val Ser Asp Tyr Ser Gly Ser Met Asn Ser His Leu Gln					215				220					225			
gat aaa aac ggt aga tct cta gga aaa gct aaa att act att tta aga	3417																
Asp Lys Asn Gly Arg Ser Leu Gly Lys Ala Lys Ile Thr Ile Leu Arg					230				235					240			
gaa gtg gtt agt gaa att tcg aaa att tta ttg cca gaa gat gtt agc	3465																
Glu Val Val Ser Glu Ile Ser Lys Ile Leu Leu Pro Glu Asp Val Ser					245				250					255			260
gaa ggt gtg agc cct ttc aac cgt att ggc ttt acg act ttt tct ggc	3513																
Glu Gly Val Ser Pro Phe Asn Arg Ile Gly Phe Thr Thr Phe Ser Gly					265				270					275			
ggt gtt aga caa cgg gat gtc act gaa ggc tgt gtg ctt cca tat gaa	3561																
Gly Val Arg Gln Arg Asp Val Thr Glu Gly Cys Val Leu Pro Tyr Glu					280				285					290			
gga aaa ata tca caa act tct cga aaa tta act att cgt tat tgg att	3609																
Gly Lys Ile Ser Gln Thr Ser Arg Lys Leu Thr Ile Arg Tyr Trp Ile					295				300					305			
acg ggt aat aat aca cct tgg aaa ttt aat gct ggg aga tgg gag aga	3657																
Thr Gly Asn Asn Thr Pro Trp Lys Phe Asn Ala Gly Arg Trp Glu Arg					310				315					320			
agt aca gtg tct ttc cag gag cat tat aaa ggc tat tat gac aaa ttc	3705																
Ser Thr Val Ser Phe Gln Glu His Tyr Lys Gly Tyr Tyr Asp Lys Phe					325				330					335			340

WO 02/075507

PCT/US02/01971

cat tct tca act tgt aga ggc tca ggg agc tct aga act tgt caa att 3753  
 His Ser Ser Thr Cys Arg Gly Ser Gly Ser Ser Arg Thr Cys Gln Ile  
 345 350 355

gat gca aat cct aag aaa att atg gat tat gca cta aaa att aat gac 3801  
 Asp Ala Asn Pro Lys Lys Ile Met Asp Tyr Ala Leu Lys Ile Asn Asp  
 360 365 370

tgg acg aca att aga gaa tta ttt aat act tat ata gat gta agt ggg 3849  
 Trp Thr Thr Ile Arg Glu Leu Phe Asn Thr Tyr Ile Asp Val Ser Gly  
 375 380 385

acg att gac caa att tcc cag ttt gat ggt tca aac aga cgt tat gat 3897  
 Thr Ile Asp Gln Ile Ser Gln Phe Asp Gly Ser Asn Arg Arg Tyr Asp  
 390 395 400

atg gtg ttt act gat gaa gaa cgg tgt ctt ggc gga aat att ggt aga 3945  
 Met Val Phe Thr Asp Glu Glu Arg Cys Leu Gly Gly Asn Ile Gly Arg  
 405 410 415 420

aga aca act cga gct tgg ttt gat caa aaa aat aaa gat att aca aga 3993  
 Arg Thr Thr Arg Ala Trp Phe Asp Gln Lys Asn Lys Asp Ile Thr Arg  
 425 430 435

gag ttg aat att gtt cgt cct tct ggt tgg act tct gca tct tgg ggg 4041  
 Glu Leu Asn Ile Val Arg Pro Ser Gly Trp Thr Ser Ala Ser Ser Gly  
 440 445 450

ctt ctt gtt gga gct aat atc atg atg gac gag aat aag aat cct gat 4089  
 Leu Leu Val Gly Ala Asn Ile Met Met Asp Glu Asn Lys Asn Pro Asp  
 455 460 465

gcg caa cct tgg aaa ctc ggg aca aat att caa cgt gtt atc tta gta 4137  
 Ala Gln Pro Ser Lys Leu Gly Thr Asn Ile Gln Arg Val Ile Leu Val  
 470 475 480

tta tct gat ggt gaa gat aac tgg cca act tat agt aca tta acg act 4185  
 Leu Ser Asp Gly Glu Asp Asn Trp Pro Thr Tyr Ser Thr Leu Thr Thr  
 485 490 495 500

ctt tta aac aat ggt atg tgt gac aaa att cga gaa caa ttg ggc aag 4233  
 Leu Leu Asn Asn Gly Met Cys Asp Lys Ile Arg Glu Gln Leu Gly Lys  
 505 510 515

tta caa gat cca aat tta cga gag tta cca gga aga att gcg ttt gtt 4281  
 Leu Gln Asp Pro Asn Leu Arg Glu Leu Pro Gly Arg Ile Ala Phe Val  
 520 525 530

gcg ttt ggc tat agt cca cca gca aac caa gtt gcc gct tgg aaa aaa 4329  
 Ala Phe Gly Tyr Ser Pro Pro Ala Asn Gln Val Ala Ala Trp Lys Lys  
 535 540 545

tgt gta ggt gat caa tat tat acg gct tat tgg aaa gaa gag ttg tta 4377  
 Cys Val Gly Asp Gln Tyr Tyr Thr Ala Tyr Ser Lys Glu Glu Leu Leu  
 550 555 560

gat agt ttc aaa caa att att gga ttt gaa gaa gag gtg ggg cgt tct 4425  
 Asp Ser Phe Lys Gln Ile Ile Gly Phe Glu Glu Glu Val Gly Arg Ser  
 565 570 575 580

tca tct cat aaa ccg aaa ttt taagattgtc caaggataac gctaaaaaat 4476  
 Ser Ser His Lys Pro Lys Phe  
 585

WO 02/075507

PCT/US02/01971

cttcttagcac aggctaagag atttttttat gtgtttttca aattttatct actggtgatt 4536  
 ttaattcatt acataacata acctttttcgt gaataatata gaatagacaa caataagaat 4596  
 taaaacgctc aaggcataga ggcttagtcg aacaaactaa gctattttgc gogattgatt 4656  
 gggatataga tgttatttca aataagcaat aacctggta ctgagaaga agatgagtc 4716  
 cgtataaag tagaagcgtat tttcttttg gctgaaaggt ggtgttagcc tttctcgct 4776  
 aaagaaaata gtagcaacgg caatataaag ggcgataaag agcattttgt aaatgaacca 4836  
 tgttgttaca ttttctgaa aaagaagaaa tagcccaatt ccgcaacaga acaacagcgt 4896  
 atcacttaag tgcggttaaga tttttaatac tttctgtct cgccaatttt tgctgttaa 4956  
 ttgcatcag ccacggataa taatagact gaggtgaga aaggcacag caatgttag 5016  
 ataataaga taatagcca tegtatttt tcctaagata aagaaagcag tagcgaggct 5076  
 actgctttaa aataatctg tatttagtga atgaattaa ctttctgccc tttcgaccgc 5136  
 accttgcct gcatacctct caatgtcttc ttcacgaca tcacaaacga gttgtaatcc 5196  
 aaccagtgtt tcactttcac ttgttcggat gagacgtact ccttgtgtat ttcgaccgat 5256  
 aatattgatt tegttaacgc gactacgtac tagcgtaccg gcatacgtaa tgagcataat 5316  
 ttgatcgctt tctcaactt gtgttctgc aacgacttta ccgttacgt cactcacttt 5376  
 aatcgagatc acgctttgg tgttactga tttagtggg tattccgcta attcagtag 5436  
 tttaccataa ccgttttgtg tggcgttaa aatggcgcct tcattttttg gaataacaag 5496  
 tgacacgact ttatcaatat tgagatccaa ggcacatta gtattctcat cagagatctc 5556  
 ttcctatcgc accgcacttt catcatccga caaatcttc gttaacgcca gtttaatacc 5616  
 gogtacaact gttgctgcac gcccatggc acgcacagca ttttactaa agcgaactac 5676  
 acgtccttgt gcggagaaga gcatgattc atttgacca tgggtgatat ccacaccgat 5736  
 aagttcgtct tcatcacgca agttgagtc aataatgcct gttgaacgag gaecactgaa 5796  
 tt 5798

<210> 59  
 <211> 587  
 <212> PRT  
 <213> Pasteurella multocida

<400> 59  
 Met Lys Lys Leu Tyr Leu Ile Arg Ser Cys Tyr Asp Ser Val Arg Lys  
 1 5 10 15  
 Phe Tyr Glu Asn Glu Leu Gly Val Tyr Thr Val Met Thr Ala Leu Leu  
 20 25 30  
 Ala Phe Pro Leu Leu Val Leu Ile Gly Phe Thr Val Asp Gly Thr Gly  
 35 40 45  
 Val Val Leu Asp Lys Ala Arg Leu Ala Gln Gly Met Asp Gln Ala Ala

WO 02/075507

PCT/US02/01971

50                    55                    60

Leu Ala Leu Val Ala Glu Asn Asn Asp Tyr Arg Glu Asn Lys Lys His  
65                    70                    75                    80

Gly Asp Val Asn Arg Gln Val Val Ser Pro Gln Asp Lys Ala Lys Phe  
85                    90                    95

Gly Gly Asn Glu Phe Met Ala Lys Gln Glu Lys Arg Asn Gln Glu Leu  
100                    105                    110

Ile Gln Gly Ile Ala Lys Leu Tyr Leu Arg Ser Glu Asn Ala Asn Ala  
115                    120                    125

Ser Ser Asp Ala Pro Ile Thr Ile Asp Lys Pro Phe His Tyr Ser Cys  
130                    135                    140

Glu Glu Leu Asp Leu Pro Thr Ala Asn Glu Tyr Ala Arg Arg Lys Pro  
145                    150                    155                    160

Ile Val Cys Glu Val Gln Gly Gly Val Asn Arg Lys Phe Trp Leu Pro  
165                    170                    175

Val Ser Glu Ser Leu Val Ser Glu Asp Lys Leu Lys Lys Asp Arg Val  
180                    185                    190

Arg Leu Glu Ser Asp Thr Ser Tyr Ala Ile Lys Glu Lys Gly Ile Val  
195                    200                    205

Ile Pro Val Glu Leu Met Leu Val Ser Asp Tyr Ser Gly Ser Met Asn  
210                    215                    220

Ser His Leu Gln Asp Lys Asn Gly Arg Ser Leu Gly Lys Ala Lys Ile  
225                    230                    235                    240

Thr Ile Leu Arg Glu Val Val Ser Glu Ile Ser Lys Ile Leu Leu Pro  
245                    250                    255

Glu Asp Val Ser Glu Gly Val Ser Pro Phe Asn Arg Ile Gly Phe Thr  
260                    265                    270

Thr Phe Ser Gly Gly Val Arg Gln Arg Asp Val Thr Glu Gly Cys Val  
275                    280                    285

Leu Pro Tyr Glu Gly Lys Ile Ser Gln Thr Ser Arg Lys Leu Thr Ile  
290                    295                    300

Arg Tyr Trp Ile Thr Gly Asn Asn Thr Pro Trp Lys Phe Asn Ala Gly  
305                    310                    315                    320

Arg Trp Glu Arg Ser Thr Val Ser Phe Gln Glu His Tyr Lys Gly Tyr  
325                    330                    335

Tyr Asp Lys Phe His Ser Ser Thr Cys Arg Gly Ser Gly Ser Ser Arg  
340                    345                    350

Thr Cys Gln Ile Asp Ala Asn Pro Lys Lys Ile Met Asp Tyr Ala Leu  
355                    360                    365

Lys Ile Asn Asp Trp Thr Thr Ile Arg Glu Leu Phe Asn Thr Tyr Ile  
370                    375                    380

Asp Val Ser Gly Thr Ile Asp Gln Ile Ser Gln Phe Asp Gly Ser Asn

WO 02/075507

PCT/US02/01971

```

385          390          395          400
Arg Arg Tyr Asp Met Val Phe Thr Asp Glu Glu Arg Cys Leu Gly Gly
      405          410          415
Asn Ile Gly Arg Arg Thr Thr Arg Ala Trp Phe Asp Gln Lys Asn Lys
      420          425          430
Asp Ile Thr Arg Glu Leu Asn Ile Val Arg Pro Ser Gly Trp Thr Ser
      435          440          445
Ala Ser Ser Gly Leu Leu Val Gly Ala Asn Ile Met Met Asp Glu Asn
      450          455          460
Lys Asn Pro Asp Ala Gln Pro Ser Lys Leu Gly Thr Asn Ile Gln Arg
      465          470          475          480
Val Ile Leu Val Leu Ser Asp Gly Glu Asp Asn Trp Pro Thr Tyr Ser
      485          490          495
Thr Leu Thr Thr Leu Leu Asn Asn Gly Met Cys Asp Lys Ile Arg Glu
      500          505          510
Gln Leu Gly Lys Leu Gln Asp Pro Asn Leu Arg Glu Leu Pro Gly Arg
      515          520          525
Ile Ala Phe Val Ala Phe Gly Tyr Ser Pro Pro Ala Asn Gln Val Ala
      530          535          540
Ala Trp Lys Lys Cys Val Gly Asp Gln Tyr Tyr Thr Ala Tyr Ser Lys
      545          550          555          560
Glu Glu Leu Leu Asp Ser Phe Lys Gln Ile Ile Gly Phe Glu Glu Glu
      565          570          575
Val Gly Arg Ser Ser Ser His Lys Pro Lys Phe
      580          585

```

```

<210> 60
<211> 5798
<212> DNA
<213> Pasteurella multocida

```

```

<220>
<221> CDS
<222> (698)..(1468)

```

```

<220>
<223> unknown D2

```

```

<400> 60
gtcgacaaga ataaaacgaa acagcaaata gaattagaat tactacttat taacaataat 60
ccttttttaa agattctagc tgttttagat aaaaatatac ggtggaaget ttgtgtcaca 120
ttattattat caggcctata ttatttatat gcagtaaaaa acgattcaaa ttttgcata 180
ggtttatcta ttattttagt ttttattatt gtcattccag ggattttgac aaatgctatt 240
ttgaaagcta aggtgaaaaa aatcatggta gatttaccag gttttattga cttagttgca 300
gtaaatgttc aaacagggat tagtattgat gggcctttaa aacaagtggc aatcgatttt 360

```

WO 02/075507

PCT/US02/01971

```

aagaaactta atccagatct tacttatgtg atgttaagga ttattagaaa atctgaactt 420
acgggattat cacaagcgtt acaggatctt tcatctcat tgccaacaac agaataaga 480
atgttttgta ctgttttaca acagagttta aattttggtt ctccaattta ttctcaacta 540
attcagttgt ctgcagatat caggagagata caattattaa tcattgagga aaagttaggt 600
acattatcag ctaaaatgag tatcccattg attttgttta ttatgttccc aataatcatt 660
ttaattctag caccaggtat aatgagggta tttccaa atg ttt ttt aaa ttt acc 715
Met Phe Phe Lys Phe Thr
1 5
aag aaa atc gtt ttt gtt agt tta gct tta tct gtc gtt ggt tgt tct 763
Lys Lys Ile Val Phe Val Ser Leu Ala Leu Ser Val Val Gly Cys Ser
10 15 20
acc cat tct cag caa ggc atg aca cag aaa agt atg tca tct gaa aca 811
Thr His Ser Gln Gln Gly Met Thr Gln Lys Ser Met Ser Ser Glu Thr
25 30 35
ata acg gca aaa gag act tta tat gaa agt acg caa aat tat tgc gca 859
Ile Thr Ala Lys Glu Thr Leu Tyr Glu Ser Thr Gln Asn Tyr Ser Ala
40 45 50
ctc att tca ctg tat cgc gat gtg ttg aaa gcc aaa gaa gat cct tca 907
Leu Ile Ser Leu Tyr Arg Asp Val Leu Lys Ala Lys Glu Asp Pro Ser
55 60 65 70
ata cgc tat aaa tta gcg aag aca tac tat cag cga ggt gac agc aaa 955
Ile Arg Tyr Lys Leu Ala Lys Thr Tyr Tyr Gln Arg Gly Asp Ser Lys
75 80 85
tct tct tta ctt tat tta acg cca tta ctg aat gat aat acg aag ctt 1003
Ser Ser Leu Leu Tyr Leu Thr Pro Leu Leu Asn Asp Asn Thr Lys Leu
90 95 100
gct aca caa gcg aaa ata tta cag ata aaa aat cta att caa tta aat 1051
Ala Thr Gln Ala Lys Ile Leu Gln Ile Lys Asn Leu Ile Gln Leu Asn
105 110 115
aal ttc caa gaa gca att tct gtc gca aat gaa ctc tta tta aaa tca 1099
Asn Phe Gln Glu Ala Ile Ser Val Ala Asn Glu Leu Leu Leu Lys Ser
120 125 130
cct aat gaa gga gaa gta tat aat tta aga ggt atc gct tat gcg caa 1147
Pro Asn Glu Gly Glu Val Tyr Asn Leu Arg Gly Ile Ala Tyr Ala Gln
135 140 145 150
aat ggg aat ttg gtg aat gcc cga aat gat atc aat aaa gca aga gag 1195
Asn Gly Asn Leu Val Asn Ala Arg Asn Asp Ile Asn Lys Ala Arg Glu
155 160 165
ttc ttt att aat gat aat gtt gct att aat aat tta gcc atg cta aat 1243
Phe Phe Ile Asn Asp Asn Val Ala Ile Asn Asn Leu Ala Met Leu Asn
170 175 180
att att aat ggc gat ttt aat aat gct gtt tct tta ctg ttg cca caa 1291
Ile Ile Asn Gly Asp Phe Asn Asn Ala Val Ser Leu Leu Leu Pro Gln
185 190 195
tat tta aat ggc gtt aag aat tct cga ttg att cat aat ctt gtt ttt 1339

```



WO 02/075507

PCT/US02/01971

Tyr Leu Asn Gly Val Lys Asn Ser Arg Leu Ile His Asn Leu Val Phe  
 200 205 210  
 gct tta gtt aaa aat ggt gat ctt gat tat gca aaa gat atc att gtt 1387  
 Ala Leu Val Lys Asn Gly Asp Leu Asp Tyr Ala Lys Asp Ile Ile Val 230  
 215 220 225  
 aaa gag cgt tta aat act tca cca gat gat tta att aat gca ttg aaa 1435  
 Lys Glu Arg Leu Asn Thr Ser Pro Asp Asp Leu Ile Asn Ala Leu Lys  
 235 240 245  
 aaa act aca cat gta tca aaa ggt gta act cgg taacactaag gatttgat 1488  
 Lys Thr Thr His Val Ser Lys Gly Val Thr Arg  
 250 255  
 gaaaaagttt ctatcaata taaaaggaac ctctgcaatt gaatttgctt tgacgatagc 1548  
 gttctattta ttgttggtga tgttatattt tgaattttgt cgttagcggg ttgacgacagc 1608  
 ttattgggat ttagctataa cggaaagtgt cagaatttgc aagaatgaac aagcaatttc 1668  
 tggaaattat gaagaagcat ttaggaaagc tcttacaag caaaaaaat tccatgatga 1728  
 atcgacaatt ggatatttgg cgttggtaga agataataaa ttgatgttaa aagtccaata 1788  
 tgtggattgt gataaagaaa cggaatgtat taaaaactct ctgcttaata aatttcgcca 1848  
 acccaaaaa aatcataaag gagagttaat ctctctacg gggagtcgag cgaactttagc 1908  
 acaatattct ttaacttata aatataagtt tatgggtccg ttagtattta ttcttgatc 1968  
 ttggtctcaa gtagtgctga accgtgaatt tgttggtga caggaatttg agcgttctca 2028  
 atttatgta ggagcaaac caagttctct tgggacgaat ccatagaaaa ttactcatt 2088  
 atttcgagct atatatgaaa ggtcaggtt tagttaaatt caagcatttt tggaaaaata 2148  
 aaaaggcgc agtgacgata gaggctcttt ttatgcaat gttcttgatt gtgctatttg 2208  
 cattctctct cgatttagta atgttacgtt ctacattagg caagttagal aatgcctcat 2268  
 atacattagt tagtattctc cgtgaacgta cacagttgta cगतगगgtt gcacaaatta 2328  
 atattgatga tcataagcaa ttgaaaagc ttgctaagaa actgatttat ggtgatcaga 2388  
 atagtaataa aaggatcgat gttgttttag aatattgggc acaagacggt tctggacgga 2448  
 ggattccaaa tatcattggc gattgtacgc cttacaaaa actttctgat ttatcctatt 2508  
 tatctctcgc ctcagaactc aataatgaaa gaaaaatacc gctttatcaa attactctt 2568  
 gtgtgaaac tcaggccttg ttgaaacaa tattactgga taagtcgag cgttcaacgg 2628  
 ggctgattag atcatcgtca atgtcagtat caccataaat tatcgttagg gaactttatg 2688  
 aaaaaacttt atttaattcg ttcttgctat gattcagtca gaaaatttta tgagaatgag 2748  
 ctagggtgtt atacagtaat gactgcatta ctagcatttc cattattagt ttgatgtga 2808  
 tttacggttg atggaactgg ggttggtctt gataaagcac gtttagctca aggaatggat 2868  
 caagctgctt tagctttggt tgcgaaaaac aatgactacc gagaaaaata aaaaatggt 2928

WO 02/075507

PCT/US02/01971

gatgttaatc ggcaagtagt atcgcctcaa gacaaagcaa aatttggtgg taatgaattt 2988  
atggcgaaac aagaaaagcg taatcaagag cttatccagg gtattgcca acctttatta 3048  
cgttcagaaa atgcgaatgc ttcacatgat gcaccaatca ctattgataa accttttcat 3108  
tattcatgtg aggagttaga tttacotaca gctaagtgtg atgcacgtcg taaacctatt 3168  
gtttgtgaag tgcagggtgg cgtcaatcgt aaattttggc ttcctgtcag tgaatcgta 3228  
gttagtgaag ataaactgaa aaaagatcga gttagactgg aatccgatac cagttatgog 3288  
atataagaaa aaggcatcgt gattcctgtg gagctaatic ttgtttogga ttattctggt 3348  
tcgatgaata gtcatttaca ggataaaaaac ggtagatctc taggaaaagc taaattact 3408  
attttaagag aagtggttag tgaatttcg aaaattttat tgcagaaga tgttagcgaa 3468  
gggtgtagcc cttcaaccg tattggcttt acgacttttt ctggcgggtg tagacaacgg 3528  
gatgtcaactg aaggctgtgt gttccatata gaagaaaaa tatcacaac ttctcgaaa 3588  
ttaatcttc gttattggat tacgggtaat aatacaccct ggaaatttaa tgctgggaga 3648  
tggagagaaa gtacagtgtc tttccaggag cattataaag gctattatga caaattccat 3708  
tcctcaact gttagagctc agggagctct agaacttctg aaattgtgc aaatcctaag 3768  
aaaattatgg attatgact aaaaattaat gactggacga caattagaga attatttaat 3828  
acttatatag atgtaagtgg gacgattgac caaatttccc agtttgatgg ttcaaacaga 3888  
cgttatgata tgggttttac tgatgaagaa cgggtctctg gcgaaaatat tggtagaaga 3948  
acaactcgag cttggtttga tcaaaaaaat aaagatatta caagagagtt gaatattggt 4008  
cgtcctctcg gttggacttc tgcactctcg gggctctctg ttggagctaa tatcatgatg 4068  
gacgagaata agaactcctga tgcgcaacct tcgaaactcg ggacaaat at caacgtgtt 4128  
atcttagtat tatctgatgg tgaagataac tggccaactt atagtacatt aacgactctt 4188  
ttaaacaatg gtatgtgtga caaaattcga gaacaattgg gcaagttaca agatccaaat 4248  
ttacgagagt taccaggaag aattgcgttt gttgcgtttg gctatagtc accagcaaac 4308  
caagttgccc cttgaaaaaa atgtgtaggt gatcaatatt atacggctta ttogaagaa 4368  
gagttgttag atagttcaa acaaatattt ggatttgaag aagaggtggg gcgttcttca 4428  
tctcataaac cgaatttta agattgtcca aggataacgc taaaaaatct cttagcacag 4488  
gctaagagat tttttatgt gtttttcaa tttatctac tggtgatttt aattcattac 4548  
ataacataac tttttcgtga ataatacaga atagacaaca ataagaatta aaacgctcaa 4608  
ggcatagagg cttagtcgaa caaactaagc tattttgccc gattgattgg gatatagatg 4668  
ttatttcaa taagcaataa ccatggtact gagaagaag atgagtgccc taataaagta 4728  
gaagcgattt ttcttttggc tgaaggtgg tgttagcctt tttcggctaa agaaaatagt 4788  
agcaacggca atataaaggg cgataaagag cattttgtaa atgaaccatg ttgttacatt 4848

WO 02/075507

PCT/US02/01971

ttgctgaaaa agaagaata gcccaattcc cgaacagAAC aacagcgtat cacttaagtg 4908  
 cggtaagatt ttaataactt ttctgtctcg ccaatttttg cctgttaatt gcatcatgcc 4968  
 acggataata aatagactga ggctgagaaa ggacacaggca atgtgtagat aaataagata 5028  
 atatgccatc gatTTTTTtc ctaagataaa gaaagcagta gcgaggctac tgcttTaaaa 5088  
 taatatcgtA tttagtgaat gaatttaact ttctgcgctt tcgaccgcac tttcgcctgc 5148  
 atcactctca atgtcttctt catcgacatc acaaacgagt tgtaatccaa ccagtgtttc 5208  
 actttcaact gtctcgatga gacgtactcc ttgtgtattt cgaccgataa tattgatttc 5268  
 gtttaacgca gtacgtacta gcgtaccgac atcagtaatg agcataattt gatcgtttc 5328  
 ctcaacttgt gttgtgcaa cgactttacc gttacgctca ctcaacttaa tcgagatcac 5388  
 gcctttggtg ttacgtgatt tagttgggta ttccgtaat tcagtagctt taccataacc 5448  
 gttttgtgtg gcggtTaaaa tggcgcttc atttttggA ataacaagt acacgacttt 5508  
 atcaatattg agatccaagg catcattagt attctcatca gagatctctt ccatatcgac 5568  
 cgcactttca tcactcgaca aatcattcgt taacgcaggt ttaataccgc gtacacctgt 5628  
 tgctgcaegc cccatggcac gcacagcatt ttcaactaaG cgaactacac gtcctgtgc 5688  
 ggagaagagc atgatttcat tttgaccatc ggtgatacc acaccgataa gttcgtcttc 5748  
 atcacgcaag ttgagtcaa taatgcctgt tgaacgagga cgactgaatt 5798

&lt;210&gt; 61

&lt;211&gt; 257

&lt;212&gt; PRT

&lt;213&gt; Pasteurella multocida

&lt;400&gt; 61

Met Phe Phe Lys Phe Thr Lys Lys Ile Val Phe Val Ser Leu Ala Leu  
 1 5 10 15  
 Ser Val Val Gly Cys Ser Thr His Ser Gln Gln Gly Met Thr Gln Lys  
 20 25 30  
 Ser Met Ser Ser Glu Thr Ile Thr Ala Lys Glu Thr Leu Tyr Glu Ser  
 35 40 45  
 Thr Gln Asn Tyr Ser Ala Leu Ile Ser Leu Tyr Arg Asp Val Leu Lys  
 50 55 60  
 Ala Lys Glu Asp Pro Ser Ile Arg Tyr Lys Leu Ala Lys Thr Tyr Tyr  
 65 70 75 80  
 Gln Arg Gly Asp Ser Lys Ser Ser Leu Leu Tyr Leu Thr Pro Leu Leu  
 85 90 95  
 Asn Asp Asn Thr Lys Leu Ala Thr Gln Ala Lys Ile Leu Gln Ile Lys  
 100 105 110  
 Asn Leu Ile Gln Leu Asn Asn Phe Gln Glu Ala Ile Ser Val Ala Asn  
 115 120 125

WO 02/075507

PCT/US02/01971

Glu Leu Leu Leu Lys Ser Pro Asn Glu Gly Glu Val Tyr Asn Leu Arg  
 130 135 140  
 Gly Ile Ala Tyr Ala Gln Asn Gly Asn Leu Val Asn Ala Arg Asn Asp  
 145 150 155 160  
 Ile Asn Lys Ala Arg Glu Phe Phe Ile Asn Asp Asn Val Ala Ile Asn  
 165 170 175  
 Asn Leu Ala Met Leu Asn Ile Ile Asn Gly Asp Phe Asn Asn Ala Val  
 180 185 190  
 Ser Leu Leu Leu Pro Gln Tyr Leu Asn Gly Val Lys Asn Ser Arg Leu  
 195 200 205  
 Ile His Asn Leu Val Phe Ala Leu Val Lys Asn Gly Asp Leu Asp Tyr  
 210 215 220  
 Ala Lys Asp Ile Ile Val Lys Glu Arg Leu Asn Thr Ser Pro Asp Asp  
 225 230 235 240  
 Leu Ile Asn Ala Leu Lys Lys Thr Thr His Val Ser Lys Gly Val Thr  
 245 250 255  
 Arg

<210> 62  
 <211> 1788  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (1)..(600)

<223>  
 <223> unknown K

<400> 62  
 gtc aac act ggg cta att cac agt aac ggt aat gcc aag ctc act ttt 48  
 Val Asn Thr Gly Leu Ile His Ser Asn Gly Asn Ala Lys Leu Thr Phe  
 1 5 10 15  
 aaa gat gac acc agt ttt gtg act gaa gga aat aac ttt atc aca gca 96  
 Lys Asp Asp Thr Ser Phe Val Thr Glu Gly Asn Asn Phe Ile Thr Ala  
 20 25 30  
 aaa gac aac tta gaa atc acg gca aaa aat gtt caa att gat caa gcg 144  
 Lys Asp Asn Leu Glu Ile Thr Ala Lys Asn Val Gln Ile Asp Gln Ala  
 35 40 45  
 aaa aat att caa tta aac gcg aat atc acg atc aat acc aag tct ggt 192  
 Lys Asn Ile Gln Leu Asn Ala Asn Ile Thr Ile Asn Thr Lys Ser Gly  
 50 55 60  
 ttt gtg aat tac ggt acc tta gca agt gct caa aat tta acg att aat 240  
 Phe Val Asn Tyr Gly Thr Leu Ala Ser Ala Gln Asn Leu Thr Ile Asn  
 65 70 75 80  
 acc gaa caa ggc agc att tat aac ata ggc ggt atc ttg ggg gcg ggt 288  
 Thr Glu Gln Gly Ser Ile Tyr Asn Ile Gly Gly Ile Leu Gly Ala Gly

WO 02/075507

PCT/US02/01971

```

      85              90              95
aaa agt ttg aat ctg agc gcg aaa aga gga gaa aac caa gga gga tat 336
Lys Ser Leu Asn Leu Ser Ala Lys Arg Gly Glu Asn Gln Gly Gly Tyr
      100              105              110
ctt att aat caa ggt aag agt cta ctc cat tct gaa ggc gcc atg aac 384
Leu Ile Asn Gln Gly Lys Ser Leu Leu His Ser Glu Gly Ala Met Asn
      115              120              125
ctc aca gcg gat cgc acg gty tac aat tta ggg aat att ttt gct aaa 432
Leu Thr Ala Asp Arg Thr Val Tyr Asn Leu Gly Asn Ile Phe Ala Lys
      130              135              140
ggg gac gcg acg atc aat gca aac gcg tta att aat gat gtt act ctc 480
Gly Asp Ala Thr Ile Asn Ala Asn Ala Leu Ile Asn Asp Val Thr Leu
      145              150              155              160
aca ggt cgt ctt gag tat caa gat ctg aaa aaa gat tat acg cgt tat 528
Thr Gly Arg Leu Glu Tyr Gln Asp Leu Lys Lys Asp Tyr Thr Arg Tyr
      165              170              175
tat cgt atc aat gaa acg gca aaa cat ggt tgg cat aat aac ttc tat 576
Tyr Arg Ile Asn Glu Thr Ala Lys His Gly Trp His Asn Asn Phe Tyr
      180              185              190
gaa tta aac gtc gac aga gtt tct tgatttggc atcaatttg taaccaccgg 630
Glu Leu Asn Val Asp Arg Val Ser
      195              200
ttaataaac accagcaatt tcaacgccat tcatggcaga taatgcccgt gcgacgatca 690
catcaggacg atccgcgaa gtgacaagta aactccaac gcggaatgt tccaccatat 750
tggtcaaat acgtgcacag aaagtgatgc cacgaatgag acgttcaatt atcgccctt 810
catgaataat gccagcacct aatgtttgg ctaaatcaat gccacgagtc gcaattaatt 870
ctgcgtcca aggaatacat gccaaagatt taattggcct ttttcaaat aatgataaa 930
tctcagatac ttgattttgt gtgtgttggg aagaatcaaa aatttctgcc aagtcagggc 990
gagtcagacc agattcatca atcggccgat taaatttatt gatcacaaca ccaagtaaat 1050
tagggttatt ttgtgtcca aataatgagg ctgcggcttt gatgcgttct ttgattctg 1110
ccggtgttcc cgtgcgcggt gctgcaacaa gaatgatttc cgcatacagt gottgagcaa 1170
ttcctagtt aatgctattg gcataagaat gcttacgcgt agggattaaa ccttccacca 1230
cgacaatttc attgtttttg gcgagttgt gatgatttcc aacaattttt tctagtacca 1290
catcagattg attttgaccg atgagtgatt cagctacact taacataaat ggttactcgg 1350
tttcaatggt ggtactggtg cgaataattg atgttgtcgg atcaatcata tcttccactg 1410
agttcggctg agaaattggt ttcataaagc cgactttcgc ccttttttgc tccagtcat 1470
gtgttaaacc taagctgaca ctggttaagc ctacaccagc actaatcggg ataaggataa 1530
ttgtacgtga cataataaac cctaatttgc tgataattta tacaaaaaga aactgccgat 1590
gaatcggcag ttaattgac tttacgcgat gcaaaggcgc gcggtatcct gtgcaataac 1650

```

WO 02/075507

PCT/US02/01971

aagttcttca ttcggtggga taaccatggc aacagcgcta ttgtctgctg taatcacccc 1710  
 ttcgatgacca aagcgagccg ctttgttttt atctgaatcc acttgataac cgaacagttt 1770  
 taaatgggtt aaggttga 1788

<210> 63  
 <211> 200  
 <212> PRT  
 <213> Pasteurella multocida

<400> 63  
 Val Asn Thr Gly Leu Ile His Ser Asn Gly Asn Ala Lys Leu Thr Phe  
 1 5 10 15  
 Lys Asp Asp Thr Ser Phe Val Thr Glu Gly Asn Asn Phe Ile Thr Ala  
 20 25 30  
 Lys Asp Asn Leu Glu Ile Thr Ala Lys Asn Val Gln Ile Asp Gln Ala  
 35 40 45  
 Lys Asn Ile Gln Leu Asn Ala Asn Ile Thr Ile Asn Thr Lys Ser Gly  
 50 55 60  
 Phe Val Asn Tyr Gly Thr Leu Ala Ser Ala Gln Asn Leu Thr Ile Asn  
 65 70 75 80  
 Thr Glu Gln Gly Ser Ile Tyr Asn Ile Gly Gly Ile Leu Gly Ala Gly  
 85 90 95  
 Lys Ser Leu Asn Leu Ser Ala Lys Arg Gly Glu Asn Gln Gly Gly Tyr  
 100 105 110  
 Leu Ile Asn Gln Gly Lys Ser Leu Leu His Ser Glu Gly Ala Met Asn  
 115 120 125  
 Leu Thr Ala Asp Arg Thr Val Tyr Asn Leu Gly Asn Ile Phe Ala Lys  
 130 135 140  
 Gly Asp Ala Thr Ile Asn Ala Asn Ala Leu Ile Asn Asp Val Thr Leu  
 145 150 155 160  
 Thr Gly Arg Leu Glu Tyr Gln Asp Leu Lys Lys Asp Tyr Thr Arg Tyr  
 165 170 175  
 Tyr Arg Ile Asn Glu Thr Ala Lys His Gly Trp His Asn Asn Phe Tyr  
 180 185 190  
 Glu Leu Asn Val Asp Arg Val Ser  
 195 200

<210> 64  
 <211> 278  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (108)..(278)  
 <220>

WO 02/075507

PCT/US02/01971

&lt;223&gt; unknown O

```
<400> 64
gaattccaac caaatctcac accagagcaa gaacgctaca tagtggaatg gttggcagaa 60
cattacccaa atggaataa accttaacca tagcaagaga gaagaaa atg aaa att 116
Met Lys Ile
1
act att aca cga aat cat cca gaa gta ttt caa gaa tcc gct cgt tta 164
Thr Ile Thr Arg Asn His Pro Glu Val Phe Gln Glu Ser Ala Arg Leu
5 10 15
gta gcc gaa aag ttc att aaa gcc caa tgt gta gaa gca tta aca ttg 212
Val Ala Glu Lys Phe Ile Lys Ala Gln Cys Val Glu Ala Leu Thr Leu
20 25 30 35
gct ttg att gag ggt gtc gag cac ttt gtg ctg gaa ggt gag gag gaa 260
Ala Leu Ile Glu Gly Val Glu His Phe Val Leu Glu Gly Glu Glu Glu
40 45 50
agc aaa agg gga cat agt 278
Ser Lys Arg Gly His Ser
55
```

&lt;210&gt; 65

&lt;211&gt; 57

&lt;212&gt; PRT

&lt;213&gt; Pasteurella multocida

```
<400> 65
Met Lys Ile Thr Ile Thr Arg Asn His Pro Glu Val Phe Gln Glu Ser
1 5 10 15
Ala Arg Leu Val Ala Glu Lys Phe Ile Lys Ala Gln Cys Val Glu Ala
20 25 30
Leu Thr Leu Ala Leu Ile Glu Gly Val Glu His Phe Val Leu Glu Gly
35 40 45
Glu Glu Glu Ser Lys Arg Gly His Ser
50 55
```

&lt;210&gt; 66

&lt;211&gt; 1020

&lt;212&gt; DNA

&lt;213&gt; Pasteurella multocida

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(597)

&lt;220&gt;

&lt;223&gt; unknown P

```
<400> 66
gtc aac aca tca aaa gtt gag att gac tat gcc gtc act cgt gcg gcg 48
Val Asn Thr Ser Lys Val Glu Ile Asp Tyr Ala Val Thr Arg Ala Ala
1 5 10 15
gca atg cgt gca tat ctt gat aaa gaa cag gcc tgg cat acg tct att 96
```

WO 02/075507

PCT/US02/01971

Ala Met Arg Ala Tyr Leu Asp Lys Glu Gln Gly Trp His Thr Ser Ile  
 20 25 30  
 tca aat aaa ggc att aat ggc gtg agc ggt gtc aca caa cca ctc tat 144  
 Ser Asn Lys Gly Ile Asn Gly Val Ser Gly Val Thr Gln Pro Leu Tyr  
 35 40 45  
 ttt gac att aac gac agc tcg act gat gtg aac tat ctc aat gaa caa 192  
 Phe Asp Ile Asn Asp Ser Ser Thr Asp Val Asn Tyr Leu Asn Glu Gln  
 50 55 60  
 ggc atc acg tgt tgc gtg aat cat aat ggc ttt cgt ttt tgg ggc tta 240  
 Gly Ile Thr Cys Cys Val Asn His Asn Gly Phe Arg Phe Trp Gly Leu  
 65 70 75 80  
 cgc acg act gca gaa gat cca tta ttc aag ttt gaa gtg tac acc cgc 288  
 Arg Thr Thr Ala Glu Asp Pro Leu Phe Lys Phe Glu Val Tyr Thr Arg  
 85 90 95  
 act gca caa atc tta aaa gat acg att gca ggg gcg ttt gat tgg gca 336  
 Thr Ala Gln Ile Leu Lys Asp Thr Ile Ala Gly Ala Phe Asp Trp Ala  
 100 105 110  
 gtg gat aaa gat att tct gtc acg cta gtg aaa gat att att gaa gca 384  
 Val Asp Lys Asp Ile Ser Val Thr Leu Val Lys Asp Ile Ile Glu Ala  
 115 120 125  
 atc aat gcg aag tgg cgt gat tac acc aca aaa ggc tac tta att ggc 432  
 Ile Asn Ala Lys Trp Arg Asp Tyr Thr Thr Lys Gly Tyr Leu Ile Gly  
 130 135 140  
 ggt aaa gcg tgg ctt aat aaa gag ctt aac agt gca acg aat tta aaa 480  
 Gly Lys Ala Trp Leu Asn Lys Glu Leu Asn Ser Ala Thr Asn Leu Lys  
 145 150 155 160  
 gat gcg aag ttg ttg atc tct tat gat tat cac cca gta cca ccg ctc 528  
 Asp Ala Lys Leu Leu Ile Ser Tyr Asp Tyr His Pro Val Pro Pro Leu  
 165 170 175  
 gaa cag cta ggc ttt aat cag tac att tct gat gaa tac ctt gtt gat 576  
 Glu Gln Leu Gly Phe Asn Gln Tyr Ile Ser Asp Glu Tyr Leu Val Asp  
 180 185 190  
 ttt tca aat cgt tta gca tcg taaggggtag aaaatggctt taccacgcaa 627  
 Phe Ser Asn Arg Leu Ala Ser  
 195  
 acctaaattg atgaatttaa tcatcgacgg taacaaatat ctcgcggaag tcacggaagt 687  
 gactcaacca aaattagcaa tgaaaatcga agaatttcgc gcggcggtg tgattggttc 747  
 ggtggatgtc aatctcgggc ttgaaaagct cgaagcggaa tttaaagccg gtggctacat 807  
 ggtcgaatta attaaaaaat tcggcgggtc aatcaacggc attccattgc gttttcttgg 867  
 ctcatatcag cgtgatgaca cagaagaagt cacatctggt gagcttctga tgcaaggtcg 927  
 atttactgaa attgacagcg gaaacagcaa agtgggggat gacactgaac aaacattcaa 987  
 agtgccttta acgtattaca aaatcattgt tga 1020

&lt;210&gt; 67



WO 02/075507

PCT/US02/01971

<211> 199  
 <212> PRT  
 <213> Pasteurella multocida

<400> 67  
 Val Asn Thr Ser Lys Val Glu Ile Asp Tyr Ala Val Thr Arg Ala Ala  
 1 5 10 15  
 Ala Met Arg Ala Tyr Leu Asp Lys Glu Gln Gly Trp His Thr Ser Ile  
 20 25 30  
 Ser Asn Lys Gly Ile Asn Gly Val Ser Gly Val Thr Gln Pro Leu Tyr  
 35 40 45  
 Phe Asp Ile Asn Asp Ser Ser Thr Asp Val Asn Tyr Leu Asn Glu Gln  
 50 55 60  
 Gly Ile Thr Cys Cys Val Asn His Asn Gly Phe Arg Phe Trp Gly Leu  
 65 70 75 80  
 Arg Thr Thr Ala Glu Asp Pro Leu Phe Lys Phe Glu Val Tyr Thr Arg  
 85 90 95  
 Thr Ala Gln Ile Leu Lys Asp Thr Ile Ala Gly Ala Phe Asp Trp Ala  
 100 105 110  
 Val Asp Lys Asp Ile Ser Val Thr Leu Val Lys Asp Ile Ile Glu Ala  
 115 120 125  
 Ile Asn Ala Lys Trp Arg Asp Tyr Thr Thr Lys Gly Tyr Leu Ile Gly  
 130 135 140  
 Gly Lys Ala Trp Leu Asn Lys Glu Leu Asn Ser Ala Thr Asn Leu Lys  
 145 150 155 160  
 Asp Ala Lys Leu Leu Ile Ser Tyr Asp Tyr His Pro Val Pro Pro Leu  
 165 170 175  
 Glu Gln Leu Gly Phe Asn Gln Tyr Ile Ser Asp Glu Tyr Leu Val Asp  
 180 185 190  
 Phe Ser Asn Arg Leu Ala Ser  
 195

<210> 68  
 <211> 2584  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (1042)..(2286)

<220>  
 <223> xylA

<400> 68  
 gtcgaccagc tttagatttg cgacgggggtt aattttctct atcgtttcaa tcattgcggtt 60  
 taaccattatt ttatggaatc ttcttggaac gatgaccatt gccaatattg aaattcctca 120  
 cgcgatggtc tttttggtct ttatttaagt gotgttttagc agtattgtgg catttaaaat 180

WO 02/075507

PCT/US02/01971

```

cggtcgccg ttaattcagc tcaattttgc caatgaacgc ttaaacgcca actaccgta 240
ttcaactatc cgtctgaaag aatatgctga aagcattgct ttttatcgtg gtgaaaaat 300
ggaaaaacgt ctattgacca cacaaatata tcaggtgatt gataacgttt ggcaagtaat 360
ctaccgcacc ttgaaattat ccggttttaa cttaatcatt acgcagattt cggcgggttt 420
tcgcctgggtg attcaagtga caggttattt tcgtcgacaa taggtgcata tgagggtggt 480
agaatagcga tactttctgt tggaaaagta aactctttaa tataaataga aatcgcttga 540
atgattctcg ggcaaaaaat aatgtactca tttgcgatct catactgata atggcgaagt 600
aaatatcttc ttacaatatt atggttaata tcaggttaata ccgtatagcc atagattcca 660
gttctatttt gttttgctaa ataattgatg agcatttgag gcgcaggtaa atccatatct 720
gcaacagaca ttgaaatcat atccttgccg tatttacagag taattgcoca tttagcacta 780
tgacaactcg atctatcagt aaaaacatca aacaaattat ccgtacatac tgttctccaa 840
tattggattt atataaactt tagaacttga ggtagattgt tggattgtt aaactcggta 900
ttctattac gttttttctt ttttggata taagccacaa taaccaataa tcttaattgt 960
taagtgaat aacgtaattg atcctcccat tgttttacta aattatgtct ctgaaactta 1020
ttgttcagg agaaatcatt t atg tcc act tac ttc gac aaa att gaa aaa 1071
Met Ser Thr Tyr Phe Asp Lys Ile Glu Lys
1 5 10
gta aat tat gaa ggt gta act tca tct aat ccg ttt gca tat aag cat 1119
Val Asn Tyr Glu Gly Val Thr Ser Ser Asn Pro Phe Ala Tyr Lys His
15 20 25
tat gat gct aat caa gtt att tta ggt aag acg atg gct gaa cac tta 1167
Tyr Asp Ala Asn Gln Val Ile Leu Gly Lys Thr Met Ala Glu His Leu
30 35 40
cgt tta gcc gtc tgt tat tgg cac act ttc tgt tgg aca ggg aat gat 1215
Arg Leu Ala Val Cys Tyr Trp His Thr Phe Cys Trp Thr Gly Asn Asp
45 50 55
atg ttc ggt gtc ggt tct ttc gat cgt tgt tgg cag aag gcg agt gat 1263
Met Phe Gly Val Gly Ser Phe Asp Arg Cys Trp Gln Lys Ala Ser Asp
60 65 70
tca tta gca ggt gca aaa caa aaa gca gat atc gct ttt gaa ttt ttc 1311
Ser Leu Ala Gly Ala Lys Gln Lys Ala Asp Ile Ala Phe Glu Phe Phe
75 80 85 90
agt aaa tta gcc ata cct tat tat tgt ttt cat gat gtt gat gtt gcg 1359
Ser Lys Leu Gly Ile Pro Tyr Tyr Cys Phe His Asp Val Asp Val Ala
95 100 105
cca gaa ggt cat tca ttt aaa gaa tat ttg tcg aac ttt aat aca atg 1407
Pro Glu Gly His Ser Phe Lys Glu Tyr Leu Ser Asn Phe Asn Thr Met
110 115 120
atc gat gtt tta gcg cag aaa caa gaa gaa aca ggc gtc aaa ttg ttg 1455
Ile Asp Val Leu Ala Gln Lys Gln Glu Glu Thr Gly Val Lys Leu Leu
125 130 135

```

WO 02/075507

PCT/US02/01971

tgg ggg act gca aat tgt ttt aca cac cct cgt tat atg tct ggt gct 1503  
 Trp Gly Thr Ala Asn Cys Phe Thr His Pro Arg Tyr Met Ser Gly Ala  
 140 145 150

gca aca aat ccg aat cca gaa att ttt gct tgg gct gct gca caa gta 1551  
 Ala Thr Asn Pro Asn Pro Glu Ile Phe Ala Trp Ala Ala Ala Gln Val  
 155 160 165 170

ttt act gcc atg ggg gca act cag cgt tta ggt ggt gaa aat tat gtt 1599  
 Phe Thr Ala Met Gly Ala Thr Gln Arg Leu Gly Gly Glu Asn Tyr Val  
 175 180 185

ttg tgg gga gga cgt gaa gga tat gaa acg tta tta aat acc aat tta 1647  
 Leu Trp Gly Gly Arg Glu Gly Tyr Glu Thr Leu Leu Asn Thr Asn Leu  
 190 195 200

aaa cag gag cga gag caa att gga cgt ttc atg caa atg gtg gtt gag 1695  
 Lys Gln Glu Arg Glu Gln Ile Gly Arg Phe Met Gln Met Val Val Glu  
 205 210 215

cat aaa tat aaa atc ggt ttt aac ggg act ttg ctg att gaa cca aag 1743  
 His Lys Tyr Lys Ile Gly Phe Asn Gly Thr Leu Leu Ile Glu Pro Lys  
 220 225 230

cca caa gag cca acg aaa cat caa tat gac tat gat gtg gcg acc gtt 1791  
 Pro Gln Glu Pro Thr Lys His Gln Tyr Asp Tyr Asp Val Ala Thr Val  
 235 240 245 250

tat ggc ttt tta aag cag ttt ggt tta gaa aaa gaa att aaa gtg aat 1839  
 Tyr Gly Phe Leu Lys Gln Phe Gly Leu Glu Lys Glu Ile Lys Val Asn  
 255 260 265

att gaa gct aat cac gca aca tta gct gga cac act ttc cag cat gaa 1887  
 Ile Glu Ala Asn His Ala Thr Leu Ala Gly His Thr Phe Gln His Glu  
 270 275 280

gtc gcc atg gct aca gcg tta gat att ttt ggt tct att gat gca aat 1935  
 Val Ala Met Ala Thr Ala Leu Asp Ile Phe Gly Ser Ile Asp Ala Asn  
 285 290 295

cgt ggt gat cca caa tta ggt tgg gat acc gat caa ttc cct aat agc 1983  
 Arg Gly Asp Pro Gln Leu Gly Trp Asp Thr Asp Gln Phe Pro Asn Ser  
 300 305 310

gta gaa gaa aat act ttg gtc ata tat gaa att ctc aaa gca ggg ggc 2031  
 Val Glu Glu Asn Thr Leu Val Ile Tyr Glu Ile Leu Lys Ala Gly Gly  
 315 320 325 330

ttt aca acc ggt ggt ttt aat ttt gat gct aaa atc cgt cgg cag agt 2079  
 Phe Thr Thr Gly Gly Phe Asn Phe Asp Ala Lys Ile Arg Arg Gln Ser  
 335 340 345

acg gat cct tac gat tta ttt cat gga cat att ggc gcg att gat gta 2127  
 Thr Asp Pro Tyr Asp Leu Phe His Gly His Ile Gly Ala Ile Asp Val  
 350 355 360

ctt gcc tta tca cta aaa tgt gcg gcg aaa atg ctt gaa gag caa gct 2175  
 Leu Ala Leu Ser Leu Lys Cys Ala Ala Lys Met Leu Glu Glu Gln Ala  
 365 370 375

tta caa aaa gtc gtc aat caa cgt tat gct ggt tgg aca tca tca ctt 2223  
 Leu Gln Lys Val Val Asn Gln Arg Tyr Ala Gly Trp Thr Ser Ser Leu  
 380 385 390

WO 02/075507

PCT/US02/01971

ggt caa ctt gtt caa atc cgg tcc tac cac gcg tgt ctg caa tac aga 2271  
 Gly Gln Leu Val Gln Ile Arg Ser Tyr His Ala Cys Leu Gln Tyr Arg  
 395 400 405 410  
 cta aca aaa gtg ctt taaaacgttc cggcttacgc cagacatcta gacgattgaa 2326  
 Leu Thr Lys Val Leu  
 415  
 taatttcaat attgtctccg cacgtaattc aaaggctttg tgtatgtgcg aatgatattc 2386  
 acaacaaagt tctgcaaaat ctgcaattgc gtgaggtaat ttaaagcgt gacataagcg 2446  
 tcttgctcgc atgacaccag ctttttcatg tccataatga tgtggcaata tttctttgg 2506  
 tgtaaggct tttcctaata catgacaaat tgcagcaaaa cgtaccgcac tttgtcact 2566  
 gtcctgtttt tctgtcga 2584

<210> 69  
 <211> 415  
 <212> PRT  
 <213> Pasteurella multocida

<400> 69  
 Met Ser Thr Tyr Phe Asp Lys Ile Glu Lys Val Asn Tyr Glu Gly Val  
 1 5 10 15  
 Thr Ser Ser Asn Pro Phe Ala Tyr Lys His Tyr Asp Ala Asn Gln Val  
 20 25 30  
 Ile Leu Gly Lys Thr Met Ala Glu His Leu Arg Leu Ala Val Cys Tyr  
 35 40 45  
 Trp His Thr Phe Cys Trp Thr Gly Asn Asp Met Phe Gly Val Gly Ser  
 50 55 60  
 Phe Asp Arg Cys Trp Gln Lys Ala Ser Asp Ser Leu Ala Gly Ala Lys  
 65 70 75 80  
 Gln Lys Ala Asp Ile Ala Phe Glu Phe Phe Ser Lys Leu Gly Ile Pro  
 85 90 95  
 Tyr Tyr Cys Phe His Asp Val Asp Val Ala Pro Glu Gly His Ser Phe  
 100 105 110  
 Lys Glu Tyr Leu Ser Asn Phe Asn Thr Met Ile Asp Val Leu Ala Gln  
 115 120 125  
 Lys Gln Glu Glu Thr Gly Val Lys Leu Leu Trp Gly Thr Ala Asn Cys  
 130 135 140  
 Phe Thr His Pro Arg Tyr Met Ser Gly Ala Ala Thr Asn Pro Asn Pro  
 145 150 155 160  
 Glu Ile Phe Ala Trp Ala Ala Ala Gln Val Phe Thr Ala Met Gly Ala  
 165 170 175  
 Thr Gln Arg Leu Gly Gly Glu Asn Tyr Val Leu Trp Gly Gly Arg Glu  
 180 185 190  
 Gly Tyr Glu Thr Leu Leu Asn Thr Asn Leu Lys Gln Glu Arg Glu Gln  
 195 200 205

WO 02/075507

PCT/US02/01971

Ile Gly Arg Phe Met Gln Met Val Val Glu His Lys Tyr Lys Ile Gly  
 210 215 220  
 Phe Asn Gly Thr Leu Leu Ile Glu Pro Lys Pro Gln Glu Pro Thr Lys  
 225 230 235 240  
 His Gln Tyr Asp Tyr Asp Val Ala Thr Val Tyr Gly Phe Leu Lys Gln  
 245 250 255  
 Phe Gly Leu Glu Lys Glu Ile Lys Val Asn Ile Glu Ala Asn His Ala  
 260 265 270  
 Thr Leu Ala Gly His Thr Phe Gln His Glu Val Ala Met Ala Thr Ala  
 275 280 285  
 Leu Asp Ile Phe Gly Ser Ile Asp Ala Asn Arg Gly Asp Pro Gln Leu  
 290 295 300  
 Gly Trp Asp Thr Asp Gln Phe Pro Asn Ser Val Glu Glu Asn Thr Leu  
 305 310 315 320  
 Val Ile Tyr Glu Ile Leu Lys Ala Gly Gly Phe Thr Thr Gly Gly Phe  
 325 330 335  
 Asn Phe Asp Ala Lys Ile Arg Arg Gln Ser Thr Asp Pro Tyr Asp Leu  
 340 345 350  
 Phe His Gly His Ile Gly Ala Ile Asp Val Leu Ala Leu Ser Leu Lys  
 355 360 365  
 Cys Ala Ala Lys Met Leu Glu Glu Gln Ala Leu Gln Lys Val Val Asn  
 370 375 380  
 Gln Arg Tyr Ala Gly Trp Thr Ser Ser Leu Gly Gln Leu Val Gln Ile  
 385 390 395 400  
 Arg Ser Tyr His Ala Cys Leu Gln Tyr Arg Leu Thr Lys Val Leu  
 405 410 415

<210> 70  
 <211> 3501  
 <212> DNA  
 <213> Pasteurella multocida  
 <220>  
 <221> CDS  
 <222> (298)..(1905)  
 <220>  
 <223> yabk

<400> 70  
 gaattcgagg aagggggcgt attacaaatt gaaacggctg cacgtgtagc acaacatgat 60  
 aatgcctgtg cggatcattt cottgccttt ttaattcctc cagaagcaca agggcattta 120  
 gtcaagaata atgtgatgtt accggtgatt aataccaata ttgaaccgca ctttgatgcc 180  
 cttagagcca cccaatgaa cacgaaagt ctcgatacct caaaagtga tgccgaacaa 240  
 gtcacaaaaat ggattgcctgt ttggcaaacg accctaacc ccaaatgttt tgcctttg 297

WO 02/075507

PCT/US02/01971

```

atg ttt aag cga ttt cgt gca ttc aca tac cgt ccc gcc agt tat ctt 345
Met Phe Lys Arg Phe Arg Ala Phe Thr Tyr Arg Pro Ala Ser Tyr Leu
1 5 10 15

ggc ggg atg ttg gtg att gtt ttt ctg agc gct ttt tat gcg ttc gcc 393
Gly Gly Met Leu Val Ile Val Phe Leu Ser Ala Phe Tyr Ala Phe Ala
20 25 30

tta ggg gcg gtt ttt tcg ctc cct ttt gcg cgc agt tgg aca gcg ttg 441
Leu Gly Ala Val Phe Ser Leu Pro Phe Ala Arg Ser Trp Thr Ala Leu
35 40 45

ttg agt gat cag tat tta caa cac gtg atc atc ttt agc ttt tgg caa 489
Leu Ser Asp Gln Tyr Leu Gln His Val Ile Ile Phe Ser Phe Trp Gln
50 55 60

gcc ttt ctg tcg gcg gta ctt gcg gtc ctc ttt ggt gcc att gta gca 537
Ala Phe Ser Leu Ser Ala Val Leu Ala Val Leu Phe Gly Gly Ile Val Ala
65 70 75 80

cga gcc ttt ttt tat caa ccg ttt gtg gcc aag aaa ctg atc ctc aaa 585
Arg Ala Phe Phe Tyr Gln Pro Phe Val Gly Lys Lys Leu Ile Leu Lys
85 90 95

tta ttt tca ctg act ttt gtg tta cct gcc tta gtg gcg att ttt ggt 633
Leu Phe Ser Leu Thr Phe Val Leu Pro Ala Leu Val Ala Ile Phe Gly
100 105 110

tta tta gcc gtg tat gcc gct tct gcc tgg tta gcg atg tta agc cag 681
Leu Leu Gly Val Tyr Gly Ala Ser Gly Trp Leu Ala Met Leu Ser Gln
115 120 125

ttt ttc gct tgg gat tgg act cct aat att tac gcc tta aca ggt att 729
Phe Phe Ala Trp Asp Trp Thr Pro Asn Ile Tyr Gly Leu Thr Gly Ile
130 135 140

tta ctg gcg cat ctt ttt ttt aat gtc cca tta gct tgt cgc ctg ttt 777
Leu Leu Ala His Leu Phe Phe Asn Val Pro Leu Ala Cys Arg Leu Phe
145 150 155 160

tta caa ggt ttg caa gca att ccg gtg caa caa cgt cag ctc gcg gca 825
Leu Gln Gly Leu Gln Ala Ile Pro Val Gln Gln Arg Gln Leu Ala Ala
165 170 175

caa ctc aat tta cgt ggt tgg cat ttt ata cgt ctg att gag tgg ccc 873
Gln Leu Asn Leu Arg Gly Trp His Phe Ile Arg Leu Ile Gln Trp Pro
180 185 190

tat tta cgc cag caa ttg tta cct gca ttt act ttg att ttc atg ctg 921
Tyr Leu Arg Gln Gln Leu Leu Pro Ala Phe Thr Leu Ile Phe Met Leu
195 200 205

tgt ttt acc agt ttt gcg att gtg ctc act tta ggt gcc gga ccg aaa 969
Cys Phe Thr Ser Phe Ala Ile Val Leu Thr Leu Gly Gly Gly Pro Lys
210 215 220

tat acc acg ttg gaa gtg gct atc tat caa gcg att tta ttt gag ttt 1017
Tyr Thr Thr Leu Glu Val Ala Ile Tyr Gln Ala Ile Leu Phe Gln Phe
225 230 235 240

gat gta ccg aaa gcc gcc tta ttt gcg tta tta caa ttt gtt ttt tgt 1065
Asp Val Pro Lys Ala Gly Leu Phe Ala Leu Leu Gln Phe Val Phe Cys
245 250 255

```

WO 02/075507

PCT/US02/01971

ttt ctg tta ttc acg ctg agt agc ttt ttt tct cca gcc ccc gcc acg 1113  
 Phe Leu Leu Phe Thr Leu Ser Ser Phe Phe Ser Pro Ala Pro Ala Thr  
 260 265 270

aca tta cac agt caa cct act tgg ttt gcg ccc caa tgg tat tgg gtt 1161  
 Thr Leu His Ser Gln Pro Thr Trp Phe Ala Pro Gln Ser Tyr Trp Val  
 275 280 285

aaa tta tgg caa cgt atg atc att gtg tgt gcg aca gta ttt atc tta 1209  
 Lys Leu Trp Gln Arg Met Ile Ile Val Cys Ala Thr Val Phe Ile Leu  
 290 295 300

tta cgg cta ctc aat acg cta gtt tct gct ttg ctt tgg tct cag ttt 1257  
 Leu Pro Leu Leu Asn Thr Leu Val Ser Ala Leu Leu Ser Ser Gln Phe  
 305 310 315

ttt acc ttg tgg tta caa cct caa tta tgg aaa gca tta ggt tac tcg 1305  
 Phe Thr Leu Trp Leu Gln Pro Gln Leu Trp Lys Ala Leu Gly Tyr Ser  
 325 330 335

ctc acc atc gcc ccc act tct gca ttg ctc gct tta gta ctg tct ttt 1353  
 Leu Thr Ile Ala Pro Thr Ser Ala Leu Leu Ala Leu Val Leu Ser Phe  
 340 345 350

gcc tta tta ttg ctt gcc aga gaa tta cat tgg cga cat tat cgc agc 1401  
 Ala Leu Leu Leu Leu Ala Arg Glu Leu His Trp Arg His Tyr Arg Ser  
 355 360 365

tta tcc cat gtg att tta aat atc ggt gcg acc att tta gcc att cca 1449  
 Leu Ser His Val Ile Leu Asn Ile Gly Ala Thr Ile Leu Ala Ile Pro  
 370 375 380

acg tta gtg tta gct att ggt tta ttc att tta tta cgt gag atc gat 1497  
 Thr Leu Val Leu Ala Ile Gly Leu Phe Ile Leu Leu Arg Glu Ile Asp  
 385 390 395 400

ttt tct cca tac cat ctt ttt ggg gtt gtg gta tgc tgt aac gcg tta 1545  
 Phe Ser Pro Tyr His Leu Phe Gly Val Val Val Cys Cys Asn Ala Leu  
 405 410 415

gct gct atg cct ttt gtg ttg cgt att ttg gct tta cgg atg cat aac 1593  
 Ala Ala Met Pro Phe Val Leu Arg Ile Leu Ala Leu Pro Met His Asn  
 420 425 430

aat atg att tat tat gaa aaa tta tgc caa tca ctt aac ctg cgt ggt 1641  
 Asn Met Ile Tyr Tyr Glu Lys Leu Cys Gln Ser Leu Asn Leu Arg Gly  
 435 440 445

tgg caa cgt ttt cga ttg att gaa tgg cac aag ctt cgt gcg cca atg 1689  
 Trp Gln Arg Phe Arg Leu Ile Glu Trp His Lys Leu Arg Ala Pro Met  
 450 455 460

aaa tac gcc ttt gca ctg gct tgt gcg tta tca tta ggc gat ttc acc 1737  
 Lys Tyr Ala Phe Ala Leu Ala Cys Ala Leu Ser Leu Gly Asp Phe Thr  
 465 470 475 480

gca atc gcg tta ttt ggt cag gct gac ttc aca tcg tta cgg cat ttg 1785  
 Ala Ile Ala Leu Phe Gly Gln Ala Asp Phe Thr Ser Leu Pro His Leu  
 485 490 495

ttg tat caa caa ttg ggg cat tat cgt agt cag gaa gcg goa gta aca 1833  
 Leu Tyr Gln Gln Leu Gly His Tyr Arg Ser Gln Glu Ala Ala Val Thr  
 500 505 510

WO 02/075507

PCT/US02/01971

```

gcg ttt att tta ttg gtt ttt tgt ttg agt gtt ttt atg att att gaa 1881
Ala Phe Ile Leu Leu Val Phe Cys Leu Ser Val Phe Met Ile Ile Glu
      515                520                525
cga cat cag gaa ccg cgt gat gat taatttaaac ggtgttcagt ttctctataa 1935
Arg His Gln Glu Pro Arg Asp Asp
      530                535

tacotttact tttagctgg atttcagat tcctgctcaa caaaaagttg ctattattgg 1995
cgccagtggc gcaggggaaga gtaccttatt aaatttgatt ggggttttg cattgccaca 2055
gcaaggggaa atttggttga atggtgaaaa tcatagccaa actcaacctt atgaacgtcc 2115
ggtatctatt ttgtttcaag aaaacaactt gtttacgcat ttgactgtgg cagagaatat 2175
ggcattaggc ctgaaaccaa gcctaaaact gaccgcactt gaacaacaac gcgtacaaca 2235
agtggcaagt gcagtgggtt tgcagggttt tcttaataca ttaccacacc agttatcggg 2295
tgggcaaaaa cagcgtgtgg cgttggcgcg ttgtttatta cgcgataagc caattttggt 2355
atggatgaa cctctttctg ccttagatcc cgatttacgg gcagaaatgt tgcatttatt 2415
gttacagtg tgtgatgaaa aaaaattaac actcctgacg gtgacacatc aagtgaacga 2475
attacagcag aaaaatggatc gtatgattcg ttttgaacat ggtaggatga gtgagtecc 2535
cattttgaag gataatttta acgaaaaaca gaccgcactt taggcggcctt attaattaga 2595
taaggaaaga gaaaaaatg acaacggcaa cggcatttga gattcgtaca cttactcctc 2655
accgcacctt agaattattg tctgtgtgta aaattgaagc cctgtttgag accccttttt 2715
tagatttggg ttatcgggct gcgcaagtgc accgagaaaa cttaatacct aaagccattc 2775
aattatccac tttaatgtcg attaaaacgg ggggatgtcc agaggattgt ggcctactgtc 2835
cgcagtcagc acgttatcat actggagtag aaaaagcagca attactcgat gtggaagaaa 2895
ttgtgaaaa agccaaaatt gccaaaagcac gtggtgcagg gcgcttttgt atgggggctg 2955
catggcgtgg accgaaaacc aaagacattg aaaaagttac cgcacatcatt aaagcggtga 3015
aagaactggg cttagaaaacc tgtggtacct ttggtttatt gcaagatggg atggcagaag 3075
atttaaaga agcgggtttg gattattata accataatct cgatacagcc ccagaacct 3135
acggtaatgt gattggtacc cgtcaatttg atgacgtat taatacgtta ggtaaaagtgc 3195
gtaaaagctg cttaaaagtg tgcctgtggcg ggattattgg catgaalgaa acccgtaaa 3255
aaagagcagg attaattgct agcttagcta atttagaccg gcaaccgaa tccgtgcgca 3315
ttaatcaatt agtgaagtg gaaggtaccc ctttagccga tgcggcagaa ttagactgga 3375
cagaatttgt gcgcactatt gcggtggcgc gtattaccat gccgaaaagc tatgtacgtt 3435
tatcagcagg gcgtcaaggc atgtcggaaag aaatgcaagc catgtgcttt atggctggcg 3495
cgaatt 3501

```



WO 02/075507

PCT/US02/01971

<210> 71  
 <211> 536  
 <212> PRT  
 <213> *Pasteurella multocida*

<400> 71  
 Met Phe Lys Arg Phe Arg Ala Phe Thr Tyr Arg Pro Ala Ser Tyr Leu  
 1 5 10 15  
 Gly Gly Met Leu Val Ile Val Phe Leu Ser Ala Phe Tyr Ala Phe Ala  
 20 25 30  
 Leu Gly Ala Val Phe Ser Leu Pro Phe Ala Arg Ser Trp Thr Ala Leu  
 35 40 45  
 Leu Ser Asp Gln Tyr Leu Gln His Val Ile Ile Phe Ser Phe Trp Gln  
 50 55 60  
 Ala Phe Leu Ser Ala Val Leu Ala Val Leu Phe Gly Gly Ile Val Ala  
 65 70 75 80  
 Arg Ala Phe Phe Tyr Gln Pro Phe Val Gly Lys Lys Leu Ile Leu Lys  
 85 90 95  
 Leu Phe Ser Leu Thr Phe Val Leu Pro Ala Leu Val Ala Ile Phe Gly  
 100 105 110  
 Leu Leu Gly Val Tyr Gly Ala Ser Gly Trp Leu Ala Met Leu Ser Gln  
 115 120 125  
 Phe Phe Ala Trp Asp Trp Thr Pro Asn Ile Tyr Gly Leu Thr Gly Ile  
 130 135 140  
 Leu Leu Ala His Leu Phe Phe Asn Val Pro Leu Ala Cys Arg Leu Phe  
 145 150 155 160  
 Leu Gln Gly Leu Gln Ala Ile Pro Val Gln Gln Arg Gln Leu Ala Ala  
 165 170 175  
 Gln Leu Asn Leu Arg Gly Trp His Phe Ile Arg Leu Ile Glu Trp Pro  
 180 185 190  
 Tyr Leu Arg Gln Gln Leu Leu Pro Ala Phe Thr Leu Ile Phe Met Leu  
 195 200 205  
 Cys Phe Thr Ser Phe Ala Ile Val Leu Thr Leu Gly Gly Pro Lys  
 210 215 220  
 Tyr Thr Thr Leu Glu Val Ala Ile Tyr Gln Ala Ile Leu Phe Glu Phe  
 225 230 235 240  
 Asp Val Pro Lys Ala Gly Leu Phe Ala Leu Leu Gln Phe Val Phe Cys  
 245 250 255  
 Phe Leu Leu Phe Thr Leu Ser Ser Phe Phe Ser Pro Ala Pro Ala Thr  
 260 265 270  
 Thr Leu His Ser Gln Pro Thr Trp Phe Ala Pro Gln Ser Tyr Trp Val  
 275 280 285  
 Lys Leu Trp Gln Arg Met Ile Ile Val Cys Ala Thr Val Phe Ile Leu  
 290 295 300

145

WO 02/075507

PCT/US02/01971

Leu Pro Leu Leu Asn Thr Leu Val Ser Ala Leu Leu Ser Ser Gln Phe  
 305 310 315 320  
 Phe Thr Leu Trp Leu Gln Pro Gln Leu Trp Lys Ala Leu Gly Tyr Ser  
 325 330 335  
 Leu Thr Ile Ala Pro Thr Ser Ala Leu Leu Ala Leu Val Leu Ser Phe  
 340 345 350  
 Ala Leu Leu Leu Ala Arg Glu Leu His Trp Arg His Tyr Arg Ser  
 355 360 365  
 Leu Ser His Val Ile Leu Asn Ile Gly Ala Thr Ile Leu Ala Ile Pro  
 370 375 380  
 Thr Leu Val Leu Ala Ile Gly Leu Phe Ile Leu Leu Arg Glu Ile Asp  
 385 390 395 400  
 Phe Ser Pro Tyr His Leu Phe Gly Val Val Val Cys Cys Asn Ala Leu  
 405 410 415  
 Ala Ala Met Pro Phe Val Leu Arg Ile Leu Ala Leu Pro Met His Asn  
 420 425 430  
 Asn Met Ile Tyr Tyr Glu Lys Leu Cys Gln Ser Leu Asn Leu Arg Gly  
 435 440 445  
 Trp Gln Arg Phe Arg Leu Ile Glu Trp His Lys Leu Arg Ala Pro Met  
 450 455 460  
 Lys Tyr Ala Phe Ala Leu Ala Cys Ala Leu Ser Leu Gly Asp Phe Thr  
 465 470 475 480  
 Ala Ile Ala Leu Phe Gly Gln Ala Asp Phe Thr Ser Leu Pro His Leu  
 485 490 495  
 Leu Tyr Gln Gln Leu Gly His Tyr Arg Ser Gln Glu Ala Ala Val Thr  
 500 505 510  
 Ala Phe Ile Leu Leu Val Phe Cys Leu Ser Val Phe Met Ile Ile Glu  
 515 520 525  
 Arg His Gln Glu Pro Arg Asp Asp  
 530 535

<210> 72  
 <211> 3182  
 <212> DNA  
 <213> *Pasteurella multocida*

<220>  
 <221> CDS  
 <222> (1544)..(2809)

<220>  
 <223> ygiK

<220>  
 <221> misc\_feature  
 <222> 452  
 <223> N = A or T or G or C

WO 02/075507

PCT/US02/01971

```

<400> 72
aactactaag gagttatgta tgaatattag aaaatcatta ctattaatat ccctagcaag 60
ctctactgca ctttcagttt cagctgcaga aattaatttg aaatttgaaa gttcgaattt 120
tgcaggagaa aaagtttatg aaatccaaaa agaattggact gacaatttg aaaaagcttc 180
caatgggaga ataagtatag agttattacc tctcgactca gtcttaaat ctagtacat 240
gctttctggt gttcgaata aaattattga tggagcggtt gcaacagcgg caatgtatgc 300
aggcactgac cctggattcg gattaattgg tgatactatt tctgcttga accatgacga 360
agatatttta aatttttact ataatggagg tggttttgaa gttgttgata atattttcca 420
acaatatggt gccaaactca ttggtgtatc anttacggga gcagaatcat taccatgcaa 480
agtaaaaaa gctaactctg aagattttaa aggtataaaa attcggggctc cctctggctc 540
tatccaaaaa ttgtttgcaa gattaggagc cgctcctggt ggtcttcctg gttcagaat 600
ctatactagt ttgaaaaaag gtattattga tgcctgcgat tctccaactg ttgcaataa 660
tcaagcacia ggagtcctatg atattgcaaa ataccaatc tatccgggaa ttcattcttc 720
accagcctgt catatgatta tgaatcataa aaactggagt agcttaactc catcggatca 780
agcattctta attgcttact ttaaaaggat ggctctcgat actctgactc gtctcatta 840
tgaagataaa ctagcatata aagaagcact tgagaaagga gtacaaccag tttcttggaa 900
tcaacaagaa attcaaaaag ttctgttctat cgctaaagaa atttggcaag agatagctca 960
acaactcgaa ataggtaatc aagtattatc aagtattaat gaaattccta gaatctcaag 1020
gaatgctgca ataactgca agatggataa gacgatctg tcttatccat taaggagtaa 1080
aaactgctta tttctaaaata tttattatgg ctctgtaata agctagatca aatattcatt 1140
aaagtagggt attacgtttc ttatatTTTT ctattagttg ttatcattgg ttttacgagg 1200
ttgtgtctgc gtatttatte tctagcccaa cactttgggt tcatgaagta acaacatttt 1260
taataagctc atcattactt tatggtggag tagcttgta cggcagtaat aaacatattg 1320
ccatgacatt tattagacaa aaattaceta ataagatcaa atggttacta gaactcttag 1380
tgaaatact tatttttacc tcttttatt tgcttagtta cggagcatac ttatcagcta 1440
gagaagcatt atttactcca tcagaaaaat tcaaaatgca aactctgga agtgtattag 1500
acatgcatt tccagcaatt gaaaaaagtt tcttctttat ttc atg cct cat cat 1555
Met Pro His His
1
tgt tgt tct ttc agt act aca tat att cag tca cat cta tac aaa ata 1603
Cys Cys Ser Phe Ser Thr Thr Tyr Ile Pro Ser His Leu Tyr Lys Ile
5 10 15 20
tca gga gga att atc atg ata agt gca ttt ggg ata ggt att gga act 1651
Ser Gly Gly Ile Ile Met Ile Ser Ala Phe Gly Ile Gly Ile Gly Thr
25 30 35

```

WO 02/075507

PCT/US02/01971

ctt att atc ttt tta atg atg att tcc ctt tta ttt att gga atg cca 1699  
 Leu Ile Ile Phe Leu Met Met Ile Ser Leu Leu Phe Ile Gly Met Pro  
                   40                  45                  50

tta ggt ttt ctc act ggg tta atc gct tta gtt att tca tat ctt tgg 1747  
 Leu Gly Phe Leu Thr Gly Leu Ile Ala Leu Val Ile Ser Tyr Leu Trp  
                   55                  60                  65

ttt gat act acc gca ata atg caa atg ata gct tca cgt gtc act gat 1795  
 Phe Asp Thr Thr Ala Ile Met Gln Met Ile Ala Ser Arg Val Thr Asp  
                   70                  75                  80

ttc aca tca tct tac act ttt gta gct gtg cct atg ttt gtt ctt atg 1843  
 Phe Thr Ser Ser Tyr Thr Phe Val Ala Val Pro Met Phe Val Leu Met  
                   85                  90                  95                  100

gca aca tta ctt gat aag act gga att gct aga gat ctc tac aac gca 1891  
 Ala Thr Leu Leu Asp Lys Thr Gly Ile Ala Arg Asp Leu Tyr Asn Ala  
                   105                  110                  115

atg cga gtc att ggc ggt cga tta cga ggt gga att gca att caa tgc 1939  
 Met Arg Val Ile Gly Gly Arg Leu Arg Gly Gly Ile Ala Ile Gln Ser  
                   120                  125                  130

atg ttt gtt gca gtt cta ctt gct acg atg tca ggt att atc ggt gga 1987  
 Met Phe Val Ala Val Leu Leu Ala Thr Met Ser Gly Ile Ile Gly Gly  
                   135                  140                  145

gaa act gtt tta tta ggc atg ttg gca tta cca caa atg tta cgc tta 2035  
 Glu Thr Val Leu Leu Gly Met Leu Ala Leu Pro Gln Met Leu Arg Leu  
                   150                  155                  160

ggc tat aat aaa aac tta gct ata gga act gtt gta gca gga gga gca 2083  
 Gly Tyr Asn Lys Asn Leu Ala Ile Gly Thr Val Val Ala Gly Gly Ala  
                   165                  170                  175                  180

ttg ggt aca atg gtt cct cca agt atc gtg ttg att att tac gga atg 2131  
 Leu Gly Thr Met Val Pro Pro Ser Ile Val Leu Ile Ile Tyr Gly Met  
                   185                  190                  195

acc gca aat gtt tct att gga gaa cta ttt ctt gca gca att cca gcc 2179  
 Thr Ala Asn Val Ser Ile Gly Glu Leu Phe Leu Ala Ala Ile Pro Ala  
                   200                  205                  210

tcc tta cta ctt tct tct aca ttc tat att tta tat att cta gta ctt tgc 2227  
 Ser Leu Leu Leu Ser Thr Phe Tyr Ile Leu Tyr Ile Leu Val Leu Cys  
                   215                  220                  225

tac ttc aaa cct agc tat ggc cct gca atg cct agc tca gaa aat cat 2275  
 Tyr Phe Lys Pro Ser Tyr Gly Pro Ala Met Pro Ser Ser Glu Asn His  
                   230                  235                  240

aca tta acg aaa gaa gat att aaa aaa att att cat gat att gca att 2323  
 Thr Leu Thr Lys Glu Asp Ile Lys Lys Ile Ile His Asp Ile Ala Ile  
                   245                  250                  255                  260

cca gta gct atc gcc aca tgg att tta gga agt att tat ggc ggg ata 2371  
 Pro Val Ala Ile Ala Thr Trp Ile Leu Gly Ser Ile Tyr Gly Gly Ile  
                   265                  270                  275

gca tca atc act gaa tct gcc tgt gtt ggt gta gtt ggg gta ata tta 2419  
 Ala Ser Ile Thr Glu Ser Ala Cys Val Gly Val Val Gly Val Ile Leu  
                   280                  285                  290

WO 02/075507

PCT/US02/01971

gca gca ttc tat cga aaa gaa tta aat ttc aaa ata gta caa gaa tca 2467  
 Ala Ala Phe Tyr Arg Lys Glu Leu Asn Phe Lys Ile Val Gln Glu Ser  
 295 300 305  
 cta aaa cat aca atc aat act gtt ggt atg ata atc tgg gtc ggc att 2515  
 Leu Lys His Thr Ile Asn Thr Val Gly Met Ile Ile Trp Val Gly Ile  
 310 315 320  
 ggc gca aca atg att ata ggt att tat aat cta atg ggt ggg gac cga 2563  
 Gly Ala Thr Met Ile Ile Gly Ile Tyr Asn Leu Met Gly Gly Asp Arg  
 325 330 335 340  
 ttt ata gct aac tta ttc gct agc tta gat gcc tct cca att tat act 2611  
 Phe Ile Ala Asn Leu Phe Ala Ser Leu Asp Ala Ser Pro Ile Tyr Thr  
 345 350 355  
 atc att att atg atg gtt att tta tta ata ctt ggt atg ttc tta gat 2659  
 Ile Ile Ile Met Met Val Ile Leu Leu Ile Leu Gly Met Phe Leu Asp  
 360 365 370  
 tgg att ggt gtt gcc atg ttg act ttc ctc aag aca agt aaa gcg aca 2707  
 Trp Ile Gly Val Ala Met Leu Thr Phe Leu Lys Thr Ser Lys Ala Thr  
 375 380 385  
 atc aat ttg tgt ttt gac ata gtc agg tac agt att tgg cgt ggt ccc 2755  
 Ile Asn Leu Cys Phe Asp Ile Val Arg Tyr Ser Ile Trp Arg Gly Pro  
 390 395 400  
 tcc ttc cac agt acc aat gtt cat cgt ggt acc ttt gtc ggg cgc ggt 2803  
 Ser Phe His Ser Thr Asn Val His Arg Gly Thr Phe Val Gly Arg Gly  
 405 410 415  
 act ttt tagtaaatct tgcgcgatac gaataaacgc attgatggca tttgctcctg 2859  
 Thr Phe  
 tttgtggatc gactgcgcga tgagcagatt tgccaaaaa ttcaattaca tacttcccaa 2919  
 tcccttttct ttgtttaag ttccactta gattgcccag aagccgatct gctgtaatgg 2979  
 gaacaagtgt tataccaaga agcgaatcca acaggtgaag tggatgctgg tatggtgggt 3039  
 aaatacaactg aattaccgga tgcctacaaa tcggttaatg aagccttgaa acacgcaggc 3099  
 ttaaaaaacc gtcttagcgt gcaaatcaaa tatattgatt cacaagatgt ggaacccaaa 3159  
 ggcacagaag tgtagaagg cgt 3182  
 <210> 73  
 <211> 422  
 <212> PRT  
 <213> Pasteurella multocida  
 <400> 73  
 Met Pro His His Cys Cys Ser Phe Ser Thr Thr Tyr Ile Pro Ser His  
 1 5 10 15  
 Leu Tyr Lys Ile Ser Gly Gly Ile Ile Met Ile Ser Ala Phe Gly Ile  
 20 25 30  
 Gly Ile Gly Thr Leu Ile Ile Phe Leu Met Met Ile Ser Leu Leu Phe  
 35 40 45

WO 02/075507

PCT/US02/01971

Ile Gly Met Pro Leu Gly Phe Leu Thr Gly Leu Ile Ala Leu Val Ile  
 50 55 60  
 Ser Tyr Leu Trp Phe Asp Thr Thr Ala Ile Met Gln Met Ile Ala Ser  
 65 70 75 80  
 Arg Val Thr Asp Phe Thr Ser Ser Tyr Thr Phe Val Ala Val Pro Met  
 85 90 95  
 Phe Val Leu Met Ala Thr Leu Leu Asp Lys Thr Gly Ile Ala Arg Asp  
 100 105 110  
 Leu Tyr Asn Ala Met Arg Val Ile Gly Gly Arg Leu Arg Gly Gly Ile  
 115 120 125  
 Ala Ile Gln Ser Met Phe Val Ala Val Leu Leu Ala Thr Met Ser Gly  
 130 135 140  
 Ile Ile Gly Gly Glu Thr Val Leu Leu Gly Met Leu Ala Leu Pro Gln  
 145 150 155 160  
 Met Leu Arg Leu Gly Tyr Asn Lys Asn Leu Ala Ile Gly Thr Val Val  
 165 170 175  
 Ala Gly Gly Ala Leu Gly Thr Met Val Pro Pro Ser Ile Val Leu Ile  
 180 185 190  
 Ile Tyr Gly Met Thr Ala Asn Val Ser Ile Gly Glu Leu Phe Leu Ala  
 195 200 205  
 Ala Ile Pro Ala Ser Leu Leu Leu Ser Thr Phe Tyr Ile Leu Tyr Ile  
 210 215 220  
 Leu Val Leu Cys Tyr Phe Lys Pro Ser Tyr Gly Pro Ala Met Pro Ser  
 225 230 235 240  
 Ser Glu Asn His Thr Leu Thr Lys Glu Asp Ile Lys Lys Ile Ile His  
 245 250 255  
 Asp Ile Ala Ile Pro Val Ala Ile Ala Thr Trp Ile Leu Gly Ser Ile  
 260 265 270  
 Tyr Gly Gly Ile Ala Ser Ile Thr Glu Ser Ala Cys Val Gly Val Val  
 275 280 285  
 Gly Val Ile Leu Ala Ala Phe Tyr Arg Lys Glu Leu Asn Phe Lys Ile  
 290 295 300  
 Val Gln Glu Ser Leu Lys His Thr Ile Asn Thr Val Gly Met Ile Ile  
 305 310 315 320  
 Trp Val Gly Ile Gly Ala Thr Met Ile Ile Gly Ile Tyr Asn Leu Met  
 325 330 335  
 Gly Gly Asp Arg Phe Ile Ala Asn Leu Phe Ala Ser Leu Asp Ala Ser  
 340 345 350  
 Pro Ile Tyr Thr Ile Ile Ile Met Met Val Ile Leu Leu Ile Leu Gly  
 355 360 365  
 Met Phe Leu Asp Trp Ile Gly Val Ala Met Leu Thr Phe Leu Lys Thr  
 370 375 380

WO 02/075507

PCT/US02/01971

Ser Lys Ala Thr Ile Asn Leu Cys Phe Asp Ile Val Arg Tyr Ser Ile  
 385 390 395 400  
 Trp Arg Gly Pro Ser Phe His Ser Thr Asn Val His Arg Gly Thr Phe  
 405 410 415  
 Val Gly Arg Gly Thr Phe  
 420

<110> 74  
 <211> 2787  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (463)...(936)

<220>  
 <223> yhcJ

<400> 74  
 gttaacacac catgattaat gatgcccgtt gaagccaactg caacgtaatc gaattgtccg 60  
 gcatacaaa caagaatgtt ggcacagtgt tcatgcatcg cattggcagc atcagcttgt 120  
 ggcgttgcaa tctgttggcg ttgtctatt ttgcccctcg ttacaatagc cgaggcaatt 180  
 ttgtttccc caatatctaa tgcataaacag cgcataaggct ctctctctgt gatgacttat 240  
 ttgcccatt tgacggcacc ggcaaacacc cttaagatat gttcagaggc agtcagcgca 300  
 gatcctacgg tgacagagta agcaccacac tcaattggcg ttttcgcca ttctgggggtg 360  
 ttatagcgcc ctctgcccac cactcggcag ccagcagcat tcaaatcttt gactaactga 420  
 taatccggtt cagctggaat ttcaccgcca gtataaccag ac atg gtg cta cca 474  
 Met Val Leu Pro  
 1

ata att tct acc cct aag ttg tgg caa tac atc cct tct tca aaa tta 522  
 ile ile Ser Thr Pro Lys Leu Trp Gln Tyr Ile Pro Ser Ser Lys Leu  
 5 10 15 20

gaa caa tcc gcc atg gct aaa caa cct aat tct ttg att cgt tta ata 570  
 Glu Gln Ser Ala Met Ala Lys Gln Pro Asn Ser Leu Ile Arg Leu Ile  
 25 30 35

atg gct tca cgt gta gtt gga cgg acg cga tcc gta cca tca aaa gca 618  
 Met Ala Ser Arg Val Val Gly Arg Thr Arg Ser Val Pro Ser Lys Ala  
 40 45 50

ata ata tcc gcc cct gct gcg gct aac tct tca atg tct tgt aaa aat 666  
 ile ile Ser Ala Pro Ala Ala Ala Asn Ser Ser Met Ser Cys Lys Asn  
 55 60 65

ggg cta ata cga acg gga ctg tca ggt aaa tcc cgt tta acg ata cca 714  
 Gly Leu Ile Arg Thr Gly Leu Ser Gly Lys Ser Arg Leu Thr Ile Pro  
 70 75 80

ata atc ggt aca ttg acg acg tta cgc gtg gct ttt aaa ttt tcc atc 762  
 ile ile Gly Thr Leu Thr Thr Leu Arg Val Ala Phe Lys Phe Ser Ile

WO 02/075507

PCT/US02/01971

```

      85              90              95              100
cct tca ata cgt aac ccg gca gca cca ccg ata acg gat gct tgc gcc 810
Pro Ser Ile Arg Asn Pro Ala Ala Pro Pro Ile Thr Asp Ala Cys Ala
      105              110              115
atg gcg gca aca att tct ggc gag tcc att ggc cca tta tct acg ggc 858
Met Ala Ala Thr Ile Ser Gly Glu Ser Ile Gly Pro Leu Ser Thr Gly
      120              125              130
tgg caa gat gcg att aag cca tat tta att tgt tct aaa act tgc gga 906
Trp Gln Asp Ala Ile Lys Pro Tyr Leu Ile Cys Ser Lys Thr Cys Gly
      135              140              145
tgt gat agt ttt gac ata tta act cca gtc taaatttacc aaaagaagat 956
Cys Asp Ser Phe Asp Ile Leu Thr Pro Val
      150              155
tgactccaat ttgcataggt taactttaga attaaaaaat aacaaccaa ataataaaa 1016
tttgagatct ttgtcgcata tttattcata gggaaatagc agcttaattt tagttatgat 1076
ttgtcaatcc ttgctatttt ttgtgtttgc tggtttgca tacactgttc taatattgct 1136
ttgagcaact gataaccttg ctcatataaa tgaatccgt cggtaacaag gcgtaaatcc 1196
agttcaccgt tagaatcaca aaagtatttt tgtgtttcaa cgtaagtcac gtctgacgga 1256
caatgttgtt ttaaataggt attgagcctg tgaatttggt cgtttagtgac cgtaataac 1316
tgattgacg gtgtggcttc taataaaaag tagtgggacg taggagaaat ggtgtgtagg 1376
tgagtcagaa tgtcatttaa ctatcgcatg acttgcgccc gtgaatcgt ttcttctta 1436
caaatatcat tgacgcttaa aaaaagaaaa acagattgtc caagtgttg aatccgttta 1496
ggtttaacga taacatccaa atattgtcgc gtactgacgc cagaaagtec taaattgccc 1556
acggtttgtc ccgtaattg aggtgtgect gctacctgtt cgtcccacat gtcaaaaagt 1616
gaatgaccaa ttaagctgat attggcaggt ttgaaaatt ccgccatttt gctctgatag 1676
cgttgataaa tatcctgata acttagcatg tgtggacctc tattttgaaa taaaacgcta 1736
agtattatat aaaacctgat atgccggtaa acagtaaaact tatcttccgt aggggtaaat 1796
attcaatttt gtgacgaacc tatcatttat gaaataaaa ttcattttct atataaaaa 1856
tagttttttc actttagaat gccaaacgtg tgaatttat ttcatcatca ttttaacgta 1916
atcccaactg aaccaataga ggagaactca taatgaaatt taaaaaacta ctacttgcac 1976
ctttatgitt aggtgtttca gcttctgtat ttgcagcaga ttacgatctt aaattcgta 2036
tgggtgctgg tccaagctca aacgaatata aagcagtaga attcttttgcg aaagaagtga 2096
aagaaaaatc caatggcaaa attgatgtgg ctattttccc tagctcacag ttaggtgatg 2156
accgtgtgat gattaacaa ttaaaagacg gtgcattaga ctttacgta ggtgaatcag 2216
cacgtttcca aatttacttc ccagaagcag aagtatttgc gttgecttat atgattccta 2276
attttgaac ctctaaaaaa gcgttgcctg acacaaaatt tggtaagggt ttattgaaaa 2336

```



WO 02/075507

PCT/US02/01971

aaattgataa agagttaaac gtacaagtgt tatctgtggc gtataacggg acacgtcaaa 2396  
 caacttctaa ccgtgcaatc aacagcattg aagacatgaa agggttaaaa ttacgtgtac 2456  
 ctaacgcggc aaccaacctt gcttatgcaa aatacgtggg tgcagcgcca acaccaatgg 2516  
 cattctctga agtttacctt gcgcttcaaa caaactctgt ggatggtcaa gaaaacctat 2576  
 taccgacaat ccaagcacia aaattctatg aagtacaaaa atacctagcg ttaactaacc 2636  
 acatcttaaa tgaccaactt tacttaatca gtaacgatac gttggcagat ttaccagaag 2696  
 attacaaaa agtgggttaa gatgcagcag cgaagccgc tgeatatcac actaaactct 2756  
 tcgttgccgg tgagaacagc ttagtgaat t 2787

<210> 75  
 <211> 158  
 <212> PRT  
 <213> Pasteurella multocida

<400> 75  
 Met Val Leu Pro Ile Ile Ser Thr Pro Lys Leu Trp Gln Tyr Ile Pro  
 1 5 10 15  
 Ser Ser Lys Leu Gln Ser Ala Met Ala Lys Gln Pro Asn Ser Leu  
 20 25 30  
 Ile Arg Leu Ile Met Ala Ser Arg Val Val Gly Arg Thr Arg Ser Val  
 35 40 45  
 Pro Ser Lys Ala Ile Ile Ser Ala Pro Ala Ala Ala Asn Ser Ser Met  
 50 55 60  
 Ser Cys Lys Asn Gly Leu Ile Arg Thr Gly Leu Ser Gly Lys Ser Arg  
 65 70 75 80  
 Leu Thr Ile Pro Ile Ile Gly Thr Leu Thr Thr Leu Arg Val Ala Phe  
 85 90 95  
 Lys Phe Ser Ile Pro Ser Ile Arg Asn Pro Ala Ala Pro Pro Ile Thr  
 100 105 110  
 Asp Ala Cys Ala Met Ala Ala Thr Ile Ser Gly Glu Ser Ile Gly Pro  
 115 120 125  
 Leu Ser Thr Gly Trp Gln Asp Ala Ile Lys Pro Tyr Leu Ile Cys Ser  
 130 135 140  
 Lys Thr Cys Gly Cys Asp Ser Phe Asp Ile Leu Thr Pro Val  
 145 150 155

<210> 76  
 <211> 2787  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (1949)..(2785)

WO 02/075507

PCT/US02/01971

<220>  
<223> yiaO  
<400> 76  
gttaacacac catgattaat gatgccggtt gaagccactg caacgtaac gaattgtccg 60  
gcatacaaac caagaatggt gccagctgtg tcatgcatcg cattggcagc atcagctgtg 120  
ggcgttgcaa tctgttggcg ttgttctatt ttgccgtctg ttacaatagc cgaggcaatt 180  
tttgttccac caatatctaa tgcataaacag cgcataagct ctccttctgt gatgacttat 240  
tttgccgatt tgacggcatc ggcaaacccag cttacgatat gttcgaggcg agtcagcgca 300  
gatcctacgc tgacagagta agcaccacac tcaattgcgg ttttcgcaa ttctggggtg 360  
ttatagcgcc cttctgocat cactcggcag ccagcagcat tcaaatcttt gactaactga 420  
taatccggtt cagctggaat ttcaccgcca gtataaccag acatggtgct accaataatt 480  
tctaccocct agttgtggca atacatccct tcttcaaat tagaacaac cgccatggct 540  
aaacaacctt attctttgat tctttaata atggttccac gtgtagttgg acggacgca 600  
tcggtaccat caaaagcaat aatctggcg cctgctgagg ctaactcttc aatgctctgt 660  
aaaaatgggc taatacgaac gggactgtca ggttaactgc gtttaacgat accaataatc 720  
ggtacattga cgacgttacg cgtggctttt aaattttcga tcccttcaat acgtaaccgg 780  
gcagcaccac cgataacgga tgcttgccgc atggcgccaa caatttctgg cgagtcacat 840  
ggcccattat ctacgggctg gcaagatgcg attaagccat atttaatttg ttctaaaaac 900  
tgccggtgtg atagttttga catattaact ccagtctaaa tttatcaaaa gaagattgac 960  
tccaatttgc ataggttaat cttagaatta aaaaaataca accaaaataa taaaaatttg 1020  
agatctttgt cgcataatta ttcataggga atagacagct taattttagt tatgatttgt 1080  
caatccttgc tattttttgt gtttctggtt ttgcgataca ctgttctaat atgcttttga 1140  
gcacttgata accttctca ttaaaatgta atccgtcgtt acaaggcgtt aaatccagtt 1200  
caccgttaga atcacaacaa gatTTTTTgt tttcaacgta agtcaagctc gacggacaat 1260  
gttgttttaa ataggtattg agcctgtgaa tttgtgcgtt agtgaccgta ttaatctgat 1320  
tgaccggtgt ggcttctaat aaaaagtagt gggacgtagg agaaatggtg tgtagggtgag 1380  
tcagaatgac atttaactat cgcattgactt gcgcccgtga atacgtttct tccttcaaaa 1440  
tatcattgac gcctaaaaaa agaaaaacag attgtccaag ttgttgaac cgtttagggt 1500  
taacgataac atccaaatat tgcctgttac tgacgccaga aagtcctaaa ttggcgacgg 1560  
tttgtcccgc taattgaggt gtgcctgcta cctgttctgc ccacatgtca aaaagtgaat 1620  
gaccaattaa gctgatattg gcaggttttg aaaaatccgc cattttgctc tgatageggt 1680  
gataaatatc ctgatcactt agcatgtgtg gacctctatt ttgaaataaa acgctaagta 1740  
ttatataaaa cctgatatgc cggtaaacag taaacttacc ttcctagggg gtaaatattc 1800

WO 02/075507

PCT/US02/01971

aattttgtga cgaacctatc atttatgaaa taaaacttca ttttctatat aaaaaatagt 1860  
tttttcaact tagaatgcc aacgtgtgaa atttatttca tcatcatttt aacgtaatcc 1920  
caacgtaacc aatagaggag aactcata atg aaa ttt aaa aaa cta cta ctt 1972  
Met Lys Phe Lys Lys Leu Leu Leu  
1 5  
gca tct tta tgt tta ggt gtt tca gct tct gta ttt gca gca gat tac 2020  
Ala Ser Leu Cys Leu Gly Val Ser Ala Ser Val Phe Ala Ala Asp Tyr  
10 15 20  
gat ctt aaa ttc ggt atg gtt gcg ggt cca agc tca aac gaa tat aaa 2068  
Asp Leu Lys Phe Phe Gly Met Val Ala Gly Pro Ser Ser Asn Glu Tyr Lys  
25 30 35 40  
gca gta gaa ttc ttt gcg aaa gaa gtg aaa gaa aaa tcc aat ggc aaa 2116  
Ala Val Glu Phe Phe Ala Lys Glu Val Lys Glu Lys Ser Asn Gly Lys  
45 50 55  
att gat gtg gct att ttc cct agc tca cag tta ggt gat gac cgt gtg 2164  
Ile Asp Val Ala Ile Phe Pro Ser Ser Glu Leu Gly Asp Asp Arg Val  
60 65 70  
atg att aaa caa tta aaa gac ggt gca tta gac ttt acg tta ggt gaa 2212  
Met Ile Lys Gln Leu Lys Asp Gly Ala Leu Asp Phe Thr Leu Gly Glu  
75 80 85  
tca gca cgt ttc caa att tac ttc cca gaa gca gaa gta ttt gcg ttg 2260  
Ser Ala Arg Phe Gln Ile Tyr Phe Pro Glu Ala Glu Val Phe Ala Leu  
90 95 100  
cct tat atg att cct aat ttt gaa acc tct aaa aaa gcg ttg ctc gac 2308  
Pro Tyr Met Ile Pro Asn Phe Glu Thr Ser Lys Lys Ala Leu Leu Asp  
105 110 115 120  
aca aaa ttt ggt caa ggt tta ttg aaa aaa att gat aaa gag tta aac 2356  
Thr Lys Phe Gly Gln Gly Leu Leu Lys Lys Ile Asp Lys Glu Leu Asn  
125 130 135  
gta caa gtg tta tct gtg gcg tat aac ggt aca cgt caa aca act tct 2404  
Val Gln Val Leu Ser Val Ala Tyr Asn Gly Thr Arg Gln Thr Thr Ser  
140 145 150  
aac cgt gca atc aac agc att gaa gac atg aaa ggg tta aaa tta cgt 2452  
Asn Arg Ala Ile Asn Ser Ile Glu Asp Met Lys Gly Leu Lys Leu Arg  
155 160 165  
gta cct aac gcg gca acc aac ctt gct tat gca aaa tac gtg ggt gca 2500  
Val Pro Asn Ala Ala Thr Asn Leu Ala Tyr Ala Lys Tyr Val Gly Ala  
170 175 180  
gcg cca aca cca atg gca ttc tct gaa gtt tac ctt gcg ctt caa aca 2548  
Ala Pro Thr Pro Met Ala Phe Ser Glu Val Tyr Leu Ala Leu Gln Thr  
185 190 195 200  
aac tct gtg gat ggt caa gaa aac cca tta cgg aca atc caa gca caa 2596  
Asn Ser Val Asp Gly Gln Glu Asn Pro Leu Pro Thr Ile Gln Ala Gln  
205 210 215  
aaa ttc tat gaa gta caa aaa tac tta gcg tta act aac cac atc tta 2644  
Lys Phe Tyr Glu Val Gln Lys Tyr Leu Ala Leu Thr Asn His Ile Leu  
220 225 230

WO 02/075507

PCT/US02/01971

```

aat gac caa ctt tac tta atc agt aac gat acg ttg gca gat tta cca 2692
Asn Asp Gln Leu Tyr Leu Ile Ser Asn Asp Thr Leu Ala Asp Leu Pro
235 240 245

gaa gat tta caa aaa gtg gtt aaa gat gca gca gcg aaa gcc gct gaa 2740
Glu Asp Leu Gln Lys Val Val Lys Asp Ala Ala Lys Ala Ala Glu
250 255 260

tat cac act aaa ctg ttc gtt gac ggt gag aac agc tta gtt gaa tt 2787
Tyr His Thr Lys Leu Phe Val Asp Gly Glu Asn Ser Leu Val Glu
265 270 275

<210> 77
<211> 279
<212> PRT
<213> Pasteurella multocida

<400> 77
Met Lys Phe Lys Lys Leu Leu Leu Ala Ser Leu Cys Leu Gly Val Ser
1 5 10 15
Ala Ser Val Phe Ala Ala Asp Tyr Asp Leu Lys Phe Gly Met Val Ala
20 25 30
Gly Pro Ser Ser Asn Glu Tyr Lys Ala Val Glu Phe Phe Ala Lys Glu
35 40 45
Val Lys Glu Lys Ser Asn Gly Lys Ile Asp Val Ala Ile Phe Pro Ser
50 55 60
Ser Gln Leu Gly Asp Asp Arg Val Met Ile Lys Gln Leu Lys Asp Gly
65 70 75 80
Ala Leu Asp Phe Thr Leu Gly Glu Ser Ala Arg Phe Gln Ile Tyr Phe
85 90 95
Pro Glu Ala Glu Val Phe Ala Leu Pro Tyr Met Ile Pro Asn Phe Glu
100 105 110
Thr Ser Lys Lys Ala Leu Leu Asp Thr Lys Phe Gly Gln Gly Leu Leu
115 120 125
Lys Lys Ile Asp Lys Glu Leu Asn Val Gln Val Leu Ser Val Ala Tyr
130 135 140
Asn Gly Thr Arg Gln Thr Thr Ser Asn Arg Ala Ile Asn Ser Ile Glu
145 150 155 160
Asp Met Lys Gly Leu Lys Leu Arg Val Pro Asn Ala Ala Thr Asn Leu
165 170 175
Ala Tyr Ala Lys Tyr Val Gly Ala Ala Pro Thr Pro Met Ala Phe Ser
180 185 190
Glu Val Tyr Leu Ala Leu Gln Thr Asn Ser Val Asp Gly Gln Glu Asn
195 200 205
Pro Leu Pro Thr Ile Gln Ala Gln Lys Phe Tyr Glu Val Gln Lys Tyr
210 215 220
Leu Ala Leu Thr Asn His Ile Leu Asn Asp Gln Leu Tyr Leu Ile Ser
225 230 235 240

```

WO 02/075507

PCT/US02/01971

Asn Asp Thr Leu Ala Asp Leu Pro Glu Asp Leu Gln Lys Val Val Lys  
 245 250 255

Asp Ala Ala Ala Lys Ala Ala Glu Tyr His Thr Lys Leu Phe Val Asp  
 260 265 270

Gly Glu Asn Ser Leu Val Glu  
 275

<210> 78  
 <211> 2590  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (908)..(1294)

<220>  
 <223> yjgF

<400> 78  
 ctgcaggctc gattagtggg gcaccgaaag aaaaaacctg gcaaattatt cacgccgcag 60  
 aacagcagcc acgcggttat tacacgggga tttttgtct gtccgatggt gagtcgttac 120  
 aaagtgcggt ggcaattcgt tttattgagc aagtggacga gaaattgatt ttccgcagcg 180  
 gtggcgggat tacgatctta agcgagctag aagacgagta ccaagaattg atccaaaag 240  
 tgtatgtacc agtaggataa gcgatgacat ttcttttatt tgagacgac gctattgtga 300  
 acggtgaaat tcagcaacct gccctgcac aacaacgta tcggccaagt ttggcgacct 360  
 tttacggcga gaaaggagcg aaagtacagg atcttgcgaa aattattcag attccgaccy 420  
 cacttgaaca cactcaacat gcgcccataa tccgtgtcgc gattgattac aatcagcaag 480  
 actgtgacgt gcattatctt cactatcaac gcaaaattta ccgcactttt cagcctgtca 540  
 ttgcyatga aattaactat gatctgaaat atgctgatcg ggcattatta aatcagttat 600  
 ttgctcagcg tagggattgt gatgagatta tgattatcaa acacggcaag gtgacggatt 660  
 gcagtattgg taatctggtg ttccgccaag gtgagcaatg gttcacgcca gatagcccg 720  
 tattttacgg cacacaacga gcctggttat tacaacaagg caaaattcaa gcccgttcca 780  
 tcttattgca agagatcgca caatttgaag aaattcgggt aattaatgca ctaaatccgc 840  
 tgtaaatctt ccttgaacag cgtaaaataa acaactttt tcagtcagat aaaaggagat 900  
 aaacgac atg acg aaa gta att cat act gac aat gca cca gcc gcc att 949  
 Met Thr Lys Val Ile His Thr Asp Asn Ala Pro Ala Ala Ile  
 1 5 10

ggg cct tat gta caa gcg gta gat tta ggt aat atg ctg tta acc tct 997  
 Gly Pro Tyr Val Gln Ala Val Asp Leu Gly Asn Met Leu Leu Thr Ser  
 15 20 25 30

ggg caa att cca gtg aat cca aaa acc ggt gaa gtg cca gcg gat atc 1045  
 Gly Gln Ile Pro Val Asn Pro Lys Thr Gly Glu Val Pro Ala Asp Ile

WO 02/075507

PCT/US02/01971

```

          35          40          45
gta gca caa gca cgt caa tgg tta gaa aac gtg aaa gcg att gtg gaa 1093
Val Ala Gln Ala Arg Gln Ser Leu Glu Asn Val Lys Ala Ile Val Glu
          50          55          60
caa gcg gga tta caa gtc gca aat atc gtg aaa acc acg gtg ttt gtg 1141
Gln Ala Gly Leu Gln Val Ala Asn Ile Val Lys Thr Thr Val Phe Val
          65          70          75
aaa gat tta aat gac ttt gca g g gtc aat gcg gag tat gaa cgt ttc 1189
Lys Asp Leu Asn Asp Phe Ala Ala Val Asn Ala Glu Tyr Glu Arg Phe
          80          85          90
ttt aaa gag aac aat cac cct agc ttc cct gct cgt tca tgt gtg gaa 1237
Phe Lys Glu Asn Asn His Pro Ser Phe Pro Ala Arg Ser Cys Val Glu
          95          100          105          110
gtg gca cgt ttg cgg aaa gat gtg ggg att gaa atc gag gca atc gct 1285
Val Ala Arg Leu Pro Lys Asp Val Gly Ile Glu Ile Glu Ala Ile Ala
          115          120          125
gta aaa gcc taatgaatag cttgcattta tcttagtcgt agcaaaaaca 1334
Val Lys Ala
tctcttttca cttgctctct tcaaaagcaag ttgataagtg atttttattg ggcgttrttc 1394
tattgatagc caaaaacgccc ctttactgat agagaataaa ctatgcaaaa tcaagtcctc 1454
gagattctac aataccgttt aaaaccacaa tcaggacaaa cgtttcaaca aattatgcgt 1514
gagatcagtg ttccactcca taaacaacat gggattgatg tcattgcgta tggaaattca 1574
ttacatgata ttgacagcta ttatttaac cgtgcatttg agacagaaac caaattgcaa 1634
cagcagctcg atgcttttta tgccagtgat gattggcgtg atggaccaag agaaagtatc 1594
atcgctga ttgaaagcag ttaaaaatcg gtgatcatgc tcccgacaca ggcaatccat 1754
gcactacgca accattatcc tcaataaaat caacaaccgc acccaatcag tgcggtcatt 1814
tttttact tttcagtc taagggaaaa acaacgatag tggacgttgt ttaatcaatt 1874
tccaaacaca ttgocgata tcaacccaac tctcaatttc tgtttctaaa gaacgcagcg 1934
caaccataa cgcgataaag aaactgacaa tcaaatcac cataccaatc aataacacga 1994
acactaaacc ttgtaagaac atctgccaag taaacgcgcc actgatcgcc atatagccca 2054
aattgcgaga agaaaacgccc acatggcgaa tatctaacgg taaattaagc aaataccgca 2114
ctaaccctgt taaaccaagc aataaaccaa aacacagatt tcccataatc gaaccgtaat 2174
tatcatgcca gtattctgca aatttgtagc gcataattacg ggtcaacaga cggcgtaaaa 2234
tagggtgatt tcttagtcgc attttaagt tcaataaatt actacgatta tcaaaaatac 2294
cagaaataat cccagaaaag aataaccaga aaccgcgaat ggcggcaaac cataaggacc 2354
ctttcatcgg atcaagggat tttgttgggt aggcaatctc cgcgtcactc aataaagggtg 2414
taccaacata atgttgatag cctagcgcaa gcaacaacgc cacagaatc gctaaagtga 2474

```

WO 02/075507

PCT/US02/01971

cattaccctaa gactgccact gtttgogagc gaaacacac gatcagcagt tgagctaatt 2534  
 cgagattaac ggatttgctt tgcattat ccaccgttcc tgcaaaact gctgca 2590

<210> 79  
 <211> 129  
 <212> PRT  
 <213> Pasteurella multocida

<400> 79  
 Met Thr Lys Val Ile His Thr Asp Asn Ala Pro Ala Ala Ile Gly Pro  
 1 5 10 15  
 Tyr Val Gln Ala Val Asp Leu Gly Asn Met Leu Leu Thr Ser Gly Gln  
 20 25 30  
 Ile Pro Val Asn Pro Lys Thr Gly Glu Val Pro Ala Asp Ile Val Ala  
 35 40 45  
 Gln Ala Arg Gln Ser Leu Glu Asn Val Lys Ala Ile Val Glu Gln Ala  
 50 55 60  
 Gly Leu Gln Val Ala Asn Ile Val Lys Thr Thr Val Phe Val Lys Asp  
 65 70 75 80  
 Leu Asn Asp Phe Ala Val Asn Ala Glu Tyr Glu Arg Phe Phe Lys  
 85 90 95  
 Glu Asn Asn His Pro Ser Phe Pro Ala Arg Ser Cys Val Glu Val Ala  
 100 105 110  
 Arg Leu Pro Lys Asp Val Gly Ile Glu Ile Glu Ala Ile Ala Val Lys  
 115 120 125  
 Ala

<210> 80  
 <211> 6642  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (463)..(1884)  
 <220>  
 <223> y1eA  
 <400> 80  
 aaccagctc agataagttt aattctgctt atggaaagt gaccaaattc ttcgatctcc 60  
 caggtttcta aggcgogata cgggcaaata cgagtatttt cgtatactg ccaagcacct 120  
 agttgtttta agagattaac ggaagcaaca ctgatcgag aaatcggaag atcgtaaaggc 180  
 gaattaggtt gaaactgtgg gagtggggcg ttttcgataa gctggacttg atgctcttgt 240  
 ttaagtaagc caagcgcaaa ggctgcacca accatgcacc cgccaaccac gatcatgtct 300  
 ttttgatga cgtccatagg attttcttt tcttttggtt acgtattcta ccgtcaatga 360

WO 02/075507

PCT/US02/01971

```

gggaattcca aaagaaatct ctttttttagc tagccagcat aggttcaaga ctgtaaaata 420
gtcagtcaca tttttatagg ttaactgaat tttttaaacg at atg acg caa aaa 474
Met Thr Gln Lys
1
tta cat att aaa acg tgg ggt tgt cag atg aat gaa tat gat tca tct 522
Leu His Ile Lys Thr Trp Gly Cys Gln Met Asn Glu Tyr Asp Ser Ser
5 10 15 20
aaa atg gca gat ctc tta aac agt act cac ggc tta gag tta aca gaa 570
Lys Met Ala Asp Leu Leu Asn Ser Thr His Gly Leu Glu Leu Thr Glu
25 30 35
att ccg gaa gaa gcg gat gtg tta ttg tta aac act tgc tca att cgt 618
Ile Pro Glu Glu Ala Asp Val Leu Leu Leu Asn Thr Cys Ser Ile Arg
40 45 50
gaa aaa gca caa gaa aaa gtt ttc cat caa tta gga cgt tgg aaa gaa 666
Glu Lys Ala Gln Glu Lys Val Phe His Gln Leu Gly Arg Trp Lys Glu
55 60 65
tta aag aaa cat aag ccg gga ctc gtt atc ggt gtt ggg ggc tgt gtt 714
Leu Lys Lys His Lys Pro Gly Leu Val Ile Gly Val Gly Gly Cys Val
70 75 80
gcc tca caa gaa gga gaa cac att cgt act cgt gct cct tat gtc gat 762
Ala Ser Gln Glu Gly Glu His Ile Arg Thr Arg Ala Pro Tyr Val Asp
85 90 95 100
att att ttt gga cca caa acc tta cat cgt tta cct gaa atg atc aat 810
Ile Ile Phe Gly Pro Gln Thr Leu His Arg Leu Pro Glu Met Ile Asn
105 110 115
cag atc aga ggt ggt aaa agc tca gta gtc gat gtc agt ttt cca gaa 858
Gln Ile Arg Gly Gly Lys Ser Ser Val Val Asp Val Ser Phe Pro Glu
120 125 130
att gaa aaa ttc gac cgt tta cca gaa ccg cgt gca gaa ggt cca act 906
Ile Glu Lys Phe Asp Arg Leu Pro Glu Pro Arg Ala Glu Gly Pro Thr
135 140 145
gct ttc gta tcc att atg gaa ggc tgt aat aaa tat tgc tca ttc tgt 954
Ala Phe Val Ser Ile Met Glu Gly Cys Asn Lys Tyr Cys Ser Phe Cys
150 155 160
gtc gtg cct tat acg cgt ggt gaa gaa gtc agt cgt cca gtg gat gat 1002
Val Val Pro Tyr Thr Arg Gly Glu Glu Val Ser Arg Pro Val Asp Asp
165 170 175
gta tta ttt gaa att gca cag ttg gca gag caa ggc gtg cgt gaa gtg 1050
Val Leu Phe Glu Ile Ala Gln Leu Ala Glu Gln Gly Val Arg Glu Val
185 190 195
aat tta tta gga caa aac gtg aac gct tat cgt ggt gca act cat gat 1098
Asn Leu Leu Gly Gln Asn Val Asn Ala Tyr Arg Gly Ala Thr His Asp
200 205 210
gac ggt att tgt act ttt gcg gaa ttg tta cgt tta gta gcc gct att 1146
Asp Gly Ile Cys Thr Phe Ala Glu Leu Leu Arg Leu Val Ala Ala Ile
215 220 225
gat ggt att gac cgt tta cgt ttt acc acc agt cac cca att gag ttc 1194

```



WO 02/075507

PCT/US02/01971

Asp Gly Ile Asp Arg Leu Arg Phe Thr Thr Ser His Pro Ile Glu Phe  
 230 235 240  
 act gat gac att att gat gtg tac cgt gat acg cca gag ttg gtg agt 1242  
 Thr Asp Asp Ile Ile Asp Val Tyr Arg Asp Thr Pro Glu Leu Val Ser  
 245 250 255 260  
 ttc tta cac tta cct gta caa agt ggt tct gat cgt gtg tta tct atg 1290  
 Phe Leu His Leu Pro Val Gln Ser Gly Ser Asp Arg Val Leu Ser Met  
 265 270 275  
 atg aaa cgc aat cat acg gca tta gaa tat aaa tcg att att cgg aag 1338  
 Met Lys Arg Asn His Thr Ala Leu Glu Tyr Lys Ser Ile Ile Arg Lys  
 280 285 290  
 tta aga gcg gtg cgt cca gag att caa att agc tca gat ttt att gtc 1386  
 Leu Arg Ala Val Arg Pro Glu Ile Gln Ile Ser Ser Asp Phe Ile Val  
 295 300 305  
 ggt ttc ccg ggc gaa aca gca gaa gat ttc gag caa acc atg aat tta 1434  
 Gly Phe Pro Gly Glu Thr Ala Glu Asp Phe Glu Gln Thr Met Asn Leu  
 310 315 320  
 att gca caa gta aat ttt gat atg agt ttc agc ttc att tat tca gca 1482  
 Ile Ala Gln Val Asn Phe Asp Met Ser Phe Ser Phe Ile Tyr Ser Ala  
 325 330 335 340  
 cgt cca ggc acg cca gca gca gat atg cct gat gat gtg aca gaa gaa 1530  
 Arg Pro Gly Thr Pro Ala Ala Asp Met Pro Asp Asp Val Thr Glu Glu  
 345 350 355  
 gag aag aaa caa cgt tta tat gtg ttg caa caa cgc att aac aat caa 1578  
 Glu Lys Lys Gln Arg Leu Tyr Val Leu Gln Gln Arg Ile Asn Asn Gln  
 360 365 370  
 gcc gcg caa ttt agt cga gca atg tta ggc aca gaa cag cgc gtg tta 1626  
 Ala Ala Gln Phe Ser Arg Ala Met Leu Gly Thr Glu Gln Arg Val Leu  
 375 380 385  
 gtg gaa gga ccc tcg aaa aaa gat tta atg gaa ctc aca ggg cgt aca 1674  
 Val Glu Gly Pro Ser Lys Lys Asp Leu Met Glu Leu Thr Gly Arg Thr  
 390 395 400  
 gaa act aat cgt atc gtc aat ttt gtg ggc acg cct gat atg att ggg 1722  
 Glu Thr Asn Arg Ile Val Asn Phe Val Gly Thr Pro Asp Met Ile Gly  
 405 410 415 420  
 aag ttt gtt gat atc aag atc acg gat gtg ttt act aac tca ctg cgt 1770  
 Lys Phe Val Asp Ile Lys Ile Thr Asp Val Phe Thr Asn Ser Leu Arg  
 425 430 435  
 ggt gaa gtc gtt aga act gaa gaa caa atg gga ctt cgc gtt gtt caa 1818  
 Gly Glu Val Val Arg Thr Glu Glu Gln Met Gly Leu Arg Val Val Gln  
 440 445 450  
 tcg cca caa atg gtg att aat cgt act cgt aaa gaa gat gaa ctc ggc 1866  
 Ser Pro Gln Met Val Ile Asn Arg Thr Arg Lys Glu Asp Glu Leu Gly  
 455 460 465  
 gtg gga cgt tat cac gcg tagtctgct atcccttcaa atatttaacc 1914  
 Val Gly Arg Tyr His Ala  
 470

WO 02/075507

PCT/US02/01971

gcctccgagt ttctcaagag cgggttattt ttatgaaaa tttttgataa attgaccgct 1974  
ctttttattg ctccatttta tgatagacag cgggttttct gttattcact gtatttcctt 2034  
ttatttcaact tcattaataa attattaat ttcaattgct tatcaaaatt gttgtttttt 2094  
gcttttttct tatttatagc atggttattt ttatatacaca catggcgat ttctccatat 2154  
ttttacaaa aactgtgact tcaactaacc tattgttctc tctgtcttta ctccatttta 2214  
taaggcgggt agtttagatc atgttgtttt tacaacatat tttagaggtt ttgaaggtt 2274  
gagcttattt tatagttgag gtgatgatga aaaaatttaa tctagtata ttggcgttgt 2334  
ccatatcaag tctgtactc acatccacat tgacctttgg tcaaatccag caacaagata 2394  
aagcactctt tgggtgaaa gaacatcaag aaagcctact ctttcatcag agcttagtag 2454  
aacaaggtag tgataatgtg ccaatttggc gcattccgct ttatttaaga acaaaagacg 2514  
gtgtattaat tgccgccgca gataagcgtt ggcaacacgc tgggtgactgg ggcgatattg 2574  
ataccgcaat ccgaattagt catgatgat ggaaaacatg gggaaatatt acaacgattt 2634  
tggatttgcc atcaagaat ggggaaaaat ccccatcagc accagatcct gtaacattca 2694  
acgctggggg agatagacaa aattgtacaa ctactgttaa ttctgttttt ttgatcgatg 2754  
ctcagatggt acaagataaa cgtaatggtt gaattttttt agcagttgat atgtttgcgc 2814  
atggagcagg tttttttggt gtaaaagaca gtgtaattgg cgcattaat attgatggtt 2874  
aacagatccc tattttaaat gaaaagcaat cgggtcgaca ttgaacctg tgttctaac 2934  
tctttcaact gctcaacggt caccggaatc acgcggtcaa taaaagtccg ttccagttt 2994  
aaaccgggtt gaacaatagc gtgtaattca ccaaaacgca tcaccacgcc acgttctgct 3054  
tctttgacag tataaaaaacc gctaacgccc cagacaattg caccaatcac cgttcaatt 3114  
ggcaataat taccagatt taacgatcca ccagaatgog agttattgcy ttaccgcca 3174  
ttccctgaac cgcctaattt ttccagcaga ttattaaaaa tctcttcaat atcaggtggt 3234  
gattgctctt gattgttttg cttacgacct gactggttat cattccaatt cggctgacgc 3294  
ccctcattat caggacgctg actctcaggt tttttctgct cgggtttgccc ccaaggatct 3354  
tgatctgaac cgttcaatga cattaagttc tccatttctc aaaaaattgt tactgttta 3414  
aacaatccc cacagtctaa acaaaatggt ggattaaagc taacgaaact cgttactaaa 3474  
tggggatatt ttttatgatt taaagtgcgc ccaataaaaa cgcacaatgg tctcattttt 3534  
acggettact acctgacttt tgctctatcg ctttgcgggt catgtttttt cattcacctt 3594  
ataataaatg cgtcgtgta aggtggttcc cgctaattt cccctctgcc aagtaaaata 3654  
gtgcacatct aagcactgtg tttggttaat aaaaaagcc aagtaaaagc gcaagcgggtg 3714  
actaaagagg agttaactaa gtttctgtat gctagcgtac tattgactct tcttgcactg 3774  
tgtttgggtt ttattcgggt gaatgaaacc ctagcgtgta tttctttggt attgttggct 3834

WO 02/075507

PCT/US02/01971

tatttaagcg ttagccgagt attatttgcg ctccgctgtg tggcggatg catgaatttg 3894  
agctattact attatctctt gtagtacctt ttattacata aatcttctt actcatggga 3954  
gtaggcatcg ttctggcact agttacgctt gttttatcac gttataacaa ggcaccgcag 4014  
gcaacattac aagctgaatc gccacaatcg tttaaccac aaacaatgtt acgtaaaaa 4074  
ctaggattca ctttgttggc gacatgtttg attgcttttg ccacgaatta tactattcat 4134  
aaatatgaag atattttaac gaatggtgag tcaattattt taaaaacggc acccgttgat 4194  
ccgcttccct tgatgcaagg ggattatag acgttgaact atgaaatctt ggcagacatt 4254  
agtgagggaat ggggaaaaaa tttagaagag gaaaaaacac agtattttgt ttatgcgttg 4314  
ttaaaccgag acagcotaag gattgctacc ttgtgtcgtc ttgaaaccaa agcaccctaca 4374  
acatttgacg ggtgtacacc aaatatttac ttaccggtga atgtcgcgat gtggtggccg 4434  
cgtttaccaa gtcaagacta cttttttgoc gagggaaaag gtgaatatta tgcacaagct 4494  
gaatgtccg aatctcgtt taaaggggga aaagcgttgt tgtccgctt actagataaa 4554  
aatttaaaag cattataaaa caaaagccg tagtgaaccg cctttatggt gtatgccact 4614  
tacttcaccg caatcattga gccaaaatta aagcattgaa accataatc cacttgttga 4674  
aaaccgactt cagctaaacg calttttatg gottgaatgc tgtctgtaey catcacattt 4734  
tcaagtccg tgctttttg gctgacttca agttcactg atccattcgc gcgtttaa 4794  
tgatgatgta aatcaatcaa caagccattc atgttttgat ctcaaaatg aaatttctcg 4854  
gatagtacca agatcccatt cggttgtaag ccttggtaaa tcttacttaa taaggctcga 4914  
cgatcttcag gtggcagaaa ttgcaaatg aaatttaaaa ttaccatgaa ggcattttcg 4974  
atctcgatat ggogtatatc atcacaaata atgtccacag gtattgtact ttgataggca 5034  
ctaactgctt ggcgacaacg atcgaccatg ggttgtgagt tatcaacacc aatgatcttg 5094  
acgcccgggtt gattaatatg acgaogtga gataatgltg ccgcaaccgc cgagcaccoc 5154  
agatcataga cgttgcattt cgcgtaaca aagcgtgatg ccaacatccc aatagcggta 5214  
atgatgttg catagccggg aatagagcgt tggatcatgt cgggaaagac ttcagctacg 5274  
ctttcatcaa aagtaaaatc ccccaattta gcaatgggga gtcgaaaata gagtatcttt 5334  
tgtcataatg tattaagac cgagaaaaag tgcggtcatt ttagaagaay ttccgaccta 5394  
tcacaaataa attatgattt cgggaataaa tgcgcatgg cactttcttc ttgtttaata 5454  
cgcacgcta ggataagcaa ataaatgggt aatccaatca atgcggtata ttttgccttg 5514  
cagaaaagcg ataaaccaat taactcggga ataatgtta agaataaatt cgggtgacgt 5574  
acgtatttaa acaagaaga gcggttaatg tgatgtccg gtaaaatgta aagttttact 5634  
gtccaaatct ctttcagttc ataaatcag taaaatgca tggcgtatgc aaagactaaa 5694  
atcgcaccgc ctatttgtga ggtgctatta aatgctgtgt tttggttatt agcttcaatg 5754

WO 02/075507

PCT/US02/01971

atcgccgga gataaaatac aacatgggca atggataaca gcgtagaatt gcgtrttacca 5814  
 tattgtattg caccttttgc aatcaatgct ttttcatggc ggattgaaat agacagacta 5874  
 taaaaacgga tcgctaaaat acaggcaaaa gtgatattga taataacat gtggttatcc 5934  
 ttaacataat tttattccaa taaagtggcg taatataaca aaaaatccga tgatatggca 5994  
 tggaaatagc cctttatctt gaacgttcat cgettttctt tttctttatt ggttgatttg 6054  
 taagcataaa taaccttttt atctctcttg gttttccgct ataattgagt gaatttttga 6114  
 gcataattaa gaggtaaaag gattttgaaa tgatgctgac acattattgc ggtgcattaa 6174  
 accgtgacaa tatcggacaa gaagtaacat tgagtgggtg ggtgcatcgt cgcctgatt 6234  
 taggtgggtt aatttttatt gatatgctg atcgtgaagg gattgtacaa gtgtgtttcg 6294  
 atccaatata tcaagaagca ctaccacag cagcaagttt acgtaatgag ttttgatttc 6354  
 aaattaaagg cgaagtgatt gcccgcccag ataataaat caacaaaaat atggcaacag 6414  
 gcgaagtgga agtgttagca aaatccctgt ctattataa cagcgagag ccattacctc 6474  
 tcgactttaa ccaaaataat acggaagaac agcgttttaa ataccgttat ttagacttac 6534  
 gtcgcccaga aatggcgcaa cgtttaaaaa cacgagccaa aattaccagc tttgtgcgtc 6594  
 gctttatgga cgaacatggt ttcttagata ttgaaacacc gatgttga 6642

<210> 81  
 <211> 474  
 <212> PRT  
 <213> Pasteurella multocida

<400> 81  
 Met Thr Gln Lys Leu His Ile Lys Thr Trp Gly Cys Gln Met Asn Glu  
 1 5 10 15  
 Tyr Asp Ser Ser Lys Met Ala Asp Leu Leu Asn Ser Thr His Gly Leu  
 20 25 30  
 Glu Leu Thr Glu Ile Pro Glu Glu Ala Asp Val Leu Leu Leu Asn Thr  
 35 40 45  
 Cys Ser Ile Arg Glu Lys Ala Gln Glu Lys Val Phe His Gln Leu Gly  
 50 55 60  
 Arg Trp Lys Glu Leu Lys Lys His Lys Pro Gly Leu Val Ile Gly Val  
 65 70 75 80  
 Gly Gly Cys Val Ala Ser Gln Glu Gly Glu His Ile Arg Thr Arg Ala  
 85 90 95  
 Pro Tyr Val Asp Ile Ile Phe Gly Pro Gln Thr Leu His Arg Leu Pro  
 100 105 110  
 Glu Met Ile Asn Gln Ile Arg Gly Gly Lys Ser Ser Val Val Asp Val  
 115 120 125  
 Ser Phe Pro Glu Ile Glu Lys Phe Asp Arg Leu Pro Glu Pro Arg Ala  
 130 135 140

WO 02/075507

PCT/US02/01971

Glu Gly Pro Thr Ala Phe Val Ser Ile Met Glu Gly Cys Asn Lys Tyr  
 145 150 155 160  
 Cys Ser Phe Cys Val Val Pro Tyr Thr Arg Gly Glu Glu Val Ser Arg  
 165 170 175  
 Pro Val Asp Asp Val Leu Phe Glu Ile Ala Gln Leu Ala Glu Gln Gly  
 180 185 190  
 Val Arg Glu Val Asn Leu Leu Gly Gln Asn Val Asn Ala Tyr Arg Gly  
 195 200 205  
 Ala Thr His Asp Asp Gly Ile Cys Thr Phe Ala Glu Leu Leu Arg Leu  
 210 215 220  
 Val Ala Ala Ile Asp Gly Ile Asp Arg Leu Arg Phe Thr Thr Ser His  
 225 230 235  
 Pro Ile Glu Phe Thr Asp Asp Ile Ile Asp Val Tyr Arg Asp Thr Pro  
 245 250 255  
 Glu Leu Val Ser Phe Leu His Leu Pro Val Gln Ser Gly Ser Asp Arg  
 260 265 270  
 Val Leu Ser Met Met Lys Arg Asn His Thr Ala Leu Glu Tyr Lys Ser  
 275 280 285  
 Ile Ile Arg Lys Leu Arg Ala Val Arg Pro Glu Ile Gln Ile Ser Ser  
 290 295 300  
 Asp Phe Ile Val Gly Phe Pro Gly Glu Thr Ala Glu Asp Phe Glu Gln  
 305 310 315 320  
 Thr Met Asn Leu Ile Ala Gln Val Asn Phe Asp Met Ser Phe Ser Phe  
 325 330 335  
 Ile Tyr Ser Ala Arg Pro Gly Thr Pro Ala Ala Asp Met Pro Asp Asp  
 340 345 350  
 Val Thr Glu Glu Glu Lys Lys Gln Arg Leu Tyr Val Leu Gln Gln Arg  
 355 360 365  
 Ile Asn Asn Gln Ala Ala Gln Phe Ser Arg Ala Met Leu Gly Thr Glu  
 370 375 380  
 Gln Arg Val Leu Val Glu Gly Pro Ser Lys Lys Asp Leu Met Glu Leu  
 385 390 395 400  
 Thr Gly Arg Thr Glu Thr Asn Arg Ile Val Asn Phe Val Gly Thr Pro  
 405 410 415  
 Asp Met Ile Gly Lys Phe Val Asp Ile Lys Ile Thr Asp Val Phe Thr  
 420 425 430  
 Asn Ser Leu Arg Gly Glu Val Val Arg Thr Glu Glu Gln Met Gly Leu  
 435 440 445  
 Arg Val Val Gln Ser Pro Gln Met Val Ile Asn Arg Thr Arg Lys Glu  
 450 455 460  
 Asp Glu Leu Gly Val Gly Arg Tyr His Ala  
 465 470

165

WO 02/075507

PCT/US02/01971

```

<210> 82
<211> 4835
<212> DNA
<213> Pasteurella multocida

<220>
<221> CDS
<222> (407)..(1156)

<220>
<223> yojB

<400> 82
gtcaacgacg gggcgggtct tagaacattg gcatacgggt acgatgacac gccgtgtccc 60
agagctccat cgtcccttcc caaataactt ggtttgatg caccattag atgcgaaaaa 120
acgtggttta cgtcatggcg ataaagttaa gatcagctca cgtcgtggcg aaatgatttc 180
tcacttagat acccgtggac gtaataaagt cccacaaggc tttagttaca ccactttctt 240
ttgatgcaggc cagttagcaa actatctcac tttagatgcg acagacccaa ttcaaaaaga 300
aacggacttc aaaaaatgtg cggtcaagt ggaaaaagcg taacacgtta aatttaatga 360
ggaacgaccg cacittgctt tcagtaaagt gcggttgaaa agtcga atg aaa aza 415
                                     Met Lys Lys
                                     1

aca gtt gtg aat cct gaa cgt cgt cga ttt ttt aaa gag gct acg cgc 463
Thr Val Val Asn Pro Glu Arg Arg Arg Phe Phe Lys Glu Ala Thr Arg
      5          10          15

act gca ggc ggg ttg gca ggg gtg act ttg etc ctt ggt ttg caa caa 511
Thr Ala Gly Gly Leu Ala Gly Val Thr Leu Leu Leu Gly Leu Gln Gln
      20          25          30          35

aag cag agt ctt gcg cgc gaa ggc gtg gcg tta cgc cca cct ttt gcc 559
Lys Gln Ser Leu Ala Arg Glu Gly Val Ala Leu Arg Pro Pro Phe Ala
      40          45          50

ctt gag aat gag aaa gcg ttt tct gct gcg tgc att cgt tgt ggt cag 607
Leu Glu Asn Glu Lys Ala Phe Ser Ala Ala Cys Ile Arg Cys Gly Gln
      55          60          65

tgt gta caa gcc tgt cca cat gag atg ttg cat ctt gcc tca ctg att 655
Cys Val Gln Ala Cys Pro His Glu Met Leu His Leu Ala Ser Leu Ile
      70          75          80

tca ccg atg gaa gca ggt aca ccg tat ttc att gcg cgc gat aag ccc 703
Ser Pro Met Glu Ala Gly Thr Pro Tyr Phe Ile Ala Arg Asp Lys Pro
      85          90          95

tgt gaa atg tgt gtg gat att cct tgt gca aaa gcc tgc cca acc ggt 751
Cys Glu Met Cys Val Asp Ile Pro Cys Ala Lys Ala Cys Pro Thr Gly
      100          105          110          115

gca ttg gat aat caa gca aca gaa atc gat gat gcg cgt atg ggg tta 799
Ala Leu Asp Asn Gln Ala Thr Glu Ile Asp Asp Ala Arg Met Gly Leu
      120          125          130

gct gtc ctg cta gat cat gaa act tgt ctg aac tgg caa ggt tta cgc 847
Ala Val Leu Leu Asp His Glu Thr Cys Leu Asn Trp Gln Gly Leu Arg

```

WO 02/075507

PCT/US02/01971

```

135          140          145
tgt gat gtg tgt tat cgc gtc tgt ccg ctg att aat aaa gcg att acg 895
Cys Asp Val Cys Tyr Arg Val Cys Pro Leu Ile Asn Lys Ala Ile Thr
150          155          160
tta gtg atg cat cgt aat gag cgt acg ggt aag cac gcc gtc ttt atc 943
Leu Val Met His Arg Asn Glu Arg Thr Gly Lys His Ala Val Phe Ile
165          170          175
cca aca gtg cat tcc gaa gcc tgt aca gga tgt gcc aaa tgt gaa gaa 991
Pro Thr Val His Ser Glu Ala Cys Thr Gly Cys Gly Lys Cys Glu Glu
180          185          190
gct tgc gtt cta gaa gaa gcg gca atc aaa gtg tta ccg atg gca tta 1039
Ala Cys Val Leu Glu Glu Ala Ala Ile Lys Val Leu Pro Met Ala Leu
200          205          210
gcg aaa gcc atg tta ggt aaa cat tac cgt tta ggt tgg gaa gag aaa 1087
Ala Lys Gly Met Leu Gly Lys His Tyr Arg Leu Gly Trp Glu Glu Lys
215          220          225
gaa aaa gcc ggg cat tcc ctt gcg cca gaa gcc att att tct ctc ccg 1135
Glu Lys Ala Gly His Ser Leu Ala Pro Glu Gly Ile Ile Ser Leu Pro
230          235          240
act cgg tta ccg gag agc ttg taatggcaaa ttcaccaaaa tatcgaggta 1186
Thr Arg Leu Pro Glu Ser Leu
245          250
aagaagcacg agaaaagtta ggtcgtggt acgccaatcg cttttgttc tggcagcgtt 1246
taeccagct gagtattctt gccatgtttt taagcggacc ttattttggg gtgtggatct 1306
tgaaggcaa ttacagtagt agtcttttgc ttgattgat cccgatgact gatcctttga 1366
ttatggcaga aagtctcgcg accggtttta tgcccaecat gaccgcgttg ttgggtgccc 1426
tgattgtggt ggtgctttat gccattttag ggagtcgcgt tttctgtct tgggtttgtc 1486
cgttaaacat cgtgacagat gcgtccgctt ggctcagacg taaattagaa attcgtcaat 1546
cggcaaaact cccacgaagt ttaagctatg ccatcttagt gatgattttg ttaggcagtg 1606
cgctaagcgy gttattactt tgggaatggc tcaatccggt tgcagcaacta ggtcgtgctg 1666
taatttacgy tttcgtgcy acagtttggc ttgttcttcg ggtgttttta tttgattat 1726
ttattgtcga gcatggttgg tgtgggcatt tatgccaat aggtgcagcc tatggtgtga 1786
ttggtgcgaa aggacttttt cgtatcaaaag ttgagcatcg ccaacaatgt gataattgca 1846
tggattgcta taacgtctgt ccagaaccac aagtgttacg cgatccatta catgcaaaaa 1906
agaglyaaag cccacttgtg ctttcaaaag attgtatcag ctgtggacgt tgtatcgacg 1966
ttgcccctga aaaagtattt atttttacaa cagatttaa tcattcagtt aatcattcgg 2026
gggagtgatc aaaatgaaaa aaacaatgct aattttgacc gcactttttg ccttcacggt 2086
caatgccaat gaagtcaaaag tgggcaaaag tttacaagat tcacctgaaa atatcgcgcc 2146
agccttccac aatacaccaa aagaaaagtgg cttggcgcgg ttaactatg tgaaccaacc 2206

```

WO 02/075507

PCT/US02/01971

accgatggtg ccacacgca cgaaaaacta tcaggtgacg aaaaatatca accaatgttt 2266  
 aacttgtcat agcccagaag cctcactgt tactggtgca acacgeatca gtccaaccca 2326  
 ctttatggat cgtgatgta acattgtcgg aggcacctca cctcgccgtt acttctgttt 2386  
 acaatgccat gtctctcaat ctgatgtga gccgattatt caaaatgaat ttaaaccgat 2446  
 ggctggtttt ggtaaataag ttaaggacgg aactatgttg aacttaatta aacgcttttg 2506  
 gaaaaggttt cgtcgcacca gtctgattgc cgttggtacc ttgattacce ttgctttat 2566  
 tgcaggtatt gtctcttggg ttgggtttaa ttatggctta gagcaaacca atacagagga 2626  
 attctgtgtt agttgtcaca gtaatgatgt gtatccagaa tatttacata cggcgcatta 2686  
 ttaaatcgc agtggagtaa aagccacttg tctgtattgc catgtaccgc acgaatttat 2746  
 tccaaaaatg atccgtaaag tccaagccag tcgagaagtg tatgcgcac ttatgggta 2806  
 tacggatacc attgataaat ttaactcccg tcgtttgcat atggcagAAC gtgaatggg 2866  
 acgattaaaa gccaat.aact cgcaggaatg ccgtaactgc cataactttg agaatatgga 2926  
 ttttagtcag caaaaaacgg tggcggaaaa aatgcattgca cttgctataa aagaagaaaa 2986  
 aactgtatt gactgtcaca aagggtattg gcaccaatta ccgatatga gcggtgttga 3046  
 gtccgggtttt agtacggaac aaaaataaca cttttctgt tctcccacag gaaatctga 3106  
 tcttattcag gtgcagattt ttttttttt acgatcatcc tcacaacctt ttegtgata 3166  
 aataggatac aacgctagct acacgctatc ttgctgtttt ttgtgtgtt gtgagggtt 3226  
 atctcatctt atctgcctct tttattactg ttgttcaaaa ttccgcgttt gggttcgtg 3286  
 gcgatccagc gtttattgga gcacatcagt ccagcggaat taatggaata tgatacaaaa 3346  
 gcccttcaac agataggctg gacggcacaag cagattcagc gttggtttac gcctgagaac 3406  
 cgttatattg atcccgogtt agcctgggta aacgaacaac aacatattgt ggattggttt 3466  
 gatctcatt atctccctt gttaaagcaa acagaagagc caccacttgt cttgtttgtg 3526  
 aaaggggaaag tggctacgct atctgcacag caagtggcga tegtggcag tegtattgt 3586  
 tcacgttatg gggaaactg ggcataatat ttcccaactc aactggctta tgccgatatt 3646  
 gtggtgacca gtggtttage gttaggattt gatggtttct cacatcaagc ggtagtggat 3706  
 atccaagga agacyattgc agtattaggc agtggtttag aggtcatta tccgaaaaaa 3766  
 caccaggtt tagccgaaaa aattattgaa catcaaggtg cgttagtgc tgaattttta 3826  
 cctttcaac cccctgtggc agaaaatttt ccacgtcgt atcgcattat tagtggttta 3886  
 tctttgggga cattagtcac tgaagcctca gaaaacagt gtcttttaac tactgcccgc 3946  
 tatgcttag agcaaaatcg agatgttttt gcgttaccgg ggcagattca gcatggatt 4006  
 agccaaggtt gcaataaact gattaaacag gggcaatat tagtcgaaag tattcaggat 4066  
 attttagaac atctctgcc ttattcgcac tgtgccatgc cagcgttgc tegtacggag 4126



WO 02/075507

PCT/US02/01971

aacgcctttt ctcaacaagt aacagacaca tcaaccatca atactgcgcg gataacgcca 4186  
 gaacatcggg aattatatgc caaaattggc tatatgcccg tcagtattga tgtattagcc 4246  
 caacaagtca atctacctat tgatacctta ttagtacagc ttttaacctt ggaattgcaa 4306  
 gacttgattg ttgctgaaaa tggattatat cagcgcaaat aacggaaaga gtaaccacaa 4366  
 atgagaaagg actgtgttga aacggotatc aacatcagtc cttgcagtat attatctcat 4426  
 atgacacgag acggcagttt catgagatta atagagacta aacgcttgya aatcggtag 4486  
 tttgcctcgt tgtagcattt tctcaatatt gcctttgtga tcatcacgac ctaagcctcg 4546  
 tagctcaata ttgataccaa tacttttgtc ataaaaaatt tgattcgcgc tttggttttc 4606  
 tttgctggtc acactacgtc gggcaaccaac attaatcgcc caacagcaag tgctgtattc 4666  
 tagtcccaaa tattgctcaa caggctttct caacgcaaga tcttgataat gacgtgctac 4726  
 caaccgccat tgatccgtga gtgcccatgc cacagttaga ccaagctggt ttatgtcttg 4786  
 tccgtagcgg ttccgcgctg aggtgaggtt ttggtcaata tattgttga 4835

<210> 83  
 <211> 250  
 <212> PRT  
 <213> Pasteurella multocida

<400> 83  
 Met Lys Lys Thr Val Val Asn Pro Glu Arg Arg Phe Phe Lys Glu  
 1 5 10 15  
 Ala Thr Arg Thr Ala Gly Gly Leu Ala Gly Val Thr Leu Leu Leu Gly  
 20 25 30  
 Leu Gln Gln Lys Gln Ser Leu Ala Arg Glu Gly Val Ala Leu Arg Pro  
 35 40 45  
 Pro Phe Ala Leu Glu Asn Glu Lys Ala Phe Ser Ala Ala Cys Ile Arg  
 50 55 60  
 Cys Gly Gln Cys Val Gln Ala Cys Pro His Glu Met Leu His Leu Ala  
 65 70 75 80  
 Ser Leu Ile Ser Pro Met Glu Ala Gly Thr Pro Tyr Phe Ile Ala Arg  
 85 90 95  
 Asp Lys Pro Cys Glu Met Cys Val Asp Ile Pro Cys Ala Lys Ala Cys  
 100 105 110  
 Pro Thr Gly Ala Leu Asp Asn Gln Ala Thr Glu Ile Asp Asp Ala Arg  
 115 120 125  
 Met Gly Leu Ala Val Leu Leu Asp His Glu Thr Cys Leu Asn Trp Gln  
 130 135 140  
 Gly Leu Arg Cys Asp Val Cys Tyr Arg Val Cys Pro Leu Ile Asn Lys  
 145 150 155 160  
 Ala Ile Thr Leu Val Met His Arg Asn Glu Arg Thr Gly Lys His Ala  
 165 170 175

WO 02/075507

PCT/US02/01971

Val Phe Ile Pro Thr Val His Ser Glu Ala Cys Thr Gly Cys Gly Lys  
 180 185 190  
 Cys Glu Glu Ala Cys Val Leu Glu Glu Ala Ala Ile Lys Val Leu Pro  
 195 200 205  
 Met Ala Leu Ala Lys Gly Met Leu Gly Lys His Tyr Arg Leu Gly Trp  
 210 215 220  
 Glu Glu Lys Glu Lys Ala Gly His Ser Leu Ala Pro Glu Gly Ile Ile  
 225 230 235 240  
 Ser Leu Pro Thr Arg Leu Pro Glu Ser Leu  
 245 250

<210> 84  
 <211> 3494  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <221> CDS  
 <222> (2411)..(2719)

<220>  
 <223> yyaM

<400> 84  
 gtcaacgatac cgaatcagac ggaagaaaac tatatgcaag tcatttatgg caagactgag 60  
 cgtctattcg aagctgogac goattgogcc gcgatacttg ctcatgagc ggaagcccaa 120  
 gaaaatgctt tacgcaata tggttgttat ctaggcacag cttttcaatt agtcgatgat 180  
 attttagatt atagtgcaga tgcaaaagca ctggcmetaa atattggtga tgatttagcg 240  
 gaaggtaaac caacattacc gttattacac gccatgcac acggcaatcc agcacaagca 300  
 aaattgatcc gogaagcgat tgagcaagg ggtaacgctg atattttaga ggatgtactg 360  
 acaattatga cagaacataa atccctogac tatgcgatga tgcgcgctaa acaagaagca 420  
 caaaaagcgg ttgatgogat tgcattattg cctgaaaatg aatataaaca agcgttaatt 480  
 tcatttagctt acctatcogt ogatogcgtt tattaaccac ttaataaggc gagacatggt 540  
 agcgtaacga ccgctaaaag tgcggtcatt tatttagtaa ttttaaacac gacaatgaca 600  
 gaacaaaaca tccctacgaa aaaaacacgc aaaggcaaaag atcctcaagc gccctttgta 660  
 cgcgaaaaat tatccctacc aaatgggcat aacaaattgt tattgcattc ttgtgtgag 720  
 cctgtctcgg gagaagtaat ggaggcaatt catgctcrag gtattgaatt tactatttac 780  
 ttctacaacc caaacattca cccattaaaa gaatatctca ttcgtaaaaga aaaaaatatt 840  
 cgttttgagg aaaaatgggg cattccggtt attgatgccc attatgatcg tcaagaatgg 900  
 tttgaccgtg ccaaaggcat ggaagatgag ccagagcgtg gtattcgttg cactatgtgc 960  
 tttgatatgc gttttgaaaa agccgcagaa tatgcacaca acaatggttt ccccgatatt 1020

WO 02/075507

PCT/US02/01971

```

actagctgct taggtatttc acgttggaac gacatgaacc aaatcaacgg ttgtggacac 1080
cgtgccgcgc aaaaatatga tgatgtatgt tattgggatt ataactggcg taaagtggt 1140
ggctcacaac gtagattga aatcagtaag cgtgaacgtt ttaccagca agaattatgc 1200
ggttgtgtgt attctttgcg tgacacgaat aaatggcgtg aagcaaacgg acgcaaaaa 1260
attgaaattg gcaaatgtta ttattccgcc gattaaaaa accaagtaaa ccatcgtgcc 1320
gtcatataac atggcggcac ttttttaggc tttatatatg caacgttttc gccaatcttt 1380
cgaacctaac tgctaaccgc tcttcaacta ttttaaatgc tggggcaaaa cgcaatacat 1440
taggaccgcg cactaaaatc attaagccat tatctgctgc tttttgaca aattcgtcgc 1500
ctcttcgctg atattgctgc ataatctctg caccaattaa caaaccttcg ccacggattt 1560
ctttaataa gccacattgc tgattaattt cttgcagctt ttgcataaat ttttcagaag 1620
tgcgctgaat tttttgcaag aatggtggtg ctgaaatgat atcaatcact ttttctgcca 1680
cggcacaagc gagaggattg ccacaaaagg tgggtccatg cagccaggtt gcaaaacttt 1740
tggcgatctc atgcgttgtc aacgaatgag aaaattgtga cagattgggc tccaacggga 1800
cgtcggatg agattgggga tacgcaagta cgttatgaaa ttgagcaggt gagttctagc 1860
aattatagtg cactgtttgt ctccatttta cagatgaaac gtaatgaggt ggtatttagt 1920
ccacatttag cggataaaca acgttatagt tctgatcgtc tgaaccaact bgttggtgaa 1980
ttagatcgtc ctatcgttaa acaagtcctg gatttgaata acagcggatt gatgcccaatt 2040
cagctctgat tcggtacgga cagtaatggg cgtactgctc tctgttagg cgcacccttt 2100
aatcatcgtt ggacaaaact aggacaagtt ttaccgcagc ttgaatttga tattaagat 2160
gaaattatgt gtcgtggggt aaggagttta aaataccgtc cagctggagc aaaaagttag 2220
tggtygccaat ttggtcgtgc tgaaggcagt agcggactga aaacaggtac ctattttatg 2280
cagttaagcg ccttagggaa gcaaatgctg gtggtgatga ccgatgatga tggcaatgcg 2340
ttatctgggg agcaagctca ggcgctttat caagcattac aaaatctctt agcgaataa 2400
tacagtcaag atg act aaa ctg agt atc cag cga gat aac ttg att tgt 2449
Met Thr Lys Leu Ser Ile Gln Arg Asp Asn Leu Ile Cys
1 5 10
ttg agt tat gtc gca tta atg gga ttc ggc ttt ccc att atg cgt tat 2497
Leu Ser Tyr Val Ala Leu Met Gly Phe Gly Phe Pro Ile Met Arg Tyr
15 20 25
atg agt att cat ttt gat aca tta aat aat aac gct gtt cgc ttt ctg 2545
Met Ser Ile His Phe Asp Thr Leu Asn Asn Asn Ala Val Arg Phe Leu
30 35 40 45
tca ggg ggc agc gtt ttt att tta gcc tgt ttt ttt tat tat cgc gct 2593
Ser Gly Gly Ser Val Phe Ile Leu Ala Cys Phe Phe Tyr Tyr Arg Ala
50 55 60
gag tta aca tct tcg ggg gct ggc gtc cag tcc gtt gcg atg ttg ccg 2641

```

WO 02/075507

PCT/US02/01971

Glu Leu Thr Ser Ser Gly Ala Gly Val Gln Ser Val Ala Met Leu Pro  
                   65                  70                  75  
 agt tca agt tta ggt ttc tta ata ttg aaa act gta cca tet ttt tca 2689  
 Ser Ser Ser Leu Gly Phe Leu Ile Leu Lys Thr Val Pro Ser Phe Ser  
                   80                  85                  90  
 tac gtt aca atc tca aca ctt aat cgc gtt tgacctccg attttgata 2739  
 Tyr Val Thr Ile Ser Thr Leu Asn Arg Val  
                   95                  100  
 gtcaaagact actgagtaac gctttagtc gcgtgaatcg actgttacat aagccgatat 2799  
 gtcagaataa gtactgccgg tatatcgtct taatctaaga ttaagcttgc cacttttgtt 2859  
 cgataaagcg tcaaacgaaa gcacgacttt accgtccttg acttccacct gatcttcaat 2919  
 gagcaactga cttagtgcga ccaatcgacc gttggcagtc agtgctgcaa tgccctgata 2979  
 cgtatcaagc gttacacgcg tattttttcc ccagttttta ttgagctttt cactatgttt 3039  
 cagtaagttt ctgccaccaa tctgcaactg attaaacctt gcttcaagcg tttcactctt 3099  
 gactgcaagc gacttggttt cattgctaac cgtctgctca agtgcctgta ttttggatgc 3159  
 taaatctaac ttagtgtcat tgacttcac cgtccattct gactttaat cttttctcgc 3219  
 aagtgaagcc acttcatctt tgctagcttt cgtttctttt aagtcagaaa tgccactagt 3279  
 atttgagcc actttagaat cgagcgttcc tagttttgta gagaagatt tgtctttttc 3339  
 gctagccgtt ttttgaatta gctgtatttc actttcctc aatccaactc tagcagttag 3399  
 actgtctagc ttgtcagcag tagatttatt cacagctcct tgtgattgct tgtgttgaat 3459  
 aatatccgcg cttacttccg agatagccac gtcca 3494  
  
 <210> 85  
 <211> 103  
 <212> PRT  
 <213> Pasteurella multocida  
  
 <400> 85  
 Met Thr Lys Leu Ser Ile Gln Arg Asp Asn Leu Ile Cys Leu Ser Tyr  
   1                  5                  10                  15  
 Val Ala Leu Met Gly Phe Gly Phe Pro Ile Met Arg Tyr Met Ser Ile  
                   20                  25                  30  
 His Phe Asp Thr Leu Asn Asn Asn Ala Val Arg Phe Leu Ser Gly Gly  
                   35                  40                  45  
 Ser Val Phe Ile Leu Ala Cys Phe Phe Tyr Tyr Arg Ala Glu Leu Thr  
                   50                  55                  60  
 Ser Ser Gly Ala Gly Val Gln Ser Val Ala Met Leu Pro Ser Ser Ser  
                   65                  70                  75                  80  
 Leu Gly Phe Leu Ile Leu Lys Thr Val Pro Ser Phe Ser Tyr Val Thr  
                   85                  90                  95  
 Ile Ser Thr Leu Asn Arg Val

WO 02/075507

PCT/US02/01971

100

<210> 86  
<211> 19  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: PRIMER  
  
<400> 86  
aggccggtagc cggccgcct 19  
  
<210> 87  
<211> 19  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: PRIMER  
  
<400> 87  
cggccggtagc cggcctagg 19  
  
<210> 88  
<211> 18  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 88  
catggtacc attctaac 18  
  
<210> 89  
<211> 18  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: primer  
  
<400> 89  
ctaggTacct acaacctc 18  
  
<210> 90  
<211> 119  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<221>  
<222>  
<223> Description of Artificial Sequence: transposon  
insert  
  
<220>

173

WO 02/075507

PCT/US02/01971

<221> misc\_feature  
<222> 25  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 27  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 29  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 31  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 33  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 35  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 37  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 39  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 41  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 43  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 45  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 47  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 49  
<223> N = A or T or G or C

WO 02/075507

PCT/US02/01971

<220>  
<221> misc\_feature  
<222> 51  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 53  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 55  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 57  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 59  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 61  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 63  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 65  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 67  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 69  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 71  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 73  
<223> N = A or T or G or C

WO 02/075507

PCT/US02/01971

<220>  
<221> misc\_feature  
<222> 75  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 77  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 79  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 81  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 83  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 85  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 87  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 89  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 91  
<223> N = A or T or G or C

<220>  
<221> misc\_feature  
<222> 93  
<223> N = A or T or G or C

<400> 90  
ctaggtacct acaacctcaa gcttnknknk nknknknknk nknknknknk nknknknknk 60  
nknknknknk nknknknknk nknknknknk nknkaagctt ggttagaatg ggtaccatg 119

<210> 91  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer



WO 02/075507

PCT/US02/01971

<400> 91 tacctacaac ctcaagct	18
<210> 92 <211> 18 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: primer	
<400> 92 taccattct aaccaagc	18
<210> 93 <211> 19 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: primer	
<400> 93 tacctacaac ctcaagctt	19
<210> 94 <211> 20 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: primer	
<400> 94 taccattct aaccaagctt	20
<210> 95 <211> 19 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: primer	
<400> 95 ggcagagcat tacgtgac	19
<210> 96 <211> 27 <212> DNA <213> Artificial Sequence	
<220> <223> Description of Artificial Sequence: primer	
<400> 96 gtaccggcca ggcggccacg cgtattc	27

WO 02/075507

PCT/US02/01971

<210> 97  
 <211> 531  
 <212> DNA  
 <213> Actinobacillus pleuropneumoniae

<220>  
 <223> atpG

<400> 97  
 tgttgagcct ggttagtag ggtcgaagg cgtaagcctt taccaaaatc taggcttaa 60  
 cgtgagatct caagtaacgg gattaggcga taatccggaa atggaacgta tcgtggcgc 120  
 agttaatgaa atgattaatg cgtccgaaa cggagaagtg gatcggttt acgtcgctta 180  
 caaccgtttt gaaaatacga tgcacaaaa acctgttacc gcacagttac tccggttacc 240  
 taaactagat gacgatgaat tagatacgaag aggttcattg gattatattt atgaaccgaa 300  
 tccacaagtt ttattggata gtttacttgt tcgttattta gaaactcagg tataccaagc 360  
 agttgatgat aacctagcct ctgaacaaag cgctcgaatg gtagcgatga aagccgcaac 420  
 agataatgcg ggtacattaa tcgatgaatt acaattagtg tataacaaag ctgcaccaagc 480  
 aagcattaca atgaattaa acgaaattgt tgcgggtgcc gcagcaattt a 531

<210> 98  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer

<400> 98  
 tctccattcc cttgctgagg cacce 25

<210> 99  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer

<400> 99  
 ggattacagc cggatccggg 20

<210> 100  
 <211> 1034  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <223> cap5E

<220>  
 <221> CDS  
 <222> (1)..(1032)

WO 02/075507

PCT/US02/01971

```

<400> 100
atg ttt aaa aat aaa aca ctt tta att aca ggt gga acg ggt tct ttt 48
Met Phe Lys Asn Lys Thr Leu Leu Ile Thr Gly Gly Thr Gly Ser Phe
1 5 10 15
ggt aat gct gta ctc aaa cgt ttc tta gaa aca gat att cga gaa att 96
Gly Asn Ala Val Leu Lys Arg Phe Leu Glu Thr Asp Ile Arg Glu Ile
20 25 30
cgt gtt ttt tcg cgt gat gag aag aaa caa gat gac atg cgg aaa aaa 144
Arg Val Phe Ser Arg Asp Glu Lys Lys Gln Asp Asp Met Arg Lys Lys
35 40 45
tat aat gat gca aaa tta aaa ttt tat att ggc gat gtt cgt gac tac 192
Tyr Asn Asp Ala Lys Leu Lys Phe Tyr Ile Gly Asp Val Arg Asp Tyr
50 55
gat agt att tta aat gcc tcg cga ggt gtt gac tat att tat cat gct 240
Asp Ser Ile Leu Asn Ala Ser Arg Gly Val Asp Tyr Ile Tyr His Ala
65 70 75 80
gcc gca tta aag caa gtg cct tca tgc gag ttt tat ccg tta gag gca 288
Ala Ala Leu Lys Gln Val Pro Ser Cys Glu Phe Tyr Pro Leu Glu Ala
85 90 95
gtg aaa acc aat att tta ggt acg gca aat gtc tta gaa gcc gcc atc 336
Val Lys Thr Asn Ile Leu Gly Thr Ala Asn Val Leu Glu Ala Ala Ile
100 105 110
caa aac cag ata aaa cgc gtc gtc tgt ctt agc aca gat aaa gcg gtg 384
Gln Asn Gln Ile Lys Arg Val Val Cys Leu Ser Thr Asp Lys Ala Val
115 120 125
tac cca att aat gcg atg gcc att tct aaa gca atg atg gaa aaa gtc 432
Tyr Pro Ile Asn Ala Met Gly Ile Ser Lys Ala Met Met Glu Lys Val
130 135 140
atc atc gca aaa tcg cgt aac cta gaa gcc aca cca acg aca atc tgt 480
Ile Ile Ala Lys Ser Arg Asn Leu Glu Gly Thr Pro Thr Thr Ile Cys
145 150 155 160
tgt act cgc tat gcc aat gtc atg gca tcg cgt ggt tcg gtt atc cca 528
Cys Thr Arg Tyr Gly Asn Val Met Ala Ser Arg Gly Ser Val Ile Pro
165 170 175
tta ttt gtc gat caa ata cgt caa gcc aag cct ttt act att act gat 576
Leu Phe Val Asp Gln Ile Arg Gln Gly Lys Pro Phe Thr Ile Thr Asp
180 185 190
cct gag atg aca cgc ttt atg atg aca ttg gaa gat gct gtg gat tta 624
Pro Glu Met Thr Arg Phe Met Met Thr Leu Glu Asp Ala Val Asp Leu
195 200 205
gtc cta tat gca ttt aaa aat ggt caa aat ggt gat gtt ttt gta caa 672
Val Leu Tyr Ala Phe Lys Asn Gly Gln Asn Gly Asp Val Phe Val Gln
210 215 220
aaa gcc ccc gca gca acc att ggt acc ctt gcc aaa gca att acc gaa 720
Lys Ala Pro Ala Ala Thr Ile Gly Thr Leu Ala Lys Ala Ile Thr Glu
225 230 235 240
tta tta tct gtc cca aat cac cct att tcc att ata ggt acg cgt cat 768
Leu Leu Ser Val Pro Asn His Pro Ile Ser Ile Ile Gly Thr Arg His

```

WO 02/075507

PCT/US02/01971

```

                245                250                255
gga gag aaa gca ttc gaa gct tta tta agc cgt gaa gaa atg gtt cat 816
Gly Glu Lys Ala Phe Glu Ala Leu Leu Ser Arg Glu Glu Met Val His
                260                265                270
gca att aat gaa ggt aat tat tat cgc atc cca gcc gat caa cgc agt 864
Ala Ile Asn Glu Gly Asn Tyr Tyr Arg Ile Pro Ala Asp Gln Arg Ser
                275                280                285
tta aat tac agt aaa tat gtc gaa aaa ggg gaa cca aaa att acc gaa 912
Leu Asn Tyr Ser Lys Tyr Val Glu Lys Gly Glu Pro Lys Ile Thr Glu
                290                295                300
gtc acc gac tac aac tca cat aat act gag cgt ttg act gtc aag gaa 960
Val Thr Asp Tyr Asn Ser His Asn Thr Glu Arg Leu Thr Val Lys Glu
                305                310                315
atg aag cag tta ctg ctt aaa ctt gaa ttc ata cag aaa atg att gag 1008
Met Lys Gln Leu Leu Leu Lys Leu Glu Phe Ile Gln Lys Met Ile Glu
                325                330                335
ggc gaa tac atc tca ccg gag gta ta 1034
Gly Glu Tyr Ile Ser Pro Glu Val
                340

```

<210> 101  
 <211> 344  
 <212> PRT  
 <213> Pasteurella multocida

```

<400> 101
Met Phe Lys Asn Lys Thr Leu Leu Ile Thr Gly Gly Thr Gly Ser Phe
 1                    5                    10                    15
Gly Asn Ala Val Leu Lys Arg Phe Leu Glu Thr Asp Ile Arg Glu Ile
 20                    25                    30
Arg Val Phe Ser Arg Asp Glu Lys Lys Gln Asp Asp Met Arg Lys Lys
 35                    40                    45
Tyr Asn Asp Ala Lys Leu Lys Phe Tyr Ile Gly Asp Val Arg Asp Tyr
 50                    55                    60
Asp Ser Ile Leu Asn Ala Ser Arg Gly Val Asp Tyr Ile Tyr His Ala
 65                    70                    75                    80
Ala Ala Leu Lys Gln Val Pro Ser Cys Glu Phe Tyr Pro Leu Glu Ala
 85                    90                    95
Val Lys Thr Asn Ile Leu Gly Thr Ala Asn Val Leu Glu Ala Ala Ile
100                    105                    110
Gln Asn Gln Ile Lys Arg Val Val Cys Leu Ser Thr Asp Lys Ala Val
115                    120                    125
Tyr Pro Ile Asn Ala Met Gly Ile Ser Lys Ala Met Met Glu Lys Val
130                    135                    140
Ile Ile Ala Lys Ser Arg Asn Leu Glu Gly Thr Pro Thr Thr Ile Cys
145                    150                    155                    160

```

WO 02/075507

PCT/US02/01971

Cys Thr Arg Tyr Gly Asn Val Met Ala Ser Arg Gly Ser Val Ile Pro  
165 170 175  
Leu Phe Val Asp Gln Ile Arg Gln Gly Lys Pro Phe Thr Ile Thr Asp  
180 185 190  
Pro Glu Met Thr Arg Phe Met Met Thr Leu Glu Asp Ala Val Asp Leu  
195 200 205  
Val Leu Tyr Ala Phe Lys Asn Gly Gln Asn Gly Asp Val Phe Val Gln  
210 215 220  
Lys Ala Pro Ala Ala Thr Ile Gly Thr Leu Ala Lys Ala Ile Thr Glu  
225 230 235 240  
Leu Leu Ser Val Pro Asn His Pro Ile Ser Ile Ile Gly Thr Arg His  
245 250 255  
Gly Glu Lys Ala Phe Glu Ala Leu Leu Ser Arg Glu Glu Met Val His  
260 265 270  
Ala Ile Asn Glu Gly Asn Tyr Tyr Arg Ile Pro Ala Asp Gln Arg Ser  
275 280 285  
Leu Asn Tyr Ser Lys Tyr Val Glu Lys Gly Glu Pro Lys Ile Thr Glu  
290 295 300  
Val Thr Asp Tyr Asn Ser His Asn Thr Glu Arg Leu Thr Val Lys Glu  
305 310 315 320  
Met Lys Gln Leu Leu Lys Leu Glu Phe Ile Gln Lys Met Ile Glu  
325 330 335  
Gly Glu Tyr Ile Ser Pro Glu Val  
340

<210> 102  
<211> 4931  
<212> DNA  
<213> Pasteurella multocida  
<220>  
<223> fhaB2  
<220>  
<221> CDS  
<222> (1)..(4929)

<220>  
<221> misc\_feature  
<222> 1632  
<223> Xaa = any or unknown amino acid

<400> 102  
atg aac aaa aat cgt tac aaa ctc att ttt agt caa gtc aaa ggt tgt 48  
Met Asn Lys Asn Arg Tyr Lys Leu Ile Phe Ser Gln Val Lys Gly Cys  
1 5 10 15  
ctc gtt cct gtg gca gaa tgt att aac tca gct att agc aat ggt tca 96  
Leu Val Pro Val Ala Glu Cys Ile Asn Ser Ala Ile Ser Asn Gly Ser

WO 02/075507

PCT/US02/01971

```

                20                25                30
tct gat tca aca tcc aca tca gaa caa gtt gaa gag gaa cct ttc ctt 144
Ser Asp Ser Thr Ser Thr Ser Glu Gln Val Glu Glu Glu Pro Phe Leu
          35                40                45
cta gaa caa tat tca ctt tcc tcc gtg tct tta tta gta aaa agc acg 192
Leu Glu Gln Tyr Ser Leu Ser Ser Val Ser Leu Leu Val Lys Ser Thr
          50                55                60
ttc aat cct gtt tgg tat gca atg caa ttg act tgg aaa cag ctt tct 240
Phe Asn Pro Val Ser Tyr Ala Met Gln Leu Thr Trip Lys Gln Leu Ser
          65                70                75
att tta ttt tta act gtg att tct gtt cct gtt ttg gct gag gga aaa 288
Ile Leu Phe Leu Thr Val Ile Ser Val Pro Val Leu Leu Ala Glu Gly Lys
          85                90                95
ggg gat gaa aga aat caa tta aca gtg att gat aat agc gat cat att 336
Gly Asp Glu Arg Asn Gln Leu Thr Val Ile Asp Asn Ser Asp His Ile
          100                105                110
aaa tta gat gca tct aat ctt gct ggt aat gat aaa aca aaa atc tat 384
Lys Leu Asp Ala Ser Asn Leu Ala Gly Asn Asp Lys Thr Lys Ile Tyr
          115                120                125
caa gca gaa aat aaa gtt ctg gtt att gat att gct aaa cca aat ggg 432
Gln Ala Glu Asn Lys Val Leu Val Ile Asp Ile Ala Lys Pro Asn Gly
          130                135                140
aaa ggg att tca gat aac cgt ttt gaa aaa ttt aat att cca aat agc 480
Lys Gly Ile Ser Asp Asn Arg Phe Glu Lys Phe Asn Ile Pro Asn Ser
          145                150                155
gcg gtg ttt aat aat aat ggg act gaa gcg cag gca aga tca aca tta 528
Ala Val Phe Asn Asn Asn Gly Thr Glu Ala Gln Ala Arg Ser Thr Leu
          165                170                175
att ggt tac att ccg caa aat caa aat tta agg gga ggg aaa gaa gct 576
Ile Gly Tyr Ile Pro Gln Asn Gln Asn Leu Arg Gly Gly Lys Glu Ala
          180                185                190
gat gtt ata tta aat caa gtg aca ggt cct caa gaa agt aaa att gtt 624
Asp Val Ile Leu Asn Gln Val Thr Gly Pro Gln Glu Ser Lys Ile Val
          195                200                205
ggc gcg ctt gaa gta tta ggt aaa aaa gct gat atc gtc att gca aac 672
Gly Ala Leu Glu Val Leu Gly Lys Lys Ala Asp Ile Val Ile Ala Asn
          210                215                220
caa aat ggt att acc tta aat ggt gta aga aca ata aat tca gat cgt 720
Gln Asn Gly Ile Thr Leu Asn Gly Val Arg Thr Ile Asn Ser Asp Arg
          225                230                235
ttt gtt gcc act acg agt gag ctt ata gat ccg aat cag atg atg tta 768
Phe Val Ala Thr Thr Ser Glu Leu Ile Asp Pro Asn Gln Met Met Leu
          245                250                255
aag gtt aca aaa gga aat gtg atc att gat att gat ggt ttt tcg aca 816
Lys Val Thr Lys Gly Asn Val Ile Ile Asp Ile Asp Gly Phe Ser Thr
          260                265                270
gat gga tta aag tat tta gat att att gct aaa aaa att gaa caa aag 864

```

WO 02/075507

PCT/US02/01971

Asp Gly Leu Lys Tyr Leu Asp Ile Ile Ala Lys Lys Ile Glu Gln Lys  
 275 280 285  
 caa tca att aca tca ggg gat aat tca gaa gca aaa aca gat gtc act 912  
 Gln Ser Ile Thr Ser Gly Asp Asn Ser Glu Ala Lys Thr Asp Val Thr  
 290 295 300  
 ctt att gcg ggt tcc agt gaa tat gat tta agc aaa cat gag ctg aaa 960  
 Leu Ile Ala Gly Ser Ser Glu Tyr Asp Leu Ser Lys His Glu Leu Lys  
 305 310 315  
 aaa acg agc ggt gaa aat gta tct aat gat gtt att gct atc acg gga 1008  
 Lys Thr Ser Gly Glu Asn Val Ser Asn Asp Val Ile Ala Ile Thr Gly  
 325 330 335  
 tct agt aca ggc gca atg cat ggt aaa aat att aag ttg att gtg aca 1056  
 Ser Ser Thr Gly Ala Met His Gly Lys Asn Ile Lys Leu Ile Val Thr  
 340 345 350  
 gat aaa ggt gca ggc gta aaa cat gat gga att att ttg tct gaa aat 1104  
 Asp Lys Gly Ala Gly Val Lys His Asp Gly Ile Ile Leu Ser Glu Asn  
 355 360 365  
 gat att cag att gaa atg aat gaa ggt gac tta gaa ctt ggc aat acg 1152  
 Asp Ile Gln Ile Glu Met Asn Glu Gly Asp Leu Glu Leu Gly Asn Thr  
 370 375 380  
 att cag caa aca gtg gta aaa aaa gac cga aat att cga gcc aag aaa 1200  
 Ile Gln Gln Thr Val Val Lys Lys Asp Arg Asn Ile Arg Ala Lys Lys  
 385 390 395 400  
 aaa att gaa gtg aaa aac gct aat cgt gtt ttt gtt ggt agt caa acg 1248  
 Lys Ile Glu Val Lys Asn Ala Asn Arg Val Phe Val Gly Ser Gln Thr  
 405 410 415  
 aaa tca gat gaa att tcg tta gag gcg aaa caa gtt aaa atc aga aaa 1296  
 Lys Ser Asp Glu Ile Ser Leu Glu Ala Lys Gln Val Lys Ile Arg Lys  
 420 425 430  
 aac gca gag att agg agt acg aca caa gcc aaa atc gta gca aag ggt 1344  
 Asn Ala Glu Ile Arg Ser Thr Thr Gln Ala Lys Ile Val Ala Lys Gly  
 435 440 445  
 gcc ctg tct att gag caa aat gcg aag ctc gtc gct aaa aag ata gat 1392  
 Ala Leu Ser Ile Glu Gln Asn Ala Lys Leu Val Ala Lys Lys Ile Asp  
 450 455 460  
 gtg gca aca gaa act cta act aat gct ggg cgt att tat ggt cga gag 1440  
 Val Ala Thr Glu Thr Leu Thr Asn Ala Gly Arg Ile Tyr Gly Arg Glu  
 465 470 475 480  
 gtt aag ctt gac act aat aat ttg att aat gat aaa gaa att tat gct 1498  
 Val Lys Leu Asp Thr Asn Asn Leu Ile Asn Asp Lys Glu Ile Tyr Ala  
 485 490 495  
 gaa cgg aaa ttg agt att ttg acg aaa gga aaa gat ctt gaa att att 1536  
 Glu Arg Lys Leu Ser Ile Leu Thr Lys Gly Lys Asp Leu Glu Ile Ile  
 500 505 510  
 caa gat aga tat ttg tct cca ctg atg cgc gta aaa agt agt gtc cgc 1584  
 Gln Asp Arg Tyr Leu Ser Pro Leu Met Arg Val Lys Ser Ser Val Arg  
 515 520 525

WO 02/075507

PCT/US02/01971

ttt tta ggc tct ccg ttt ttc tca ata tct ccg tog atg ctc gca agc 1632  
 Phe Leu Gly Ser Pro Phe Phe Ser Ile Ser Pro Ser Met Leu Ala Ser  
 530 535 540

ctt agt gca cag ttt aag cct ggt ttt gtg aat aag gga ctc att gaa 1680  
 Leu Ser Ala Gln Phe Lys Pro Gly Phe Val Asn Lys Gly Leu Ile Glu  
 545 550 555 560

agt gcg ggg agt gca gaa tta act ttt aaa gaa aaa acc agt ttt tta 1728  
 Ser Ala Gly Ser Ala Glu Leu Thr Phe Lys Glu Lys Thr Ser Phe Leu  
 565 570 575

aca gag ggc aat aat ttt att aga gct aaa gat gcg tta act att aac 1776  
 Thr Glu Gly Asn Asn Phe Ile Arg Ala Lys Asp Ala Leu Thr Ile Asn  
 580 585 590

gcc caa aat att gaa att gat aaa aat caa gat att caa ttg ggt gct 1824  
 Ala Gln Asn Ile Glu Ile Asp Lys Asn Gln Asp Ile Gln Leu Gly Ala  
 595 600 605

aat ata acg ttg aat gtg gaa gaa aac ttt gtt aat cgt gca gga aca 1872  
 Asn Ile Thr Leu Asn Val Glu Glu Asn Phe Val Asn Arg Ala Gly Thr  
 610 615 620

ctg gca act ggt aaa aca ctg aca att aat acc gaa agt ggc agt att 1920  
 Leu Ala Thr Gly Lys Thr Leu Thr Ile Asn Thr Glu Ser Gly Ser Ile  
 625 630 635 640

tac aat ctt ggt ggg aca tta ggt gct gga aaa tca tta aaa ctg act 1968  
 Tyr Asn Leu Gly Gly Thr Leu Gly Ala Gly Lys Ser Leu Lys Leu Thr  
 645 650 655

gct aaa tca acg gaa gaa ggt atg gga aat att gtt aac caa gaa aac 2016  
 Ala Lys Ser Thr Glu Glu Gly Met Gly Asn Ile Val Asn Gln Glu Asn  
 660 665 670

ggt tta ttc cat aca ctc ggt aat atg atg tta gaa gca gag cgt tct 2064  
 Gly Leu Phe His Thr Leu Gly Asn Met Met Leu Glu Ala Glu Arg Ser  
 675 680 685

gtt tat aat att ggc gat att tat gcg agt aaa aaa tta aca gtt cat 2112  
 Val Tyr Asn Ile Gly Asp Ile Tyr Ala Ser Lys Lys Leu Thr Val His  
 690 695 700

act cat aat ttg att aat gat gtg cgt tta tct ggc aat gtg agt tat 2160  
 Thr His Asn Leu Ile Asn Asp Val Arg Leu Ser Gly Asn Val Ser Tyr  
 705 710 715 720

aag cct atc ggt tca agt cgt gat tat gat atc agt cgt gtt gcg gta 2208  
 Lys Pro Ile Gly Ser Ser Arg Asp Tyr Asp Ile Ser Arg Val Ala Val  
 725 730 735

cat ggt tgg cac aat aat gtt tat aag ctc aac tta aat ctg caa gaa 2256  
 His Gly Trp His Asn Asn Val Tyr Lys Leu Asn Leu Asn Leu Gln Glu  
 740 745 750

caa gat aaa acc gat att aaa gtt gtg aaa atg ggg gct atc cgt tct 2304  
 Gln Asp Lys Thr Asp Ile Lys Val Val Lys Met Gly Ala Ile Arg Ser  
 755 760 765

gat ggt gat ttt gac ttt aag gga ata aag gcg aca tca tca gaa tca 2352  
 Asp Gly Asp Phe Asp Phe Lys Gly Ile Lys Ala Thr Ser Ser Glu Ser  
 770 775 780



WO 02/075507

PCT/US02/01971

```

aaa ccg cag tta att aat cat gga tta att aat gtc aaa gga aca ttt 2400
Lys Pro Gln Leu Ile Asn His Gly Leu Ile Asn Val Lys Gly Thr Phe
785          790          795          800

aat gcg gaa gct gat caa gtg gtg aac caa atg aaa gcg ttt aac caa 2448
Asn Ala Glu Ala Asp Gln Val Val Asn Gln Met Lys Ala Phe Asn Gln
805          810          815

aat gca tta gca agc gtg ttt aag aat cca gcg aaa atc acg atg tac 2496
Asn Ala Leu Ala Ser Val Phe Lys Asn Pro Ala Lys Ile Thr Met Tyr
820          825          830

tat caa cca ctt act cgt tat att tgg aca cca tta tcg ggt aat gca 2544
Tyr Gln Pro Leu Thr Arg Tyr Ile Trp Thr Pro Leu Ser Gly Asn Ala
835          840          845

tcg cgt gaa ttt aac aat tta gag tct ttc ctc gat gcc ttg ttt gcc 2592
Ser Arg Glu Phe Asn Asn Leu Glu Ser Phe Leu Asp Ala Leu Phe Gly
850          855          860

tca aca aca atc tta aaa tca agt ttc tat agt acg gaa aat ttt agt 2640
Ser Thr Thr Ile Leu Lys Ser Ser Phe Tyr Ser Thr Glu Asn Phe Ser
865          870          875

gct tat cag ctt cta tct cat att cag cat tca cca atg tac caa aaa 2688
Ala Tyr Gln Leu Leu Ser His Ile Gln His Ser Pro Met Tyr Gln Lys
885          890          895

gcg atg gca caa gtg ttt ggt gca gag tgg cat agt aaa tcc tat gat 2736
Ala Met Ala Gln Val Phe Gly Ala Glu Trp His Ser Lys Ser Tyr Asp
900          905          910

gag atg cga aac aaa tgg aaa agc ttt aaa gaa aat cca aca gat ttc 2784
Glu Met Arg Asn Lys Trp Lys Ser Phe Lys Glu Asn Pro Thr Asp Phe
915          920          925

att tat tac cca tca gaa aaa gca aaa atc cta gcg gga aaa cta gaa 2832
Ile Tyr Tyr Pro Ser Glu Lys Ala Lys Ile Leu Ala Gly Lys Leu Glu
930          935          940

ggt aag ctt aca acg cta caa aat ggt gaa tat gcc gaa cgt ggt aag 2880
Gly Lys Leu Thr Thr Leu Gln Asn Gly Glu Tyr Ala Glu Arg Gly Lys
945          950          955

ttt gat gag agt atc caa att ggt aaa cac caa tta tcg cta cca tca 2928
Phe Asp Glu Ser Ile Gln Ile Gly Lys His Gln Leu Ser Leu Pro Ser
965          970          975

gta gag ctt aaa gcg gag ttt agt gat aaa gaa cgt ttg gaa gag gac 2976
Val Glu Leu Lys Ala Glu Phe Ser Asp Lys Glu Arg Leu Glu Glu Asp
980          985          990

ggg gta gat tta tcc tcg atc gcc gaa ctc tta gaa atg cca aac tta 3024
Gly Val Asp Leu Ser Ser Ile Ala Glu Leu Leu Glu Met Pro Asn Leu
995          1000          1005

ttt att gat aat agt atc caa tta gaa aag aaa aag ttg tct cct att 3072
Phe Ile Asp Asn Ser Ile Gln Leu Glu Lys Lys Lys Leu Ser Pro Ile
1010          1015          1020

gag gat cta gat gaa gaa cca cgt aaa aat ctg gat ata gaa gaa agc 3120
Glu Asp Leu Asp Glu Glu Pro Arg Lys Asn Leu Asp Ile Glu Glu Ser
1025          1030          1035          1040

```

WO 02/075507

PCT/US02/01971

cat tct aat tca tcg gat gac gtg ctt agc atg aat gat gat gag tct 3168  
 His Ser Asn Ser Ser Asp Asp Val Leu Ser Met Asn Asp Asp Glu Ser  
 1045 1050 1055

gat aca gac gat agc aag tgg agt atg ggc aat gat gag aaa gag atg 3216  
 Asp Thr Asp Asp Ser Lys Trp Ser Met Gly Asn Asp Glu Lys Glu Met  
 1060 1065 1070

ccc gat gat aag ctg ggt ata agt cgt gat gat cgt gga aat aaa cca 3264  
 Pro Asp Asp Lys Leu Gly Ile Ser Arg Asp Asp Arg Gly Asn Lys Pro  
 1075 1080 1085

cct cgt act gat cct aca gtt gat tat ctt aac cct gat gaa ttc ttt 3312  
 Pro Arg Thr Asp Pro Thr Val Asp Tyr Leu Asn Pro Asp Glu Phe Phe  
 1090 1095 1100

gaa aat ggt tat ctc ttg aat gag cta cta cag gag ctt gga gaa gag 3360  
 Glu Asn Gly Tyr Leu Leu Asn Glu Leu Leu Gln Glu Leu Gly Glu Glu  
 1105 1110 1115 1120

ccg tta cta aaa gaa ggg gaa gat cat ttt aaa cgt tct acc aat cta 3408  
 Pro Leu Leu Lys Glu Gly Glu Asp His Phe Lys Arg Ser Thr Asn Leu  
 1125 1130 1135

gtc cgt cta ggc gag aga gat agg caa aat aga gaa aag aga gaa aaa 3456  
 Val Arg Leu Gly Glu Arg Asp Arg Gln Asn Arg Glu Lys Arg Glu Lys  
 1140 1145 1150

gag ggg tat ttt gat ctg cct ggt aca tta gat atg aaa ctg cag gag 3504  
 Glu Gly Tyr Phe Asp Leu Pro Gly Thr Leu Asp Met Lys Leu Gln Glu  
 1155 1160 1165

tta ttc gaa aaa aga aaa caa aaa cac gaa gca gaa cag aaa gca aga 3552  
 Leu Phe Glu Lys Arg Lys Gln Lys His Glu Ala Glu Gln Lys Ala Arg  
 1170 1175 1180

ata gaa aaa gca ctt cta caa aaa tca gaa caa caa gaa aaa cgt gtt 3600  
 Ile Glu Lys Ala Leu Leu Gln Lys Ser Glu Gln Gln Glu Lys Arg Val  
 1185 1190 1195 1200

gaa gaa cgt aag caa gag gaa aaa cgt caa gcg caa gat aaa att gct 3648  
 Glu Glu Arg Lys Gln Glu Glu Lys Arg Gln Ala Gln Asp Lys Ile Ala  
 1205 1210 1215

aag caa gta gaa att gca aaa gaa atg caa cgg gta gaa gaa att cgc 3696  
 Lys Gln Val Glu Ile Ala Lys Glu Met Gln Arg Val Glu Glu Ile Arg  
 1220 1225 1230

cag aga gaa aaa caa ctt gcg atc caa ctg caa gaa gaa gag aag aaa 3744  
 Gln Arg Glu Lys Gln Leu Ala Ile Gln Leu Gln Glu Glu Glu Lys Lys  
 1235 1240 1245

caa caa gaa gaa aaa cat tta tcc gag gag aaa aaa caa gct gaa cag 3792  
 Gln Gln Glu Glu Lys His Leu Ser Glu Glu Lys Lys Gln Ala Glu Gln  
 1250 1255 1260

aaa caa aaa gct gag gag aaa gtt gca caa gaa aga tta gac att gaa 3840  
 Lys Gln Lys Ala Glu Glu Lys Val Ala Gln Glu Arg Leu Asp Ile Glu  
 1265 1270 1275 1280

caa cag aaa gcg tat gaa gaa atg gcg aag cga gag gca gag gca tca 3888  
 Gln Gln Lys Ala Tyr Glu Glu Met Ala Lys Arg Glu Ala Glu Ala Ser  
 1285 1290 1295

WO 02/075507

PCT/US02/01971

aaa aat gtt tta ttg aaa gcg att gat gaa gaa cgt cca aaa gtg gaa 3936  
 Lys Asn Val Leu Leu Lys Ala Ile Asp Glu Glu Arg Pro Lys Val Glu  
 1300 1305 1310

act gat cca ctt ttc cgt aca aaa ttg aaa tat atc aat caa gat gac 3984  
 Thr Asp Pro Leu Phe Arg Thr Lys Leu Lys Tyr Ile Asn Gln Asp Asp  
 1315 1320 1325

tat gct ggt gca aat tat ttc ttc aat aaa gtt ggt tta aat aca aaa 4032  
 Tyr Ala Gly Ala Asn Tyr Phe Phe Asn Lys Val Gly Leu Asn Thr Lys  
 1330 1335 1340

ggt cat caa aaa gta aat gtg tta ggg gat aac tat ttt gat cat caa 4080  
 Gly His Gln Lys Val Asn Val Leu Gly Asp Asn Tyr Phe Asp His Gln  
 1345 1350 1355 1360

gtg att act cgc tcg att gag aaa aaa gta gat aac cac ctt aac caa 4128  
 Val Ile Thr Arg Ser Ile Glu Lys Lys Val Asp Asn His Leu Asn Gln  
 1365 1370 1375

aaa tac aat ctc agc gat gtg gaa tta gtt aaa cag ctg atg gac aat 4176  
 Lys Tyr Asn Leu Ser Asp Val Glu Leu Val Lys Gln Leu Met Asp Asn  
 1380 1385 1390

tcc aca aca caa gcg cag gag ttg gat ttg aaa cta ggt gcg gca tta 4224  
 Ser Thr Thr Gln Ala Gln Glu Leu Asp Leu Lys Leu Gly Ala Ala Leu  
 1395 1400 1405

act aaa gaa caa caa gct aac ttg acc caa gat atc gtt tgg tat gtc 4272  
 Thr Lys Glu Gln Gln Ala Asn Leu Thr Gln Asp Ile Val Trp Tyr Val  
 1410 1415 1420

aaa acg aag gta aag ggc aaa gat gtg ttt gtt cca aag gtt tat ttc 4320  
 Lys Thr Lys Val Lys Gly Lys Asp Val Phe Val Pro Lys Val Tyr Phe  
 1425 1430 1435 1440

gct tct gaa acg ctc gta gaa gcc caa aaa tta caa ggt tta ggc act 4368  
 Ala Ser Glu Thr Leu Val Glu Ala Gln Lys Leu Gln Gly Leu Gly Thr  
 1445 1450 1455

ggg act atc aga gtt ggt gaa gct aag att aaa gcc aaa gat gtg gtg 4416  
 Gly Thr Ile Arg Val Gly Glu Ala Lys Ile Lys Ala Lys Asp Val Val  
 1460 1465 1470

aat acc ggg aca tta gct ggg aga aaa ctc aat gtt gaa gcg agt aat 4464  
 Asn Thr Gly Thr Leu Ala Gly Arg Lys Leu Asn Val Glu Ala Ser Asn  
 1475 1480 1485

aaa atc aaa aat caa ggg agt atc tta agt act caa gaa aca cgt tta 4512  
 Lys Ile Lys Asn Gln Gly Ser Ile Leu Ser Thr Gln Glu Thr Arg Leu  
 1490 1495 1500

gtc ggg cgt aaa ggt att gaa aac gta tct cgt tca ttt gca aat gat 4560  
 Val Gly Arg Lys Gly Ile Glu Asn Val Ser Arg Ser Phe Ala Asn Asp  
 1505 1510 1515 1520

gaa tta gga gtc act gca caa cgc tca gaa atc aaa acg gaa ggt cat 4608  
 Glu Leu Gly Val Thr Ala Gln Arg Ser Glu Ile Lys Thr Glu Gly His  
 1525 1530 1535

tta cat ctt gaa aca gat aag gat tca act att gat gta caa gca tcg 4656  
 Leu His Leu Glu Thr Asp Lys Asp Ser Thr Ile Asp Val Gln Ala Ser  
 1540 1545 1550

WO 02/075507

PCT/US02/01971

```

gat att aaa gca aaa aca agc ttt gtg aag act ggt gat gtg aat ctc 4704
Asp Ile Lys Ala Lys Thr Ser Phe Val Lys Thr Gly Asp Val Asn Leu
1555 1560 1565

aaa aat aca tac aat act aaa cat gcc tac cgt gag aaa ttc tog ccg 4752
Lys Asn Thr Tyr Asn Thr Lys His Ala Tyr Arg Glu Lys Phe Ser Pro
1570 1575 1580

agt gca cta caa gtt gca gaa ctt gat gtg gca ggg ctt aaa gtc cca 4800
Ser Ala Leu Gln Val Ala Glu Leu Asp Val Ala Gly Leu Lys Val Pro
1585 1590 1595 1600

ctt tta ggc gtg tcc gtc tcc atc cag ttt att cag agc ata cta gtg 4848
Leu Leu Gly Val Ser Val Ser Ile Gln Phe Ile Gln Ser Ile Leu Val
1605 1610 1615

agg caa ctt caa gag gga tca atc ttc gaa gta ggg cac tta cat ntt 4896
Arg Gln Leu Gln Glu Gly Ser Ile Phe Glu Val Gly His Leu His Xaa
1620 1625 1630

gcg gta gac aga aga tgt gaa cca agc ggg gag ta 4931
Ala Val Asp Arg Arg Cys Glu Pro Ser Gly Glu
1635 1640

```

```

<210> 103
<211> 1643
<212> PRT
<213> Pasteurella multocida

```

```

<220>
<221> misc_feature
<222> 1632
<223> Xaa = any or unknown amino acid

```

```

<400> 103
Met Asn Lys Asn Arg Tyr Lys Leu Ile Phe Ser Gln Val Lys Gly Cys
1 5 10 15

Leu Val Pro Val Ala Glu Cys Ile Asn Ser Ala Ile Ser Asn Gly Ser
20 25 30

Ser Asp Ser Thr Ser Thr Ser Glu Gln Val Glu Glu Glu Pro Phe Leu
35 40 45

Leu Glu Gln Tyr Ser Leu Ser Ser Val Ser Leu Leu Val Lys Ser Thr
50 55 60

Phe Asn Pro Val Ser Tyr Ala Met Gln Leu Thr Trp Lys Gln Leu Ser
65 70 75 80

Ile Leu Phe Leu Thr Val Ile Ser Val Pro Val Leu Ala Glu Gly Lys
85 90 95

Gly Asp Glu Arg Asn Gln Leu Thr Val Ile Asp Asn Ser Asp His Ile
100 105 110

Lys Leu Asp Ala Ser Asn Leu Ala Gly Asn Asp Lys Thr Lys Ile Tyr
115 120 125

Gln Ala Glu Asn Lys Val Leu Val Ile Asp Ile Ala Lys Pro Asn Gly
130 135 140

```

WO 02/075507

PCT/US02/01971

Lys Gly Ile Ser Asp Asn Arg Phe Glu Lys Phe Asn Ile Pro Asn Ser  
 145 150 155 160  
 Ala Val Phe Asn Asn Asn Gly Thr Glu Ala Gln Ala Arg Ser Thr Leu  
 165 170 175  
 Ile Gly Tyr Ile Pro Gln Asn Gln Asn Leu Arg Gly Gly Lys Glu Ala  
 180 185 190  
 Asp Val Ile Leu Asn Gln Val Thr Gly Pro Gln Glu Ser Lys Ile Val  
 195 200 205  
 Gly Ala Leu Glu Val Leu Gly Lys Lys Ala Asp Ile Val Ile Ala Asn  
 210 215 220  
 Gln Asn Gly Ile Thr Leu Asn Gly Val Arg Thr Ile Asn Ser Asp Arg  
 225 230 235 240  
 Phe Val Ala Thr Thr Ser Glu Leu Ile Asp Pro Asn Gln Met Met Leu  
 245 250 255  
 Lys Val Thr Lys Gly Asn Val Ile Ile Asp Ile Asp Gly Phe Ser Thr  
 260 265 270  
 Asp Gly Leu Lys Tyr Leu Asp Ile Ile Ala Lys Lys Ile Glu Gln Lys  
 275 280 285  
 Gln Ser Ile, Thr Ser Gly Asp Asn Ser Glu Ala Lys Thr Asp Val Thr  
 290 295 300  
 Leu Ile Ala Gly Ser Ser Glu Tyr Asp Leu Ser Lys His Glu Leu Lys  
 305 310 315 320  
 Lys Thr Ser Gly Glu Asn Val Ser Asn Asp Val Ile Ala Ile Thr Gly  
 325 330 335  
 Ser Ser Thr Gly Ala Met His Gly Lys Asn Ile Lys Leu Ile Val Thr  
 340 345 350  
 Asp Lys Gly Ala Gly Val Lys His Asp Gly Ile Ile Leu Ser Glu Asn  
 355 360 365  
 Asp Ile Gln Ile Glu Met Asn Glu Gly Asp Leu Glu Leu Gly Asn Thr  
 370 375 380  
 Ile Gln Gln Thr Val Val Lys Lys Asp Arg Asn Ile Arg Ala Lys Lys  
 385 390 395 400  
 Lys Ile Glu Val Lys Asn Ala Asn Arg Val Phe Val Gly Ser Gln Thr  
 405 410 415  
 Lys Ser Asp Glu Ile Ser Leu Glu Ala Lys Gln Val Lys Ile Arg Lys  
 420 425 430  
 Asn Ala Glu Ile Arg Ser Thr Thr Gln Ala Lys Ile Val Ala Lys Gly  
 435 440 445  
 Ala Leu Ser Ile Glu Gln Asn Ala Lys Leu Val Ala Lys Lys Ile Asp  
 450 455 460  
 Val Ala Thr Glu Thr Leu Thr Asn Ala Gly Arg Ile Tyr Gly Arg Glu  
 465 470 475 480

WO 02/075507

PCT/US02/01971

Val Lys Leu Asp Thr Asn Asn Leu Ile Asn Asp Lys Glu Ile Tyr Ala  
485 490 495

Glu Arg Lys Leu Ser Ile Leu Thr Lys Gly Lys Asp Leu Glu Ile Ile  
500 505 510

Gln Asp Arg Tyr Leu Ser Pro Leu Met Arg Val Lys Ser Ser Val Arg  
515 520 525

Phe Leu Gly Ser Pro Phe Phe Ser Ile Ser Pro Ser Met Leu Ala Ser  
530 535 540

Leu Ser Ala Gln Phe Lys Pro Gly Phe Val Asn Lys Gly Leu Ile Glu  
545 550 555 560

Ser Ala Gly Ser Ala Glu Leu Thr Phe Lys Glu Lys Thr Ser Phe Leu  
565 570 575

Thr Glu Gly Asn Asn Phe Ile Arg Ala Lys Asp Ala Leu Thr Ile Asn  
580 585 590

Ala Gln Asn Ile Glu Ile Asp Lys Asn Gln Asp Ile Gln Leu Gly Ala  
595 600 605

Asn Ile Thr Leu Asn Val Glu Glu Asn Phe Val Asn Arg Ala Gly Thr  
610 615 620

Leu Ala Thr Gly Lys Thr Leu Thr Ile Asn Thr Glu Ser Gly Ser Ile  
625 630 635 640

Tyr Asn Leu Gly Gly Thr Leu Gly Ala Gly Lys Ser Leu Lys Leu Thr  
645 650 655

Ala Lys Ser Thr Glu Glu Gly Met Gly Asn Ile Val Asn Gln Glu Asn  
660 665 670

Gly Leu Phe His Thr Leu Gly Asn Met Met Leu Glu Ala Glu Arg Ser  
675 680 685

Val Tyr Asn Ile Gly Asp Ile Tyr Ala Ser Lys Lys Leu Thr Val His  
690 695 700

Thr His Asn Leu Ile Asn Asp Val Arg Leu Ser Gly Asn Val Ser Tyr  
705 710 715 720

Lys Pro Ile Gly Ser Ser Arg Asp Tyr Asp Ile Ser Arg Val Ala Val  
725 730 735

His Gly Trp His Asn Asn Val Tyr Lys Leu Asn Leu Asn Leu Gln Glu  
740 745 750

Gln Asp Lys Thr Asp Ile Lys Val Val Lys Met Gly Ala Ile Arg Ser  
755 760 765

Asp Gly Asp Phe Asp Phe Lys Gly Ile Lys Ala Thr Ser Ser Glu Ser  
770 775 780

Lys Pro Gln Leu Ile Asn His Gly Leu Ile Asn Val Lys Gly Thr Phe  
785 790 795 800

Asn Ala Glu Ala Asp Gln Val Val Asn Gln Met Lys Ala Phe Asn Gln  
805 810 815

WO 02/075507

PCT/US02/01971

Asn Ala Leu Ala Ser Val Phe Lys Asn Pro Ala Lys Ile Thr Met Tyr  
 820 825 830  
 Tyr Gln Pro Leu Thr Arg Tyr Ile Trp Thr Pro Leu Ser Gly Asn Ala  
 835 840 845  
 Ser Arg Glu Phe Asn Asn Leu Glu Ser Phe Leu Asp Ala Leu Phe Gly  
 850 855 860  
 Ser Thr Thr Ile Leu Lys Ser Ser Phe Tyr Ser Thr Glu Asn Phe Ser  
 865 870 875 880  
 Ala Tyr Gln Leu Leu Ser His Ile Gln His Ser Pro Met Tyr Gln Lys  
 885 890 895  
 Ala Met Ala Gln Val Phe Gly Ala Glu Trp His Ser Lys Ser Tyr Asp  
 900 905 910  
 Glu Met Arg Asn Lys Trp Lys Ser Phe Lys Glu Asn Pro Thr Asp Phe  
 915 920 925  
 Ile Tyr Tyr Pro Ser Glu Lys Ala Lys Ile Leu Ala Gly Lys Leu Glu  
 930 935 940  
 Gly Lys Leu Thr Thr Leu Gln Asn Gly Glu Tyr Ala Glu Arg Gly Lys  
 945 950 955 960  
 Phe Asp Glu Ser Ile Gln Ile Gly Lys His Gln Leu Ser Leu Pro Ser  
 965 970 975  
 Val Glu Leu Lys Ala Glu Phe Ser Asp Lys Glu Arg Leu Glu Asp  
 980 985 990  
 Gly Val Asp Leu Ser Ser Ile Ala Glu Leu Leu Glu Met Pro Asn Leu  
 995 1000 1005  
 Phe Ile Asp Asn Ser Ile Gln Leu Glu Lys Lys Lys Leu Ser Pro Ile  
 1010 1015 1020  
 Glu Asp Leu Asp Glu Glu Pro Arg Lys Asn Leu Asp Ile Glu Glu Ser  
 1025 1030 1035 1040  
 His Ser Asn Ser Ser Asp Asp Val Leu Ser Met Asn Asp Asp Glu Ser  
 1045 1050 1055  
 Asp Thr Asp Asp Ser Lys Trp Ser Met Gly Asn Asp Glu Lys Glu Met  
 1060 1065 1070  
 Pro Asp Asp Lys Leu Gly Ile Ser Arg Asp Asp Arg Gly Asn Lys Pro  
 1075 1080 1085  
 Pro Arg Thr Asp Pro Thr Val Asp Tyr Leu Asn Pro Asp Glu Phe Phe  
 1090 1095 1100  
 Glu Asn Gly Tyr Leu Leu Asn Glu Leu Leu Gln Glu Leu Gly Glu Glu  
 1105 1110 1115 1120  
 Pro Leu Leu Lys Glu Gly Glu Asp His Phe Lys Arg Ser Thr Asn Leu  
 1125 1130 1135  
 Val Arg Leu Gly Glu Arg Asp Arg Gln Asn Arg Glu Lys Arg Glu Lys  
 1140 1145 1150

WO 02/075507

PCT/US02/01971

Glu Gly Tyr Phe Asp Leu Pro Gly Thr Leu Asp Met Lys Leu Gln Glu  
 1155 1160 1165  
 Leu Phe Glu Lys Arg Lys Gln Lys His Glu Ala Glu Gln Lys Ala Arg  
 1170 1175 1180  
 Ile Glu Lys Ala Leu Leu Gln Lys Ser Glu Gln Gln Glu Lys Arg Val  
 1185 1190 1195  
 Glu Glu Arg Lys Gln Glu Glu Lys Arg Gln Ala Gln Asp Lys Ile Ala  
 1205 1210 1215  
 Lys Gln Val Glu Ile Ala Lys Glu Met Gln Arg Val Glu Glu Ile Arg  
 1220 1225 1230  
 Gln Arg Glu Lys Gln Leu Ala Ile Gln Leu Gln Glu Glu Lys Lys  
 1235 1240 1245  
 Gln Gln Glu Glu Lys His Leu Ser Glu Glu Lys Lys Gln Ala Glu Gln  
 1250 1255 1260  
 Lys Gln Lys Ala Glu Glu Lys Val Ala Gln Glu Arg Leu Asp Ile Glu  
 1265 1270 1275  
 Gln Gln Lys Ala Tyr Glu Glu Met Ala Lys Arg Glu Ala Glu Ala Ser  
 1285 1290 1295  
 Lys Asn Val Leu Leu Lys Ala Ile Asp Glu Glu Arg Pro Lys Val Glu  
 1300 1305 1310  
 Thr Asp Pro Leu Phe Arg Thr Lys Leu Lys Tyr Ile Asn Gln Asp Asp  
 1315 1320 1325  
 Tyr Ala Gly Ala Asn Tyr Phe Phe Asn Lys Val Gly Leu Asn Thr Lys  
 1330 1335 1340  
 Gly His Gln Lys Val Asn Val Leu Gly Asp Asn Tyr Phe Asp His Gln  
 1345 1350 1355  
 Val Ile Thr Arg Ser Ile Glu Lys Lys Val Asp Asn His Leu Asn Gln  
 1365 1370 1375  
 Lys Tyr Asn Leu Ser Asp Val Glu Leu Val Lys Gln Leu Met Asp Asn  
 1380 1385 1390  
 Ser Thr Thr Gln Ala Gln Glu Leu Asp Leu Lys Leu Gly Ala Ala Leu  
 1395 1400 1405  
 Thr Lys Glu Gln Gln Ala Asn Leu Thr Gln Asp Ile Val Trp Tyr Val  
 1410 1415 1420  
 Lys Thr Lys Val Lys Gly Lys Asp Val Phe Val Pro Lys Val Tyr Phe  
 1425 1430 1435 1440  
 Ala Ser Glu Thr Leu Val Glu Ala Gln Lys Leu Gln Gly Leu Gly Thr  
 1445 1450 1455  
 Gly Thr Ile Arg Val Gly Glu Ala Lys Ile Lys Ala Lys Asp Val Val  
 1460 1465 1470  
 Asn Thr Gly Thr Leu Ala Gly Arg Lys Leu Asn Val Glu Ala Ser Asn  
 1475 1480 1485



WO 02/075507

PCT/US02/01971

Lys Ile Lys Asn Gln Gly Ser Ile Leu Ser Thr Gln Glu Thr Arg Leu  
1490 1495 1500  
Val Gly Arg Lys Gly Ile Glu Asn Val Ser Arg Ser Phe Ala Asn Asp  
1505 1510 1515 1520  
Glu Leu Gly Val Thr Ala Gln Arg Ser Glu Ile Lys Thr Glu Gly His  
1525 1530 1535  
Leu His Leu Glu Thr Asp Lys Asp Ser Thr Ile Asp Val Gln Ala Ser  
1540 1545 1550  
Asp Ile Lys Ala Lys Thr Ser Phe Val Lys Thr Gly Asp Val Asn Leu  
1555 1560 1565  
Lys Asn Thr Tyr Asn Thr Lys His Ala Tyr Arg Glu Lys Phe Ser Pro  
1570 1575 1580  
Ser Ala Leu Gln Val Ala Glu Leu Asp Val Ala Gly Leu Lys Val Pro  
1585 1590 1595 1600  
Leu Leu Gly Val Ser Val Ser Ile Gln Phe Ile Gln Ser Ile Leu Val  
1605 1610 1615  
Arg Gln Leu Gln Glu Gly Ser Ile Phe Glu Val Gly His Leu His Xaa  
1620 1625 1630  
Ala Val Asp Arg Arg Cys Glu Pro Ser Gly Glu  
1635 1640

<210> 104  
<211> 2009  
<212> DNA  
<213> Pasteurella multocida

<220>  
<223> hmbR

<220>  
<221> CDS  
<222> (1)..(2007)

<400> 104  
atc cgt ggc gtt gat aaa gat cgt gtc gct gtt att gtt gat gga ata 48  
Ile Arg Gly Val Asp Lys Asp Arg Val Ala Val Ile Val Asp Gly Ile  
1 5 10 15  
cgg cag gct gaa tcg act ata tct act tcc gca cgt tat tcg act gaa 96  
Pro Gln Ala Glu Ser Thr Ile Ser Thr Ser Ala Arg Tyr Ser Thr Glu  
20 25 30  
cgt cat aat ggt aat att aat aat att gaa tac gaa aat gtt agt tcg 144  
Arg His Asn Gly Asn Ile Asn Asn Ile Glu Tyr Glu Asn Val Ser Ser  
35 40 45  
ttg aaa gtt caa aaa ggg gca gct tct gta atg tat ggt agc ggt gcg 192  
Leu Lys Val Gln Lys Gly Ala Ala Ser Val Met Tyr Gly Ser Gly Ala  
50 55 60  
tta ggt gga acc gtg gag ttt acc aca aaa gat att gag gac ttt gtc 240  
Leu Gly Gly Thr Val Glu Phe Thr Thr Lys Asp Ile Glu Asp Phe Val  
65 70 75 80

WO 02/075507

PCT/US02/01971

gaa cct ggt cgc cat ttg ggc ttt ttg tct aaa acc ggc tat act tca 288  
 Glu Pro Gly Arg His Leu Gly Phe Leu Ser Lys Thr Gly Tyr Thr Ser 95  
 85  
 aaa aac aga gaa tat cgt caa gtc atc gga gtt gga ggg aaa ggg gaa 336  
 Lys Asn Arg Glu Tyr Arg Gln Val Ile Gly Val Gly Lys Gly Glu 110  
 100 105  
 cac ttt ttt ggt ttt gta caa tra acc aaa cgt tgg ggg cat gaa aca 384  
 His Phe Phe Gly Phe Val Gln Leu Thr Lys Arg Trp Gly His Glu Thr 125  
 115 120  
 atc aac aac ggc aaa ggt aca gac att ctc ggc gaa cat cga ggt aaa 432  
 Ile Asn Asn Gly Lys Gly Thr Asp Ile Leu Gly Glu His Arg Gly Lys 140  
 130 135  
 ccc aat ccg ctc aac tac tat act aca tca tgg tta acg aaa gtc ggt 480  
 Pro Asn Pro Leu Asn Tyr Thr Thr Ser Trp Leu Thr Lys Val Gly 160  
 145 150  
 tac gat att aat aac act cat cgt ttt aca ctg ttt tta gaa gat cgc 528  
 Tyr Asp Ile Asn Asn Thr His Arg Phe Thr Leu Phe Leu Glu Asp Arg 175  
 165 170  
 cgt gaa aag aag ctt acc gaa gaa aaa aca tta ggg ctt gat gca 576  
 Arg Glu Lys Lys Leu Thr Glu Glu Lys Thr Leu Gly Leu Ser Asp Ala 190  
 180 185  
 gtg cgt ttt gct aat gat caa acc cct tat ctc cgt tat ggt att gaa 624  
 Val Arg Phe Ala Asn Asp Gln Thr Pro Tyr Leu Arg Tyr Gly Ile Glu 205  
 195 200  
 tat cga tat aac ggc ttg tct tgg ttg gaa acg gta aag ctt ttt ttg 672  
 Tyr Arg Tyr Asn Gly Leu Ser Trp Leu Glu Thr Val Lys Leu Phe Leu 220  
 210 215  
 gca aag cag aaa atc gaa caa cgt tct gct ctc caa gag ttt gat att 720  
 Ala Lys Gln Lys Ile Glu Gln Arg Ser Ala Leu Gln Glu Phe Asp Ile 240  
 225 230 235  
 aat aat agg aat aaa ttg gat tgc act atg tgc ttt gta tat tta caa 768  
 Asn Asn Arg Asn Lys Leu Asp Ser Thr Met Ser Phe Val Tyr Leu Gln 255  
 245 250  
 aga cag aat ata gct cgg gga gaa ttt tca acg agt cct tta tat tgg 816  
 Arg Gln Asn Ile Ala Arg Gly Glu Phe Ser Thr Ser Pro Leu Tyr Trp 270  
 260 265  
 ggg ccg agt cgc cat cgt tta tct gcg aaa ttc gaa ttt cgt gat aag 864  
 Gly Pro Ser Arg His Arg Leu Ser Ala Lys Phe Glu Phe Arg Asp Lys 285  
 275 280  
 ttt tta gaa aat atg aat aag cat ttt acg ttt cgg ccg tgg caa atc 912  
 Phe Leu Glu Asn Met Asn Lys His Phe Thr Phe Arg Pro Trp Gln Ile 300  
 290 295  
 aat aga ttc aga caa caa ggt cga aat aac tat aca gaa gtg ttt ccc 960  
 Asn Arg Phe Arg Gln Gln Gly Arg Asn Asn Tyr Thr Glu Val Phe Pro 320  
 305 310 315  
 gtt aaa tcc cga gag ttt tct ttt tct ctt atg gac gac att aag att 1008  
 Val Lys Ser Arg Glu Phe Ser Phe Ser Leu Met Asp Asp Ile Lys Ile 335  
 325 330

WO 02/075507

PCT/US02/01971

ggc gaa ttg cta cat ctc gga ttg ggc ggt cgg tgg gat cac tat aac 1056  
 Gly Glu Leu Leu His Leu Gly Leu Gly Gly Arg Trp Asp His Tyr Asn  
 340 345 350

tat aag cca tta tta aat tct cag cat aat atc aac agg aca cag aga 1104  
 Tyr Lys Pro Leu Leu Asn Ser Gln His Asn Ile Asn Arg Thr Gln Arg  
 355 360 365

tta cct tat cca aaa aca tca tcc aaa ttt tgg tat caa ttg agt tta 1152  
 Leu Pro Tyr Pro Lys Thr Ser Ser Lys Phe Ser Tyr Gln Leu Ser Leu  
 370 375 380

gag tat caa tta cat cca tca cat caa att gca tac cgt tta agt acc 1200  
 Glu Tyr Gln Leu His Pro Ser His Gln Ile Ala Tyr Arg Leu Ser Thr  
 385 390 395

ggt ttt agg gtt ccc cgt gtt gaa gat ctt tat ttt gaa gac cga gga 1248  
 Gly Phe Arg Val Pro Arg Val Glu Asp Leu Tyr Phe Glu Asp Arg Gly  
 405 410 415

aaa agt tct tca caa ttt ctt cct aac ccc gat cta caa ccg gaa act 1296  
 Lys Ser Ser Ser Gln Phe Leu Pro Asn Pro Asp Leu Gln Pro Glu Thr  
 420 425 430

gca ctg aat cat gaa ata agt tac cgt ttc caa aat caa tat gcc cat 1344  
 Ala Leu Asn His Glu Ile Ser Tyr Arg Phe Gln Asn Gln Tyr Ala His  
 435 440 445

ttc agc gtc ggg ctt ttc cgt aca cgt tat cat aac ttt att caa gaa 1392  
 Phe Ser Val Gly Leu Phe Arg Thr Arg Tyr His Asn Phe Ile Gln Glu  
 450 455 460

cgt gag atg acc tgt gat aaa att cca tat gag tat aat agg act tat 1440  
 Arg Glu Met Thr Cys Asp Lys Ile Pro Tyr Glu Tyr Asn Arg Thr Tyr  
 465 470 475 480

gga tat tgc acg cat aat act tat gta atg ttt gtt aat gaa cct gaa 1488  
 Gly Tyr Cys Thr His Asn Thr Tyr Val Met Phe Val Asn Glu Pro Glu  
 485 490 495

gcc gtg att aaa ggg gtt gaa gta agc ggt gct tta aat ggg tgg gca 1536  
 Ala Val Ile Lys Gly Val Glu Val Ser Gly Ala Leu Asn Gly Ser Ala  
 500 505 510

ttc gga ctt tcc gac ggt tta act ttc cgt ctc aaa ggg agc tac agc 1584  
 Phe Gly Leu Ser Asp Gly Leu Thr Phe Arg Leu Lys Gly Ser Tyr Ser  
 515 520 525

aaa ggt caa aat cat gac ggc gat ccg tta aaa tct att caa cca tgg 1632  
 Lys Gly Gln Asn His Asp Gly Asp Pro Leu Lys Ser Ile Gln Pro Trp  
 530 535 540

aca gtg gta acc ggt att gat tac gaa act gaa ggg tgg agc gtg agt 1680  
 Thr Val Val Thr Gly Ile Asp Tyr Glu Thr Glu Gly Trp Ser Val Ser  
 545 550 555 560

tgg agc ggg cgt tat agt gcg gct aaa aaa gcc aaa gat gcg ata gaa 1728  
 Leu Ser Gly Arg Tyr Ser Ala Ala Lys Lys Ala Lys Asp Ala Ile Glu  
 565 570 575

acg gaa tac aca cat gat aaa aag gtt gtc aaa caa tgg ccg cat tta 1776  
 Thr Glu Tyr Thr His Asp Lys Lys Val Val Lys Gln Trp Pro His Leu  
 580 585 590

WO 02/075507

PCT/US02/01971

```

agt cca tcc tac ttt gtt gtt gat ttt acg ggg caa gtt aac ctc agt 1824
Ser Pro Ser Tyr Phe Val Val Asp Phe Thr Gly Gln Val Asn Leu Ser
595 600 605
aaa aat gtc att ttg aat atg ggg gta ttt aac ttg ttc aat cgt gat 1872
Lys Asn Val Ile Leu Asn Met Gly Val Phe Asn Leu Phe Asn Arg Asp
610 615 620
tat atg acg tgg gac agt gca tat aac ttg ttt act agg ggg tat act 1920
Tyr Met Thr Trp Asp Ser Ala Tyr Asn Leu Phe Thr Arg Gly Tyr Thr
625 630 635 640
tcc cgt tct gtc cgt gct aac agc cca ggc att aat cgg ttt acc gca 1968
Ser Arg Ser Val Arg Ala Asn Ser Pro Gly Ile Asn Arg Phe Thr Ala
645 650 655
cca aaa cgt aat ttt gct gcc tcg gtg gaa att cgt ttt ta 2009
Pro Lys Arg Asn Phe Ala Ala Ser Val Glu Ile Arg Phe
660 665

```

```

<210> 105
<211> 669
<212> PRT
<213> Pasteurella multocida

```

```

<400> 105
Ile Arg Gly Val Asp Lys Asp Arg Val Ala Val Ile Val Asp Gly Ile
1 5 10 15
Pro Gln Ala Glu Ser Thr Ile Ser Thr Ser Ala Arg Tyr Ser Thr Glu
20 25 30
Arg His Asn Gly Asn Ile Asn Asn Ile Glu Tyr Glu Asn Val Ser Ser
35 40 45
Leu Lys Val Gln Lys Gly Ala Ala Ser Val Met Tyr Gly Ser Gly Ala
50 55 60
Leu Gly Gly Thr Val Glu Phe Thr Thr Lys Asp Ile Glu Asp Phe Val
65 70 75 80
Glu Pro Gly Arg His Leu Gly Phe Leu Ser Lys Thr Gly Tyr Thr Ser
85 90 95
Lys Asn Arg Glu Tyr Arg Gln Val Ile Gly Val Gly Gly Lys Gly Glu
100 105 110
His Phe Phe Gly Phe Val Gln Leu Thr Lys Arg Trp Gly His Glu Thr
115 120 125
Ile Asn Asn Gly Lys Gly Thr Asp Ile Leu Gly Glu His Arg Gly Lys
130 135 140
Pro Asn Pro Leu Asn Tyr Tyr Thr Thr Ser Trp Leu Thr Lys Val Gly
145 150 155 160
Tyr Asp Ile Asn Asn Thr His Arg Phe Thr Leu Phe Leu Glu Asp Arg
165 170 175
Arg Glu Lys Lys Leu Thr Glu Glu Lys Thr Leu Gly Leu Ser Asp Ala
180 185 190

```

WO 02/075507

PCT/US02/01971

Val Arg Phe Ala Asn Asp Gln Thr Pro Tyr Leu Arg Tyr Gly Ile Glu  
195 200 205

Tyr Arg Tyr Asn Gly Leu Ser Trp Leu Glu Thr Val Lys Leu Phe Leu  
210 215 220

Ala Lys Gln Lys Ile Glu Gln Arg Ser Ala Leu Gln Glu Phe Asp Ile  
225 230 235 240

Asn Asn Arg Asn Lys Leu Asp Ser Thr Met Ser Phe Val Tyr Leu Gln  
245 250 255

Arg Gln Asn Ile Ala Arg Gly Glu Phe Ser Thr Ser Pro Leu Tyr Trp  
260 265 270

Gly Pro Ser Arg His Arg Leu Ser Ala Lys Phe Glu Phe Arg Asp Lys  
275 280 285

Phe Leu Glu Asn Met Asn Lys His Phe Thr Phe Arg Pro Trp Gln Ile  
290 295 300

Asn Arg Phe Arg Gln Gln Gly Arg Asn Asn Tyr Thr Glu Val Phe Pro  
305 310 315 320

Val Lys Ser Arg Glu Phe Ser Phe Ser Leu Met Asp Asp Ile Lys Ile  
325 330 335

Gly Glu Leu Leu His Leu Gly Leu Gly Gly Arg Trp Asp His Tyr Asn  
340 345 350

Tyr Lys Pro Leu Leu Asn Ser Gln His Asn Ile Asn Arg Thr Gln Arg  
355 360 365

Leu Pro Tyr Pro Lys Thr Ser Ser Lys Phe Ser Tyr Gln Leu Ser Leu  
370 375 380

Gly Tyr Gln Leu His Pro Ser His Gln Ile Ala Tyr Arg Leu Ser Thr  
385 390 395 400

Gly Phe Arg Val Pro Arg Val Glu Asp Leu Tyr Phe Glu Asp Arg Gly  
405 410 415

Lys Ser Ser Ser Gln Phe Leu Pro Asn Pro Asp Leu Gln Pro Glu Thr  
420 425 430

Ala Leu Asn His Glu Ile Ser Tyr Arg Phe Gln Asn Gln Tyr Ala His  
435 440 445

Phe Ser Val Gly Leu Phe Arg Thr Arg Tyr His Asn Phe Ile Gln Glu  
450 455 460

Arg Glu Met Thr Cys Asp Lys Ile Pro Tyr Glu Tyr Asn Arg Thr Tyr  
465 470 475 480

Gly Tyr Cys Thr His Asn Thr Tyr Val Met Phe Val Asn Glu Pro Glu  
485 490 495

Ala Val Ile Lys Gly Val Glu Val Ser Gly Ala Leu Asn Gly Ser Ala  
500 505 510

Phe Gly Leu Ser Asp Gly Leu Thr Phe Arg Leu Lys Gly Ser Tyr Ser  
515 520 525

WO 02/075507

PCT/US02/01971

Lys Gly Gln Asn His Asp Gly Asp Pro Leu Lys Ser Ile Gln Pro Trp  
530 535 540

Thr Val Val Thr Thr Gly Ile Asp Tyr Glu Thr Glu Gly Trp Ser Val Ser  
545 550 555 560

Leu Ser Gly Arg Tyr Ser Ala Ala Lys Lys Ala Lys Asp Ala Ile Glu  
565 570 575

Thr Glu Tyr Thr His Asp Lys Lys Val Val Lys Gln Trp Pro His Leu  
580 585 590

Ser Pro Ser Tyr Phe Val Val Asp Phe Thr Gly Gln Val Asn Leu Ser  
595 600 605

Lys Asn Val Ile Leu Asn Met Gly Val Phe Asn Leu Phe Asn Arg Asp  
610 615 620

Tyr Met Thr Trp Asp Ser Ala Tyr Asn Leu Phe Thr Arg Gly Tyr Thr  
625 630 635 640

Ser Arg Ser Val Arg Ala Asn Ser Pro Gly Ile Asn Arg Phe Thr Ala  
645 650 655

Pro Lys Arg Asn Phe Ala Ala Ser Val Glu Ile Arg Phe  
660 665

<210> 106  
<211> 908  
<212> DNA  
<213> Pasteurella multocida

<220>  
<223> lgtC

<220>  
<221> CDS  
<222> (1)..(906)

<400> 106  
atg aat att tta ttt gtt tct gat gat gtt tat gct aaa cat ctg gtg 48  
Met Asn Ile Leu Phe Val Ser Asp Asp Val Tyr Ala Lys His Leu Val  
1 5 10 15

ggt gcg att aaa agc att ata aat cat aat gaa aaa ggt att tca ttt 96  
Val Ala Ile Lys Ser Ile Ile Asn His Asn Glu Lys Gly Ile Ser Phe  
20 25 30

tat att ttt gat ttg ggt ata aag gat gaa aat aag aga aat att aat 144  
Tyr Ile Phe Asp Leu Gly Ile Lys Asp Glu Asn Lys Arg Asn Ile Asn  
35 40 45

gat att gtt tct tct tat gga agt gaa gtc aac ttt att gct gtg aat 192  
Asp Ile Val Ser Ser Tyr Gly Ser Glu Val Asn Phe Ile Ala Val Asn  
50 55 60

gag aaa gaa ttt gag agt ttt cct gtt caa att agt tat att tct tta 240  
Glu Lys Glu Phe Glu Ser Phe Pro Val Gln Ile Ser Tyr Ile Ser Leu  
65 70 75 80

WO 02/075507

PCT/US02/01971

gca aca tat gca agg cta aaa gcg gca gag tat ttg ccg gat aat tta 288  
 Ala Thr Tyr Ala Arg Leu Lys Ala Ala Glu Tyr Leu Pro Asp Asn Leu  
 85 90 95  
 aat aaa att att tat tta gat gtt gat gtt ttg gtt ttt aac tca tta 336  
 Asn Lys Ile Ile Tyr Leu Asp Val Asp Val Leu Val Phe Asn Ser Leu  
 100 105 110  
 gaa atg tta tgg aat gtt gat gtt aat aat ttt ctt acc gca gcc tgt 384  
 Glu Met Leu Trp Asn Val Asp Val Asn Asn Phe Leu Thr Ala Ala Cys  
 115 120 125  
 tat gat tct ttc atc gaa aat gaa aag cct gag cat aaa aaa tgg att 432  
 Tyr Asp Ser Phe Ile Glu Asn Glu Lys Ser Glu His Lys Lys Ser Ile  
 130 135 140  
 tca atg tca gat aag gaa tat tat ttt aat gca gga gta atg cta ttt 480  
 Ser Met Ser Asp Lys Glu Tyr Tyr Phe Asn Ala Gly Val Met Leu Phe  
 145 150 155 160  
 aat tta gat gaa tgg cgg aag atg gat gta ttc tca aga gct tta gac 528  
 Asn Leu Asp Glu Trp Arg Lys Met Asp Val Phe Ser Arg Ala Leu Asp  
 165 170 175  
 ctg tta gct atg tat cct aat caa atg att tat cag gat caa gat ata 576  
 Leu Leu Ala Met Tyr Pro Asn Gln Met Ile Tyr Gln Asp Gln Asp Ile  
 180 185 190  
 ttg aat atc ctt ttt agg aat aaa gtc tgt tat tta gat tgc aga ttt 624  
 Leu Asn Ile Leu Phe Arg Asn Lys Val Cys Tyr Leu Asp Cys Arg Phe  
 195 200 205  
 aat ttc atg cca aat caa ctt gaa aga ata aaa caa tac cat aaa gga 672  
 Asn Phe Met Pro Asn Gln Leu Glu Arg Ile Lys Gln Tyr His Lys Gly  
 210 215 220  
 aaa ttg agc aac tta cat tct tta gaa aaa aca acg atg cct gtc gtt 720  
 Lys Leu Ser Asn Leu His Ser Leu Glu Lys Thr Thr Met Pro Val Val  
 225 230 235 240  
 att tca cat tat tgt ggt cca gaa aaa gcg tgg cat gcg gat tgt aaa 768  
 Ile Ser His Tyr Cys Gly Pro Glu Lys Ala Trp His Ala Asp Cys Lys  
 245 250 255  
 cat ttt aat gta tat ttc tat cag aaa ata tta gca gaa ata acg aga 816  
 His Phe Asn Val Tyr Phe Tyr Gln Lys Ile Leu Ala Glu Ile Thr Arg  
 260 265 270  
 ggc acg gat aaa gaa cgc gta tta tct ata aaa act tat ctc aag gcc 864  
 Gly Thr Asp Lys Glu Arg Val Leu Ser Ile Lys Thr Tyr Leu Lys Ala  
 275 280 285  
 ttg att aga agg att aga tat aaa ttc aaa tat caa gtc tat ta 908  
 Leu Ile Arg Arg Ile Arg Tyr Lys Phe Lys Tyr Gln Val Tyr  
 290 295 300

<210> 107  
 <211> 302  
 <212> PRT  
 <213> Pasteurella multocida  
 <400> 107

WO 02/075507

PCT/US02/01971

Met Asn Ile Leu Phe Val Ser Asp Asp Val Tyr Ala Lys His Leu Val  
 1 5 10 15  
 Val Ala Ile Lys Ser Ile Ile Asn His Asn Glu Lys Gly Ile Ser Phe  
 20 25 30  
 Tyr Ile Phe Asp Leu Gly Ile Lys Asp Glu Asn Lys Arg Asn Ile Asn  
 35 40 45  
 Asp Ile Val Ser Ser Tyr Gly Ser Glu Val Asn Phe Ile Ala Val Asn  
 50 55 60  
 Glu Lys Glu Phe Glu Ser Phe Pro Val Gln Ile Ser Tyr Ile Ser Leu  
 65 70 75 80  
 Ala Thr Tyr Ala Arg Leu Lys Ala Ala Glu Tyr Leu Pro Asp Asn Leu  
 85 90 95  
 Asn Lys Ile Ile Tyr Leu Asp Val Asp Val Leu Val Phe Asn Ser Leu  
 100 105 110  
 Glu Met Leu Trp Asn Val Asp Val Asn Asn Phe Leu Thr Ala Ala Cys  
 115 120 125  
 Tyr Asp Ser Phe Ile Glu Asn Glu Lys Ser Glu His Lys Lys Ser Ile  
 130 135 140  
 Ser Met Ser Asp Lys Glu Tyr Tyr Phe Asn Ala Gly Val Met Leu Phe  
 145 150 155 160  
 Asn Leu Asp Glu Trp Arg Lys Met Asp Val Phe Ser Arg Ala Leu Asp  
 165 170 175  
 Leu Leu Ala Met Tyr Pro Asn Gln Met Ile Tyr Gln Asp Gln Asp Ile  
 180 185 190  
 Leu Asn Ile Leu Phe Arg Asn Lys Val Cys Tyr Leu Asp Cys Arg Phe  
 195 200 205  
 Asn Phe Met Pro Asn Gln Leu Glu Arg Ile Lys Gln Tyr His Lys Gly  
 210 215 220  
 Lys Leu Ser Asn Leu His Ser Leu Glu Lys Thr Thr Met Pro Val Val  
 225 230 235 240  
 Ile Ser His Tyr Cys Gly Pro Glu Lys Ala Trp His Ala Asp Cys Lys  
 245 250 255  
 His Phe Asn Val Tyr Phe Tyr Gln Lys Ile Leu Ala Glu Ile Thr Arg  
 260 265 270  
 Gly Thr Asp Lys Glu Arg Val Leu Ser Ile Lys Thr Tyr Leu Lys Ala  
 275 280 285  
 Leu Ile Arg Arg Ile Arg Tyr Lys Phe Lys Tyr Gln Val Tyr  
 290 295 300

<210> 108  
 <211> 2054  
 <212> DNA  
 <213> Pasteurella multocida



WO 02/075507

PCT/US02/01971

```

<220>
<223> pnp
<220>
<221> CDS
<222> (1)..(2052)
<400> 108
atg gca agt atg gat gat act act gtg ttt gtc aca gtg gtt gcc aaa 48
Met Ala Ser Met Asp Asp Thr Thr Val Phe Val Thr Val Val Ala Lys
1 5 10 15
aaa gat gtg aaa gaa ggt caa gac ttc ttc cca tta act gtt aac tat 96
Lys Asp Val Lys Glu Gly Gln Asp Phe Phe Pro Leu Thr Val Asn Tyr
20 25 30
caa gag cgt act tat gct gca ggc cgt att cct ggt ggc ttt ttc aaa 144
Gln Glu Arg Thr Tyr Ala Ala Gly Arg Ile Pro Gly Gly Phe Phe Lys
35 40 45
cgt gaa ggt cgt cct tct gaa ggc gaa act tta att gct cgt tta att 192
Arg Glu Gly Arg Pro Ser Glu Gly Glu Thr Leu Ile Ala Arg Leu Ile
50 55 60
gac cgt cca att cgt cct ctt ttc cca gaa ggt ttt tat aac gaa atc 240
Asp Arg Pro Ile Arg Pro Leu Phe Pro Glu Gly Phe Tyr Asn Glu Ile
65 70 75 80
caa atc gtg gog aca gtg gtg tct gtt aat cag caa att tgt cca gat 288
Gln Ile Val Ala Thr Val Val Ser Val Asn Pro Gln Ile Cys Pro Asp
85 90 95
tta gtg gca atg atc ggt gca tct gcg gca ctt tct tta tca ggt gtg 336
Leu Val Ala Met Ile Gly Ala Ser Ala Ala Leu Ser Leu Ser Gly Val
100 105 110
cca ttt aat ggc cct atc ggt gcg gca cgt gtt ggt ttt att gat gat 384
Pro Phe Asn Gly Pro Ile Gly Ala Ala Arg Val Gly Phe Ile Asp Asp
115 120 125
caa ttt gtg tta aac cca acc atg aac gag caa aaa caa agc cgt tta 432
Gln Phe Val Leu Asn Pro Thr Met Asn Glu Gln Lys Gln Ser Arg Leu
130 135 140
gac ttg gtt etc gcg gga aca gat aaa gcg gtg tta atg gtg gaa tct 480
Asp Leu Val Val Ala Gly Thr Asp Lys Ala Val Leu Met Val Glu Ser
145 150 155 160
gaa gcc gat gta tta acc gaa gaa caa atg tta gct gcg gtg gtg ttt 528
Glu Ala Asp Val Leu Thr Glu Glu Gln Met Leu Ala Ala Val Val Phe
165 170 175
ggt cat cag caa caa caa gtg gtg att gac gcg atc aaa gaa ttt acc 576
Gly His Gln Gln Gln Gln Val Val Ile Asp Ala Ile Lys Glu Phe Thr
180 185 190
gca gaa gcc ggt aaa ccg cgt tgg gat tgg gtg gca cct gaa cca aat 624
Ala Glu Ala Gly Lys Pro Arg Trp Asp Trp Val Ala Pro Glu Pro Asn
195 200 205
acc gcg tta att gaa aaa gtg aaa gcg att gca gaa gcg cgt tta ggc 672
Thr Ala Leu Ile Glu Lys Val Lys Ala Ile Ala Glu Ala Arg Leu Gly
210 215 220

```

WO 02/075507

PCT/US02/01971

gaa gca tac cgt atc act gaa aaa caa gca cgt tat gaa caa att gat 720  
 Glu Ala Tyr Arg Ile Thr Glu Lys Gln Ala Arg Tyr Glu Gln Ile Asp 240  
 225 230 235

gcg att aaa gct gat gtg att gca caa atc aca gct gaa gta gca gaa 768  
 Ala Ile Lys Ala Asp Val Ile Ala Gln Ile Thr Ala Glu Val Ala Glu 255  
 245 250

ggc gaa gac atc agt gaa ggg aaa att gtc gat att ttc acc gca ctt 816  
 Gly Glu Asp Ile Ser Glu Gly Lys Ile Val Asp Ile Phe Thr Ala Leu 270  
 260 265

gaa agc caa atc gta cgt agc cgt atc att gct ggt gaa cca cgt att 864  
 Glu Ser Gln Ile Val Arg Ser Arg Ile Ile Ala Gly Glu Pro Arg Ile 285  
 275 280

gat ggt cgt aca gtg gat act gtt cgt gca tta gat att tgt act ggt 912  
 Asp Gly Arg Thr Val Asp Thr Val Arg Ala Leu Asp Ile Cys Thr Gly 300  
 290 295

gtt tta cca cgt aca cac ggt tct gcg att ttc acc cgt ggt gaa aca 960  
 Val Leu Pro Arg Thr His Gly Ser Ala Ile Phe Thr Arg Gly Glu Thr 320  
 305 310 315

cag gcg tta gct gtc gcg aca tta ggt aca gaa cgt gat gca caa att 1008  
 Gln Ala Leu Ala Val Ala Thr Leu Gly Thr Glu Arg Asp Ala Gln Ile 335  
 325 330

att gat gaa tta aca ggt gag cgt tca gat cac ttc tta ttc cac tac 1056  
 Ile Asp Glu Leu Thr Gly Glu Arg Ser Asp His Phe Leu Phe His Tyr 350  
 340 345

aac ttc cgc cca tat tct gtg ggt gaa acc ggt atg att ggt tca cca 1104  
 Asn Phe Pro Pro Tyr Ser Val Gly Glu Thr Gly Met Ile Gly Ser Pro 365  
 355 360

aaa cgt cgt gaa att ggt cat ggt cgt tta gcg aaa cgc ggt gta gct 1152  
 Lys Arg Arg Glu Ile Gly His Gly Arg Leu Ala Lys Arg Gly Val Ala 380  
 370 375

gca gtg atg cca aca ctt gcc gag ttc cgc tat gtg gta cgt gtt gtc 1200  
 Ala Val Met Pro Thr Leu Ala Glu Phe Pro Tyr Val Val Arg Val Val 400  
 385 390 395

tct gaa atc aca gaa tca aat ggt tct tct tct atg gca tgc gtt tgt 1248  
 Ser Glu Ile Thr Glu Ser Asn Gly Ser Ser Ser Met Ala Ser Val Cys 415  
 405 410

ggt gcg tct tta gca tta atg gat gcg ggt gta cca att aaa gcg gcg 1296  
 Gly Ala Ser Leu Ala Leu Met Asp Ala Gly Val Pro Ile Lys Ala Ala 430  
 420 425

gtt gca ggt att gca atg ggc tta gtc aaa gaa gac gaa aaa ttt gtg 1344  
 Val Ala Gly Ile Ala Met Gly Leu Val Lys Glu Asp Glu Lys Phe Val 445  
 435 440

gtg ctt tca gac atc tta ggt gat gaa gat cac tta ggt gac atg gac 1392  
 Val Leu Ser Asp Ile Leu Gly Asp Glu Asp His Leu Gly Asp Met Asp 460  
 450 455

ttc aaa gtc gcg ggt aca cgt acg ggt gtg acg gca tta caa atg gat 1440  
 Phe Lys Val Ala Gly Thr Arg Thr Gly Val Thr Ala Leu Gln Met Asp 480  
 465 470 475

WO 02/075507

PCT/US02/01971

```

atc aaa atc gaa ggt atc aca gca gaa atc atg caa att gcg tta aac 1488
ile lys ile glu gly ile thr ala glu ile met gin ile ala leu asn
      485      490      495

caa gcg aaa agc gca cgt tta cac att tta ggt gtg atg gag caa gcg 1536
gin ala lys ser ala arg leu his ile leu gly val met glu gin ala
      500      505      510

atc cca gcg cca cgt gcg gat att tct gat ttt gca ccg cgt att tac 1584
ile pro ala pro arg ala asp ile ser asp phe ala pro arg ile tyr
      515      520      525

act atg aaa att gat ccg aag aaa atc aaa gat gtg atc ggt aaa ggt 1632
thr met lys ile asp pro lys lys ile lys asp val ile gly lys gly
      530      535      540

ggt gca acc att cgt gcc tta aca gaa gaa aca ggt acc tca att gat 1680
gly ala thr ile arg ala leu thr glu glu thr gly thr ser ile asp
      545      550      555

atc gat gat gat ggt acg gtg aag att gct gcg gtt gat ggc aat tca 1728
ile asp asp asp gly thr val lys ile ala ala val asp gly asn ser
      565      570      575

gca aaa gag gtg atg gcg cgt att gaa gat att act gca gaa gtt gaa 1776
ala lys glu val met ala arg ile glu asp ile thr ala glu val glu
      580      585      590

gcg ggt gca gtg tat aaa ggt aaa gtt act cgt tta gct gat ttt ggt 1824
ala gly ala val tyr lys gly lys val thr arg leu ala asp phe gly
      595      600      605

gcc ttc gtt tct atc gta ggt aac aaa gaa ggc tta gtg cat att tct 1872
ala phe val ser ile val gly asn lys glu gly leu val his ile ser
      610      615      620

caa atc gcg gaa gag cgt gtt gag aaa gtg agt gat tat ctt gca gtg 1920
gin ile ala glu glu arg val glu lys val ser asp tyr leu ala val
      625      630      635

ggg caa gaa gtg act gtt aaa gtg gtt gag att gat cgt caa ggt cgt 1968
gly gin glu val thr val lys val val glu ile asp arg gin gly arg
      645      650      655

att cgt tta acc atg aaa gaa gtt gca cca aag caa gaa cac gtt gat 2016
ile arg leu thr met lys glu val ala pro lys gin glu his val asp
      660      665      670

tct gtt gtc gca gac gtt gcc gca gaa gaa aac gca ta 2054
ser val val ala asp val ala ala glu glu asn ala
      675      680

<210> 109
<211> 684
<212> PRT
<213> Pasteurella multocida

<400> 109
Met Ala Ser Met Asp Asp Thr Thr Val Phe Val Thr Val Val Ala Lys
 1          5          10          15
Lys Asp Val Lys Glu Gly Gln Asp Phe Phe Pro Leu Thr Val Asn Tyr

```

WO 02/075507

PCT/US02/01971

```

                20          25          30
Gln Glu Arg Thr Tyr Ala Ala Gly Arg Ile Pro Gly Gly Phe Phe Lys
      35          40          45
Arg Glu Gly Arg Pro Ser Glu Gly Glu Thr Leu Ile Ala Arg Leu Ile
      50          55          60
Asp Arg Pro Ile Arg Pro Leu Phe Pro Glu Gly Phe Tyr Asn Glu Ile
      65          70          75          80
Gln Ile Val Ala Thr Val Val Ser Val Asn Pro Gln Ile Cys Pro Asp
      85          90          95
Leu Val Ala Met Ile Gly Ala Ser Ala Ala Leu Ser Leu Ser Gly Val
      100          105          110
Pro Phe Asn Gly Pro Ile Gly Ala Ala Arg Val Gly Phe Ile Asp Asp
      115          120          125
Gln Phe Val Leu Asn Pro Thr Met Asn Glu Gln Lys Gln Ser Arg Leu
      130          135          140
Asp Leu Val Val Ala Gly Thr Asp Lys Ala Val Leu Met Val Glu Ser
      145          150          155          160
Glu Ala Asp Val Leu Thr Glu Glu Gln Met Leu Ala Ala Val Val Phe
      165          170          175
Gly His Gln Gln Gln Val Val Ile Asp Ala Ile Lys Glu Phe Thr
      180          185          190
Ala Glu Ala Gly Lys Pro Arg Trp Asp Trp Val Ala Pro Glu Pro Asn
      195          200          205
Thr Ala Leu Ile Glu Lys Val Lys Ala Ile Ala Glu Ala Arg Leu Gly
      210          215          220
Glu Ala Tyr Arg Ile Thr Glu Lys Gln Ala Arg Tyr Glu Gln Ile Asp
      225          230          235          240
Ala Ile Lys Ala Asp Val Ile Ala Gln Ile Thr Ala Glu Val Ala Glu
      245          250          255
Gly Glu Asp Ile Ser Glu Gly Lys Ile Val Asp Ile Phe Thr Ala Leu
      260          265          270
Glu Ser Gln Ile Val Arg Ser Arg Ile Ile Ala Gly Glu Pro Arg Ile
      275          280          285
Asp Gly Arg Thr Val Asp Thr Val Arg Ala Leu Asp Ile Cys Thr Gly
      290          295          300
Val Leu Pro Arg Thr His Gly Ser Ala Ile Phe Thr Arg Gly Glu Thr
      305          310          315          320
Gln Ala Leu Ala Val Ala Thr Leu Gly Thr Glu Arg Asp Ala Gln Ile
      325          330          335
Ile Asp Glu Leu Thr Gly Glu Arg Ser Asp His Phe Leu Phe His Tyr
      340          345          350
Asn Phe Pro Pro Tyr Ser Val Gly Glu Thr Gly Met Ile Gly Ser Pro

```

204

WO 02/075507

PCT/US02/01971

355                    360                    365

Lys Arg Arg Glu Ile Gly His Gly Arg Leu Ala Lys Arg Gly Val Ala  
370                    375                    380

Ala Val Met Pro Thr Leu Ala Glu Phe Pro Tyr Val Val Arg Val Val  
385                    390                    395                    400

Ser Glu Ile Thr Glu Ser Asn Gly Ser Ser Ser Met Ala Ser Val Cys  
405                    410                    415

Gly Ala Ser Leu Ala Leu Met Asp Ala Gly Val Pro Ile Lys Ala Ala  
420                    425                    430

Val Ala Gly Ile Ala Met Gly Leu Val Lys Glu Asp Glu Lys Phe Val  
435                    440                    445

Val Leu Ser Asp Ile Leu Gly Asp Glu Asp His Leu Gly Asp Met Asp  
450                    455                    460

Phe Lys Val Ala Gly Thr Arg Thr Gly Val Thr Ala Leu Gln Met Asp  
465                    470                    475                    480

Ile Lys Ile Glu Gly Ile Thr Ala Glu Ile Met Gln Ile Ala Leu Asn  
485                    490                    495

Gln Ala Lys Ser Ala Arg Leu His Ile Leu Gly Val Met Glu Gln Ala  
500                    505                    510

Ile Pro Ala Pro Arg Ala Asp Ile Ser Asp Phe Ala Pro Arg Ile Tyr  
515                    520                    525

Thr Met Lys Ile Asp Pro Lys Lys Ile Lys Asp Val Ile Gly Lys Gly  
530                    535                    540

Gly Ala Thr Ile Arg Ala Leu Thr Glu Glu Thr Gly Thr Ser Ile Asp  
545                    550                    555                    560

Ile Asp Asp Asp Gly Thr Val Lys Ile Ala Ala Val Asp Gly Asn Ser  
565                    570                    575

Ala Lys Glu Val Met Ala Arg Ile Glu Asp Ile Thr Ala Glu Val Glu  
580                    585                    590

Ala Gly Ala Val Tyr Lys Gly Lys Val Thr Arg Leu Ala Asp Phe Gly  
595                    600                    605

Ala Phe Val Ser Ile Val Gly Asn Lys Glu Gly Leu Val His Ile Ser  
610                    615                    620

Gln Ile Ala Glu Glu Arg Val Glu Lys Val Ser Asp Tyr Leu Ala Val  
625                    630                    635                    640

Gly Gln Glu Val Thr Val Lys Val Val Glu Ile Asp Arg Gln Gly Arg  
645                    650                    655

Ile Arg Leu Thr Met Lys Glu Val Ala Pro Lys Gln Glu His Val Asp  
660                    665                    670

Ser Val Val Ala Asp Val Ala Ala Glu Glu Asn Ala  
675                    680

WO 02/075507

PCT/US02/01971

```

<210> 110
<211> 1514
<212> DNA
<213> Pasteurella multocida

<220>
<223> purF

<220>
<221> CDS
<222> (1)..(1512)

<400> 110
atg cgt ggt att gtt ggt att gtt agc caa agc ccc gtt aac caa tca 48
Met Cys Gly Ile Val Gly Ile Val Ser Gln Ser Pro Val Asn Gln Ser
1 5 10 15

att tat gat gcg tta acc tta ttg caa cac cgc ggg caa gac gcc gcc 96
Ile Tyr Asp Ala Leu Thr Leu Leu Gln His Arg Gly Gln Asp Ala Ala
20 25 30

ggg att gta acc gta gat gat gaa aac cga ttc cgc ttg cgt aaa gcg 144
Gly Ile Val Thr Val Asp Asp Glu Asn Arg Phe Arg Leu Arg Lys Ala
35 40 45

aac ggg tta gtc agc gat gta ttt gaa caa gtt cat atg tta cgt tta 192
Asn Gly Leu Val Ser Asp Val Phe Glu Gln Val His Met Leu Arg Leu
50 55 60

caa ggc aat gct ggc att gga cat gtt cgt tat cct acg gct ggg agc 240
Gln Gly Asn Ala Gly Ile Gly His Val Arg Tyr Pro Thr Ala Gly Ser
65 70 75 80

tca agt gtc tct gaa gcg caa cct ttt tat gta aat tcg cct tat gcc 288
Ser Ser Val Ser Glu Ala Gln Pro Phe Tyr Val Asn Ser Pro Tyr Gly
85 90 95

tta acc tta gtg cat aat ggt aac ttg acc aat tca agt gaa tta aaa 336
Leu Thr Leu Val His Asn Gly Asn Leu Thr Asn Ser Ser Glu Leu Lys
100 105 110

gaa aag tta ttt cgt ctc gca cgt cgc cat gta aat acc aat tca gat 384
Glu Lys Leu Phe Arg Leu Ala Arg Arg His Val Asn Thr Asn Ser Asp
115 120 125

tct gaa tta tta ctc aat atc tta gcc aat cac ctt gat cac ttc gaa 432
Ser Glu Leu Leu Leu Asn Ile Leu Ala Asn His Leu Asp His Phe Glu
130 135 140

aaa tac caa tta gat ccg caa gat gta ttc agt gct gtc aaa caa acg 480
Lys Tyr Gln Leu Asp Pro Gln Asp Val Phe Ser Ala Val Lys Gln Thr
145 150 155 160

cat cag gat att cgt ggt gct tat gct tgt atc gcc atg att att ggt 528
His Gln Asp Ile Arg Gly Ala Tyr Ala Cys Ile Ala Met Ile Ile Gly
165 170 175

cat ggt atg gtc gcg ttt cgt gat ccg aac ggt atc cgt ccg tta gtg 576
His Gly Met Val Ala Phe Arg Asp Pro Asn Gly Ile Arg Pro Leu Val
180 185 190

tta ggg aaa cgc gag gaa aat ggc aaa aca gag tat atg ttt gcc tcc 624
Leu Gly Lys Arg Glu Glu Asn Gly Lys Thr Glu Tyr Met Phe Ala Ser

```

WO 02/075507

PCT/US02/01971

195	200	205	
gaa agt atc gca tta gat aca gtg ggt ttt gag ttt gta cga gat gta Glu Ser Ile Ala Leu Asp Thr Val Gly Phe Glu Phe Val Arg Asp Val 210 215 220			672
caa ccc ggc gaa gcg att tat gtc acg ttt gaa ggg gaa atg tat gct Gln Pro Gly Glu Ala Ile Tyr Val Thr Phe Glu Gly Glu Met Tyr Ala 225 230 235 240			720
cag caa tgc gca gac aaa cca aca tta aca cct tgt att ttt gaa tac Gln Gln Cys Ala Asp Lys Pro Thr Leu Thr Pro Cys Ile Phe Glu Tyr 245 250 255			768
gtc tat ttt gca cgt cca gac tct tgc atc gat ggg gtt tct gtt tat Val Tyr Phe Ala Arg Pro Asp Ser Cys Ile Asp Gly Val Ser Val Tyr 260 265 270			816
gct gcc cgt gtt cat atg gga caa cgt tta ggt gaa aaa att gca cgg Ala Ala Arg Val His Met Gly Gln Arg Leu Gly Glu Lys Ile Ala Arg 275 280 285			864
gaa tgg gcg gat gtg gat gat att gat gtg gtc att cct gtg cct gaa Glu Trp Ala Asp Val Asp Ile Asp Val Val Ile Pro Val Pro Glu 290 295 300			912
acc tct aac gat att gct tta cgt att gcg cgc gtg tta aat aaa ccg Thr Ser Asn Asp Ile Ala Leu Arg Ile Ala Arg Val Leu Asn Lys Pro 305 310 315 320			960
tat cgt caa ggt ttt gtg aaa aat cgc tat gta gga cgt acg ttt att Tyr Arg Gln Gly Phe Val Lys Asn Arg Tyr Val Gly Arg Thr Phe Ile 325 330 335			1008
atg ccg ggg cag gca ttg cga gtc agt tct gtt aga cgt aaa ctc aat Met Pro Gly Gln Ala Leu Arg Val Ser Ser Val Arg Arg Lys Leu Asn 340 345 350			1056
acc att gct tca gaa ttt aaa gat aag aat gtg tta tta gtt gac gac Thr Ile Ala Ser Glu Phe Lys Asp Lys Asn Val Leu Leu Val Asp Asp 355 360 365			1104
tcg att gta cgt ggt acc acg tct gaa caa att gtc gaa atg gcg aga Ser Ile Val Arg Gly Thr Thr Ser Glu Gln Ile Val Glu Met Ala Arg 370 375 380			1152
ggg gca ggt gcg aag aaa att tat ttt gcc tct gct gca cca gaa att Ala Ala Gly Ala Lys Lys Ile Tyr Phe Ala Ser Ala Ala Pro Glu Ile 385 390 395 400			1200
cgt tat cca aat gtg tat ggt att gat atg cca acc aaa aat gaa ttg Arg Tyr Pro Asn Val Tyr Gly Ile Asp Met Pro Thr Lys Asn Glu Leu 405 410 415			1248
atc gct tat ggt cgt gat gta gat gaa att gct aac tta att ggt gtg Ile Ala Tyr Gly Arg Asp Val Asp Glu Ile Ala Asn Leu Ile Gly Val 420 425 430			1296
gat aaa ttg att ttc caa gat ttg gat gcg tta act ggt tct gtg caa Asp Lys Leu Ile Phe Gln Asp Leu Asp Ala Leu Thr Gly Ser Val Gln 435 440 445			1344
caa gaa aat cca agt att caa gac ttt gat tgt tcg gtg ttt aca ggg			1392

207

WO 02/075507

PCT/US02/01971

Gln Glu Asn Pro Ser Ile Gln Asp Phe Asp Cys Ser Val Phe Thr Gly  
 450 455 460

gtt tat gtg acg ggc gat att aca cct gaa tat ctg gat aat att gca 1440  
 Val Tyr Val Thr Gly Asp Ile Thr Pro Glu Tyr Leu Asp Asn Ile Ala  
 465 470 475 480

gaa cag cgt aat gat atc gcc aag aaa aag cgt gaa aaa gat gct acc 1488  
 Glu Gln Arg Asn Asp Ile Ala Lys Lys Arg Glu Lys Asp Ala Thr  
 485 490 495

aat ctt gaa atg cac aat gaa aaa ta 1514  
 Asn Leu Glu Met His Asn Glu Lys  
 500

<210> 111  
 <211> 504  
 <212> PRT  
 <213> Pasteurella multocida

<400> 111  
 Met Cys Gly Ile Val Gly Ile Val Ser Gln Ser Pro Val Asn Gln Ser  
 1 5 10 15

Ile Tyr Asp Ala Leu Thr Leu Leu Gln His Arg Gly Gln Asp Ala Ala  
 20 25 30

Gly Ile Val Thr Val Asp Asp Glu Asn Arg Phe Arg Leu Arg Lys Ala  
 35 40 45

Asn Gly Leu Val Ser Asp Val Phe Glu Gln Val His Met Leu Arg Leu  
 50 55 60

Gln Gly Asn Ala Gly Ile Gly His Val Arg Tyr Pro Thr Ala Gly Ser  
 65 70 75 80

Ser Ser Val Ser Glu Ala Gln Pro Phe Tyr Val Asn Ser Pro Tyr Gly  
 85 90 95

Leu Thr Leu Val His Asn Gly Asn Leu Thr Asn Ser Ser Glu Leu Lys  
 100 105 110

Glu Lys Leu Phe Arg Leu Ala Arg Arg His Val Asn Thr Asn Ser Asp  
 115 120 125

Ser Glu Leu Leu Leu Asn Ile Leu Ala Asn His Leu Asp His Phe Glu  
 130 135 140

Lys Tyr Gln Leu Asp Pro Gln Asp Val Phe Ser Ala Val Lys Gln Thr  
 145 150 155 160

His Gln Asp Ile Arg Gly Ala Tyr Ala Cys Ile Ala Met Ile Ile Gly  
 165 170 175

His Gly Met Val Ala Phe Arg Asp Pro Asn Gly Ile Arg Pro Leu Val  
 180 185 190

Leu Gly Lys Arg Glu Glu Asn Gly Lys Thr Glu Tyr Met Phe Ala Ser  
 195 200 205

Glu Ser Ile Ala Leu Asp Thr Val Gly Phe Glu Phe Val Arg Asp Val  
 210 215 220



WO 02/075507

PCT/US02/01971

Gln Pro Gly Glu Ala Ile Tyr Val Thr Phe Glu Gly Glu Met Tyr Ala  
 225 230 235 240  
 Gln Gln Cys Ala Asp Lys Pro Thr Leu Thr Pro Cys Ile Phe Glu Tyr  
 245 250 255  
 Val Tyr Phe Ala Arg Pro Asp Ser Cys Ile Asp Gly Val Ser Val Tyr  
 260 265 270  
 Ala Ala Arg Val His Met Gly Gln Arg Leu Gly Glu Lys Ile Ala Arg  
 275 280 285  
 Glu Trp Ala Asp Val Asp Asp Ile Asp Val Val Ile Pro Val Pro Glu  
 290 295 300  
 Thr Ser Asn Asp Ile Ala Leu Arg Ile Ala Arg Val Leu Asn Lys Pro  
 305 310 315  
 Tyr Arg Gln Gly Phe Val Lys Asn Arg Tyr Val Gly Arg Thr Phe Ile  
 325 330 335  
 Met Pro Gly Gln Ala Leu Arg Val Ser Val Arg Arg Lys Leu Asn  
 340 345 350  
 Thr Ile Ala Ser Glu Phe Lys Asp Lys Asn Val Leu Leu Val Asp Asp  
 355 360 365  
 Ser Ile Val Arg Gly Thr Thr Ser Glu Gln Ile Val Glu Met Ala Arg  
 370 375 380  
 Ala Ala Gly Ala Lys Lys Ile Tyr Phe Ala Ser Ala Ala Pro Glu Ile  
 385 390 395 400  
 Arg Tyr Pro Asn Val Tyr Gly Ile Asp Met Pro Thr Lys Asn Glu Leu  
 405 410 415  
 Ile Ala Tyr Gly Arg Asp Val Asp Glu Ile Ala Asn Leu Ile Gly Val  
 420 425 430  
 Asp Lys Leu Ile Phe Gln Asp Leu Asp Ala Leu Thr Gly Ser Val Gln  
 435 440 445  
 Gln Glu Asn Pro Ser Ile Gln Asp Phe Asp Cys Ser Val Phe Thr Gly  
 450 455 460  
 Val Tyr Val Thr Gly Asp Ile Thr Pro Glu Tyr Leu Asp Asn Ile Ala  
 465 470 475 480  
 Glu Gln Arg Asn Asp Ile Ala Lys Lys Lys Arg Glu Lys Asp Ala Thr  
 485 490 495  
 Asn Leu Glu Met His Asn Glu Lys  
 500

<210> 112  
 <211> 989  
 <212> DNA  
 <213> Pasteurella multocida  
 <220>  
 <223> rci

WO 02/075507

PCT/US02/01971

```

<220>
<221> CDS
<222> (1)..(987)

<400> 112
atg gca aca ata aga aaa cgt ggt aac tca tat cgt gct gag ata agc 48
Met Ala Thr Ile Arg Lys Arg Gly Asn Ser Tyr Arg Ala Glu Ile Ser
1 5 10 15

aaa aac gga gta agg aaa tca gca aca ttt aag act aaa tca gaa gct 96
Lys Asn Gly Val Arg Lys Ser Ala Thr Phe Lys Thr Lys Ser Glu Ala
20 25 30

aat gcg tgg gct gtt gac gag gag aga aaa tta gct gat ttg gca aaa 144
Asn Ala Trp Ala Val Asp Glu Glu Arg Lys Leu Ala Asp Leu Ala Lys
35 40 45

ggt atc gct cca gat att att ttt aga gat gta ata gaa cgc tat caa 192
Gly Ile Ala Pro Asp Ile Ile Phe Arg Asp Val Ile Glu Arg Tyr Gln
50 55 60

aat gaa gtg tct ata act aaa aaa ggc gcg cga aat gaa att ata aga 240
Asn Glu Val Ser Ile Thr Lys Lys Gly Ala Arg Asn Glu Ile Ile Arg
65 70 75

tta aac cgc ttt tta aga tat gat att tct aat ctg tat att cgt gat 288
Leu Asn Arg Phe Leu Arg Tyr Asp Ile Ser Asn Leu Tyr Ile Arg Asp
85 90 95

tta aga aaa gaa gat ttt gag gag tgg atc aga att cgc cta acc gaa 336
Leu Arg Lys Glu Asp Phe Glu Glu Trp Ile Arg Ile Arg Leu Thr Glu
100 105 110

gta tcg gat gct agc gtt aga cgt gag ctt gtt act ata tcg tca gcg 384
Val Ser Asp Ala Ser Val Arg Arg Glu Leu Val Thr Ile Ser Ser Val
115 120 125

ctg aca aca gca ata aat aag tgg gga tat att tca agg cat cca atg 432
Leu Thr Thr Ala Ile Asn Lys Trp Gly Tyr Ile Ser Arg His Pro Met
130 135 140

act ggt att gaa aaa cca aaa aac tcg gca gaa aga aaa gaa cga tat 480
Thr Gly Ile Glu Lys Pro Lys Asn Ser Ala Glu Arg Lys Glu Arg Tyr
145 150 155

tca gaa cag gac att aaa aca ata tta gaa aca gct aga tat tgt gaa 528
Ser Glu Gln Asp Ile Lys Thr Ile Leu Glu Thr Ala Arg Tyr Cys Glu
165 170 175

gat aaa cta ccc ata aca ctc aaa caa aga gta gca att gca atg tta 576
Asp Lys Leu Pro Ile Thr Leu Lys Gln Arg Val Ala Ile Ala Met Leu
180 185 190

ttt gct att gaa acg gct atg cgt gct ggt gag att gct agt ata aaa 624
Phe Ala Ile Glu Thr Ala Met Arg Ala Gly Glu Ile Ala Ser Ile Lys
195 200 205

tgg gat aat gtt ttt ctt gaa aag aga ata gta cat tta ccg aca act 672
Trp Asp Asn Val Phe Leu Glu Lys Arg Ile Val His Leu Pro Thr Thr
210 215 220

```

WO 02/075507

PCT/US02/01971

aaa aac ggg cac tct aga gat gtg ccg ctt tcg caa aga gct gtt gcg 720  
 Lys Asn Gly His Ser Arg Asp Val Pro Leu Ser Gln Arg Ala Val Phe Ala  
 225 230 235 240  
 cta att tta aaa atg aaa gag gta gaa aat gga gat ctt gtg ttt cag 768  
 Leu Ile Leu Lys Met Lys Glu Val Glu Asn Gly Asp Leu Val Phe Gln  
 245 250 255  
 acc acg cct gaa tca tta agc acc acg ttt aga gtg tta aag aaa gag 816  
 Thr Thr Pro Glu Ser Leu Ser Thr Thr Phe Arg Val Leu Lys Lys Glu  
 260 265 270  
 tgt gga ctt gaa cat ctc cat ttt cat gat acg aga agg gaa gcg ttg 864  
 Cys Gly Leu Glu His Leu His Phe His Asp Thr Arg Arg Glu Ala Leu  
 275 280 285  
 acg aga tta tct aag aaa gta gat gta atg act cta gcc aaa att agc 912  
 Thr Arg Leu Ser Lys Lys Val Asp Val Met Thr Leu Ala Lys Ile Ser  
 290 295 300  
 gga cat aga gat tta aga att tta caa aac aca tat tac gca ccg aat 960  
 Gly His Arg Asp Leu Arg Ile Leu Gln Asn Thr Tyr Tyr Ala Pro Asn  
 305 310 315 320  
 atg agt gaa gtg gca aac ttg ttg gat ta 989  
 Met Ser Glu Val Ala Asn Leu Leu Asp  
 325

&lt;210&gt; 113

&lt;211&gt; 329

&lt;212&gt; PRT

<213> *Pasteurella multocida*

&lt;400&gt; 113

Met Ala Thr Ile Arg Lys Arg Gly Asn Ser Tyr Arg Ala Glu Ile Ser  
 1 5 10 15  
 Lys Asn Gly Val Arg Lys Ser Ala Thr Phe Lys Thr Lys Ser Glu Ala  
 20 25 30  
 Asn Ala Trp Ala Val Asp Glu Glu Arg Lys Leu Ala Asp Leu Ala Lys  
 35 40 45  
 Gly Ile Ala Pro Asp Ile Ile Phe Arg Asp Val Ile Glu Arg Tyr Gln  
 50 55 60  
 Asn Glu Val Ser Ile Thr Lys Lys Gly Ala Arg Asn Glu Ile Ile Arg  
 65 70 75 80  
 Leu Asn Arg Phe Leu Arg Tyr Asp Ile Ser Asn Leu Tyr Ile Arg Asp  
 85 90 95  
 Leu Arg Lys Glu Asp Phe Glu Glu Trp Ile Arg Ile Arg Leu Thr Glu  
 100 105 110  
 Val Ser Asp Ala Ser Val Arg Arg Glu Leu Val Thr Ile Ser Ser Val  
 115 120 125  
 Leu Thr Thr Ala Ile Asn Lys Trp Gly Tyr Ile Ser Arg His Pro Met  
 130 135 140  
 Thr Gly Ile Glu Lys Pro Lys Asn Ser Ala Glu Arg Lys Glu Arg Tyr



WO 02/075507

PCT/US02/01971

```

      50              55              60
ggc acg ctt tca cgt gcg ctt gac ggg att tct gat gta gtc aat tgc 240
Gly Thr Leu Ser Arg Ala Leu Asp Gly Ile Ser Asp Val Val Asn Cys
65              70              75              80

aaa gtg att gtt gtg cga gtg caa gaa agt gcg caa gaa gac gaa gaa 288
Lys Val Ile Val Val Arg Val Gln Glu Ser Ala Gln Glu Asp Glu Glu
85              90              95

aca aaa gca agt gaa atg aac acg gca att att ggc aca atc aca gaa 336
Thr Lys Ala Ser Glu Met Asn Thr Ala Ile Ile Gly Thr Ile Thr Glu
100             105             110

gaa ggg cag tac aca gcc ttg aag gcg tta ttg att gcg aaa aac aaa 384
Glu Gly Gln Tyr Thr Gly Leu Lys Ala Leu Leu Ile Ala Lys Asn Lys
115             120             125

ttc ggt atc aaa cca cgt att tta tgt gtg cca aaa ttc gac aca aaa 432
Phe Gly Ile Lys Pro Arg Ile Leu Cys Val Pro Lys Phe Asp Thr Lys
130             135             140

gaa gtc gcc aca gag ctt gca agt atc gcc gcc aaa ctc aac gca ttt 480
Glu Val Ala Thr Glu Leu Ala Ser Ile Ala Ala Lys Leu Asn Ala Phe
145             150             155

gct tac att tca tgt caa ggg tgt aaa acg aaa gaa caa gcg gtg caa 528
Ala Tyr Ile Ser Cys Gln Gly Cys Lys Thr Lys Glu Gln Ala Val Gln
165             170             175

tat aaa cgc aac ttc tca caa cgt gaa gtc atg ctg atc atg ggc gat 576
Tyr Lys Arg Asn Phe Ser Gln Arg Glu Val Met Leu Ile Met Gly Asp
180             185             190

ttt ctg tca ttt aat gtc aac aca tca aaa gtt gag att gac tat gcc 624
Phe Leu Ser Phe Asn Val Asn Thr Ser Lys Val Glu Ile Asp Tyr Ala
195             200             205

gtc act cgt gcg gcg gca atg cgt gca tat ctt gat aaa gaa cag gcc 672
Val Thr Arg Ala Ala Ala Met Arg Ala Tyr Leu Asp Lys Glu Gln Gly
210             215             220

tgg cat acg tct att tca aat aaa ggc att aat ggc gtg agc ggt gtc 720
Trp His Thr Ser Ile Ser Asn Lys Gly Ile Asn Gly Val Ser Gly Val
225             230             235             240

aca caa cca ctc tat ttt gac att aac gac agc tcg act gat gtg aac 768
Thr Gln Pro Leu Tyr Phe Asp Ile Asn Asp Ser Ser Thr Asp Val Asn
245             250             255

tat ctc aat gaa caa gcc atc acg tgt tgc gtg aat cat aat ggc ttt 816
Tyr Leu Asn Glu Gln Gly Ile Thr Cys Cys Val Asn His Asn Gly Phe
260             265             270

cgt ttt tgg ggc tta cgc acg act gca gaa gat cca tta ttc aag ttt 864
Arg Phe Trp Gly Leu Arg Thr Thr Ala Glu Asp Pro Leu Phe Lys Phe
275             280             285

gaa gtg tac acc cgc act gca caa atc tta aaa gat acg att gca ggg 912
Glu Val Tyr Thr Arg Thr Ala Gln Ile Leu Lys Asp Thr Ile Ala Gly
290             295             300

gcg ttt gat tgg gca gtg gat aaa gat att tct gtc acg cta gtg aaa 960

```

WO 02/075507

PCT/US02/01971

Ala Phe Asp Trp Ala Val Asp Lys Asp Ile Ser Val Thr Leu Val Lys  
 305 310 315 320

gat att att gaa gca atc aat gcg aag tgg cgt gat tac acc aca aaa 1008  
 Asp Ile Ile Glu Ala Ile Asn Ala Lys Trp Arg Asp Tyr Thr Thr Lys  
 325 330 335

ggc tac tra att ggc ggt aaa gcg tgg ctt aat aaa gag ctt aac agt 1056  
 Gly Tyr Leu Ile Gly Gly Lys Ala Trp Leu Asn Lys Glu Leu Asn Ser  
 340 345 350

gca acg aat tta aaa gat gcg aag ttg ttg atc tct tat gat tat cac 1104  
 Ala Thr Asn Leu Lys Asp Ala Lys Leu Leu Ile Ser Tyr Asp Tyr His  
 355 360 365

cca gta cca ccg ctc gaa cag cta ggc ttt aat cag tac att tct gat 1152  
 Pro Val Pro Pro Leu Glu Gln Leu Gly Phe Asn Gln Tyr Ile Ser Asp  
 370 375 380

gaa tac ctt gtt gat ttt tca aat cgt tta gca tcg ta 1190  
 Glu Tyr Leu Val Asp Phe Ser Asn Arg Leu Ala Ser  
 385 390 395

<210> 115  
 <211> 396  
 <212> PRT  
 <213> Pasteurella multocida

<400> 115  
 Met Ser Glu Glu Tyr Leu His Gly Val Lys Val Thr Glu Ile Asn Gln  
 1 5 10 15

Ala Ile Arg Thr Ile Gln Ser Leu Ser Thr Ala Val Ile Gly Ile Val  
 20 25 30

Cys Thr Ala Asn Asp Ala Asp Asn Glu Thr Phe Pro Leu Asn Glu Pro  
 35 40 45

Val Leu Ile Thr Asn Val Ala Ala Ala Ile Gly Lys Ala Gly Lys Gln  
 50 55 60

Gly Thr Leu Ser Arg Ala Leu Asp Gly Ile Ser Asp Val Val Asn Cys  
 65 70 75 80

Lys Val Ile Val Val Arg Val Gln Glu Ser Ala Gln Glu Asp Glu Glu  
 85 90 95

Thr Lys Ala Ser Glu Met Asn Thr Ala Ile Ile Gly Thr Ile Thr Glu  
 100 105 110

Glu Gly Gln Tyr Thr Gly Leu Lys Ala Leu Leu Ile Ala Lys Asn Lys  
 115 120 125

Phe Gly Ile Lys Pro Arg Ile Leu Cys Val Pro Lys Phe Asp Thr Lys  
 130 135 140

Glu Val Ala Thr Glu Leu Ala Ser Ile Ala Ala Lys Leu Asn Ala Phe  
 145 150 155 160

Ala Tyr Ile Ser Cys Gln Gly Cys Lys Thr Lys Glu Gln Ala Val Gln  
 165 170 175

WO 02/075507

PCT/US02/01971

Tyr Lys Arg Asn Phe Ser Gln Arg Glu Val Met Leu Ile Met Gly Asp  
 180 185 190  
 Phe Leu Ser Phe Asn Val Asn Thr Ser Lys Val Glu Ile Asp Tyr Ala  
 195 200 205  
 Val Thr Arg Ala Ala Met Arg Ala Tyr Leu Asp Lys Glu Gln Gly  
 210 215 220  
 Trp His Thr Ser Ile Ser Asn Lys Gly Ile Asn Gly Val Ser Gly Val  
 225 230 235 240  
 Thr Gln Pro Leu Tyr Phe Asp Ile Asn Asp Ser Ser Thr Asp Val Asn  
 245 250 255  
 Tyr Leu Asn Glu Gln Gly Ile Thr Cys Cys Val Asn His Asn Gly Phe  
 260 265 270  
 Arg Phe Trp Gly Leu Arg Thr Thr Ala Glu Asp Pro Leu Phe Lys Phe  
 275 280 285  
 Glu Val Tyr Thr Arg Thr Ala Gln Ile Leu Lys Asp Thr Ile Ala Gly  
 290 295 300  
 Ala Phe Asp Trp Ala Val Asp Lys Asp Ile Ser Val Thr Leu Val Lys  
 305 310 315 320  
 Asp Ile Ile Glu Ala Ile Asn Ala Lys Trp Arg Asp Tyr Thr Thr Lys  
 325 330 335  
 Gly Tyr Leu Ile Gly Gly Lys Ala Trp Leu Asn Lys Glu Leu Asn Ser  
 340 345 350  
 Ala Thr Asn Leu Lys Asp Ala Lys Leu Ile Ser Tyr Asp Tyr His  
 355 360 365  
 Pro Val Pro Pro Leu Glu Gln Leu Gly Phe Asn Gln Tyr Ile Ser Asp  
 370 375 380  
 Glu Tyr Leu Val Asp Phe Ser Asn Arg Leu Ala Ser  
 385 390 395

&lt;210&gt; 116

&lt;211&gt; 2204

&lt;212&gt; DNA

&lt;213&gt; Pasteurella multocida

&lt;220&gt;

&lt;223&gt; unkk

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(2202)

&lt;400&gt; 116

atg aat aaa aat cgc tat aaa ctc att ttt agt aaa act aaa ggc tgt 48  
 Met Asn Lys Asn Arg Tyr Lys Leu Ile Phe Ser Lys Thr Lys Gly Cys  
 1 5 10 15

ctt gta cct gtt gct gaa acg att aat tct gca gta gga aat gcc tca 96  
 Leu Val Pro Val Ala Glu Thr Ile Asn Ser Ala Val Gly Asn Ala Ser  
 20 25 30

WO 02/075507

PCT/US02/01971

tca aaa gac gtt tct gac acc gag ata agt gct tct caa cca gcg ctc 144  
 Ser Lys Asp Val Ser Asp Thr Leu Ser Val Leu Ser Ala Ser Gln Pro Ala Leu  
 35 40 45

aac tcg ccg ctt tgg acc ctt tct gta tta gtc aaa acc gca ttt aat 192  
 Asn Ser Pro Leu Ser Thr Leu Ser Val Leu Val Lys Thr Ala Phe Asn  
 50 55 60

ccg gtt tca aca ttg atg tgg ttg act tgg aaa gaa tac gcc gtt tta 240  
 Pro Val Ser Thr Leu Met Ser Leu Thr Trp Lys Glu Tyr Ala Val Leu  
 65 70 75 80

tta tta agt gtg gtg tct ttt cct ctt atg gca caa gcc tct gat aca 288  
 Leu Leu Ser Val Val Ser Phe Pro Leu Met Ala Gln Ala Ser Asp Thr  
 85 90 95

gat tca gtg gta caa aga aaa cct gaa tta act gat gtg acg aat agc 336  
 Asp Ser Val Val Gln Arg Lys Pro Glu Leu Thr Asp Val Thr Asn Ser  
 100 105 110

aac agc tat cat gtg gaa tta gat aga gag cat cat aaa ggg gag cat 384  
 Asn Ser Tyr His Val Glu Leu Asp Arg Glu His His Lys Gly Glu His  
 115 120 125

caa aca aaa atc aaa cat act gag aat aat gtc atc att gtt gat att 432  
 Gln Thr Lys Ile Lys His Thr Glu Asn Asn Val Ile Ile Val Asp Ile  
 130 135 140

gca aaa cca aac caa aag ggc att tca gat aac cgt ttt aaa cac ttc 480  
 Ala Lys Pro Asn Gln Lys Gly Ile Ser Asp Asn Arg Phe Lys His Phe  
 145 150 155 160

aac atc cca aat ggg gcg gta ttt aac aat agc gcc aag gaa aaa cgc 528  
 Asn Ile Pro Asn Gly Ala Val Phe Asn Asn Ser Ala Lys Glu Lys Arg  
 165 170 175

tca cag tta gtg ggg tat ttg cca ggt aac cag aat tta acg gaa ggt 576  
 Ser Gln Leu Val Gly Tyr Leu Pro Gly Asn Gln Asn Leu Thr Glu Gly  
 180 185 190

agt gaa gca aaa gcg atc tta aat cag gtg act gga ccg gat gcc agt 624  
 Ser Glu Ala Lys Ala Ile Leu Asn Gln Val Thr Gly Pro Asp Ala Ser  
 195 200 205

aaa att gaa ggc gcc ctt gaa att tta ggg caa aaa gcc gat ttg gtg 672  
 Lys Ile Glu Gly Ala Leu Glu Ile Leu Gly Gln Lys Ala Asp Leu Val  
 210 215 220

att gcg aac caa aat ggc att gtg ctt aat ggg gta aaa acc att aat 720  
 Ile Ala Asn Gln Asn Gly Ile Val Leu Asn Gly Val Lys Thr Ile Asn  
 225 230 235 240

gcc aat cgt ttt gtg gca aca acc agt agt acc att gat cct gag caa 768  
 Ala Asn Arg Phe Val Ala Thr Thr Ser Thr Thr Ile Asp Pro Glu Gln  
 245 250 255

atg cag tta aat gtc acg caa ggt aca gtg aca att ggg gtg gat gga 816  
 Met Gln Leu Asn Val Thr Gln Gly Thr Val Thr Ile Gly Val Asp Gly  
 260 265 270

ttt gcc aca gat ggc tta cct tat ttg gat atc att gcc aaa aag att 864  
 Phe Ala Thr Asp Gly Leu Pro Tyr Leu Asp Ile Ile Ala Lys Lys Ile  
 275 280 285



WO 02/075507

PCT/US02/01971

gaa caa aaa caa gcg att aca aaa gaa aga aca gga aat tcc gaa acc 912  
 Glu Gln Lys Gln Ala Ile Thr Lys Lys Glu Arg Thr Gly Asn Ser Glu Thr  
 290 295 300

gat atc act ttt gtc gca ggt aac agt aaa tat gat tta aag aca cat 960  
 Asp Ile Thr Phe Val Ala Gly Asn Ser Lys Tyr Asp Leu Lys Thr His  
 305 310 315

caa gtg aca gaa aag cat acc gct gag gca caa ggt gaa att gcg att 1008  
 Gln Val Thr Glu Lys His Thr Ala Glu Ala Gln Gly Glu Ile Ala Ile  
 325 330 335

agc ggt gcg agt acc ggt gca atg tac ggt aaa aat atc aaa tta atc 1056  
 Ser Gly Ala Ser Thr Gly Ala Met Tyr Gly Lys Asn Ile Lys Leu Ile  
 340 345 350

gta acg gat aaa ggc gct ggg gta aaa cat gat ggc att att tta tct 1104  
 Val Thr Asp Lys Gly Ala Gly Val Lys His Asp Gly Ile Ile Leu Ser  
 355 360 365

gag gcg gat att caa att gaa acc cat gag ggc gat gtt gaa tta ggc 1152  
 Glu Ala Asp Ile Gln Ile Glu Thr His Glu Gly Asp Val Glu Leu Gly  
 370 375 380

aat aca aaa aat aat cag aat gag aat tat gcc aaa gct cat gcg gaa 1200  
 Asn Thr Lys Asn Asn Gln Asn Glu Asn Tyr Ala Lys Ala His Ala Glu  
 385 390 395 400

ggg aat ttt acg gtt aaa ggc ggt aag cac gtt att att ggt aag gaa 1248  
 Gly Asn Phe Thr Val Lys Gly Gly Lys His Val Ile Ile Gly Lys Glu  
 405 410 415

gtt aaa gcc aac aaa gcg gtc gat att caa gca caa gaa aca aca gta 1296  
 Val Lys Ala Asn Lys Ala Val Asp Ile Gln Ala Gln Glu Thr Thr Val  
 420 425 430

aga caa aat gcg aaa tta act gcc aaa acg agt gcc aaa att aca gca 1344  
 Arg Gln Asn Ala Lys Leu Thr Ala Lys Thr Ser Ala Lys Ile Thr Ala  
 435 440 445

agt aag agt gtg aat ctt gaa gat aac gcg aaa ctt att gct aat geg 1392  
 Ser Lys Ser Val Asn Leu Glu Asp Asn Ala Lys Leu Ile Ala Asn Glu  
 450 455 460

ctg agc aca aca acc aat aaa tta acc aat aaa ggt agc att tac ggc 1440  
 Leu Ser Thr Thr Thr Asn Lys Leu Thr Asn Lys Gly Ser Ile Tyr Gly  
 465 470 475 480

aag aaa gtg acg cta gat gct gat aat tta gtc aat agt aaa gaa atc 1488  
 Lys Lys Val Thr Leu Asp Ala Asp Asn Leu Val Asn Ser Lys Glu Ile  
 485 490 495

tat gcg tct agc gaa ctt gat att caa acc aaa ggt cgt gat ctt tta 1536  
 Tyr Ala Ser Ser Glu Leu Asp Ile Gln Thr Lys Gly Arg Asp Leu Leu  
 500 505 510

ctt gag gat ggg gtt aat caa cca ctg agt ttc tta aaa ggc gct tca 1584  
 Leu Glu Asp Gly Val Asn Gln Pro Leu Ser Phe Leu Lys Gly Ala Ser  
 515 520 525

ttg tta gcg ccg ggg ttt gtc aac act ggg cta att cac agt aac ggt 1632  
 Leu Leu Ala Pro Gly Phe Val Asn Thr Gly Leu Ile His Ser Asn Gly  
 530 535 540

WO 02/075507

PCT/US02/01971

aat gcc aag ctc act ttt aaa gat gac acc agt ttt gtg act gaa gga 1680  
 Asn Ala Lys Leu Thr Phe Lys Asp Asp Thr Ser Phe Val Thr Glu Gly  
 545 550 555 560

aat aac ttt atc aca gca aaa gac aac tta gaa atc acg gca aaa aat 1728  
 Asn Asn Phe Ile Thr Ala Lys Asp Asn Leu Glu Ile Thr Ala Lys Asn  
 565 570 575

gtt caa att gat caa gcg aaa aat att caa tta aac gcg aat atc acg 1776  
 Val Gln Ile Asp Gln Ala Lys Asn Ile Gln Leu Asn Ala Asn Ile Thr  
 580 585 590

atc aat acc aag tct ggt ttt gtg aat tac ggt acc tta gca agt gct 1824  
 Ile Asn Thr Lys Ser Gly Phe Val Asn Tyr Gly Thr Leu Ala Ser Ala  
 595 600 605

caa aat tta acg att aat acc gaa caa ggc agc att tat aac sta ggc 1872  
 Gln Asn Leu Thr Ile Asn Thr Glu Gln Gly Ser Ile Tyr Asn Ile Gly  
 610 615 620

ggt atc ttg ggc gcg ggt aaa agt ttg aat ctg agc gcg aaa aga gga 1920  
 Gly Ile Leu Gly Ala Gly Lys Ser Leu Asn Leu Ser Ala Lys Arg Gly  
 625 630 635 640

gaa aac caa gga gga tat ctt att aat caa ggt aag agt cta ctc cat 1968  
 Glu Asn Gln Gly Gly Tyr Leu Ile Asn Gln Gly Lys Ser Leu Leu His  
 645 650 655

tct gaa ggc gcc atg aac ctc aca gcg gat cgc acg gtg tac aat tta 2016  
 Ser Glu Gly Ala Met Asn Leu Thr Ala Asp Arg Thr Val Tyr Asn Leu  
 660 665 670

ggg aat att ttt gct aaa ggt gac gcg acg atc aat gca aac gcg tta 2064  
 Gly Asn Ile Phe Ala Lys Gly Asp Ala Thr Ile Asn Ala Asn Ala Leu  
 675 680 685

att aat gat gtt act ctc aca ggt cgt ctt gag tat caa gat ctg aaa 2112  
 Ile Asn Asp Val Thr Leu Thr Gly Arg Leu Glu Tyr Gln Asp Leu Lys  
 690 695 700

aaa gat tat acg cgt tat tat cgt atc aat gaa acg gca aaa cat ggt 2160  
 Lys Asp Tyr Thr Arg Tyr Tyr Arg Ile Asn Glu Thr Ala Lys His Gly  
 705 710 715 720

tgg cat aat aac ttc tat gaa tta aac gtc gac aga gtt tct tg 2204  
 Trp His Asn Asn Phe Tyr Glu Leu Asn Val Asp Arg Val Ser  
 725 730

<210> 117  
 <211> 734  
 <212> PRT  
 <213> Pasteurella multocida

<400> 117  
 Met Asn Lys Asn Arg Tyr Lys Leu Ile Phe Ser Lys Thr Lys Gly Cys  
 1 5 10 15  
 Leu Val Pro Val Ala Glu Thr Ile Asn Ser Ala Val Gly Asn Ala Ser  
 20 25 30  
 Ser Lys Asp Val Ser Asp Thr Glu Ile Ser Ala Ser Gln Pro Ala Leu  
 35 40 45

WO 02/075507

PCT/US02/01971

Asn Ser Pro Leu Ser Thr Leu Ser Val Leu Val Lys Thr Ala Phe Asn  
 50 55 60  
 Pro Val Ser Thr Leu Met Ser Leu Thr Trp Lys Glu Tyr Ala Val Leu  
 65 70 75  
 Leu Leu Ser Val Val Ser Phe Pro Leu Met Ala Gln Ala Ser Asp Thr  
 85 90  
 Asp Ser Val Val Gln Arg Lys Pro Glu Leu Thr Asp Val Thr Asn Ser  
 100 105 110  
 Asn Ser Tyr His Val Glu Leu Asp Arg Glu His His Lys Gly Glu His  
 115 120 125  
 Gln Thr Lys Ile Lys His Thr Glu Asn Asn Val Ile Ile Val Asp Ile  
 130 135 140  
 Ala Lys Pro Asn Gln Lys Gly Ile Ser Asp Asn Arg Phe Lys His Phe  
 145 150 155 160  
 Asn Ile Pro Asn Gly Ala Val Phe Asn Asn Ser Ala Lys Glu Lys Arg  
 165 170 175  
 Ser Gln Leu Val Gly Tyr Leu Pro Gly Asn Gln Asn Leu Thr Glu Gly  
 180 185 190  
 Ser Glu Ala Lys Ala Ile Leu Asn Gln Val Thr Gly Pro Asp Ala Ser  
 195 200 205  
 Lys Ile Glu Gly Ala Leu Glu Ile Leu Gly Gln Lys Ala Asp Leu Val  
 210 215 220  
 Ile Ala Asn Gln Asn Gly Ile Val Leu Asn Gly Val Lys Thr Ile Asn  
 225 230 235 240  
 Ala Asn Arg Phe Val Ala Thr Thr Ser Ser Thr Ile Asp Pro Glu Gln  
 245 250 255  
 Met Gln Leu Asn Val Thr Gln Gly Thr Val Thr Ile Gly Val Asp Gly  
 260 265 270  
 Phe Ala Thr Asp Gly Leu Pro Tyr Leu Asp Ile Ile Ala Lys Lys Ile  
 275 280 285  
 Glu Gln Lys Gln Ala Ile Thr Lys Glu Arg Thr Gly Asn Ser Glu Thr  
 290 295 300  
 Asp Ile Thr Phe Val Ala Gly Asn Ser Lys Tyr Asp Leu Lys Thr His  
 305 310 315 320  
 Gln Val Thr Glu Lys His Thr Ala Glu Ala Gln Gly Glu Ile Ala Ile  
 325 330 335  
 Ser Gly Ala Ser Thr Gly Ala Met Tyr Gly Lys Asn Ile Lys Leu Ile  
 340 345 350  
 Val Thr Asp Lys Gly Ala Gly Val Lys His Asp Gly Ile Ile Leu Ser  
 355 360 365  
 Glu Ala Asp Ile Gln Ile Glu Thr His Glu Gly Asp Val Glu Leu Gly  
 370 375 380

WO 02/075507

PCT/US02/01971

Asn Thr Lys Asn Asn Gln Asn Glu Asn Tyr Ala Lys Ala His Ala Glu  
 385 390 395 400  
 Gly Asn Phe Thr Val Lys Gly Gly Lys His Val Ile Ile Gly Lys Glu  
 405 410 415  
 Val Lys Ala Asn Lys Ala Val Asp Ile Gln Ala Gln Glu Thr Thr Val  
 420 425 430  
 Arg Gln Asn Ala Lys Leu Thr Ala Lys Thr Ser Ala Lys Ile Thr Ala  
 435 440 445  
 Ser Lys Ser Val Asn Leu Glu Asp Asn Ala Lys Leu Ile Ala Asn Glu  
 450 455 460  
 Leu Ser Thr Thr Thr Asn Lys Leu Thr Asn Lys Gly Ser Ile Tyr Gly  
 465 470 475 480  
 Lys Lys Val Thr Leu Asp Ala Asp Asn Leu Val Asn Ser Lys Glu Ile  
 485 490 495  
 Tyr Ala Ser Ser Glu Leu Asp Ile Gln Thr Lys Gly Arg Asp Leu Leu  
 500 505 510  
 Leu Glu Asp Gly Val Asn Gln Pro Leu Ser Phe Leu Lys Gly Ala Ser  
 515 520 525  
 Leu Leu Ala Pro Gly Phe Val Asn Thr Gly Leu Ile His Ser Asn Gly  
 530 535 540  
 Asn Ala Lys Leu Thr Phe Lys Asp Asp Thr Ser Phe Val Thr Glu Gly  
 545 550 555 560  
 Asn Asn Phe Ile Thr Ala Lys Asp Asn Leu Glu Ile Thr Ala Lys Asn  
 565 570 575  
 Val Gln Ile Asp Gln Ala Lys Asn Ile Gln Leu Asn Ala Asn Ile Thr  
 580 585 590  
 Ile Asn Thr Lys Ser Gly Phe Val Asn Tyr Gly Thr Leu Ala Ser Ala  
 595 600 605  
 Gln Asn Leu Thr Ile Asn Thr Glu Gln Gly Ser Ile Tyr Asn Ile Gly  
 610 615 620  
 Gly Ile Leu Gly Ala Gly Lys Ser Leu Asn Leu Ser Ala Lys Arg Gly  
 625 630 635 640  
 Glu Asn Gln Gly Gly Tyr Leu Ile Asn Gln Gly Lys Ser Leu Leu His  
 645 650 655  
 Ser Glu Gly Ala Met Asn Leu Thr Ala Asp Arg Thr Val Tyr Asn Leu  
 660 665 670  
 Gly Asn Ile Phe Ala Lys Gly Asp Ala Thr Ile Asn Ala Asn Ala Leu  
 675 680 685  
 Ile Asn Asp Val Thr Leu Thr Gly Arg Leu Glu Tyr Gln Asp Leu Lys  
 690 695 700  
 Lys Asp Tyr Thr Arg Tyr Tyr Arg Ile Asn Glu Thr Ala Lys His Gly  
 705 710 715 720

WO 02/075507

PCT/US02/01971

Trp His Asn Asn Phe Tyr Glu Leu Asn Val Asp Arg Val Ser  
 725 730

<210> 118  
 <211> 251  
 <212> DNA  
 <213> Pasteurella multocida

<220>  
 <223> unko

<220>  
 <221> CDS  
 <222> (1)..(249)

<400> 118  
 atg aaa att act att aca cga aat cat cca gaa gta ttt caa gaa tcc 48  
 Met Lys Ile Thr Ile Thr Arg Asn His Pro Glu Val Phe Gln Glu Ser  
 1 5 10 15  
 gct cgt tta gta gcc gaa aag ttc att aaa gcc caa tgt gta gaa gca 96  
 Ala Arg Leu Val Ala Glu Lys Phe Ile Lys Ala Gln Cys Val Glu Ala  
 20 25 30  
 tta aca ttg gct ttg att gag ggt gtc gag cac ttt gtg ctg gaa ggt 144  
 Leu Thr Leu Ala Leu Ile Glu Gly Val Glu His Phe Val Leu Glu Gly  
 35 40 45  
 gag gag gaa agc aaa agg gga cat agt att aag gtt gta tta aaa gga 192  
 Glu Glu Glu Ser Lys Arg Gly His Ser Ile Lys Val Val Leu Lys Gly  
 50 55 60  
 agt cac gaa gtt att aag tca gag gtg aat aca aat gaa aaa aat cat 240  
 Ser His Glu Val Ile Lys Ser Glu Val Asn Thr Asn Glu Lys Asn His  
 65 70 75 80  
 tgt aat cat ta 251  
 Cys Asn His

<210> 119  
 <211> 83  
 <212> PRT  
 <213> Pasteurella multocida

<400> 119  
 Met Lys Ile Thr Ile Thr Arg Asn His Pro Glu Val Phe Gln Glu Ser  
 1 5 10 15  
 Ala Arg Leu Val Ala Glu Lys Phe Ile Lys Ala Gln Cys Val Glu Ala  
 20 25 30  
 Leu Thr Leu Ala Leu Ile Glu Gly Val Glu His Phe Val Leu Glu Gly  
 35 40 45  
 Glu Glu Glu Ser Lys Arg Gly His Ser Ile Lys Val Val Leu Lys Gly  
 50 55 60  
 Ser His Glu Val Ile Lys Ser Glu Val Asn Thr Asn Glu Lys Asn His  
 65 70 75 80

WO 02/075507

PCT/US02/01971

Cys Asn His

&lt;210&gt; 120

&lt;211&gt; 548

&lt;212&gt; DNA

&lt;213&gt; Pasteurella multocida

&lt;220&gt;

&lt;223&gt; unkP

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(546)

&lt;400&gt; 120

```

atg cgt gca tat ctt gat aaa gaa cag ggc tgg cat acg tct att tca 48
Met Arg Ala Tyr Leu Asp Lys Glu Gln Gly Trp His Thr Ser Ile Ser
1 5 10 15
aat aaa ggc att aat ggc gtg agc ggt gtc aca caa cca ctc tat ttt 96
Asn Lys Gly Ile Asn Gly Val Ser Gly Val Thr Gln Pro Leu Tyr Phe
20 25 30
gac att aac gac agc tcg act gat gtg aac tat ctc aat gaa caa ggc 144
Asp Ile Asn Asp Ser Ser Thr Asp Val Asn Tyr Leu Asn Glu Gln Gly
35 40 45
atc acg tgt tgc gtg aat cat aat ggc ttt cgt ttt tgg ggc tta cgc 192
Ile Thr Cys Cys Val Asn His Asn Gly Phe Arg Phe Trp Gly Leu Arg
50 55 60
acg act gca gaa gat cca tta ttc aag ttt gaa gtg tac acc cgc act 240
Thr Thr Ala Glu Asp Pro Leu Phe Lys Phe Glu Val Tyr Thr Arg Thr
65 70 75 80
gca caa atc tta aaa gat acg att gca ggg gcs ttt gat tgg gca gtg 288
Ala Gln Ile Leu Lys Asp Thr Ile Ala Gly Ala Phe Asp Trp Ala Val
85 90 95
gat aaa gat att tct gtc acg cta gtg aaa gat att att gaa gca atc 336
Asp Lys Asp Ile Ser Val Thr Leu Val Lys Asp Ile Ile Glu Ala Ile
100 105 110
aat gcg aag tgg cgt gat tac acc aca aaa ggc tac tta att ggc ggt 384
Asn Ala Lys Trp Arg Asp Tyr Thr Thr Lys Gly Tyr Leu Ile Gly Gly
115 120 125
aaa gcg tgg ctt aat aaa gag ctt aac agt gca acg aat tta aaa gat 432
Lys Ala Trp Leu Asn Lys Glu Leu Asn Ser Ala Thr Asn Leu Lys Asp
130 135 140
gcg aag ttg ttg atc tct tat gat tat cac cca gta cca ccg ctc gaa 480
Ala Lys Leu Leu Ile Ser Tyr Asp Tyr His Pro Val Pro Pro Leu Glu
145 150 155 160
cag cta ggc ttt aat cag tac att tct gat gaa tac ctt gtt gat ttt 528
Gln Leu Gly Phe Asn Gln Tyr Ile Ser Asp Glu Tyr Leu Val Asp Phe
165 170 175
tca aat cgt tta gca tcg ta 548

```

222

WO 02/075507

PCT/US02/01971

Ser Asn Arg Leu Ala Ser  
180

<210> 121  
<211> 182  
<212> PRT  
<213> Pasteurella multocida

<400> 121  
Met Arg Ala Tyr Leu Asp Lys Glu Gln Gly Trp His Thr Ser Ile Ser  
1 5 10 15  
Asn Lys Gly Ile Asn Gly Val Ser Gly Val Thr Gln Pro Leu Tyr Phe  
20 25 30  
Asp Ile Asn Asp Ser Ser Thr Asp Val Asn Tyr Leu Asn Glu Gln Gly  
35 40 45  
Ile Thr Cys Cys Val Asn His Asn Gly Phe Arg Phe Trp Gly Leu Arg  
50 55 60  
Thr Thr Ala Glu Asp Pro Leu Phe Lys Phe Glu Val Tyr Thr Arg Thr  
65 70 75 80  
Ala Gln Ile Leu Lys Asp Thr Ile Ala Gly Ala Phe Asp Trp Ala Val  
85 90 95  
Asp Lys Asp Ile Ser Val Thr Leu Val Lys Asp Ile Ile Glu Ala Ile  
100 105 110  
Asn Ala Lys Trp Arg Asp Tyr Thr Thr Lys Gly Tyr Leu Ile Gly Gly  
115 120 125  
Lys Ala Trp Leu Asn Lys Glu Leu Asn Ser Ala Thr Asn Leu Lys Asp  
130 135 140  
Ala Lys Leu Leu Ile Ser Tyr Asp Tyr His Pro Val Pro Pro Leu Glu  
145 150 155 160  
Gln Leu Gly Phe Asn Gln Tyr Ile Ser Asp Glu Tyr Leu Val Asp Phe  
165 170 175

Ser Asn Arg Leu Ala Ser  
180

<210> 122  
<211> 69  
<212> DNA  
<213> Actinobacillus pleuropneumoniae

<220>  
<223> apvA-or1  
<220>  
<221> CDS  
<222> (1)..(69)

<400> 122  
atg ttt tat gtc atg ctt gcc aat agg acg tct ata att tca tca atc 48  
Met Phe Tyr Val Met Leu Ala Asn Arg Thr Ser Ile Ile Ser Ser Ile  
1 5 10 15

WO 02/075507

PCT/US02/01971

gat aag ttt aag ata ctt agc  
 Asp Lys Phe Lys Ile Leu Ser  
 20

69

<210> 123  
 <211> 23  
 <212> PRT  
 <213> Actinobacillus pleuropneumoniae

<400> 123  
 Met Phe Tyr Val Met Leu Ala Asn Arg Thr Ser Ile Ile Ser Ser Ile  
 1 5 10 15

Asp Lys Phe Lys Ile Leu Ser  
 20

<210> 124  
 <211> 64  
 <212> DNA  
 <213> Actinobacillus pleuropneumoniae

<220>  
 <223> apvA-or2

<220>  
 <221> CDS  
 <222> (3)..(62)

<400> 124  
 ag cta agt atc tta aac tta tcg att gat gaa att ata gac gtc cta 47  
 Leu Ser Ile Leu Asn Leu Ser Ile Asp Glu Ile Ile Asp Val Leu  
 1 5 10 15

ttg gca agc atg aca ta 64  
 Leu Ala Ser Met Thr  
 20

<210> 125  
 <211> 20  
 <212> PRT  
 <213> Actinobacillus pleuropneumoniae

<400> 125  
 Leu Ser Ile Leu Asn Leu Ser Ile Asp Glu Ile Ile Asp Val Leu Leu  
 1 5 10 15

Ala Ser Met Thr  
 20

<210> 126  
 <211> 653  
 <212> DNA  
 <213> Actinobacillus pleuropneumoniae

<220>  
 <223> apvB

<220>  
 <221> CDS



WO 02/075507

PCT/US02/01971

<222> (1)..(651)

<400> 126

tta	att	agc	ttt	cct	ttt	att	act	ttt	gca	agt	aat	gtt	aat	gga	gcc	48
Leu	Ile	Ser	Phe	Pro	Phe	Ile	Thr	Phe	Ala	Ser	Asn	Val	Asn	Gly	Ala	
1			5						10					15		

gaa	att	gga	ttg	gga	gga	gcc	cgt	gag	agt	agt	att	tac	tat	tct	aaa	96
Glu	Ile	Gly	Leu	Gly	Gly	Ala	Arg	Glu	Ser	Ser	Ile	Tyr	Tyr	Ser	Lys	
			20					25				30				

cat	aaa	gta	gca	aca	aat	ccc	ttt	tta	gca	ctt	gat	ctt	tct	tta	ggt	144
His	Lys	Val	Ala	Thr	Asn	Pro	Phe	Leu	Ala	Leu	Asp	Leu	Ser	Leu	Gly	
		35					40				45					

aat	ttt	tat	atg	aga	ggg	act	gca	gga	att	agc	gaa	ata	gga	tat	gaa	192
Asn	Phe	Tyr	Met	Arg	Gly	Thr	Ala	Gly	Ile	Ser	Glu	Ile	Gly	Tyr	Glu	
		50				55					60					

caa	tct	ttc	act	gac	aat	ttc	agc	gta	tca	ctg	ttt	ggt	aac	cca	ttt	240
Gln	Ser	Phe	Thr	Asp	Asn	Phe	Ser	Val	Ser	Leu	Phe	Val	Asn	Pro	Phe	
		65			70			75						80		

gat	ggt	ttt	tca	att	aaa	gga	aaa	gac	ttg	tta	cct	gga	tat	caa	agt	288
Asp	Gly	Phe	Ser	Ile	Lys	Gly	Lys	Asp	Leu	Leu	Pro	Gly	Tyr	Gln	Ser	
				85				90								

att	caa	act	cgc	aaa	act	caa	ttt	gcc	ttt	ggt	tgg	gga	tta	aat	tat	336
Ile	Gln	Thr	Arg	Lys	Thr	Gln	Phe	Ala	Phe	Gly	Trp	Gly	Leu	Asn	Tyr	
			100					105					110			

aat	ttg	gga	ggt	tta	ttc	ggc	tta	aat	gat	act	ttt	ata	tcc	ttg	gaa	384
Asn	Leu	Gly	Gly	Leu	Phe	Gly	Leu	Asn	Asp	Thr	Phe	Ile	Ser	Leu	Glu	
		115				120					125					

gga	aaa	agc	gga	aaa	cgt	ggt	gcg	agt	agt	aat	gtc	agc	tta	ctt	aaa	432
Gly	Lys	Ser	Gly	Lys	Arg	Gly	Ala	Ser	Ser	Asn	Val	Ser	Leu	Leu	Lys	
		130			135						140					

tcg	ttt	aat	atg	acg	aaa	aat	tgg	aaa	ggt	tca	cca	tat	att	ggc	tca	480
Ser	Phe	Asn	Met	Thr	Lys	Asn	Trp	Lys	Val	Ser	Pro	Tyr	Ile	Gly	Ser	
		145			150					155				160		

agt	tat	tat	tca	tct	aaa	tat	aca	gat	tat	tac	ttt	ggt	att	aaa	caa	528
Ser	Tyr	Tyr	Ser	Lys	Tyr	Thr	Asp	Tyr	Tyr	Phe	Gly	Ile	Lys	Gln		
			165					170					175			

tcc	gaa	tta	ggt	aat	aaa	att	aca	tcc	gta	tat	aaa	cct	aaa	gca	gct	576
Ser	Glu	Leu	Gly	Asn	Lys	Ile	Thr	Ser	Val	Tyr	Lys	Pro	Lys	Ala	Ala	
		180					185					190				

tat	gca	aca	cac	ata	ggt	att	aat	act	gat	tat	gct	ttc	acg	aac	aat	624
Tyr	Ala	Thr	His	Ile	Gly	Ile	Asn	Thr	Asp	Tyr	Ala	Phe	Thr	Asn	Asn	
		195			200						205					

ctt	ggc	atg	ggt	tta	tct	gtc	ggt	tgg	at							653
Leu	Gly	Met	Gly	Leu	Ser	Val	Gly	Trp								
		210			215											

<210> 127

<211> 217

<212> PRT

WO 02/075507

PCT/US02/01971

<213> Actinobacillus pleuropneumoniae

<400> 127

Leu Ile Ser Phe Pro Phe Ile Thr Phe Ala Ser Asn Val Asn Gly Ala  
 1 5 10 15  
 Glu Ile Gly Leu Gly Gly Ala Arg Glu Ser Ser Ile Tyr Tyr Ser Lys  
 20 25 30  
 His Lys Val Ala Thr Asn Pro Phe Leu Ala Leu Asp Leu Ser Leu Gly  
 35 40 45  
 Asn Phe Tyr Met Arg Gly Thr Ala Gly Ile Ser Glu Ile Gly Tyr Glu  
 50 55 60  
 Gln Ser Phe Thr Asp Asn Phe Ser Val Ser Leu Phe Val Asn Pro Phe  
 65 70 75 80  
 Asp Gly Phe Ser Ile Lys Gly Lys Asp Leu Leu Pro Gly Tyr Gln Ser  
 85 90 95  
 Ile Gln Thr Arg Lys Thr Gln Phe Ala Phe Gly Trp Gly Leu Asn Tyr  
 100 105 110  
 Asn Leu Gly Gly Leu Phe Gly Leu Asn Asp Thr Phe Ile Ser Leu Glu  
 115 120 125  
 Gly Lys Ser Gly Lys Arg Gly Ala Ser Ser Asn Val Ser Leu Leu Lys  
 130 135 140  
 Ser Phe Asn Met Thr Lys Asn Trp Lys Val Ser Pro Tyr Ile Gly Ser  
 145 150 155 160  
 Ser Tyr Tyr Ser Ser Lys Tyr Thr Asp Tyr Tyr Phe Gly Ile Lys Gln  
 165 170 175  
 Ser Glu Leu Gly Asn Lys Ile Thr Ser Val Tyr Lys Pro Lys Ala Ala  
 180 185 190  
 Tyr Ala Thr His Ile Gly Ile Asn Thr Asp Tyr Ala Phe Thr Asn Asn  
 195 200 205  
 Leu Gly Met Gly Leu Ser Val Gly Trp  
 210 215

<210> 128

<211> 242

<212> DNA

<213> Actinobacillus pleuropneumoniae

<220>

<223> apvC

<220>

<221> CDS

<222> (1)..(240)

<400> 128

atg tgg cgg atg gga gat ttt atg tct aaa aaa gag agg ctg aat gat 48  
 Met Trp Arg Met Gly Asp Phe Met Ser Lys Lys Glu Arg Leu Asn Asp  
 1 5 10 15

WO 02/075507

PCT/US02/01971

```

atg gct cgc cag att tta tca gcg gcg gag ttg ctc att gca aag gaa 96
Met Ala Arg Gln Ile Leu Ser Ala Ala Glu Leu Leu Ile Ala Lys Glu
      20      25      30

ggg ttg caa aat tta tcg atg agg aaa atc gca agt gaa gcc ggt atc 144
Gly Leu Gln Asn Leu Ser Met Arg Lys Ile Ala Ser Glu Ala Gly Ile
      35      40      45

gca aca gcc acg ctt tat ctc tat ttc aaa acg aaa gac gag tta ctg 192
Ala Thr Gly Thr Leu Tyr Leu Tyr Phe Lys Thr Lys Asp Glu Leu Leu
      50      55      60

gat tgt ttg gcg gaa caa tta cat gaa cga tat tat cgt tat ctg aat 240
Asp Cys Leu Ala Glu Gln Leu His Glu Arg Tyr Tyr Arg Tyr Leu Asn
      65      70      75      80

at 242

<210> 129
<211> 80
<212> PRT
<213> Actinobacillus pleuropneumoniae

<400> 129
Met Trp Arg Met Gly Asp Phe Met Ser Lys Lys Glu Arg Leu Asn Asp
 1      5      10      15

Met Ala Arg Gln Ile Leu Ser Ala Ala Glu Leu Leu Ile Ala Lys Glu
 20      25      30

Gly Leu Gln Asn Leu Ser Met Arg Lys Ile Ala Ser Glu Ala Gly Ile
 35      40      45

Ala Thr Gly Thr Leu Tyr Leu Tyr Phe Lys Thr Lys Asp Glu Leu Leu
 50      55      60

Asp Cys Leu Ala Glu Gln Leu His Glu Arg Tyr Tyr Arg Tyr Leu Asn
 65      70      75      80

<210> 130
<211> 527
<212> DNA
<213> Actinobacillus pleuropneumoniae

<220>
<223> apvD

<220>
<221> CDS
<222> (1)..(525)

<400> 130
aat att caa aaa aca gtt att gct agc ggc aca ttg caa gcg act gaa 48
Asn Ile Gln Lys Thr Val Ile Ala Ser Gly Thr Leu Gln Ala Thr Glu
 1      5      10      15

caa gta gat att ggt gca caa gta tct ggg cag att aag cat att tta 96
Gln Val Asp Ile Gly Ala Gln Val Ser Gly Gln Ile Lys His Ile Leu
 20      25      30

gta caa gaa gga cag aag gtt aaa aaa ggt gag cta tta gct gta att 144

```

WO 02/075507

PCT/US02/01971

Val Gln Glu Gly Gln Lys Val Lys Lys Gly Glu Leu Leu Ala Val Ile  
35 40 45  
gat cca cgt ctg gct gaa acg gaa tta aaa cta gca aaa gct gag cta 192  
Asp Pro Arg Leu Ala Glu Thr Glu Leu Lys Leu Ala Lys Ala Glu Leu  
50 55 60  
gca aat gct tct gct aat ttg gat aca aaa aaa att aat ctt aag caa 240  
Ala Asn Ala Ser Ala Asn Leu Asp Thr Lys Lys Ile Asn Leu Lys Gln  
65 70 75 80  
ctg caa tca gat tgg gaa cgt cat caa cgt ttg ata cga acc aat gcg 288  
Leu Gln Ser Asp Trp Glu Arg His Gln Arg Leu Ile Arg Thr Asn Ala  
85 90 95  
aca agc caa aag gaa aca gaa gaa gca aaa agt aga tta aat acg gcc 336  
Thr Ser Gln Lys Glu Thr Glu Glu Ala Lys Ser Arg Leu Asn Thr Ala  
100 105 110  
aaa gca gaa ctt caa att gcg caa aat aat cta gat atc gct aaa atc 384  
Lys Ala Glu Leu Gln Ile Ala Gln Asn Asn Leu Asp Ile Ala Lys Ile  
115 120 125  
aga gtg gaa aaa gct gaa acc gaa cta gga tat aca gaa att cgt tct 432  
Arg Val Glu Lys Ala Glu Thr Glu Leu Gly Tyr Thr Glu Ile Arg Ser  
130 135 140  
cca ctt gat gca aca gta att tca gta ttt gcg caa aat ggt caa act 480  
Pro Leu Asp Ala Thr Val Ile Ser Val Phe Ala Gln Asn Gly Gln Thr  
145 150 155 160  
tta gtc acc acc caa caa gta cca gtg ctg atg aaa tta gct aat at 527  
Leu Val Thr Thr Gln Gln Val Pro Val Leu Met Lys Leu Ala Asn  
165 170 175

<210> 131  
<211> 175  
<212> PRT  
<213> Actinobacillus pleuropneumoniae

<400> 131  
Asn Ile Gln Lys Thr Val Ile Ala Ser Gly Thr Leu Gln Ala Thr Glu  
1 5 10 15  
Gln Val Asp Ile Gly Ala Gln Val Ser Gly Gln Ile Lys His Ile Leu  
20 25 30  
Val Gln Glu Gly Gln Lys Val Lys Lys Gly Glu Leu Leu Ala Val Ile  
35 40 45  
Asp Pro Arg Leu Ala Glu Thr Glu Leu Lys Leu Ala Lys Ala Glu Leu  
50 55 60  
Ala Asn Ala Ser Ala Asn Leu Asp Thr Lys Lys Ile Asn Leu Lys Gln  
65 70 75 80  
Leu Gln Ser Asp Trp Glu Arg His Gln Arg Leu Ile Arg Thr Asn Ala  
85 90 95  
Thr Ser Gln Lys Glu Thr Glu Glu Ala Lys Ser Arg Leu Asn Thr Ala  
100 105 110

WO 02/075507

PCT/US02/01971

```

Lys Ala Glu Leu Gln Ile Ala Gln Asn Asn Leu Asp Ile Ala Lys Ile
    115                120                125
Arg Val Glu Lys Ala Glu Thr Glu Leu Gly Tyr Thr Glu Ile Arg Ser
    130                135                140
Pro Leu Asp Ala Thr Val Ile Ser Val Phe Ala Gln Asn Gly Gln Thr
    145                150                155                160
Leu Val Thr Thr Gln Gln Val Pro Val Leu Met Lys Leu Ala Asn
    165                170                175

<210> 132
<211> 867
<212> DNA
<213> Actinobacillus pleuropneumoniae

<220>
<223> atpG

<220>
<221> CDS
<222> (1)..(864)

<400> 132
atg gca ggt gcg aaa gag ata aga acc aaa att gca agt gtg aaa aat 48
Met Ala Gly Ala Lys Glu Ile Arg Thr Lys Ile Ala Ser Val Lys Asn
    1                5                10                15
act caa aaa atc acc aaa gca atg gaa atg gtt gct acc tct aaa atg 96
Thr Gln Lys Ile Thr Lys Ala Met Glu Met Val Ala Thr Ser Lys Met
    20                25                30
cgt aaa acg caa gag cgt atg gct gcc agt cgt cct tat tcg gaa aca 144
Arg Lys Thr Gln Glu Arg Met Ala Ala Ser Arg Pro Tyr Ser Glu Thr
    35                40                45
atc cgt aag gtg att agc cat att gcg aaa gga agc att ggt tat aag 192
Ile Arg Lys Val Ile Ser His Ile Ala Lys Gly Ser Ile Gly Tyr Lys
    50                55                60
cac cag ttt tta act gaa cgt gat att aaa aaa gta ggc tat ctt gtc 240
His Pro Phe Leu Thr Glu Arg Asp Ile Lys Lys Val Gly Tyr Leu Val
    65                70                75                80
gtt tcg acc gat cgc ggt tta tgc ggt gcc ctt aat atc aat tta ttc 288
Val Ser Thr Asp Arg Gly Leu Cys Gly Gly Leu Asn Ile Asn Leu Phe
    85                90                95
aaa gcg act ttg aat gaa ttt aaa acg tgg aaa gat aaa gac gtt agt 336
Lys Ala Thr Leu Asn Glu Phe Lys Thr Trp Lys Asp Lys Asp Val Ser
    100                105
ggt gag ctt ggt tta gta ggg tcg aaa ggc gta agc ttt tac caa aat 384
Val Glu Leu Gly Leu Val Gly Ser Lys Gly Val Ser Phe Tyr Gln Asn
    115                120                125
cta ggc tta aac gtg aga tct caa gta acg gga tta ggc gat aat cag 432
Leu Gly Leu Asn Val Arg Ser Gln Val Thr Gly Leu Gly Asp Asn Pro
    130                135                140
gaa atg gaa cgt atc gtg ggc gca gtt aat gaa atg att aat gcg ttc 480

```

WO 02/075507

PCT/US02/01971

```

Glu Met Glu Arg Ile Val Gly Ala Val Asn Glu Met Ile Asn Ala Phe
145                150                155                160
cga aac gga gaa gtg gat gcg gtt tac gtc gct tac aac cgt ttt gaa 528
Arg Asn Gly Glu Val Asp Ala Val Tyr Val Ala Tyr Asn Arg Phe Glu
165                170
aat acg atg tca caa aaa cct gtt atc gca cag tta ctt ccg tta cct 576
Asn Thr Met Ser Gln Lys Pro Val Ile Ala Gln Leu Leu Pro Leu Pro
180                185                190
aaa cta gat gac gat gaa tta gat acg aaa ggt tca tgg gat tat att 624
Lys Leu Asp Asp Asp Glu Leu Asp Thr Lys Gly Ser Trp Asp Tyr Ile
195                200                205
tat gaa ccg aat cca caa gtt tta ttg gat agt tta ctt gtt cgt tat 672
Tyr Glu Pro Asn Pro Gln Val Leu Leu Asp Ser Leu Leu Val Arg Tyr
210                215                220
tta gaa act cag gta tac caa gca gtt gta gat aac cta gct tct gaa 720
Leu Glu Thr Gln Val Tyr Gln Ala Val Val Asp Asn Leu Ala Ser Glu
225                230                235
caa gcc gct cga atg gta gcg atg aaa gcc gca aca gat aat gcg ggt 768
Gln Ala Ala Arg Met Val Ala Met Lys Ala Ala Thr Asp Asn Ala Gly
245                250                255
aca tta atc gat gaa tta caa tta gtg tat aac aaa gct cgc caa gca 816
Thr Leu Ile Asp Glu Leu Gln Leu Val Tyr Asn Lys Ala Arg Gln Ala
260                265                270
agc att aca aat gaa tta aac gaa att gtt gcg ggt gcc gca gca att 864
Ser Ile Thr Asn Glu Leu Asn Glu Ile Val Ala Gly Ala Ala Ala Ile
275                280                285
taa
867

<210> 133
<211> 288
<212> PRT
<213> Actinobacillus pleuropneumoniae

<400> 133
Met Ala Gly Ala Lys Glu Ile Arg Thr Lys Ile Ala Ser Val Lys Asn
1                5                10                15
Thr Gln Lys Ile Thr Lys Ala Met Glu Met Val Ala Thr Ser Lys Met
20                25                30
Arg Lys Thr Gln Glu Arg Met Ala Ala Ser Arg Pro Tyr Ser Glu Thr
35                40                45
Ile Arg Lys Val Ile Ser His Ile Ala Lys Gly Ser Ile Gly Tyr Lys
50                55                60
His Pro Phe Leu Thr Glu Arg Asp Ile Lys Lys Val Gly Tyr Leu Val
65                70                75                80
Val Ser Thr Asp Arg Gly Leu Cys Gly Gly Leu Asn Ile Asn Leu Phe
85                90                95

```

WO 02/075507

PCT/US02/01971

Lys Ala Thr Leu Asn Glu Phe Lys Thr Trp Lys Asp Lys Asp Val Ser  
 100 105 110  
 Val Glu Leu Gly Leu Val Gly Ser Lys Gly Val Ser Phe Tyr Gln Asn  
 115 120 125  
 Leu Gly Leu Asn Val Arg Ser Gln Val Thr Gly Leu Gly Asp Asn Pro  
 130 135 140  
 Glu Met Glu Arg Ile Val Gly Ala Val Asn Glu Met Ile Asn Ala Phe  
 145 150 155 160  
 Arg Asn Gly Glu Val Asp Ala Val Tyr Val Ala Tyr Asn Arg Phe Glu  
 165 170 175  
 Asn Thr Met Ser Gln Lys Pro Val Ile Ala Gln Leu Leu Pro Leu Pro  
 180 185 190  
 Lys Leu Asp Asp Asp Glu Leu Asp Thr Lys Gly Ser Trp Asp Tyr Ile  
 195 200 205  
 Tyr Glu Pro Asn Pro Gln Val Leu Leu Asp Ser Leu Leu Val Arg Tyr  
 210 215 220  
 Leu Glu Thr Gln Val Tyr Gln Ala Val Val Asp Asn Leu Ala Ser Glu  
 225 230 235 240  
 Gln Ala Ala Arg Met Val Ala Met Lys Ala Ala Thr Asp Asn Ala Gly  
 245 250 255  
 Thr Leu Ile Asp Glu Leu Gln Leu Val Tyr Asn Lys Ala Arg Gln Ala  
 260 265 270  
 Ser Ile Thr Asn Glu Leu Asn Glu Ile Val Ala Gly Ala Ala Ala Ile  
 275 280 285

<210> 134  
 <211> 534  
 <212> DNA  
 <213> Actinobacillus pleuropneumoniae

<220>  
 <223> atpH

<220>  
 <221> CDS  
 <222> (1)..(531)

<400> 134  
 atg tca gaa tta agt aca gta gct cgc ccc tac gct aaa gca gct ttt 48  
 Met Ser Glu Leu Ser Thr Val Ala Arg Pro Tyr Ala Lys Ala Ala Phe  
 1 5 10 15  
 gat ttt gct tta gaa caa ggt cag ttg gac aaa tgg caa gaa atg tta 96  
 Asp Phe Ala Leu Glu Gln Gly Gln Leu Asp Lys Trp Gln Glu Met Leu  
 20 25 30  
 cag ttt tgc gca ttc gtt gct gaa aac gaa caa gtg gcg gaa tat att 144  
 Gln Phe Ser Ala Phe Val Ala Glu Asn Glu Gln Val Ala Glu Tyr Ile  
 35 40 45  
 aat tct tcc ctt gca agc ggt cag att tct gaa act ttt atc aaa atc 192

WO 02/075507

PCT/US02/01971

```

Asn Ser Ser Leu Ala Ser Gly Gln Ile Ser Glu Thr Phe Ile Lys Ile
 50          55          60
tgc ggc gac caa ctt gat caa tat ggg caa aat ttt att cgt gta atg 240
Cys Gly Asp Gln Leu Asp Gln Tyr Gly Gln Asn Phe Ile Arg Val Met
 65          70          75          80
gct gaa aat aaa cgt ctg gct gtg ttg cct atg gtt ttt gat act ttc 288
Ala Glu Asn Lys Arg Leu Ala Val Leu Pro Met Val Phe Asp Thr Phe
 85          90          95
gta tca tta cga gcg gaa cat gaa gcg gta aaa gat gta aca att gtt 336
Val Ser Leu Arg Ala Glu His Glu Ala Val Lys Asp Val Thr Ile Val
 100         105         110
tcg gca aac gaa tta agt caa gca caa gaa gat aaa atc gca aaa gcg 384
Ser Ala Asn Glu Leu Ser Gln Ala Gln Glu Asp Lys Ile Ala Lys Ala
 115         120         125
atg gaa aaa cgc tta ggt caa aaa gtt cgt tta acc aac caa atc gat 432
Met Glu Lys Arg Leu Gly Gln Lys Val Arg Leu Thr Asn Gln Ile Asp
 130         135         140
aac agc ctg att gca ggc gta att att aaa tac gat gat gtt gtt att 480
Asn Ser Leu Ile Ala Gly Val Ile Ile Lys Tyr Asp Asp Val Val Ile
 145         150         155         160
gat ggt agt agc cgc ggt cag tta aat cgc tta gcg tca gcg ttg agc 528
Asp Gly Ser Ser Arg Gly Gln Leu Asn Arg Leu Ala Ser Ala Leu Ser
 165         170         175

ttg taa 534
Leu

<210> 135
<211> 177
<212> PRT
<213> Actinobacillus pleuropneumoniae

<400> 135
Met Ser Glu Leu Ser Thr Val Ala Arg Pro Tyr Ala Lys Ala Ala Phe
 1          5          10          15
Asp Phe Ala Leu Glu Gln Gly Gln Leu Asp Lys Trp Gln Glu Met Leu
 20         25         30
Gln Phe Ser Ala Phe Val Ala Glu Asn Glu Gln Val Ala Glu Tyr Ile
 35         40         45
Asn Ser Ser Leu Ala Ser Gly Gln Ile Ser Glu Thr Phe Ile Lys Ile
 50          55          60
Cys Gly Asp Gln Leu Asp Gln Tyr Gly Gln Asn Phe Ile Arg Val Met
 65          70          75          80
Ala Glu Asn Lys Arg Leu Ala Val Leu Pro Met Val Phe Asp Thr Phe
 85          90          95
Val Ser Leu Arg Ala Glu His Glu Ala Val Lys Asp Val Thr Ile Val
 100         105         110

```



WO 02/075507

PCT/US02/01971

Ser Ala Asn Glu Leu Ser Gln Ala Gln Glu Asp Lys Ile Ala Lys Ala  
 115 120 125

Met Glu Lys Arg Leu Gly Gln Lys Val Arg Leu Thr Asn Gln Ile Asp  
 130 135 140

Asn Ser Leu Ile Ala Gly Val Ile Ile Lys Tyr Asp Asp Val Val Ile  
 145 150 155 160

Asp Gly Ser Ser Arg Gly Gln Leu Asn Arg Leu Ala Ser Ala Leu Ser  
 165 170 175

Leu

<210> 136  
 <211> 321  
 <212> DNA  
 <213> Actinobacillus pleuropneumoniae

<220>  
 <223> dksA

<220>  
 <221> CDS  
 <222> (1)..(318)

<400> 136  
 gca tgg cat gtg caa att atg gac gaa gct gag cgt aca aaa aac caa 48  
 Ala Trp His Val Gln Ile Met Asp Glu Ala Glu Arg Thr Lys Asn Gln  
 1 5 10 15

atg cag gaa gaa gtc gct aat ttc gcc gat cct gcg gac cgc gcc act 96  
 Met Gln Glu Glu Val Ala Asn Phe Ala Asp Pro Ala Asp Arg Ala Thr  
 20 25 30

cag gaa gaa gaa ttc agt ctt gaa tta aga aac cgt gac cgt gag cgt 144  
 Gln Glu Glu Glu Phe Ser Leu Glu Leu Arg Asn Arg Asp Arg Glu Arg  
 35 40 45

aaa ttg ctt aag aag att gag caa acg tta aat agc att gcc gaa gac 192  
 Lys Leu Leu Lys Lys Ile Glu Gln Thr Leu Asn Ser Ile Ala Glu Asp  
 50 55 60

gaa tac ggc tat tgc gaa act tgc ggt gtt gaa atc ggt tta cgt cgt 240  
 Glu Tyr Gly Tyr Cys Glu Thr Cys Gly Val Glu Ile Gly Leu Arg Arg  
 65 70 75 80

tta gaa gcg cgc ccg acc gcg gat atg tgt atc gat tgc aaa aca ctt 288  
 Leu Glu Ala Arg Pro Thr Ala Asp Met Cys Ile Asp Cys Lys Thr Leu  
 85 90 95

gcg gaa atc cgt gaa aag caa atg gcc tta taa 321  
 Ala Glu Ile Arg Glu Lys Gln Met Gly Leu  
 100 105

<210> 137  
 <211> 106  
 <212> PRT  
 <213> Actinobacillus pleuropneumoniae

WO 02/075507

PCT/US02/01971

```

<400> 137
Ala Trp His Val Gln Ile Met Asp Glu Ala Glu Arg Thr Lys Asn Gln
 1           5           10           15
Met Gln Glu Glu Val Ala Asn Phe Ala Asp Pro Ala Asp Arg Ala Thr
 20           25           30
Gln Glu Glu Glu Phe Ser Leu Glu Leu Arg Asn Arg Asp Arg Glu Arg
 35           40           45
Lys Leu Leu Lys Lys Ile Glu Gln Thr Leu Asn Ser Ile Ala Glu Asp
 50           55           60
Glu Tyr Gly Tyr Cys Glu Thr Cys Gly Val Glu Ile Gly Leu Arg Arg
 65           70           75           80
Leu Glu Ala Arg Pro Thr Ala Asp Met Cys Ile Asp Cys Lys Thr Leu
 85           90           95
Ala Glu Ile Arg Glu Lys Gln Met Gly Leu
 100           105

```

```

<210> 138
<211> 33
<212> DNA
<213> Actinobacillus pleuropneumoniae

```

```

<220>
<223> dnaK
<220>
<221> CDS
<222> (1)..(30)

```

```

<400> 138
gct gag ttt gaa gaa gtg aaa gat aat aaa taa
Ala Glu Phe Glu Glu Val Lys Asp Asn Lys
 1           5           10

```

```

<210> 139
<211> 10
<212> PRT
<213> Actinobacillus pleuropneumoniae

```

```

<400> 139
Ala Glu Phe Glu Glu Val Lys Asp Asn Lys
 1           5           10

```

```

<210> 140
<211> 453
<212> DNA
<213> Actinobacillus pleuropneumoniae

```

```

<220>
<223> exbB
<220>
<221> CDS
<222> (1)..(450)

```

WO 02/075507

PCT/US02/01971

```

<400> 140
atg gaa caa atg ctt gaa ctt tta caa ggt cat gtt gat tat att att 48
Met Glu Gln Met Leu Glu Leu Leu Gln Gly His Val Asp Tyr Ile Ile
1 5 10 15
tta ggc tta tta cta tta atg agt gtt gtg ttg gta tgg aaa att att 96
Leu Gly Leu Leu Leu Met Ser Val Val Leu Val Trp Lys Ile Ile
20 25 30
gaa cgc gta ctt ttc tac aaa caa ttg gat gtg acc aaa tat gac acg 144
Glu Arg Val Leu Phe Tyr Lys Gln Leu Asp Val Thr Lys Tyr Asp Thr
35 40 45
cta caa gat ttg gaa att gat acc act cgc aat tta acc acc att tcc 192
Leu Gln Asp Leu Glu Ile Asp Thr Thr Arg Asn Leu Thr Thr Ile Ser
50 55 60
act atc ggt gcc aac gcc cct tat atc ggt tta tta gga acc gta tta 240
Thr Ile Gly Ala Asn Ala Pro Tyr Ile Gly Leu Leu Gly Thr Val Leu
65 70 75 80
ggg atc tta ctt acc ttc tat cat tta ggg cat tcc ggc ggt gat att 288
Gly Ile Leu Leu Thr Phe Tyr His Leu Gly His Ser Gly Gly Asp Ile
85 90 95
gac gcc gca tcc att atg gtt cac ctt tcc ctt gca tta aaa gca acc 336
Asp Ala Ala Ser Ile Met Val His Leu Ser Leu Ala Leu Lys Ala Thr
100 105 110
gca gcc ggt atc tta gtc gct att ccg gca atg atg ttc tac agc ggt 384
Ala Ala Gly Ile Leu Val Ala Ile Pro Ala Met Met Phe Tyr Ser Gly
115 120 125
ttt aac cgt aaa gtg gat gaa agc aaa ctt aaa tgg caa gcg att caa 432
Phe Asn Arg Lys Val Asp Glu Ser Lys Leu Lys Trp Gln Ala Ile Gln
130 135 140
gct cgt aaa gcc aat caa taa 453
Ala Arg Lys Ala Asn Gln
145 150

```

```

<210> 141
<211> 150
<212> PRT
<213> Actinobacillus pleuropneumoniae

```

```

<400> 141
Met Glu Gln Met Leu Glu Leu Leu Gln Gly His Val Asp Tyr Ile Ile
1 5 10 15
Leu Gly Leu Leu Leu Met Ser Val Val Leu Val Trp Lys Ile Ile
20 25 30
Glu Arg Val Leu Phe Tyr Lys Gln Leu Asp Val Thr Lys Tyr Asp Thr
35 40 45
Leu Gln Asp Leu Glu Ile Asp Thr Thr Arg Asn Leu Thr Thr Ile Ser
50 55 60
Thr Ile Gly Ala Asn Ala Pro Tyr Ile Gly Leu Leu Gly Thr Val Leu
65 70 75 80

```

WO 02/075507

PCT/US02/01971

Gly Ile Leu Leu Thr Phe Tyr His Leu Gly His Ser Gly Gly Asp Ile  
 85 90 95  
 Asp Ala Ala Ser Ile Met Val His Leu Ser Leu Ala Leu Lys Ala Thr  
 100 105 110  
 Ala Ala Gly Ile Leu Val Ala Ile Pro Ala Met Met Phe Tyr Ser Gly  
 115 120 125  
 Phe Asn Arg Lys Val Asp Glu Ser Lys Leu Lys Trp Gln Ala Ile Gln  
 130 135 140  
 Ala Arg Lys Ala Asn Gln  
 145 150

<210> 142  
 <211> 720  
 <212> DNA  
 <213> Actinobacillus pleuropneumoniae

<220>  
 <223> fkpA

<220>  
 <221> CDS  
 <222> (1)..(717)

<400> 142  
 atg tta aaa aat aaa ctt tct gtt ctt gca atc gta gcc ggt acg ttc 48  
 Met Leu Lys Asn Lys Leu Ser Val Leu Ala Ile Val Ala Gly Thr Phe  
 1 5 10 15  
 gtt tca gct caa act gca ttt gca gcg gat caa aaa ttc att gac gat 96  
 Val Ser Ala Gln Thr Ala Phe Ala Ala Asp Gln Lys Phe Ile Asp Asp  
 20 25 30  
 tca tca tat gca gtc ggc gta ttg atg ggt aaa aat atc gaa ggc gtc 144  
 Ser Ser Tyr Ala Val Gly Val Leu Met Gly Lys Asn Ile Glu Gly Val  
 35 40 45  
 gtt gaa tca caa aaa gaa att ttt tct tat aac caa gat aaa atc ttg 192  
 Val Glu Ser Gln Lys Glu Ile Phe Ser Tyr Asn Gln Asp Lys Ile Leu  
 50 55 60  
 gcg ggt gtc caa gat acc atc aaa aaa acc ggt aaa tta acc gat gaa 240  
 Ala Gly Val Gln Asp Thr Ile Lys Lys Thr Gly Lys Leu Thr Asp Glu  
 65 70 75 80  
 gat cta caa aaa caa tta aaa tcg ctt gat act tat ctt gca agt caa 288  
 Asp Leu Gln Lys Gln Leu Lys Ser Leu Asp Thr Tyr Leu Ala Ser Gln  
 85 90 95  
 gaa agc aaa att gcg gcg gag aaa agc aaa gca acc gta gaa gcc ggt 336  
 Glu Ser Lys Ile Ala Ala Glu Lys Ser Lys Ala Thr Val Glu Ala Gly  
 100 105 110  
 aat aaa ttt cgt acc gac tac gaa aaa caa agc ggc gtg aaa aaa acc 384  
 Asn Lys Phe Arg Thr Asp Tyr Glu Lys Gln Ser Gly Val Lys Lys Thr  
 115 120 125  
 gct tcc ggt tta ctt tat aaa att gaa aaa gcc ggc acg ggc gaa tcg 432

WO 02/075507

PCT/US02/01971

Ala Ser Gly Leu Leu Tyr Lys Ile Glu Lys Ala Gly Thr Gly Glu Ser  
 130 135 140  
 cct aaa gcg gaa gat acc gtt aaa gtt cac tat aaa ggg aca tta acc 480  
 Pro Lys Ala Glu Asp Thr Val Lys Val His Tyr Lys Gly Thr Leu Thr  
 145 150 155 160  
 gat ggt acg gta ttc gat agc tca tac gat cgc ggt gag ccg att gaa 528  
 Asp Gly Thr Val Phe Asp Ser Ser Tyr Asp Arg Gly Glu Pro Ile Glu  
 165 170 175  
 ttc caa tta aac caa tta att ccg ggt tgg att gaa gcg att cca atg 576  
 Phe Gln Leu Asn Gln Leu Ile Pro Gly Trp Ile Glu Ala Ile Pro Met  
 180 185 190  
 ttg aaa aaa ggc gga aaa atg gaa atc gtc gtt ccg cct gaa ctt ggt 624  
 Leu Lys Lys Gly Gly Lys Met Glu Ile Val Val Pro Pro Glu Leu Gly  
 195 200 205  
 tac ggc gaa gcg caa gca ggt aag att ccg gca agt tca acc tta aaa 672  
 Tyr Gly Glu Arg Gln Ala Gly Lys Ile Pro Ala Ser Ser Thr Leu Lys  
 210 215 220  
 ttc gag att gaa ttg tta gat ttc aaa gcg gcc gaa gcg aaa aaa taa 720  
 Phe Glu Ile Glu Leu Leu Asp Phe Lys Ala Ala Glu Ala Lys Lys  
 225 230 235

<210> 143  
 <211> 239  
 <212> PRT  
 <213> Actinobacillus pleuropneumoniae

<400> 143  
 Met Leu Lys Asn Lys Leu Ser Val Leu Ala Ile Val Ala Gly Thr Phe  
 1 5 10 15  
 Val Ser Ala Gln Thr Ala Phe Ala Ala Asp Gln Lys Phe Ile Asp Asp  
 20 25 30  
 Ser Ser Tyr Ala Val Gly Val Leu Met Gly Lys Asn Ile Glu Gly Val  
 35 40 45  
 Val Glu Ser Gln Lys Glu Ile Phe Ser Tyr Asn Gln Asp Lys Ile Leu  
 50 55 60  
 Ala Gly Val Gln Asp Thr Ile Lys Lys Thr Gly Lys Leu Thr Asp Glu  
 65 70 75 80  
 Asp Leu Gln Lys Gln Leu Lys Ser Leu Asp Thr Tyr Leu Ala Ser Gln  
 85 90 95  
 Glu Ser Lys Ile Ala Ala Glu Lys Ser Lys Ala Thr Val Glu Ala Gly  
 100 105 110  
 Asn Lys Phe Arg Thr Asp Tyr Glu Lys Gln Ser Gly Val Lys Lys Thr  
 115 120 125  
 Ala Ser Gly Leu Leu Tyr Lys Ile Glu Lys Ala Gly Thr Gly Glu Ser  
 130 135 140  
 Pro Lys Ala Glu Asp Thr Val Lys Val His Tyr Lys Gly Thr Leu Thr  
 145 150 155 160

WO 02/075507

PCT/US02/01971

Asp Gly Thr Val Phe Asp Ser Ser Tyr Asp Arg Gly Glu Pro Ile Glu  
 165 170 175  
 Phe Gln Leu Asn Gln Leu Ile Pro Gly Trp Ile Glu Ala Ile Pro Met  
 180 185 190  
 Leu Lys Lys Gly Gly Lys Met Glu Ile Val Val Pro Pro Glu Leu Gly  
 195 200 205  
 Tyr Gly Glu Arg Gln Ala Gly Lys Ile Pro Ala Ser Ser Thr Leu Lys  
 210 215 220  
 Phe Glu Ile Glu Leu Leu Asp Phe Lys Ala Ala Glu Ala Lys Lys  
 225 230 235

<210> 144  
 <211> 290  
 <212> DNA  
 <213> Actinobacillus pleuropneumoniae

<220>  
 <221> HI0379  
 <222> CDS  
 <222> (3)..(287)

<400> 144  
 tg cat agc gtg aga ggt ccg ggc ggc ggt tat caa ctc ggt aag caa 47  
 His Ser Val Arg Gly Pro Gly Gly Tyr Gln Leu Gly Lys Gln  
 1 5 10 15  
 cct gaa gag att agt gtg ggg atg att att gcg gcg gtg aat gaa aat 95  
 Pro Glu Glu Ile Ser Val Gly Met Ile Ile Ala Ala Val Asn Glu Asn  
 20 25 30  
 ctc gac gta acc aaa tgt aaa ggt agc ggc aac tgt agc aaa aac tct 143  
 Leu Asp Val Thr Lys Cys Lys Gly Ser Gly Asn Cys Ser Lys Asn Ser  
 35 40 45  
 cag tgc tta acc cat cat tta tgg gaa cgt tta gaa gaa caa atc ggt 191  
 Gln Cys Leu Thr His His Leu Trp Glu Arg Leu Glu Glu Gln Ile Gly  
 50 55 60  
 gtg ttt tta aat acg att act tta gcg gaa ctt gtt gaa gaa cat tcg 239  
 Val Phe Leu Asn Thr Ile Thr Leu Ala Glu Leu Val Glu Glu His Ser  
 65 70 75  
 gat cac gat tgt gaa aaa gaa cat tgc cac gat cat tca cac aaa cat 287  
 Asp His Asp Cys Glu Lys Glu His Cys His Asp His Ser His Lys His  
 80 85 90 95  
 taa 290

<210> 145  
 <211> 95  
 <212> PRT  
 <213> Actinobacillus pleuropneumoniae

<400> 145  
 His Ser Val Arg Gly Pro Gly Gly Tyr Gln Leu Gly Lys Gln Pro

WO 02/075507

PCT/US02/01971

```

1           5           10           15
Glu Glu Ile Ser Val Gly Met Ile Ile Ala Ala Val Asn Glu Asn Leu
      20           25           30
Asp Val Thr Lys Cys Lys Gly Ser Gly Asn Cys Ser Lys Asn Ser Gln
      35           40           45
Cys Leu Thr His His Leu Trp Glu Arg Leu Glu Glu Gln Ile Gly Val
      50           55           60
Phe Leu Asn Thr Ile Thr Leu Ala Glu Leu Val Glu Glu His Ser Asp
      65           70           75           80
His Asp Cys Glu Lys Glu His Cys His Asp His Ser His Lys His
      85           90           95

```

```

<210> 146
<211> 273
<212> DNA
<213> Actinobacillus pleuropneumoniae
<220>
<223> hupA

```

```

<220>
<221> CDS
<222> (1)..(270)

```

```

<400> 146
atg aac aaa act gag tta atc gat gca atc gca gct ggt gca gag tta 48
Met Asn Lys Thr Glu Leu Ile Asp Ala Ile Ala Ala Gly Ala Glu Leu
      1           5           10           15
agc aag aaa gac gcg aaa gcg gca tta gaa gcg act tta aat gcg atc 96
Ser Lys Lys Asp Ala Lys Ala Ala Leu Glu Ala Thr Leu Asn Ala Ile
      20           25           30
tct gaa agc cta aaa aat ggc gac acc gtt cag tta atc ggc ttc ggt 144
Ser Glu Ser Leu Lys Asn Gly Asp Thr Val Gln Leu Ile Gly Phe Gly
      35           40           45
act ttt aaa gta aac gag cgt aat gca cgt acg ggt cgt aac ccg cgt 192
Thr Phe Lys Val Asn Glu Arg Asn Ala Arg Thr Gly Arg Asn Pro Arg
      50           55           60
acc ggc gaa gaa atc aaa atc gca gca tct aaa gtg ccg gcg ttt gtt 240
Thr Gly Glu Glu Ile Lys Ile Ala Ala Ser Lys Val Pro Ala Phe Val
      65           70           75           80
gca ggt aaa gca tta aaa gat tta gta aaa taa 273
Ala Gly Lys Ala Leu Lys Asp Leu Val Lys
      85           90

```

```

<210> 147
<211> 90
<212> PRT
<213> Actinobacillus pleuropneumoniae
<400> 147
Met Asn Lys Thr Glu Leu Ile Asp Ala Ile Ala Ala Gly Ala Glu Leu

```

WO 02/075507

PCT/US02/01971

```

1           5           10           15
Ser Lys Lys Asp Ala Lys Ala Ala Leu Glu Ala Thr Leu Asn Ala Ile
      20           25           30
Ser Glu Ser Leu Lys Asn Gly Asp Thr Val Gln Leu Ile Gly Phe Gly
      35           40           45
Thr Phe Lys Val Asn Glu Arg Asn Ala Arg Thr Gly Arg Asn Pro Arg
      50           55           60
Thr Gly Glu Glu Ile Lys Ile Ala Ala Ser Lys Val Pro Ala Phe Val
      65           70           75           80
Ala Gly Lys Ala Leu Lys Asp Leu Val Lys
      85           90

```

```

<210> 148
<211> 551
<212> DNA
<213> Actinobacillus pleuropneumoniae

```

```

<220>
<223> lpdA

```

```

<220>
<221> CDS
<222> (1)...(549)

```

```

<400> 148
atg agc aaa gaa atc aaa acg caa gtc gtg gta ctt ggt gcg ggt cct 48
Met Ser Lys Glu Ile Lys Thr Gln Val Val Val Leu Gly Ala Gly Pro
      1           5           10           15
gcc ggt tat tca gcg gca ttc cgt tgt gcc gac tta ggc tta gaa aca 96
Ala Gly Tyr Ser Ala Ala Phe Arg Cys Ala Asp Leu Gly Leu Glu Thr
      20           25           30
gta att gtc gaa cgt tat tca act ttg gcc ggt gta tgc tta aac gta 144
Val Ile Val Glu Arg Tyr Ser Thr Leu Gly Gly Val Cys Leu Asn Val
      35           40           45
ggt tgt att ccg tct aaa gca tta tta cac gtt gca aaa gtt atc gaa 192
Gly Cys Ile Pro Ser Lys Ala Leu Leu His Val Ala Lys Val Ile Glu
      50           55           60
gaa gca aaa cac gca gag aaa aac ggt att act ttc ggt gag ccc aac 240
Glu Ala Lys His Ala Glu Lys Asn Gly Ile Thr Phe Gly Glu Pro Asn
      65           70           75           80
att gat tta gat aaa gtg cgt gcg ggt aaa gaa gcg gtt gtt tct aaa 288
Ile Asp Leu Asp Lys Val Arg Ala Gly Lys Glu Ala Val Val Ser Lys
      85           90           95
tta acc gcc ggt tta gcg ggt atg gct aaa gca cgt aaa gta aca gta 336
Leu Thr Gly Gly Leu Ala Gly Met Ala Lys Ala Arg Lys Val Thr Val
      100           105           110
gtg gaa ggt tta gcg gcg ttt acc gat ccg aat act tta gta gct cgt 384
Val Glu Gly Leu Ala Ala Phe Thr Asp Pro Asn Thr Leu Val Ala Arg
      115           120           125

```



WO 02/075507

PCT/US02/01971

gac cgt gac ggt aat ccg aca acg att aaa ttt gat tat gca att att 432  
 Asp Arg Asp Gly Asn Pro Thr Thr Ile Lys Phe Asp Tyr Ala Ile Ile  
 130 135 140

gca gcc ggt tct cgt ccg att cag ctt ccg ttc att cca cac gaa gat 480  
 Ala Ala Gly Ser Arg Pro Ile Gln Leu Pro Phe Ile Pro His Glu Asp  
 145 150 155 160

ccg cgt gtg tgg gat tct acg gat gca ctt aaa tta aaa gaa gta ccc 528  
 Pro Arg Val Trp Asp Ser Thr Asp Ala Leu Lys Leu Lys Glu Val Pro  
 165 170 175

gaa aaa att act cat tat ggg cc 551  
 Glu Lys Ile Thr His Tyr Gly  
 180

<210> 149  
 <211> 183  
 <212> PRT  
 <213> Actinobacillus pleuropneumoniae

<400> 149  
 Met Ser Lys Glu Ile Lys Thr Gln Val Val Val Leu Gly Ala Gly Pro  
 1 5 10 15  
 Ala Gly Tyr Ser Ala Ala Phe Arg Cys Ala Asp Leu Gly Leu Glu Thr  
 20 25 30  
 Val Ile Val Glu Arg Tyr Ser Thr Leu Gly Gly Val Cys Leu Asn Val  
 35 40 45  
 Gly Cys Ile Pro Ser Lys Ala Leu Leu His Val Ala Lys Val Ile Glu  
 50 55 60  
 Glu Ala Lys His Ala Glu Lys Asn Gly Ile Thr Phe Gly Glu Pro Asn  
 65 70 75 80  
 Ile Asp Leu Asp Lys Val Arg Ala Gly Lys Glu Ala Val Val Ser Lys  
 85 90 95  
 Leu Thr Gly Gly Leu Ala Gly Met Ala Lys Ala Arg Lys Val Thr Val  
 100 105 110  
 Val Glu Gly Leu Ala Ala Phe Thr Asp Pro Asn Thr Leu Val Ala Arg  
 115 120 125  
 Asp Arg Asp Gly Asn Pro Thr Thr Ile Lys Phe Asp Tyr Ala Ile Ile  
 130 135 140  
 Ala Ala Gly Ser Arg Pro Ile Gln Leu Pro Phe Ile Pro His Glu Asp  
 145 150 155 160  
 Pro Arg Val Trp Asp Ser Thr Asp Ala Leu Lys Leu Lys Glu Val Pro  
 165 170 175  
 Glu Lys Ile Thr His Tyr Gly  
 180

<210> 150  
 <211> 1095  
 <212> DNA

WO 02/075507

PCT/US02/01971

&lt;213&gt; Actinobacillus pleuropneumoniae

&lt;220&gt;

&lt;223&gt; Omp5-2

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1092)

&lt;400&gt; 150

```

atg aaa aaa tca tta gtt gct tta aca gta tta tcg gct gca gcg gta 48
Met Lys Lys Ser Leu Val Ala Leu Thr Val Leu Ser Ala Ala Ala Val
  1           5           10          15

gct caa gca gcg cca caa caa aat act ttc tac gca ggt gcg aaa gca 96
Ala Gln Ala Ala Pro Gln Gln Asn Thr Phe Tyr Ala Gly Ala Lys Ala
  20           25           30

ggt tgg gcg tca ttc cat gat ggt atc gaa caa tta gat tca gct aaa 144
Gly Trp Ala Ser Phe His Asp Gly Ile Glu Gln Leu Asp Ser Ala Lys
  35           40           45

aac aca gat cgc ggt aca aaa tac ggt atc aac cgt aat tca gta act 192
Asn Thr Asp Arg Gly Thr Lys Tyr Gly Ile Asn Arg Asn Ser Val Thr
  50           55           60

tac gcc gta ttc gcc ggt tac caa att tta aac caa gac aaa tta ggt 240
Tyr Gly Val Phe Gly Gly Tyr Gln Ile Leu Asn Gln Asp Lys Leu Gly
  65           70           75           80

tta gcg gct gaa tta ggt tat gac tat ttc ggt cgt gtg cgc ggt tct 288
Leu Ala Ala Glu Leu Gly Tyr Asp Tyr Phe Gly Arg Val Arg Gly Ser
  85           90           95

gaa aaa cca aac ggt aaa gcg gac aag aaa act ttc cgt cac gct gca 336
Glu Lys Pro Asn Gly Lys Ala Asp Lys Lys Thr Phe Arg His Ala Ala
  100          105          110

cac ggt gcg aca atc gca tta aaa cct agc tac gaa gta tta cct gac 384
His Gly Ala Thr Ile Ala Leu Lys Pro Ser Tyr Glu Val Leu Pro Asp
  115          120          125

tta gac gtt tac ggt aaa gta ggt atc gca tta gta aac aat aca tat 432
Leu Asp Val Tyr Gly Lys Val Gly Ile Ala Leu Val Asn Asn Thr Tyr
  130          135          140

aaa aca ttc aat gca gca caa gag aaa gtg aaa act cgt cgt ttc caa 480
Lys Thr Phe Asn Ala Ala Gln Glu Lys Val Lys Thr Arg Arg Phe Gln
  145          150          155          160

agt tct tta att tta ggt gcg ggt gtt gag tac gca att ctt cct gaa 528
Ser Ser Leu Ile Leu Gly Ala Gly Val Glu Tyr Ala Ile Leu Pro Glu
  165          170          175

tta gcg gca cgt gtt gaa tac caa tgg tta aac aac gca ggt aaa gca 576
Leu Ala Ala Arg Val Glu Tyr Gln Trp Leu Asn Asn Ala Gly Lys Ala
  180          185          190

agc tac tct act tta aat cgt atg ggt gca act gac tac cgt tcg gat 624
Ser Tyr Ser Thr Leu Asn Arg Met Gly Ala Thr Asp Tyr Arg Ser Asp
  195          200          205

```

242

WO 02/075507

PCT/US02/01971

```

atc agt tcc gta tct gca ggt tta agc tac cgt ttc ggt caa ggt gcg 672
Ile Ser Ser Val Ser Ala Gly Leu Ser Tyr Arg Phe Gly Gln Gly Ala
210 215 220

gca ccg gtt gca gct ccg gca gtt gaa act aaa aac ttc gca ttc agc 720
Ala Pro Val Ala Ala Pro Ala Val Glu Thr Lys Asn Phe Ala Phe Ser
225 230 235 240

tct gac gta tta ttc gca ttc ggt aaa tca aac tta aaa ccg gct gcg 768
Ser Asp Val Leu Phe Ala Phe Gly Lys Ser Asn Leu Lys Pro Ala Ala
245 250 255

gca aca gca tta gat gca atg caa acc gaa atc aat aac gca ggt tta 816
Ala Thr Ala Leu Asp Ala Met Gln Thr Glu Ile Asn Asn Ala Gly Leu
260 265 270

tca aat gct gcg atc caa gta aac ggt tac acg gac cgt atc ggt aaa 864
Ser Asn Ala Ala Ile Gln Val Asn Gly Tyr Thr Asp Arg Ile Gly Lys
275 280 285

gaa gct tca aac tta aaa ctt tca caa cgt cgt gcg gaa aca gta gct 912
Glu Ala Ser Asn Leu Lys Leu Ser Gln Arg Arg Ala Glu Thr Val Ala
290 295 300

aac tac atc gtt tct aaa ggt gct ccg gca gct aac gta act gca gta 960
Asn Tyr Ile Val Ser Lys Gly Ala Pro Ala Ala Asn Val Thr Ala Val
305 310 315 320

ggt tac ggt gaa gca aac cct gta acc ggc gca aca tgt gac aaa gtt 1008
Gly Tyr Gly Glu Ala Asn Pro Val Thr Gly Ala Thr Cys Asp Lys Val
325 330 335

aaa ggt cgt aaa gca tta atc gct tgc tta gca ccg gat cgt cgt gtt 1056
Lys Gly Arg Lys Ala Leu Ile Ala Cys Leu Ala Pro Asp Arg Arg Val
340 345 350

gaa gtt caa gtt caa ggt act aaa gaa gta act atg taa 1095
Glu Val Gln Val Gln Gly Thr Lys Glu Val Thr Met
355 360

```

```

<210> 151
<211> 364
<212> PRT
<213> Actinobacillus pleuropneumoniae

```

```

<400> 151
Met Lys Lys Ser Leu Val Ala Leu Thr Val Leu Ser Ala Ala Ala Val
1 5 10 15
Ala Gln Ala Ala Pro Gln Gln Asn Thr Phe Tyr Ala Gly Ala Lys Ala
20 25 30
Gly Trp Ala Ser Phe His Asp Gly Ile Glu Gln Leu Asp Ser Ala Lys
35 40 45
Asn Thr Asp Arg Gly Thr Lys Tyr Gly Ile Asn Arg Asn Ser Val Thr
50 55 60
Tyr Gly Val Phe Gly Gly Tyr Gln Ile Leu Asn Gln Asp Lys Leu Gly
65 70 75 80
Leu Ala Ala Glu Leu Gly Tyr Asp Tyr Phe Gly Arg Val Arg Gly Ser

```

243

WO 02/075507

PCT/US02/01971

```

      85          90          95
Glu Lys Pro Asn Gly Lys Ala Asp Lys Lys Thr Phe Arg His Ala Ala
100          105          110
His Gly Ala Thr Ile Ala Leu Lys Pro Ser Tyr Glu Val Leu Pro Asp
115          120          125
Leu Asp Val Tyr Gly Lys Val Gly Ile Ala Leu Val Asn Asn Thr Tyr
130          135          140
Lys Thr Phe Asn Ala Ala Gln Glu Lys Val Lys Thr Arg Arg Phe Gln
145          150          155          160
Ser Ser Leu Ile Leu Gly Ala Gly Val Glu Tyr Ala Ile Leu Pro Glu
165          170          175
Leu Ala Ala Arg Val Glu Tyr Gln Trp Leu Asn Asn Ala Gly Lys Ala
180          185          190
Ser Tyr Ser Thr Leu Asn Arg Met Gly Ala Thr Asp Tyr Arg Ser Asp
195          200          205
Ile Ser Ser Val Ser Ala Gly Leu Ser Tyr Arg Phe Gly Gln Gly Ala
210          215          220
Ala Pro Val Ala Ala Pro Ala Val Glu Thr Lys Asn Phe Ala Phe Ser
225          230          235          240
Ser Asp Val Leu Phe Ala Phe Gly Lys Ser Asn Leu Lys Pro Ala Ala
245          250          255
Ala Thr Ala Leu Asp Ala Met Gln Thr Glu Ile Asn Asn Ala Gly Leu
260          265          270
Ser Asn Ala Ala Ile Gln Val Asn Gly Tyr Thr Asp Arg Ile Gly Lys
275          280          285
Glu Ala Ser Asn Leu Lys Leu Ser Gln Arg Arg Ala Glu Thr Val Ala
290          295          300
Asn Tyr Ile Val Ser Lys Gly Ala Pro Ala Ala Asn Val Thr Ala Val
305          310          315          320
Gly Tyr Gly Glu Ala Asn Pro Val Thr Gly Ala Thr Cys Asp Lys Val
325          330          335
Lys Gly Arg Lys Ala Leu Ile Ala Cys Leu Ala Pro Asp Arg Arg Val
340          345          350
Glu Val Gln Val Gln Gly Thr Lys Glu Val Thr Met
355          360

```

```

<210> 152
<211> 1110
<212> DNA
<213> Actinobacillus pleuropneumoniae

<220>
<223> Omp5

<220>

```

WO 02/075507

PCT/US02/01971

&lt;221&gt; CDS

&lt;222&gt; (1)..(1107)

&lt;400&gt; 152

```

atg aaa aaa tca tta gtt gct tta gca gta tta tgg gct gca gca gta 48
Met Lys Lys Ser Leu Val Ala Leu Ala Val Leu Ser Ala Ala Ala Val
1 5 10 15
gct caa gca gct cca caa caa aat act ttc tac gca ggt gcg aaa gtt 96
Ala Gln Ala Ala Pro Gln Gln Asn Thr Phe Tyr Ala Gly Ala Lys Val
20 25 30
ggt caa tca tca ttt cac cac ggt gtt aac caa tta aaa tct ggt cac 144
Gly Gln Ser Ser Phe His His Gly Val Asn Gln Leu Lys Ser Gly His
35 40 45
gat gat cgt tat aat gat aaa aca cgt aag tat ggt atc aac cgt aac 192
Asp Asp Arg Tyr Asn Asp Lys Thr Arg Lys Tyr Gly Ile Asn Arg Asn
50 55 60
tct gta act tac ggt gta ttc ggc ggt tac caa atc tta aac caa aat 240
Ser Val Thr Tyr Gly Val Phe Gly Gly Tyr Gln Ile Leu Asn Gln Asn
65 70 75 80
aac ttc ggt tta gca gct gaa tta ggc tat gac tac tac ggt gcg gta 288
Asn Phe Gly Leu Ala Ala Glu Leu Gly Tyr Asp Tyr Tyr Gly Arg Val
85 90 95
cgt ggt aac gta gat gaa ttc cgt aca gtt aaa cac tct gct cac ggt 336
Arg Gly Asn Val Asp Glu Phe Arg Thr Val Lys His Ser Ala His Gly
100 105 110
tta aac tta gcg tta aaa cca agc tac gaa gta tta cct gac tta gac 384
Leu Asn Leu Ala Leu Lys Pro Ser Tyr Glu Val Leu Pro Asp Leu Asp
115 120 125
ggt tac ggt aaa gta ggt att gcg gtt gtt cgt aat gac tat aaa aaa 432
Val Tyr Gly Lys Val Gly Ile Ala Val Val Arg Asn Asp Tyr Lys Lys
130 135 140
tat ggt gcg gaa aac act aac gaa tca aca aca aaa ttc cac aaa tta 480
Tyr Gly Ala Glu Asn Thr Asn Glu Ser Thr Thr Lys Phe His Lys Leu
145 150 155 160
aaa gca tca act att tta ggt gca ggt gtt gag tac gca att ctt cct 528
Lys Ala Ser Thr Ile Leu Gly Ala Gly Val Glu Tyr Ala Ile Leu Pro
165 170 175
gaa tta gcg gca cgt gtt gaa tac caa tac tta aac aaa gcg ggt aac 576
Glu Leu Ala Ala Arg Val Glu Tyr Gln Tyr Leu Asn Lys Ala Gly Asn
180 185 190
tta aat aaa gca tta gtt cgt tca ggc aca caa gat gtg gac ttc caa 624
Leu Asn Lys Ala Leu Val Arg Ser Gly Thr Gln Asp Val Asp Phe Gln
195 200 205
tat gct cct gat atc cac tct gta aca gca ggt tta tca tac cgt ttc 672
Tyr Ala Pro Asp Ile His Ser Val Thr Ala Gly Leu Ser Tyr Arg Phe
210 215 220
ggt caa ggc gct gta gca cca gtt gtt gag cca gaa gtt gta act aaa 720
Gly Gln Gly Ala Val Ala Pro Val Val Glu Pro Glu Val Val Thr Lys
225 230 235 240

```

245

WO 02/075507

PCT/US02/01971

```

aac ttc gca ttc agc tca gac gtt tta ttt gat ttc ggt aaa tca agc 768
Asn Phe Ala Phe Ser Ser Asp Val Leu Phe Asp Phe Gly Lys Ser Ser
245 250 255

tta aaa cca gca gca gca aca gct tta gac gca gct aac act gaa atc 816
Leu Lys Pro Ala Ala Ala Thr Ala Leu Asp Ala Ala Asn Thr Glu Ile
260 265 270

gct aac tta ggt tta gca act cca gct atc caa gtt aac ggt tat aca 864
Ala Asn Leu Gly Leu Ala Thr Pro Ala Ile Gln Val Asn Gly Tyr Thr
275 280 285

gac cgt atc ggt aaa gaa gct tca aac tta aaa ctt tca caa cgc cgt 912
Asp Arg Ile Gly Lys Glu Ala Ser Asn Leu Lys Leu Ser Gln Arg Arg
290 295 300

gca gaa act gta gct aac tac tta gtt tct aaa ggt caa aac cct gca 960
Ala Glu Thr Val Ala Asn Tyr Leu Val Ser Lys Gly Gln Asn Pro Ala
305 310 315

aac gta act gca gta ggt tac ggt gaa gca aac cca gta acc ggc gca 1008
Asn Val Thr Ala Val Gly Tyr Gly Glu Ala Asn Pro Val Thr Gly Ala
325 330 335

aca tgt gat gca gtt aaa ggt cgt aaa gca tta atc gct tgc tta gca 1056
Thr Cys Asp Ala Val Lys Gly Arg Lys Ala Leu Ile Ala Cys Leu Ala
340 345 350

ccg gat cgt cgt gtt gaa gtt caa gta caa ggt gct aaa aac gta gct 1104
Pro Asp Arg Arg Val Glu Val Gln Val Gln Gly Ala Lys Asn Val Ala
355 360 365

atg taa 1110
Met

<210> 153
<211> 369
<212> PRT
<213> Actinobacillus pleuropneumoniae

<400> 153
Met Lys Lys Ser Leu Val Ala Leu Ala Val Leu Ser Ala Ala Ala Val
1 5 10 15
Ala Gln Ala Ala Pro Gln Gln Asn Thr Phe Tyr Ala Gly Ala Lys Val
20 25 30
Gly Gln Ser Ser Phe His His Gly Val Asn Gln Leu Lys Ser Gly His
35 40 45
Asp Asp Arg Tyr Asn Asp Lys Thr Arg Lys Tyr Gly Ile Asn Arg Asn
50 55 60

Ser Val Thr Tyr Gly Val Phe Gly Gly Tyr Gln Ile Leu Asn Gln Asn
65 70 75 80
Asn Phe Gly Leu Ala Ala Glu Leu Gly Tyr Asp Tyr Tyr Gly Arg Val
85 90 95
Arg Gly Asn Val Asp Glu Phe Arg Thr Val Lys His Ser Ala His Gly
100 105 110

```

246

WO 02/075507

PCT/US02/01971

Leu Asn Leu Ala Leu Lys Pro Ser Tyr Glu Val Leu Pro Asp Leu Asp  
 115 120 125  
 Val Tyr Gly Lys Val Gly Ile Ala Val Val Arg Asn Asp Tyr Lys Lys  
 130 135 140  
 Tyr Gly Ala Glu Asn Thr Asn Glu Ser Thr Thr Lys Phe His Lys Leu  
 145 150 155 160  
 Lys Ala Ser Thr Ile Leu Gly Ala Gly Val Glu Tyr Ala Ile Leu Pro  
 165 170 175  
 Glu Leu Ala Ala Arg Val Glu Tyr Gln Tyr Leu Asn Lys Ala Gly Asn  
 180 185 190  
 Leu Asn Lys Ala Leu Val Arg Ser Gly Thr Gln Asp Val Asp Phe Gln  
 195 200 205  
 Tyr Ala Pro Asp Ile His Ser Val Thr Ala Gly Leu Ser Tyr Arg Phe  
 210 215 220  
 Gly Gln Gly Ala Val Ala Pro Val Val Glu Pro Glu Val Val Thr Lys  
 225 230 235 240  
 Asn Phe Ala Phe Ser Ser Asp Val Leu Phe Asp Phe Gly Lys Ser Ser  
 245 250 255  
 Leu Lys Pro Ala Ala Ala Thr Ala Leu Asp Ala Ala Asn Thr Glu Ile  
 260 265 270  
 Ala Asn Leu Gly Leu Ala Thr Pro Ala Ile Gln Val Asn Gly Tyr Thr  
 275 280 285  
 Asp Arg Ile Gly Lys Glu Ala Ser Asn Leu Lys Leu Ser Gln Arg Arg  
 290 295 300  
 Ala Glu Thr Val Ala Asn Tyr Leu Val Ser Lys Gly Gln Asn Pro Ala  
 305 310 315 320  
 Asn Val Thr Ala Val Gly Tyr Gly Glu Ala Asn Pro Val Thr Gly Ala  
 325 330 335  
 Thr Cys Asp Ala Val Lys Gly Arg Lys Ala Leu Ile Ala Cys Leu Ala  
 340 345 350  
 Pro Asp Arg Arg Val Glu Val Gln Val Gln Gly Ala Lys Asn Val Ala  
 355 360 365

Met

<210> 154  
 <211> 1076  
 <212> DNA  
 <213> Actinobacillus pleuropneumoniae

<220>  
 <223> pnp new

<220>  
 <221> CDS  
 <222> (1) .. (1074)

WO 02/075507

PCT/US02/01971

```

<400> 154
aat att aaa gaa ttc gta aaa gaa gcg ggt aaa ccg cgt tgg gat tgg 48
Asn Ile Lys Glu Phe Val Lys Glu Ala Gly Lys Pro Arg Trp Asp Trp
1 5 10 15
ggt gcg ccg gaa ccg aat acc gca tta atc aac caa gtt aaa cgg tta 96
Val Ala Pro Glu Pro Asn Thr Ala Leu Ile Asn Gln Val Lys Ala Leu
20 25 30
gca gaa gcg cgt atc ggc gat ccg tat cgt att aca gaa aaa caa gca 144
Ala Glu Ala Arg Ile Gly Asp Ala Tyr Arg Ile Thr Glu Lys Gln Ala
35 40 45
cgt tac gaa caa atc gat gca att aaa cgg gat gtt atc gca caa tta 192
Arg Tyr Glu Gln Ile Asp Ala Ile Lys Ala Asp Val Ile Ala Gln Leu
50 55 60
acc gca caa gac gaa acc gtt tct gaa ggt cgg att att gat att att 240
Thr Ala Gln Asp Glu Thr Val Ser Glu Gly Ala Ile Ile Asp Ile Ile
65 70 75 80
acc gca tta gaa agt tct att gtt cgc ggt cgt att att gcc ggc gaa 288
Thr Ala Leu Glu Ser Ser Ile Val Arg Gly Arg Ile Ile Ala Gly Glu
85 90 95
ccg cgt att gac ggt cgt acg gta gat acg gtt cgt gca tta gac att 336
Pro Arg Ile Asp Gly Arg Thr Val Asp Thr Val Arg Ala Leu Asp Ile
100 105 110
tgc acc ggc gta tta cct cgt acg cac ggt tct gca atc ttt act cgc 384
Cys Thr Gly Val Leu Pro Arg Thr His Gly Ser Ala Ile Phe Thr Arg
115 120 125
ggt gaa aca caa gca tta gcg gtt gca acc tta ggt act gag cgc gat 432
Gly Glu Thr Gln Ala Leu Ala Val Ala Thr Leu Gly Thr Glu Arg Asp
130 135 140
gca caa att gtt gac gaa tta acc ggc gag aaa tca gac cgt ttc tta 480
Ala Gln Ile Val Asp Glu Leu Thr Gly Glu Lys Ser Asp Arg Phe Leu
145 150 155
ttc cac tat aac ttc cct ccg tac tct gtc ggt gaa acc ggt cgt atc 528
Phe His Tyr Asn Phe Pro Pro Tyr Ser Val Gly Glu Thr Gly Arg Ile
165 170 175
ggt tgg ccg aaa cgt cgt gaa atc ggc cac ggt cgt tta gcg aaa cgc 576
Gly Ser Pro Lys Arg Arg Glu Ile Gly His Gly Arg Leu Ala Lys Arg
180 185 190
ggt gta tta gcg gta atg ccg act gct gaa gaa ttc ccg tat gta gtg 624
Gly Val Leu Ala Val Met Pro Thr Ala Glu Glu Phe Pro Tyr Val Val
195 200 205
cgc gta gta tct gaa att acc gaa tca aac ggt tct tct tca atg gct 672
Arg Val Val Ser Glu Ile Thr Glu Ser Asn Gly Ser Ser Ser Met Ala
210 215 220
tcc gta tgc ggc gca tct tta gcg tta atg gac gca ggc gta ccg att 720
Ser Val Cys Gly Ala Ser Leu Ala Leu Met Asp Ala Gly Val Pro Ile
225 230 235 240
aaa gcg gcg gtt gcg ggt atc gca atg ggc tta gtg aaa gaa gaa gaa 768
Lys Ala Ala Val Ala Gly Ile Ala Met Gly Leu Val Lys Glu Glu Glu

```



WO 02/075507

PCT/US02/01971

```

                245                250                255
aaa ttt gtg gtg ctt tca gac atc tta ggt gac gaa gac cat tta ggc 816
Lys Phe Val Val Leu Ser Asp Ile Leu Gly Asp Glu Asp His Leu Gly
                260                265                270
gat atg gac ttc aaa gta gcc ggt acg cgt gaa ggt gta acc gca ctt 864
Asp Met Asp Phe Lys Val Ala Gly Thr Arg Glu Gly Val Thr Ala Leu
                275                280                285
caa atg gat att aaa atc gaa ggt atc acg cct gaa att atg caa atc 912
Gln Met Asp Ile Lys Ile Glu Gly Ile Thr Pro Glu Ile Met Gln Ile
                290                295                300
gca tta aat caa gcg aaa ggt gcg cgt atg cac atc tta agc gtg atg 960
Ala Leu Asn Gln Ala Lys Gly Ala Arg Met His Ile Leu Ser Val Met
305                310                315
gaa caa gcg att cct gca cct cgt gcc gat att tcc gat ttt gcg cct 1008
Glu Gln Ala Ile Pro Ala Pro Arg Ala Asp Ile Ser Asp Phe Ala Pro
325                330                335
cgt att cat acg atg aag atc gat ccg aag aaa atc aaa gac gtg atc 1056
Arg Ile His Thr Met Lys Ile Asp Pro Lys Lys Ile Lys Asp Val Ile
340                345                350
ggg aaa gcg ggt gcg gtt at 1076
Gly Lys Gly Gly Ala Val
355

<210> 155
<211> 358
<212> PRT
<213> Actinobacillus pleuropneumoniae

<400> 155
Asn Ile Lys Glu Phe Val Lys Glu Ala Gly Lys Pro Arg Trp Asp Trp
1 5 10 15
Val Ala Pro Glu Pro Asn Thr Ala Leu Ile Asn Gln Val Lys Ala Leu
20 25 30
Ala Glu Ala Arg Ile Gly Asp Ala Tyr Arg Ile Thr Glu Lys Gln Ala
35 40 45
Arg Tyr Glu Gln Ile Asp Ala Ile Lys Ala Asp Val Ile Ala Gln Leu
50 55 60
Thr Ala Gln Asp Glu Thr Val Ser Glu Gly Ala Ile Ile Asp Ile Ile
65 70 75 80

Thr Ala Leu Glu Ser Ser Ile Val Arg Gly Arg Ile Ile Ala Gly Glu
85 90 95
Pro Arg Ile Asp Gly Arg Thr Val Asp Thr Val Arg Ala Leu Asp Ile
100 105 110
Cys Thr Gly Val Leu Pro Arg Thr His Gly Ser Ala Ile Phe Thr Arg
115 120 125
Gly Glu Thr Gln Ala Leu Ala Val Ala Thr Leu Gly Thr Glu Arg Asp

```

WO 02/075507

PCT/US02/01971

130 135 140  
Ala Gln Ile Val Asp Glu Leu Thr Gly Glu Lys Ser Asp Arg Phe Leu  
145 150 155 160  
Phe His Tyr Asn Phe Pro Pro Tyr Ser Val Gly Glu Thr Gly Arg Ile  
165 170 175  
Gly Ser Pro Lys Arg Arg Glu Ile Gly His Gly Arg Leu Ala Lys Arg  
180 185 190  
Gly Val Leu Ala Val Met Pro Thr Ala Glu Glu Phe Pro Tyr Val Val  
195 200 205  
Arg Val Val Ser Glu Ile Thr Glu Ser Asn Gly Ser Ser Ser Met Ala  
210 215 220  
Ser Val Cys Gly Ala Ser Leu Ala Leu Met Asp Ala Gly Val Pro Ile  
225 230 235 240  
Lys Ala Ala Val Ala Gly Ile Ala Met Gly Leu Val Lys Glu Glu Glu  
245 250 255  
Lys Phe Val Val Leu Ser Asp Ile Leu Gly Asp Glu Asp His Leu Gly  
260 265 270  
Asp Met Asp Phe Lys Val Ala Gly Thr Arg Glu Gly Val Thr Ala Leu  
275 280 285  
Gln Met Asp Ile Lys Ile Glu Gly Ile Thr Pro Glu Ile Met Gln Ile  
290 295 300  
Ala Leu Asn Gln Ala Lys Gly Ala Arg Met His Ile Leu Ser Val Met  
305 310 315 320  
Glu Gln Ala Ile Pro Ala Pro Arg Ala Asp Ile Ser Asp Phe Ala Pro  
325 330 335  
Arg Ile His Thr Met Lys Ile Asp Pro Lys Lys Ile Lys Asp Val Ile  
340 345 350  
Gly Lys Gly Gly Ala Val  
355

<210> 156  
<211> 1055  
<212> DNA  
<213> Actinobacillus pleuropneumoniae

<220>  
<223> potD

<220>  
<221> CDS  
<222> (1)..(1053)

<400> 156  
atg aaa aaa tta gcg ggt tta ttt gca gca ggt tta gcg aca gtt gca 48  
Met Lys Lys Leu Ala Gly Leu Phe Ala Ala Gly Leu Ala Thr Val Ala  
1 5 10 15  
tta aca gcg tgt aat gaa gaa aag cca aaa gcg gct gaa gca gcg gct 96

WO 02/075507

PCT/US02/01971

Leu Thr Ala Cys Asn Glu Glu Lys Pro Lys Ala Ala Glu Ala Ala Ala  
                   20                                  25                                  30  
 caa ccg gca gca gcg gga aca gtt cac ctt tat act tgg act gaa tat 144  
 Gln Pro Ala Ala Ala Gly Thr Val His Leu Tyr Thr Trp Thr Glu Tyr  
                   35                                  40                                  45  
 gtg cct gaa ggc ttg tta gat gaa ttt aca aag caa acc ggt atc aaa 192  
 Val Pro Glu Gly Leu Leu Asp Glu Phe Thr Lys Gln Thr Gly Ile Lys  
                   50                                  55                                  60  
 gta gag gtt tca agc ctt gaa tct aac gaa acc atg tat gcg aaa tta 240  
 Val Glu Val Ser Ser Leu Glu Ser Asn Glu Thr Met Tyr Ala Lys Leu  
                   65                                  70                                  75                                  80  
 aaa tta caa ggt aaa gac ggc ggt tac gat gtt atc gca cct tct aac 288  
 Lys Leu Gln Gly Lys Asp Gly Gly Tyr Asp Val Ile Ala Pro Ser Asn  
                   85                                  90                                  95  
 tac ttc gtt tca aaa atg gcg aaa gaa ggt atg tta gcg gaa tta gat 336  
 Tyr Phe Val Ser Lys Met Ala Lys Glu Gly Met Leu Ala Glu Leu Asp  
                   100                                  105                                  110  
 cac gca aaa ctt cct gta atc aaa gag tta aac caa gat tgg tta aac 384  
 His Ala Lys Leu Pro Val Ile Lys Glu Leu Asn Gln Asp Trp Leu Asn  
                   115                                  120                                  125  
 aaa cct tat gac caa ggt aac aaa tac tct tta ccg caa tta tta ggt 432  
 Lys Pro Tyr Asp Gln Gly Asn Lys Tyr Ser Leu Pro Gln Leu Leu Gly  
                   130                                  135                                  140  
 gca ccg ggt atc gca ttt aac tca aat gac tat aag ggc gat gcg ttc 480  
 Ala Pro Gly Ile Ala Phe Asn Ser Asn Asp Tyr Lys Gly Asp Ala Phe  
                   145                                  150                                  155                                  160  
 act tct tgg ggt gat tta tgg aaa cct gag ttt gcg aat aaa gta caa 528  
 Thr Ser Trp Gly Asp Leu Trp Lys Pro Glu Phe Ala Asn Lys Val Gln  
                   165                                  170                                  175  
 tta tta gat gac gca cgt gaa gta ttt aac att gcg tta tta aaa tta 576  
 Leu Leu Asp Asp Ala Arg Glu Val Phe Asn Ile Ala Leu Leu Lys Leu  
                   180                                  185                                  190  
 ggt aaa aac cct aat aca acc aat ccg gaa gag att aaa gcg gct tac 624  
 Gly Lys Asn Pro Asn Thr Thr Asn Pro Glu Glu Ile Lys Ala Ala Tyr  
                   195                                  200                                  205  
 gaa gag tta aga aaa tta cgt cca aac gta ctt tct ttc act tca gac 672  
 Glu Glu Leu Arg Lys Leu Arg Pro Asn Val Leu Ser Phe Thr Ser Asp  
                   210                                  215                                  220  
  
 aac cca gcg aac tca ttt atc gca ggt gaa gta tct gta ggt caa tta 720  
 Asn Pro Ala Asn Ser Phe Ile Ala Gly Glu Val Ser Val Gly Gln Leu  
                   225                                  230                                  235                                  240  
 tgg aac ggt tct gta cgt att gcg aaa aaa gaa caa gcg ccg gta aac 768  
 Trp Asn Gly Ser Val Arg Ile Ala Lys Lys Glu Gln Ala Pro Val Asn  
                   245                                  250                                  255  
 atg gtg ttc cca aaa gaa ggt cct gta ctt tgg gtt gat acg tta gcc 816  
 Met Val Phe Pro Lys Glu Gly Pro Val Leu Trp Val Asp Thr Leu Ala

WO 02/075507

PCT/US02/01971

```

                260                265                270
att ccg gcg aat gcg aaa aac aaa gaa aat gcg cat aag tta atc aac 864
ile pro ala asn ala lys asn lys glu asn ala his lys leu ile asn
      275                280                285

tac tta tta agc gca ccg gtt gcg gaa aaa tta acg tta gaa atc ggt 912
tyr leu leu ser ala pro val ala glu lys leu thr leu glu ile gly
      290                295                300

tat ccg act tca aac gta gaa gcg tta aaa aca tta cca aaa gag att 960
tyr pro thr ser asn val glu ala leu lys thr leu pro lys glu ile
      305                310                315

acc gaa gat ccg gca atc tat ccg aca gct gat gtg tta aaa gcg gca 1008
thr glu asp pro ala ile tyr pro thr ala asp val leu lys ala ala
      325                330                335

caa tgg caa gac gat gta ggt aat gca atc gaa ctt tac gaa aaa ta 1055
gln trp gln asp asp val gly asn ala ile glu leu tyr glu lys
      340                345                350

<210> 157
<211> 351
<212> PRT
<213> Actinobacillus pleuropneumoniae

<400> 157
Met Lys Lys Leu Ala Gly Leu Phe Ala Ala Gly Leu Ala Thr Val Ala
  1          5          10          15
Leu Thr Ala Cys Asn Glu Glu Lys Pro Lys Ala Ala Glu Ala Ala Ala
  20          25          30
Gln Pro Ala Ala Ala Gly Thr Val His Leu Tyr Thr Trp Thr Glu Tyr
  35          40          45
Val Pro Glu Gly Leu Leu Asp Glu Phe Thr Lys Gln Thr Gly Ile Lys
  50          55          60
Val Glu Val Ser Ser Leu Glu Ser Asn Glu Thr Met Tyr Ala Lys Leu
  65          70          75          80
Lys Leu Gln Gly Lys Asp Gly Gly Tyr Asp Val Ile Ala Pro Ser Asn
  85          90          95
Tyr Phe Val Ser Lys Met Ala Lys Glu Gly Met Leu Ala Glu Leu Asp
 100          105          110
His Ala Lys Leu Pro Val Ile Lys Glu Leu Asn Gln Asp Trp Leu Asn
 115          120          125
Lys Pro Tyr Asp Gln Gly Asn Lys Tyr Ser Leu Pro Gln Leu Leu Gly
 130          135          140
Ala Pro Gly Ile Ala Phe Asn Ser Asn Asp Tyr Lys Gly Asp Ala Phe
 145          150          155
Thr Ser Trp Gly Asp Leu Trp Lys Pro Glu Phe Ala Asn Lys Val Gln
 165          170          175
Leu Leu Asp Asp Ala Arg Glu Val Phe Asn Ile Ala Leu Leu Lys Leu

```

252

WO 02/075507

PCT/US02/01971

```

180          185          190
Gly Lys Asn Pro Asn Thr Thr Asn Pro Glu Glu Ile Lys Ala Ala Tyr
195          200          205
Glu Glu Leu Arg Lys Leu Arg Pro Asn Val Leu Ser Phe Thr Ser Asp
210          215          220
Asn Pro Ala Asn Ser Phe Ile Ala Gly Glu Val Ser Val Gly Gln Leu
225          230          235
Trp Asn Gly Ser Val Arg Ile Ala Lys Lys Glu Gln Ala Pro Val Asn
245          250          255
Met Val Phe Pro Lys Glu Gly Pro Val Leu Trp Val Asp Thr Leu Ala
260          265          270
Ile Pro Ala Asn Ala Lys Asn Lys Glu Asn Ala His Lys Leu Ile Asn
275          280          285
Tyr Leu Leu Ser Ala Pro Val Ala Glu Lys Leu Thr Leu Glu Ile Gly
290          295          300
Tyr Pro Thr Ser Asn Val Glu Ala Leu Lys Thr Leu Pro Lys Glu Ile
305          310          315
Thr Glu Asp Pro Ala Ile Tyr Pro Thr Ala Asp Val Leu Lys Ala Ala
325          330          335
Gln Trp Gln Asp Asp Val Gly Asn Ala Ile Glu Leu Tyr Glu Lys
340          345          350

<210> 158
<211> 525
<212> DNA
<213> Actinobacillus pleuropneumoniae

<220>
<223> rpmF

<220>
<221> CDS
<222> (1)...(522)

<400> 158
atg caa aag gta aaa cta ccc ctc acc att gac cca tat aaa gac gct 48
Met Gln Lys Val Lys Leu Pro Leu Thr Ile Asp Pro Tyr Lys Asp Ala
1 5 10 15
cag cgt cga atg gat tac gaa ggc tac atc tca cgt agt ctg ctt aat 96
Gln Arg Arg Met Asp Tyr Glu Gly Tyr Ile Ser Arg Ser Leu Leu Asn
20 25 30
cgt ttg ggt gaa tct gtg agc aat gtg cta agc gat gca caa gtt act 144
Arg Leu Gly Glu Ser Val Ser Asn Val Leu Ser Asp Ala Gln Val Thr
35 40 45
ctc tcg tta tat atc gat cag caa cgc tta acc gtt att aaa ggt acg 192
Leu Ser Leu Tyr Ile Asp Pro Gln Arg Leu Thr Val Ile Lys Gly Thr
50 55 60
scg aca gtg gaa gtg gaa ttc gat tgc caa cga tgc ggt aac cag ttt 240

```

253

WO 02/075507

PCT/US02/01971

Ala Thr Val Glu Val Glu Phe Asp Cys Gln Arg Cys Gly Asn Pro Phe  
65 70 75 80  
aca caa acg ctt gac tgt tct ttt tgt ttc agt ccg gtg tcc aat atg 288  
Thr Gln Thr Leu Asp Cys Ser Phe Cys Phe Ser Pro Val Ser Asn Met  
85 90 95  
gat cag gcg gac aat ttg ccc gaa att tat gaa cca atc gaa gta aac 336  
Asp Gln Ala Asp Asn Leu Pro Glu Ile Tyr Glu Pro Ile Glu Val Asn  
100 105 110  
gag ttc ggt gaa gta aat tta cta gat atg atc gaa gat gga ttt atc 384  
Glu Phe Gly Glu Val Asn Leu Leu Asp Met Ile Glu Asp Gly Phe Ile  
115 120 125  
atc gaa ttg cct cta gtc ccg atg cat agt gaa gaa cac tgt gaa gtg 432  
Ile Glu Leu Pro Leu Val Pro Met His Ser Glu Glu His Cys Glu Val  
130 135 140  
tcc gtg agt gaa cag gtg ttt ggc gaa ttg cct gaa gaa ttg gcg aaa 480  
Ser Val Ser Glu Gln Val Phe Gly Glu Leu Pro Glu Glu Leu Ala Lys  
145 150 155 160  
aaa cct aac ccg ttc gct gta tta gct aat tta aag aaa aac tag 525  
Lys Pro Asn Pro Phe Ala Val Leu Ala Asn Leu Lys Lys Asn  
165 170

<210> 159  
<211> 174  
<212> PRT  
<213> Actinobacillus pleuropneumoniae

<400> 159  
Met Gln Lys Val Lys Leu Pro Leu Thr Ile Asp Pro Tyr Lys Asp Ala  
1 5 10 15  
Gln Arg Arg Met Asp Tyr Glu Gly Tyr Ile Ser Arg Ser Leu Leu Asn  
20 25 30  
Arg Leu Gly Glu Ser Val Ser Asn Val Leu Ser Asp Ala Gln Val Thr  
35 40 45  
Leu Ser Leu Tyr Ile Asp Pro Gln Arg Leu Thr Val Ile Lys Gly Thr  
50 55 60  
Ala Thr Val Glu Val Glu Phe Asp Cys Gln Arg Cys Gly Asn Pro Phe  
65 70 75 80  
Thr Gln Thr Leu Asp Cys Ser Phe Cys Phe Ser Pro Val Ser Asn Met  
85 90 95  
Asp Gln Ala Asp Asn Leu Pro Glu Ile Tyr Glu Pro Ile Glu Val Asn  
100 105 110  
Glu Phe Gly Glu Val Asn Leu Leu Asp Met Ile Glu Asp Gly Phe Ile  
115 120 125  
Ile Glu Leu Pro Leu Val Pro Met His Ser Glu Glu His Cys Glu Val  
130 135 140  
Ser Val Ser Glu Gln Val Phe Gly Glu Leu Pro Glu Glu Leu Ala Lys  
145 150 155 160

WO 02/075507

PCT/US02/01971

Lys Pro Asn Pro Phe Ala Val Leu Ala Asn Leu Lys Lys Asn  
 165 170

<210> 160  
 <211> 1302  
 <212> DNA  
 <213> Actinobacillus pleuropneumoniae  
 <220>  
 <223> tig  
 <220>  
 <221> CDS  
 <222> (1)..(1299)  
 <400> 160  
 atg tca att tct att gaa act tta gaa ggc tta caa cgc cgc gta act 48  
 Met Ser Ile Ser Ile Glu Thr Leu Glu Gly Leu Gln Arg Arg Val Thr  
 1 5 10 15  
 att acc gta gct gct gat aaa atc gaa ggc gct tac aaa gag caa tta 96  
 Ile Thr Val Ala Ala Asp Lys Ile Glu Ala Ala Tyr Lys Glu Gln Leu  
 20 25 30  
 aaa ggc tat cgc aaa aac gct cgt gta gac ggt ttc cgt aaa ggt aaa 144  
 Lys Gly Tyr Ala Lys Asn Ala Arg Val Asp Gly Phe Arg Lys Gly Lys  
 35 40 45  
 gta ccg cac gca att atc gaa caa cgt ttc ggt tta cgc gct cgc caa 192  
 Val Pro His Ala Ile Ile Glu Gln Arg Phe Gly Leu Ala Ala Arg Gln  
 50 55 60  
 gac gta tta tcc gat gaa atg caa cgt cgc ttc ttt gat cgc gta atc 240  
 Asp Val Leu Ser Asp Glu Met Gln Arg Ala Phe Phe Asp Ala Val Ile  
 65 70 75 80  
 gct gag aaa att aac ctt gcc ggt cgt cct acc ttc aca cgc aac aac 288  
 Ala Glu Lys Ile Asn Leu Ala Gly Arg Pro Thr Phe Thr Pro Asn Asn  
 85 90 95  
 tac caa ccg agt caa gaa ttc agc ttc act gca act ttt gaa gta ttc 336  
 Tyr Gln Pro Ser Gln Glu Phe Ser Phe Thr Ala Thr Phe Glu Val Phe  
 100 105 110  
 ccg gaa gtt gaa tta aaa ggc tta gaa aat atc gaa gtt gaa aaa ccg 384  
 Pro Glu Val Glu Leu Lys Gly Leu Glu Asn Ile Glu Val Glu Lys Pro  
 115 120 125  
 gtt gta gaa atc aca gaa gct gat tta gac aaa atg atc gat gtg tta 432  
 Val Val Glu Ile Thr Glu Ala Asp Leu Asp Lys Met Ile Asp Val Leu  
 130 135 140  
 cgt aaa caa caa cgc act tgg gct gaa tct caa gca cgc gca caa cgc 480  
 Arg Lys Gln Gln Ala Thr Trp Ala Glu Ser Gln Ala Ala Ala Gln Ala  
 145 150 155 160  
 gaa gac cgt gtt gta atc gac ttc gta ggt tct gta gac ggt gaa gag 528  
 Glu Asp Arg Val Val Ile Asp Phe Val Gly Ser Val Asp Gly Glu Glu  
 165 170 175  
 ttt gaa ggc ggt aaa cgc aca gac ttc act tta gca atg ggt caa agt 576  
 Phe Glu Gly Gly Lys Ala Thr Asp Phe Thr Leu Ala Met Gly Gln Ser

WO 02/075507

PCT/US02/01971

180	185	190	
cgt atg atc cct ggt ttt gaa gaa ggt atc gtt ggt cac aaa gcc ggc Arg Met Ile Pro Gly Phe Glu Glu Gly Ile Val Gly His Lys Ala Gly 195 200 205			624
gaa caa ttc gat atc gat gtt act ttc cct gaa gaa tac cac gct gaa Glu Gln Phe Asp Ile Asp Val Thr Phe Pro Glu Glu Tyr His Ala Glu 210 215 220			672
aac tta aaa ggt aaa gcg gcg aaa ttc gca att aca ctt aag aaa gta Asn Leu Lys Gly Lys Ala Ala Lys Phe Ala Ile Thr Leu Lys Lys Val 225 230 235 240			720
gaa aat atc gta tta cct gaa tta acc gaa gaa ttc gtg aaa aaa ttc Glu Asn Ile Val Leu Pro Glu Leu Thr Glu Glu Phe Val Lys Lys Phe 245 250			768
ggt tca gca aaa act gta gaa gat tta cgt gcg gaa att aag aaa aat Gly Ser Ala Lys Thr Val Glu Asp Leu Arg Ala Glu Ile Lys Lys Asn 260 265 270			816
atg caa cgt gaa ctt aaa aac gca gta acc gca cgc gtt aaa aac caa Met Gln Arg Glu Leu Lys Asn Ala Val Thr Ala Arg Val Lys Asn Gln 275 280 285			864
gta atc aac ggt tta atc gca caa aat gaa att gaa gtg ccg gct gca Val Ile Asn Gly Leu Ile Ala Gln Asn Glu Ile Glu Val Pro Ala Ala 290 295 300			912
gcg gta gcg gaa gaa gtg gac gta tta cgt cgt caa gcg gtt caa cgt Ala Val Ala Glu Glu Val Asp Val Leu Arg Arg Gln Ala Val Gln Arg 305 310 315 320			960
ttc ggt ggt aaa ccg gaa atg gct gca caa tta ccg gcg gaa tta ttc Phe Gly Gly Lys Pro Glu Met Ala Ala Gln Leu Pro Ala Glu Leu Phe 325 330 335			1008
gaa gcg gat gca aaa cgt cgt gtt caa gta ggt tta tta ctt tca acc Glu Ala Asp Ala Lys Arg Arg Val Gln Val Gly Leu Leu Ser Thr 340 345 350			1056
gta atc ggt act aac gaa tta aaa gtt gat gaa aaa cgt gtt gaa gaa Val Ile Gly Thr Asn Glu Leu Lys Val Asp Glu Lys Arg Val Glu Glu 355 360 365			1104
acg att gca gaa atc gct tca gct tac gaa caa ccg gcg gaa gtt gtt Thr Ile Ala Glu Ile Ala Ser Ala Tyr Glu Gln Pro Ala Glu Val Val 370 375 380			1152
gct cat tat gcg aaa aac cgt caa tta acc gaa aat atc cgt aac gta Ala His Tyr Ala Lys Asn Arg Gln Leu Thr Glu Asn Ile Arg Asn Val 385 390 395 400			1200
gtg tta gaa gag caa gcg gtt gaa gtt gta ctt gcg aaa gca aaa gta Val Leu Glu Glu Gln Ala Val Glu Val Val Leu Ala Lys Ala Lys Val 405 410 415			1248
act gaa aaa gcg act tct ttt gat gaa gta atg gct caa caa gct caa Thr Glu Lys Ala Thr Ser Phe Asp Glu Val Met Ala Gln Gln Ala Gln 420 425 430			1296
ggc taa			1302

256



WO 02/075507

PCT/US02/01971

Gly

<210> 161  
 <211> 433  
 <212> PRT  
 <213> Actinobacillus pleuropneumoniae

<400> 161  
 Met Ser Ile Ser Ile Glu Thr Leu Glu Gly Leu Gln Arg Arg Val Thr  
 1 5 10 15  
 Ile Thr Val Ala Ala Asp Lys Ile Glu Ala Ala Tyr Lys Glu Gln Leu  
 20 25 30  
 Lys Gly Tyr Ala Lys Asn Ala Arg Val Asp Gly Phe Arg Lys Gly Lys  
 35 40 45  
 Val Pro His Ala Ile Ile Glu Gln Arg Phe Gly Leu Ala Ala Arg Gln  
 50 55 60  
 Asp Val Leu Ser Asp Glu Met Gln Arg Ala Phe Phe Asp Ala Val Ile  
 65 70 75 80  
 Ala Glu Lys Ile Asn Leu Ala Gly Arg Pro Thr Phe Thr Pro Asn Asn  
 85 90 95  
 Tyr Gln Pro Ser Gln Glu Phe Ser Phe Thr Ala Thr Phe Glu Val Phe  
 100 105 110  
 Pro Glu Val Glu Leu Lys Gly Leu Glu Asn Ile Glu Val Glu Lys Pro  
 115 120 125  
 Val Val Glu Ile Thr Glu Ala Asp Leu Asp Lys Met Ile Asp Val Leu  
 130 135 140  
 Arg Lys Gln Gln Ala Thr Trp Ala Glu Ser Gln Ala Ala Ala Gln Ala  
 145 150 155 160  
 Glu Asp Arg Val Val Ile Asp Phe Val Gly Ser Val Asp Gly Glu Glu  
 165 170 175  
 Phe Glu Gly Gly Lys Ala Thr Asp Phe Thr Leu Ala Met Gly Gln Ser  
 180 185 190  
 Arg Met Ile Pro Gly Phe Glu Glu Gly Ile Val Gly His Lys Ala Gly  
 195 200 205  
 Glu Gln Phe Asp Ile Asp Val Thr Phe Pro Glu Glu Tyr His Ala Glu  
 210 215 220  
 Asn Leu Lys Gly Lys Ala Ala Lys Phe Ala Ile Thr Leu Lys Lys Val  
 225 230 235 240  
 Glu Asn Ile Val Leu Pro Glu Leu Thr Glu Glu Phe Val Lys Lys Phe  
 245 250 255  
 Gly Ser Ala Lys Thr Val Glu Asp Leu Arg Ala Glu Ile Lys Lys Asn  
 260 265 270  
 Met Gln Arg Glu Leu Lys Asn Ala Val Thr Ala Arg Val Lys Asn Gln  
 275 280 285

WO 02/075507

PCT/US02/01971

Val Ile Asn Gly Leu Ile Ala Gln Asn Glu Ile Glu Val Pro Ala Ala  
 290 295 300

Ala Val Ala Glu Glu Val Asp Val Leu Arg Arg Gln Ala Val Gln Arg  
 305 310 315 320

Phe Gly Gly Lys Pro Glu Met Ala Ala Gln Leu Pro Ala Glu Leu Phe  
 325 330 335

Glu Ala Asp Ala Lys Arg Arg Val Gln Val Gly Leu Leu Leu Ser Thr  
 340 345 350

Val Ile Gly Thr Asn Glu Leu Lys Val Asp Glu Lys Arg Val Glu Glu  
 355 360 365

Thr Ile Ala Glu Ile Ala Ser Ala Tyr Glu Gln Pro Ala Glu Val Val  
 370 375 380

Ala His Tyr Ala Lys Asn Arg Gln Leu Thr Glu Asn Ile Arg Asn Val  
 385 390 395 400

Val Leu Glu Glu Gln Ala Val Glu Val Val Leu Ala Lys Ala Lys Val  
 405 410 415

Thr Glu Lys Ala Thr Ser Phe Asp Glu Val Met Ala Gln Gln Ala Gln  
 420 425 430

Gly

<210> 162  
 <211> 316  
 <212> DNA  
 <213> Actinobacillus pleuropneumoniae

<220>  
 <223> tRNA-glu

<400> 162  
 aatattgcgc tcaaatggca aagcggagag catctttaa tgtgtcccc atcgtctaga 60  
 ggcctaggac atgcgccctt cagcgcgta accggggttc gaatccccgt ggggacgcca 120  
 tttaaagatg acttttggtg tctgaattgt tctttaaaaa attggaaca agctgaaaac 180  
 tgagagattt tcgaagaaaa gcttgagtag taaaagataa gtaattatct tgaaaaatctt 240  
 agctgaacaa aagcagcetaa gtgttagtt gaataaagta tcgcgttgaa tgcgttcaaa 300  
 taaaattga aatat 316

<210> 163  
 <211> 85  
 <212> DNA  
 <213> Actinobacillus pleuropneumoniae

<220>  
 <223> tRNA-leu

<400> 163  
 gctctggcgg tgggaattggt agacacgeta tcttgagggg gtagtgcca taggatgtgc 60

WO 02/075507

PCT/US02/01971

gagttcgagt ctgcccaga gcacc 85

<210> 164  
 <211> 623  
 <212> DNA  
 <213> Actinobacillus pleuropneumoniae

<220>  
 <223> yaeE

<220>  
 <221> CDS  
 <222> (1)...(621)

<400> 164  
 atg caa gaa ctc aca cct caa atg tgg ggc tta gtc ggc act tca acg 48  
 Met Gln Glu Leu Thr Pro Gln Met Trp Gly Leu Val Gly Thr Ser Thr  
 1 5 10 15  
 ctt gaa acg ctc tat atg ggc ttt gcg gcg act tta ctt gct gtg gta 96  
 Leu Glu Thr Leu Tyr Met Gly Phe Ala Ala Thr Leu Leu Ala Val Val  
 20 25 30  
 gtc ggt ttg ccg atc ggt ttt ctg gca ttt tta acc ggt aaa gga gag 144  
 Val Gly Leu Pro Ile Gly Phe Leu Ala Phe Leu Thr Gly Lys Gly Glu  
 35 40 45  
 att tta gag aat ccg cgt tta cat caa gta tta gat gtg att att aat 192  
 Ile Leu Glu Asn Pro Arg Leu His Gln Val Leu Asp Val Ile Ile Asn  
 50 55 60  
 atc ggt cgt tcc gta ccg ttt att att ttg tta gtc gtg ttg tta cct 240  
 Ile Gly Arg Ser Val Pro Phe Ile Ile Leu Leu Val Val Leu Leu Pro  
 65 70 75 80  
 ttt acg cgt tta ttg gtc ggg aca acg ctc ggt act acg gcg gcg att 288  
 Phe Thr Arg Leu Leu Val Gly Thr Thr Leu Gly Thr Thr Ala Ala Ile  
 85 90 95  
 gtg ccg tta agc gtt tcg gca att ccg ttt ttt gcg cgt tta act tca 336  
 Val Pro Leu Ser Val Ser Ala Ile Pro Phe Phe Ala Arg Leu Thr Ser  
 100 105 110  
 aat gcg tta tta gaa atc cca gca ggt tta acc gaa gcg gcg aaa tcg 384  
 Asn Ala Leu Leu Glu Ile Pro Ala Gly Leu Thr Glu Ala Ala Lys Ser  
 115 120 125  
 atg gcg gca acg aat tgg caa gtg gtc agt aaa ttt tat tta ccg gaa 432  
 Met Gly Ala Thr Asn Trp Gln Val Val Ser Lys Phe Tyr Leu Pro Glu  
 130 135 140  
 tca ctg ccg att tta atc aat ggt atc aca tta act tta gtc gct tta 480  
 Ser Leu Pro Ile Leu Ile Asn Gly Ile Thr Leu Thr Leu Val Ala Leu  
 145 150 155 160  
 atc ggt tat tcg gca atg gcg ggt gcg gtc ggc ggc ggc ggt ttg ggt 528  
 Ile Gly Tyr Ser Ala Met Ala Gly Ala Val Gly Gly Gly Gly Leu Gly  
 165 170 175  
 aac ctt gcc atc agt tac ggt gaa cac cga aat atg gtc tat gta aaa 576  
 Asn Leu Ala Ile Ser Tyr Gly Glu His Arg Asn Met Val Tyr Val Lys  
 180 185 190

WO 02/075507

PCT/US02/01971

tgg atc tca aca att att atc gta gcg att gtg atg atc agt caa aa 623  
 Trp Ile Ser Thr Ile Ile Ile Val Ala Ile Val Met Ile Ser Gln  
 195 200 205

&lt;210&gt; 165

&lt;211&gt; 207

&lt;212&gt; PRT

&lt;213&gt; Actinobacillus pleuropneumoniae

&lt;400&gt; 165

Met Gln Glu Leu Thr Pro Gln Met Trp Gly Leu Val Gly Thr Ser Thr  
 1 5 10 15  
 Leu Glu Thr Leu Tyr Met Gly Phe Ala Ala Thr Leu Leu Ala Val Val  
 20 25 30  
 Val Gly Leu Pro Ile Gly Phe Leu Ala Phe Leu Thr Gly Lys Gly Glu  
 35 40 45  
 Ile Leu Glu Asn Pro Arg Leu His Gln Val Leu Asp Val Ile Ile Asn  
 50 55 60  
 Ile Gly Arg Ser Val Pro Phe Ile Ile Leu Leu Val Val Leu Leu Pro  
 65 70 75 80  
 Phe Thr Arg Leu Leu Val Gly Thr Thr Leu Gly Thr Thr Ala Ala Ile  
 85 90 95  
 Val Pro Leu Ser Val Ser Ala Ile Pro Phe Phe Ala Arg Leu Thr Ser  
 100 105 110  
 Asn Ala Leu Leu Glu Ile Pro Ala Gly Leu Thr Glu Ala Ala Lys Ser  
 115 120 125  
 Met Gly Ala Thr Asn Trp Gln Val Val Ser Lys Phe Tyr Leu Pro Glu  
 130 135 140  
 Ser Leu Pro Ile Leu Ile Asn Gly Ile Thr Leu Thr Leu Val Ala Leu  
 145 150 155 160  
 Ile Gly Tyr Ser Ala Met Ala Gly Ala Val Gly Gly Gly Gly Leu Gly  
 165 170 175  
 Asn Leu Ala Ile Ser Tyr Gly Glu His Arg Asn Met Val Tyr Val Lys  
 180 185 190  
 Trp Ile Ser Thr Ile Ile Ile Val Ala Ile Val Met Ile Ser Gln  
 195 200 205

&lt;210&gt; 166

&lt;211&gt; 866

&lt;212&gt; DNA

&lt;213&gt; Pasteurella (Mannheimia) haemolytica

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(864)

&lt;220&gt;

&lt;223&gt; atpG

WO 02/075507

PCT/US02/01971

```

<400> 166
atg gca ggt gct aaa gag ata aga acc aaa att gca agt gtt cgt aat 48
Met Ala Gly Ala Lys Glu Ile Arg Thr Lys Ile Ala Ser Val Arg Asn
1 5 10 15
aca caa aaa att acc aaa gcg atg gaa atg gtt gcc gca tca aaa atg 96
Thr Gln Lys Ile Thr Lys Ala Met Glu Met Val Ala Ala Ser Lys Met
20 25 30
cgt aaa acc caa gag cgt atg gcg gct tct cgc cct tat gct gaa agt 144
Arg Lys Thr Gln Glu Arg Met Ala Ala Ser Arg Pro Tyr Ala Glu Ser
35 40 45
att cgc aag gca att agc cat att gcc aaa ggt aac att gag tat aaa 192
Ile Arg Lys Ala Ile Ser His Ile Ala Lys Gly Asn Ile Glu Tyr Lys
50 55 60
cac cca ttt ttg acc cca cgt cgg gta aaa aaa gtt gcc tat tta gta 240
His Pro Phe Leu Thr Pro Arg Pro Val Lys Lys Val Gly Tyr Leu Val
65 70 75 80
ggt tca acc gat cgc ggt tta tgt ggt gcc tta aat atc aat tta ttt 288
Val Ser Thr Asp Arg Gly Leu Cys Gly Gly Leu Asn Ile Asn Leu Phe
85 90 95
aaa acc gtt tta cat gaa ttg aaa gaa aaa gat gac caa ggt gtt aag 336
Lys Thr Val Leu His Glu Leu Lys Glu Lys Asp Asp Gln Gly Val Lys
100 105 110
tct cga ctt gct gtg gtg gga aat aaa ggg atc tcc ttt ttt aac cca 384
Ser Arg Leu Ala Val Val Gly Asn Lys Gly Ile Ser Phe Phe Asn Pro
115 120 125
atg ggg cta gag att aaa ggt cat atc aat gga ttg ggt gat aca ccg 432
Met Gly Leu Glu Ile Lys Gly His Ile Asn Gly Leu Gly Asp Thr Pro
130 135 140
gca atg gaa gat tta gtc ggt att gtt aat ggt atg gta aat gcc tac 480
Ala Met Glu Asp Leu Val Gly Ile Val Asn Gly Met Val Asn Ala Tyr
145 150 155 160
cgt gaa ggc gaa att gat gaa gtg tat gtg gta tat aac cgt ttt ata 528
Arg Glu Gly Glu Ile Asp Glu Val Tyr Val Val Tyr Asn Arg Phe Ile
165 170 175
aac acg atg tca caa aaa ccg aca gta caa cag ttg ctt cct ttg cct 576
Asn Thr Met Ser Gln Lys Pro Thr Val Gln Gln Leu Leu Pro Leu Pro
180 185 190
gca ctg gaa aat gac tca tta gag caa act ggt tct tgg gat tat ctc 624
Ala Leu Glu Asn Asp Ser Leu Glu Gln Thr Gly Ser Trp Asp Tyr Leu
195 200 205
tat gaa cca aat cca caa gcg tta tta gac agc tta ctg gtt cgt tat 672
Tyr Glu Pro Asn Pro Gln Ala Leu Leu Asp Ser Leu Leu Val Arg Tyr
210 215 220
tta gaa tct caa gtt tat cag gca gtg gta gat aat ctt cgc tct gaa 720
Leu Glu Ser Gln Val Tyr Gln Ala Val Val Asp Asn Leu Ala Ser Glu
225 230 235 240
cag gct gct cga atg gtg gca atg aaa gca gca acc gat aac gca ggt 768
Gln Ala Ala Arg Met Val Ala Met Lys Ala Ala Thr Asp Asn Ala Gly

```

WO 02/075507

PCT/US02/01971

```

                245                250                255
aat ctg att aat gag tta cag tta gtg tat aac aaa gct cgt caa gca 816
Asn Leu Ile Asn Glu Leu Gln Leu Val Tyr Asn Lys Ala Arg Gln Ala
      260                265                270

agt att acg aat gaa tta aat gaa att gtc gcg ggt gcc gca gca att 864
Ser Ile Thr Asn Glu Leu Asn Glu Ile Val Ala Gly Ala Ala Ala Ile
      275                280                285

ta 866

<210> 167
<211> 298
<212> PRT
<213> Pasteurella (Mannheimia) haemolytica

<400> 167
Met Ala Gly Ala Lys Glu Ile Arg Thr Lys Ile Ala Ser Val Arg Asn
  1                5                10                15

Thr Gln Lys Ile Thr Lys Ala Met Glu Met Val Ala Ala Ser Lys Met
  20                25                30

Arg Lys Thr Gln Glu Arg Met Ala Ala Ser Arg Pro Tyr Ala Glu Ser
  35                40                45

Ile Arg Lys Ala Ile Ser His Ile Ala Lys Gly Asn Ile Glu Tyr Lys
  50                55                60

His Pro Phe Leu Thr Pro Arg Pro Val Lys Lys Val Gly Tyr Leu Val
  65                70                75                80

Val Ser Thr Asp Arg Gly Leu Cys Gly Gly Leu Asn Ile Asn Leu Phe
  85                90                95

Lys Thr Val Leu His Glu Leu Lys Glu Lys Asp Asp Gln Gly Val Lys
  100               105               110

Ser Arg Leu Ala Val Val Gly Asn Lys Gly Ile Ser Phe Phe Asn Pro
  115               120               125

Met Gly Leu Glu Ile Lys Gly His Ile Asn Gly Leu Gly Asp Thr Pro
  130               135               140

Ala Met Glu Asp Leu Val Gly Ile Val Asn Gly Met Val Asn Ala Tyr
  145               150               155               160

Arg Glu Gly Glu Ile Asp Glu Val Tyr Val Val Tyr Asn Arg Phe Ile
  165               170               175

Asn Thr Met Ser Gln Lys Pro Thr Val Gln Gln Leu Leu Pro Leu Pro
  180               185               190

Ala Leu Glu Asn Asp Ser Leu Glu Gln Thr Gly Ser Trp Asp Tyr Leu
  195               200               205

Tyr Glu Pro Asn Pro Gln Ala Leu Leu Asp Ser Leu Leu Val Arg Tyr
  210               215               220

Leu Glu Ser Gln Val Tyr Gln Ala Val Val Asp Asn Leu Ala Ser Glu
  225               230               235               240

```

262

WO 02/075507

PCT/US02/01971

Gln Ala Ala Arg Met Val Ala Met Lys Ala Ala Thr Asp Asn Ala Gly  
 245 250 255

Asn Leu Ile Asn Glu Leu Gln Leu Val Tyr Asn Lys Ala Arg Gln Ala  
 260 265 270

Ser Ile Thr Asn Glu Leu Asn Glu Ile Val Ala Gly Ala Ala Ala Ile  
 275 280 285

<210> 168  
 <211> 1463  
 <212> DNA  
 <213> Pasteurella (Mannheimia) haemolytica

<220>  
 <221> CDS  
 <222> (1)..(1461)

<220>  
 <223> guaB

<400> 168  
 atg cta cga att aaa caa gaa gcc ctc act ttt gat gat gtt ctt ctc 48  
 Met Leu Arg ile Lys Gln Glu Ala Leu Thr Phe Asp Asp Val Leu Leu  
 1 5 10 15

gtc ccg gca cat tct act gtg ctt cct aat act gct gat ctt tct act 96  
 Val Pro Ala His Ser Thr Val Leu Pro Asn Thr Ala Asp Leu Ser Thr  
 20 25 30

caa tta act aaa acc att cgt tta aac att ccg atg ctt tct gct gca 144  
 Gln Leu Thr Lys Thr Ile Arg Leu Asn Ile Pro Met Leu Ser Ala Ala  
 35 40 45

atg gat acc gtt aca gaa act aag ctt gcg atc tcc ctt gct caa gaa 192  
 Met Asp Thr Val Thr Glu Thr Lys Leu Ala ile Ser Leu Ala Gln Glu  
 50 55 60

ggc ggc att ggt ttt atc cat aaa aat atg tcg att gaa cgc cag gca 240  
 Gly Gly Ile Gly Phe Ile His Lys Asn Met Ser Ile Glu Arg Gln Ala  
 65 70 75 80

gac cgt gtg cgt aaa gtg aaa aaa ttt gaa agt ggt att gtt tct gag 288  
 Asp Arg Val Arg Lys Val Lys Lys Phe Glu Ser Gly Ile Val Ser Glu  
 85 90 95

cca gtg acg att tct cct gat atg aca tta gcg gaa ttg gct gaa ttg 336  
 Pro Val Thr Ile Ser Pro Asp Met Thr Leu Ala Glu Leu Ala Glu Leu  
 100 105 110

gtg aaa aag aac ggt ttt gca ggc tat ccg gtg att gat gaa aac caa 384  
 Val Lys Lys Asn Gly Phe Ala Gly Tyr Pro Val Ile Asp Glu Asn Gln  
 115 120 125

aat tta gtg gga att att acc gga cgt gat acc cga ttt gtc acg gat 432  
 Asn Leu Val Gly Ile Ile Thr Gly Arg Asp Thr Arg Phe Val Thr Asp  
 130 135 140

tta agc aaa aca gtg cgt gaa ttt atg aca cca aaa gac cgt tta gtg 480  
 Leu Ser Lys Thr Val Arg Glu Phe Met Thr Pro Lys Asp Arg Leu Val  
 145 150 155 160

WO 02/075507

PCT/US02/01971

acg gta aaa gaa aac gca agc cgt gaa gaa att ttc cac tta atg cac 528  
 Thr Val Lys Glu Val Asn Ala Ser Arg Glu Glu Ile Phe His Leu Met His  
 165 170 175

gaa cac cga gtg gag aaa gtg ctg gta gtg aat aat gaa ttt cag tta 576  
 Glu His Arg Val Glu Lys Val Leu Val Val Asn Asn Glu Phe Gln Leu  
 180 185 190

aaa gga atg att acc cta aaa gac tac caa aaa gcg gaa agc aaa ccg 624  
 Lys Gly Met Ile Thr Leu Lys Asp Tyr Gln Lys Ala Glu Ser Lys Pro  
 195 200 205

aat gcc tgt aaa gat gag ttt ggg cgt ttg cgt gtg ggg gcg gca gtg 672  
 Asn Ala Cys Lys Asp Glu Phe Gly Arg Leu Arg Val Gly Ala Ala Val  
 210 215 220

gga gcc ggt ccg ggc aat gaa gaa cga att gat gct tta gta aaa gcg 720  
 Gly Ala Gly Pro Gly Asn Glu Glu Arg Ile Asp Ala Leu Val Lys Ala  
 225 230 235

ggt gtc gat gtg cta tta atc gac tct tcg cac ggg cat tct gaa ggt 768  
 Gly Val Asp Val Leu Leu Ile Asp Ser Ser His Gly His Ser Glu Gly  
 245 250 255

gta tta caa cgt gtg cgt gaa acc cgt gca aaa tac cct gat tta ccg 816  
 Val Leu Gln Arg Val Arg Glu Thr Arg Ala Lys Tyr Pro Asp Leu Pro  
 260 265 270

att gtt gcc ggt aat att gcc act gca gaa gga gcg att gcg tta gct 864  
 Ile Val Ala Gly Asn Ile Ala Thr Ala Glu Gly Ala Ile Ala Leu Ala  
 275 280 285

gat gca gga gcc agt gct gtg aaa gta gga atc ggc ccg ggt tca att 912  
 Asp Ala Gly Ala Ser Ala Val Lys Val Gly Ile Gly Pro Gly Ser Ile  
 290 295 300

tgt acc acc aga att gta aca ggc gtt ggc gtg cca caa atc acg gca 960  
 Cys Thr Thr Arg Ile Val Thr Gly Val Gly Val Pro Gln Ile Thr Ala  
 305 310 315 320

atc gca gaa gcg gca gct gcg ctt aaa gaa cga ggc att cct gtg att 1008  
 Ile Ala Glu Ala Ala Ala Leu Lys Glu Arg Gly Ile Pro Val Ile  
 325 330 335

gct gat ggt gga att cgt tat tca ggc gat att tca aaa gct att gcc 1056  
 Ala Asp Gly Gly Ile Arg Tyr Ser Gly Asp Ile Ser Lys Ala Ile Ala  
 340 345 350

gcc ggt gca agt tgc gta atg gtc ggt tcg atg ttt gcc ggc aca gaa 1104  
 Ala Gly Ala Ser Cys Val Met Val Gly Ser Met Phe Ala Gly Thr Glu  
 355 360 365

gaa gcc ccg ggt gaa att gag ctt tat caa ggc aga gca ttc aaa tcc 1152  
 Glu Ala Pro Gly Glu Ile Glu Leu Tyr Gln Gly Arg Ala Phe Lys Ser  
 370 375 380

tac cgt gga atg gga tca tta ggt gca atg agt aaa ggc tcg tca gat 1200  
 Tyr Arg Gly Met Gly Ser Leu Gly Ala Met Ser Lys Gly Ser Ser Asp  
 385 390 395 400

cgc tat ttc caa tct gat aat gcc gcc gac aag ctc gta ccg gaa ggg 1248  
 Arg Tyr Phe Gln Ser Asp Asn Ala Ala Asp Lys Leu Val Pro Glu Gly  
 405 410 415



WO 02/075507

PCT/US02/01971

att gaa ggg cgt atc gct tac aaa ggc tac ttg aaa gaa att atc cac 1296  
 ile glu gly arg ile ala tyr lys gly tyr leu lys glu ile ile his  
 420 425 430

caa caa atg ggc ggc tta cgc tcc tgt atg gga tta acc ggc tgt gcc 1344  
 gln gln met gly gly leu arg ser cys met gly leu thr gly cys ala  
 435 440 445

act att gaa gaa ctc cgc acc aaa gca gaa ttt gtc cgc att agt ggt 1392  
 thr ile glu glu leu arg thr lys ala glu phe val arg ile ser gly  
 450 455 460

gct ggt att aaa gaa agc cac gtc cac gat gtg aca att acc aaa gaa 1440  
 ala gly ile lys glu ser his val his asp val thr ile thr lys glu  
 465 470 475 480

gca cag aac tac cga atg ggt ta 1463  
 ala pro asn tyr arg met gly  
 485

&lt;210&gt; 169

&lt;211&gt; 487

&lt;212&gt; PRT

&lt;213&gt; Pasteurella (Mannheimia) haemolytica

&lt;400&gt; 169

Met Leu Arg ile lys gln glu ala leu thr phe asp asp val leu leu  
 1 5 10 15

Val Pro Ala His Ser Thr Val Leu Pro Asn Thr Ala Asp Leu Ser Thr  
 20 25 30

Gln Leu Thr Lys Thr ile arg leu asn ile pro met leu ser ala ala  
 35 40 45

Met Asp Thr Val Thr Glu Thr Lys Leu Ala ile ser leu ala gln glu  
 50 55 60

Gly Gly ile gly phe ile his lys asn met ser ile glu arg gln ala  
 65 70 75 80

Asp Arg Val Arg Lys Val Lys Lys phe glu ser gly ile val ser glu  
 85 90 95

Pro Val Thr ile ser pro asp met thr leu ala glu leu ala glu leu  
 100 105 110

Val Lys Lys Asn Gly phe ala gly tyr pro val ile asp glu asn gln  
 115 120 125

Asn Leu Val Gly ile ile thr gly arg asp thr arg phe val thr asp  
 130 135 140

Leu Ser Lys Thr Val Arg Glu phe met thr pro lys asp arg leu val  
 145 150 155 160

Thr Val Lys Glu Asn Ala Ser Arg Glu Glu ile phe his leu met his  
 165 170 175

Glu His Arg Val Glu Lys Val Leu Val Val Asn Asn Glu phe gln leu  
 180 185 190

WO 02/075507

PCT/US02/01971

Lys Gly Met Ile Thr Leu Lys Asp Tyr Gln Lys Ala Glu Ser Lys Pro  
 195 200 205  
 Asn Ala Cys Lys Asp Glu Phe Gly Arg Leu Arg Val Gly Ala Ala Val  
 210 215 220  
 Gly Ala Gly Pro Gly Asn Glu Glu Arg Ile Asp Ala Leu Val Lys Ala  
 225 230 235 240  
 Gly Val Asp Val Leu Leu Ile Asp Ser Ser His Gly His Ser Glu Gly  
 245 250 255  
 Val Leu Gln Arg Val Arg Glu Thr Arg Ala Lys Tyr Pro Asp Leu Pro  
 260 265 270  
 Ile Val Ala Gly Asn Ile Ala Thr Ala Glu Gly Ala Ile Ala Leu Ala  
 275 280 285  
 Asp Ala Gly Ala Ser Ala Val Lys Val Gly Ile Gly Pro Gly Ser Ile  
 290 295 300  
 Cys Thr Thr Arg Ile Val Thr Gly Val Gly Val Pro Gln Ile Thr Ala  
 305 310 315 320  
 Ile Ala Glu Ala Ala Ala Ala Leu Lys Glu Arg Gly Ile Pro Val Ile  
 325 330 335  
 Ala Asp Gly Gly Ile Arg Tyr Ser Gly Asp Ile Ser Lys Ala Ile Ala  
 340 345 350  
 Ala Gly Ala Ser Cys Val Met Val Gly Ser Met Phe Ala Gly Thr Glu  
 355 360 365  
 Glu Ala Pro Gly Glu Ile Glu Leu Tyr Gln Gly Arg Ala Phe Lys Ser  
 370 375 380  
 Tyr Arg Gly Met Gly Ser Leu Gly Ala Met Ser Lys Gly Ser Ser Asp  
 385 390 395 400  
 Arg Tyr Phe Gln Ser Asp Asn Ala Ala Asp Lys Leu Val Pro Glu Gly  
 405 410 415  
 Ile Glu Gly Arg Ile Ala Tyr Lys Gly Tyr Leu Lys Glu Ile Ile His  
 420 425 430  
 Gln Gln Met Gly Gly Leu Arg Ser Cys Met Gly Leu Thr Gly Cys Ala  
 435 440 445  
 Thr Ile Glu Glu Leu Arg Thr Lys Ala Glu Phe Val Arg Ile Ser Gly  
 450 455 460  
 Ala Gly Ile Lys Glu Ser His Val His Asp Val Thr Ile Thr Lys Glu  
 465 470 475 480  
 Ala Pro Asn Tyr Arg Met Gly  
 485

<210> 170  
 <211> 2150  
 <212> DNA  
 <213> Pasteurella (Mannheimia) haemolytica

WO 02/075507

PCT/US02/01971

```

<220>
<221> CDS
<222> (1)..(2148)

<220>
<223> pnp

<400> 170
atg act cca att gta aaa cag ttt aaa tac ggt cag cac acc gtg acc 48
Met Thr Pro Ile Val Lys Gln Phe Lys Tyr Gly Gln His Thr Val Thr
1 5 10 15

tta gaa acc ggt gct atc gca cgc caa gca acg gca gca gta atg gca 96
Leu Glu Thr Gly Ala Ile Ala Arg Gln Ala Thr Ala Ala Val Met Ala
20 25 30

agt atg gac gac aca acc gta ttt gtt acc gta gta gcg aaa aaa gac 144
Ser Met Asp Asp Thr Thr Val Phe Val Thr Val Val Ala Lys Lys Asp
35 40 45

gta aaa gaa ggg caa gat ttc ttc cca tta acc gta gat tat caa gag 192
Val Lys Glu Gly Gln Asp Phe Phe Pro Leu Thr Val Asp Tyr Gln Glu
50 55 60

cgt act tac gca gcc ggt cgt att ccg gcc ggt ttc ttc aaa cgt gaa 240
Arg Thr Tyr Ala Ala Gly Arg Ile Pro Gly Gly Phe Phe Lys Arg Glu
65 70 75 80

gga cgt cct agc gaa ggt gaa acc tta atc gct cgc ttg atc gac cgt 288
Gly Arg Pro Ser Glu Gly Glu Thr Leu Ile Ala Arg Leu Ile Asp Arg
85 90 95

cct gtg cgt cca ctt ttc cca gaa ggt ttc ttt aac gaa att caa gtg 336
Pro Val Arg Pro Leu Phe Pro Glu Gly Phe Phe Asn Glu Ile Gln Val
100 105 110

att gcg acc gta gta tog gta aac coa caa atc agt cct gat ctg gtt 384
Ile Ala Thr Val Val Ser Val Asn Pro Gln Ile Ser Pro Asp Leu Val
115 120 125

gcg atg atc ggt gca tog gct gcc ctt toa tta tcc gcc gtg ccg ttt 432
Ala Met Ile Gly Ala Ser Ala Ala Leu Ser Leu Ser Gly Val Pro Phe
130 135 140

aac ggt cca atc ggt gcg gct cgt gtc ggt ttt atc aac gat caa ttc 480
Asn Gly Pro Ile Gly Ala Ala Arg Val Gly Phe Ile Asn Asp Gln Phe
145 150 155 160

gta tta aac cca acc acc agc gag caa aaa atc agc cgc tta gat tta 528
Val Leu Asn Pro Thr Thr Ser Glu Gln Lys Ile Ser Arg Leu Asp Leu
165 170 175

gtg gtt tca ggt aca gac aaa gcc gtg ttg atg gtg gaa tct gaa gcg 576
Val Val Ser Gly Thr Asp Lys Ala Val Leu Met Val Glu Ser Glu Ala
180 185 190

gat atc tta acc gaa gag caa atg tta gcg gcg gtg gtg ttc gcc cac 624
Asp Ile Leu Thr Glu Glu Gln Met Leu Ala Ala Val Val Phe Gly His
195 200 205

gag caa caa cag gtt gta atc gaa aac atc aaa gaa ttt gtt aaa gaa 672
Glu Gln Gln Gln Val Val Ile Glu Asn Ile Lys Glu Phe Val Lys Glu
210 215 220

```

WO 02/075507

PCT/US02/01971

gcg ggc aaa cca cgt tgg gat tgg gtt gca cca gag cca aat aca gat 720  
Ala Gly Lys Pro Arg Trp Asp Trp Val Ala Pro Glu Pro Asn Thr Asp  
225 230 235 240

tta atc aac aaa gta aaa gca tta gca gaa aca cgc ctt ggc gat gct 768  
Leu Ile Asn Lys Val Lys Ala Leu Ala Glu Thr Arg Leu Gly Asp Ala  
245 250 255

tat cgt atc gta gaa aaa caa gtt cgt tac gag caa atc gat gcg att 816  
Tyr Arg Ile Val Glu Lys Gln Val Arg Tyr Glu Gln Ile Asp Ala Ile  
260 265 270

aaa gca gag gtg att gca caa ctt acc gca gaa gat gaa act gtt tct 864  
Lys Ala Glu Val Ile Ala Gln Leu Thr Ala Glu Asp Glu Thr Val Ser  
275 280 285

gaa ggg act atc atc gac atc atc acc gca tta gag agc caa atc gtg 912  
Glu Gly Thr Ile Ile Asp Ile Ile Thr Ala Leu Glu Ser Gln Ile Val  
290 295 300

cgt agc cgt att att gca ggc gaa cca cgc att gac ggc cgt acg gtg 960  
Arg Ser Arg Ile Ile Ala Gly Glu Pro Arg Ile Asp Gly Arg Thr Val  
305 310 315 320

gat acc gtg cgt gca ttg gat att tgc acc agt gtg tta cca cgc acc 1008  
Asp Thr Val Arg Ala Leu Asp Ile Cys Thr Ser Val Leu Pro Arg Thr  
325 330 335

cac ggt tct gct ctt ttc acc cgt ggc gaa acc caa gca tta gca gta 1056  
His Gly Ser Ala Leu Phe Thr Arg Gly Glu Thr Gln Ala Leu Ala Val  
340 345 350

gca aca ttg ggc aca gag cgt gat gcc caa atc att gac gaa ttg acc 1104  
Ala Thr Leu Gly Thr Glu Arg Asp Ala Gln Ile Ile Asp Glu Leu Thr  
355 360 365

ggc gaa aaa tct gac cgt ttc tta ttc cac tac aat ttc cct cca tac 1152  
Gly Glu Lys Ser Asp Arg Phe Leu Phe His Tyr Asn Phe Pro Pro Tyr  
370 375 380

tct gtg ggc gaa acc ggt cgt atc ggc tgc cca aaa cgc cgt gaa atc 1200  
Ser Val Gly Glu Thr Gly Arg Ile Gly Ser Pro Lys Arg Arg Glu Ile  
385 390 395 400

ggt cac ggt cgt tta gca aaa cgt ggc gta tta gcc gtg atg cca acc 1248  
Gly His Gly Arg Leu Ala Lys Arg Gly Val Leu Ala Val Met Pro Thr  
405 410 415

gct gaa gag ttc ccg tat gta gtg cgt gtg gtg tct gaa atc act gaa 1296  
Ala Glu Glu Phe Pro Tyr Val Val Arg Val Val Ser Glu Ile Thr Glu  
420 425 430

tct aac ggt tct tct tca atg gca tct gtg tgt ggt gcg tct ctt gcg 1344  
Ser Asn Gly Ser Ser Ser Met Ala Ser Val Cys Gly Ala Ser Leu Ala  
435 440 445

ttg atg gac gca ggt gtg cca atc aaa gca gcg gtt gcc ggt atc gca 1392  
Leu Met Asp Ala Gly Val Pro Ile Lys Ala Ala Val Ala Gly Ile Ala  
450 455 460

atg ggg ctc gtg aaa gaa gac gag aaa ttc gtg gta ctt tct gac atc 1440  
Met Gly Leu Val Lys Glu Asp Glu Lys Phe Val Val Leu Ser Asp Ile  
465 470 475 480

WO 02/075507

PCT/US02/01971

tta ggt gat gaa gac cac tta ggc gat atg gac ttt aaa gta gcg gga 1488  
 Leu Gly Asp Glu Asp His Leu Gly Asp Met Asp Phe Lys Val Ala Gly  
 485 490 495

acc cgt acc ggt gtg act gcg ctg caa atg gac atc aaa atc gaa ggg 1536  
 Thr Arg Thr Gly Val Thr Ala Leu Gln Met Asp Ile Lys Ile Glu Gly  
 500 505 510

atc acc cct gaa att atg cgt att gcc tta aac caa gct aaa ggt gca 1584  
 Ile Thr Pro Glu Ile Met Arg Ile Ala Leu Asn Gln Ala Lys Gly Ala  
 515 520 525

aga atg cac att tta ggt gta atg gaa caa gcc att cgg gca cct cgt 1632  
 Arg Met His Ile Leu Gly Val Met Glu Gln Ala Ile Pro Ala Pro Arg  
 530 535 540

gca gat att tct gac tat gcc cca cgc att cac aca atg aag atc gat 1680  
 Ala Asp Ile Ser Asp Tyr Ala Pro Arg Ile His Thr Met Lys Ile Asp  
 545 550 555

ccg aag aaa atc aaa gat gtg att ggt aaa ggc ggt gca aca att cgt 1728  
 Pro Lys Lys Ile Lys Asp Val Ile Gly Lys Gly Gly Ala Thr Ile Arg  
 565 570 575

gct tta acc gaa gag acc aat act tct atc gac att gat gat gac ggt 1776  
 Ala Leu Thr Glu Glu Thr Asn Thr Ser Ile Asp Ile Asp Asp Asp Gly  
 580 585 590

acg gtg aaa att gcg gca act gac gcc aat gca gcg aaa gca gta atg 1824  
 Thr Val Lys Ile Ala Ala Thr Asp Gly Asn Ala Ala Lys Ala Val Met  
 595 600 605

gct cgt att gaa gag atc gtt gcc gaa gtg gaa gta aac caa atc tac 1872  
 Ala Arg Ile Glu Glu Ile Val Ala Glu Val Glu Val Asn Gln Ile Tyr  
 610 615 620

aac ggt aaa gta acc cgt gtg gtg gac ttc ggt gca ttc gtt tcc atc 1920  
 Asn Gly Lys Val Thr Arg Val Val Asp Phe Gly Ala Phe Val Ser Ile  
 625 630 635 640

tta ggt ggc aaa gaa ggt tta gtc cac att tca caa atc acc aac gaa 1968  
 Leu Gly Gly Lys Glu Gly Leu Val His Ile Ser Gln Ile Thr Asn Glu  
 645 650 655

cgt gtt gag cgt gta gcg gac tac tta acc gtt ggt caa gaa gta caa 2016  
 Arg Val Glu Arg Val Ala Asp Tyr Leu Thr Val Gly Gln Glu Val Gln  
 660 665 670

gtg aaa gtg gta gaa att gac cgt caa gga cgc att cgt ctg acg atg 2064  
 Val Lys Val Val Glu Ile Asp Arg Gln Gly Arg Ile Arg Leu Thr Met  
 675 680 685

aaa gac atc aat aat acc aac gag gca aat gca gaa gaa act gta gct 2112  
 Lys Asp Ile Asn Asn Thr Asn Glu Ala Asn Ala Glu Glu Thr Val Ala  
 690 695 700

gaa aat gtg gta gaa aca gaa caa gaa aat aat ttc ta 2150  
 Glu Asn Val Val Glu Thr Glu Gln Glu Asn Asn Phe  
 705 710 715

&lt;210&gt; 171

&lt;211&gt; 716

WO 02/075507

PCT/US02/01971

&lt;212&gt; PRT

&lt;213&gt; Pasteurella (Mannheimia) haemolytica

&lt;400&gt; 171

```

Met Thr Pro Ile Val Lys Gln Phe Lys Tyr Gly Gln His Thr Val Thr
 1          5          10          15
Leu Glu Thr Gly Ala Ile Ala Arg Gln Ala Thr Ala Ala Val Met Ala
 20          25          30
Ser Met Asp Asp Thr Thr Val Phe Val Thr Val Val Ala Lys Lys Asp
 35          40          45
Val Lys Glu Gly Gln Asp Phe Phe Pro Leu Thr Val Asp Tyr Gln Glu
 50          55          60
Arg Thr Tyr Ala Ala Gly Arg Ile Pro Gly Gly Phe Phe Lys Arg Glu
 65          70          75          80
Gly Arg Pro Ser Glu Gly Glu Thr Leu Ile Ala Arg Leu Ile Asp Arg
 85          90          95
Pro Val Arg Pro Leu Phe Pro Glu Gly Phe Phe Asn Glu Ile Gln Val
100          105          110
Ile Ala Thr Val Val Ser Val Asn Pro Gln Ile Ser Pro Asp Leu Val
115          120          125
Ala Met Ile Gly Ala Ser Ala Ala Leu Ser Leu Ser Gly Val Pro Phe
130          135          140
Asn Gly Pro Ile Gly Ala Ala Arg Val Gly Phe Ile Asn Asp Gln Phe
145          150          155          160
Val Leu Asn Pro Thr Thr Ser Glu Gln Lys Ile Ser Arg Leu Asp Leu
165          170          175
Val Val Ser Gly Thr Asp Lys Ala Val Leu Met Val Glu Ser Glu Ala
180          185          190
Asp Ile Leu Thr Glu Glu Gln Met Leu Ala Ala Val Val Phe Gly His
195          200          205
Glu Gln Gln Gln Val Val Ile Glu Asn Ile Lys Glu Phe Val Lys Glu
210          215          220
Ala Gly Lys Pro Arg Trp Asp Trp Val Ala Pro Glu Pro Asn Thr Asp
225          230          235          240
Leu Ile Asn Lys Val Lys Ala Leu Ala Glu Thr Arg Leu Gly Asp Ala
245          250          255
Tyr Arg Ile Val Glu Lys Gln Val Arg Tyr Glu Gln Ile Asp Ala Ile
260          265          270
Lys Ala Glu Val Ile Ala Gln Leu Thr Ala Glu Asp Glu Thr Val Ser
275          280          285
Glu Gly Thr Ile Ile Asp Ile Ile Thr Ala Leu Glu Ser Gln Ile Val
290          295          300
Arg Ser Arg Ile Ile Ala Gly Glu Pro Arg Ile Asp Gly Arg Thr Val
305          310          315          320

```

270

WO 02/075507

PCT/US02/01971

Asp Thr Val Arg Ala Leu Asp Ile Cys Thr Ser Val Leu Pro Arg Thr  
 325 330 335  
 His Gly Ser Ala Leu Phe Thr Arg Gly Glu Thr Gln Ala Leu Ala Val  
 340 345 350  
 Ala Thr Leu Gly Thr Glu Arg Asp Ala Gln Ile Ile Asp Glu Leu Thr  
 355 360 365  
 Gly Glu Lys Ser Asp Arg Phe Leu Phe His Tyr Asn Phe Pro Pro Tyr  
 370 375 380  
 Ser Val Gly Glu Thr Gly Arg Ile Gly Ser Pro Lys Arg Arg Glu Ile  
 385 390 395 400  
 Gly His Gly Arg Leu Ala Lys Arg Gly Val Leu Ala Val Met Pro Thr  
 405 410 415  
 Ala Glu Glu Phe Pro Tyr Val Val Arg Val Val Ser Glu Ile Thr Glu  
 420 425 430  
 Ser Asn Gly Ser Ser Ser Met Ala Ser Val Cys Gly Ala Ser Leu Ala  
 435 440 445  
 Leu Met Asp Ala Gly Val Pro Ile Lys Ala Ala Val Ala Gly Ile Ala  
 450 455 460  
 Met Gly Leu Val Lys Glu Asp Glu Lys Phe Val Val Leu Ser Asp Ile  
 465 470 475 480  
 Leu Gly Asp Glu Asp His Leu Gly Asp Met Asp Phe Lys Val Ala Gly  
 485 490 495  
 Thr Arg Thr Gly Val Thr Ala Leu Gln Met Asp Ile Lys Ile Glu Gly  
 500 505 510  
 Ile Thr Pro Glu Ile Met Arg Ile Ala Leu Asn Gln Ala Lys Gly Ala  
 515 520 525  
 Arg Met His Ile Leu Gly Val Met Glu Gln Ala Ile Pro Ala Pro Arg  
 530 535 540  
 Ala Asp Ile Ser Asp Tyr Ala Pro Arg Ile His Thr Met Lys Ile Asp  
 545 550 555 560  
 Pro Lys Lys Ile Lys Asp Val Ile Gly Lys Gly Gly Ala Thr Ile Arg  
 565 570 575  
 Ala Leu Thr Glu Glu Thr Asn Thr Ser Ile Asp Ile Asp Asp Gly  
 580 585 590  
 Thr Val Lys Ile Ala Ala Thr Asp Gly Asn Ala Ala Lys Ala Val Met  
 595 600 605  
 Ala Arg Ile Glu Glu Ile Val Ala Glu Val Glu Val Asn Gln Ile Tyr  
 610 615 620  
 Asn Gly Lys Val Thr Arg Val Val Asp Phe Gly Ala Phe Val Ser Ile  
 625 630 635 640  
 Leu Gly Gly Lys Glu Gly Leu Val His Ile Ser Gln Ile Thr Asn Glu  
 645 650 655

WO 02/075507

PCT/US02/01971

```

Arg Val Glu Arg Val Ala Asp Tyr Leu Thr Val Gly Gln Glu Val Gln
660                               665                               670

Val Lys Val Val Glu Ile Asp Arg Gln Gly Arg Ile Arg Leu Thr Met
675                               680                               685

Lys Asp Ile Asn Asn Thr Asn Glu Ala Asn Ala Glu Glu Thr Val Ala
690                               695                               700

Glu Asn Val Val Glu Thr Glu Gln Glu Asn Asn Phe
705                               710                               715

<210> 172
<211> 1517
<212> DNA
<213> Pasteurella (Mannheimia) haemolytica

<220>
<221> CDS
<222> (1)..(1515)

<220>
<223> purF

<400> 172
atg tgc ggc att gtc ggt att att ggg aat tcg ccg gtg aat cag gcg 48
Met Cys Gly Ile Val Gly Ile Ile Gly Asn Ser Pro Val Asn Gln Ala
1 5 10 15

att tat gat ggt tta aca tta ctt caa cac cga gga caa gat gcc gca 96
Ile Tyr Asp Gly Leu Thr Leu Leu Gln His Arg Gly Gln Asp Ala Ala
20 25 30

ggg atc gtc acc ata gac gat gaa aat cgt ttc cgc tta cgc aaa gct 144
Gly Ile Val Thr Ile Asp Asp Glu Asn Arg Phe Arg Leu Arg Lys Ala
35 40 45

aac ggc tta gtc agc gat gtt ttc cag caa gag cat atg gtg aga tta 192
Asn Gly Leu Val Ser Asp Val Phe Gln Gln Glu His Met Val Arg Leu
50 55 60

caa ggc aat gtt gga att ggt cac gtt cgc tac cca aca gca ggt agc 240
Gln Gly Asn Val Gly Ile Gly His Val Arg Tyr Pro Thr Ala Gly Ser
65 70 75 80

tca agt gtg tct gaa gcc cag cca ttt tat gtc aat tca cct ttc ggt 288
Ser Ser Val Ser Glu Ala Gln Pro Phe Tyr Val Asn Ser Pro Phe Gly
85 90 95

att acc tta gtt cac aac ggt aat tta act aat aat gcg gaa ctt aaa 336
Ile Thr Leu Val His Asn Gly Asn Leu Thr Asn Asn Ala Glu Leu Lys
100 105 110

gct cgc tta tac aac gaa gcc cgc cgc cat gtg aac act aat tct gat 384
Ala Arg Leu Tyr Asn Glu Ala Arg Arg His Val Asn Thr Asn Ser Asp
115 120 125

tct gaa tcc ctt ctt aat att ttt gct tac ttt tta gat ctc tat tcc 432
Ser Glu Ser Leu Leu Asn Ile Phe Ala Tyr Phe Leu Asp Leu Tyr Ser
130 135 140

act cag cat tta agc cca gac aat atc ttt gaa acg gtt cgt aaa acc 480

```



WO 02/075507

PCT/US02/01971

```

Thr Gln His Leu Ser Pro Asp Asn Ile Phe Glu Thr Val Arg Lys Thr
145                               150                               155                               160
aat gat agc att cgt ggt gct tat gct tgc att gcg atg att atc gga 528
Asn Asp Ser Ile Arg Gly Ala Tyr Ala Cys Ile Ala Met Ile Ile Gly
165                               170                               175

cac ggt atg gtt gct ttc cgt gac cca ttc ggt att cgc cgg tta gtg 576
His Gly Met Val Ala Phe Arg Asp Pro Phe Gly Ile Arg Pro Leu Val
180                               185                               190

ctg ggt aaa cgt gaa atc gag ggt aaa acc gaa tat atg ttt gct tcg 624
Leu Gly Lys Arg Glu Ile Glu Gly Lys Thr Glu Tyr Met Phe Ala Ser
195                               200                               205

gaa agt gtg gct ctt gat gta gtg ggg ttt gaa ttt gtg cga gat gtg 672
Glu Ser Val Ala Leu Asp Val Val Gly Phe Glu Phe Val Arg Asp Val
210                               215                               220

ctg ccg ggt gaa gcg att tat gtt acc ttt gat ggg caa tta cat tcg 720
Leu Pro Gly Glu Ala Ile Tyr Val Thr Phe Asp Gly Gln Leu His Ser
225                               230                               235

caa att tgt gcc gat aat cca aaa ctg aat cct tgt att ttt gaa tat 768
Gln Ile Cys Ala Asp Asn Pro Lys Leu Asn Pro Cys Ile Phe Glu Tyr
245                               250                               255

ggt tat ttt gcc cgt cct gat tcc gtc att gat ggc gtt tct gta tat 816
Val Tyr Phe Ala Arg Pro Asp Ser Val Ile Asp Gly Val Ser Val Tyr
260                               265                               270

tct gca cga gtg cat atg ggc gaa tta tta ggt gag aaa att aaa cgt 864
Ser Ala Arg Val His Met Gly Glu Leu Leu Gly Glu Lys Ile Lys Arg
275                               280                               285

gaa tgg gga cga att atc gat gat att gat gtg gtg atc ccg att cct 912
Glu Trp Gly Arg Ile Ile Asp Asp Ile Asp Val Val Ile Pro Ile Pro
290                               295                               300

gaa acc tca aat gat att gcg gta cgt att gct aat atg ttg tat aaa 960
Glu Thr Ser Asn Asp Ile Ala Val Arg Ile Ala Asn Met Leu Tyr Lys
305                               310                               315

ccc tat cgt caa ggg ttt gtt aaa aac cgc tat gta gct cga act ttt 1008
Pro Tyr Arg Gln Gly Phe Val Lys Asn Arg Tyr Val Ala Arg Thr Phe
325                               330                               335

att atg ccg ggg caa gca cag cgt aaa agc tcg gtt cgc cgt aaa tta 1056
Ile Met Pro Gly Gln Ala Gln Arg Lys Ser Ser Val Arg Arg Lys Leu
340                               345                               350

aat gcg att gcc tct gaa ttt aaa ggc aaa agc gtg tta ctg gtt gat 1104
Asn Ala Ile Ala Ser Glu Phe Lys Gly Lys Ser Val Leu Leu Val Asp
355                               360                               365

gat tct att gta cga ggt aca acg tct gaa caa atc gtg gaa atg gca 1152
Asp Ser Ile Val Arg Gly Thr Thr Ser Glu Gln Ile Val Glu Met Ala
370                               375                               380

cga gca gct ggt gca aaa cgg gtt tat ttt gcc tct gcc gca ccg gaa 1200
Arg Ala Ala Gly Ala Lys Arg Val Tyr Phe Ala Ser Ala Ala Pro Glu
385                               390                               395                               400

```

WO 02/075507

PCT/US02/01971

```

att cgc tac ccg aat gtg tat ggc att gat atg ccg act tgt gaa gaa 1248
ile arg tyr pro asn val tyr gly ile asp met pro thr cys glu glu
      405                410                415

tta gtg gct tat gat cgc tca gtg gaa gag gtt gca cag atg ata ggg 1296
leu val ala tyr asp arg ser val glu glu val ala gln met ile gly
      420                425                430

gtg gat aaa ttg att ttc caa gac ctt gaa gca ctt tat aag tct att 1344
val asp lys leu ile phe gln asp leu glu ala leu tyr lys ser ile
      435                440                445

caa ctg gaa aat ccg act att cat cgc ttt gat gac tct gta ttt aca 1392
gln leu glu asn pro thr ile his arg phe asp asp ser val phe thr
      450                455                460

gga gaa tat att aca ggt gat gta gat aaa tgc tat tta gac agt ata 1440
gly glu tyr ile thr gly asp val asp lys cys tyr leu asp ser ile
      465                470                475

gca aga tct cga aac gat aaa gca aaa gca gag gcg gca aaa caa gcc 1488
ala arg ser arg asn asp lys ala lys ala glu ala ala lys gln ala
      485                490                495

acc aat tta gaa att cat aac gaa aga ta 1517
thr asn leu glu ile his asn glu arg
      500                505

```

&lt;210&gt; 173

&lt;211&gt; 505

&lt;212&gt; PRT

&lt;213&gt; Pasteurella (Mannheimia) haemolytica

&lt;400&gt; 173

```

Met Cys Gly Ile Val Gly Ile Ile Gly Asn Ser Pro Val Asn Gln Ala
 1                5                10                15

Ile Tyr Asp Gly Leu Thr Leu Leu Gln His Arg Gly Gln Asp Ala Ala
 20                25                30

Gly Ile Val Thr Ile Asp Asp Glu Asn Arg Phe Arg Leu Arg Lys Ala
 35                40                45

Asn Gly Leu Val Ser Asp Val Phe Gln Gln Glu His Met Val Arg Leu
 50                55                60

Gln Gly Asn Val Gly Ile Gly His Val Arg Tyr Pro Thr Ala Gly Ser
 65                70                75                80

Ser Ser Val Ser Glu Ala Gln Pro Phe Tyr Val Asn Ser Pro Phe Gly
 85                90                95

Ile Thr Leu Val His Asn Gly Asn Leu Thr Asn Asn Ala Glu Leu Lys
100                105                110

Ala Arg Leu Tyr Asn Glu Ala Arg Arg His Val Asn Thr Asn Ser Asp
115                120                125

Ser Glu Ser Leu Leu Asn Ile Phe Ala Tyr Phe Leu Asp Leu Tyr Ser
130                135                140

```

WO 02/075507

PCT/US02/01971

Thr Gln His Leu Ser Pro Asp Asn Ile Phe Glu Thr Val Arg Lys Thr  
145 150 155 160

Asn Asp Ser Ile Arg Gly Ala Tyr Ala Cys Ile Ala Met Ile Ile Gly  
165 170 175

His Gly Met Val Ala Phe Arg Asp Pro Phe Gly Ile Arg Pro Leu Val  
180 185 190

Leu Gly Lys Arg Glu Ile Glu Gly Lys Thr Glu Tyr Met Phe Ala Ser  
195 200 205

Glu Ser Val Ala Leu Asp Val Val Gly Phe Glu Phe Val Arg Asp Val  
210 215 220

Leu Pro Gly Glu Ala Ile Tyr Val Thr Phe Asp Gly Gln Leu His Ser  
225 230 235 240

Gln Ile Cys Ala Asp Asn Pro Lys Leu Asn Pro Cys Ile Phe Glu Tyr  
245 250 255

Val Tyr Phe Ala Arg Pro Asp Ser Val Ile Asp Gly Val Ser Val Tyr  
260 265 270

Ser Ala Arg Val His Met Gly Glu Leu Leu Gly Glu Lys Ile Lys Arg  
275 280 285

Glu Trp Gly Arg Ile Ile Asp Asp Ile Asp Val Val Ile Pro Ile Pro  
290 295 300

Glu Thr Ser Asn Asp Ile Ala Val Arg Ile Ala Asn Met Leu Tyr Lys  
305 310 315 320

Pro Tyr Arg Gln Gly Phe Val Lys Asn Arg Tyr Val Ala Arg Thr Phe  
325 330 335

Ile Met Pro Gly Gln Ala Gln Arg Lys Ser Ser Val Arg Arg Lys Leu  
340 345 350

Asn Ala Ile Ala Ser Glu Phe Lys Gly Lys Ser Val Leu Leu Val Asp  
355 360 365

Asp Ser Ile Val Arg Gly Thr Thr Ser Glu Gln Ile Val Glu Met Ala  
370 375 380

Arg Ala Ala Gly Ala Lys Arg Val Tyr Phe Ala Ser Ala Ala Pro Glu  
385 390 395 400

Ile Arg Tyr Pro Asn Val Tyr Gly Ile Asp Met Pro Thr Cys Glu Glu  
405 410 415

Leu Val Ala Tyr Asp Arg Ser Val Glu Glu Val Ala Gln Met Ile Gly  
420 425 430

Val Asp Lys Leu Ile Phe Gln Asp Leu Glu Ala Leu Tyr Lys Ser Ile  
435 440 445

Gln Leu Glu Asn Pro Thr Ile His Arg Phe Asp Asp Ser Val Phe Thr  
450 455 460

Gly Glu Tyr Ile Thr Gly Asp Val Asp Lys Cys Tyr Leu Asp Ser Ile  
465 470 475 480

WO 02/075507

PCT/US02/01971

Ala Arg Ser Arg Asn Asp Lys Ala Lys Ala Glu Ala Ala Lys Gln Ala  
485 490 495

Thr Asn Leu Glu Ile His Asn Glu Arg  
500 505

<210> 174  
<211> 386  
<212> DNA  
<213> Pasteurella (Mannheimia) haemolytica

<220>  
<221> CDS  
<222> (1)..(384)

<220>  
<223> yjgF

<400> 174  
atg aca gtt atc cac aca gaa aat gca cgc gca gcg att ggg cct tat 48  
Met Thr Val Ile His Thr Glu Asn Ala Pro Ala Ala Ile Gly Pro Tyr  
1 5 10 15  
gtg caa gca gtt gat tta ggc aat atg gtt tta act tct ggg caa att 96  
Val Gln Ala Val Asp Leu Gly Asn Met Val Leu Thr Ser Gly Gln Ile  
20 25 30  
ccc gtg aat cct gaa acc ggc gaa atc ccg agt gat att gtg caa caa 144  
Pro Val Asn Pro Glu Thr Gly Glu Ile Pro Ser Asp Ile Val Gln Gln  
35 40 45  
acc cgc caa tct ctg aac aac gtg aaa gcc att atc gaa caa gcc gcc 192  
Thr Arg Gln Ser Leu Asn Asn Val Lys Ala Ile Ile Glu Gln Ala Gly  
50 55 60  
tta acc gtt gcc gat att gta aag acc acc gta ttt gtc aaa gat ctt 240  
Leu Thr Val Ala Asp Ile Val Lys Thr Thr Val Phe Val Lys Asp Leu  
65 70 75 80  
aac gac ttc gca aag gta aat gcg gaa tac caa gcc ttc ttc caa gaa 288  
Asn Asp Phe Ala Lys Val Asn Ala Glu Tyr Gln Ala Phe Phe Gln Glu  
85 90 95  
aac gaa cac cct aat ttt ccg gct cgt tct tgc gta gaa gtg gct cgt 336  
Asn Glu His Pro Asn Phe Pro Ala Arg Ser Cys Val Glu Val Ala Arg  
100 105 110  
tta cca aaa gat gtt ggc att gag atc gaa gcg att gca gta cgc cga 384  
Leu Pro Lys Asp Val Gly Ile Glu Ile Glu Ala Ile Ala Val Arg Arg  
115 120 125  
ta 386

<210> 175  
<211> 128  
<212> PRT  
<213> Pasteurella (Mannheimia) haemolytica

<400> 175  
Met Thr Val Ile His Thr Glu Asn Ala Pro Ala Ala Ile Gly Pro Tyr  
1 5 10 15

WO 02/075507

PCT/US02/01971

Val Gln Ala Val Asp Leu Gly Asn Met Val Leu Thr Ser Gly Gln Ile  
 20 25 30  
 Pro Val Asn Pro Glu Thr Gly Glu Ile Pro Ser Asp Ile Val Gln Gln  
 35 40 45  
 Thr Arg Gln Ser Leu Asn Asn Val Lys Ala Ile Ile Glu Gln Ala Gly  
 50 55 60  
 Leu Thr Val Ala Asp Ile Val Lys Thr Thr Val Phe Val Lys Asp Leu  
 65 70 75 80  
 Asn Asp Phe Ala Lys Val Asn Ala Glu Tyr Gln Ala Phe Phe Gln Glu  
 85 90 95  
 Asn Glu His Pro Asn Phe Pro Ala Arg Ser Cys Val Glu Val Ala Arg  
 100 105 110  
 Leu Pro Lys Asp Val Gly Ile Glu Ile Glu Ala Ile Ala Val Arg Arg  
 115 120 125

<210> 176  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>  
 <222>  
 <223> Description of Artificial Sequence: PRIMER

<400> 176  
 atggcngng cnaargarat 20

<210> 177  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <221>  
 <222>  
 <223> Description of Artificial Sequence: PRIMER

<220>  
 <221> misc\_feature  
 <222> 3  
 <223> n = A or T or G or C

<220>  
 <221> misc\_feature  
 <222> 12  
 <223> n = A or T or G or C

<220>  
 <221> misc\_feature  
 <222> 15  
 <223> n = A or T or G or C

<400> 177  
 gngcyttca tngcnaccat 20

<210> 178

WO 02/075507

PCT/US02/01971

<211> 21  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: PRIMER  
  
 <220>  
 <221> misc\_feature  
 <222> 3  
 <223> N = A or T or G or C  
  
 <400> 178  
 ggnttyatyc ayaaaaayat g 21  
  
 <210> 179  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: PRIMER  
  
 <220>  
 <221> misc\_feature  
 <222> 6  
 <223> N = A or T or G or C  
  
 <220>  
 <221> misc\_feature  
 <222> 12  
 <223> N = A or T or G or C  
  
 <220>  
 <221> misc\_feature  
 <222> 15  
 <223> N = A or T or G or C  
  
 <400> 179  
 tctttngtra tngtnacac rtg 23  
  
 <210> 180  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: PRIMER  
  
 <400> 180  
 gcgggyaac crcgttgga ttgg 24  
  
 <210> 181  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: PRIMER  
  
 <400> 181  
 crcctaarat rtctgaaagc accac 25

WO 02/075507

PCT/US02/01971

```

<210> 182
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER

<220>
<221> misc_feature
<222> 9
<223> N = A or T or G or C

<220>
<221> misc_feature
<222> 15
<223> N = A or T or G or C

<220>
<221> misc_feature
<222> 18
<223> N = A or T or G or C

<400> 182
atgtgyggna tygtnggnat                20

<210> 183
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER

<400> 183
catatcaata ccatacacat t                21

<210> 184
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER

<220>
<221> misc_feature
<222> 3
<223> N = A or T or G or C

<220>
<221> misc_feature
<222> 5
<223> N = A or T or G or C

<220>
<221> misc_feature
<222> 12
<223> N = A or T or G or C

<400> 184
ggncnctayg tncarg                    16

```

WO 02/075507

PCT/US02/01971

<210> 185  
 <211> 15  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: PRIMER  
  
 <220>  
 <221> misc\_feature  
 <222> 1  
 <223> N = A or T or G or C  
  
 <220>  
 <221> misc\_feature  
 <222> 4  
 <223> N = A or T or G or C  
  
 <220>  
 <221> misc\_feature  
 <222> 10  
 <223> N = A or T or G or C  
  
 <400> 185  
 ngcncacytcn acrca 15  
  
 <210> 186  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: PRIMER  
  
 <400> 186  
 gaagccgccca tacgctcttg gg 22  
  
 <210> 187  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: PRIMER  
  
 <400> 187  
 gttgcttccct ttgcctgcac tgg 23  
  
 <210> 188  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: PRIMER  
  
 <400> 188  
 ggctcagaaa caataccact ttca 24  
  
 <210> 189  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence



WO 02/075507

PCT/US02/01971

```

<220>
<223> Description of Artificial Sequence: PRIMER
<400> 189
gcaccaaagc agaattgtc c                               21
<210> 190
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER
<400> 190
ggtgatgatg tcgatgatag tocc                            24
<210> 191
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER
<400> 191
ggcgtattag ccgatgccc aacc                             24
<210> 192
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER
<400> 192
gaccacttag gcgatatgga ctt                             23
<210> 193
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER
<400> 193
accatcataa atgcctgat tc                               22
<210> 194
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER
<400> 194
acctgaggca tttgtcctc                                 20
<210> 195
<211> 20

```

WO 02/075507

PCT/US02/01971

<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: PRIMER  
  
<400> 195  
acgggtttat ttgacctcg 20  
  
<210> 196  
<211> 22  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: PRIMER  
  
<400> 196  
cgccggtttc aggattcacg gg 22  
  
<210> 197  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: PRIMER  
  
<400> 197  
ctgaacaacg tgaagccat 20

## 【国際公開パンフレット(コレクション)】

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number  
**WO 02/075507 A3**(51) International Patent Classification: C12N 1/20,  
A61K 39/102, 35/74, C12N 15/31, 15/63, C07K 14/285,  
16/12, C12Q 1/18, G01N 33/68

(21) International Application Number: PCT/US02/01971

(22) International Filing Date: 17 January 2002 (17.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 09/809,665 15 March 2001 (15.03.2001) US

(71) Applicant (for all designated States except US): PHAR-  
MACIA & LIPJOHN COMPANY [US/US]; 301 Henri-  
etta Street, Kalamazoo, MI 49007 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LOWERY, David,  
E. [US/US]; 1207 Woodland Drive, Portage, MI 49024  
(US); FULLER, Troy, E. [US/US]; 111 Dreamfield Drive,  
Bentle Creek, MI 49014 (US); KENNEDY, Michael, J.  
[US/US]; 2364 Quincey Avenue, Portage, MI 49024 (US).(74) Agent: WILLIAMS, Joseph, A., Jr.; Marshall, Gerstein  
& Borun, 6300 Sears Tower, 233 South Wacker Drive,  
Chicago, IL 60606 (US).(81) Designated States (national): AF, AG, AI, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GI,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GI, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).Published:  
— with international search report(88) Date of publication of the international search report:  
12 September 2003For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 02/075507 A3

(54) Title: ANTI-BACTERIAL VACCINE COMPOSITIONS

(57) Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of anti-bacterial agents that target these virulence genes and their products, and the provision of gram negative bacterial mutants useful in vaccines.

## 【国際公開パンフレット(コレクトバージョン)】

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
26 September 2002 (26.09.2002)

PCT

(10) International Publication Number  
WO 02/075507 A3

- (51) International Patent Classification: C12N 1/20, A61K 39/02, 35/74, C12N 15/31, 15/63, C07K 14/285, 16/12, C12Q 1/18, G01N 33/68
- (21) International Application Number: PCT/US02/01971
- (22) International Filing Date: 17 January 2002 (17.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/809,665 15 March 2001 (15.03.2001) US
- (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49007 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LOWERY, David, E. [US/US]; 1207 Woodland Drive, Portage, MI 49024 (US). FULLER, Troy, E. [US/US]; 111 Dreamfield Drive, Battle Creek, MI 49014 (US). KENNEDY, Michael, J. [US/US]; 2364 Quincey Avenue, Portage, MI 49024 (US).
- (74) Agent: WILLIAMS, Joseph, A., Jr.; Marshall, Gerstein & Hornin, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606 (US).
- (81) Designated States (national): AI, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GI, GM, GR, GU, HD, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TH, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CI, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NI, SN, TD, TG).
- Published:  
with international search report  
with amended claims
- (88) Date of publication of the international search report: 12 September 2003  
Date of publication of the amended claims: 11 December 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/075507 A3

(54) Title: ANTI-BACTERIAL VACCINE COMPOSITIONS

(57) Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of anti-bacterial agents that target these virulence genes and their products, and the provision of gram negative bacterial mutants useful in vaccines.

## 【 国際調査報告 】

INTERNATIONAL SEARCH REPORT		International Application No. PCT/US 02/01971
<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 C12N1/20 A61K39/102 A61K35/74 C12N15/31 C12N15/63 C07K14/285 C07K16/12 C12Q1/18 G01N33/68		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N A61K C07K C12Q G01N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
EMBL, EPO-Internal, WPI Data, BIOSIS, MEDLINE		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL [Online] 10 February 2001 (2001-02-10) MAY B.J. ET AL.: "Pasteurella multocida PM70 section 152 of 204 of the complete genome" Database accession no. AE006064 XP002224305	1-41
X	nucleotides 3352-4146 & DATABASE EMBL [Online] Entry AE006064, 10 February 2001 (2001-02-10) MAY B.J. ET AL.: "Pasteurella multocida PM70 section 31 of 204 of the complete genome" the whole document	5-23,25, 28
A	& BARBARA J. MAY ET AL.: "Complete genomic sequence of Pasteurella multocida, Pm70" PROCEEDINGS OF THE NATIONAL ACADEMY OF -/--	1-41
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "Z" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
12 May 2003		16. 05. 2003
Name and mailing address of the ISA European Patent Office, P.B. 2918 Patentlaan 2 NL - 2203 HV Rijswijk Tel: (+31-70) 546-2040; Tx: 31 851 epo nl, Fax: (+31-70) 546-3916		Authorized officer  Montero Lopez, B

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 02/01971

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCIENCES OF USA, vol. 98, no. 6, 13 March 2001 (2001-03-13), pages 3460-3465, XP002202785 WASHINGTON US page 3463, right-hand column, paragraph 2 -page 3464, left-hand column, paragraph 1 --- COONEY ET AL: "Three contiguous lipoprotein genes in Pasteurella haemolytica A1 which are homologous to a lipoprotein gene in Haemophilus influenza Type b" INFECTION AND IMMUNITY, AMERICAN SOCIETY OF MICROBIOLOGY, WASHINGTON, DC, US, vol. 61, no. 11, November 1993 (1993-11), pages 4682-4688, XP002148894 ISSN: 0019-9567 abstract page 4683, left-hand column, last paragraph -page 4685, left-hand column, paragraph 1; figures 3,4 page 4686, right-hand column, paragraph 2 ---	5-23,25, 28
A	TROY E. FULLER ET AL.: "Identification of Pasteurella multocida virulence genes in a septicemic mouse model using signature-tagged mutagenesis" MICROBIAL PATHOGENESIS, vol. 29, 2000, pages 25-38, XP002224304 the whole document -----	1-41

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US 02/01971

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
**1-41 partially**
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

International Application No. PCT/US 02/01971

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

## 1. Claims: 1-41 partially

Gram-negative bacteria comprising a mutation in a gene of sequence SEQ ID NO:1 resulting in decreased activity of the gene product; immunogenic composition comprising the bacteria; method of producing such mutant bacteria; nucleotide sequence comprising SEQ ID NO:1, vector and host cell comprising the same and use thereof to produce a polypeptide; encoded polypeptide of sequence SEQ ID NO:2; antibody against it; use of the polypeptide of sequence SEQ ID NO:2 for identifying antibacterial agents.

## 2. Claims: 1-41 partially

Idem as subject 1 for, respectively sequences SEQ ID NO:3 and 4; 7 and 8; 9 and 10; 21 and 22; 25 and 26.

## 3. Claims: 1-4, 21-23, 27, 28 partially

Gram-negative bacteria comprising a mutation in a gene of sequence SEQ ID NO:27 resulting in decreased activity of the gene product; immunogenic composition comprising the bacteria; nucleotide sequence comprising SEQ ID NO:27.

## 4. Claims: 1-41 partially

Idem as subject 1 for, respectively, sequences SEQ ID NOs:29 and 30; 39 and 40; 41 and 42; 51 and 52; 53 and 54; 55 and 56.

## 5. Claims: 1-28 partially

Gram-negative bacteria comprising a mutation in a gene of sequence SEQ ID NO:57 resulting in decreased activity of the gene product; immunogenic composition comprising the bacteria; method of producing such mutant bacteria; nucleotide sequence comprising SEQ ID NO:57.

## 6. Claims: 1-41 partially

Idem as subject 1 for, respectively sequences SEQ ID NOs:58 and 59; 60 and 61; 68 and 69; 72 and 73; 74 and 75; 76 and 77; 78 and 79; 80 and 81; 82 and 83; 84 and 85; 104 and 105; 108 and 109; 112 and 113; 116 and 117; 118 and 119; 120 and 121; 122 and 123; 124 and 125; 126 and 127; 128 and 129; 130 and 131



International Application No. PCT/US 02/01971

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 7. Claims: 5-26, 29-41 partially

Attenuated Pasteurellaceae bacteria comprising a mutation in a gene of sequence SEQ ID NO:11; immunogenic composition containing it; method of producing such mutant bacteria; nucleotide sequence comprising SEQ ID NO:11, vector and host cell comprising the same and use thereof to produce a polypeptide; encoded polypeptide of sequence SEQ ID NO:12; antibody against it; use of the polypeptide of sequence SEQ ID NO:12 for identifying antibacterial agents.

## 8. Claims: 5-26, 28-41 partially

Idem as subject 36 for, respectively, sequences SEQ ID NOs:13 and 14; 15 and 16; 17 and 18; 19 and 20; 23 and 24; 31 and 32; 33 and 34; 35 and 36; 37 and 38; 70 and 71; 100 and 101; 102 and 103; 106 and 107; 110 and 111; 114 and 115; 132 and 133; 134 and 135; 136 and 137; 138 and 139; 140 and 141; 142 and 143; 144 and 145; 146 and 147; 148 and 149; 150 and 151; 152 and 153; 154 and 155; 156 and 157; 158 and 159; 160 and 161

## 9. Claims: 5-26 partially

Attenuated Pasteurellaceae bacteria comprising a mutation in, respectively a gene of sequence SEQ ID NO:162 and 163; immunogenic composition containing it; method of producing such mutant bacteria; nucleotide sequence comprising SEQ ID NO:162 or 163.

## 10. Claims: 5-26, 28-41 partially

Idem as subject 36 for, respectively, sequences SEQ ID NOs:164 and 165; 166 and 167; 168 and 169; 170 and 171; 172 and 173; 174 and 175

## フロントページの続き

(51) Int.Cl. <sup>7</sup>	F I	テーマコード(参考)
C 1 2 N 1/15	C 0 7 K 16/12	4 C 0 8 5
C 1 2 N 1/19	C 1 2 N 1/15	4 H 0 4 5
C 1 2 N 1/21	C 1 2 N 1/19	
C 1 2 N 5/10	C 1 2 N 1/21	
C 1 2 P 21/02	C 1 2 P 21/02	C
C 1 2 Q 1/68	C 1 2 Q 1/68	A
G 0 1 N 33/15	G 0 1 N 33/15	Z
G 0 1 N 33/50	G 0 1 N 33/50	Z
G 0 1 N 33/53	G 0 1 N 33/53	D
G 0 1 N 33/569	G 0 1 N 33/569	F
G 0 1 N 33/577	G 0 1 N 33/577	B
	C 1 2 N 5/00	A

(81) 指定国 AP(GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), EA(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), EP(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OA(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG), AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

(72) 発明者 デイビッド・イー・ローワリー

アメリカ合衆国 4 9 0 2 4 ミシガン州ポーターティジ、ウッドランド・ドライブ 1 2 0 7 番

(72) 発明者 トロイ・イー・フラー

アメリカ合衆国 4 9 0 1 4 ミシガン州バトル・クリーク、ドリームフィールド・ドライブ 1 1 1 番

(72) 発明者 マイケル・ジェイ・ケネディ

アメリカ合衆国 4 9 0 2 4 ミシガン州ポーターティジ、クインシー・アベニュー 2 3 6 4 番

F ターム(参考) 2G045 AA35 AA40 BB50 BB51 CB21 DA13 DA36 FB02 FB12 GC15

4B024 AA01 AA11 BA38 CA02 DA02 DA06 DA12 EA04 HA14

4B063 QA01 QA05 QA11 QQ05 QQ42 QQ79 QR32 QR74 QR80

4B064 AG30 CA01 CA19 CC24 DA01 DA13

4B065 AA01Y AB01 AC14 BA02 CA24 CA44 CA46

4C085 AA03 BA18 CC07 DD23 DD62 EE01 EE06 FF24

4H045 AA10 AA11 AA20 AA30 BA10 CA11 DA83 EA20 EA50 FA74